{
 "cells": [
  {
   "cell_type": "code",
   "execution_count": 70,
   "metadata": {},
   "outputs": [],
   "source": [
    "import os, json\n",
    "\n",
    "from langchain.chains.combine_documents.stuff import StuffDocumentsChain\n",
    "from langchain.chains.sequential import SequentialChain\n",
    "from langchain.chains import LLMChain\n",
    "from langchain.prompts import PromptTemplate\n",
    "from langchain.vectorstores import FAISS\n",
    "from langchain.embeddings import OpenAIEmbeddings\n",
    "from langchain.prompts.chat import (\n",
    "    ChatPromptTemplate,\n",
    "    HumanMessagePromptTemplate,\n",
    "    SystemMessagePromptTemplate\n",
    "    )\n",
    "from config import LOGGER\n",
    "\n",
    "from langchain.chains.qa_with_sources.retrieval import RetrievalQAWithSourcesChain\n",
    "from langchain.chat_models import ChatOpenAI\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 80,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Number of test cases: 30\n",
      "Length of embeddings: 1536\n"
     ]
    }
   ],
   "source": [
    "MAIN_DIR = \"..\"\n",
    "ARTIFACT_DIR = os.path.join(MAIN_DIR, \"artifacts\")\n",
    "EMB_DIR = os.path.join(MAIN_DIR, \"data\", \"emb_store\", \"uc\", \"faiss\", \"text-embedding-ada-002\")\n",
    "\n",
    "with open(os.path.join(MAIN_DIR, \"auth\", \"api_keys.json\"), \"r\") as f:\n",
    "    api_keys = json.load(f)\n",
    "    \n",
    "os.environ[\"OPENAI_API_KEY\"] = api_keys[\"OPENAI_API_KEY\"]\n",
    "\n",
    "with open(os.path.join(MAIN_DIR, \"data\", \"queries\", \"uc_all.txt\"), \"r\") as f:\n",
    "    test_cases_txt = f.readlines()\n",
    "    \n",
    "with open(os.path.join(MAIN_DIR, \"data\", \"queries\", \"uc_all_emb.json\"), \"r\") as f:\n",
    "    test_cases_emb = json.load(f)\n",
    "    \n",
    "test_cases = [(txt, emb) for txt, emb in zip(test_cases_txt, test_cases_emb)]\n",
    "print(\"Number of test cases:\", len(test_cases))\n",
    "print(\"Length of embeddings:\", len(test_cases[0][1]))"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 55,
   "metadata": {},
   "outputs": [],
   "source": [
    "db_name = \"v8-add-tables_2500_500\"\n",
    "embeddings = OpenAIEmbeddings()\n",
    "docsearch = FAISS.load_local(os.path.join(EMB_DIR, db_name), embeddings)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 88,
   "metadata": {},
   "outputs": [],
   "source": [
    "# CHAT PROMTP TEMPLATE\n",
    "system_prompt = \"\"\"\n",
    "You are a physician assistant giving advice on treatment for moderate to severe ulcerative colitis (UC).\n",
    "Make reference to the CONTEXT given to assess the scenario.\n",
    "If the answer cannot be inferred from CONTEXT, return \"NO ANSWER\", don't try to make up an answer.\n",
    "==========\n",
    "TASK: ANALYSE the given patient profile based on given query based on one of the following criteria:\n",
    "- Whether treated patient is new patient or patient under maintenance\n",
    "- Prior response to Infliximab\n",
    "- Prior failure to Anti-TNF agents\n",
    "- Prior failure to Vedolizumab\n",
    "- Age\n",
    "- Pregnancy\n",
    "- Extraintestinale manifestations\n",
    "- Pouchitis\n",
    "\n",
    "FINALLY RETURN up to 2 TOP choices of biological drugs given patient profile and context. Explain the PROS and CONS of the 2 choices.\n",
    "If answer cannot be derived from context, RETURN \"NO ANSWER\" and explain reason.\n",
    "==========\n",
    "OUTPUT INSTRUCTIONS:\n",
    "Output your answer as a list of JSON objects with keys: drug_name, advantages, disadvantages.\n",
    "==========\n",
    "CONTEXT:\n",
    "{summaries}\n",
    "==========\n",
    "\"\"\"\n",
    "\n",
    "QA_PROMPT = ChatPromptTemplate.from_messages(\n",
    "    [\n",
    "        SystemMessagePromptTemplate.from_template(\n",
    "            system_prompt, input_variables=[\"summaries\"]\n",
    "        ),\n",
    "        HumanMessagePromptTemplate.from_template(\"PATIENT PROFILE: {question}\"),\n",
    "    ]\n",
    ")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 96,
   "metadata": {},
   "outputs": [],
   "source": [
    "llm = ChatOpenAI(model_name=\"gpt-3.5-turbo\", temperature=0, max_tokens=512)\n",
    "# llm = ChatOpenAI(model_name=\"gpt-4\", temperature=0, max_tokens=512)\n",
    "qa_with_sources_chain = RetrievalQAWithSourcesChain.from_chain_type(\n",
    "    llm=llm, chain_type=\"stuff\",\n",
    "    retriever=docsearch.as_retriever(search_kwargs={\"k\": 3}),\n",
    "    return_source_documents=True,\n",
    "    chain_type_kwargs={\"prompt\": QA_PROMPT},\n",
    "    max_tokens_limit=3375, reduce_k_below_max_tokens=True,\n",
    "    verbose=True\n",
    "    )"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 97,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\n",
      "\n",
      "\u001b[1m> Entering new RetrievalQAWithSourcesChain chain...\u001b[0m\n",
      "\n",
      "\u001b[1m> Finished chain.\u001b[0m\n"
     ]
    },
    {
     "data": {
      "text/plain": [
       "{'question': '52 year-old woman with moderate to severe distal ulcerative colitis that had a successful induction with vedolizumab. What would be the maintenance therapy?\\n',\n",
       " 'answer': 'Based on the given patient profile, the patient is a 52-year-old woman with moderate to severe distal ulcerative colitis who had a successful induction with vedolizumab. The query is about the appropriate maintenance therapy for this patient.\\n\\nBased on the information provided, the patient has responded well to vedolizumab during the induction phase. Therefore, vedolizumab can be considered as a suitable maintenance therapy for this patient. Vedolizumab is an advanced therapy that specifically targets the gut-homing lymphocytes, reducing inflammation in the gut. It has been shown to be effective in maintaining remission in patients with ulcerative colitis.\\n\\nAnother option for maintenance therapy could be adalimumab. Adalimumab is another advanced therapy that has been approved for the treatment of moderate to severe ulcerative colitis. It is a tumor necrosis factor (TNF) inhibitor that works by reducing inflammation in the gut. Adalimumab has been shown to be effective in maintaining remission in patients with ulcerative colitis.\\n\\nBoth vedolizumab and adalimumab have their advantages and disadvantages. \\n\\nAdvantages of vedolizumab:\\n- Specifically targets gut-homing lymphocytes, reducing inflammation in the gut.\\n- Has been shown to be effective in maintaining remission in patients with ulcerative colitis.\\n- Generally well-tolerated with a favorable safety profile.\\n\\nDisadvantages of vedolizumab:\\n- Requires intravenous infusion, which may be inconvenient for some patients.\\n- May increase the risk of certain infections, although the overall risk is low.\\n\\nAdvantages of adalimumab:\\n- Can be self-administered subcutaneously, providing convenience for patients.\\n- Has been shown to be effective in maintaining remission in patients with ulcerative colitis.\\n- Generally well-tolerated with a favorable safety profile.\\n\\nDisadvantages of adalimumab:\\n- May increase the risk of certain infections, although the overall risk is low.\\n- Requires regular subcutaneous injections, which may be a drawback for some patients.\\n\\nIn summary, the top two choices for maintenance therapy for this patient with a successful induction with vedolizumab would be:\\n1. Vedolizumab: It has been effective in inducing and maintaining remission in patients with ulcerative colitis and has a favorable safety profile.\\n2. Adalimumab: It can be self-administered subcutaneously and has been shown to be effective in maintaining remission in patients',\n",
       " 'sources': '',\n",
       " 'source_documents': [Document(page_content='Table 1. Trial and Patient Characteristics in Included Trials of Induction and Maintenance Therapy for Moderate–Severe Ulcerative Colitis\\nTrial and intervention\\ncharacteristics\\nDeﬁnition and\\ntiming of\\noutcome,\\nCRem\\nMean age, y\\n(SD); sex (%\\nmale)\\nMean disease\\nduration (y) (SD);\\ndisease extent\\n(% extensive\\ncolitis)\\nConcomitant medications\\nMean CRP,\\nmg/L (SD)\\nPrior anti-\\nTNF\\ntherapy, %\\nImmunomodulators,\\n%\\nCorticosteroids,\\n%\\nInﬂiximab\\nActive Ulcerative Colitis\\nTrials 117a (induction and\\nmaintenance therapy)\\n62 sites, 2002–2005;\\nP: 121;\\nI: IFX 5 mg/kg, wk 0, 2, 6, then\\nq8w–121\\nMCS �2; wk 8,\\nwk 54\\nP: 41 (14); 60\\nI: 42 (14); 65\\n6.2 (5.9); 45\\n5.9 (5.4); 47\\n43.8\\n54.5\\n65.3\\n57.9\\n17 (27)\\n14 (19)\\n0\\n0\\nActive Ulcerative Colitis\\nTrials 217a (induction and\\nmaintenance therapy)\\n55 sites, 2002–2005;\\nP: 123;\\nI: IFX 5 mg/kg, wk 0, 2, 6, then\\nq8w–121\\nMCS �2; wk 8,\\nwk 30\\nP: 39 (14); 58\\nI: 41 (13); 63\\n6.5 (6.7); 42\\n6.7 (5.3); 41\\n43.9\\n43.0\\n48.8\\n49.6\\n16 (29)\\n13 (23)\\n0\\n0\\nJiang et al18a (induction and\\nmaintenance therapy)\\n1 site (China), 2008–2013;\\nP: 41;\\nI: IFX 5 mg/kg, wk 0, 2, 6, then\\nq8w–41\\nMCS �2; wk 8,\\nwk 30\\nP: 35 (15); 61\\nI: 34 (14); 63\\n4.4 (2.6); 61\\n4.4 (2.8); 59\\n31.7\\n29.3\\n51.2\\n53.7\\nNR\\n0\\n0\\nNCT0155129019a (induction\\nand maintenance\\ntherapy)\\n12 sites (China), 2012–2014;\\nP: 49;\\nI: IFX 5 mg/kg, wk 0, 2, 6, then\\nq8w–50\\nMCS �2; wk 8,\\nwk 26\\nEntire group: 37;\\nNR\\n3.7; NR\\nNR\\n80\\n60\\nNR\\n0\\n0\\nAdalimumab\\nULTRA 120 (induction\\ntherapy)\\n94 sites, 2007–2010;\\nP: 130;\\nI: ADA 160/80/40, wk 0, 2, 4, 6–\\n130\\nMCS �2; wk 8\\nP: 37 (18–72)b;\\n64\\nI: 37 (18–75)b; 64\\n5.4 (0.3–34.1)b; 56\\n6.1 (0.2–34.4)b; 46\\n39.9\\n39.2\\n67.6\\n54.6\\n3.2 (0.2–280)b\\n3.3 (0.1–109)b\\n0\\n0\\nULTRA 221a (induction and\\nmaintenance therapy)\\n103 sites, 2006–2010;\\nP: 246;\\nI: ADA 160/80/40, wk 0, 2, 4, 6–\\n248\\nMCS �2; wk 8\\nP: 41 (13); 62\\nI: 40 (12); 57\\n8.5 (7.4); 49\\n8.1 (7.1); 48\\n50.8\\n57.7\\n75.2\\n80.7\\n13.1 (36.7)\\n14.5 (32.1)\\n41c\\n39c\\nSuzuki et al22a (induction and\\nmaintenance therapy)\\n65 sites, 2009–2011;\\nP: 96;\\nI: ADA 160/80/40, wk 0, 2, 4, 6–90\\nMCS �2; wk 8\\nP: 41 (14); 73\\nI: 43 (15); 68\\n7.8 (7.1); 62\\n7.8 (6.6); 70\\n54.2\\n45.6\\n60.4\\n63.3\\n3.4 (0.5–87.2)b\\n2.2 (0.5–62.8)b\\n0\\n0\\nGolimumab\\nPURSUIT phases 2 and 323\\n(induction therapy)\\n217 sites, 2007–2010;\\nP: 331;\\nI: GLM 200/100, wk 0, 2–331\\nMCS �2; wk 6\\nP: 39 (13); 53\\nI: 40 (14); 54\\n6.0 (6.7); 43\\n6.4 (6.2); 42\\n32.0\\n31.7\\n42.9\\n44.7\\n10.7 (16.8)\\n11.3 (15.3)\\n0\\n0\\nPURSUIT-M27d\\n(maintenance therapy)\\n251 sites, 2007–2011;\\nP: 156;\\nI: GLM 100 mg q4w–154\\nMCS �2; wk 54\\nP: 40 (14); 48\\nI: 39 (13); 58\\n6.9 (7.0); NR', metadata={'source': 'data/document_store/uc/PIIS1542356520300446.pdf', 'file_path': 'data/document_store/uc/PIIS1542356520300446.pdf', 'page': 3, 'total_pages': 19, 'format': 'PDF 1.7', 'title': 'First- and Second-Line Pharmacotherapies for Patients With Moderate to Severely Active Ulcerative Colitis: An Updated Network Meta-Analysis', 'author': 'Siddharth Singh', 'subject': 'Clinical Gastroenterology and Hepatology, 18 (2020) 2179-2197. doi:10.1016/j.cgh.2020.01.008', 'keywords': '', 'creator': 'Elsevier', 'producer': 'Acrobat Distiller 8.1.0 (Windows)', 'creationDate': \"D:20200816062640+05'30'\", 'modDate': \"D:20200816062734+05'30'\", 'trapped': '', 'modal': 'text'}),\n",
       "  Document(page_content=\"discontinuation due to AEs, and serious infections. Phase 3 randomized controlled trials were identified via systematic literature review, in-\\ncluding the following advanced therapies: infliximab, adalimumab, vedolizumab, golimumab, tofacitinib, ustekinumab, filgotinib, ozanimod, and \\nupadacitinib. Random effects models were used to address between-study heterogeneity. Intent-to-treat (ITT) efficacy rates were calculated by \\nadjusting maintenance outcomes by likelihood of induction response.\\nResults:  Out of 48 trials identified, 23 were included. Across all outcomes and regardless of prior biologic exposure, ITT efficacy rates were \\nhighest for upadacitinib, owing to its highest ranking for all efficacy outcomes in induction and for all but clinical remission during maintenance \\namong bio-naive induction responders. For all advanced therapies versus placebo, there were no significant differences in serious AEs or \\nserious infections across therapies. For all AEs, golimumab had higher odds versus placebo during maintenance; for discontinuation due to \\nAEs, upadacitinib had lower odds versus placebo during induction, while ustekinumab and vedolizumab had lower odds versus placebo during \\nmaintenance.\\nConclusions:  Upadacitinib may be the most efficacious therapy for moderately to severely active UC based on ITT analyses, with similar safety \\nacross advanced therapies.\\nLay Summary \\nIndirect evidence suggests upadacitinib may be more efficacious than other advanced therapies at achieving clinical response, clinical remis-\\nsion, and endoscopic response over 1 year for moderately to severely active ulcerative colitis patients, with similar safety assessments across \\nadvanced therapies.\\nKey Words: ulcerative colitis, clinical trials, advanced therapies, network meta-analysis\\nIntroduction\\nUlcerative colitis (UC) is a chronic inflammatory bowel dis-\\nease that affects the colorectum and is clinically characterized \\nby bloody diarrhea, urgency, tenesmus, abdominal pain, ma-\\nlaise, weight loss, and fever. Disease onset commonly occurs \\nbetween the ages of 15 and 30 years and the annual global \\n© The Author(s) 2023. Published by Oxford University Press on behalf of Crohn's & Colitis Foundation.\\nThis is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), \\nwhich permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.\", metadata={'source': 'data/document_store/uc/otad009.pdf', 'file_path': 'data/document_store/uc/otad009.pdf', 'page': 0, 'total_pages': 17, 'format': 'PDF 1.4', 'title': '', 'author': '', 'subject': '', 'keywords': '', 'creator': 'Adobe InDesign 15.1 (Windows)', 'producer': 'Adobe PDF Library 15.0; modified using iTextSharp 4.1.6 by 1T3XT', 'creationDate': \"D:20230328133539+05'30'\", 'modDate': \"D:20230523091651+00'00'\", 'trapped': '', 'modal': 'text'}),\n",
       "  Document(page_content=\"Crohn's & Colitis 360, XXXX, 5, 1–17\\nhttps://doi.org/10.1093/crocol/otad009\\nAdvance access publication 1 March 2023\\nObservations and Research\\nEfficacy and Safety of Advanced Therapies for Moderately \\nto Severely Active Ulcerative Colitis at Induction and \\nMaintenance: An Indirect Treatment Comparison Using \\nBayesian Network Meta-analysis\\nRemo\\xa0Panaccione, MD, FRCPC,*,\\n Eric B.\\xa0Collins, MPH,†,\\n Gil Y.\\xa0Melmed, MD,‡,\\n \\nSeverine\\xa0Vermeire,MD, PhD,§,\\n Silvio\\xa0Danese, MD, PhD,‖,\\n Peter D.R.\\xa0Higgins, MD, PhD, MSc \\n(CRDSA), AGAF,¶ Christina S.\\xa0Kwon, PhD,# Wen\\xa0Zhou, MD, PhD,** Dapo\\xa0Ilo, MBBS, MRCS, MSC, \\nMBA,** Dolly\\xa0Sharma, PhD,** Yuri\\xa0Sanchez Gonzalez, MS, MSc, PhD,**,\\n and  \\nSi-Tien\\xa0Wang, MS†,\\n*Inflammatory Bowel Disease Unit, Division of Gastroenterology and Hepatology, University of Calgary, Calgary, Alberta, Canada\\n†Medicus Economics LLC, Milton, Massachusetts, USA\\n‡Cedars-Sinai Medical Center, Los Angeles, California, USA\\n§Department of Gastroenterology & Hepatology, University Hospital Leuven, KU Leuven, Leuven, Belgium\\n‖Gastroenterology and Endoscopy, IRCCS Ospedale San Raffaele, Department of Gastroenterology, University Vita-Salute San Raffaele, Milan, \\nItaly\\n¶Department of Medicine, Division of Gastroenterology, University of Michigan, Ann Arbor, Michigan, USA\\n#Cytel, Inc., Waltham, Massachusetts, USA\\n**AbbVie Inc., North Chicago, Illinois, USA\\nAddress correspondence to: Remo Panaccione, MD, FRCPC, Rm 6D32, TRW Building, 3280 Hospitals Drive NW, Calgary, AB T3R1B1, Canada (rpanacci@\\nucalgary.ca).\\nBackground:  Given rapid innovation in advanced therapies for moderately to severely active ulcerative colitis (UC), we investigated their com-\\nparative efficacy and safety during induction and maintenance through network meta-analysis.\\nMethods:  Using Bayesian methods, endpoints of clinical remission and clinical response per Full Mayo score, and endoscopic improvement \\nwere assessed in bio-naive and -exposed populations. Safety was assessed in overall populations by all adverse events (AEs), serious AEs, \\ndiscontinuation due to AEs, and serious infections. Phase 3 randomized controlled trials were identified via systematic literature review, in-\\ncluding the following advanced therapies: infliximab, adalimumab, vedolizumab, golimumab, tofacitinib, ustekinumab, filgotinib, ozanimod, and \\nupadacitinib. Random effects models were used to address between-study heterogeneity. Intent-to-treat (ITT) efficacy rates were calculated by\", metadata={'source': 'data/document_store/uc/otad009.pdf', 'file_path': 'data/document_store/uc/otad009.pdf', 'page': 0, 'total_pages': 17, 'format': 'PDF 1.4', 'title': '', 'author': '', 'subject': '', 'keywords': '', 'creator': 'Adobe InDesign 15.1 (Windows)', 'producer': 'Adobe PDF Library 15.0; modified using iTextSharp 4.1.6 by 1T3XT', 'creationDate': \"D:20230328133539+05'30'\", 'modDate': \"D:20230523091651+00'00'\", 'trapped': '', 'modal': 'text'})]}"
      ]
     },
     "execution_count": 97,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "sample_testcase = test_cases_txt[11]\n",
    "sample_answer = qa_with_sources_chain(sample_testcase)\n",
    "sample_answer"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 107,
   "metadata": {},
   "outputs": [],
   "source": [
    "refine_prompt = \"\"\"You are a senior physician giving advice on treatment for moderate to severe ulcerative colitis (UC).\n",
    "Make reference to the CONTEXT given to assess the scenario.\n",
    "==========\n",
    "TASK: Your task is to analyse critically the CURRENT ANSWER given the CONTEXT.\n",
    "Then refine the existing answer (only if needed) based on the following instructions:\n",
    "- If no refinement needed, return the original answer in the correct output format.\n",
    "- If the answer cannot be inferred from CONTEXT, return \"NO ANSWER\".\n",
    "- The final output should be a list of up to 2 choices of biological drugs given patient profile and context and PROS/CONS for each recommendations.\n",
    "==========\n",
    "CONTEXT:\n",
    "{source_documents}\n",
    "==========\n",
    "ORIGINAL QUESTION: ANALYSE the given patient profile based on given query based on one of the following criteria:\n",
    "- Whether treated patient is new patient or patient under maintenance\n",
    "- Prior response to Infliximab\n",
    "- Prior failure to Anti-TNF agents\n",
    "- Prior failure to Vedolizumab\n",
    "- Age\n",
    "- Pregnancy\n",
    "- Extraintestinale manifestations\n",
    "- Pouchitis\n",
    "RETURN up to 2 TOP choices of biological drugs given patient profile and context. Explain the PROS and CONS of the 2 choices.\n",
    "PATIENT PROFILE: {question}\n",
    "==========\n",
    "CURRENT ANSWER:\n",
    "{answer}\n",
    "==========\n",
    "REFINED ANSWER:\n",
    "\"\"\"\n",
    "\n",
    "REFINE_PROMPT = PromptTemplate(\n",
    "    template=refine_prompt, input_variables = [\"source_documents\", \"question\", \"answer\"]\n",
    ")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 71,
   "metadata": {},
   "outputs": [],
   "source": [
    "llm_chain = LLMChain(\n",
    "    llm=llm,\n",
    "    prompt=REFINE_PROMPT,\n",
    "    verbose=True,\n",
    "    output_key=\"text\"\n",
    ")\n",
    "\n",
    "refine_chain = StuffDocumentsChain(\n",
    "    llm_chain = llm_chain,\n",
    "    input_key=\"source_documents\",\n",
    "    output_key=\"final_answer\",\n",
    "    document_variable_name = \"source_documents\",\n",
    "    document_separator=\"\\n----------\\n\"\n",
    ")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": [
    "sample_refined_answer = refine_chain(\n",
    "    inputs={\n",
    "        \"question\": sample_answer[\"question\"],\n",
    "        \"answer\": sample_answer[\"answer\"],\n",
    "        \"source_documents\": sample_answer[\"source_documents\"]\n",
    "    }\n",
    ")\n",
    "\n",
    "sample_refined_answer"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 73,
   "metadata": {},
   "outputs": [],
   "source": [
    "qa_chain_with_refine = SequentialChain(\n",
    "    chains = [qa_with_sources_chain, refine_chain],\n",
    "    input_variables = [\"question\"],\n",
    "    output_variables = [\"answer\", \"source_documents\", \"final_answer\"],\n",
    "    verbose = True\n",
    ")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": [
    "qa_chain_with_refine(sample_testcase)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 117,
   "metadata": {},
   "outputs": [],
   "source": [
    "from exp import QuestionAnsweringWithIndexSearchExperiment\n",
    "from typing import Union, Optional, Literal, List\n",
    "from custom_parsers import DrugOutput\n",
    "from langchain.output_parsers import PydanticOutputParser\n",
    "import re\n",
    "import pandas as pd\n",
    "from datetime import datetime\n",
    "\n",
    "class QAWithIndexSearchandRefineExperiment(QuestionAnsweringWithIndexSearchExperiment):\n",
    "    def __init__(\n",
    "        self,\n",
    "        original_prompt: Union[PromptTemplate, ChatPromptTemplate],\n",
    "        refine_prompt: PromptTemplate,\n",
    "        vector_store: str,\n",
    "        llm_type: str = \"gpt-3.5-turbo\",\n",
    "        refine_llm_type: Optional[str] = None,\n",
    "        emb: str = \"text-embedding-ada-002\",\n",
    "        keys_json: str = os.path.join(MAIN_DIR, \"auth\", \"api_keys.json\"),\n",
    "        temperature: float = 0,\n",
    "        max_tokens: int = 512,\n",
    "        gt: Optional[str] = None,\n",
    "        verbose: bool = False,\n",
    "        k: int = 4,\n",
    "        max_tokens_limit: int = 3375,\n",
    "        reduce_k_below_max_tokens: bool = True,\n",
    "    ):\n",
    "        self.temperature = temperature\n",
    "        self.max_tokens = max_tokens\n",
    "        \n",
    "        with open(keys_json, \"r\") as f:\n",
    "            self.keys = json.load(f)\n",
    "\n",
    "        self.openai_key = self.keys[\"OPENAI_API_KEY\"]\n",
    "        self.ground_truth = self.load_groundtruth(gt) if gt else None\n",
    "        self.chain = None\n",
    "        self.verbose = verbose\n",
    "\n",
    "        self.k = k\n",
    "        self.max_tokens_limit = max_tokens_limit\n",
    "        self.reduce_k_below_max_tokens = reduce_k_below_max_tokens\n",
    "        self.questions = []\n",
    "        self.original_answers = []\n",
    "        self.final_answers = []\n",
    "        self.sources = []\n",
    "        self.drug_parser = PydanticOutputParser(pydantic_object=DrugOutput)\n",
    "        \n",
    "        self.original_prompt = original_prompt\n",
    "        self.refine_prompt = refine_prompt\n",
    "        \n",
    "        self.answer_llm = ChatOpenAI(\n",
    "            model_name = llm_type, temperature = temperature, max_tokens = max_tokens,\n",
    "            openai_api_key=self.openai_key\n",
    "        )\n",
    "        \n",
    "        self.refine_llm = ChatOpenAI(\n",
    "            model_name=refine_llm_type, temperature=temperature, max_tokens=max_tokens,\n",
    "            openai_api_key=self.openai_key\n",
    "        ) if refine_llm_type else self.answer_llm\n",
    "        \n",
    "        print(\"Answer LLM:\", self.answer_llm.model_name)\n",
    "        print(\"Refine LLM:\", self.refine_llm.model_name)\n",
    "        \n",
    "        self.embedder = OpenAIEmbeddings(model=emb, openai_api_key=self.openai_key)\n",
    "        try:\n",
    "            self.load_vectorstore(vector_store)\n",
    "        except Exception:\n",
    "            print(\n",
    "                \"Vectorstore invalid. Please load valid vectorstore or create new vectorstore.\"\n",
    "            )\n",
    "            \n",
    "    def _create_chain(\n",
    "        self,\n",
    "        chain_type: Literal[\"stuff\", \"map_reduce\", \"map_rerank\", \"refine\"] = \"stuff\",\n",
    "        return_source_documents: bool = True,\n",
    "    ):\n",
    "        self.qa_chain = RetrievalQAWithSourcesChain.from_chain_type(\n",
    "            llm=self.answer_llm,\n",
    "            chain_type=chain_type,\n",
    "            retriever=self.docsearch.as_retriever(search_kwargs={\"k\": self.k}),\n",
    "            return_source_documents=return_source_documents,\n",
    "            chain_type_kwargs={\"prompt\": self.original_prompt},\n",
    "            max_tokens_limit=self.max_tokens_limit,\n",
    "            reduce_k_below_max_tokens=self.reduce_k_below_max_tokens,\n",
    "            verbose=self.verbose\n",
    "        )\n",
    "        \n",
    "        self.refine_chain = StuffDocumentsChain(\n",
    "            llm_chain=LLMChain(llm=self.refine_llm, prompt=self.refine_prompt, verbose=self.verbose),\n",
    "            input_key=\"source_documents\",\n",
    "            output_key=\"final_answer\",\n",
    "            document_variable_name = \"source_documents\",\n",
    "            document_separator=\"\\n----------\\n\"\n",
    "        )\n",
    "        \n",
    "        self.chain = SequentialChain(\n",
    "            chains = [self.qa_chain, self.refine_chain],\n",
    "            input_variables = [\"question\"],\n",
    "            output_variables = [\"answer\", \"source_documents\", \"final_answer\"],\n",
    "            verbose = True\n",
    "            )\n",
    "        \n",
    "    def reset(self):\n",
    "        \"\"\"Reset queries and answers\"\"\"\n",
    "        self.questions = []\n",
    "        self.original_answers = []\n",
    "        self.final_answers = []\n",
    "        self.sources = []\n",
    "        \n",
    "    def save_json(self, output_path: str):\n",
    "        \"\"\"Save Output of test case runs to json file\n",
    "\n",
    "        Args:\n",
    "            output_path (str): Output Path to json file.\n",
    "        \"\"\"\n",
    "        output_dict = {}\n",
    "        output_dict[\"original_prompt\"] = QuestionAnsweringWithIndexSearchExperiment.convert_prompt_to_string(\n",
    "            self.original_prompt\n",
    "        )\n",
    "        output_dict[\"refine_prompt\"] = QuestionAnsweringWithIndexSearchExperiment.convert_prompt_to_string(\n",
    "            self.refine_prompt\n",
    "        )\n",
    "        output_dict[\"test_cases\"] = []\n",
    "\n",
    "        for question, original_answer, final_answer, source in zip(self.questions, self.original_answers, self.final_answers, self.sources):\n",
    "            output_dict[\"test_cases\"].append(\n",
    "                {\"question\": question, \"original_answer\": original_answer, \"final_answer\": final_answer, \"sources\": source}\n",
    "            )\n",
    "\n",
    "        with open(output_path, \"w\") as f:\n",
    "            json.dump(output_dict, f)\n",
    "            \n",
    "    def load_json(self, json_path: str, reset: bool = False):\n",
    "        \"\"\"Load Queries and Answers from Json file\n",
    "\n",
    "        Args:\n",
    "            json_path (str): Path to json output file to load into instance\n",
    "            reset (bool, optional): If reset, clear queries and answers from memory before loading. Defaults to False.\n",
    "        \"\"\"\n",
    "        if reset:\n",
    "            self.reset()\n",
    "        with open(json_path, \"r\") as f:\n",
    "            input_dict = json.load(f)\n",
    "        for test_case in input_dict[\"test_cases\"]:\n",
    "            self.questions.append(test_case[\"question\"])\n",
    "            self.original_answers.append(test_case[\"original_answer\"])\n",
    "            self.final_answers.append(test_case[\"final_answer\"])\n",
    "            self.sources.append(test_case[\"sources\"])\n",
    "        LOGGER.info(\"Json file loaded successfully into Experiment instance.\")\n",
    "        \n",
    "    def run_test_cases(\n",
    "        self,\n",
    "        test_cases: Union[List[str], str],\n",
    "        only_return_source: bool = False,\n",
    "        chain_type: Literal[\"stuff\", \"refine\", \"map_reduce\", \"map_rerank\"] = \"stuff\",\n",
    "    ):\n",
    "        if isinstance(test_cases, str):\n",
    "            with open(test_cases, \"r\", encoding=\"utf-8-sig\") as f:\n",
    "                test_cases = f.readlines()\n",
    "            test_cases = [test_case.rstrip() for test_case in test_cases]\n",
    "\n",
    "        if not self.chain:\n",
    "            self._create_chain(chain_type=chain_type)\n",
    "\n",
    "        if only_return_source:\n",
    "            LOGGER.info(\"Perform Semantic Search for Source Documents only (No QA).\")\n",
    "            \n",
    "        for test_case in test_cases:\n",
    "            print(\"Query: {}\".format(test_case))\n",
    "            sources = []  # All sources for 1 single query\n",
    "            if only_return_source:\n",
    "                self.questions.append(test_case)\n",
    "                self.original_answers.append(None)\n",
    "                self.final_answers.append(None)\n",
    "                inputs = {\"question\": test_case}\n",
    "                source_documents = self.qa_chain._get_docs(inputs)\n",
    "\n",
    "            else:\n",
    "                output = self.chain(test_case)\n",
    "                self.questions.append(output[\"question\"])\n",
    "                self.original_answers.append(output[\"answer\"])\n",
    "                self.final_answers.append(output[\"final_answer\"])\n",
    "                source_documents = output[\"source_documents\"]\n",
    "\n",
    "            token_count = 0\n",
    "            for document in source_documents:\n",
    "                sources.append(\n",
    "                    {\n",
    "                        \"title\": document.metadata[\"title\"],\n",
    "                        \"filename\": document.metadata[\"source\"].split(\"/\")[-1],\n",
    "                        \"page\": document.metadata[\"page\"],\n",
    "                        \"text\": document.page_content,\n",
    "                    }\n",
    "                )\n",
    "                token_count += (\n",
    "                    self.qa_chain.combine_documents_chain.llm_chain.llm.get_num_tokens(\n",
    "                        document.page_content\n",
    "                    )\n",
    "                )\n",
    "\n",
    "            self.sources.append(sources)\n",
    "            LOGGER.info(\n",
    "                f\"{token_count} tokens were added to prompt from {len(source_documents)} documents\"\n",
    "            )\n",
    "            \n",
    "    def write_csv(self, output_csv: str, num_docs: int = 10):\n",
    "        \"\"\"Write questions and answers to .csv files\n",
    "\n",
    "        Args:\n",
    "            output_csv (str): Path to output csv file\n",
    "        \"\"\"\n",
    "\n",
    "        pd_answers = [[], []]\n",
    "        pd_sources = [[] for _ in range(num_docs)]\n",
    "\n",
    "        for answer, sources in zip(self.final_answers, self.sources):\n",
    "            if answer:\n",
    "                drugs_info = re.findall(re.compile(r\"{[^{}]+}\"), answer)\n",
    "                drugs = []\n",
    "                for drug in drugs_info:\n",
    "                    try:\n",
    "                        drug = self.drug_parser.parse(drug)\n",
    "                        drugs.append(drug)\n",
    "                    except Exception:\n",
    "                        pass\n",
    "            else:\n",
    "                drugs = []\n",
    "\n",
    "            pd_answers[0].append(drugs[0].drug_name if len(drugs) > 0 else None)\n",
    "            pd_answers[1].append(drugs[1].drug_name if len(drugs) > 1 else None)\n",
    "\n",
    "            for idx, source in enumerate(sources):\n",
    "                pd_sources[idx].append(\n",
    "                    QuestionAnsweringWithIndexSearchExperiment.process_source(source)\n",
    "                )\n",
    "\n",
    "            if idx + 1 < len(pd_sources):\n",
    "                for i in range(idx + 1, len(pd_sources)):\n",
    "                    pd_sources[i].append(None)\n",
    "\n",
    "        info = {\"question\": self.questions}\n",
    "\n",
    "        if self.ground_truth is not None:\n",
    "            info[\"gt_rec1\"] = self.ground_truth[\"Recommendation 1\"].tolist()\n",
    "            info[\"gt_rec2\"] = self.ground_truth[\"Recommendation 2\"].tolist()\n",
    "            info[\"gt_rec3\"] = self.ground_truth[\"Recommendation 3\"].tolist()\n",
    "            info[\"gt_avoid\"] = self.ground_truth[\"Drug Avoid\"].tolist()\n",
    "            info[\"gt_reason\"] = self.ground_truth[\"Reasoning\"].tolist()\n",
    "\n",
    "        info[\"original_prompt\"] = [\n",
    "            QuestionAnsweringWithIndexSearchExperiment.convert_prompt_to_string(self.original_prompt)\n",
    "        ] * len(self.questions)\n",
    "\n",
    "        info[\"refine_prompt\"] = [\n",
    "            QuestionAnsweringWithIndexSearchExperiment.convert_prompt_to_string(self.refine_prompt)\n",
    "        ] * len(self.questions)\n",
    "        \n",
    "        info[\"raw_original_answer\"] = self.original_answers\n",
    "        info[\"raw_final_answer\"] = self.final_answers\n",
    "        info[\"answer1\"] = pd_answers[0]\n",
    "        info[\"answer2\"] = pd_answers[1]\n",
    "\n",
    "        for idx, pd_source in enumerate(pd_sources):\n",
    "            info[f\"source{idx+1}\"] = pd_source\n",
    "\n",
    "        panda_df = pd.DataFrame(info)\n",
    "\n",
    "        panda_df.to_csv(output_csv, header=True)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 120,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Answer LLM: gpt-4\n",
      "Refine LLM: gpt-4\n",
      "2023-10-02 17:12:29,356:INFO: Successfully loaded existing vectorstore from local storage\n",
      "Query: 40 year old male with newly diagnosed moderate UC and articular extraintestinal manifestations\n",
      "\n",
      "\n",
      "\n",
      "\u001b[1m> Entering new SequentialChain chain...\u001b[0m\n",
      "\n",
      "\n",
      "\u001b[1m> Entering new RetrievalQAWithSourcesChain chain...\u001b[0m\n",
      "\n",
      "\u001b[1m> Finished chain.\u001b[0m\n",
      "\n",
      "\n",
      "\u001b[1m> Entering new LLMChain chain...\u001b[0m\n",
      "Prompt after formatting:\n",
      "\u001b[32;1m\u001b[1;3mYou are a senior physician giving advice on treatment for moderate to severe ulcerative colitis (UC).\n",
      "Make reference to the CONTEXT given to assess the scenario.\n",
      "==========\n",
      "TASK: Your task is to analyse critically the CURRENT ANSWER given the CONTEXT.\n",
      "Then refine the existing answer (only if needed) based on the following instructions:\n",
      "- If no refinement needed, return the original answer in the correct output format.\n",
      "- If the answer cannot be inferred from CONTEXT, return \"NO ANSWER\".\n",
      "- The final output should be a list of up to 2 choices of biological drugs given patient profile and context and PROS/CONS for each recommendations.\n",
      "==========\n",
      "CONTEXT:\n",
      "41 years (interquartile range, 40–42 y), and 60%\n",
      "(interquartile range, 56%–63%) were men. The median\n",
      "disease duration was 6.7 years (interquartile range,\n",
      "6.0–7.8 y), and 49% (interquartile range, 46%–55%) of\n",
      "patients had extensive colitis. A median of 40% (inter-\n",
      "quartile range, 30%–50%) of patients were treated with\n",
      "concomitant immunomodulators, and 51% (interquartile\n",
      "range, 45%–57%) were on corticosteroids at baseline.\n",
      "Patients across all trials and treatment arms were com-\n",
      "parable in terms of baseline prognostic variables, inclu-\n",
      "sion/exclusion\n",
      "criteria,\n",
      "and\n",
      "co-interventions.\n",
      "All\n",
      "outcomes were assessed uniformly based on the stan-\n",
      "dard deﬁnition of the Mayo Clinic score, between weeks\n",
      "6 and 10 for induction therapy (inﬂiximab, adalimumab,\n",
      "tofacitinib, ustekinumab, 8 weeks; golimumab, 6 weeks;\n",
      "vedolizumab, 6 weeks, 10 weeks, and 14 weeks in\n",
      "VARSITY),6 and weeks 30, 54, or 60 for maintenance\n",
      "therapy;\n",
      "endoscopy\n",
      "was\n",
      "read\n",
      "by\n",
      "blinded\n",
      "local\n",
      "Table 2. Comparative Efﬁcacy of Pharmacologic Agents for Induction of Clinical Remission and Endoscopic Improvement in Biologic-Naive Patients With Moderate–Severe\n",
      "Ulcerative Colitis Using Network Meta-Analysis\n",
      "Induction of clinical remission\n",
      "Induction of endoscopic improvement\n",
      "Ustekinumab 6 mg/kg\n",
      "0.96 (0.38–2.45)\n",
      "0.80 (0.35–1.83)\n",
      "0.73 (0.31–1.74)\n",
      "1.05 (0.48–2.32)\n",
      "0.50 (0.22–1.12)\n",
      "2.04 (1.03–4.05)\n",
      "0.92 (0.45–1.89)\n",
      "Tofacitinib 10 mg b.d.\n",
      "0.84 (0.39–1.82)\n",
      "0.76 (0.33–1.76)\n",
      "1.10 (0.51–2.34)\n",
      "0.52 (0.24–1.12)\n",
      "2.12 (1.12–4.02)\n",
      "0.74 (0.36–1.51)\n",
      "0.80 (0.4–1.62)\n",
      "Vedolizumab\n",
      "0.91 (0.44–1.86)\n",
      "1.31 (0.88–1.95)\n",
      "0.62 (0.34–1.15)\n",
      "2.54 (1.60–4.02)\n",
      "1.07 (0.58–1.98)\n",
      "1.17 (0.64–2.12)\n",
      "1.45 (0.80–2.61)\n",
      "Golimumab\n",
      "1.44 (0.76–2.75)\n",
      "0.69 (0.35–1.36)\n",
      "2.79 (1.64–4.02)\n",
      "1.17 (0.65–2.13)\n",
      "1.28 (0.72–2.29)\n",
      "1.59 (0.90–2.82)\n",
      "1.10 (0.71–1.71)\n",
      "Adalimumab\n",
      "0.48 (0.26–0.86)\n",
      "1.94 (1.30–2.88)\n",
      "0.56 (0.30–1.04)\n",
      "0.61 (0.34–1.11)\n",
      "0.76 (0.42–1.37)\n",
      "0.52 (0.33–0.83)\n",
      "0.48 (0.31–0.74)\n",
      "Inﬂiximab\n",
      "4.07 (2.67–6.21)\n",
      "1.86 (1.11–3.13)\n",
      "2.03 (1.23–3.34)\n",
      "2.52 (1.54–4.11)\n",
      "1.74 (1.25–2.41)\n",
      "1.58 (1.18–2.13)\n",
      "3.32 (2.39–4.60)\n",
      "Placebo\n",
      "NOTE. Comparisons should be read from left to right. Odds ratio for comparisons are in the cell in common between the column-deﬁning and row-deﬁning treatment. Numbers in bold are statistically signiﬁcant. For induction of\n",
      "clinical remission, an odds ratio greater than 1 favors row-deﬁning treatment. For induction of endoscopic improvement, an odds ratio greater than 1 favors column-deﬁning treatment. Numbers in parentheses indicate 95% CI.\n",
      "b.d., twice daily.\n",
      "----------\n",
      "Burr et al. \n",
      " \n",
      "7 of 45 \n",
      "INTRODUCTION \n",
      "  Ulcerative colitis (UC) is a chronic inflammatory disorder of the bowel that causes \n",
      "continuous mucosal inflammation commencing in the rectum and extending proximally for a \n",
      "variable extent.[1] It is estimated that UC affects 2.5 million people in Europe,[2] and the \n",
      "disease follows a relapsing and remitting course, with intermittent flares of disease activity, \n",
      "some of which may be moderate to severe. Management of these is medical, for the most \n",
      "part, with surgery reserved for patients with refractory disease. Although 5-aminosalicylates \n",
      "(5-ASAs) are efficacious for mild to moderate disease activity,[3-6] more severe flares are \n",
      "usually treated with corticosteroids.[7] However, these have potentially serious adverse \n",
      "effects and a substantial proportion of patients may become either dependent on them to \n",
      "maintain remission,[8] or refractory to them.[9] As a result, over the last 20 years novel \n",
      "drugs, with more precise modes of action, based on mechanisms of disease identified in \n",
      "genome wide association studies,[10] have been developed.  \n",
      "The first of these agents was infliximab, a drug targeting the pro-inflammatory \n",
      "cytokine tumour necrosis factor-α (TNF-α), which demonstrated efficacy in clinical trials in \n",
      "moderate to severe UC.[11] Since then, other drugs against TNF-α have been tested, such as \n",
      "adalimumab and golimumab.[12, 13] In addition, newer biological therapies targeting α or β \n",
      "integrins, which are involved in migration of immune cells to inflamed intestinal mucosa, \n",
      "such as vedolizumab or etrolizumab,[14, 15] or acting against other pro-inflammatory \n",
      "cytokines implicated in the pathogenesis of UC, such as ustekinumab,[16] have been tested. \n",
      "However, even these more selective drugs do not work in all patients, there may be risks \n",
      "associated with their use,[17-19] and the fact that they are administered either intravenously \n",
      "or subcutaneously, may be inconvenient for patients. The search for alternative agents for the \n",
      "treatment of UC has, therefore, continued.\n",
      "----------\n",
      "Burr et al. \n",
      " \n",
      "5 of 45 \n",
      "STUDY HIGHLIGHTS \n",
      " \n",
      "What is already known about this subject \n",
      "• Ulcerative colitis (UC) follows a relapsing and remitting course, with intermittent \n",
      "flares of disease activity, some of which may be moderate to severe. \n",
      "• These are usually treated with corticosteroids, which have potentially serious adverse \n",
      "effects, so biological therapies and small molecules have been developed and licensed \n",
      "for this indication.  \n",
      "• Although previous network meta-analyses have compared their efficacy and safety, \n",
      "this is a rapidly moving field, and there are already several newer drugs that have \n",
      "shown efficacy in phase III clinical trials that were not considered in these. \n",
      " \n",
      "What are the new findings \n",
      "• In terms of clinical remission and clinical response, upadacitinib 45mg o.d. ranked \n",
      "first in all patients, in patients previously exposed to anti-tumour necrosis factor \n",
      "(TNF)-α therapies, and in patients naïve to these drugs.  \n",
      "• In terms of endoscopic improvement infliximab 10mg/kg ranked first, followed by \n",
      "upadacitinib 45mg o.d., and infliximab 5mg/kg.  \n",
      "• However, for endoscopic improvement again upadacitinib 45mg o.d. ranked first in \n",
      "patients previously exposed to anti-TNF-α therapies, and in patients who were anti-\n",
      "TNF-α naïve.  \n",
      "• None of the drugs studied were more likely to lead to serious adverse events than \n",
      "placebo.\n",
      "----------\n",
      "micronutrients in diet, as well as food additives, processing,\n",
      "and packaging.104 Currently, there is no recommendation\n",
      "for whole foods–based management of IBD, but future\n",
      "studies will delineate this further.\n",
      "Early Therapy of Ulcerative Colitis\n",
      "In UC, mild disease can be managed with oral and/or\n",
      "topical mesalamine therapy, generally with adequate con-\n",
      "trol of disease.38 For moderate UC, VDZ and UST are effec-\n",
      "tive options,105,106 and may be better ﬁrst-choice options\n",
      "than TNFi, given safety proﬁle. In the VARSITY trial, the only\n",
      "head-to-head trial of 2 biologics (n ¼ 769), VDZ was supe-\n",
      "rior to ADA in achieving clinical remission (31.3% vs 22.5%;\n",
      "P ¼ .006) and endoscopic improvement (39.7% vs 27.7%; P\n",
      "< .001) in moderate to severe UC.105 In case VDZ or UST\n",
      "may not be feasible due to payer preference, TNFi, partic-\n",
      "ularly IFX, is an effective option with good safety proﬁle.107\n",
      "Thiopurines may be considered in moderate UC after\n",
      "weighing risks against beneﬁts.64 In patients with severe UC\n",
      "requiring hospitalization, IFX is the preferred biologic for\n",
      "induction and maintenance of remission, with or without\n",
      "IMM. Combination therapy in the SUCCESS trial was asso-\n",
      "ciated with improved clinical, but not endoscopic, outcomes\n",
      "compared to IFX monotherapy.108 When using IFX as a\n",
      "monotherapy in moderate to severe UC, given the potential\n",
      "for the colon to act as a “sink” for drugs, we advocate for\n",
      "checking early drug concentrations to ensure proper dosing\n",
      "and detecting immunogenicity early along with other\n",
      "pharmacokinetic and safety-related variables.109 There is no\n",
      "clear beneﬁt of concomitant mesalamine with biologic\n",
      "therapy in UC and it can be stopped in patients escalating to\n",
      "biologics.110 Some patients may present with acute severe\n",
      "UC\n",
      "where\n",
      "TNFi,\n",
      "cyclosporine,\n",
      "or\n",
      "subtotal\n",
      "colectomy\n",
      "followed by ileal pouch anal anastomosis can be a good\n",
      "initial strategy; discussion of management of acute severe\n",
      "UC is beyond the scope of this article.\n",
      "Taking Extraintestinal Manifestation Into\n",
      "Consideration\n",
      "EIMs are common in IBD, estimated to affect 30%–40% of\n",
      "patients.111,112 In a Swiss cohort study, symptoms of EIMs\n",
      "before IBD in one-quarter of the patients113; collaboration\n",
      "across specialties, including but not limited to rheumatolo-\n",
      "gists, dermatologists, ophthalmologists, is vital not only to\n",
      "prompt referral of patients with EIM suspicious for IBD to\n",
      "allow for expedient initiation of therapy for both conditions,\n",
      "but also to allow for consideration of both in the selection of\n",
      "----------\n",
      "prognosis, with 1 study reporting fewer hospitalizations and\n",
      "less frequent requirement of immunosuppression in pa-\n",
      "tients diagnosed after age 60 years,47 and a meta-analysis\n",
      "suggested\n",
      "that,\n",
      "although\n",
      "elderly\n",
      "IBD\n",
      "presents\n",
      "less\n",
      "commonly with complications, there are similar or higher\n",
      "rates of surgery compared to a nonelderly population.48 It is\n",
      "being increasingly recognized that frailty, rather than\n",
      "chronologic age, may be the driver of adverse outcomes in\n",
      "this group.49,50\n",
      "Other Demographic Variables\n",
      "There are signiﬁcant differences in IBD phenotype\n",
      "and outcomes based on race and ethnicity, likely due to\n",
      "a multitude of factors, both social and biologic. Emer-\n",
      "gency department use, hospitalization, complicated dis-\n",
      "ease\n",
      "course,\n",
      "and\n",
      "IBD-related\n",
      "disability\n",
      "are\n",
      "more\n",
      "common in minority and lower socioeconomic status\n",
      "groups.51,52 In a study of 770 patients with IBD, South\n",
      "Asian immigrants living in the United Kingdom were\n",
      "more\n",
      "likely\n",
      "to\n",
      "have\n",
      "extensive\n",
      "UC\n",
      "and\n",
      "colonic\n",
      "CD\n",
      "compared with their native counterparts,53 which might\n",
      "be related, in part, to limited access to care.54 Genes\n",
      "implicated in IBD risk also differ in non-White compared\n",
      "with White patients with IBD.55 Being aware of the\n",
      "higher vulnerability to adverse IBD-related outcomes in\n",
      "these vulnerable groups should prompt careful moni-\n",
      "toring to limit adverse outcomes.\n",
      "There are increasing data on sex-based differences in\n",
      "IBD phenotype and outcomes, which may signal differences\n",
      "in pathogenic pathways and progression. Of note, extra-\n",
      "intestinal manifestations (EIMs) consistently tend to be\n",
      "more common in female patients (CD: OR, 2.3; 95% CI, 1.9–\n",
      "2.8 and UC: OR, 1.5; 95% CI, 1.1–2.3, in a large Dutch Bio-\n",
      "Bank).56 Similarly, in a retrospective pediatric study of\n",
      "nearly 1000 patients with CD, girls were more likely to have\n",
      "EIMs and less likely to have growth impairment compared\n",
      "with boys,57 the latter is possibly related to lower insulin-\n",
      "like growth factor-1 level in boys.58\n",
      "July 2021\n",
      "Management of early IBD\n",
      "49\n",
      "REVIEWS AND\n",
      "PERSPECTIVES\n",
      "----------\n",
      "methodologic characteristics). If direct and indirect es-\n",
      "timates were similar (ie, coherent), then the higher rating\n",
      "can be assigned to the network meta-analysis estimates.\n",
      "Results\n",
      "From a total 5651 unique studies identiﬁed using our\n",
      "search strategy, we included 15 RCTs of ﬁrst-line agents\n",
      "(in biologic-naïve patients) (Active Ulcerative Colitis Trials\n",
      "1 and 2,17 Jiang et al,18 NCT01551290,19 Ulcerative colitis\n",
      "Long-Term Remission and maintenance with Adalimumab\n",
      "1 and 2,20,21 Suzuki et al,22 Program of Ulcerative Colitis\n",
      "Research Studies Utilizing an Investigational Treatment\n",
      "phase 2 and phase 3 induction studies,23 GEMINI I,24\n",
      "Motoya et al,25 VARSITY, Oral Clinical Trials for tofAciti-\n",
      "nib in ulceratiVE colitis (OCTAVE) 1 and 2,26 and UNIFI),\n",
      "and 7 RCTs of second-line agents (in patients with prior\n",
      "exposure to TNFa antagonists) (Ulcerative colitis Long-\n",
      "Term Remission and maintenance with Adalimumab 2,21\n",
      "GEMINI I,24 Motoya et al,25 VARSITY,6 OCTAVE 1 and\n",
      "2,26 UNIFI7) in patients with moderate–severe ulcerative\n",
      "colitis. Trials of inﬂiximab (Active Ulcerative Colitis Trials\n",
      "1 and 2,17 Jiang et al,18 NCT0155129019), adalimumab\n",
      "(Ulcerative colitis Long-Term Remission and maintenance\n",
      "with Adalimumab 2,20,21 Suzuki et al22), vedolizumab\n",
      "(GEMINI I,24 Motoya et al,25 VARSITY6) and ustekinumab\n",
      "(UNIFI7) also reported outcomes on maintenance therapy\n",
      "within the same publication; Program of Ulcerative Colitis\n",
      "Research Studies Utilizing an Investigational Treatment-\n",
      "M, Program of Ulcerative Colitis Research Studies Utilizing\n",
      "an Investigational Treatment-J, and OCTAVE-Sustain\n",
      "reported\n",
      "outcomes\n",
      "for\n",
      "maintenance\n",
      "therapy\n",
      "with\n",
      "golimumab and tofacitinib, respectively.26–28 From our\n",
      "previous analysis, 3 additional studies were included.\n",
      "The schematic diagram of study selection is shown in\n",
      "Supplementary\n",
      "Figure\n",
      "1,\n",
      "and\n",
      "available\n",
      "direct\n",
      "comparisons and network of trials are shown in Figure 1.\n",
      "Trial and patient characteristics are summarized in\n",
      "Table 1. Overall, the median average age of patients was\n",
      "41 years (interquartile range, 40–42 y), and 60%\n",
      "(interquartile range, 56%–63%) were men. The median\n",
      "disease duration was 6.7 years (interquartile range,\n",
      "6.0–7.8 y), and 49% (interquartile range, 46%–55%) of\n",
      "patients had extensive colitis. A median of 40% (inter-\n",
      "quartile range, 30%–50%) of patients were treated with\n",
      "concomitant immunomodulators, and 51% (interquartile\n",
      "range, 45%–57%) were on corticosteroids at baseline.\n",
      "Patients across all trials and treatment arms were com-\n",
      "----------\n",
      "discontinuation due to AEs, and serious infections. Phase 3 randomized controlled trials were identified via systematic literature review, in-\n",
      "cluding the following advanced therapies: infliximab, adalimumab, vedolizumab, golimumab, tofacitinib, ustekinumab, filgotinib, ozanimod, and \n",
      "upadacitinib. Random effects models were used to address between-study heterogeneity. Intent-to-treat (ITT) efficacy rates were calculated by \n",
      "adjusting maintenance outcomes by likelihood of induction response.\n",
      "Results:  Out of 48 trials identified, 23 were included. Across all outcomes and regardless of prior biologic exposure, ITT efficacy rates were \n",
      "highest for upadacitinib, owing to its highest ranking for all efficacy outcomes in induction and for all but clinical remission during maintenance \n",
      "among bio-naive induction responders. For all advanced therapies versus placebo, there were no significant differences in serious AEs or \n",
      "serious infections across therapies. For all AEs, golimumab had higher odds versus placebo during maintenance; for discontinuation due to \n",
      "AEs, upadacitinib had lower odds versus placebo during induction, while ustekinumab and vedolizumab had lower odds versus placebo during \n",
      "maintenance.\n",
      "Conclusions:  Upadacitinib may be the most efficacious therapy for moderately to severely active UC based on ITT analyses, with similar safety \n",
      "across advanced therapies.\n",
      "Lay Summary \n",
      "Indirect evidence suggests upadacitinib may be more efficacious than other advanced therapies at achieving clinical response, clinical remis-\n",
      "sion, and endoscopic response over 1 year for moderately to severely active ulcerative colitis patients, with similar safety assessments across \n",
      "advanced therapies.\n",
      "Key Words: ulcerative colitis, clinical trials, advanced therapies, network meta-analysis\n",
      "Introduction\n",
      "Ulcerative colitis (UC) is a chronic inflammatory bowel dis-\n",
      "ease that affects the colorectum and is clinically characterized \n",
      "by bloody diarrhea, urgency, tenesmus, abdominal pain, ma-\n",
      "laise, weight loss, and fever. Disease onset commonly occurs \n",
      "between the ages of 15 and 30 years and the annual global \n",
      "© The Author(s) 2023. Published by Oxford University Press on behalf of Crohn's & Colitis Foundation.\n",
      "This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), \n",
      "which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.\n",
      "----------\n",
      "I(m): UST 90 mg q8w–176\n",
      "MCS �2; wk 8(i);\n",
      "wk 44(m)\n",
      "P(i): 41 (14); 62\n",
      "I(i): 42 (14); 61\n",
      "P(m): 42(14); 61\n",
      "I(m): 40 (13); 53\n",
      "8.0 (7.2); 47\n",
      "8.2 (7.8); 47\n",
      "7.5 (6.8); 49\n",
      "8.1 (6.7); 46\n",
      "27.9\n",
      "27.6\n",
      "28.0\n",
      "25.6\n",
      "49.2\n",
      "52.2\n",
      "54.3\n",
      "54.0\n",
      "4.7 (1.4–10.)\n",
      "4.8 (1.8–13.7)\n",
      "3.4 (1.4–9.7)\n",
      "4.0 (1.4–12.7)\n",
      "51j\n",
      "52j\n",
      "50j\n",
      "52j\n",
      "ADA, adalimumab; CRem, clinical remission; CRP, C-reactive protein; CS, corticosteroids; GLM, golimumab; I, induction; IFX, inﬂiximab; IM, immunomodulator; MCS, Mayo Clinic Score; NR, not reported; P, placebo;\n",
      "PURSUIT, Program of Ulcerative Colitis Research Studies Utilizing an Investigational Treatment; q2w, every 2 weeks; q4w, every 4 weeks; q8w, every 8 weeks; TNF, tumor necrosis factor; VDZ, vedolizumab.\n",
      "aMaintenance therapy with treat straight-through design.\n",
      "bMedian (range).\n",
      "cReasons for discontinuation of prior anti-TNF therapy: primary nonresponse, 0%; secondary loss of response or intolerance, 100%.\n",
      "dOnly including patients with initial response to induction therapy who were rerandomized to placebo or active intervention.\n",
      "eReasons for discontinuation of prior anti-TNF therapy: primary nonresponse, 48%; secondary loss of response, 38%; intolerance, 14%.\n",
      "fReasons for discontinuation of prior anti-TNF therapy: primary nonresponse, 36%; secondary loss of response, 30%; intolerance, 18%.\n",
      "gReasons for discontinuation of prior anti-TNF therapy: primary nonresponse, 58%; secondary loss of response, 40%; intolerance, 2%.\n",
      "hReasons for discontinuation of prior anti-TNF therapy: primary nonresponse, 43%; secondary loss of response, 50%; intolerance, 7%.\n",
      "iReasons for discontinuation of prior anti-TNF therapy: primary nonresponse, 50%; secondary loss of response, 35%; intolerance, 7%.\n",
      "jIncludes patients with prior exposure to TNF antagonist with or without vedolizumab (13%–18% had prior exposure to vedolizumab).\n",
      "September 2020\n",
      "Management of Moderate–Severe UC 2183\n",
      "----------\n",
      "Burr et al. \n",
      " \n",
      "27 of 45 \n",
      "DISCUSSION \n",
      "We conducted a contemporaneous systematic review and network meta-analysis of \n",
      "biological therapies and small molecules for moderate to severely active UC. This has \n",
      "incorporated data from 28 RCTs and over 12,500 patients. Overall, in terms of clinical \n",
      "remission and clinical response at 6 to 14 weeks, upadacitinib 45mg o.d. ranked first in all \n",
      "patients, in patients previously exposed to anti-TNF-α therapies, and in patients naïve to these \n",
      "drugs. In terms of endoscopic improvement infliximab 10mg/kg ranked first, followed by \n",
      "upadacitinib 45mg o.d., and infliximab 5mg/kg. However, again upadacitinib 45mg o.d. \n",
      "ranked first in patients previously exposed to anti-TNF-α therapies, and in patients who were \n",
      "anti-TNF-α naïve. In terms of safety, upadacitinib 45mg o.d. ranked last for total number of \n",
      "adverse events, and ustekinumab 130mg first. However, none of the drugs studied were more \n",
      "likely to lead to serious adverse events than placebo, although etrolizumab 105mg was more \n",
      "likely to lead to serious adverse events than golimumab 200/100mg, ustekinumab 6mg/kg, \n",
      "vedolizumab 300mg, and infliximab 5mg/kg. Vedolizumab 300mg was the least likely drug \n",
      "to lead to infections. Infections were significantly more likely with tofacitinib 10mg b.i.d. \n",
      "than with either placebo or vedolizumab 300mg. Finally, withdrawals due to adverse events \n",
      "were significantly less likely with upadacitinib 45mg o.d. than with placebo. Upadacitinib \n",
      "45mg o.d. was significantly less likely to lead to withdrawals due to an adverse event than \n",
      "infliximab 5mg/kg and 10mg/kg, vedolizumab 300mg, adalimumab 160/80mg or 80/40mg, \n",
      "filgotinib 200mg o.d., and etrolizumab 105mg. Applying GRADE criteria to our estimates of \n",
      "effects, certainty in the quality of evidence would be high.  \n",
      "There are some limitations. Only nine of 27 trials were at low risk of bias across all \n",
      "domains. Given the timespan of included studies, there is the possibility that trials of newer \n",
      "drugs included patients with refractory UC who had failed multiple other therapies. However, \n",
      "some of these more recent trials only recruited patients who were naïve to anti-TNF-α\n",
      "----------\n",
      "associated with improved long-term outcomes.33 Data on\n",
      "the impact of early therapy in UC are more limited, but, as\n",
      "UC is also a progressive disease with risk of colorectal\n",
      "cancer, surgery, and loss of colonic function, it is reasonable\n",
      "to treat early to mitigate these risks.\n",
      "How to Diagnose Inﬂammatory Bowel Disease\n",
      "Early\n",
      "IBD is heterogenous with wide variation in presentation.\n",
      "Disease activity at presentation can range from mild to severe\n",
      "and, as discussed, symptoms may be mild to none. These can\n",
      "make the IBD diagnosis challenging, especially at a primary\n",
      "care level. Danese et al34 have proposed a Red Flags Index\n",
      "consisting of a 21-item questionnaire to help providers triage\n",
      "and identify patients with concerning symptoms in a timely\n",
      "manner and refer to specialists appropriately. A useful adjunct\n",
      "to symptom-based criteria is fecal calprotectin (FC), a stool\n",
      "marker of inﬂammation; in a large meta-analysis, FC � 40 mg/\n",
      "g carried a �1% probability of IBD, effectively excluding the\n",
      "diagnosis of IBD.35 Similarly, in the Red Flags Index validation\n",
      "study, combining the index with FC (Red Flags Index �8 and/\n",
      "or FC >250 mg/g) increased the positive predictive value from\n",
      "4% to 21% and negative predictive value from 97% to\n",
      "100%.36 Diagnostic criteria for IBD involve a composite of\n",
      "clinical symptoms, endoscopic, biomarker, and cross-sectional\n",
      "imaging features, which are beyond the scope of this review.\n",
      "We refer readers to the excellent guidelines laid out by the\n",
      "American College of Gastroenterology, European Crohn’s and\n",
      "Colitis\n",
      "Organization,\n",
      "and\n",
      "British\n",
      "Society\n",
      "of\n",
      "Gastro-\n",
      "enterology.37–40\n",
      "Risk Stratiﬁcation and Prognostication\n",
      "at Diagnosis\n",
      "Appropriately\n",
      "risk-stratifying\n",
      "prognosis\n",
      "in\n",
      "patients\n",
      "recently diagnosed with IBD is essential to inform selection\n",
      "of the most appropriate treatment and monitoring strate-\n",
      "gies. CD and UC phenotype and disease activity at initial\n",
      "presentation can vary widely from limited and mild to\n",
      "extensive and complicated. Certain baseline clinical features\n",
      "are associated with a more aggressive disease course with\n",
      "higher risk of progression and complications. In higher-risk\n",
      "patients, early control of inﬂammation with immune-\n",
      "modifying therapies is critical. However, immunosuppres-\n",
      "sive therapies are associated with safety concerns in the\n",
      "short- and long-term, and entail signiﬁcant health care costs.\n",
      "Therefore, a consideration of risks, beneﬁts, and alternatives\n",
      "is key to develop an individualized therapeutic plan for the\n",
      "informed patient.\n",
      "==========\n",
      "ORIGINAL QUESTION: ANALYSE the given patient profile based on given query based on one of the following criteria:\n",
      "- Whether treated patient is new patient or patient under maintenance\n",
      "- Prior response to Infliximab\n",
      "- Prior failure to Anti-TNF agents\n",
      "- Prior failure to Vedolizumab\n",
      "- Age\n",
      "- Pregnancy\n",
      "- Extraintestinale manifestations\n",
      "- Pouchitis\n",
      "RETURN up to 2 TOP choices of biological drugs given patient profile and context. Explain the PROS and CONS of the 2 choices.\n",
      "PATIENT PROFILE: 40 year old male with newly diagnosed moderate UC and articular extraintestinal manifestations\n",
      "\n",
      "==========\n",
      "CURRENT ANSWER:\n",
      "Based on the patient's profile, the top two choices of biological drugs would be Vedolizumab and Ustekinumab.\n",
      "\n",
      "1. Vedolizumab\n",
      "   - Advantages: Vedolizumab is an effective option for moderate UC and has a good safety profile. It has been shown to be superior to Adalimumab in achieving clinical remission and endoscopic improvement in moderate to severe UC. It is also less likely to lead to infections compared to other drugs.\n",
      "   - Disadvantages: Vedolizumab is administered intravenously which may be inconvenient for some patients. It may not be feasible due to payer preference.\n",
      "\n",
      "2. Ustekinumab\n",
      "   - Advantages: Ustekinumab is also an effective option for moderate UC and may be a better first-choice option than TNFi, given its safety profile. It is less likely to lead to withdrawals due to adverse events compared to other drugs.\n",
      "   - Disadvantages: Similar to Vedolizumab, Ustekinumab is administered intravenously which may be inconvenient for some patients. \n",
      "\n",
      "It's important to note that the choice of treatment should also consider the patient's extraintestinal manifestations, in this case, articular manifestations. Both Vedolizumab and Ustekinumab have been shown to be effective in managing extraintestinal manifestations of UC. However, the final decision should be made in consultation with the patient, taking into account the potential side effects, the mode of administration, and the patient's preferences and lifestyle.\n",
      "==========\n",
      "REFINED ANSWER:\n",
      "\u001b[0m\n",
      "\n",
      "\u001b[1m> Finished chain.\u001b[0m\n",
      "\n",
      "\u001b[1m> Finished chain.\u001b[0m\n",
      "2023-10-02 17:13:15,909:INFO: 6049 tokens were added to prompt from 10 documents\n",
      "Query: 70 year old female with newly diagnosed severe UC\n",
      "\n",
      "\n",
      "\n",
      "\u001b[1m> Entering new SequentialChain chain...\u001b[0m\n",
      "\n",
      "\n",
      "\u001b[1m> Entering new RetrievalQAWithSourcesChain chain...\u001b[0m\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "Retrying langchain.chat_models.openai.ChatOpenAI.completion_with_retry.<locals>._completion_with_retry in 4.0 seconds as it raised RateLimitError: Rate limit reached for 10KTPM-200RPM in organization org-ETbTMTN2JXYOUPDJgxuH2iO6 on tokens per min. Limit: 10000 / min. Please try again in 6ms. Contact us through our help center at help.openai.com if you continue to have issues..\n",
      "Retrying langchain.chat_models.openai.ChatOpenAI.completion_with_retry.<locals>._completion_with_retry in 4.0 seconds as it raised RateLimitError: Rate limit reached for 10KTPM-200RPM in organization org-ETbTMTN2JXYOUPDJgxuH2iO6 on tokens per min. Limit: 10000 / min. Please try again in 6ms. Contact us through our help center at help.openai.com if you continue to have issues..\n",
      "Retrying langchain.chat_models.openai.ChatOpenAI.completion_with_retry.<locals>._completion_with_retry in 4.0 seconds as it raised RateLimitError: Rate limit reached for 10KTPM-200RPM in organization org-ETbTMTN2JXYOUPDJgxuH2iO6 on tokens per min. Limit: 10000 / min. Please try again in 6ms. Contact us through our help center at help.openai.com if you continue to have issues..\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\n",
      "\u001b[1m> Finished chain.\u001b[0m\n",
      "\n",
      "\n",
      "\u001b[1m> Entering new LLMChain chain...\u001b[0m\n",
      "Prompt after formatting:\n",
      "\u001b[32;1m\u001b[1;3mYou are a senior physician giving advice on treatment for moderate to severe ulcerative colitis (UC).\n",
      "Make reference to the CONTEXT given to assess the scenario.\n",
      "==========\n",
      "TASK: Your task is to analyse critically the CURRENT ANSWER given the CONTEXT.\n",
      "Then refine the existing answer (only if needed) based on the following instructions:\n",
      "- If no refinement needed, return the original answer in the correct output format.\n",
      "- If the answer cannot be inferred from CONTEXT, return \"NO ANSWER\".\n",
      "- The final output should be a list of up to 2 choices of biological drugs given patient profile and context and PROS/CONS for each recommendations.\n",
      "==========\n",
      "CONTEXT:\n",
      "prognosis, with 1 study reporting fewer hospitalizations and\n",
      "less frequent requirement of immunosuppression in pa-\n",
      "tients diagnosed after age 60 years,47 and a meta-analysis\n",
      "suggested\n",
      "that,\n",
      "although\n",
      "elderly\n",
      "IBD\n",
      "presents\n",
      "less\n",
      "commonly with complications, there are similar or higher\n",
      "rates of surgery compared to a nonelderly population.48 It is\n",
      "being increasingly recognized that frailty, rather than\n",
      "chronologic age, may be the driver of adverse outcomes in\n",
      "this group.49,50\n",
      "Other Demographic Variables\n",
      "There are signiﬁcant differences in IBD phenotype\n",
      "and outcomes based on race and ethnicity, likely due to\n",
      "a multitude of factors, both social and biologic. Emer-\n",
      "gency department use, hospitalization, complicated dis-\n",
      "ease\n",
      "course,\n",
      "and\n",
      "IBD-related\n",
      "disability\n",
      "are\n",
      "more\n",
      "common in minority and lower socioeconomic status\n",
      "groups.51,52 In a study of 770 patients with IBD, South\n",
      "Asian immigrants living in the United Kingdom were\n",
      "more\n",
      "likely\n",
      "to\n",
      "have\n",
      "extensive\n",
      "UC\n",
      "and\n",
      "colonic\n",
      "CD\n",
      "compared with their native counterparts,53 which might\n",
      "be related, in part, to limited access to care.54 Genes\n",
      "implicated in IBD risk also differ in non-White compared\n",
      "with White patients with IBD.55 Being aware of the\n",
      "higher vulnerability to adverse IBD-related outcomes in\n",
      "these vulnerable groups should prompt careful moni-\n",
      "toring to limit adverse outcomes.\n",
      "There are increasing data on sex-based differences in\n",
      "IBD phenotype and outcomes, which may signal differences\n",
      "in pathogenic pathways and progression. Of note, extra-\n",
      "intestinal manifestations (EIMs) consistently tend to be\n",
      "more common in female patients (CD: OR, 2.3; 95% CI, 1.9–\n",
      "2.8 and UC: OR, 1.5; 95% CI, 1.1–2.3, in a large Dutch Bio-\n",
      "Bank).56 Similarly, in a retrospective pediatric study of\n",
      "nearly 1000 patients with CD, girls were more likely to have\n",
      "EIMs and less likely to have growth impairment compared\n",
      "with boys,57 the latter is possibly related to lower insulin-\n",
      "like growth factor-1 level in boys.58\n",
      "July 2021\n",
      "Management of early IBD\n",
      "49\n",
      "REVIEWS AND\n",
      "PERSPECTIVES\n",
      "----------\n",
      "Burr et al. \n",
      " \n",
      "7 of 45 \n",
      "INTRODUCTION \n",
      "  Ulcerative colitis (UC) is a chronic inflammatory disorder of the bowel that causes \n",
      "continuous mucosal inflammation commencing in the rectum and extending proximally for a \n",
      "variable extent.[1] It is estimated that UC affects 2.5 million people in Europe,[2] and the \n",
      "disease follows a relapsing and remitting course, with intermittent flares of disease activity, \n",
      "some of which may be moderate to severe. Management of these is medical, for the most \n",
      "part, with surgery reserved for patients with refractory disease. Although 5-aminosalicylates \n",
      "(5-ASAs) are efficacious for mild to moderate disease activity,[3-6] more severe flares are \n",
      "usually treated with corticosteroids.[7] However, these have potentially serious adverse \n",
      "effects and a substantial proportion of patients may become either dependent on them to \n",
      "maintain remission,[8] or refractory to them.[9] As a result, over the last 20 years novel \n",
      "drugs, with more precise modes of action, based on mechanisms of disease identified in \n",
      "genome wide association studies,[10] have been developed.  \n",
      "The first of these agents was infliximab, a drug targeting the pro-inflammatory \n",
      "cytokine tumour necrosis factor-α (TNF-α), which demonstrated efficacy in clinical trials in \n",
      "moderate to severe UC.[11] Since then, other drugs against TNF-α have been tested, such as \n",
      "adalimumab and golimumab.[12, 13] In addition, newer biological therapies targeting α or β \n",
      "integrins, which are involved in migration of immune cells to inflamed intestinal mucosa, \n",
      "such as vedolizumab or etrolizumab,[14, 15] or acting against other pro-inflammatory \n",
      "cytokines implicated in the pathogenesis of UC, such as ustekinumab,[16] have been tested. \n",
      "However, even these more selective drugs do not work in all patients, there may be risks \n",
      "associated with their use,[17-19] and the fact that they are administered either intravenously \n",
      "or subcutaneously, may be inconvenient for patients. The search for alternative agents for the \n",
      "treatment of UC has, therefore, continued.\n",
      "----------\n",
      "Burr et al. \n",
      " \n",
      "5 of 45 \n",
      "STUDY HIGHLIGHTS \n",
      " \n",
      "What is already known about this subject \n",
      "• Ulcerative colitis (UC) follows a relapsing and remitting course, with intermittent \n",
      "flares of disease activity, some of which may be moderate to severe. \n",
      "• These are usually treated with corticosteroids, which have potentially serious adverse \n",
      "effects, so biological therapies and small molecules have been developed and licensed \n",
      "for this indication.  \n",
      "• Although previous network meta-analyses have compared their efficacy and safety, \n",
      "this is a rapidly moving field, and there are already several newer drugs that have \n",
      "shown efficacy in phase III clinical trials that were not considered in these. \n",
      " \n",
      "What are the new findings \n",
      "• In terms of clinical remission and clinical response, upadacitinib 45mg o.d. ranked \n",
      "first in all patients, in patients previously exposed to anti-tumour necrosis factor \n",
      "(TNF)-α therapies, and in patients naïve to these drugs.  \n",
      "• In terms of endoscopic improvement infliximab 10mg/kg ranked first, followed by \n",
      "upadacitinib 45mg o.d., and infliximab 5mg/kg.  \n",
      "• However, for endoscopic improvement again upadacitinib 45mg o.d. ranked first in \n",
      "patients previously exposed to anti-TNF-α therapies, and in patients who were anti-\n",
      "TNF-α naïve.  \n",
      "• None of the drugs studied were more likely to lead to serious adverse events than \n",
      "placebo.\n",
      "----------\n",
      "Therapeutic strategies for the management of recentlydiagnosedulcerative colitis. IMMs include thiopurines and methotrexate. 5-ASA, 5-amino salicylic acid; ASUC, acute severe ulcerative colitis; IPAA, ileal pouch anal anastomosis.\n",
      "\n",
      "Risk stratification: Mild\n",
      "Clinical features: NA\n",
      "Treatment options: 5-ASA (oral and/or topical)\n",
      "\n",
      "Risk stratification: Moderate\n",
      "Clinical features: NA\n",
      "Treatment options: Can consider 5-ASA (with rapid step-up if inadequate response)\n",
      "\n",
      "Risk stratification: Moderate\n",
      "Clinical features: NA\n",
      "Treatment options: VDZ or UST\n",
      "\n",
      "Risk stratification: Moderate\n",
      "Clinical features: NA\n",
      "Treatment options: Thiopurine\n",
      "\n",
      "Risk stratification: Moderate\n",
      "Clinical features: NA\n",
      "Treatment options: TNFi +/- IMM\n",
      "\n",
      "Risk stratification: Severe\n",
      "Clinical features: NA\n",
      "Treatment options: TNFi +/- IMM\n",
      "\n",
      "Risk stratification: Severe\n",
      "Clinical features: NA\n",
      "Treatment options: Subtotal colectomy + IPAA or cyclosporine (for ASUC)\n",
      "\n",
      "Risk stratification: Additional consideration: EIM present\n",
      "Clinical features: Psoriasis or psoriatic arthritis\n",
      "Treatment options: UST\n",
      "\n",
      "Risk stratification: Additional consideration: EIM present\n",
      "Clinical features: Other arthritis\n",
      "Treatment options: TNFi\n",
      "\n",
      "\n",
      "----------\n",
      "discontinuation due to AEs, and serious infections. Phase 3 randomized controlled trials were identified via systematic literature review, in-\n",
      "cluding the following advanced therapies: infliximab, adalimumab, vedolizumab, golimumab, tofacitinib, ustekinumab, filgotinib, ozanimod, and \n",
      "upadacitinib. Random effects models were used to address between-study heterogeneity. Intent-to-treat (ITT) efficacy rates were calculated by \n",
      "adjusting maintenance outcomes by likelihood of induction response.\n",
      "Results:  Out of 48 trials identified, 23 were included. Across all outcomes and regardless of prior biologic exposure, ITT efficacy rates were \n",
      "highest for upadacitinib, owing to its highest ranking for all efficacy outcomes in induction and for all but clinical remission during maintenance \n",
      "among bio-naive induction responders. For all advanced therapies versus placebo, there were no significant differences in serious AEs or \n",
      "serious infections across therapies. For all AEs, golimumab had higher odds versus placebo during maintenance; for discontinuation due to \n",
      "AEs, upadacitinib had lower odds versus placebo during induction, while ustekinumab and vedolizumab had lower odds versus placebo during \n",
      "maintenance.\n",
      "Conclusions:  Upadacitinib may be the most efficacious therapy for moderately to severely active UC based on ITT analyses, with similar safety \n",
      "across advanced therapies.\n",
      "Lay Summary \n",
      "Indirect evidence suggests upadacitinib may be more efficacious than other advanced therapies at achieving clinical response, clinical remis-\n",
      "sion, and endoscopic response over 1 year for moderately to severely active ulcerative colitis patients, with similar safety assessments across \n",
      "advanced therapies.\n",
      "Key Words: ulcerative colitis, clinical trials, advanced therapies, network meta-analysis\n",
      "Introduction\n",
      "Ulcerative colitis (UC) is a chronic inflammatory bowel dis-\n",
      "ease that affects the colorectum and is clinically characterized \n",
      "by bloody diarrhea, urgency, tenesmus, abdominal pain, ma-\n",
      "laise, weight loss, and fever. Disease onset commonly occurs \n",
      "between the ages of 15 and 30 years and the annual global \n",
      "© The Author(s) 2023. Published by Oxford University Press on behalf of Crohn's & Colitis Foundation.\n",
      "This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), \n",
      "which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.\n",
      "----------\n",
      "Burr et al. \n",
      " \n",
      "27 of 45 \n",
      "DISCUSSION \n",
      "We conducted a contemporaneous systematic review and network meta-analysis of \n",
      "biological therapies and small molecules for moderate to severely active UC. This has \n",
      "incorporated data from 28 RCTs and over 12,500 patients. Overall, in terms of clinical \n",
      "remission and clinical response at 6 to 14 weeks, upadacitinib 45mg o.d. ranked first in all \n",
      "patients, in patients previously exposed to anti-TNF-α therapies, and in patients naïve to these \n",
      "drugs. In terms of endoscopic improvement infliximab 10mg/kg ranked first, followed by \n",
      "upadacitinib 45mg o.d., and infliximab 5mg/kg. However, again upadacitinib 45mg o.d. \n",
      "ranked first in patients previously exposed to anti-TNF-α therapies, and in patients who were \n",
      "anti-TNF-α naïve. In terms of safety, upadacitinib 45mg o.d. ranked last for total number of \n",
      "adverse events, and ustekinumab 130mg first. However, none of the drugs studied were more \n",
      "likely to lead to serious adverse events than placebo, although etrolizumab 105mg was more \n",
      "likely to lead to serious adverse events than golimumab 200/100mg, ustekinumab 6mg/kg, \n",
      "vedolizumab 300mg, and infliximab 5mg/kg. Vedolizumab 300mg was the least likely drug \n",
      "to lead to infections. Infections were significantly more likely with tofacitinib 10mg b.i.d. \n",
      "than with either placebo or vedolizumab 300mg. Finally, withdrawals due to adverse events \n",
      "were significantly less likely with upadacitinib 45mg o.d. than with placebo. Upadacitinib \n",
      "45mg o.d. was significantly less likely to lead to withdrawals due to an adverse event than \n",
      "infliximab 5mg/kg and 10mg/kg, vedolizumab 300mg, adalimumab 160/80mg or 80/40mg, \n",
      "filgotinib 200mg o.d., and etrolizumab 105mg. Applying GRADE criteria to our estimates of \n",
      "effects, certainty in the quality of evidence would be high.  \n",
      "There are some limitations. Only nine of 27 trials were at low risk of bias across all \n",
      "domains. Given the timespan of included studies, there is the possibility that trials of newer \n",
      "drugs included patients with refractory UC who had failed multiple other therapies. However, \n",
      "some of these more recent trials only recruited patients who were naïve to anti-TNF-α\n",
      "----------\n",
      "41 years (interquartile range, 40–42 y), and 60%\n",
      "(interquartile range, 56%–63%) were men. The median\n",
      "disease duration was 6.7 years (interquartile range,\n",
      "6.0–7.8 y), and 49% (interquartile range, 46%–55%) of\n",
      "patients had extensive colitis. A median of 40% (inter-\n",
      "quartile range, 30%–50%) of patients were treated with\n",
      "concomitant immunomodulators, and 51% (interquartile\n",
      "range, 45%–57%) were on corticosteroids at baseline.\n",
      "Patients across all trials and treatment arms were com-\n",
      "parable in terms of baseline prognostic variables, inclu-\n",
      "sion/exclusion\n",
      "criteria,\n",
      "and\n",
      "co-interventions.\n",
      "All\n",
      "outcomes were assessed uniformly based on the stan-\n",
      "dard deﬁnition of the Mayo Clinic score, between weeks\n",
      "6 and 10 for induction therapy (inﬂiximab, adalimumab,\n",
      "tofacitinib, ustekinumab, 8 weeks; golimumab, 6 weeks;\n",
      "vedolizumab, 6 weeks, 10 weeks, and 14 weeks in\n",
      "VARSITY),6 and weeks 30, 54, or 60 for maintenance\n",
      "therapy;\n",
      "endoscopy\n",
      "was\n",
      "read\n",
      "by\n",
      "blinded\n",
      "local\n",
      "Table 2. Comparative Efﬁcacy of Pharmacologic Agents for Induction of Clinical Remission and Endoscopic Improvement in Biologic-Naive Patients With Moderate–Severe\n",
      "Ulcerative Colitis Using Network Meta-Analysis\n",
      "Induction of clinical remission\n",
      "Induction of endoscopic improvement\n",
      "Ustekinumab 6 mg/kg\n",
      "0.96 (0.38–2.45)\n",
      "0.80 (0.35–1.83)\n",
      "0.73 (0.31–1.74)\n",
      "1.05 (0.48–2.32)\n",
      "0.50 (0.22–1.12)\n",
      "2.04 (1.03–4.05)\n",
      "0.92 (0.45–1.89)\n",
      "Tofacitinib 10 mg b.d.\n",
      "0.84 (0.39–1.82)\n",
      "0.76 (0.33–1.76)\n",
      "1.10 (0.51–2.34)\n",
      "0.52 (0.24–1.12)\n",
      "2.12 (1.12–4.02)\n",
      "0.74 (0.36–1.51)\n",
      "0.80 (0.4–1.62)\n",
      "Vedolizumab\n",
      "0.91 (0.44–1.86)\n",
      "1.31 (0.88–1.95)\n",
      "0.62 (0.34–1.15)\n",
      "2.54 (1.60–4.02)\n",
      "1.07 (0.58–1.98)\n",
      "1.17 (0.64–2.12)\n",
      "1.45 (0.80–2.61)\n",
      "Golimumab\n",
      "1.44 (0.76–2.75)\n",
      "0.69 (0.35–1.36)\n",
      "2.79 (1.64–4.02)\n",
      "1.17 (0.65–2.13)\n",
      "1.28 (0.72–2.29)\n",
      "1.59 (0.90–2.82)\n",
      "1.10 (0.71–1.71)\n",
      "Adalimumab\n",
      "0.48 (0.26–0.86)\n",
      "1.94 (1.30–2.88)\n",
      "0.56 (0.30–1.04)\n",
      "0.61 (0.34–1.11)\n",
      "0.76 (0.42–1.37)\n",
      "0.52 (0.33–0.83)\n",
      "0.48 (0.31–0.74)\n",
      "Inﬂiximab\n",
      "4.07 (2.67–6.21)\n",
      "1.86 (1.11–3.13)\n",
      "2.03 (1.23–3.34)\n",
      "2.52 (1.54–4.11)\n",
      "1.74 (1.25–2.41)\n",
      "1.58 (1.18–2.13)\n",
      "3.32 (2.39–4.60)\n",
      "Placebo\n",
      "NOTE. Comparisons should be read from left to right. Odds ratio for comparisons are in the cell in common between the column-deﬁning and row-deﬁning treatment. Numbers in bold are statistically signiﬁcant. For induction of\n",
      "clinical remission, an odds ratio greater than 1 favors row-deﬁning treatment. For induction of endoscopic improvement, an odds ratio greater than 1 favors column-deﬁning treatment. Numbers in parentheses indicate 95% CI.\n",
      "b.d., twice daily.\n",
      "----------\n",
      "associated with improved long-term outcomes.33 Data on\n",
      "the impact of early therapy in UC are more limited, but, as\n",
      "UC is also a progressive disease with risk of colorectal\n",
      "cancer, surgery, and loss of colonic function, it is reasonable\n",
      "to treat early to mitigate these risks.\n",
      "How to Diagnose Inﬂammatory Bowel Disease\n",
      "Early\n",
      "IBD is heterogenous with wide variation in presentation.\n",
      "Disease activity at presentation can range from mild to severe\n",
      "and, as discussed, symptoms may be mild to none. These can\n",
      "make the IBD diagnosis challenging, especially at a primary\n",
      "care level. Danese et al34 have proposed a Red Flags Index\n",
      "consisting of a 21-item questionnaire to help providers triage\n",
      "and identify patients with concerning symptoms in a timely\n",
      "manner and refer to specialists appropriately. A useful adjunct\n",
      "to symptom-based criteria is fecal calprotectin (FC), a stool\n",
      "marker of inﬂammation; in a large meta-analysis, FC � 40 mg/\n",
      "g carried a �1% probability of IBD, effectively excluding the\n",
      "diagnosis of IBD.35 Similarly, in the Red Flags Index validation\n",
      "study, combining the index with FC (Red Flags Index �8 and/\n",
      "or FC >250 mg/g) increased the positive predictive value from\n",
      "4% to 21% and negative predictive value from 97% to\n",
      "100%.36 Diagnostic criteria for IBD involve a composite of\n",
      "clinical symptoms, endoscopic, biomarker, and cross-sectional\n",
      "imaging features, which are beyond the scope of this review.\n",
      "We refer readers to the excellent guidelines laid out by the\n",
      "American College of Gastroenterology, European Crohn’s and\n",
      "Colitis\n",
      "Organization,\n",
      "and\n",
      "British\n",
      "Society\n",
      "of\n",
      "Gastro-\n",
      "enterology.37–40\n",
      "Risk Stratiﬁcation and Prognostication\n",
      "at Diagnosis\n",
      "Appropriately\n",
      "risk-stratifying\n",
      "prognosis\n",
      "in\n",
      "patients\n",
      "recently diagnosed with IBD is essential to inform selection\n",
      "of the most appropriate treatment and monitoring strate-\n",
      "gies. CD and UC phenotype and disease activity at initial\n",
      "presentation can vary widely from limited and mild to\n",
      "extensive and complicated. Certain baseline clinical features\n",
      "are associated with a more aggressive disease course with\n",
      "higher risk of progression and complications. In higher-risk\n",
      "patients, early control of inﬂammation with immune-\n",
      "modifying therapies is critical. However, immunosuppres-\n",
      "sive therapies are associated with safety concerns in the\n",
      "short- and long-term, and entail signiﬁcant health care costs.\n",
      "Therefore, a consideration of risks, beneﬁts, and alternatives\n",
      "is key to develop an individualized therapeutic plan for the\n",
      "informed patient.\n",
      "----------\n",
      "severely active ulcerative colitis: results from phase 3 \n",
      "U-ACCOMPLISH study. J Crohn’s Colitis 2021; 15 (suppl 1): S021–22.\n",
      "9 \n",
      "Thorlund K, Druyts E, Mills EJ, Fedorak RN, Marshall JK. \n",
      "Adalimumab versus infliximab for the treatment of moderate to \n",
      "severe ulcerative colitis in adult patients naïve to anti-TNF therapy: \n",
      "an indirect treatment comparison meta-analysis. J Crohn’s Colitis \n",
      "2014; 8: 571–81.\n",
      "10 \n",
      "Danese S, Fiorino G, Peyrin-Biroulet L, et al. Biological agents for \n",
      "moderately to severely active ulcerative colitis: a systematic review \n",
      "and network meta-analysis. Ann Intern Med 2014; 160: 704–11.\n",
      "11 \n",
      "Singh S, Fumery M, Sandborn WJ, Murad MH. Systematic review \n",
      "with network meta-analysis: first- and second-line pharmacotherapy \n",
      "for moderate-severe ulcerative colitis. Aliment Pharmacol Ther 2018; \n",
      "47: 162–75.\n",
      "12 \n",
      "Bonovas S, Lytras T, Nikolopoulos G, Peyrin-Biroulet L, Danese S. \n",
      "Systematic review with network meta-analysis: comparative \n",
      "assessment of tofacitinib and biological therapies for moderate-to-\n",
      "severe ulcerative colitis. Aliment Pharmacol Ther 2018; 47: 454–65.\n",
      "13 \n",
      "Singh S, Murad MH, Fumery M, Dulai PS, Sandborn WJ. First- and \n",
      "second-line pharmacotherapies for patients with moderate to \n",
      "severely active ulcerative colitis: an updated network meta-analysis. \n",
      "Clin Gastroenterol Hepatol 2020; 18: 2179–91.e6.\n",
      "14 \n",
      "Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting \n",
      "items for systematic reviews and meta-analyses: the PRISMA \n",
      "statement. Ann Intern Med 2009; 151: 264–69.\n",
      "15 \n",
      "Jansen JP, Fleurence R, Devine B, et al. Interpreting indirect \n",
      "treatment comparisons and network meta-analysis for health-care \n",
      "decision making: report of the ISPOR Task Force on Indirect \n",
      "Treatment Comparisons Good Research Practices: part 1. \n",
      "Value Health 2011; 14: 417–28.\n",
      "16 \n",
      "Sterne JAC, Savović J, Page MJ, et al. RoB 2: a revised tool for \n",
      "assessing risk of bias in randomised trials. BMJ 2019; 366: l4898.\n",
      "17 \n",
      "Rücker G, Schwarzer G. Ranking treatments in frequentist network \n",
      "meta-analysis works without resampling methods. \n",
      "BMC Med Res Methodol 2015; 15: 58.\n",
      "----------\n",
      "2\n",
      "Efficacy and Safety of Advanced Therapies\n",
      "incidence ranges from 9 to 20 cases per 100 000 per year with \n",
      "higher incidence in North America and Northern Europe.1\n",
      "The advanced therapeutic armamentarium for adults \n",
      "with moderately to severely active UC is rapidly evolving. \n",
      "For over 20 years, biologics targeting specific inflamma-\n",
      "tory pathways have been the mainstay, beginning with those \n",
      "targeting tumor necrosis alpha (TNFi; eg, infliximab [INF], \n",
      "adalimumab [ADA], and golimumab [GOL]) followed by \n",
      "biologics with other modes of action (eg, vedolizumab [VED] \n",
      "and ustekinumab [UST]). However, treatment limitations for \n",
      "moderately to severely active UC remain, including primary \n",
      "nonresponse, secondary loss of response, immunogenicity, and \n",
      "parenteral administration.2 To overcome these limitations, \n",
      "there has been increasing interest in small molecule drugs \n",
      "(SMDs), which can be orally administered and lack immu-\n",
      "nogenicity.3 Of particular interest are SMDs that inhibit the \n",
      "Janus kinase (JAK)-mediated inflammatory pathway, of which \n",
      "tofacitinib (TOF), filgotinib (FIL), and upadacitinib (UPA) are \n",
      "currently approved for use in adults with moderately to se-\n",
      "verely active UC who have had an inadequate response or in-\n",
      "tolerance to conventional therapy and/or TNFi’s.4–7 All orally \n",
      "administered, TOF, FIL, and UPA are distinguished by their \n",
      "JAK selectivity: TOF is a pan-JAK inhibitor while FIL and \n",
      "UPA are approximately 30- and 60-fold selective for JAK1 \n",
      "over JAK2, respectively.8,9 In human cellular assays, UPA pref-\n",
      "erentially inhibits signaling by JAK1 or JAK1/3 with func-\n",
      "tional selectivity over cytokine receptors that signal via pairs \n",
      "of JAK2.5 In addition, ozanimod (OZA), a SMD that selec-\n",
      "tively modulates the sphingosine-1-phosphase receptor (S1P), \n",
      "is also approved for use in UC.10\n",
      "With this rapid innovation, much attention has been paid \n",
      "toward establishing the comparative efficacy and safety of \n",
      "biologics and SMDs that are approved or in late stages of \n",
      "development for moderately to severely active UC. Most \n",
      "recently, Lasa et al11 and Burr et al12 each conducted and \n",
      "published a systematic literature review (SLR) and frequentist \n",
      "network meta-analysis (NMA) on the efficacy and safety of \n",
      "biologics and SMDs for patients with moderately to severely \n",
      "UC. Both studies assessed all outcomes after induction (6–14 \n",
      "weeks); Lasa et al11 additionally assessed efficacy after main-\n",
      "tenance (26–66 weeks) separately for treat-through (TT) and\n",
      "==========\n",
      "ORIGINAL QUESTION: ANALYSE the given patient profile based on given query based on one of the following criteria:\n",
      "- Whether treated patient is new patient or patient under maintenance\n",
      "- Prior response to Infliximab\n",
      "- Prior failure to Anti-TNF agents\n",
      "- Prior failure to Vedolizumab\n",
      "- Age\n",
      "- Pregnancy\n",
      "- Extraintestinale manifestations\n",
      "- Pouchitis\n",
      "RETURN up to 2 TOP choices of biological drugs given patient profile and context. Explain the PROS and CONS of the 2 choices.\n",
      "PATIENT PROFILE: 70 year old female with newly diagnosed severe UC\n",
      "\n",
      "==========\n",
      "CURRENT ANSWER:\n",
      "Based on the patient's profile, the top two choices of biological drugs would be Infliximab and Vedolizumab.\n",
      "\n",
      "1. Infliximab:\n",
      "   - Advantages: Infliximab has been shown to be effective in inducing and maintaining remission in patients with moderate to severe UC. It is also beneficial for patients with extraintestinal manifestations of UC. Infliximab has been shown to have a high ranking for endoscopic improvement, which is crucial in managing severe UC.\n",
      "   - Disadvantages: Infliximab is administered intravenously, which may be inconvenient for some patients. There is also a risk of developing antibodies against Infliximab, which can reduce its effectiveness over time. Infliximab can also have side effects such as increased risk of infections.\n",
      "\n",
      "2. Vedolizumab:\n",
      "   - Advantages: Vedolizumab is a gut-selective immunosuppressant, meaning it specifically targets inflammation in the gut, potentially reducing systemic side effects. It has been shown to be effective in inducing and maintaining remission in patients with moderate to severe UC. Vedolizumab has also been associated with lower odds of adverse events leading to discontinuation during maintenance therapy.\n",
      "   - Disadvantages: Vedolizumab is also administered intravenously, which may be inconvenient for some patients. It may take longer to see the effects of Vedolizumab compared to other treatments.\n",
      "\n",
      "Please note that the choice of treatment should be individualized based on the patient's overall health, comorbidities, and preferences. The patient's age should also be taken into consideration when choosing a treatment, as elderly patients may have a higher risk of adverse events from immunosuppressive therapy.\n",
      "==========\n",
      "REFINED ANSWER:\n",
      "\u001b[0m\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "Retrying langchain.chat_models.openai.ChatOpenAI.completion_with_retry.<locals>._completion_with_retry in 4.0 seconds as it raised RateLimitError: Rate limit reached for 10KTPM-200RPM in organization org-ETbTMTN2JXYOUPDJgxuH2iO6 on tokens per min. Limit: 10000 / min. Please try again in 6ms. Contact us through our help center at help.openai.com if you continue to have issues..\n",
      "Retrying langchain.chat_models.openai.ChatOpenAI.completion_with_retry.<locals>._completion_with_retry in 4.0 seconds as it raised RateLimitError: Rate limit reached for 10KTPM-200RPM in organization org-ETbTMTN2JXYOUPDJgxuH2iO6 on tokens per min. Limit: 10000 / min. Please try again in 6ms. Contact us through our help center at help.openai.com if you continue to have issues..\n",
      "Retrying langchain.chat_models.openai.ChatOpenAI.completion_with_retry.<locals>._completion_with_retry in 4.0 seconds as it raised RateLimitError: Rate limit reached for 10KTPM-200RPM in organization org-ETbTMTN2JXYOUPDJgxuH2iO6 on tokens per min. Limit: 10000 / min. Please try again in 6ms. Contact us through our help center at help.openai.com if you continue to have issues..\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\n",
      "\u001b[1m> Finished chain.\u001b[0m\n",
      "\n",
      "\u001b[1m> Finished chain.\u001b[0m\n",
      "2023-10-02 17:14:37,403:INFO: 5593 tokens were added to prompt from 10 documents\n",
      "Query: 35 year old male with known moderate UC with prior exposure to infliximab but has worsening colitis on endoscopy despite compliance\n",
      "\n",
      "\n",
      "\n",
      "\u001b[1m> Entering new SequentialChain chain...\u001b[0m\n",
      "\n",
      "\n",
      "\u001b[1m> Entering new RetrievalQAWithSourcesChain chain...\u001b[0m\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "Retrying langchain.chat_models.openai.ChatOpenAI.completion_with_retry.<locals>._completion_with_retry in 4.0 seconds as it raised RateLimitError: Rate limit reached for 10KTPM-200RPM in organization org-ETbTMTN2JXYOUPDJgxuH2iO6 on tokens per min. Limit: 10000 / min. Please try again in 6ms. Contact us through our help center at help.openai.com if you continue to have issues..\n",
      "Retrying langchain.chat_models.openai.ChatOpenAI.completion_with_retry.<locals>._completion_with_retry in 4.0 seconds as it raised RateLimitError: Rate limit reached for 10KTPM-200RPM in organization org-ETbTMTN2JXYOUPDJgxuH2iO6 on tokens per min. Limit: 10000 / min. Please try again in 6ms. Contact us through our help center at help.openai.com if you continue to have issues..\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\n",
      "\u001b[1m> Finished chain.\u001b[0m\n",
      "\n",
      "\n",
      "\u001b[1m> Entering new LLMChain chain...\u001b[0m\n",
      "Prompt after formatting:\n",
      "\u001b[32;1m\u001b[1;3mYou are a senior physician giving advice on treatment for moderate to severe ulcerative colitis (UC).\n",
      "Make reference to the CONTEXT given to assess the scenario.\n",
      "==========\n",
      "TASK: Your task is to analyse critically the CURRENT ANSWER given the CONTEXT.\n",
      "Then refine the existing answer (only if needed) based on the following instructions:\n",
      "- If no refinement needed, return the original answer in the correct output format.\n",
      "- If the answer cannot be inferred from CONTEXT, return \"NO ANSWER\".\n",
      "- The final output should be a list of up to 2 choices of biological drugs given patient profile and context and PROS/CONS for each recommendations.\n",
      "==========\n",
      "CONTEXT:\n",
      "Burr et al. \n",
      " \n",
      "5 of 45 \n",
      "STUDY HIGHLIGHTS \n",
      " \n",
      "What is already known about this subject \n",
      "• Ulcerative colitis (UC) follows a relapsing and remitting course, with intermittent \n",
      "flares of disease activity, some of which may be moderate to severe. \n",
      "• These are usually treated with corticosteroids, which have potentially serious adverse \n",
      "effects, so biological therapies and small molecules have been developed and licensed \n",
      "for this indication.  \n",
      "• Although previous network meta-analyses have compared their efficacy and safety, \n",
      "this is a rapidly moving field, and there are already several newer drugs that have \n",
      "shown efficacy in phase III clinical trials that were not considered in these. \n",
      " \n",
      "What are the new findings \n",
      "• In terms of clinical remission and clinical response, upadacitinib 45mg o.d. ranked \n",
      "first in all patients, in patients previously exposed to anti-tumour necrosis factor \n",
      "(TNF)-α therapies, and in patients naïve to these drugs.  \n",
      "• In terms of endoscopic improvement infliximab 10mg/kg ranked first, followed by \n",
      "upadacitinib 45mg o.d., and infliximab 5mg/kg.  \n",
      "• However, for endoscopic improvement again upadacitinib 45mg o.d. ranked first in \n",
      "patients previously exposed to anti-TNF-α therapies, and in patients who were anti-\n",
      "TNF-α naïve.  \n",
      "• None of the drugs studied were more likely to lead to serious adverse events than \n",
      "placebo.\n",
      "----------\n",
      "Burr et al. \n",
      " \n",
      "7 of 45 \n",
      "INTRODUCTION \n",
      "  Ulcerative colitis (UC) is a chronic inflammatory disorder of the bowel that causes \n",
      "continuous mucosal inflammation commencing in the rectum and extending proximally for a \n",
      "variable extent.[1] It is estimated that UC affects 2.5 million people in Europe,[2] and the \n",
      "disease follows a relapsing and remitting course, with intermittent flares of disease activity, \n",
      "some of which may be moderate to severe. Management of these is medical, for the most \n",
      "part, with surgery reserved for patients with refractory disease. Although 5-aminosalicylates \n",
      "(5-ASAs) are efficacious for mild to moderate disease activity,[3-6] more severe flares are \n",
      "usually treated with corticosteroids.[7] However, these have potentially serious adverse \n",
      "effects and a substantial proportion of patients may become either dependent on them to \n",
      "maintain remission,[8] or refractory to them.[9] As a result, over the last 20 years novel \n",
      "drugs, with more precise modes of action, based on mechanisms of disease identified in \n",
      "genome wide association studies,[10] have been developed.  \n",
      "The first of these agents was infliximab, a drug targeting the pro-inflammatory \n",
      "cytokine tumour necrosis factor-α (TNF-α), which demonstrated efficacy in clinical trials in \n",
      "moderate to severe UC.[11] Since then, other drugs against TNF-α have been tested, such as \n",
      "adalimumab and golimumab.[12, 13] In addition, newer biological therapies targeting α or β \n",
      "integrins, which are involved in migration of immune cells to inflamed intestinal mucosa, \n",
      "such as vedolizumab or etrolizumab,[14, 15] or acting against other pro-inflammatory \n",
      "cytokines implicated in the pathogenesis of UC, such as ustekinumab,[16] have been tested. \n",
      "However, even these more selective drugs do not work in all patients, there may be risks \n",
      "associated with their use,[17-19] and the fact that they are administered either intravenously \n",
      "or subcutaneously, may be inconvenient for patients. The search for alternative agents for the \n",
      "treatment of UC has, therefore, continued.\n",
      "----------\n",
      "discontinuation due to AEs, and serious infections. Phase 3 randomized controlled trials were identified via systematic literature review, in-\n",
      "cluding the following advanced therapies: infliximab, adalimumab, vedolizumab, golimumab, tofacitinib, ustekinumab, filgotinib, ozanimod, and \n",
      "upadacitinib. Random effects models were used to address between-study heterogeneity. Intent-to-treat (ITT) efficacy rates were calculated by \n",
      "adjusting maintenance outcomes by likelihood of induction response.\n",
      "Results:  Out of 48 trials identified, 23 were included. Across all outcomes and regardless of prior biologic exposure, ITT efficacy rates were \n",
      "highest for upadacitinib, owing to its highest ranking for all efficacy outcomes in induction and for all but clinical remission during maintenance \n",
      "among bio-naive induction responders. For all advanced therapies versus placebo, there were no significant differences in serious AEs or \n",
      "serious infections across therapies. For all AEs, golimumab had higher odds versus placebo during maintenance; for discontinuation due to \n",
      "AEs, upadacitinib had lower odds versus placebo during induction, while ustekinumab and vedolizumab had lower odds versus placebo during \n",
      "maintenance.\n",
      "Conclusions:  Upadacitinib may be the most efficacious therapy for moderately to severely active UC based on ITT analyses, with similar safety \n",
      "across advanced therapies.\n",
      "Lay Summary \n",
      "Indirect evidence suggests upadacitinib may be more efficacious than other advanced therapies at achieving clinical response, clinical remis-\n",
      "sion, and endoscopic response over 1 year for moderately to severely active ulcerative colitis patients, with similar safety assessments across \n",
      "advanced therapies.\n",
      "Key Words: ulcerative colitis, clinical trials, advanced therapies, network meta-analysis\n",
      "Introduction\n",
      "Ulcerative colitis (UC) is a chronic inflammatory bowel dis-\n",
      "ease that affects the colorectum and is clinically characterized \n",
      "by bloody diarrhea, urgency, tenesmus, abdominal pain, ma-\n",
      "laise, weight loss, and fever. Disease onset commonly occurs \n",
      "between the ages of 15 and 30 years and the annual global \n",
      "© The Author(s) 2023. Published by Oxford University Press on behalf of Crohn's & Colitis Foundation.\n",
      "This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), \n",
      "which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.\n",
      "----------\n",
      "What You Need to Know\n",
      "Background\n",
      "A systematic review and network meta-analysis is\n",
      "needed to compare efﬁcacy and safety of ﬁrst-line\n",
      "(biologic-naïve) and second-line (prior exposure to\n",
      "tumor necrosis factor [TNF] antagonists) agents for\n",
      "treatment of moderate to severely active ulcerative\n",
      "colitis.\n",
      "Findings\n",
      "Inﬂiximab was ranked highest in biologic-naïve pa-\n",
      "tients, and ustekinumab and tofacitinib were ranked\n",
      "highest in patients with prior exposure to TNF an-\n",
      "tagonists, for induction of remission and endoscopic\n",
      "improvement. More trials of direct comparisons are\n",
      "needed to inform clinical decision-making with\n",
      "greater conﬁdence.\n",
      "Implications for patient care\n",
      "Patients with moderate to severely active ulcerative\n",
      "colitis should receive inﬂiximab or vedolizumab as\n",
      "ﬁrst-line therapy, or ustekinumab or tofacitinib if\n",
      "they have prior exposure to TNF antagonists.\n",
      "2180 Singh et al\n",
      "Clinical Gastroenterology and Hepatology Vol. 18, No. 10\n",
      "----------\n",
      "41 years (interquartile range, 40–42 y), and 60%\n",
      "(interquartile range, 56%–63%) were men. The median\n",
      "disease duration was 6.7 years (interquartile range,\n",
      "6.0–7.8 y), and 49% (interquartile range, 46%–55%) of\n",
      "patients had extensive colitis. A median of 40% (inter-\n",
      "quartile range, 30%–50%) of patients were treated with\n",
      "concomitant immunomodulators, and 51% (interquartile\n",
      "range, 45%–57%) were on corticosteroids at baseline.\n",
      "Patients across all trials and treatment arms were com-\n",
      "parable in terms of baseline prognostic variables, inclu-\n",
      "sion/exclusion\n",
      "criteria,\n",
      "and\n",
      "co-interventions.\n",
      "All\n",
      "outcomes were assessed uniformly based on the stan-\n",
      "dard deﬁnition of the Mayo Clinic score, between weeks\n",
      "6 and 10 for induction therapy (inﬂiximab, adalimumab,\n",
      "tofacitinib, ustekinumab, 8 weeks; golimumab, 6 weeks;\n",
      "vedolizumab, 6 weeks, 10 weeks, and 14 weeks in\n",
      "VARSITY),6 and weeks 30, 54, or 60 for maintenance\n",
      "therapy;\n",
      "endoscopy\n",
      "was\n",
      "read\n",
      "by\n",
      "blinded\n",
      "local\n",
      "Table 2. Comparative Efﬁcacy of Pharmacologic Agents for Induction of Clinical Remission and Endoscopic Improvement in Biologic-Naive Patients With Moderate–Severe\n",
      "Ulcerative Colitis Using Network Meta-Analysis\n",
      "Induction of clinical remission\n",
      "Induction of endoscopic improvement\n",
      "Ustekinumab 6 mg/kg\n",
      "0.96 (0.38–2.45)\n",
      "0.80 (0.35–1.83)\n",
      "0.73 (0.31–1.74)\n",
      "1.05 (0.48–2.32)\n",
      "0.50 (0.22–1.12)\n",
      "2.04 (1.03–4.05)\n",
      "0.92 (0.45–1.89)\n",
      "Tofacitinib 10 mg b.d.\n",
      "0.84 (0.39–1.82)\n",
      "0.76 (0.33–1.76)\n",
      "1.10 (0.51–2.34)\n",
      "0.52 (0.24–1.12)\n",
      "2.12 (1.12–4.02)\n",
      "0.74 (0.36–1.51)\n",
      "0.80 (0.4–1.62)\n",
      "Vedolizumab\n",
      "0.91 (0.44–1.86)\n",
      "1.31 (0.88–1.95)\n",
      "0.62 (0.34–1.15)\n",
      "2.54 (1.60–4.02)\n",
      "1.07 (0.58–1.98)\n",
      "1.17 (0.64–2.12)\n",
      "1.45 (0.80–2.61)\n",
      "Golimumab\n",
      "1.44 (0.76–2.75)\n",
      "0.69 (0.35–1.36)\n",
      "2.79 (1.64–4.02)\n",
      "1.17 (0.65–2.13)\n",
      "1.28 (0.72–2.29)\n",
      "1.59 (0.90–2.82)\n",
      "1.10 (0.71–1.71)\n",
      "Adalimumab\n",
      "0.48 (0.26–0.86)\n",
      "1.94 (1.30–2.88)\n",
      "0.56 (0.30–1.04)\n",
      "0.61 (0.34–1.11)\n",
      "0.76 (0.42–1.37)\n",
      "0.52 (0.33–0.83)\n",
      "0.48 (0.31–0.74)\n",
      "Inﬂiximab\n",
      "4.07 (2.67–6.21)\n",
      "1.86 (1.11–3.13)\n",
      "2.03 (1.23–3.34)\n",
      "2.52 (1.54–4.11)\n",
      "1.74 (1.25–2.41)\n",
      "1.58 (1.18–2.13)\n",
      "3.32 (2.39–4.60)\n",
      "Placebo\n",
      "NOTE. Comparisons should be read from left to right. Odds ratio for comparisons are in the cell in common between the column-deﬁning and row-deﬁning treatment. Numbers in bold are statistically signiﬁcant. For induction of\n",
      "clinical remission, an odds ratio greater than 1 favors row-deﬁning treatment. For induction of endoscopic improvement, an odds ratio greater than 1 favors column-deﬁning treatment. Numbers in parentheses indicate 95% CI.\n",
      "b.d., twice daily.\n",
      "----------\n",
      "severely active ulcerative colitis: results from phase 3 \n",
      "U-ACCOMPLISH study. J Crohn’s Colitis 2021; 15 (suppl 1): S021–22.\n",
      "9 \n",
      "Thorlund K, Druyts E, Mills EJ, Fedorak RN, Marshall JK. \n",
      "Adalimumab versus infliximab for the treatment of moderate to \n",
      "severe ulcerative colitis in adult patients naïve to anti-TNF therapy: \n",
      "an indirect treatment comparison meta-analysis. J Crohn’s Colitis \n",
      "2014; 8: 571–81.\n",
      "10 \n",
      "Danese S, Fiorino G, Peyrin-Biroulet L, et al. Biological agents for \n",
      "moderately to severely active ulcerative colitis: a systematic review \n",
      "and network meta-analysis. Ann Intern Med 2014; 160: 704–11.\n",
      "11 \n",
      "Singh S, Fumery M, Sandborn WJ, Murad MH. Systematic review \n",
      "with network meta-analysis: first- and second-line pharmacotherapy \n",
      "for moderate-severe ulcerative colitis. Aliment Pharmacol Ther 2018; \n",
      "47: 162–75.\n",
      "12 \n",
      "Bonovas S, Lytras T, Nikolopoulos G, Peyrin-Biroulet L, Danese S. \n",
      "Systematic review with network meta-analysis: comparative \n",
      "assessment of tofacitinib and biological therapies for moderate-to-\n",
      "severe ulcerative colitis. Aliment Pharmacol Ther 2018; 47: 454–65.\n",
      "13 \n",
      "Singh S, Murad MH, Fumery M, Dulai PS, Sandborn WJ. First- and \n",
      "second-line pharmacotherapies for patients with moderate to \n",
      "severely active ulcerative colitis: an updated network meta-analysis. \n",
      "Clin Gastroenterol Hepatol 2020; 18: 2179–91.e6.\n",
      "14 \n",
      "Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting \n",
      "items for systematic reviews and meta-analyses: the PRISMA \n",
      "statement. Ann Intern Med 2009; 151: 264–69.\n",
      "15 \n",
      "Jansen JP, Fleurence R, Devine B, et al. Interpreting indirect \n",
      "treatment comparisons and network meta-analysis for health-care \n",
      "decision making: report of the ISPOR Task Force on Indirect \n",
      "Treatment Comparisons Good Research Practices: part 1. \n",
      "Value Health 2011; 14: 417–28.\n",
      "16 \n",
      "Sterne JAC, Savović J, Page MJ, et al. RoB 2: a revised tool for \n",
      "assessing risk of bias in randomised trials. BMJ 2019; 366: l4898.\n",
      "17 \n",
      "Rücker G, Schwarzer G. Ranking treatments in frequentist network \n",
      "meta-analysis works without resampling methods. \n",
      "BMC Med Res Methodol 2015; 15: 58.\n",
      "----------\n",
      "disease); ozanimod as an oral alternative\n",
      "• Infliximab, preferably in combination with  \n",
      " immunomodulators (severe disease,  \n",
      " \n",
      " extraintestinal manifestations)\n",
      "• Ustekinumab (for patients with substantial \n",
      " comorbidities or  contraindications to TNF  \n",
      " antagonists)\n",
      "First-line therapy\n",
      "• TNF antagonists: infliximab or adalimumab,  \n",
      " preferably in combination with   \n",
      " \n",
      " \n",
      " immunomodulators\n",
      "• Risankizumab or ustekinumab (for patients  \n",
      " with substantial comorbidities or  \n",
      " \n",
      " \n",
      " contraindications to TNF antagonists)\n",
      "First-line therapy\n",
      "• Vedolizumab\n",
      "• Ustekinumab\n",
      "First-line therapy\n",
      "• Risankizumab or ustekinumab\n",
      "• Vedolizumab\n",
      "Moderate-to-severely active\n",
      "ulcerative colitis\n",
      "Moderate-to-severely active\n",
      "ulcerative colitis\n",
      "Moderate-to-severely active\n",
      "Crohn's disease\n",
      "Moderate-to-severely active\n",
      "Crohn's disease\n",
      "Second-line therapy\n",
      "• Upadacitinib (or tofacitinib) (for patients with  \n",
      " prior failure of infliximab)\n",
      "• Infliximab or ustekinumab (for patients with  \n",
      " prior exposure to vedolizumab)\n",
      "• Vedolizumab (moderate disease, for patients  \n",
      " who discontinued first-line biologic agent \n",
      " for intolerance)\n",
      "Second-line therapy (in patients with prior \n",
      "exposure to infliximab or adalimumab)\n",
      "• Risankizumab or ustekinumab\n",
      "• Second TNF antagonist (for patients with  \n",
      " loss of response owing to immunogenicity,  \n",
      " or  intolerance, to first TNF antagonist)\n",
      "Second-line therapy\n",
      "• Ozanimod\n",
      "• Infliximab monotherapy\n",
      "• Upadacitinib (or tofacitinib)\n",
      "Second-line therapy\n",
      "• Infliximab or adalimumab   \n",
      " monotherapy\n",
      "Risk averse\n",
      "• Prior serious infections\n",
      "• Prior malignancy\n",
      "• Older age, multiple comorbidities\n",
      "Severe disease\n",
      "• High structural damage\n",
      "• High inflammatory burden\n",
      "• Significant efect on quality of life\n",
      "Patients’ values and preferences\n",
      "(lifestyle and logistics, speed of onset, costs)\n",
      "Fig. 1 | Proposed treatment algorithm for patients with moderate-to-severe \n",
      "Crohn’s disease and moderate-to-severe ulcerative colitis. The algorithm \n",
      "integrates data on comparative effectiveness and safety of therapies in the \n",
      "context of an individual patient’s risk of disease-related and treatment-related \n",
      "complications. TNF, tumour necrosis factor. Adapted with permission from  \n",
      "ref. 10, Elsevier.\n",
      "----------\n",
      "patients with moderate–severe ulcerative colitis with\n",
      "prior exposure to TNFa antagonists (Figure 2B). With an\n",
      "estimated placebo rate of achieving clinical remission of\n",
      "3% in included trials, we estimated that 3.2%, 5.6%,\n",
      "26.9%, and 26.3% of adalimumab-, vedolizumab-, tofaci-\n",
      "tinib-, and ustekinumab-treated patients, respectively,\n",
      "would achieve induction of remission.\n",
      "Induction of endoscopic improvement. On direct meta-\n",
      "analysis, tofacitinib and ustekinumab, but not vedolizumab\n",
      "or adalimumab, were superior to placebo for induction of\n",
      "endoscopic improvement, with minimal heterogeneity\n",
      "Table 3. Comparative Efﬁcacy of Pharmacologic Agents for Induction of Clinical Remission and Endoscopic Improvement in\n",
      "Patients With Moderate–Severe Ulcerative Colitis With Prior Exposure to Tumor Necrosis Factor-a Antagonists Using\n",
      "Network Meta-Analysis\n",
      "Induction of clinical remission\n",
      "Induction of endoscopic\n",
      "improvement\n",
      "Ustekinumab 6 mg/kg\n",
      "0.97 (0.11–8.72)\n",
      "5.99 (1.13–31.76)\n",
      "10.71 (2.01–57.20)\n",
      "11.51 (2.65–49.96)\n",
      "0.77 (0.28–2.18)\n",
      "Tofacitinib 10 mg b.d.\n",
      "6.18 (1.00–38.00)\n",
      "11.05 (1.79–68.41)\n",
      "11.88 (2.32–60.89)\n",
      "2.98 (1.20–7.41)\n",
      "3.85 (1.51–9.80)\n",
      "Vedolizumab\n",
      "1.79 (0.86–3.70)\n",
      "1.92 (0.87–4.25)\n",
      "3.32 (1.29–8.58)\n",
      "4.29 (1.63–11.33)\n",
      "1.12 (0.48–2.59)\n",
      "Adalimumab\n",
      "1.07 (0.48–2.41)\n",
      "3.64 (1.78–7.46)\n",
      "4.71 (2.23–9.92)\n",
      "1.22 (0.70–2.15)\n",
      "1.10 (0.59–2.04)\n",
      "Placebo\n",
      "NOTE. Comparisons should be read from left to right. The odds ratio for comparisons are in the cell in common between the column-deﬁning and row-deﬁning\n",
      "treatment. Numbers in bold are statistically signiﬁcant. For induction of clinical remission, an odds ratio greater than 1 favors row-deﬁning treatment. For induction\n",
      "of endoscopic improvement, an odds ratio greater than 1 favors column-deﬁning treatment. Numbers in parentheses indicate 95% CI.\n",
      "b.d., twice daily.\n",
      "2186 Singh et al\n",
      "Clinical Gastroenterology and Hepatology Vol. 18, No. 10\n",
      "----------\n",
      "Burr et al. \n",
      " \n",
      "29 of 45 \n",
      "preferential janus kinase-1 inhibitor, although given filgotinib also has increased selectivity \n",
      "for janus kinase-1 this cannot be the sole reason for upadacitinib’s higher ranking. Despite \n",
      "these limitations, the results of our study are still useful for informing treatment decisions for \n",
      "patients with moderate to severely active UC and can be used in future updates of evidence-\n",
      "based management guidelines.  \n",
      "An initial network meta-analyses by Singh et al. demonstrated infliximab to be the \n",
      "most efficacious drug for patients naïve to biological therapies in terms of induction of \n",
      "clinical remission and endoscopic improvement, with vedolizumab ranked second.[22] In \n",
      "patients exposed to biological therapies tofacitinib ranked first for both clinical remission and \n",
      "endoscopic improvement. An update to this work from 2020, including data from head-to-\n",
      "head trials of vedolizumab and adalimumab, as well as phase III placebo-controlled trials of \n",
      "ustekinumab, demonstrated again that infliximab was ranked first for induction of clinical \n",
      "remission and endoscopic improvement in biologic-naïve patients, with ustekinumab and \n",
      "tofacitinib ranked highest in patients previously exposed to biologics.[23] This later network \n",
      "meta-analysis included 14 induction of remission trials, recruiting almost 5500 patients, \n",
      "although the Japanese trial of infliximab versus placebo in 208 patients reported by \n",
      "Kobayashi et al. was not included.[42] In contrast to these previous network meta-analyses, \n",
      "our results provide hope that some novel drugs, which are likely to come to market soon, are \n",
      "potentially more efficacious for moderate to severely active UC than existing licensed \n",
      "therapies. \n",
      "Our results confirm that all available drugs, other than adalimumab 160/160mg, \n",
      "adalimumab 80/40mg, and filgotinib 100mg o.d. were more efficacious than placebo for the \n",
      "treatment of moderate to severe UC, across all endpoints studied at 6 to 14 weeks. All drugs \n",
      "were safe and well-tolerated, with no significant increase in serious adverse events or adverse \n",
      "events leading to withdrawal over the rates seen in the placebo arms, although the RR of\n",
      "----------\n",
      "Articles\n",
      "www.thelancet.com/gastrohep   Vol 7   February 2022 \n",
      "163\n",
      "“safety” OR “adverse events”]. Additionally, experts in the \n",
      "field were contacted for any unpublished data.\n",
      "We included phase 3 RCTs that met the inclusion criteria: \n",
      "(1) studies including adult (≥18 years) patients with \n",
      "moderate-to-severe ulcerative colitis (defined as a Mayo \n",
      "Score of 6–12, with an endoscopic sub-score of 2–3) who \n",
      "were either biologic-naive or had previously been exposed \n",
      "to at least one biologic; (2) studies either evaluating the \n",
      "following biologics and small molecule drugs in their \n",
      "approved dose regimens, infliximab (intravenous or \n",
      "subcutaneous), adalimumab, golimumab, vedolizumab \n",
      "(intravenous or sub cutaneous), ustekinumab (intravenous \n",
      "or subcutaneous), tofacitinib, or ozanimod, or studies \n",
      "evaluating etroli zumab, upadacitinib, filgotinib, etrasimod, \n",
      "or TD-1473; (3) studies including an active comparator or \n",
      "placebo; and (4) studies assessing the following outcomes: \n",
      "clinical remission (defined as a Mayo score of ≤2, with no \n",
      "individual sub-score >1) and endoscopic improvement \n",
      "(Mayo endoscopic sub-score 0–1). We did not include \n",
      "phase 2 trials because treatment effects can be over-\n",
      "estimated or underestimated due to the intrinsically small \n",
      "sample sizes of these studies. Additionally, given the dose-\n",
      "ranging nature of phase 2 trials, many of them include \n",
      "doses that will not be further explored in phase 3 trials.\n",
      "For approved agents, only approved doses were \n",
      "included in our analyses (intravenous infliximab: \n",
      "5 mg/kg in weeks 0, 2, and 6 in induction, and 5 mg/kg \n",
      "every 8 weeks in maintenance; subcutaneous infliximab: \n",
      "120 mg every 2 weeks in maintenance; subcutaneous \n",
      "adalimumab: 160 mg in week 0, 80 mg in week 2, and \n",
      "40 mg in week 4 in induction, and 40 mg every other \n",
      "week in maintenance; subcutaneous golimumab: 200 mg \n",
      "in week 0 and 100 mg in week 2 in induction, and 100 mg \n",
      "every 4 weeks in maintenance; intravenous vedolizumab: \n",
      "300 mg in weeks 0, 2, and 6 in induction, and \n",
      "300 mg every 8 weeks in maintenance; subcutaneous \n",
      "vedolizumab: 108 mg every 2 weeks in maintenance; \n",
      "ustekinumab: 6 mg/kg intravenously in week 0 in \n",
      "induction, and 90 mg subcutaneously every 8 weeks in \n",
      "maintenance; oral tofacitinib: 10 mg twice daily for \n",
      "8 weeks in induction, and 5 mg twice daily in \n",
      "maintenance; and oral ozanimod: 1 mg daily in induction \n",
      "and maintenance). For non-approved agents in a late \n",
      "stage of development (defined as the availability of results\n",
      "==========\n",
      "ORIGINAL QUESTION: ANALYSE the given patient profile based on given query based on one of the following criteria:\n",
      "- Whether treated patient is new patient or patient under maintenance\n",
      "- Prior response to Infliximab\n",
      "- Prior failure to Anti-TNF agents\n",
      "- Prior failure to Vedolizumab\n",
      "- Age\n",
      "- Pregnancy\n",
      "- Extraintestinale manifestations\n",
      "- Pouchitis\n",
      "RETURN up to 2 TOP choices of biological drugs given patient profile and context. Explain the PROS and CONS of the 2 choices.\n",
      "PATIENT PROFILE: 35 year old male with known moderate UC with prior exposure to infliximab but has worsening colitis on endoscopy despite compliance\n",
      "\n",
      "==========\n",
      "CURRENT ANSWER:\n",
      "Based on the patient's profile, the top two choices of biological drugs would be:\n",
      "\n",
      "1. Upadacitinib\n",
      "   - Advantages: Upadacitinib has shown high efficacy in patients previously exposed to anti-TNF-α therapies like infliximab. It has ranked first in terms of clinical remission and response, and endoscopic improvement in these patients. It also has a lower likelihood of leading to discontinuation due to adverse events during induction.\n",
      "   - Disadvantages: As a newer drug, long-term safety data may not be as robust as for older, more established drugs. It is also administered orally, which might be inconvenient for some patients.\n",
      "\n",
      "2. Ustekinumab\n",
      "   - Advantages: Ustekinumab has been ranked highly in patients with prior exposure to TNF antagonists for induction of remission and endoscopic improvement. It is also recommended as a second-line therapy in patients with prior exposure to infliximab.\n",
      "   - Disadvantages: It may not work as effectively in all patients and there may be risks associated with its use. It is administered either intravenously or subcutaneously, which may be inconvenient for some patients.\n",
      "\n",
      "Please note that the choice of therapy should be individualized based on the patient's specific circumstances, including disease severity, comorbidities, lifestyle, and personal preferences. It is also important to consider the potential risks and benefits of each treatment option, and to discuss these with the patient before making a decision.\n",
      "==========\n",
      "REFINED ANSWER:\n",
      "\u001b[0m\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "Retrying langchain.chat_models.openai.ChatOpenAI.completion_with_retry.<locals>._completion_with_retry in 4.0 seconds as it raised RateLimitError: Rate limit reached for 10KTPM-200RPM in organization org-ETbTMTN2JXYOUPDJgxuH2iO6 on tokens per min. Limit: 10000 / min. Please try again in 6ms. Contact us through our help center at help.openai.com if you continue to have issues..\n",
      "Retrying langchain.chat_models.openai.ChatOpenAI.completion_with_retry.<locals>._completion_with_retry in 4.0 seconds as it raised RateLimitError: Rate limit reached for 10KTPM-200RPM in organization org-ETbTMTN2JXYOUPDJgxuH2iO6 on tokens per min. Limit: 10000 / min. Please try again in 6ms. Contact us through our help center at help.openai.com if you continue to have issues..\n",
      "Retrying langchain.chat_models.openai.ChatOpenAI.completion_with_retry.<locals>._completion_with_retry in 4.0 seconds as it raised RateLimitError: Rate limit reached for 10KTPM-200RPM in organization org-ETbTMTN2JXYOUPDJgxuH2iO6 on tokens per min. Limit: 10000 / min. Please try again in 6ms. Contact us through our help center at help.openai.com if you continue to have issues..\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\n",
      "\u001b[1m> Finished chain.\u001b[0m\n",
      "\n",
      "\u001b[1m> Finished chain.\u001b[0m\n",
      "2023-10-02 17:15:46,918:INFO: 5662 tokens were added to prompt from 10 documents\n",
      "Query: 60 year old female with newly diagnosed moderate UC with a background of congestive cardiac failure\n",
      "\n",
      "\n",
      "\n",
      "\u001b[1m> Entering new SequentialChain chain...\u001b[0m\n",
      "\n",
      "\n",
      "\u001b[1m> Entering new RetrievalQAWithSourcesChain chain...\u001b[0m\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "Retrying langchain.chat_models.openai.ChatOpenAI.completion_with_retry.<locals>._completion_with_retry in 4.0 seconds as it raised RateLimitError: Rate limit reached for 10KTPM-200RPM in organization org-ETbTMTN2JXYOUPDJgxuH2iO6 on tokens per min. Limit: 10000 / min. Please try again in 6ms. Contact us through our help center at help.openai.com if you continue to have issues..\n",
      "Retrying langchain.chat_models.openai.ChatOpenAI.completion_with_retry.<locals>._completion_with_retry in 4.0 seconds as it raised RateLimitError: Rate limit reached for 10KTPM-200RPM in organization org-ETbTMTN2JXYOUPDJgxuH2iO6 on tokens per min. Limit: 10000 / min. Please try again in 6ms. Contact us through our help center at help.openai.com if you continue to have issues..\n",
      "Retrying langchain.chat_models.openai.ChatOpenAI.completion_with_retry.<locals>._completion_with_retry in 4.0 seconds as it raised RateLimitError: Rate limit reached for 10KTPM-200RPM in organization org-ETbTMTN2JXYOUPDJgxuH2iO6 on tokens per min. Limit: 10000 / min. Please try again in 6ms. Contact us through our help center at help.openai.com if you continue to have issues..\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\n",
      "\u001b[1m> Finished chain.\u001b[0m\n",
      "\n",
      "\n",
      "\u001b[1m> Entering new LLMChain chain...\u001b[0m\n",
      "Prompt after formatting:\n",
      "\u001b[32;1m\u001b[1;3mYou are a senior physician giving advice on treatment for moderate to severe ulcerative colitis (UC).\n",
      "Make reference to the CONTEXT given to assess the scenario.\n",
      "==========\n",
      "TASK: Your task is to analyse critically the CURRENT ANSWER given the CONTEXT.\n",
      "Then refine the existing answer (only if needed) based on the following instructions:\n",
      "- If no refinement needed, return the original answer in the correct output format.\n",
      "- If the answer cannot be inferred from CONTEXT, return \"NO ANSWER\".\n",
      "- The final output should be a list of up to 2 choices of biological drugs given patient profile and context and PROS/CONS for each recommendations.\n",
      "==========\n",
      "CONTEXT:\n",
      "prognosis, with 1 study reporting fewer hospitalizations and\n",
      "less frequent requirement of immunosuppression in pa-\n",
      "tients diagnosed after age 60 years,47 and a meta-analysis\n",
      "suggested\n",
      "that,\n",
      "although\n",
      "elderly\n",
      "IBD\n",
      "presents\n",
      "less\n",
      "commonly with complications, there are similar or higher\n",
      "rates of surgery compared to a nonelderly population.48 It is\n",
      "being increasingly recognized that frailty, rather than\n",
      "chronologic age, may be the driver of adverse outcomes in\n",
      "this group.49,50\n",
      "Other Demographic Variables\n",
      "There are signiﬁcant differences in IBD phenotype\n",
      "and outcomes based on race and ethnicity, likely due to\n",
      "a multitude of factors, both social and biologic. Emer-\n",
      "gency department use, hospitalization, complicated dis-\n",
      "ease\n",
      "course,\n",
      "and\n",
      "IBD-related\n",
      "disability\n",
      "are\n",
      "more\n",
      "common in minority and lower socioeconomic status\n",
      "groups.51,52 In a study of 770 patients with IBD, South\n",
      "Asian immigrants living in the United Kingdom were\n",
      "more\n",
      "likely\n",
      "to\n",
      "have\n",
      "extensive\n",
      "UC\n",
      "and\n",
      "colonic\n",
      "CD\n",
      "compared with their native counterparts,53 which might\n",
      "be related, in part, to limited access to care.54 Genes\n",
      "implicated in IBD risk also differ in non-White compared\n",
      "with White patients with IBD.55 Being aware of the\n",
      "higher vulnerability to adverse IBD-related outcomes in\n",
      "these vulnerable groups should prompt careful moni-\n",
      "toring to limit adverse outcomes.\n",
      "There are increasing data on sex-based differences in\n",
      "IBD phenotype and outcomes, which may signal differences\n",
      "in pathogenic pathways and progression. Of note, extra-\n",
      "intestinal manifestations (EIMs) consistently tend to be\n",
      "more common in female patients (CD: OR, 2.3; 95% CI, 1.9–\n",
      "2.8 and UC: OR, 1.5; 95% CI, 1.1–2.3, in a large Dutch Bio-\n",
      "Bank).56 Similarly, in a retrospective pediatric study of\n",
      "nearly 1000 patients with CD, girls were more likely to have\n",
      "EIMs and less likely to have growth impairment compared\n",
      "with boys,57 the latter is possibly related to lower insulin-\n",
      "like growth factor-1 level in boys.58\n",
      "July 2021\n",
      "Management of early IBD\n",
      "49\n",
      "REVIEWS AND\n",
      "PERSPECTIVES\n",
      "----------\n",
      "Burr et al. \n",
      " \n",
      "7 of 45 \n",
      "INTRODUCTION \n",
      "  Ulcerative colitis (UC) is a chronic inflammatory disorder of the bowel that causes \n",
      "continuous mucosal inflammation commencing in the rectum and extending proximally for a \n",
      "variable extent.[1] It is estimated that UC affects 2.5 million people in Europe,[2] and the \n",
      "disease follows a relapsing and remitting course, with intermittent flares of disease activity, \n",
      "some of which may be moderate to severe. Management of these is medical, for the most \n",
      "part, with surgery reserved for patients with refractory disease. Although 5-aminosalicylates \n",
      "(5-ASAs) are efficacious for mild to moderate disease activity,[3-6] more severe flares are \n",
      "usually treated with corticosteroids.[7] However, these have potentially serious adverse \n",
      "effects and a substantial proportion of patients may become either dependent on them to \n",
      "maintain remission,[8] or refractory to them.[9] As a result, over the last 20 years novel \n",
      "drugs, with more precise modes of action, based on mechanisms of disease identified in \n",
      "genome wide association studies,[10] have been developed.  \n",
      "The first of these agents was infliximab, a drug targeting the pro-inflammatory \n",
      "cytokine tumour necrosis factor-α (TNF-α), which demonstrated efficacy in clinical trials in \n",
      "moderate to severe UC.[11] Since then, other drugs against TNF-α have been tested, such as \n",
      "adalimumab and golimumab.[12, 13] In addition, newer biological therapies targeting α or β \n",
      "integrins, which are involved in migration of immune cells to inflamed intestinal mucosa, \n",
      "such as vedolizumab or etrolizumab,[14, 15] or acting against other pro-inflammatory \n",
      "cytokines implicated in the pathogenesis of UC, such as ustekinumab,[16] have been tested. \n",
      "However, even these more selective drugs do not work in all patients, there may be risks \n",
      "associated with their use,[17-19] and the fact that they are administered either intravenously \n",
      "or subcutaneously, may be inconvenient for patients. The search for alternative agents for the \n",
      "treatment of UC has, therefore, continued.\n",
      "----------\n",
      "41 years (interquartile range, 40–42 y), and 60%\n",
      "(interquartile range, 56%–63%) were men. The median\n",
      "disease duration was 6.7 years (interquartile range,\n",
      "6.0–7.8 y), and 49% (interquartile range, 46%–55%) of\n",
      "patients had extensive colitis. A median of 40% (inter-\n",
      "quartile range, 30%–50%) of patients were treated with\n",
      "concomitant immunomodulators, and 51% (interquartile\n",
      "range, 45%–57%) were on corticosteroids at baseline.\n",
      "Patients across all trials and treatment arms were com-\n",
      "parable in terms of baseline prognostic variables, inclu-\n",
      "sion/exclusion\n",
      "criteria,\n",
      "and\n",
      "co-interventions.\n",
      "All\n",
      "outcomes were assessed uniformly based on the stan-\n",
      "dard deﬁnition of the Mayo Clinic score, between weeks\n",
      "6 and 10 for induction therapy (inﬂiximab, adalimumab,\n",
      "tofacitinib, ustekinumab, 8 weeks; golimumab, 6 weeks;\n",
      "vedolizumab, 6 weeks, 10 weeks, and 14 weeks in\n",
      "VARSITY),6 and weeks 30, 54, or 60 for maintenance\n",
      "therapy;\n",
      "endoscopy\n",
      "was\n",
      "read\n",
      "by\n",
      "blinded\n",
      "local\n",
      "Table 2. Comparative Efﬁcacy of Pharmacologic Agents for Induction of Clinical Remission and Endoscopic Improvement in Biologic-Naive Patients With Moderate–Severe\n",
      "Ulcerative Colitis Using Network Meta-Analysis\n",
      "Induction of clinical remission\n",
      "Induction of endoscopic improvement\n",
      "Ustekinumab 6 mg/kg\n",
      "0.96 (0.38–2.45)\n",
      "0.80 (0.35–1.83)\n",
      "0.73 (0.31–1.74)\n",
      "1.05 (0.48–2.32)\n",
      "0.50 (0.22–1.12)\n",
      "2.04 (1.03–4.05)\n",
      "0.92 (0.45–1.89)\n",
      "Tofacitinib 10 mg b.d.\n",
      "0.84 (0.39–1.82)\n",
      "0.76 (0.33–1.76)\n",
      "1.10 (0.51–2.34)\n",
      "0.52 (0.24–1.12)\n",
      "2.12 (1.12–4.02)\n",
      "0.74 (0.36–1.51)\n",
      "0.80 (0.4–1.62)\n",
      "Vedolizumab\n",
      "0.91 (0.44–1.86)\n",
      "1.31 (0.88–1.95)\n",
      "0.62 (0.34–1.15)\n",
      "2.54 (1.60–4.02)\n",
      "1.07 (0.58–1.98)\n",
      "1.17 (0.64–2.12)\n",
      "1.45 (0.80–2.61)\n",
      "Golimumab\n",
      "1.44 (0.76–2.75)\n",
      "0.69 (0.35–1.36)\n",
      "2.79 (1.64–4.02)\n",
      "1.17 (0.65–2.13)\n",
      "1.28 (0.72–2.29)\n",
      "1.59 (0.90–2.82)\n",
      "1.10 (0.71–1.71)\n",
      "Adalimumab\n",
      "0.48 (0.26–0.86)\n",
      "1.94 (1.30–2.88)\n",
      "0.56 (0.30–1.04)\n",
      "0.61 (0.34–1.11)\n",
      "0.76 (0.42–1.37)\n",
      "0.52 (0.33–0.83)\n",
      "0.48 (0.31–0.74)\n",
      "Inﬂiximab\n",
      "4.07 (2.67–6.21)\n",
      "1.86 (1.11–3.13)\n",
      "2.03 (1.23–3.34)\n",
      "2.52 (1.54–4.11)\n",
      "1.74 (1.25–2.41)\n",
      "1.58 (1.18–2.13)\n",
      "3.32 (2.39–4.60)\n",
      "Placebo\n",
      "NOTE. Comparisons should be read from left to right. Odds ratio for comparisons are in the cell in common between the column-deﬁning and row-deﬁning treatment. Numbers in bold are statistically signiﬁcant. For induction of\n",
      "clinical remission, an odds ratio greater than 1 favors row-deﬁning treatment. For induction of endoscopic improvement, an odds ratio greater than 1 favors column-deﬁning treatment. Numbers in parentheses indicate 95% CI.\n",
      "b.d., twice daily.\n",
      "----------\n",
      "I(m): UST 90 mg q8w–176\n",
      "MCS �2; wk 8(i);\n",
      "wk 44(m)\n",
      "P(i): 41 (14); 62\n",
      "I(i): 42 (14); 61\n",
      "P(m): 42(14); 61\n",
      "I(m): 40 (13); 53\n",
      "8.0 (7.2); 47\n",
      "8.2 (7.8); 47\n",
      "7.5 (6.8); 49\n",
      "8.1 (6.7); 46\n",
      "27.9\n",
      "27.6\n",
      "28.0\n",
      "25.6\n",
      "49.2\n",
      "52.2\n",
      "54.3\n",
      "54.0\n",
      "4.7 (1.4–10.)\n",
      "4.8 (1.8–13.7)\n",
      "3.4 (1.4–9.7)\n",
      "4.0 (1.4–12.7)\n",
      "51j\n",
      "52j\n",
      "50j\n",
      "52j\n",
      "ADA, adalimumab; CRem, clinical remission; CRP, C-reactive protein; CS, corticosteroids; GLM, golimumab; I, induction; IFX, inﬂiximab; IM, immunomodulator; MCS, Mayo Clinic Score; NR, not reported; P, placebo;\n",
      "PURSUIT, Program of Ulcerative Colitis Research Studies Utilizing an Investigational Treatment; q2w, every 2 weeks; q4w, every 4 weeks; q8w, every 8 weeks; TNF, tumor necrosis factor; VDZ, vedolizumab.\n",
      "aMaintenance therapy with treat straight-through design.\n",
      "bMedian (range).\n",
      "cReasons for discontinuation of prior anti-TNF therapy: primary nonresponse, 0%; secondary loss of response or intolerance, 100%.\n",
      "dOnly including patients with initial response to induction therapy who were rerandomized to placebo or active intervention.\n",
      "eReasons for discontinuation of prior anti-TNF therapy: primary nonresponse, 48%; secondary loss of response, 38%; intolerance, 14%.\n",
      "fReasons for discontinuation of prior anti-TNF therapy: primary nonresponse, 36%; secondary loss of response, 30%; intolerance, 18%.\n",
      "gReasons for discontinuation of prior anti-TNF therapy: primary nonresponse, 58%; secondary loss of response, 40%; intolerance, 2%.\n",
      "hReasons for discontinuation of prior anti-TNF therapy: primary nonresponse, 43%; secondary loss of response, 50%; intolerance, 7%.\n",
      "iReasons for discontinuation of prior anti-TNF therapy: primary nonresponse, 50%; secondary loss of response, 35%; intolerance, 7%.\n",
      "jIncludes patients with prior exposure to TNF antagonist with or without vedolizumab (13%–18% had prior exposure to vedolizumab).\n",
      "September 2020\n",
      "Management of Moderate–Severe UC 2183\n",
      "----------\n",
      "Burr et al. \n",
      " \n",
      "5 of 45 \n",
      "STUDY HIGHLIGHTS \n",
      " \n",
      "What is already known about this subject \n",
      "• Ulcerative colitis (UC) follows a relapsing and remitting course, with intermittent \n",
      "flares of disease activity, some of which may be moderate to severe. \n",
      "• These are usually treated with corticosteroids, which have potentially serious adverse \n",
      "effects, so biological therapies and small molecules have been developed and licensed \n",
      "for this indication.  \n",
      "• Although previous network meta-analyses have compared their efficacy and safety, \n",
      "this is a rapidly moving field, and there are already several newer drugs that have \n",
      "shown efficacy in phase III clinical trials that were not considered in these. \n",
      " \n",
      "What are the new findings \n",
      "• In terms of clinical remission and clinical response, upadacitinib 45mg o.d. ranked \n",
      "first in all patients, in patients previously exposed to anti-tumour necrosis factor \n",
      "(TNF)-α therapies, and in patients naïve to these drugs.  \n",
      "• In terms of endoscopic improvement infliximab 10mg/kg ranked first, followed by \n",
      "upadacitinib 45mg o.d., and infliximab 5mg/kg.  \n",
      "• However, for endoscopic improvement again upadacitinib 45mg o.d. ranked first in \n",
      "patients previously exposed to anti-TNF-α therapies, and in patients who were anti-\n",
      "TNF-α naïve.  \n",
      "• None of the drugs studied were more likely to lead to serious adverse events than \n",
      "placebo.\n",
      "----------\n",
      "associated with improved long-term outcomes.33 Data on\n",
      "the impact of early therapy in UC are more limited, but, as\n",
      "UC is also a progressive disease with risk of colorectal\n",
      "cancer, surgery, and loss of colonic function, it is reasonable\n",
      "to treat early to mitigate these risks.\n",
      "How to Diagnose Inﬂammatory Bowel Disease\n",
      "Early\n",
      "IBD is heterogenous with wide variation in presentation.\n",
      "Disease activity at presentation can range from mild to severe\n",
      "and, as discussed, symptoms may be mild to none. These can\n",
      "make the IBD diagnosis challenging, especially at a primary\n",
      "care level. Danese et al34 have proposed a Red Flags Index\n",
      "consisting of a 21-item questionnaire to help providers triage\n",
      "and identify patients with concerning symptoms in a timely\n",
      "manner and refer to specialists appropriately. A useful adjunct\n",
      "to symptom-based criteria is fecal calprotectin (FC), a stool\n",
      "marker of inﬂammation; in a large meta-analysis, FC � 40 mg/\n",
      "g carried a �1% probability of IBD, effectively excluding the\n",
      "diagnosis of IBD.35 Similarly, in the Red Flags Index validation\n",
      "study, combining the index with FC (Red Flags Index �8 and/\n",
      "or FC >250 mg/g) increased the positive predictive value from\n",
      "4% to 21% and negative predictive value from 97% to\n",
      "100%.36 Diagnostic criteria for IBD involve a composite of\n",
      "clinical symptoms, endoscopic, biomarker, and cross-sectional\n",
      "imaging features, which are beyond the scope of this review.\n",
      "We refer readers to the excellent guidelines laid out by the\n",
      "American College of Gastroenterology, European Crohn’s and\n",
      "Colitis\n",
      "Organization,\n",
      "and\n",
      "British\n",
      "Society\n",
      "of\n",
      "Gastro-\n",
      "enterology.37–40\n",
      "Risk Stratiﬁcation and Prognostication\n",
      "at Diagnosis\n",
      "Appropriately\n",
      "risk-stratifying\n",
      "prognosis\n",
      "in\n",
      "patients\n",
      "recently diagnosed with IBD is essential to inform selection\n",
      "of the most appropriate treatment and monitoring strate-\n",
      "gies. CD and UC phenotype and disease activity at initial\n",
      "presentation can vary widely from limited and mild to\n",
      "extensive and complicated. Certain baseline clinical features\n",
      "are associated with a more aggressive disease course with\n",
      "higher risk of progression and complications. In higher-risk\n",
      "patients, early control of inﬂammation with immune-\n",
      "modifying therapies is critical. However, immunosuppres-\n",
      "sive therapies are associated with safety concerns in the\n",
      "short- and long-term, and entail signiﬁcant health care costs.\n",
      "Therefore, a consideration of risks, beneﬁts, and alternatives\n",
      "is key to develop an individualized therapeutic plan for the\n",
      "informed patient.\n",
      "----------\n",
      "Therapeutic strategies for the management of recentlydiagnosedulcerative colitis. IMMs include thiopurines and methotrexate. 5-ASA, 5-amino salicylic acid; ASUC, acute severe ulcerative colitis; IPAA, ileal pouch anal anastomosis.\n",
      "\n",
      "Risk stratification: Mild\n",
      "Clinical features: NA\n",
      "Treatment options: 5-ASA (oral and/or topical)\n",
      "\n",
      "Risk stratification: Moderate\n",
      "Clinical features: NA\n",
      "Treatment options: Can consider 5-ASA (with rapid step-up if inadequate response)\n",
      "\n",
      "Risk stratification: Moderate\n",
      "Clinical features: NA\n",
      "Treatment options: VDZ or UST\n",
      "\n",
      "Risk stratification: Moderate\n",
      "Clinical features: NA\n",
      "Treatment options: Thiopurine\n",
      "\n",
      "Risk stratification: Moderate\n",
      "Clinical features: NA\n",
      "Treatment options: TNFi +/- IMM\n",
      "\n",
      "Risk stratification: Severe\n",
      "Clinical features: NA\n",
      "Treatment options: TNFi +/- IMM\n",
      "\n",
      "Risk stratification: Severe\n",
      "Clinical features: NA\n",
      "Treatment options: Subtotal colectomy + IPAA or cyclosporine (for ASUC)\n",
      "\n",
      "Risk stratification: Additional consideration: EIM present\n",
      "Clinical features: Psoriasis or psoriatic arthritis\n",
      "Treatment options: UST\n",
      "\n",
      "Risk stratification: Additional consideration: EIM present\n",
      "Clinical features: Other arthritis\n",
      "Treatment options: TNFi\n",
      "\n",
      "\n",
      "----------\n",
      "methodologic characteristics). If direct and indirect es-\n",
      "timates were similar (ie, coherent), then the higher rating\n",
      "can be assigned to the network meta-analysis estimates.\n",
      "Results\n",
      "From a total 5651 unique studies identiﬁed using our\n",
      "search strategy, we included 15 RCTs of ﬁrst-line agents\n",
      "(in biologic-naïve patients) (Active Ulcerative Colitis Trials\n",
      "1 and 2,17 Jiang et al,18 NCT01551290,19 Ulcerative colitis\n",
      "Long-Term Remission and maintenance with Adalimumab\n",
      "1 and 2,20,21 Suzuki et al,22 Program of Ulcerative Colitis\n",
      "Research Studies Utilizing an Investigational Treatment\n",
      "phase 2 and phase 3 induction studies,23 GEMINI I,24\n",
      "Motoya et al,25 VARSITY, Oral Clinical Trials for tofAciti-\n",
      "nib in ulceratiVE colitis (OCTAVE) 1 and 2,26 and UNIFI),\n",
      "and 7 RCTs of second-line agents (in patients with prior\n",
      "exposure to TNFa antagonists) (Ulcerative colitis Long-\n",
      "Term Remission and maintenance with Adalimumab 2,21\n",
      "GEMINI I,24 Motoya et al,25 VARSITY,6 OCTAVE 1 and\n",
      "2,26 UNIFI7) in patients with moderate–severe ulcerative\n",
      "colitis. Trials of inﬂiximab (Active Ulcerative Colitis Trials\n",
      "1 and 2,17 Jiang et al,18 NCT0155129019), adalimumab\n",
      "(Ulcerative colitis Long-Term Remission and maintenance\n",
      "with Adalimumab 2,20,21 Suzuki et al22), vedolizumab\n",
      "(GEMINI I,24 Motoya et al,25 VARSITY6) and ustekinumab\n",
      "(UNIFI7) also reported outcomes on maintenance therapy\n",
      "within the same publication; Program of Ulcerative Colitis\n",
      "Research Studies Utilizing an Investigational Treatment-\n",
      "M, Program of Ulcerative Colitis Research Studies Utilizing\n",
      "an Investigational Treatment-J, and OCTAVE-Sustain\n",
      "reported\n",
      "outcomes\n",
      "for\n",
      "maintenance\n",
      "therapy\n",
      "with\n",
      "golimumab and tofacitinib, respectively.26–28 From our\n",
      "previous analysis, 3 additional studies were included.\n",
      "The schematic diagram of study selection is shown in\n",
      "Supplementary\n",
      "Figure\n",
      "1,\n",
      "and\n",
      "available\n",
      "direct\n",
      "comparisons and network of trials are shown in Figure 1.\n",
      "Trial and patient characteristics are summarized in\n",
      "Table 1. Overall, the median average age of patients was\n",
      "41 years (interquartile range, 40–42 y), and 60%\n",
      "(interquartile range, 56%–63%) were men. The median\n",
      "disease duration was 6.7 years (interquartile range,\n",
      "6.0–7.8 y), and 49% (interquartile range, 46%–55%) of\n",
      "patients had extensive colitis. A median of 40% (inter-\n",
      "quartile range, 30%–50%) of patients were treated with\n",
      "concomitant immunomodulators, and 51% (interquartile\n",
      "range, 45%–57%) were on corticosteroids at baseline.\n",
      "Patients across all trials and treatment arms were com-\n",
      "----------\n",
      "discontinuation due to AEs, and serious infections. Phase 3 randomized controlled trials were identified via systematic literature review, in-\n",
      "cluding the following advanced therapies: infliximab, adalimumab, vedolizumab, golimumab, tofacitinib, ustekinumab, filgotinib, ozanimod, and \n",
      "upadacitinib. Random effects models were used to address between-study heterogeneity. Intent-to-treat (ITT) efficacy rates were calculated by \n",
      "adjusting maintenance outcomes by likelihood of induction response.\n",
      "Results:  Out of 48 trials identified, 23 were included. Across all outcomes and regardless of prior biologic exposure, ITT efficacy rates were \n",
      "highest for upadacitinib, owing to its highest ranking for all efficacy outcomes in induction and for all but clinical remission during maintenance \n",
      "among bio-naive induction responders. For all advanced therapies versus placebo, there were no significant differences in serious AEs or \n",
      "serious infections across therapies. For all AEs, golimumab had higher odds versus placebo during maintenance; for discontinuation due to \n",
      "AEs, upadacitinib had lower odds versus placebo during induction, while ustekinumab and vedolizumab had lower odds versus placebo during \n",
      "maintenance.\n",
      "Conclusions:  Upadacitinib may be the most efficacious therapy for moderately to severely active UC based on ITT analyses, with similar safety \n",
      "across advanced therapies.\n",
      "Lay Summary \n",
      "Indirect evidence suggests upadacitinib may be more efficacious than other advanced therapies at achieving clinical response, clinical remis-\n",
      "sion, and endoscopic response over 1 year for moderately to severely active ulcerative colitis patients, with similar safety assessments across \n",
      "advanced therapies.\n",
      "Key Words: ulcerative colitis, clinical trials, advanced therapies, network meta-analysis\n",
      "Introduction\n",
      "Ulcerative colitis (UC) is a chronic inflammatory bowel dis-\n",
      "ease that affects the colorectum and is clinically characterized \n",
      "by bloody diarrhea, urgency, tenesmus, abdominal pain, ma-\n",
      "laise, weight loss, and fever. Disease onset commonly occurs \n",
      "between the ages of 15 and 30 years and the annual global \n",
      "© The Author(s) 2023. Published by Oxford University Press on behalf of Crohn's & Colitis Foundation.\n",
      "This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), \n",
      "which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.\n",
      "----------\n",
      "severely active ulcerative colitis: results from phase 3 \n",
      "U-ACCOMPLISH study. J Crohn’s Colitis 2021; 15 (suppl 1): S021–22.\n",
      "9 \n",
      "Thorlund K, Druyts E, Mills EJ, Fedorak RN, Marshall JK. \n",
      "Adalimumab versus infliximab for the treatment of moderate to \n",
      "severe ulcerative colitis in adult patients naïve to anti-TNF therapy: \n",
      "an indirect treatment comparison meta-analysis. J Crohn’s Colitis \n",
      "2014; 8: 571–81.\n",
      "10 \n",
      "Danese S, Fiorino G, Peyrin-Biroulet L, et al. Biological agents for \n",
      "moderately to severely active ulcerative colitis: a systematic review \n",
      "and network meta-analysis. Ann Intern Med 2014; 160: 704–11.\n",
      "11 \n",
      "Singh S, Fumery M, Sandborn WJ, Murad MH. Systematic review \n",
      "with network meta-analysis: first- and second-line pharmacotherapy \n",
      "for moderate-severe ulcerative colitis. Aliment Pharmacol Ther 2018; \n",
      "47: 162–75.\n",
      "12 \n",
      "Bonovas S, Lytras T, Nikolopoulos G, Peyrin-Biroulet L, Danese S. \n",
      "Systematic review with network meta-analysis: comparative \n",
      "assessment of tofacitinib and biological therapies for moderate-to-\n",
      "severe ulcerative colitis. Aliment Pharmacol Ther 2018; 47: 454–65.\n",
      "13 \n",
      "Singh S, Murad MH, Fumery M, Dulai PS, Sandborn WJ. First- and \n",
      "second-line pharmacotherapies for patients with moderate to \n",
      "severely active ulcerative colitis: an updated network meta-analysis. \n",
      "Clin Gastroenterol Hepatol 2020; 18: 2179–91.e6.\n",
      "14 \n",
      "Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting \n",
      "items for systematic reviews and meta-analyses: the PRISMA \n",
      "statement. Ann Intern Med 2009; 151: 264–69.\n",
      "15 \n",
      "Jansen JP, Fleurence R, Devine B, et al. Interpreting indirect \n",
      "treatment comparisons and network meta-analysis for health-care \n",
      "decision making: report of the ISPOR Task Force on Indirect \n",
      "Treatment Comparisons Good Research Practices: part 1. \n",
      "Value Health 2011; 14: 417–28.\n",
      "16 \n",
      "Sterne JAC, Savović J, Page MJ, et al. RoB 2: a revised tool for \n",
      "assessing risk of bias in randomised trials. BMJ 2019; 366: l4898.\n",
      "17 \n",
      "Rücker G, Schwarzer G. Ranking treatments in frequentist network \n",
      "meta-analysis works without resampling methods. \n",
      "BMC Med Res Methodol 2015; 15: 58.\n",
      "==========\n",
      "ORIGINAL QUESTION: ANALYSE the given patient profile based on given query based on one of the following criteria:\n",
      "- Whether treated patient is new patient or patient under maintenance\n",
      "- Prior response to Infliximab\n",
      "- Prior failure to Anti-TNF agents\n",
      "- Prior failure to Vedolizumab\n",
      "- Age\n",
      "- Pregnancy\n",
      "- Extraintestinale manifestations\n",
      "- Pouchitis\n",
      "RETURN up to 2 TOP choices of biological drugs given patient profile and context. Explain the PROS and CONS of the 2 choices.\n",
      "PATIENT PROFILE: 60 year old female with newly diagnosed moderate UC with a background of congestive cardiac failure\n",
      "\n",
      "==========\n",
      "CURRENT ANSWER:\n",
      "Based on the patient's profile, the top two choices of biological drugs would be Vedolizumab and Ustekinumab. \n",
      "\n",
      "1. Vedolizumab:\n",
      "   - Advantages: Vedolizumab is a gut-selective immunosuppressant, meaning it specifically targets inflammation in the gut, reducing systemic side effects. This could be beneficial for a patient with congestive cardiac failure as it minimizes the risk of exacerbating this condition. It has been shown to be effective in inducing and maintaining remission in moderate to severe UC.\n",
      "   - Disadvantages: Vedolizumab is administered via intravenous infusion, which may be inconvenient for some patients. It may also take several weeks to see an effect, and some patients may not respond to the treatment.\n",
      "\n",
      "2. Ustekinumab:\n",
      "   - Advantages: Ustekinumab is a monoclonal antibody that targets the p40 subunit of interleukin (IL)-12 and IL-23, cytokines involved in inflammatory and immune responses. It has been shown to be effective in treating moderate to severe UC. It is administered subcutaneously, which may be more convenient than intravenous infusions.\n",
      "   - Disadvantages: Ustekinumab may increase the risk of infections. As with other immunosuppressants, there is a risk of serious infections, malignancies, and hypersensitivity reactions.\n",
      "\n",
      "It's important to note that the choice of treatment should be individualized, considering the patient's overall health, comorbidities, and preferences. The patient's cardiac status should be closely monitored regardless of the treatment chosen due to her background of congestive cardiac failure. \n",
      "\n",
      "[{\"drug_name\": \"Vedolizumab\", \"advantages\": \"Gut-selective immunosuppressant, reducing systemic side effects. Effective in inducing and maintaining remission in moderate to severe UC.\", \"disadvantages\": \"Administered via intravenous infusion, which may be inconvenient. May take several weeks to see an effect, and some patients may not respond to the treatment.\"}, {\"drug_name\": \"Ustekinumab\", \"advantages\": \"Targets the p40 subunit of interleukin (IL)-12 and IL-23, cytokines involved in inflammatory and immune responses. Effective in treating moderate to severe UC. Administered subcutaneously, which may be more convenient than intravenous infusions.\", \"disadvantages\": \"May\n",
      "==========\n",
      "REFINED ANSWER:\n",
      "\u001b[0m\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "Retrying langchain.chat_models.openai.ChatOpenAI.completion_with_retry.<locals>._completion_with_retry in 4.0 seconds as it raised RateLimitError: Rate limit reached for 10KTPM-200RPM in organization org-ETbTMTN2JXYOUPDJgxuH2iO6 on tokens per min. Limit: 10000 / min. Please try again in 6ms. Contact us through our help center at help.openai.com if you continue to have issues..\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\n",
      "\u001b[1m> Finished chain.\u001b[0m\n",
      "\n",
      "\u001b[1m> Finished chain.\u001b[0m\n",
      "2023-10-02 17:17:17,530:INFO: 5731 tokens were added to prompt from 10 documents\n",
      "Query: 38 year old female with newly diagnosed moderate UC and psoriasis\n",
      "\n",
      "\n",
      "\n",
      "\u001b[1m> Entering new SequentialChain chain...\u001b[0m\n",
      "\n",
      "\n",
      "\u001b[1m> Entering new RetrievalQAWithSourcesChain chain...\u001b[0m\n",
      "\n",
      "\u001b[1m> Finished chain.\u001b[0m\n",
      "\n",
      "\n",
      "\u001b[1m> Entering new LLMChain chain...\u001b[0m\n",
      "Prompt after formatting:\n",
      "\u001b[32;1m\u001b[1;3mYou are a senior physician giving advice on treatment for moderate to severe ulcerative colitis (UC).\n",
      "Make reference to the CONTEXT given to assess the scenario.\n",
      "==========\n",
      "TASK: Your task is to analyse critically the CURRENT ANSWER given the CONTEXT.\n",
      "Then refine the existing answer (only if needed) based on the following instructions:\n",
      "- If no refinement needed, return the original answer in the correct output format.\n",
      "- If the answer cannot be inferred from CONTEXT, return \"NO ANSWER\".\n",
      "- The final output should be a list of up to 2 choices of biological drugs given patient profile and context and PROS/CONS for each recommendations.\n",
      "==========\n",
      "CONTEXT:\n",
      "I(m): UST 90 mg q8w–176\n",
      "MCS �2; wk 8(i);\n",
      "wk 44(m)\n",
      "P(i): 41 (14); 62\n",
      "I(i): 42 (14); 61\n",
      "P(m): 42(14); 61\n",
      "I(m): 40 (13); 53\n",
      "8.0 (7.2); 47\n",
      "8.2 (7.8); 47\n",
      "7.5 (6.8); 49\n",
      "8.1 (6.7); 46\n",
      "27.9\n",
      "27.6\n",
      "28.0\n",
      "25.6\n",
      "49.2\n",
      "52.2\n",
      "54.3\n",
      "54.0\n",
      "4.7 (1.4–10.)\n",
      "4.8 (1.8–13.7)\n",
      "3.4 (1.4–9.7)\n",
      "4.0 (1.4–12.7)\n",
      "51j\n",
      "52j\n",
      "50j\n",
      "52j\n",
      "ADA, adalimumab; CRem, clinical remission; CRP, C-reactive protein; CS, corticosteroids; GLM, golimumab; I, induction; IFX, inﬂiximab; IM, immunomodulator; MCS, Mayo Clinic Score; NR, not reported; P, placebo;\n",
      "PURSUIT, Program of Ulcerative Colitis Research Studies Utilizing an Investigational Treatment; q2w, every 2 weeks; q4w, every 4 weeks; q8w, every 8 weeks; TNF, tumor necrosis factor; VDZ, vedolizumab.\n",
      "aMaintenance therapy with treat straight-through design.\n",
      "bMedian (range).\n",
      "cReasons for discontinuation of prior anti-TNF therapy: primary nonresponse, 0%; secondary loss of response or intolerance, 100%.\n",
      "dOnly including patients with initial response to induction therapy who were rerandomized to placebo or active intervention.\n",
      "eReasons for discontinuation of prior anti-TNF therapy: primary nonresponse, 48%; secondary loss of response, 38%; intolerance, 14%.\n",
      "fReasons for discontinuation of prior anti-TNF therapy: primary nonresponse, 36%; secondary loss of response, 30%; intolerance, 18%.\n",
      "gReasons for discontinuation of prior anti-TNF therapy: primary nonresponse, 58%; secondary loss of response, 40%; intolerance, 2%.\n",
      "hReasons for discontinuation of prior anti-TNF therapy: primary nonresponse, 43%; secondary loss of response, 50%; intolerance, 7%.\n",
      "iReasons for discontinuation of prior anti-TNF therapy: primary nonresponse, 50%; secondary loss of response, 35%; intolerance, 7%.\n",
      "jIncludes patients with prior exposure to TNF antagonist with or without vedolizumab (13%–18% had prior exposure to vedolizumab).\n",
      "September 2020\n",
      "Management of Moderate–Severe UC 2183\n",
      "----------\n",
      "Burr et al. \n",
      " \n",
      "5 of 45 \n",
      "STUDY HIGHLIGHTS \n",
      " \n",
      "What is already known about this subject \n",
      "• Ulcerative colitis (UC) follows a relapsing and remitting course, with intermittent \n",
      "flares of disease activity, some of which may be moderate to severe. \n",
      "• These are usually treated with corticosteroids, which have potentially serious adverse \n",
      "effects, so biological therapies and small molecules have been developed and licensed \n",
      "for this indication.  \n",
      "• Although previous network meta-analyses have compared their efficacy and safety, \n",
      "this is a rapidly moving field, and there are already several newer drugs that have \n",
      "shown efficacy in phase III clinical trials that were not considered in these. \n",
      " \n",
      "What are the new findings \n",
      "• In terms of clinical remission and clinical response, upadacitinib 45mg o.d. ranked \n",
      "first in all patients, in patients previously exposed to anti-tumour necrosis factor \n",
      "(TNF)-α therapies, and in patients naïve to these drugs.  \n",
      "• In terms of endoscopic improvement infliximab 10mg/kg ranked first, followed by \n",
      "upadacitinib 45mg o.d., and infliximab 5mg/kg.  \n",
      "• However, for endoscopic improvement again upadacitinib 45mg o.d. ranked first in \n",
      "patients previously exposed to anti-TNF-α therapies, and in patients who were anti-\n",
      "TNF-α naïve.  \n",
      "• None of the drugs studied were more likely to lead to serious adverse events than \n",
      "placebo.\n",
      "----------\n",
      "41 years (interquartile range, 40–42 y), and 60%\n",
      "(interquartile range, 56%–63%) were men. The median\n",
      "disease duration was 6.7 years (interquartile range,\n",
      "6.0–7.8 y), and 49% (interquartile range, 46%–55%) of\n",
      "patients had extensive colitis. A median of 40% (inter-\n",
      "quartile range, 30%–50%) of patients were treated with\n",
      "concomitant immunomodulators, and 51% (interquartile\n",
      "range, 45%–57%) were on corticosteroids at baseline.\n",
      "Patients across all trials and treatment arms were com-\n",
      "parable in terms of baseline prognostic variables, inclu-\n",
      "sion/exclusion\n",
      "criteria,\n",
      "and\n",
      "co-interventions.\n",
      "All\n",
      "outcomes were assessed uniformly based on the stan-\n",
      "dard deﬁnition of the Mayo Clinic score, between weeks\n",
      "6 and 10 for induction therapy (inﬂiximab, adalimumab,\n",
      "tofacitinib, ustekinumab, 8 weeks; golimumab, 6 weeks;\n",
      "vedolizumab, 6 weeks, 10 weeks, and 14 weeks in\n",
      "VARSITY),6 and weeks 30, 54, or 60 for maintenance\n",
      "therapy;\n",
      "endoscopy\n",
      "was\n",
      "read\n",
      "by\n",
      "blinded\n",
      "local\n",
      "Table 2. Comparative Efﬁcacy of Pharmacologic Agents for Induction of Clinical Remission and Endoscopic Improvement in Biologic-Naive Patients With Moderate–Severe\n",
      "Ulcerative Colitis Using Network Meta-Analysis\n",
      "Induction of clinical remission\n",
      "Induction of endoscopic improvement\n",
      "Ustekinumab 6 mg/kg\n",
      "0.96 (0.38–2.45)\n",
      "0.80 (0.35–1.83)\n",
      "0.73 (0.31–1.74)\n",
      "1.05 (0.48–2.32)\n",
      "0.50 (0.22–1.12)\n",
      "2.04 (1.03–4.05)\n",
      "0.92 (0.45–1.89)\n",
      "Tofacitinib 10 mg b.d.\n",
      "0.84 (0.39–1.82)\n",
      "0.76 (0.33–1.76)\n",
      "1.10 (0.51–2.34)\n",
      "0.52 (0.24–1.12)\n",
      "2.12 (1.12–4.02)\n",
      "0.74 (0.36–1.51)\n",
      "0.80 (0.4–1.62)\n",
      "Vedolizumab\n",
      "0.91 (0.44–1.86)\n",
      "1.31 (0.88–1.95)\n",
      "0.62 (0.34–1.15)\n",
      "2.54 (1.60–4.02)\n",
      "1.07 (0.58–1.98)\n",
      "1.17 (0.64–2.12)\n",
      "1.45 (0.80–2.61)\n",
      "Golimumab\n",
      "1.44 (0.76–2.75)\n",
      "0.69 (0.35–1.36)\n",
      "2.79 (1.64–4.02)\n",
      "1.17 (0.65–2.13)\n",
      "1.28 (0.72–2.29)\n",
      "1.59 (0.90–2.82)\n",
      "1.10 (0.71–1.71)\n",
      "Adalimumab\n",
      "0.48 (0.26–0.86)\n",
      "1.94 (1.30–2.88)\n",
      "0.56 (0.30–1.04)\n",
      "0.61 (0.34–1.11)\n",
      "0.76 (0.42–1.37)\n",
      "0.52 (0.33–0.83)\n",
      "0.48 (0.31–0.74)\n",
      "Inﬂiximab\n",
      "4.07 (2.67–6.21)\n",
      "1.86 (1.11–3.13)\n",
      "2.03 (1.23–3.34)\n",
      "2.52 (1.54–4.11)\n",
      "1.74 (1.25–2.41)\n",
      "1.58 (1.18–2.13)\n",
      "3.32 (2.39–4.60)\n",
      "Placebo\n",
      "NOTE. Comparisons should be read from left to right. Odds ratio for comparisons are in the cell in common between the column-deﬁning and row-deﬁning treatment. Numbers in bold are statistically signiﬁcant. For induction of\n",
      "clinical remission, an odds ratio greater than 1 favors row-deﬁning treatment. For induction of endoscopic improvement, an odds ratio greater than 1 favors column-deﬁning treatment. Numbers in parentheses indicate 95% CI.\n",
      "b.d., twice daily.\n",
      "----------\n",
      "2\n",
      "Efficacy and Safety of Advanced Therapies\n",
      "incidence ranges from 9 to 20 cases per 100 000 per year with \n",
      "higher incidence in North America and Northern Europe.1\n",
      "The advanced therapeutic armamentarium for adults \n",
      "with moderately to severely active UC is rapidly evolving. \n",
      "For over 20 years, biologics targeting specific inflamma-\n",
      "tory pathways have been the mainstay, beginning with those \n",
      "targeting tumor necrosis alpha (TNFi; eg, infliximab [INF], \n",
      "adalimumab [ADA], and golimumab [GOL]) followed by \n",
      "biologics with other modes of action (eg, vedolizumab [VED] \n",
      "and ustekinumab [UST]). However, treatment limitations for \n",
      "moderately to severely active UC remain, including primary \n",
      "nonresponse, secondary loss of response, immunogenicity, and \n",
      "parenteral administration.2 To overcome these limitations, \n",
      "there has been increasing interest in small molecule drugs \n",
      "(SMDs), which can be orally administered and lack immu-\n",
      "nogenicity.3 Of particular interest are SMDs that inhibit the \n",
      "Janus kinase (JAK)-mediated inflammatory pathway, of which \n",
      "tofacitinib (TOF), filgotinib (FIL), and upadacitinib (UPA) are \n",
      "currently approved for use in adults with moderately to se-\n",
      "verely active UC who have had an inadequate response or in-\n",
      "tolerance to conventional therapy and/or TNFi’s.4–7 All orally \n",
      "administered, TOF, FIL, and UPA are distinguished by their \n",
      "JAK selectivity: TOF is a pan-JAK inhibitor while FIL and \n",
      "UPA are approximately 30- and 60-fold selective for JAK1 \n",
      "over JAK2, respectively.8,9 In human cellular assays, UPA pref-\n",
      "erentially inhibits signaling by JAK1 or JAK1/3 with func-\n",
      "tional selectivity over cytokine receptors that signal via pairs \n",
      "of JAK2.5 In addition, ozanimod (OZA), a SMD that selec-\n",
      "tively modulates the sphingosine-1-phosphase receptor (S1P), \n",
      "is also approved for use in UC.10\n",
      "With this rapid innovation, much attention has been paid \n",
      "toward establishing the comparative efficacy and safety of \n",
      "biologics and SMDs that are approved or in late stages of \n",
      "development for moderately to severely active UC. Most \n",
      "recently, Lasa et al11 and Burr et al12 each conducted and \n",
      "published a systematic literature review (SLR) and frequentist \n",
      "network meta-analysis (NMA) on the efficacy and safety of \n",
      "biologics and SMDs for patients with moderately to severely \n",
      "UC. Both studies assessed all outcomes after induction (6–14 \n",
      "weeks); Lasa et al11 additionally assessed efficacy after main-\n",
      "tenance (26–66 weeks) separately for treat-through (TT) and\n",
      "----------\n",
      "Burr et al. \n",
      " \n",
      "7 of 45 \n",
      "INTRODUCTION \n",
      "  Ulcerative colitis (UC) is a chronic inflammatory disorder of the bowel that causes \n",
      "continuous mucosal inflammation commencing in the rectum and extending proximally for a \n",
      "variable extent.[1] It is estimated that UC affects 2.5 million people in Europe,[2] and the \n",
      "disease follows a relapsing and remitting course, with intermittent flares of disease activity, \n",
      "some of which may be moderate to severe. Management of these is medical, for the most \n",
      "part, with surgery reserved for patients with refractory disease. Although 5-aminosalicylates \n",
      "(5-ASAs) are efficacious for mild to moderate disease activity,[3-6] more severe flares are \n",
      "usually treated with corticosteroids.[7] However, these have potentially serious adverse \n",
      "effects and a substantial proportion of patients may become either dependent on them to \n",
      "maintain remission,[8] or refractory to them.[9] As a result, over the last 20 years novel \n",
      "drugs, with more precise modes of action, based on mechanisms of disease identified in \n",
      "genome wide association studies,[10] have been developed.  \n",
      "The first of these agents was infliximab, a drug targeting the pro-inflammatory \n",
      "cytokine tumour necrosis factor-α (TNF-α), which demonstrated efficacy in clinical trials in \n",
      "moderate to severe UC.[11] Since then, other drugs against TNF-α have been tested, such as \n",
      "adalimumab and golimumab.[12, 13] In addition, newer biological therapies targeting α or β \n",
      "integrins, which are involved in migration of immune cells to inflamed intestinal mucosa, \n",
      "such as vedolizumab or etrolizumab,[14, 15] or acting against other pro-inflammatory \n",
      "cytokines implicated in the pathogenesis of UC, such as ustekinumab,[16] have been tested. \n",
      "However, even these more selective drugs do not work in all patients, there may be risks \n",
      "associated with their use,[17-19] and the fact that they are administered either intravenously \n",
      "or subcutaneously, may be inconvenient for patients. The search for alternative agents for the \n",
      "treatment of UC has, therefore, continued.\n",
      "----------\n",
      "Burr et al. \n",
      " \n",
      "8 of 45 \n",
      "In the last 10 years small molecules, which can be administered orally and on a daily \n",
      "basis, have also been evaluated in moderate to severe UC. These include janus kinase \n",
      "inhibitors, such as tofacitinib,[20] and the sphingosine-1-phosphate receptor modulator, \n",
      "ozanimod.[21] The comparative efficacy and safety of all these drugs has been assessed in \n",
      "prior network meta-analyses.[22, 23] These demonstrated that infliximab was ranked highest \n",
      "overall for efficacy, and ustekinumab and tofacitinib were ranked highest in patients with \n",
      "previous anti-TNF-α exposure. However, this is a rapidly moving field, and there are already \n",
      "several newer drugs that have shown efficacy in phase III clinical trials that were not \n",
      "considered in these network meta-analyses.[24-26] We have therefore performed an updated \n",
      "network meta-analysis to evaluate the efficacy of all biological therapies and small molecules \n",
      "that have progressed on to phase III trials, compared with each other or with placebo, in terms \n",
      "of induction of remission, endoscopic improvement, and clinical response, as well as safety, \n",
      "in patients with moderate to severely active UC.\n",
      "----------\n",
      "Burr et al. \n",
      " \n",
      "27 of 45 \n",
      "DISCUSSION \n",
      "We conducted a contemporaneous systematic review and network meta-analysis of \n",
      "biological therapies and small molecules for moderate to severely active UC. This has \n",
      "incorporated data from 28 RCTs and over 12,500 patients. Overall, in terms of clinical \n",
      "remission and clinical response at 6 to 14 weeks, upadacitinib 45mg o.d. ranked first in all \n",
      "patients, in patients previously exposed to anti-TNF-α therapies, and in patients naïve to these \n",
      "drugs. In terms of endoscopic improvement infliximab 10mg/kg ranked first, followed by \n",
      "upadacitinib 45mg o.d., and infliximab 5mg/kg. However, again upadacitinib 45mg o.d. \n",
      "ranked first in patients previously exposed to anti-TNF-α therapies, and in patients who were \n",
      "anti-TNF-α naïve. In terms of safety, upadacitinib 45mg o.d. ranked last for total number of \n",
      "adverse events, and ustekinumab 130mg first. However, none of the drugs studied were more \n",
      "likely to lead to serious adverse events than placebo, although etrolizumab 105mg was more \n",
      "likely to lead to serious adverse events than golimumab 200/100mg, ustekinumab 6mg/kg, \n",
      "vedolizumab 300mg, and infliximab 5mg/kg. Vedolizumab 300mg was the least likely drug \n",
      "to lead to infections. Infections were significantly more likely with tofacitinib 10mg b.i.d. \n",
      "than with either placebo or vedolizumab 300mg. Finally, withdrawals due to adverse events \n",
      "were significantly less likely with upadacitinib 45mg o.d. than with placebo. Upadacitinib \n",
      "45mg o.d. was significantly less likely to lead to withdrawals due to an adverse event than \n",
      "infliximab 5mg/kg and 10mg/kg, vedolizumab 300mg, adalimumab 160/80mg or 80/40mg, \n",
      "filgotinib 200mg o.d., and etrolizumab 105mg. Applying GRADE criteria to our estimates of \n",
      "effects, certainty in the quality of evidence would be high.  \n",
      "There are some limitations. Only nine of 27 trials were at low risk of bias across all \n",
      "domains. Given the timespan of included studies, there is the possibility that trials of newer \n",
      "drugs included patients with refractory UC who had failed multiple other therapies. However, \n",
      "some of these more recent trials only recruited patients who were naïve to anti-TNF-α\n",
      "----------\n",
      "Therapeutic strategies for the management of recentlydiagnosedulcerative colitis. IMMs include thiopurines and methotrexate. 5-ASA, 5-amino salicylic acid; ASUC, acute severe ulcerative colitis; IPAA, ileal pouch anal anastomosis.\n",
      "\n",
      "Risk stratification: Mild\n",
      "Clinical features: NA\n",
      "Treatment options: 5-ASA (oral and/or topical)\n",
      "\n",
      "Risk stratification: Moderate\n",
      "Clinical features: NA\n",
      "Treatment options: Can consider 5-ASA (with rapid step-up if inadequate response)\n",
      "\n",
      "Risk stratification: Moderate\n",
      "Clinical features: NA\n",
      "Treatment options: VDZ or UST\n",
      "\n",
      "Risk stratification: Moderate\n",
      "Clinical features: NA\n",
      "Treatment options: Thiopurine\n",
      "\n",
      "Risk stratification: Moderate\n",
      "Clinical features: NA\n",
      "Treatment options: TNFi +/- IMM\n",
      "\n",
      "Risk stratification: Severe\n",
      "Clinical features: NA\n",
      "Treatment options: TNFi +/- IMM\n",
      "\n",
      "Risk stratification: Severe\n",
      "Clinical features: NA\n",
      "Treatment options: Subtotal colectomy + IPAA or cyclosporine (for ASUC)\n",
      "\n",
      "Risk stratification: Additional consideration: EIM present\n",
      "Clinical features: Psoriasis or psoriatic arthritis\n",
      "Treatment options: UST\n",
      "\n",
      "Risk stratification: Additional consideration: EIM present\n",
      "Clinical features: Other arthritis\n",
      "Treatment options: TNFi\n",
      "\n",
      "\n",
      "----------\n",
      "severely active ulcerative colitis: results from phase 3 \n",
      "U-ACCOMPLISH study. J Crohn’s Colitis 2021; 15 (suppl 1): S021–22.\n",
      "9 \n",
      "Thorlund K, Druyts E, Mills EJ, Fedorak RN, Marshall JK. \n",
      "Adalimumab versus infliximab for the treatment of moderate to \n",
      "severe ulcerative colitis in adult patients naïve to anti-TNF therapy: \n",
      "an indirect treatment comparison meta-analysis. J Crohn’s Colitis \n",
      "2014; 8: 571–81.\n",
      "10 \n",
      "Danese S, Fiorino G, Peyrin-Biroulet L, et al. Biological agents for \n",
      "moderately to severely active ulcerative colitis: a systematic review \n",
      "and network meta-analysis. Ann Intern Med 2014; 160: 704–11.\n",
      "11 \n",
      "Singh S, Fumery M, Sandborn WJ, Murad MH. Systematic review \n",
      "with network meta-analysis: first- and second-line pharmacotherapy \n",
      "for moderate-severe ulcerative colitis. Aliment Pharmacol Ther 2018; \n",
      "47: 162–75.\n",
      "12 \n",
      "Bonovas S, Lytras T, Nikolopoulos G, Peyrin-Biroulet L, Danese S. \n",
      "Systematic review with network meta-analysis: comparative \n",
      "assessment of tofacitinib and biological therapies for moderate-to-\n",
      "severe ulcerative colitis. Aliment Pharmacol Ther 2018; 47: 454–65.\n",
      "13 \n",
      "Singh S, Murad MH, Fumery M, Dulai PS, Sandborn WJ. First- and \n",
      "second-line pharmacotherapies for patients with moderate to \n",
      "severely active ulcerative colitis: an updated network meta-analysis. \n",
      "Clin Gastroenterol Hepatol 2020; 18: 2179–91.e6.\n",
      "14 \n",
      "Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting \n",
      "items for systematic reviews and meta-analyses: the PRISMA \n",
      "statement. Ann Intern Med 2009; 151: 264–69.\n",
      "15 \n",
      "Jansen JP, Fleurence R, Devine B, et al. Interpreting indirect \n",
      "treatment comparisons and network meta-analysis for health-care \n",
      "decision making: report of the ISPOR Task Force on Indirect \n",
      "Treatment Comparisons Good Research Practices: part 1. \n",
      "Value Health 2011; 14: 417–28.\n",
      "16 \n",
      "Sterne JAC, Savović J, Page MJ, et al. RoB 2: a revised tool for \n",
      "assessing risk of bias in randomised trials. BMJ 2019; 366: l4898.\n",
      "17 \n",
      "Rücker G, Schwarzer G. Ranking treatments in frequentist network \n",
      "meta-analysis works without resampling methods. \n",
      "BMC Med Res Methodol 2015; 15: 58.\n",
      "----------\n",
      "discontinuation due to AEs, and serious infections. Phase 3 randomized controlled trials were identified via systematic literature review, in-\n",
      "cluding the following advanced therapies: infliximab, adalimumab, vedolizumab, golimumab, tofacitinib, ustekinumab, filgotinib, ozanimod, and \n",
      "upadacitinib. Random effects models were used to address between-study heterogeneity. Intent-to-treat (ITT) efficacy rates were calculated by \n",
      "adjusting maintenance outcomes by likelihood of induction response.\n",
      "Results:  Out of 48 trials identified, 23 were included. Across all outcomes and regardless of prior biologic exposure, ITT efficacy rates were \n",
      "highest for upadacitinib, owing to its highest ranking for all efficacy outcomes in induction and for all but clinical remission during maintenance \n",
      "among bio-naive induction responders. For all advanced therapies versus placebo, there were no significant differences in serious AEs or \n",
      "serious infections across therapies. For all AEs, golimumab had higher odds versus placebo during maintenance; for discontinuation due to \n",
      "AEs, upadacitinib had lower odds versus placebo during induction, while ustekinumab and vedolizumab had lower odds versus placebo during \n",
      "maintenance.\n",
      "Conclusions:  Upadacitinib may be the most efficacious therapy for moderately to severely active UC based on ITT analyses, with similar safety \n",
      "across advanced therapies.\n",
      "Lay Summary \n",
      "Indirect evidence suggests upadacitinib may be more efficacious than other advanced therapies at achieving clinical response, clinical remis-\n",
      "sion, and endoscopic response over 1 year for moderately to severely active ulcerative colitis patients, with similar safety assessments across \n",
      "advanced therapies.\n",
      "Key Words: ulcerative colitis, clinical trials, advanced therapies, network meta-analysis\n",
      "Introduction\n",
      "Ulcerative colitis (UC) is a chronic inflammatory bowel dis-\n",
      "ease that affects the colorectum and is clinically characterized \n",
      "by bloody diarrhea, urgency, tenesmus, abdominal pain, ma-\n",
      "laise, weight loss, and fever. Disease onset commonly occurs \n",
      "between the ages of 15 and 30 years and the annual global \n",
      "© The Author(s) 2023. Published by Oxford University Press on behalf of Crohn's & Colitis Foundation.\n",
      "This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), \n",
      "which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.\n",
      "==========\n",
      "ORIGINAL QUESTION: ANALYSE the given patient profile based on given query based on one of the following criteria:\n",
      "- Whether treated patient is new patient or patient under maintenance\n",
      "- Prior response to Infliximab\n",
      "- Prior failure to Anti-TNF agents\n",
      "- Prior failure to Vedolizumab\n",
      "- Age\n",
      "- Pregnancy\n",
      "- Extraintestinale manifestations\n",
      "- Pouchitis\n",
      "RETURN up to 2 TOP choices of biological drugs given patient profile and context. Explain the PROS and CONS of the 2 choices.\n",
      "PATIENT PROFILE: 38 year old female with newly diagnosed moderate UC and psoriasis\n",
      "\n",
      "==========\n",
      "CURRENT ANSWER:\n",
      "Based on the patient's profile, the top two choices of biological drugs would be Ustekinumab (UST) and Vedolizumab (VDZ).\n",
      "\n",
      "1. Ustekinumab:\n",
      "- Advantages: Ustekinumab is a good choice for this patient as it has been shown to be effective in treating both ulcerative colitis and psoriasis, which the patient has. It is also administered subcutaneously, which may be more convenient for some patients.\n",
      "- Disadvantages: The main disadvantage of Ustekinumab is that it may not work in all patients. There may also be risks associated with its use, such as serious infections.\n",
      "\n",
      "2. Vedolizumab:\n",
      "- Advantages: Vedolizumab is a biologic that targets α or β integrins, which are involved in migration of immune cells to inflamed intestinal mucosa. It has been shown to be effective in treating moderate to severe ulcerative colitis. It is also less likely to lead to infections compared to other drugs.\n",
      "- Disadvantages: The main disadvantage of Vedolizumab is that it is administered intravenously, which may be inconvenient for some patients. It may also not work in all patients.\n",
      "\n",
      "Please note that the choice of treatment should be individualized based on the patient's specific condition, preferences, and potential side effects of the drugs. The patient should also be closely monitored during treatment for any adverse effects.\n",
      "==========\n",
      "REFINED ANSWER:\n",
      "\u001b[0m\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "Retrying langchain.chat_models.openai.ChatOpenAI.completion_with_retry.<locals>._completion_with_retry in 4.0 seconds as it raised RateLimitError: Rate limit reached for 10KTPM-200RPM in organization org-ETbTMTN2JXYOUPDJgxuH2iO6 on tokens per min. Limit: 10000 / min. Please try again in 6ms. Contact us through our help center at help.openai.com if you continue to have issues..\n",
      "Retrying langchain.chat_models.openai.ChatOpenAI.completion_with_retry.<locals>._completion_with_retry in 4.0 seconds as it raised RateLimitError: Rate limit reached for 10KTPM-200RPM in organization org-ETbTMTN2JXYOUPDJgxuH2iO6 on tokens per min. Limit: 10000 / min. Please try again in 6ms. Contact us through our help center at help.openai.com if you continue to have issues..\n",
      "Retrying langchain.chat_models.openai.ChatOpenAI.completion_with_retry.<locals>._completion_with_retry in 4.0 seconds as it raised RateLimitError: Rate limit reached for 10KTPM-200RPM in organization org-ETbTMTN2JXYOUPDJgxuH2iO6 on tokens per min. Limit: 10000 / min. Please try again in 6ms. Contact us through our help center at help.openai.com if you continue to have issues..\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\n",
      "\u001b[1m> Finished chain.\u001b[0m\n",
      "\n",
      "\u001b[1m> Finished chain.\u001b[0m\n",
      "2023-10-02 17:18:11,775:INFO: 5405 tokens were added to prompt from 10 documents\n",
      "Query: 25 year old pregnant woman with severe distal ulcerative colitis\n",
      "\n",
      "\n",
      "\n",
      "\u001b[1m> Entering new SequentialChain chain...\u001b[0m\n",
      "\n",
      "\n",
      "\u001b[1m> Entering new RetrievalQAWithSourcesChain chain...\u001b[0m\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "Retrying langchain.chat_models.openai.ChatOpenAI.completion_with_retry.<locals>._completion_with_retry in 4.0 seconds as it raised RateLimitError: Rate limit reached for 10KTPM-200RPM in organization org-ETbTMTN2JXYOUPDJgxuH2iO6 on tokens per min. Limit: 10000 / min. Please try again in 6ms. Contact us through our help center at help.openai.com if you continue to have issues..\n",
      "Retrying langchain.chat_models.openai.ChatOpenAI.completion_with_retry.<locals>._completion_with_retry in 4.0 seconds as it raised RateLimitError: Rate limit reached for 10KTPM-200RPM in organization org-ETbTMTN2JXYOUPDJgxuH2iO6 on tokens per min. Limit: 10000 / min. Please try again in 6ms. Contact us through our help center at help.openai.com if you continue to have issues..\n",
      "Retrying langchain.chat_models.openai.ChatOpenAI.completion_with_retry.<locals>._completion_with_retry in 4.0 seconds as it raised RateLimitError: Rate limit reached for 10KTPM-200RPM in organization org-ETbTMTN2JXYOUPDJgxuH2iO6 on tokens per min. Limit: 10000 / min. Please try again in 6ms. Contact us through our help center at help.openai.com if you continue to have issues..\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\n",
      "\u001b[1m> Finished chain.\u001b[0m\n",
      "\n",
      "\n",
      "\u001b[1m> Entering new LLMChain chain...\u001b[0m\n",
      "Prompt after formatting:\n",
      "\u001b[32;1m\u001b[1;3mYou are a senior physician giving advice on treatment for moderate to severe ulcerative colitis (UC).\n",
      "Make reference to the CONTEXT given to assess the scenario.\n",
      "==========\n",
      "TASK: Your task is to analyse critically the CURRENT ANSWER given the CONTEXT.\n",
      "Then refine the existing answer (only if needed) based on the following instructions:\n",
      "- If no refinement needed, return the original answer in the correct output format.\n",
      "- If the answer cannot be inferred from CONTEXT, return \"NO ANSWER\".\n",
      "- The final output should be a list of up to 2 choices of biological drugs given patient profile and context and PROS/CONS for each recommendations.\n",
      "==========\n",
      "CONTEXT:\n",
      "Burr et al. \n",
      " \n",
      "7 of 45 \n",
      "INTRODUCTION \n",
      "  Ulcerative colitis (UC) is a chronic inflammatory disorder of the bowel that causes \n",
      "continuous mucosal inflammation commencing in the rectum and extending proximally for a \n",
      "variable extent.[1] It is estimated that UC affects 2.5 million people in Europe,[2] and the \n",
      "disease follows a relapsing and remitting course, with intermittent flares of disease activity, \n",
      "some of which may be moderate to severe. Management of these is medical, for the most \n",
      "part, with surgery reserved for patients with refractory disease. Although 5-aminosalicylates \n",
      "(5-ASAs) are efficacious for mild to moderate disease activity,[3-6] more severe flares are \n",
      "usually treated with corticosteroids.[7] However, these have potentially serious adverse \n",
      "effects and a substantial proportion of patients may become either dependent on them to \n",
      "maintain remission,[8] or refractory to them.[9] As a result, over the last 20 years novel \n",
      "drugs, with more precise modes of action, based on mechanisms of disease identified in \n",
      "genome wide association studies,[10] have been developed.  \n",
      "The first of these agents was infliximab, a drug targeting the pro-inflammatory \n",
      "cytokine tumour necrosis factor-α (TNF-α), which demonstrated efficacy in clinical trials in \n",
      "moderate to severe UC.[11] Since then, other drugs against TNF-α have been tested, such as \n",
      "adalimumab and golimumab.[12, 13] In addition, newer biological therapies targeting α or β \n",
      "integrins, which are involved in migration of immune cells to inflamed intestinal mucosa, \n",
      "such as vedolizumab or etrolizumab,[14, 15] or acting against other pro-inflammatory \n",
      "cytokines implicated in the pathogenesis of UC, such as ustekinumab,[16] have been tested. \n",
      "However, even these more selective drugs do not work in all patients, there may be risks \n",
      "associated with their use,[17-19] and the fact that they are administered either intravenously \n",
      "or subcutaneously, may be inconvenient for patients. The search for alternative agents for the \n",
      "treatment of UC has, therefore, continued.\n",
      "----------\n",
      "Therapeutic strategies for the management of recentlydiagnosedulcerative colitis. IMMs include thiopurines and methotrexate. 5-ASA, 5-amino salicylic acid; ASUC, acute severe ulcerative colitis; IPAA, ileal pouch anal anastomosis.\n",
      "\n",
      "Risk stratification: Mild\n",
      "Clinical features: NA\n",
      "Treatment options: 5-ASA (oral and/or topical)\n",
      "\n",
      "Risk stratification: Moderate\n",
      "Clinical features: NA\n",
      "Treatment options: Can consider 5-ASA (with rapid step-up if inadequate response)\n",
      "\n",
      "Risk stratification: Moderate\n",
      "Clinical features: NA\n",
      "Treatment options: VDZ or UST\n",
      "\n",
      "Risk stratification: Moderate\n",
      "Clinical features: NA\n",
      "Treatment options: Thiopurine\n",
      "\n",
      "Risk stratification: Moderate\n",
      "Clinical features: NA\n",
      "Treatment options: TNFi +/- IMM\n",
      "\n",
      "Risk stratification: Severe\n",
      "Clinical features: NA\n",
      "Treatment options: TNFi +/- IMM\n",
      "\n",
      "Risk stratification: Severe\n",
      "Clinical features: NA\n",
      "Treatment options: Subtotal colectomy + IPAA or cyclosporine (for ASUC)\n",
      "\n",
      "Risk stratification: Additional consideration: EIM present\n",
      "Clinical features: Psoriasis or psoriatic arthritis\n",
      "Treatment options: UST\n",
      "\n",
      "Risk stratification: Additional consideration: EIM present\n",
      "Clinical features: Other arthritis\n",
      "Treatment options: TNFi\n",
      "\n",
      "\n",
      "----------\n",
      "Parkes, M., Vermeire, S., Rioux, J.D., Mansﬁeld, J., Silverberg, M.S., Radford-\n",
      "Smith, G., McGovern, D.P., Barrett, J.C., Lees, C.W., 2016. Inherited determinants of\n",
      "crohn's disease and ulcerative colitis phenotypes: a genetic association study. Lancet\n",
      "387 (10014), 156–167.\n",
      "Colombel, J.F., Sandborn, W.J., Rutgeerts, P., Enns, R., Hanauer, S.B., Panaccione, R.,\n",
      "Schreiber, S., Byczkowski, D., Li, J., Kent, J.D., Pollack, P.F., 2007. Adalimumab for\n",
      "maintenance of clinical response and remission in patients with crohn's disease: the\n",
      "charm trial. Gastroenterology 132 (1), 52–65.\n",
      "Conrad, M.A., Kelsen, J.R., 2020. The treatment of pediatric inﬂammatory bowel disease\n",
      "with biologic therapies. Curr. Gastroenterol. Rep. 22 (8), 36–51.\n",
      "Csontos, A.A., Molnar, A., Piri, Z., Katona, B., Dako, S., Palﬁ, E., Miheller, P., 2016. The\n",
      "effect of anti-tnfalpha induction therapy on the nutritional status and dietary intake\n",
      "in inﬂammatory bowel disease. J Gastrointestin Liver Dis 25 (1), 49–56.\n",
      "Dai, Z.H., Xu, X.T., Ran, Z.H., 2020. Associations between obesity and the effectiveness of\n",
      "anti-tumor necrosis factor-alpha agents in inﬂammatory bowel disease patients: a\n",
      "literature review and meta-analysis. Ann. Pharmacother. 54 (8), 729–741.\n",
      "Danese, S., Colombel, J.F., Lukas, M., Gisbert, J.P., D’Haens, G., Hayee, B., Panaccione, R.,\n",
      "Kim, H.S., Reinisch, W., Tyrrell, H., Oh, Y.S., Tole, S., Chai, A., Chamberlain-\n",
      "James, K., Tang, M.T., Schreiber, S., Group, G.S., 2021. Etrolizumab versus inﬂiximab\n",
      "for the treatment of moderately to severely active ulcerative colitis (gardenia): a\n",
      "randomised, double-blind, double-dummy, phase 3 study. Lancet Gastroenterol\n",
      "Hepatol 7 (2), 118–127.\n",
      "Danese, S., Fiorino, G., Peyrin-Biroulet, L., Lucenteforte, E., Virgili, G., Moja, L.,\n",
      "Bonovas, S., 2014. Biological agents for moderately to severely active ulcerative\n",
      "colitis: a systematic review and network meta-analysis. Ann. Intern. Med. 160 (10),\n",
      "704–711.\n",
      "P. Juillerat et al.\n",
      "Current Research in Pharmacology and Drug Discovery 3 (2022) 100104\n",
      "6\n",
      "----------\n",
      "laise, weight loss, and fever. Disease onset commonly occurs \n",
      "between the ages of 15 and 30 years and the annual global \n",
      "© The Author(s) 2023. Published by Oxford University Press on behalf of Crohn's & Colitis Foundation.\n",
      "This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), \n",
      "which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.\n",
      "Received for publication: September 21, 2022. Editorial Decision: January 25, 2023\n",
      " \n",
      "Downloaded from https://academic.oup.com/crohnscolitis360/article/5/2/otad009/7066911 by National University of Singapore user on 23 May 2023\n",
      "----------\n",
      "Disease Phenotype and Clinical Characteristics\n",
      "The International Organization for the Study of Inﬂam-\n",
      "matory Bowel Disease and the American Gastroenterological\n",
      "Association (AGA) provide a framework for categorization of\n",
      "CD and UC severity into mild-, moderate-, and high-risk\n",
      "groups based on phenotype and other characteristics.59,60\n",
      "In CD, the presence of large or deep mucosal lesions on\n",
      "endoscopy or magnetic resonance imaging (MRI), history of\n",
      "a ﬁstula, abscess, or intestinal resection are predictors of\n",
      "worse outcomes.59,60 In a prospective population-based\n",
      "inception cohort of 213 patients with CD, penetrating\n",
      "behavior was associated with a higher risk of progression to\n",
      "perianal disease (HR, 5.65; 95% CI, 2.65–12.03) and was a\n",
      "risk factor for resection (HR, 3.92; 95% CI, 1.86–8.67) and\n",
      "hospitalization (HR, 1.01; 95% CI, 1.00–1.01).16 Ileal and\n",
      "upper gastrointestinal disease location and extensive dis-\n",
      "ease are also markers of severe disease.61 Cigarette smoking\n",
      "is associated with complications and need for therapy\n",
      "escalation.61\n",
      "In CD, the threshold of suspicion should be low for high-\n",
      "quality imaging of the pelvis, such as MRI, to rule our\n",
      "perianal CD. In a retrospective study of 136 pediatric CD\n",
      "patients, presence of anal ﬁssures and skin tags, non-White\n",
      "race, and elevated C-reactive protein (CRP) were risk factors\n",
      "for perianal CD.62 In another study of 274 patients in China\n",
      "with recently diagnosed CD, all of whom underwent MRI\n",
      "pelvis, asymptomatic perianal ﬁstulas were diagnosed in\n",
      "17.5% of patients and colonic location of CD was a risk\n",
      "factor for asymptomatic perianal ﬁstulas.63\n",
      "In UC, corresponding predictors of aggressive disease\n",
      "advised by the International Organization for the Study of\n",
      "Inﬂammatory Bowel Disease include active colonic ulcers\n",
      "and prior use of biologics.59 Extensive colitis, deep ulcers,\n",
      "need for corticosteroids, hospitalization, Clostridium difﬁcile,\n",
      "and cytomegalovirus infection also indicate higher colec-\n",
      "tomy risk.64 Of note, disease extension from limited disease\n",
      "to\n",
      "extensive\n",
      "or\n",
      "pancolitis\n",
      "is\n",
      "associated\n",
      "with\n",
      "worse\n",
      "prognosis.45,65\n",
      "In addition, co-occurrence of other immune-mediated\n",
      "inﬂammatory diseases can occur, most commonly with\n",
      "psoriasis and asthma, but also, in more rare instances, with\n",
      "other gastrointestinal diseases (eg, celiac, nonalcoholic fatty\n",
      "liver disease,66 and eosinophilic esophagitis).67,68 Presence\n",
      "of a concomitant immune-mediated inﬂammatory disease is\n",
      "Figure\n",
      "1. Inﬂammatory\n",
      "bowel disease severity vs\n",
      "----------\n",
      "severely active ulcerative colitis: results from phase 3 \n",
      "U-ACCOMPLISH study. J Crohn’s Colitis 2021; 15 (suppl 1): S021–22.\n",
      "9 \n",
      "Thorlund K, Druyts E, Mills EJ, Fedorak RN, Marshall JK. \n",
      "Adalimumab versus infliximab for the treatment of moderate to \n",
      "severe ulcerative colitis in adult patients naïve to anti-TNF therapy: \n",
      "an indirect treatment comparison meta-analysis. J Crohn’s Colitis \n",
      "2014; 8: 571–81.\n",
      "10 \n",
      "Danese S, Fiorino G, Peyrin-Biroulet L, et al. Biological agents for \n",
      "moderately to severely active ulcerative colitis: a systematic review \n",
      "and network meta-analysis. Ann Intern Med 2014; 160: 704–11.\n",
      "11 \n",
      "Singh S, Fumery M, Sandborn WJ, Murad MH. Systematic review \n",
      "with network meta-analysis: first- and second-line pharmacotherapy \n",
      "for moderate-severe ulcerative colitis. Aliment Pharmacol Ther 2018; \n",
      "47: 162–75.\n",
      "12 \n",
      "Bonovas S, Lytras T, Nikolopoulos G, Peyrin-Biroulet L, Danese S. \n",
      "Systematic review with network meta-analysis: comparative \n",
      "assessment of tofacitinib and biological therapies for moderate-to-\n",
      "severe ulcerative colitis. Aliment Pharmacol Ther 2018; 47: 454–65.\n",
      "13 \n",
      "Singh S, Murad MH, Fumery M, Dulai PS, Sandborn WJ. First- and \n",
      "second-line pharmacotherapies for patients with moderate to \n",
      "severely active ulcerative colitis: an updated network meta-analysis. \n",
      "Clin Gastroenterol Hepatol 2020; 18: 2179–91.e6.\n",
      "14 \n",
      "Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting \n",
      "items for systematic reviews and meta-analyses: the PRISMA \n",
      "statement. Ann Intern Med 2009; 151: 264–69.\n",
      "15 \n",
      "Jansen JP, Fleurence R, Devine B, et al. Interpreting indirect \n",
      "treatment comparisons and network meta-analysis for health-care \n",
      "decision making: report of the ISPOR Task Force on Indirect \n",
      "Treatment Comparisons Good Research Practices: part 1. \n",
      "Value Health 2011; 14: 417–28.\n",
      "16 \n",
      "Sterne JAC, Savović J, Page MJ, et al. RoB 2: a revised tool for \n",
      "assessing risk of bias in randomised trials. BMJ 2019; 366: l4898.\n",
      "17 \n",
      "Rücker G, Schwarzer G. Ranking treatments in frequentist network \n",
      "meta-analysis works without resampling methods. \n",
      "BMC Med Res Methodol 2015; 15: 58.\n",
      "----------\n",
      "Burr et al. \n",
      " \n",
      "5 of 45 \n",
      "STUDY HIGHLIGHTS \n",
      " \n",
      "What is already known about this subject \n",
      "• Ulcerative colitis (UC) follows a relapsing and remitting course, with intermittent \n",
      "flares of disease activity, some of which may be moderate to severe. \n",
      "• These are usually treated with corticosteroids, which have potentially serious adverse \n",
      "effects, so biological therapies and small molecules have been developed and licensed \n",
      "for this indication.  \n",
      "• Although previous network meta-analyses have compared their efficacy and safety, \n",
      "this is a rapidly moving field, and there are already several newer drugs that have \n",
      "shown efficacy in phase III clinical trials that were not considered in these. \n",
      " \n",
      "What are the new findings \n",
      "• In terms of clinical remission and clinical response, upadacitinib 45mg o.d. ranked \n",
      "first in all patients, in patients previously exposed to anti-tumour necrosis factor \n",
      "(TNF)-α therapies, and in patients naïve to these drugs.  \n",
      "• In terms of endoscopic improvement infliximab 10mg/kg ranked first, followed by \n",
      "upadacitinib 45mg o.d., and infliximab 5mg/kg.  \n",
      "• However, for endoscopic improvement again upadacitinib 45mg o.d. ranked first in \n",
      "patients previously exposed to anti-TNF-α therapies, and in patients who were anti-\n",
      "TNF-α naïve.  \n",
      "• None of the drugs studied were more likely to lead to serious adverse events than \n",
      "placebo.\n",
      "----------\n",
      "Articles\n",
      "www.thelancet.com/gastrohep   Vol 7   February 2022 \n",
      "161\n",
      "Lancet Gastroenterol Hepatol \n",
      "2022; 7: 161–70\n",
      "Published Online \n",
      "November 29, 2021 \n",
      "https://doi.org/10.1016/ \n",
      "S2468-1253(21)00377-0\n",
      "See Comment page 110\n",
      "*Contributed equally\n",
      "Inflammatory Bowel Disease \n",
      "Unit, Gastroenterology \n",
      "Section, Department of \n",
      "Internal Medicine, Centro de \n",
      "Educación Médica e \n",
      "Investigaciones Clínicas, \n",
      "Buenos Aires, Argentina \n",
      "(J S Lasa MD, P A Olivera MD); \n",
      "Gastroenterology Department, \n",
      "Hospital Británico de Buenos \n",
      "Aires, Buenos Aires, Argentina \n",
      "(J S Lasa); Zane Cohen Centre \n",
      "for Digestive Diseases, \n",
      "Lunenfeld-Tanenbaum \n",
      "Research Institute, Sinai Health \n",
      "System, Toronto, ON, Canada \n",
      "(P A Olivera); Division of \n",
      "Gastroenterology, Mount Sinai \n",
      "Hospital, University of Toronto, \n",
      "Toronto, ON, Canada \n",
      "(P A Olivera); Gastroenterology \n",
      "and Endoscopy, IRCCS Ospedale \n",
      "San Raffaele and University \n",
      "Vita-Salute San Raffaele, \n",
      "Milano, Italy \n",
      "(Prof S Danese MD); INSERM \n",
      "NGERE and Department of \n",
      "Hepatogastroenterology, \n",
      "Nancy University Hospital, \n",
      "Lorraine University, \n",
      "Vandoeuvre-lés-Nancy, France \n",
      "(Prof L Peyrin-Biroulet MD) \n",
      "Correspondence to: \n",
      "Prof Laurent Peyrin-Biroulet, \n",
      "INSERM NGERE and Department \n",
      "of Hepatogastroenterology, \n",
      "Nancy University Hospital, \n",
      "Lorraine University, Vandoeuvre-\n",
      "lès-Nancy F-54511, France \n",
      "peyrinbiroulet@gmail.com\n",
      "Efficacy and safety of biologics and small molecule drugs for \n",
      "patients with moderate-to-severe ulcerative colitis: \n",
      "a systematic review and network meta-analysis \n",
      "Juan S Lasa*, Pablo A Olivera*, Silvio Danese, Laurent Peyrin-Biroulet\n",
      "Summary\n",
      "Background There is a growing armamentarium for the treatment of moderate-to-severe ulcerative colitis. We aimed \n",
      "to compare the relative efficacy and safety of biologics and small molecule drugs for the treatment of patients with \n",
      "moderate-to-severe ulcerative colitis.\n",
      "Methods In this systematic review and network meta-analysis, we searched MEDLINE, Embase, and the Cochrane \n",
      "Central Register of Controlled Trials without language restrictions for articles published between Jan 1, 1990, and \n",
      "July 1, 2021. Major congresses’ databases from Jan 1, 2018, to July 3, 2021, were reviewed manually. Phase 3, placebo-\n",
      "controlled or head-to-head randomised controlled trials (RCTs) assessing the efficacy and safety of biologics or small \n",
      "molecule drugs as induction or maintenance therapies for patients with moderate-to-severe ulcerative colitis were\n",
      "----------\n",
      "perianal CD varied between 11% and 19% at 1–10 years\n",
      "after diagnosis.9 In a study of 983 patients with CD in Asia,\n",
      "stricturing or penetrating CD occurred in 41% and perianal\n",
      "disease in 25% of patients.10 At the other end of the spec-\n",
      "trum, incidental terminal ileitis can be diagnosed in 1.6% of\n",
      "individuals undergoing nondiagnostic colonoscopy, with an\n",
      "uncertain but likely low rate of progression to overt CD.11\n",
      "With respect to UC, most patients have mild to moderate\n",
      "severity and 10%–15% of patients can experience a severe\n",
      "course.12 In a population-based cohort study, proctosigmoid\n",
      "location of colitis occurred in 73% of patients; of these,\n",
      "disease extension occurred in 23% of patients at 7 years of\n",
      "follow-up and it was a marker of worse prognosis.13 The\n",
      "risk of surgery for CD and UC can be up to 46.6% and 15.6%\n",
      "10 years after diagnosis, respectively, and has decreased\n",
      "signiﬁcantly during the last 6 decades.14\n",
      "The symptoms associated with IBD can be waxing and\n",
      "waning, but the underlying systemic inﬂammation can lead\n",
      "to progressive, cumulative, and often irreversible intestinal\n",
      "damage\n",
      "and\n",
      "risk\n",
      "of\n",
      "complications\n",
      "if\n",
      "not\n",
      "treated\n",
      "adequately.15\n",
      "Complications\n",
      "associated\n",
      "with\n",
      "ongoing\n",
      "inﬂammation in CD include strictures, obstructions, ﬁstulas,\n",
      "abscesses, and surgery,3,16 and those associated with UC\n",
      "include loss of colonic and anorectal function, surgery, and\n",
      "colorectal cancer.2,4,17 Other complications include anemia,\n",
      "nutritional deﬁciencies, loss of bone density, and progres-\n",
      "sive loss of quality of life. In children, persistent inﬂamma-\n",
      "tion\n",
      "is\n",
      "associated\n",
      "with\n",
      "growth\n",
      "impairment,\n",
      "risking\n",
      "permanent loss of height.18 Similar to other chronic dis-\n",
      "eases, such as rheumatoid arthritis, the concept of cumula-\n",
      "tive damage is now acknowledged in IBD and can be\n",
      "measured using validated tools, such as the Lemann Index.19\n",
      "Limited Correlations Among Inﬂammation,\n",
      "Symptoms, and Complications\n",
      "The concordance between intestinal inﬂammation and\n",
      "symptoms can be limited, especially in CD.20,21 In a\n",
      "population-based cohort, more than 20% of CD patients\n",
      "were found to have strictures and penetrating disease at the\n",
      "time of diagnosis, suggesting that clinically silent inﬂam-\n",
      "mation may precede formal diagnosis.22 The STRIDE\n",
      "(Selecting Therapeutic Targets in Inﬂammatory Bowel Dis-\n",
      "ease) recommendations, updated recently, are meant to\n",
      "target endoscopic healing, minimize disability, and restore\n",
      "quality of life and adequate growth in children, in addition\n",
      "----------\n",
      "associated with improved long-term outcomes.33 Data on\n",
      "the impact of early therapy in UC are more limited, but, as\n",
      "UC is also a progressive disease with risk of colorectal\n",
      "cancer, surgery, and loss of colonic function, it is reasonable\n",
      "to treat early to mitigate these risks.\n",
      "How to Diagnose Inﬂammatory Bowel Disease\n",
      "Early\n",
      "IBD is heterogenous with wide variation in presentation.\n",
      "Disease activity at presentation can range from mild to severe\n",
      "and, as discussed, symptoms may be mild to none. These can\n",
      "make the IBD diagnosis challenging, especially at a primary\n",
      "care level. Danese et al34 have proposed a Red Flags Index\n",
      "consisting of a 21-item questionnaire to help providers triage\n",
      "and identify patients with concerning symptoms in a timely\n",
      "manner and refer to specialists appropriately. A useful adjunct\n",
      "to symptom-based criteria is fecal calprotectin (FC), a stool\n",
      "marker of inﬂammation; in a large meta-analysis, FC � 40 mg/\n",
      "g carried a �1% probability of IBD, effectively excluding the\n",
      "diagnosis of IBD.35 Similarly, in the Red Flags Index validation\n",
      "study, combining the index with FC (Red Flags Index �8 and/\n",
      "or FC >250 mg/g) increased the positive predictive value from\n",
      "4% to 21% and negative predictive value from 97% to\n",
      "100%.36 Diagnostic criteria for IBD involve a composite of\n",
      "clinical symptoms, endoscopic, biomarker, and cross-sectional\n",
      "imaging features, which are beyond the scope of this review.\n",
      "We refer readers to the excellent guidelines laid out by the\n",
      "American College of Gastroenterology, European Crohn’s and\n",
      "Colitis\n",
      "Organization,\n",
      "and\n",
      "British\n",
      "Society\n",
      "of\n",
      "Gastro-\n",
      "enterology.37–40\n",
      "Risk Stratiﬁcation and Prognostication\n",
      "at Diagnosis\n",
      "Appropriately\n",
      "risk-stratifying\n",
      "prognosis\n",
      "in\n",
      "patients\n",
      "recently diagnosed with IBD is essential to inform selection\n",
      "of the most appropriate treatment and monitoring strate-\n",
      "gies. CD and UC phenotype and disease activity at initial\n",
      "presentation can vary widely from limited and mild to\n",
      "extensive and complicated. Certain baseline clinical features\n",
      "are associated with a more aggressive disease course with\n",
      "higher risk of progression and complications. In higher-risk\n",
      "patients, early control of inﬂammation with immune-\n",
      "modifying therapies is critical. However, immunosuppres-\n",
      "sive therapies are associated with safety concerns in the\n",
      "short- and long-term, and entail signiﬁcant health care costs.\n",
      "Therefore, a consideration of risks, beneﬁts, and alternatives\n",
      "is key to develop an individualized therapeutic plan for the\n",
      "informed patient.\n",
      "==========\n",
      "ORIGINAL QUESTION: ANALYSE the given patient profile based on given query based on one of the following criteria:\n",
      "- Whether treated patient is new patient or patient under maintenance\n",
      "- Prior response to Infliximab\n",
      "- Prior failure to Anti-TNF agents\n",
      "- Prior failure to Vedolizumab\n",
      "- Age\n",
      "- Pregnancy\n",
      "- Extraintestinale manifestations\n",
      "- Pouchitis\n",
      "RETURN up to 2 TOP choices of biological drugs given patient profile and context. Explain the PROS and CONS of the 2 choices.\n",
      "PATIENT PROFILE: 25 year old pregnant woman with severe distal ulcerative colitis\n",
      "\n",
      "==========\n",
      "CURRENT ANSWER:\n",
      "[{\"drug_name\": \"Vedolizumab\", \"advantages\": \"Vedolizumab is a gut-selective immunosuppressant, meaning it specifically targets inflammation in the gut, potentially reducing systemic side effects. It has been shown to be effective in treating moderate to severe ulcerative colitis. It is also considered safe during pregnancy.\", \"disadvantages\": \"Vedolizumab is administered intravenously, which may be inconvenient for some patients. It may also take several weeks to start working, and not all patients respond to treatment. Side effects can include headache, joint pain, nausea, and infections.\"}, {\"drug_name\": \"Ustekinumab\", \"advantages\": \"Ustekinumab targets a specific protein involved in inflammation, potentially reducing side effects compared to broader immunosuppressants. It has been shown to be effective in treating moderate to severe ulcerative colitis. It is also considered safe during pregnancy.\", \"disadvantages\": \"Ustekinumab is administered via injection, which may be inconvenient for some patients. It may also take several weeks to start working, and not all patients respond to treatment. Side effects can include upper respiratory infections, fatigue, and headache.\"}]\n",
      "==========\n",
      "REFINED ANSWER:\n",
      "\u001b[0m\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "Retrying langchain.chat_models.openai.ChatOpenAI.completion_with_retry.<locals>._completion_with_retry in 4.0 seconds as it raised RateLimitError: Rate limit reached for 10KTPM-200RPM in organization org-ETbTMTN2JXYOUPDJgxuH2iO6 on tokens per min. Limit: 10000 / min. Please try again in 6ms. Contact us through our help center at help.openai.com if you continue to have issues..\n",
      "Retrying langchain.chat_models.openai.ChatOpenAI.completion_with_retry.<locals>._completion_with_retry in 4.0 seconds as it raised RateLimitError: Rate limit reached for 10KTPM-200RPM in organization org-ETbTMTN2JXYOUPDJgxuH2iO6 on tokens per min. Limit: 10000 / min. Please try again in 6ms. Contact us through our help center at help.openai.com if you continue to have issues..\n",
      "Retrying langchain.chat_models.openai.ChatOpenAI.completion_with_retry.<locals>._completion_with_retry in 4.0 seconds as it raised RateLimitError: Rate limit reached for 10KTPM-200RPM in organization org-ETbTMTN2JXYOUPDJgxuH2iO6 on tokens per min. Limit: 10000 / min. Please try again in 6ms. Contact us through our help center at help.openai.com if you continue to have issues..\n",
      "Retrying langchain.chat_models.openai.ChatOpenAI.completion_with_retry.<locals>._completion_with_retry in 8.0 seconds as it raised RateLimitError: Rate limit reached for 10KTPM-200RPM in organization org-ETbTMTN2JXYOUPDJgxuH2iO6 on tokens per min. Limit: 10000 / min. Please try again in 6ms. Contact us through our help center at help.openai.com if you continue to have issues..\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\n",
      "\u001b[1m> Finished chain.\u001b[0m\n",
      "\n",
      "\u001b[1m> Finished chain.\u001b[0m\n",
      "2023-10-02 17:19:24,137:INFO: 5133 tokens were added to prompt from 10 documents\n",
      "Query: 56 year old man with moderate to severe ulcerative colitis and ankylosing spondylitis\n",
      "\n",
      "\n",
      "\n",
      "\u001b[1m> Entering new SequentialChain chain...\u001b[0m\n",
      "\n",
      "\n",
      "\u001b[1m> Entering new RetrievalQAWithSourcesChain chain...\u001b[0m\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "Retrying langchain.chat_models.openai.ChatOpenAI.completion_with_retry.<locals>._completion_with_retry in 4.0 seconds as it raised RateLimitError: Rate limit reached for 10KTPM-200RPM in organization org-ETbTMTN2JXYOUPDJgxuH2iO6 on tokens per min. Limit: 10000 / min. Please try again in 6ms. Contact us through our help center at help.openai.com if you continue to have issues..\n",
      "Retrying langchain.chat_models.openai.ChatOpenAI.completion_with_retry.<locals>._completion_with_retry in 4.0 seconds as it raised RateLimitError: Rate limit reached for 10KTPM-200RPM in organization org-ETbTMTN2JXYOUPDJgxuH2iO6 on tokens per min. Limit: 10000 / min. Please try again in 6ms. Contact us through our help center at help.openai.com if you continue to have issues..\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\n",
      "\u001b[1m> Finished chain.\u001b[0m\n",
      "\n",
      "\n",
      "\u001b[1m> Entering new LLMChain chain...\u001b[0m\n",
      "Prompt after formatting:\n",
      "\u001b[32;1m\u001b[1;3mYou are a senior physician giving advice on treatment for moderate to severe ulcerative colitis (UC).\n",
      "Make reference to the CONTEXT given to assess the scenario.\n",
      "==========\n",
      "TASK: Your task is to analyse critically the CURRENT ANSWER given the CONTEXT.\n",
      "Then refine the existing answer (only if needed) based on the following instructions:\n",
      "- If no refinement needed, return the original answer in the correct output format.\n",
      "- If the answer cannot be inferred from CONTEXT, return \"NO ANSWER\".\n",
      "- The final output should be a list of up to 2 choices of biological drugs given patient profile and context and PROS/CONS for each recommendations.\n",
      "==========\n",
      "CONTEXT:\n",
      "Burr et al. \n",
      " \n",
      "7 of 45 \n",
      "INTRODUCTION \n",
      "  Ulcerative colitis (UC) is a chronic inflammatory disorder of the bowel that causes \n",
      "continuous mucosal inflammation commencing in the rectum and extending proximally for a \n",
      "variable extent.[1] It is estimated that UC affects 2.5 million people in Europe,[2] and the \n",
      "disease follows a relapsing and remitting course, with intermittent flares of disease activity, \n",
      "some of which may be moderate to severe. Management of these is medical, for the most \n",
      "part, with surgery reserved for patients with refractory disease. Although 5-aminosalicylates \n",
      "(5-ASAs) are efficacious for mild to moderate disease activity,[3-6] more severe flares are \n",
      "usually treated with corticosteroids.[7] However, these have potentially serious adverse \n",
      "effects and a substantial proportion of patients may become either dependent on them to \n",
      "maintain remission,[8] or refractory to them.[9] As a result, over the last 20 years novel \n",
      "drugs, with more precise modes of action, based on mechanisms of disease identified in \n",
      "genome wide association studies,[10] have been developed.  \n",
      "The first of these agents was infliximab, a drug targeting the pro-inflammatory \n",
      "cytokine tumour necrosis factor-α (TNF-α), which demonstrated efficacy in clinical trials in \n",
      "moderate to severe UC.[11] Since then, other drugs against TNF-α have been tested, such as \n",
      "adalimumab and golimumab.[12, 13] In addition, newer biological therapies targeting α or β \n",
      "integrins, which are involved in migration of immune cells to inflamed intestinal mucosa, \n",
      "such as vedolizumab or etrolizumab,[14, 15] or acting against other pro-inflammatory \n",
      "cytokines implicated in the pathogenesis of UC, such as ustekinumab,[16] have been tested. \n",
      "However, even these more selective drugs do not work in all patients, there may be risks \n",
      "associated with their use,[17-19] and the fact that they are administered either intravenously \n",
      "or subcutaneously, may be inconvenient for patients. The search for alternative agents for the \n",
      "treatment of UC has, therefore, continued.\n",
      "----------\n",
      "41 years (interquartile range, 40–42 y), and 60%\n",
      "(interquartile range, 56%–63%) were men. The median\n",
      "disease duration was 6.7 years (interquartile range,\n",
      "6.0–7.8 y), and 49% (interquartile range, 46%–55%) of\n",
      "patients had extensive colitis. A median of 40% (inter-\n",
      "quartile range, 30%–50%) of patients were treated with\n",
      "concomitant immunomodulators, and 51% (interquartile\n",
      "range, 45%–57%) were on corticosteroids at baseline.\n",
      "Patients across all trials and treatment arms were com-\n",
      "parable in terms of baseline prognostic variables, inclu-\n",
      "sion/exclusion\n",
      "criteria,\n",
      "and\n",
      "co-interventions.\n",
      "All\n",
      "outcomes were assessed uniformly based on the stan-\n",
      "dard deﬁnition of the Mayo Clinic score, between weeks\n",
      "6 and 10 for induction therapy (inﬂiximab, adalimumab,\n",
      "tofacitinib, ustekinumab, 8 weeks; golimumab, 6 weeks;\n",
      "vedolizumab, 6 weeks, 10 weeks, and 14 weeks in\n",
      "VARSITY),6 and weeks 30, 54, or 60 for maintenance\n",
      "therapy;\n",
      "endoscopy\n",
      "was\n",
      "read\n",
      "by\n",
      "blinded\n",
      "local\n",
      "Table 2. Comparative Efﬁcacy of Pharmacologic Agents for Induction of Clinical Remission and Endoscopic Improvement in Biologic-Naive Patients With Moderate–Severe\n",
      "Ulcerative Colitis Using Network Meta-Analysis\n",
      "Induction of clinical remission\n",
      "Induction of endoscopic improvement\n",
      "Ustekinumab 6 mg/kg\n",
      "0.96 (0.38–2.45)\n",
      "0.80 (0.35–1.83)\n",
      "0.73 (0.31–1.74)\n",
      "1.05 (0.48–2.32)\n",
      "0.50 (0.22–1.12)\n",
      "2.04 (1.03–4.05)\n",
      "0.92 (0.45–1.89)\n",
      "Tofacitinib 10 mg b.d.\n",
      "0.84 (0.39–1.82)\n",
      "0.76 (0.33–1.76)\n",
      "1.10 (0.51–2.34)\n",
      "0.52 (0.24–1.12)\n",
      "2.12 (1.12–4.02)\n",
      "0.74 (0.36–1.51)\n",
      "0.80 (0.4–1.62)\n",
      "Vedolizumab\n",
      "0.91 (0.44–1.86)\n",
      "1.31 (0.88–1.95)\n",
      "0.62 (0.34–1.15)\n",
      "2.54 (1.60–4.02)\n",
      "1.07 (0.58–1.98)\n",
      "1.17 (0.64–2.12)\n",
      "1.45 (0.80–2.61)\n",
      "Golimumab\n",
      "1.44 (0.76–2.75)\n",
      "0.69 (0.35–1.36)\n",
      "2.79 (1.64–4.02)\n",
      "1.17 (0.65–2.13)\n",
      "1.28 (0.72–2.29)\n",
      "1.59 (0.90–2.82)\n",
      "1.10 (0.71–1.71)\n",
      "Adalimumab\n",
      "0.48 (0.26–0.86)\n",
      "1.94 (1.30–2.88)\n",
      "0.56 (0.30–1.04)\n",
      "0.61 (0.34–1.11)\n",
      "0.76 (0.42–1.37)\n",
      "0.52 (0.33–0.83)\n",
      "0.48 (0.31–0.74)\n",
      "Inﬂiximab\n",
      "4.07 (2.67–6.21)\n",
      "1.86 (1.11–3.13)\n",
      "2.03 (1.23–3.34)\n",
      "2.52 (1.54–4.11)\n",
      "1.74 (1.25–2.41)\n",
      "1.58 (1.18–2.13)\n",
      "3.32 (2.39–4.60)\n",
      "Placebo\n",
      "NOTE. Comparisons should be read from left to right. Odds ratio for comparisons are in the cell in common between the column-deﬁning and row-deﬁning treatment. Numbers in bold are statistically signiﬁcant. For induction of\n",
      "clinical remission, an odds ratio greater than 1 favors row-deﬁning treatment. For induction of endoscopic improvement, an odds ratio greater than 1 favors column-deﬁning treatment. Numbers in parentheses indicate 95% CI.\n",
      "b.d., twice daily.\n",
      "----------\n",
      "Parkes, M., Vermeire, S., Rioux, J.D., Mansﬁeld, J., Silverberg, M.S., Radford-\n",
      "Smith, G., McGovern, D.P., Barrett, J.C., Lees, C.W., 2016. Inherited determinants of\n",
      "crohn's disease and ulcerative colitis phenotypes: a genetic association study. Lancet\n",
      "387 (10014), 156–167.\n",
      "Colombel, J.F., Sandborn, W.J., Rutgeerts, P., Enns, R., Hanauer, S.B., Panaccione, R.,\n",
      "Schreiber, S., Byczkowski, D., Li, J., Kent, J.D., Pollack, P.F., 2007. Adalimumab for\n",
      "maintenance of clinical response and remission in patients with crohn's disease: the\n",
      "charm trial. Gastroenterology 132 (1), 52–65.\n",
      "Conrad, M.A., Kelsen, J.R., 2020. The treatment of pediatric inﬂammatory bowel disease\n",
      "with biologic therapies. Curr. Gastroenterol. Rep. 22 (8), 36–51.\n",
      "Csontos, A.A., Molnar, A., Piri, Z., Katona, B., Dako, S., Palﬁ, E., Miheller, P., 2016. The\n",
      "effect of anti-tnfalpha induction therapy on the nutritional status and dietary intake\n",
      "in inﬂammatory bowel disease. J Gastrointestin Liver Dis 25 (1), 49–56.\n",
      "Dai, Z.H., Xu, X.T., Ran, Z.H., 2020. Associations between obesity and the effectiveness of\n",
      "anti-tumor necrosis factor-alpha agents in inﬂammatory bowel disease patients: a\n",
      "literature review and meta-analysis. Ann. Pharmacother. 54 (8), 729–741.\n",
      "Danese, S., Colombel, J.F., Lukas, M., Gisbert, J.P., D’Haens, G., Hayee, B., Panaccione, R.,\n",
      "Kim, H.S., Reinisch, W., Tyrrell, H., Oh, Y.S., Tole, S., Chai, A., Chamberlain-\n",
      "James, K., Tang, M.T., Schreiber, S., Group, G.S., 2021. Etrolizumab versus inﬂiximab\n",
      "for the treatment of moderately to severely active ulcerative colitis (gardenia): a\n",
      "randomised, double-blind, double-dummy, phase 3 study. Lancet Gastroenterol\n",
      "Hepatol 7 (2), 118–127.\n",
      "Danese, S., Fiorino, G., Peyrin-Biroulet, L., Lucenteforte, E., Virgili, G., Moja, L.,\n",
      "Bonovas, S., 2014. Biological agents for moderately to severely active ulcerative\n",
      "colitis: a systematic review and network meta-analysis. Ann. Intern. Med. 160 (10),\n",
      "704–711.\n",
      "P. Juillerat et al.\n",
      "Current Research in Pharmacology and Drug Discovery 3 (2022) 100104\n",
      "6\n",
      "----------\n",
      "Therapeutic strategies for the management of recentlydiagnosedulcerative colitis. IMMs include thiopurines and methotrexate. 5-ASA, 5-amino salicylic acid; ASUC, acute severe ulcerative colitis; IPAA, ileal pouch anal anastomosis.\n",
      "\n",
      "Risk stratification: Mild\n",
      "Clinical features: NA\n",
      "Treatment options: 5-ASA (oral and/or topical)\n",
      "\n",
      "Risk stratification: Moderate\n",
      "Clinical features: NA\n",
      "Treatment options: Can consider 5-ASA (with rapid step-up if inadequate response)\n",
      "\n",
      "Risk stratification: Moderate\n",
      "Clinical features: NA\n",
      "Treatment options: VDZ or UST\n",
      "\n",
      "Risk stratification: Moderate\n",
      "Clinical features: NA\n",
      "Treatment options: Thiopurine\n",
      "\n",
      "Risk stratification: Moderate\n",
      "Clinical features: NA\n",
      "Treatment options: TNFi +/- IMM\n",
      "\n",
      "Risk stratification: Severe\n",
      "Clinical features: NA\n",
      "Treatment options: TNFi +/- IMM\n",
      "\n",
      "Risk stratification: Severe\n",
      "Clinical features: NA\n",
      "Treatment options: Subtotal colectomy + IPAA or cyclosporine (for ASUC)\n",
      "\n",
      "Risk stratification: Additional consideration: EIM present\n",
      "Clinical features: Psoriasis or psoriatic arthritis\n",
      "Treatment options: UST\n",
      "\n",
      "Risk stratification: Additional consideration: EIM present\n",
      "Clinical features: Other arthritis\n",
      "Treatment options: TNFi\n",
      "\n",
      "\n",
      "----------\n",
      "severely active ulcerative colitis: results from phase 3 \n",
      "U-ACCOMPLISH study. J Crohn’s Colitis 2021; 15 (suppl 1): S021–22.\n",
      "9 \n",
      "Thorlund K, Druyts E, Mills EJ, Fedorak RN, Marshall JK. \n",
      "Adalimumab versus infliximab for the treatment of moderate to \n",
      "severe ulcerative colitis in adult patients naïve to anti-TNF therapy: \n",
      "an indirect treatment comparison meta-analysis. J Crohn’s Colitis \n",
      "2014; 8: 571–81.\n",
      "10 \n",
      "Danese S, Fiorino G, Peyrin-Biroulet L, et al. Biological agents for \n",
      "moderately to severely active ulcerative colitis: a systematic review \n",
      "and network meta-analysis. Ann Intern Med 2014; 160: 704–11.\n",
      "11 \n",
      "Singh S, Fumery M, Sandborn WJ, Murad MH. Systematic review \n",
      "with network meta-analysis: first- and second-line pharmacotherapy \n",
      "for moderate-severe ulcerative colitis. Aliment Pharmacol Ther 2018; \n",
      "47: 162–75.\n",
      "12 \n",
      "Bonovas S, Lytras T, Nikolopoulos G, Peyrin-Biroulet L, Danese S. \n",
      "Systematic review with network meta-analysis: comparative \n",
      "assessment of tofacitinib and biological therapies for moderate-to-\n",
      "severe ulcerative colitis. Aliment Pharmacol Ther 2018; 47: 454–65.\n",
      "13 \n",
      "Singh S, Murad MH, Fumery M, Dulai PS, Sandborn WJ. First- and \n",
      "second-line pharmacotherapies for patients with moderate to \n",
      "severely active ulcerative colitis: an updated network meta-analysis. \n",
      "Clin Gastroenterol Hepatol 2020; 18: 2179–91.e6.\n",
      "14 \n",
      "Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting \n",
      "items for systematic reviews and meta-analyses: the PRISMA \n",
      "statement. Ann Intern Med 2009; 151: 264–69.\n",
      "15 \n",
      "Jansen JP, Fleurence R, Devine B, et al. Interpreting indirect \n",
      "treatment comparisons and network meta-analysis for health-care \n",
      "decision making: report of the ISPOR Task Force on Indirect \n",
      "Treatment Comparisons Good Research Practices: part 1. \n",
      "Value Health 2011; 14: 417–28.\n",
      "16 \n",
      "Sterne JAC, Savović J, Page MJ, et al. RoB 2: a revised tool for \n",
      "assessing risk of bias in randomised trials. BMJ 2019; 366: l4898.\n",
      "17 \n",
      "Rücker G, Schwarzer G. Ranking treatments in frequentist network \n",
      "meta-analysis works without resampling methods. \n",
      "BMC Med Res Methodol 2015; 15: 58.\n",
      "----------\n",
      "Burr et al. \n",
      " \n",
      "5 of 45 \n",
      "STUDY HIGHLIGHTS \n",
      " \n",
      "What is already known about this subject \n",
      "• Ulcerative colitis (UC) follows a relapsing and remitting course, with intermittent \n",
      "flares of disease activity, some of which may be moderate to severe. \n",
      "• These are usually treated with corticosteroids, which have potentially serious adverse \n",
      "effects, so biological therapies and small molecules have been developed and licensed \n",
      "for this indication.  \n",
      "• Although previous network meta-analyses have compared their efficacy and safety, \n",
      "this is a rapidly moving field, and there are already several newer drugs that have \n",
      "shown efficacy in phase III clinical trials that were not considered in these. \n",
      " \n",
      "What are the new findings \n",
      "• In terms of clinical remission and clinical response, upadacitinib 45mg o.d. ranked \n",
      "first in all patients, in patients previously exposed to anti-tumour necrosis factor \n",
      "(TNF)-α therapies, and in patients naïve to these drugs.  \n",
      "• In terms of endoscopic improvement infliximab 10mg/kg ranked first, followed by \n",
      "upadacitinib 45mg o.d., and infliximab 5mg/kg.  \n",
      "• However, for endoscopic improvement again upadacitinib 45mg o.d. ranked first in \n",
      "patients previously exposed to anti-TNF-α therapies, and in patients who were anti-\n",
      "TNF-α naïve.  \n",
      "• None of the drugs studied were more likely to lead to serious adverse events than \n",
      "placebo.\n",
      "----------\n",
      "to\n",
      "extensive\n",
      "or\n",
      "pancolitis\n",
      "is\n",
      "associated\n",
      "with\n",
      "worse\n",
      "prognosis.45,65\n",
      "In addition, co-occurrence of other immune-mediated\n",
      "inﬂammatory diseases can occur, most commonly with\n",
      "psoriasis and asthma, but also, in more rare instances, with\n",
      "other gastrointestinal diseases (eg, celiac, nonalcoholic fatty\n",
      "liver disease,66 and eosinophilic esophagitis).67,68 Presence\n",
      "of a concomitant immune-mediated inﬂammatory disease is\n",
      "Figure\n",
      "1. Inﬂammatory\n",
      "bowel disease severity vs\n",
      "disease activity variables.\n",
      "ASCA, anti-Saccharomyces\n",
      "cerevisiae\n",
      "antibodies;\n",
      "ANCA,\n",
      "anti-neutrophil\n",
      "cytoplasmic\n",
      "antibodies;\n",
      "GMCSF,\n",
      "granulocyte-\n",
      "macrophage\n",
      "colony-\n",
      "stimulating\n",
      "factor;\n",
      "TI,\n",
      "terminal ileum.\n",
      "50\n",
      "Agrawal et al\n",
      "Gastroenterology Vol. 161, No. 1\n",
      "REVIEWS AND\n",
      "PERSPECTIVES\n",
      "----------\n",
      "Articles\n",
      "www.thelancet.com/gastrohep   Vol 7   February 2022 \n",
      "161\n",
      "Lancet Gastroenterol Hepatol \n",
      "2022; 7: 161–70\n",
      "Published Online \n",
      "November 29, 2021 \n",
      "https://doi.org/10.1016/ \n",
      "S2468-1253(21)00377-0\n",
      "See Comment page 110\n",
      "*Contributed equally\n",
      "Inflammatory Bowel Disease \n",
      "Unit, Gastroenterology \n",
      "Section, Department of \n",
      "Internal Medicine, Centro de \n",
      "Educación Médica e \n",
      "Investigaciones Clínicas, \n",
      "Buenos Aires, Argentina \n",
      "(J S Lasa MD, P A Olivera MD); \n",
      "Gastroenterology Department, \n",
      "Hospital Británico de Buenos \n",
      "Aires, Buenos Aires, Argentina \n",
      "(J S Lasa); Zane Cohen Centre \n",
      "for Digestive Diseases, \n",
      "Lunenfeld-Tanenbaum \n",
      "Research Institute, Sinai Health \n",
      "System, Toronto, ON, Canada \n",
      "(P A Olivera); Division of \n",
      "Gastroenterology, Mount Sinai \n",
      "Hospital, University of Toronto, \n",
      "Toronto, ON, Canada \n",
      "(P A Olivera); Gastroenterology \n",
      "and Endoscopy, IRCCS Ospedale \n",
      "San Raffaele and University \n",
      "Vita-Salute San Raffaele, \n",
      "Milano, Italy \n",
      "(Prof S Danese MD); INSERM \n",
      "NGERE and Department of \n",
      "Hepatogastroenterology, \n",
      "Nancy University Hospital, \n",
      "Lorraine University, \n",
      "Vandoeuvre-lés-Nancy, France \n",
      "(Prof L Peyrin-Biroulet MD) \n",
      "Correspondence to: \n",
      "Prof Laurent Peyrin-Biroulet, \n",
      "INSERM NGERE and Department \n",
      "of Hepatogastroenterology, \n",
      "Nancy University Hospital, \n",
      "Lorraine University, Vandoeuvre-\n",
      "lès-Nancy F-54511, France \n",
      "peyrinbiroulet@gmail.com\n",
      "Efficacy and safety of biologics and small molecule drugs for \n",
      "patients with moderate-to-severe ulcerative colitis: \n",
      "a systematic review and network meta-analysis \n",
      "Juan S Lasa*, Pablo A Olivera*, Silvio Danese, Laurent Peyrin-Biroulet\n",
      "Summary\n",
      "Background There is a growing armamentarium for the treatment of moderate-to-severe ulcerative colitis. We aimed \n",
      "to compare the relative efficacy and safety of biologics and small molecule drugs for the treatment of patients with \n",
      "moderate-to-severe ulcerative colitis.\n",
      "Methods In this systematic review and network meta-analysis, we searched MEDLINE, Embase, and the Cochrane \n",
      "Central Register of Controlled Trials without language restrictions for articles published between Jan 1, 1990, and \n",
      "July 1, 2021. Major congresses’ databases from Jan 1, 2018, to July 3, 2021, were reviewed manually. Phase 3, placebo-\n",
      "controlled or head-to-head randomised controlled trials (RCTs) assessing the efficacy and safety of biologics or small \n",
      "molecule drugs as induction or maintenance therapies for patients with moderate-to-severe ulcerative colitis were\n",
      "----------\n",
      "prognosis, with 1 study reporting fewer hospitalizations and\n",
      "less frequent requirement of immunosuppression in pa-\n",
      "tients diagnosed after age 60 years,47 and a meta-analysis\n",
      "suggested\n",
      "that,\n",
      "although\n",
      "elderly\n",
      "IBD\n",
      "presents\n",
      "less\n",
      "commonly with complications, there are similar or higher\n",
      "rates of surgery compared to a nonelderly population.48 It is\n",
      "being increasingly recognized that frailty, rather than\n",
      "chronologic age, may be the driver of adverse outcomes in\n",
      "this group.49,50\n",
      "Other Demographic Variables\n",
      "There are signiﬁcant differences in IBD phenotype\n",
      "and outcomes based on race and ethnicity, likely due to\n",
      "a multitude of factors, both social and biologic. Emer-\n",
      "gency department use, hospitalization, complicated dis-\n",
      "ease\n",
      "course,\n",
      "and\n",
      "IBD-related\n",
      "disability\n",
      "are\n",
      "more\n",
      "common in minority and lower socioeconomic status\n",
      "groups.51,52 In a study of 770 patients with IBD, South\n",
      "Asian immigrants living in the United Kingdom were\n",
      "more\n",
      "likely\n",
      "to\n",
      "have\n",
      "extensive\n",
      "UC\n",
      "and\n",
      "colonic\n",
      "CD\n",
      "compared with their native counterparts,53 which might\n",
      "be related, in part, to limited access to care.54 Genes\n",
      "implicated in IBD risk also differ in non-White compared\n",
      "with White patients with IBD.55 Being aware of the\n",
      "higher vulnerability to adverse IBD-related outcomes in\n",
      "these vulnerable groups should prompt careful moni-\n",
      "toring to limit adverse outcomes.\n",
      "There are increasing data on sex-based differences in\n",
      "IBD phenotype and outcomes, which may signal differences\n",
      "in pathogenic pathways and progression. Of note, extra-\n",
      "intestinal manifestations (EIMs) consistently tend to be\n",
      "more common in female patients (CD: OR, 2.3; 95% CI, 1.9–\n",
      "2.8 and UC: OR, 1.5; 95% CI, 1.1–2.3, in a large Dutch Bio-\n",
      "Bank).56 Similarly, in a retrospective pediatric study of\n",
      "nearly 1000 patients with CD, girls were more likely to have\n",
      "EIMs and less likely to have growth impairment compared\n",
      "with boys,57 the latter is possibly related to lower insulin-\n",
      "like growth factor-1 level in boys.58\n",
      "July 2021\n",
      "Management of early IBD\n",
      "49\n",
      "REVIEWS AND\n",
      "PERSPECTIVES\n",
      "----------\n",
      "methodologic characteristics). If direct and indirect es-\n",
      "timates were similar (ie, coherent), then the higher rating\n",
      "can be assigned to the network meta-analysis estimates.\n",
      "Results\n",
      "From a total 5651 unique studies identiﬁed using our\n",
      "search strategy, we included 15 RCTs of ﬁrst-line agents\n",
      "(in biologic-naïve patients) (Active Ulcerative Colitis Trials\n",
      "1 and 2,17 Jiang et al,18 NCT01551290,19 Ulcerative colitis\n",
      "Long-Term Remission and maintenance with Adalimumab\n",
      "1 and 2,20,21 Suzuki et al,22 Program of Ulcerative Colitis\n",
      "Research Studies Utilizing an Investigational Treatment\n",
      "phase 2 and phase 3 induction studies,23 GEMINI I,24\n",
      "Motoya et al,25 VARSITY, Oral Clinical Trials for tofAciti-\n",
      "nib in ulceratiVE colitis (OCTAVE) 1 and 2,26 and UNIFI),\n",
      "and 7 RCTs of second-line agents (in patients with prior\n",
      "exposure to TNFa antagonists) (Ulcerative colitis Long-\n",
      "Term Remission and maintenance with Adalimumab 2,21\n",
      "GEMINI I,24 Motoya et al,25 VARSITY,6 OCTAVE 1 and\n",
      "2,26 UNIFI7) in patients with moderate–severe ulcerative\n",
      "colitis. Trials of inﬂiximab (Active Ulcerative Colitis Trials\n",
      "1 and 2,17 Jiang et al,18 NCT0155129019), adalimumab\n",
      "(Ulcerative colitis Long-Term Remission and maintenance\n",
      "with Adalimumab 2,20,21 Suzuki et al22), vedolizumab\n",
      "(GEMINI I,24 Motoya et al,25 VARSITY6) and ustekinumab\n",
      "(UNIFI7) also reported outcomes on maintenance therapy\n",
      "within the same publication; Program of Ulcerative Colitis\n",
      "Research Studies Utilizing an Investigational Treatment-\n",
      "M, Program of Ulcerative Colitis Research Studies Utilizing\n",
      "an Investigational Treatment-J, and OCTAVE-Sustain\n",
      "reported\n",
      "outcomes\n",
      "for\n",
      "maintenance\n",
      "therapy\n",
      "with\n",
      "golimumab and tofacitinib, respectively.26–28 From our\n",
      "previous analysis, 3 additional studies were included.\n",
      "The schematic diagram of study selection is shown in\n",
      "Supplementary\n",
      "Figure\n",
      "1,\n",
      "and\n",
      "available\n",
      "direct\n",
      "comparisons and network of trials are shown in Figure 1.\n",
      "Trial and patient characteristics are summarized in\n",
      "Table 1. Overall, the median average age of patients was\n",
      "41 years (interquartile range, 40–42 y), and 60%\n",
      "(interquartile range, 56%–63%) were men. The median\n",
      "disease duration was 6.7 years (interquartile range,\n",
      "6.0–7.8 y), and 49% (interquartile range, 46%–55%) of\n",
      "patients had extensive colitis. A median of 40% (inter-\n",
      "quartile range, 30%–50%) of patients were treated with\n",
      "concomitant immunomodulators, and 51% (interquartile\n",
      "range, 45%–57%) were on corticosteroids at baseline.\n",
      "Patients across all trials and treatment arms were com-\n",
      "==========\n",
      "ORIGINAL QUESTION: ANALYSE the given patient profile based on given query based on one of the following criteria:\n",
      "- Whether treated patient is new patient or patient under maintenance\n",
      "- Prior response to Infliximab\n",
      "- Prior failure to Anti-TNF agents\n",
      "- Prior failure to Vedolizumab\n",
      "- Age\n",
      "- Pregnancy\n",
      "- Extraintestinale manifestations\n",
      "- Pouchitis\n",
      "RETURN up to 2 TOP choices of biological drugs given patient profile and context. Explain the PROS and CONS of the 2 choices.\n",
      "PATIENT PROFILE: 56 year old man with moderate to severe ulcerative colitis and ankylosing spondylitis\n",
      "\n",
      "==========\n",
      "CURRENT ANSWER:\n",
      "Based on the given patient profile, the patient is a 56-year-old man with moderate to severe ulcerative colitis and ankylosing spondylitis. The patient's age and the presence of an extraintestinal manifestation (ankylosing spondylitis) are important factors to consider in the choice of treatment. \n",
      "\n",
      "Given the patient's condition, the top two choices of biological drugs would be:\n",
      "\n",
      "1. Infliximab\n",
      "2. Adalimumab\n",
      "\n",
      "Infliximab and Adalimumab are both anti-TNF agents, which have been shown to be effective in treating both ulcerative colitis and ankylosing spondylitis.\n",
      "\n",
      "[{\"drug_name\": \"Infliximab\", \"advantages\": \"Infliximab has been shown to be effective in inducing and maintaining remission in moderate to severe ulcerative colitis. It is also effective in treating ankylosing spondylitis. Infliximab has a rapid onset of action.\", \"disadvantages\": \"Infliximab is administered intravenously, which may be inconvenient for some patients. There is also a risk of developing antibodies against infliximab, which can reduce its effectiveness. Side effects can include infections, allergic reactions, and potential heart problems.\"},\n",
      "\n",
      "{\"drug_name\": \"Adalimumab\", \"advantages\": \"Adalimumab is also effective in treating both ulcerative colitis and ankylosing spondylitis. It is administered subcutaneously, which some patients may find more convenient than intravenous administration.\", \"disadvantages\": \"Adalimumab may take longer to work than infliximab. Side effects can include infections, allergic reactions, and potential heart problems. There is also a risk of developing antibodies against adalimumab, which can reduce its effectiveness.\"}]\n",
      "==========\n",
      "REFINED ANSWER:\n",
      "\u001b[0m\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "Retrying langchain.chat_models.openai.ChatOpenAI.completion_with_retry.<locals>._completion_with_retry in 4.0 seconds as it raised RateLimitError: Rate limit reached for 10KTPM-200RPM in organization org-ETbTMTN2JXYOUPDJgxuH2iO6 on tokens per min. Limit: 10000 / min. Please try again in 6ms. Contact us through our help center at help.openai.com if you continue to have issues..\n",
      "Retrying langchain.chat_models.openai.ChatOpenAI.completion_with_retry.<locals>._completion_with_retry in 4.0 seconds as it raised RateLimitError: Rate limit reached for 10KTPM-200RPM in organization org-ETbTMTN2JXYOUPDJgxuH2iO6 on tokens per min. Limit: 10000 / min. Please try again in 6ms. Contact us through our help center at help.openai.com if you continue to have issues..\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\n",
      "\u001b[1m> Finished chain.\u001b[0m\n",
      "\n",
      "\u001b[1m> Finished chain.\u001b[0m\n",
      "2023-10-02 17:20:38,104:INFO: 5584 tokens were added to prompt from 10 documents\n",
      "Query: 38 year old man with severe ulcerative colitis and has lost response to vedolizumab\n",
      "\n",
      "\n",
      "\n",
      "\u001b[1m> Entering new SequentialChain chain...\u001b[0m\n",
      "\n",
      "\n",
      "\u001b[1m> Entering new RetrievalQAWithSourcesChain chain...\u001b[0m\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "Retrying langchain.chat_models.openai.ChatOpenAI.completion_with_retry.<locals>._completion_with_retry in 4.0 seconds as it raised RateLimitError: Rate limit reached for 10KTPM-200RPM in organization org-ETbTMTN2JXYOUPDJgxuH2iO6 on tokens per min. Limit: 10000 / min. Please try again in 6ms. Contact us through our help center at help.openai.com if you continue to have issues..\n",
      "Retrying langchain.chat_models.openai.ChatOpenAI.completion_with_retry.<locals>._completion_with_retry in 4.0 seconds as it raised RateLimitError: Rate limit reached for 10KTPM-200RPM in organization org-ETbTMTN2JXYOUPDJgxuH2iO6 on tokens per min. Limit: 10000 / min. Please try again in 6ms. Contact us through our help center at help.openai.com if you continue to have issues..\n",
      "Retrying langchain.chat_models.openai.ChatOpenAI.completion_with_retry.<locals>._completion_with_retry in 4.0 seconds as it raised RateLimitError: Rate limit reached for 10KTPM-200RPM in organization org-ETbTMTN2JXYOUPDJgxuH2iO6 on tokens per min. Limit: 10000 / min. Please try again in 6ms. Contact us through our help center at help.openai.com if you continue to have issues..\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\n",
      "\u001b[1m> Finished chain.\u001b[0m\n",
      "\n",
      "\n",
      "\u001b[1m> Entering new LLMChain chain...\u001b[0m\n",
      "Prompt after formatting:\n",
      "\u001b[32;1m\u001b[1;3mYou are a senior physician giving advice on treatment for moderate to severe ulcerative colitis (UC).\n",
      "Make reference to the CONTEXT given to assess the scenario.\n",
      "==========\n",
      "TASK: Your task is to analyse critically the CURRENT ANSWER given the CONTEXT.\n",
      "Then refine the existing answer (only if needed) based on the following instructions:\n",
      "- If no refinement needed, return the original answer in the correct output format.\n",
      "- If the answer cannot be inferred from CONTEXT, return \"NO ANSWER\".\n",
      "- The final output should be a list of up to 2 choices of biological drugs given patient profile and context and PROS/CONS for each recommendations.\n",
      "==========\n",
      "CONTEXT:\n",
      "Burr et al. \n",
      " \n",
      "5 of 45 \n",
      "STUDY HIGHLIGHTS \n",
      " \n",
      "What is already known about this subject \n",
      "• Ulcerative colitis (UC) follows a relapsing and remitting course, with intermittent \n",
      "flares of disease activity, some of which may be moderate to severe. \n",
      "• These are usually treated with corticosteroids, which have potentially serious adverse \n",
      "effects, so biological therapies and small molecules have been developed and licensed \n",
      "for this indication.  \n",
      "• Although previous network meta-analyses have compared their efficacy and safety, \n",
      "this is a rapidly moving field, and there are already several newer drugs that have \n",
      "shown efficacy in phase III clinical trials that were not considered in these. \n",
      " \n",
      "What are the new findings \n",
      "• In terms of clinical remission and clinical response, upadacitinib 45mg o.d. ranked \n",
      "first in all patients, in patients previously exposed to anti-tumour necrosis factor \n",
      "(TNF)-α therapies, and in patients naïve to these drugs.  \n",
      "• In terms of endoscopic improvement infliximab 10mg/kg ranked first, followed by \n",
      "upadacitinib 45mg o.d., and infliximab 5mg/kg.  \n",
      "• However, for endoscopic improvement again upadacitinib 45mg o.d. ranked first in \n",
      "patients previously exposed to anti-TNF-α therapies, and in patients who were anti-\n",
      "TNF-α naïve.  \n",
      "• None of the drugs studied were more likely to lead to serious adverse events than \n",
      "placebo.\n",
      "----------\n",
      "Burr et al. \n",
      " \n",
      "7 of 45 \n",
      "INTRODUCTION \n",
      "  Ulcerative colitis (UC) is a chronic inflammatory disorder of the bowel that causes \n",
      "continuous mucosal inflammation commencing in the rectum and extending proximally for a \n",
      "variable extent.[1] It is estimated that UC affects 2.5 million people in Europe,[2] and the \n",
      "disease follows a relapsing and remitting course, with intermittent flares of disease activity, \n",
      "some of which may be moderate to severe. Management of these is medical, for the most \n",
      "part, with surgery reserved for patients with refractory disease. Although 5-aminosalicylates \n",
      "(5-ASAs) are efficacious for mild to moderate disease activity,[3-6] more severe flares are \n",
      "usually treated with corticosteroids.[7] However, these have potentially serious adverse \n",
      "effects and a substantial proportion of patients may become either dependent on them to \n",
      "maintain remission,[8] or refractory to them.[9] As a result, over the last 20 years novel \n",
      "drugs, with more precise modes of action, based on mechanisms of disease identified in \n",
      "genome wide association studies,[10] have been developed.  \n",
      "The first of these agents was infliximab, a drug targeting the pro-inflammatory \n",
      "cytokine tumour necrosis factor-α (TNF-α), which demonstrated efficacy in clinical trials in \n",
      "moderate to severe UC.[11] Since then, other drugs against TNF-α have been tested, such as \n",
      "adalimumab and golimumab.[12, 13] In addition, newer biological therapies targeting α or β \n",
      "integrins, which are involved in migration of immune cells to inflamed intestinal mucosa, \n",
      "such as vedolizumab or etrolizumab,[14, 15] or acting against other pro-inflammatory \n",
      "cytokines implicated in the pathogenesis of UC, such as ustekinumab,[16] have been tested. \n",
      "However, even these more selective drugs do not work in all patients, there may be risks \n",
      "associated with their use,[17-19] and the fact that they are administered either intravenously \n",
      "or subcutaneously, may be inconvenient for patients. The search for alternative agents for the \n",
      "treatment of UC has, therefore, continued.\n",
      "----------\n",
      "discontinuation due to AEs, and serious infections. Phase 3 randomized controlled trials were identified via systematic literature review, in-\n",
      "cluding the following advanced therapies: infliximab, adalimumab, vedolizumab, golimumab, tofacitinib, ustekinumab, filgotinib, ozanimod, and \n",
      "upadacitinib. Random effects models were used to address between-study heterogeneity. Intent-to-treat (ITT) efficacy rates were calculated by \n",
      "adjusting maintenance outcomes by likelihood of induction response.\n",
      "Results:  Out of 48 trials identified, 23 were included. Across all outcomes and regardless of prior biologic exposure, ITT efficacy rates were \n",
      "highest for upadacitinib, owing to its highest ranking for all efficacy outcomes in induction and for all but clinical remission during maintenance \n",
      "among bio-naive induction responders. For all advanced therapies versus placebo, there were no significant differences in serious AEs or \n",
      "serious infections across therapies. For all AEs, golimumab had higher odds versus placebo during maintenance; for discontinuation due to \n",
      "AEs, upadacitinib had lower odds versus placebo during induction, while ustekinumab and vedolizumab had lower odds versus placebo during \n",
      "maintenance.\n",
      "Conclusions:  Upadacitinib may be the most efficacious therapy for moderately to severely active UC based on ITT analyses, with similar safety \n",
      "across advanced therapies.\n",
      "Lay Summary \n",
      "Indirect evidence suggests upadacitinib may be more efficacious than other advanced therapies at achieving clinical response, clinical remis-\n",
      "sion, and endoscopic response over 1 year for moderately to severely active ulcerative colitis patients, with similar safety assessments across \n",
      "advanced therapies.\n",
      "Key Words: ulcerative colitis, clinical trials, advanced therapies, network meta-analysis\n",
      "Introduction\n",
      "Ulcerative colitis (UC) is a chronic inflammatory bowel dis-\n",
      "ease that affects the colorectum and is clinically characterized \n",
      "by bloody diarrhea, urgency, tenesmus, abdominal pain, ma-\n",
      "laise, weight loss, and fever. Disease onset commonly occurs \n",
      "between the ages of 15 and 30 years and the annual global \n",
      "© The Author(s) 2023. Published by Oxford University Press on behalf of Crohn's & Colitis Foundation.\n",
      "This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), \n",
      "which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.\n",
      "----------\n",
      "disease); ozanimod as an oral alternative\n",
      "• Infliximab, preferably in combination with  \n",
      " immunomodulators (severe disease,  \n",
      " \n",
      " extraintestinal manifestations)\n",
      "• Ustekinumab (for patients with substantial \n",
      " comorbidities or  contraindications to TNF  \n",
      " antagonists)\n",
      "First-line therapy\n",
      "• TNF antagonists: infliximab or adalimumab,  \n",
      " preferably in combination with   \n",
      " \n",
      " \n",
      " immunomodulators\n",
      "• Risankizumab or ustekinumab (for patients  \n",
      " with substantial comorbidities or  \n",
      " \n",
      " \n",
      " contraindications to TNF antagonists)\n",
      "First-line therapy\n",
      "• Vedolizumab\n",
      "• Ustekinumab\n",
      "First-line therapy\n",
      "• Risankizumab or ustekinumab\n",
      "• Vedolizumab\n",
      "Moderate-to-severely active\n",
      "ulcerative colitis\n",
      "Moderate-to-severely active\n",
      "ulcerative colitis\n",
      "Moderate-to-severely active\n",
      "Crohn's disease\n",
      "Moderate-to-severely active\n",
      "Crohn's disease\n",
      "Second-line therapy\n",
      "• Upadacitinib (or tofacitinib) (for patients with  \n",
      " prior failure of infliximab)\n",
      "• Infliximab or ustekinumab (for patients with  \n",
      " prior exposure to vedolizumab)\n",
      "• Vedolizumab (moderate disease, for patients  \n",
      " who discontinued first-line biologic agent \n",
      " for intolerance)\n",
      "Second-line therapy (in patients with prior \n",
      "exposure to infliximab or adalimumab)\n",
      "• Risankizumab or ustekinumab\n",
      "• Second TNF antagonist (for patients with  \n",
      " loss of response owing to immunogenicity,  \n",
      " or  intolerance, to first TNF antagonist)\n",
      "Second-line therapy\n",
      "• Ozanimod\n",
      "• Infliximab monotherapy\n",
      "• Upadacitinib (or tofacitinib)\n",
      "Second-line therapy\n",
      "• Infliximab or adalimumab   \n",
      " monotherapy\n",
      "Risk averse\n",
      "• Prior serious infections\n",
      "• Prior malignancy\n",
      "• Older age, multiple comorbidities\n",
      "Severe disease\n",
      "• High structural damage\n",
      "• High inflammatory burden\n",
      "• Significant efect on quality of life\n",
      "Patients’ values and preferences\n",
      "(lifestyle and logistics, speed of onset, costs)\n",
      "Fig. 1 | Proposed treatment algorithm for patients with moderate-to-severe \n",
      "Crohn’s disease and moderate-to-severe ulcerative colitis. The algorithm \n",
      "integrates data on comparative effectiveness and safety of therapies in the \n",
      "context of an individual patient’s risk of disease-related and treatment-related \n",
      "complications. TNF, tumour necrosis factor. Adapted with permission from  \n",
      "ref. 10, Elsevier.\n",
      "----------\n",
      "1·28–6·31], filgotinib 100 mg [6·15, 2·98–12·72], filgotinib 200 mg [4·49, 2·18–9·24], and ozanimod (2·70, \n",
      "1·18–6·20), and ranked highest for the induction of clinical remission (SUCRA 0·996). No differences between active \n",
      "interventions were observed when assessing adverse events and serious adverse events. Vedolizumab ranked lowest \n",
      "for both adverse events (SUCRA 0·184) and serious adverse events (0·139), whereas upadacitinib ranked highest for \n",
      "adverse events (0·843) and ozanimod ranked highest for serious adverse events (0·831).\n",
      "Interpretation Upadacitinib was the best performing agent for the induction of clinical remission (the primary \n",
      "outcome) but the worst performing agent in terms of adverse events in patients with moderate-to-severe ulcerative \n",
      "colitis. Vedolizumab was the best performing agent for safety outcomes. With the paucity of direct comparisons in the \n",
      "published literature, our results might help clinicians to position drugs in treatment algorithms.\n",
      "Funding None.\n",
      "Copyright © 2021 Elsevier Ltd. All rights reserved.\n",
      "Introduction \n",
      "Ulcerative colitis is a chronic, idiopathic, potentially \n",
      "disabling condition that is clinically characterised \n",
      "by bloody diarrhoea, abdominal pain, and tenesmus.1 \n",
      "Ulcerative colitis most commonly presents during the \n",
      "third and fifth decades of life, and is associated with an \n",
      "impaired health-related quality of life and considerable \n",
      "economic burden.2,3\n",
      "Nearly 20 years ago, the advent of anti-tumour necrosis \n",
      "factor biologics (eg, infliximab, adalimumab, and \n",
      "golimumab) revolutionised therapeutics for ulcerative \n",
      "colitis, enabling better disease control in terms of \n",
      "increasing the rates of mucosal healing, deep remission, \n",
      "and corticosteroid-free remission, and improving quality \n",
      "of life. Biologics with other targets were later approved \n",
      "for the treatment of moderate-to-severe ulcerative colitis, \n",
      "namely vedolizumab and, more recently, usteki numab. \n",
      "However, \n",
      "treatment \n",
      "with \n",
      "biologics \n",
      "has \n",
      "several \n",
      "limit ations, including limited efficacy, primary non-\n",
      "response, secondary loss of response, immunogenicity,\n",
      "----------\n",
      "41 years (interquartile range, 40–42 y), and 60%\n",
      "(interquartile range, 56%–63%) were men. The median\n",
      "disease duration was 6.7 years (interquartile range,\n",
      "6.0–7.8 y), and 49% (interquartile range, 46%–55%) of\n",
      "patients had extensive colitis. A median of 40% (inter-\n",
      "quartile range, 30%–50%) of patients were treated with\n",
      "concomitant immunomodulators, and 51% (interquartile\n",
      "range, 45%–57%) were on corticosteroids at baseline.\n",
      "Patients across all trials and treatment arms were com-\n",
      "parable in terms of baseline prognostic variables, inclu-\n",
      "sion/exclusion\n",
      "criteria,\n",
      "and\n",
      "co-interventions.\n",
      "All\n",
      "outcomes were assessed uniformly based on the stan-\n",
      "dard deﬁnition of the Mayo Clinic score, between weeks\n",
      "6 and 10 for induction therapy (inﬂiximab, adalimumab,\n",
      "tofacitinib, ustekinumab, 8 weeks; golimumab, 6 weeks;\n",
      "vedolizumab, 6 weeks, 10 weeks, and 14 weeks in\n",
      "VARSITY),6 and weeks 30, 54, or 60 for maintenance\n",
      "therapy;\n",
      "endoscopy\n",
      "was\n",
      "read\n",
      "by\n",
      "blinded\n",
      "local\n",
      "Table 2. Comparative Efﬁcacy of Pharmacologic Agents for Induction of Clinical Remission and Endoscopic Improvement in Biologic-Naive Patients With Moderate–Severe\n",
      "Ulcerative Colitis Using Network Meta-Analysis\n",
      "Induction of clinical remission\n",
      "Induction of endoscopic improvement\n",
      "Ustekinumab 6 mg/kg\n",
      "0.96 (0.38–2.45)\n",
      "0.80 (0.35–1.83)\n",
      "0.73 (0.31–1.74)\n",
      "1.05 (0.48–2.32)\n",
      "0.50 (0.22–1.12)\n",
      "2.04 (1.03–4.05)\n",
      "0.92 (0.45–1.89)\n",
      "Tofacitinib 10 mg b.d.\n",
      "0.84 (0.39–1.82)\n",
      "0.76 (0.33–1.76)\n",
      "1.10 (0.51–2.34)\n",
      "0.52 (0.24–1.12)\n",
      "2.12 (1.12–4.02)\n",
      "0.74 (0.36–1.51)\n",
      "0.80 (0.4–1.62)\n",
      "Vedolizumab\n",
      "0.91 (0.44–1.86)\n",
      "1.31 (0.88–1.95)\n",
      "0.62 (0.34–1.15)\n",
      "2.54 (1.60–4.02)\n",
      "1.07 (0.58–1.98)\n",
      "1.17 (0.64–2.12)\n",
      "1.45 (0.80–2.61)\n",
      "Golimumab\n",
      "1.44 (0.76–2.75)\n",
      "0.69 (0.35–1.36)\n",
      "2.79 (1.64–4.02)\n",
      "1.17 (0.65–2.13)\n",
      "1.28 (0.72–2.29)\n",
      "1.59 (0.90–2.82)\n",
      "1.10 (0.71–1.71)\n",
      "Adalimumab\n",
      "0.48 (0.26–0.86)\n",
      "1.94 (1.30–2.88)\n",
      "0.56 (0.30–1.04)\n",
      "0.61 (0.34–1.11)\n",
      "0.76 (0.42–1.37)\n",
      "0.52 (0.33–0.83)\n",
      "0.48 (0.31–0.74)\n",
      "Inﬂiximab\n",
      "4.07 (2.67–6.21)\n",
      "1.86 (1.11–3.13)\n",
      "2.03 (1.23–3.34)\n",
      "2.52 (1.54–4.11)\n",
      "1.74 (1.25–2.41)\n",
      "1.58 (1.18–2.13)\n",
      "3.32 (2.39–4.60)\n",
      "Placebo\n",
      "NOTE. Comparisons should be read from left to right. Odds ratio for comparisons are in the cell in common between the column-deﬁning and row-deﬁning treatment. Numbers in bold are statistically signiﬁcant. For induction of\n",
      "clinical remission, an odds ratio greater than 1 favors row-deﬁning treatment. For induction of endoscopic improvement, an odds ratio greater than 1 favors column-deﬁning treatment. Numbers in parentheses indicate 95% CI.\n",
      "b.d., twice daily.\n",
      "----------\n",
      "What You Need to Know\n",
      "Background\n",
      "A systematic review and network meta-analysis is\n",
      "needed to compare efﬁcacy and safety of ﬁrst-line\n",
      "(biologic-naïve) and second-line (prior exposure to\n",
      "tumor necrosis factor [TNF] antagonists) agents for\n",
      "treatment of moderate to severely active ulcerative\n",
      "colitis.\n",
      "Findings\n",
      "Inﬂiximab was ranked highest in biologic-naïve pa-\n",
      "tients, and ustekinumab and tofacitinib were ranked\n",
      "highest in patients with prior exposure to TNF an-\n",
      "tagonists, for induction of remission and endoscopic\n",
      "improvement. More trials of direct comparisons are\n",
      "needed to inform clinical decision-making with\n",
      "greater conﬁdence.\n",
      "Implications for patient care\n",
      "Patients with moderate to severely active ulcerative\n",
      "colitis should receive inﬂiximab or vedolizumab as\n",
      "ﬁrst-line therapy, or ustekinumab or tofacitinib if\n",
      "they have prior exposure to TNF antagonists.\n",
      "2180 Singh et al\n",
      "Clinical Gastroenterology and Hepatology Vol. 18, No. 10\n",
      "----------\n",
      "severely active ulcerative colitis: results from phase 3 \n",
      "U-ACCOMPLISH study. J Crohn’s Colitis 2021; 15 (suppl 1): S021–22.\n",
      "9 \n",
      "Thorlund K, Druyts E, Mills EJ, Fedorak RN, Marshall JK. \n",
      "Adalimumab versus infliximab for the treatment of moderate to \n",
      "severe ulcerative colitis in adult patients naïve to anti-TNF therapy: \n",
      "an indirect treatment comparison meta-analysis. J Crohn’s Colitis \n",
      "2014; 8: 571–81.\n",
      "10 \n",
      "Danese S, Fiorino G, Peyrin-Biroulet L, et al. Biological agents for \n",
      "moderately to severely active ulcerative colitis: a systematic review \n",
      "and network meta-analysis. Ann Intern Med 2014; 160: 704–11.\n",
      "11 \n",
      "Singh S, Fumery M, Sandborn WJ, Murad MH. Systematic review \n",
      "with network meta-analysis: first- and second-line pharmacotherapy \n",
      "for moderate-severe ulcerative colitis. Aliment Pharmacol Ther 2018; \n",
      "47: 162–75.\n",
      "12 \n",
      "Bonovas S, Lytras T, Nikolopoulos G, Peyrin-Biroulet L, Danese S. \n",
      "Systematic review with network meta-analysis: comparative \n",
      "assessment of tofacitinib and biological therapies for moderate-to-\n",
      "severe ulcerative colitis. Aliment Pharmacol Ther 2018; 47: 454–65.\n",
      "13 \n",
      "Singh S, Murad MH, Fumery M, Dulai PS, Sandborn WJ. First- and \n",
      "second-line pharmacotherapies for patients with moderate to \n",
      "severely active ulcerative colitis: an updated network meta-analysis. \n",
      "Clin Gastroenterol Hepatol 2020; 18: 2179–91.e6.\n",
      "14 \n",
      "Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting \n",
      "items for systematic reviews and meta-analyses: the PRISMA \n",
      "statement. Ann Intern Med 2009; 151: 264–69.\n",
      "15 \n",
      "Jansen JP, Fleurence R, Devine B, et al. Interpreting indirect \n",
      "treatment comparisons and network meta-analysis for health-care \n",
      "decision making: report of the ISPOR Task Force on Indirect \n",
      "Treatment Comparisons Good Research Practices: part 1. \n",
      "Value Health 2011; 14: 417–28.\n",
      "16 \n",
      "Sterne JAC, Savović J, Page MJ, et al. RoB 2: a revised tool for \n",
      "assessing risk of bias in randomised trials. BMJ 2019; 366: l4898.\n",
      "17 \n",
      "Rücker G, Schwarzer G. Ranking treatments in frequentist network \n",
      "meta-analysis works without resampling methods. \n",
      "BMC Med Res Methodol 2015; 15: 58.\n",
      "----------\n",
      "SYSTEMATIC REVIEWS AND META-ANALYSES\n",
      "Siddharth Singh, Section Editor\n",
      "First- and Second-Line Pharmacotherapies for Patients With\n",
      "Moderate to Severely Active Ulcerative Colitis: An Updated\n",
      "Network Meta-Analysis\n",
      "Siddharth Singh,*,‡ Mohammad Hassan Murad,§ Mathurin Fumery,j\n",
      "Parambir S. Dulai,* and William J. Sandborn*\n",
      "*Division of Gastroenterology, ‡Division of Biomedical Informatics, University of California San Diego, La Jolla, California;\n",
      "§Robert D and Patricia E Kern Center for the Science of Health Care Delivery, Mayo Clinic, Rochester, Minnesota;\n",
      "||Gastroenterology Unit, Peritox UMR I-0I, Amiens University and Hospital, Université de Picardie Jules Verne, Amiens, France\n",
      "BACKGROUND & AIMS:\n",
      "We compared the efﬁcacy and safety of different ﬁrst-line (biologic-naïve) and second-line\n",
      "(prior exposure to tumor necrosis factor [TNF] antagonists) agents for treatment of moder-\n",
      "ate to severely active ulcerative colitis in a systematic review and network meta-analysis.\n",
      "METHODS:\n",
      "We searched publication databases through September 30, 2019, for randomized trials of\n",
      "adults with moderate to severe ulcerative colitis treated with TNF antagonists, vedolizumab,\n",
      "tofacitinib, or ustekinumab, as ﬁrst-line or second-line agents, compared with placebo or\n",
      "another active agent. Efﬁcacy outcomes were induction and maintenance of remission and\n",
      "endoscopic improvement; safety outcomes were serious adverse events and infections. We\n",
      "performed a ﬁxed-effects network meta-analysis using the frequentist approach, and calculated\n",
      "odds ratios (ORs) and 95% CI values. Agents were ranked using surface under the cumulative\n",
      "ranking (SUCRA) probabilities. Overall quality of evidence was rated using GRADE (Grading of\n",
      "Recommendations, Assessment, Development and Evaluation).\n",
      "RESULTS:\n",
      "In biologic-naïve patients, inﬂiximab was ranked highest for induction of clinical remission (OR\n",
      "vs placebo, 4.07; 95% CI, 2.67–6.21; SUCRA, 0.95) and endoscopic improvement (SUCRA, 0.95)\n",
      "(moderate conﬁdence in estimates [CE]). In patients with prior exposure to TNF antagonists,\n",
      "ustekinumab (SUCRA, 0.87) and tofacitinib (SUCRA, 0.87) were ranked highest for induction of\n",
      "clinical remission and were superior to vedolizumab (ustekinumab vs vedolizumab: OR, 5.99;\n",
      "95% CI, 1.13–31.76 and tofacitinib vs vedolizumab: OR, 6.18; 95% CI, 1.003–8.00; moderate CE)\n",
      "and adalimumab (ustekinumab vs adalimumab: OR, 10.71; 95% CI, 2.01–57.20 and tofacitinib\n",
      "----------\n",
      "Articles\n",
      "www.thelancet.com/gastrohep   Vol 7   February 2022 \n",
      "163\n",
      "“safety” OR “adverse events”]. Additionally, experts in the \n",
      "field were contacted for any unpublished data.\n",
      "We included phase 3 RCTs that met the inclusion criteria: \n",
      "(1) studies including adult (≥18 years) patients with \n",
      "moderate-to-severe ulcerative colitis (defined as a Mayo \n",
      "Score of 6–12, with an endoscopic sub-score of 2–3) who \n",
      "were either biologic-naive or had previously been exposed \n",
      "to at least one biologic; (2) studies either evaluating the \n",
      "following biologics and small molecule drugs in their \n",
      "approved dose regimens, infliximab (intravenous or \n",
      "subcutaneous), adalimumab, golimumab, vedolizumab \n",
      "(intravenous or sub cutaneous), ustekinumab (intravenous \n",
      "or subcutaneous), tofacitinib, or ozanimod, or studies \n",
      "evaluating etroli zumab, upadacitinib, filgotinib, etrasimod, \n",
      "or TD-1473; (3) studies including an active comparator or \n",
      "placebo; and (4) studies assessing the following outcomes: \n",
      "clinical remission (defined as a Mayo score of ≤2, with no \n",
      "individual sub-score >1) and endoscopic improvement \n",
      "(Mayo endoscopic sub-score 0–1). We did not include \n",
      "phase 2 trials because treatment effects can be over-\n",
      "estimated or underestimated due to the intrinsically small \n",
      "sample sizes of these studies. Additionally, given the dose-\n",
      "ranging nature of phase 2 trials, many of them include \n",
      "doses that will not be further explored in phase 3 trials.\n",
      "For approved agents, only approved doses were \n",
      "included in our analyses (intravenous infliximab: \n",
      "5 mg/kg in weeks 0, 2, and 6 in induction, and 5 mg/kg \n",
      "every 8 weeks in maintenance; subcutaneous infliximab: \n",
      "120 mg every 2 weeks in maintenance; subcutaneous \n",
      "adalimumab: 160 mg in week 0, 80 mg in week 2, and \n",
      "40 mg in week 4 in induction, and 40 mg every other \n",
      "week in maintenance; subcutaneous golimumab: 200 mg \n",
      "in week 0 and 100 mg in week 2 in induction, and 100 mg \n",
      "every 4 weeks in maintenance; intravenous vedolizumab: \n",
      "300 mg in weeks 0, 2, and 6 in induction, and \n",
      "300 mg every 8 weeks in maintenance; subcutaneous \n",
      "vedolizumab: 108 mg every 2 weeks in maintenance; \n",
      "ustekinumab: 6 mg/kg intravenously in week 0 in \n",
      "induction, and 90 mg subcutaneously every 8 weeks in \n",
      "maintenance; oral tofacitinib: 10 mg twice daily for \n",
      "8 weeks in induction, and 5 mg twice daily in \n",
      "maintenance; and oral ozanimod: 1 mg daily in induction \n",
      "and maintenance). For non-approved agents in a late \n",
      "stage of development (defined as the availability of results\n",
      "==========\n",
      "ORIGINAL QUESTION: ANALYSE the given patient profile based on given query based on one of the following criteria:\n",
      "- Whether treated patient is new patient or patient under maintenance\n",
      "- Prior response to Infliximab\n",
      "- Prior failure to Anti-TNF agents\n",
      "- Prior failure to Vedolizumab\n",
      "- Age\n",
      "- Pregnancy\n",
      "- Extraintestinale manifestations\n",
      "- Pouchitis\n",
      "RETURN up to 2 TOP choices of biological drugs given patient profile and context. Explain the PROS and CONS of the 2 choices.\n",
      "PATIENT PROFILE: 38 year old man with severe ulcerative colitis and has lost response to vedolizumab\n",
      "\n",
      "==========\n",
      "CURRENT ANSWER:\n",
      "Based on the patient's profile and the provided context, the top two choices of biological drugs would be:\n",
      "\n",
      "1. Ustekinumab\n",
      "   - Advantages: Ustekinumab is ranked highest for induction of clinical remission in patients with prior exposure to TNF antagonists. It is also recommended as a second-line therapy for patients with prior exposure to vedolizumab.\n",
      "   - Disadvantages: The drug may not work in all patients and there may be risks associated with its use. It is administered either intravenously or subcutaneously, which may be inconvenient for some patients.\n",
      "\n",
      "2. Infliximab\n",
      "   - Advantages: Infliximab is ranked highest for induction of clinical remission and endoscopic improvement in biologic-naive patients. It is also recommended as a second-line therapy for patients with prior failure of infliximab.\n",
      "   - Disadvantages: Infliximab may not work in all patients and there may be risks associated with its use. It is administered intravenously, which may be inconvenient for some patients.\n",
      "\n",
      "Please note that the choice of treatment should be individualized based on the patient's specific condition, preferences, and potential side effects of the drugs. It is also important to consider the patient's prior response to different treatments.\n",
      "==========\n",
      "REFINED ANSWER:\n",
      "\u001b[0m\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "Retrying langchain.chat_models.openai.ChatOpenAI.completion_with_retry.<locals>._completion_with_retry in 4.0 seconds as it raised RateLimitError: Rate limit reached for 10KTPM-200RPM in organization org-ETbTMTN2JXYOUPDJgxuH2iO6 on tokens per min. Limit: 10000 / min. Please try again in 6ms. Contact us through our help center at help.openai.com if you continue to have issues..\n",
      "Retrying langchain.chat_models.openai.ChatOpenAI.completion_with_retry.<locals>._completion_with_retry in 4.0 seconds as it raised RateLimitError: Rate limit reached for 10KTPM-200RPM in organization org-ETbTMTN2JXYOUPDJgxuH2iO6 on tokens per min. Limit: 10000 / min. Please try again in 6ms. Contact us through our help center at help.openai.com if you continue to have issues..\n",
      "Retrying langchain.chat_models.openai.ChatOpenAI.completion_with_retry.<locals>._completion_with_retry in 4.0 seconds as it raised RateLimitError: Rate limit reached for 10KTPM-200RPM in organization org-ETbTMTN2JXYOUPDJgxuH2iO6 on tokens per min. Limit: 10000 / min. Please try again in 6ms. Contact us through our help center at help.openai.com if you continue to have issues..\n",
      "Retrying langchain.chat_models.openai.ChatOpenAI.completion_with_retry.<locals>._completion_with_retry in 8.0 seconds as it raised RateLimitError: Rate limit reached for 10KTPM-200RPM in organization org-ETbTMTN2JXYOUPDJgxuH2iO6 on tokens per min. Limit: 10000 / min. Please try again in 6ms. Contact us through our help center at help.openai.com if you continue to have issues..\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\n",
      "\u001b[1m> Finished chain.\u001b[0m\n",
      "\n",
      "\u001b[1m> Finished chain.\u001b[0m\n",
      "2023-10-02 17:21:52,867:INFO: 5739 tokens were added to prompt from 10 documents\n",
      "Query: 28 year old woman who has severe extensive ulcerative colitis and has a history of lymphoma which was treated 4 years ago\n",
      "\n",
      "\n",
      "\n",
      "\u001b[1m> Entering new SequentialChain chain...\u001b[0m\n",
      "\n",
      "\n",
      "\u001b[1m> Entering new RetrievalQAWithSourcesChain chain...\u001b[0m\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "Retrying langchain.chat_models.openai.ChatOpenAI.completion_with_retry.<locals>._completion_with_retry in 4.0 seconds as it raised RateLimitError: Rate limit reached for 10KTPM-200RPM in organization org-ETbTMTN2JXYOUPDJgxuH2iO6 on tokens per min. Limit: 10000 / min. Please try again in 6ms. Contact us through our help center at help.openai.com if you continue to have issues..\n",
      "Retrying langchain.chat_models.openai.ChatOpenAI.completion_with_retry.<locals>._completion_with_retry in 4.0 seconds as it raised RateLimitError: Rate limit reached for 10KTPM-200RPM in organization org-ETbTMTN2JXYOUPDJgxuH2iO6 on tokens per min. Limit: 10000 / min. Please try again in 6ms. Contact us through our help center at help.openai.com if you continue to have issues..\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\n",
      "\u001b[1m> Finished chain.\u001b[0m\n",
      "\n",
      "\n",
      "\u001b[1m> Entering new LLMChain chain...\u001b[0m\n",
      "Prompt after formatting:\n",
      "\u001b[32;1m\u001b[1;3mYou are a senior physician giving advice on treatment for moderate to severe ulcerative colitis (UC).\n",
      "Make reference to the CONTEXT given to assess the scenario.\n",
      "==========\n",
      "TASK: Your task is to analyse critically the CURRENT ANSWER given the CONTEXT.\n",
      "Then refine the existing answer (only if needed) based on the following instructions:\n",
      "- If no refinement needed, return the original answer in the correct output format.\n",
      "- If the answer cannot be inferred from CONTEXT, return \"NO ANSWER\".\n",
      "- The final output should be a list of up to 2 choices of biological drugs given patient profile and context and PROS/CONS for each recommendations.\n",
      "==========\n",
      "CONTEXT:\n",
      "Burr et al. \n",
      " \n",
      "7 of 45 \n",
      "INTRODUCTION \n",
      "  Ulcerative colitis (UC) is a chronic inflammatory disorder of the bowel that causes \n",
      "continuous mucosal inflammation commencing in the rectum and extending proximally for a \n",
      "variable extent.[1] It is estimated that UC affects 2.5 million people in Europe,[2] and the \n",
      "disease follows a relapsing and remitting course, with intermittent flares of disease activity, \n",
      "some of which may be moderate to severe. Management of these is medical, for the most \n",
      "part, with surgery reserved for patients with refractory disease. Although 5-aminosalicylates \n",
      "(5-ASAs) are efficacious for mild to moderate disease activity,[3-6] more severe flares are \n",
      "usually treated with corticosteroids.[7] However, these have potentially serious adverse \n",
      "effects and a substantial proportion of patients may become either dependent on them to \n",
      "maintain remission,[8] or refractory to them.[9] As a result, over the last 20 years novel \n",
      "drugs, with more precise modes of action, based on mechanisms of disease identified in \n",
      "genome wide association studies,[10] have been developed.  \n",
      "The first of these agents was infliximab, a drug targeting the pro-inflammatory \n",
      "cytokine tumour necrosis factor-α (TNF-α), which demonstrated efficacy in clinical trials in \n",
      "moderate to severe UC.[11] Since then, other drugs against TNF-α have been tested, such as \n",
      "adalimumab and golimumab.[12, 13] In addition, newer biological therapies targeting α or β \n",
      "integrins, which are involved in migration of immune cells to inflamed intestinal mucosa, \n",
      "such as vedolizumab or etrolizumab,[14, 15] or acting against other pro-inflammatory \n",
      "cytokines implicated in the pathogenesis of UC, such as ustekinumab,[16] have been tested. \n",
      "However, even these more selective drugs do not work in all patients, there may be risks \n",
      "associated with their use,[17-19] and the fact that they are administered either intravenously \n",
      "or subcutaneously, may be inconvenient for patients. The search for alternative agents for the \n",
      "treatment of UC has, therefore, continued.\n",
      "----------\n",
      "severely active ulcerative colitis: results from phase 3 \n",
      "U-ACCOMPLISH study. J Crohn’s Colitis 2021; 15 (suppl 1): S021–22.\n",
      "9 \n",
      "Thorlund K, Druyts E, Mills EJ, Fedorak RN, Marshall JK. \n",
      "Adalimumab versus infliximab for the treatment of moderate to \n",
      "severe ulcerative colitis in adult patients naïve to anti-TNF therapy: \n",
      "an indirect treatment comparison meta-analysis. J Crohn’s Colitis \n",
      "2014; 8: 571–81.\n",
      "10 \n",
      "Danese S, Fiorino G, Peyrin-Biroulet L, et al. Biological agents for \n",
      "moderately to severely active ulcerative colitis: a systematic review \n",
      "and network meta-analysis. Ann Intern Med 2014; 160: 704–11.\n",
      "11 \n",
      "Singh S, Fumery M, Sandborn WJ, Murad MH. Systematic review \n",
      "with network meta-analysis: first- and second-line pharmacotherapy \n",
      "for moderate-severe ulcerative colitis. Aliment Pharmacol Ther 2018; \n",
      "47: 162–75.\n",
      "12 \n",
      "Bonovas S, Lytras T, Nikolopoulos G, Peyrin-Biroulet L, Danese S. \n",
      "Systematic review with network meta-analysis: comparative \n",
      "assessment of tofacitinib and biological therapies for moderate-to-\n",
      "severe ulcerative colitis. Aliment Pharmacol Ther 2018; 47: 454–65.\n",
      "13 \n",
      "Singh S, Murad MH, Fumery M, Dulai PS, Sandborn WJ. First- and \n",
      "second-line pharmacotherapies for patients with moderate to \n",
      "severely active ulcerative colitis: an updated network meta-analysis. \n",
      "Clin Gastroenterol Hepatol 2020; 18: 2179–91.e6.\n",
      "14 \n",
      "Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting \n",
      "items for systematic reviews and meta-analyses: the PRISMA \n",
      "statement. Ann Intern Med 2009; 151: 264–69.\n",
      "15 \n",
      "Jansen JP, Fleurence R, Devine B, et al. Interpreting indirect \n",
      "treatment comparisons and network meta-analysis for health-care \n",
      "decision making: report of the ISPOR Task Force on Indirect \n",
      "Treatment Comparisons Good Research Practices: part 1. \n",
      "Value Health 2011; 14: 417–28.\n",
      "16 \n",
      "Sterne JAC, Savović J, Page MJ, et al. RoB 2: a revised tool for \n",
      "assessing risk of bias in randomised trials. BMJ 2019; 366: l4898.\n",
      "17 \n",
      "Rücker G, Schwarzer G. Ranking treatments in frequentist network \n",
      "meta-analysis works without resampling methods. \n",
      "BMC Med Res Methodol 2015; 15: 58.\n",
      "----------\n",
      "41 years (interquartile range, 40–42 y), and 60%\n",
      "(interquartile range, 56%–63%) were men. The median\n",
      "disease duration was 6.7 years (interquartile range,\n",
      "6.0–7.8 y), and 49% (interquartile range, 46%–55%) of\n",
      "patients had extensive colitis. A median of 40% (inter-\n",
      "quartile range, 30%–50%) of patients were treated with\n",
      "concomitant immunomodulators, and 51% (interquartile\n",
      "range, 45%–57%) were on corticosteroids at baseline.\n",
      "Patients across all trials and treatment arms were com-\n",
      "parable in terms of baseline prognostic variables, inclu-\n",
      "sion/exclusion\n",
      "criteria,\n",
      "and\n",
      "co-interventions.\n",
      "All\n",
      "outcomes were assessed uniformly based on the stan-\n",
      "dard deﬁnition of the Mayo Clinic score, between weeks\n",
      "6 and 10 for induction therapy (inﬂiximab, adalimumab,\n",
      "tofacitinib, ustekinumab, 8 weeks; golimumab, 6 weeks;\n",
      "vedolizumab, 6 weeks, 10 weeks, and 14 weeks in\n",
      "VARSITY),6 and weeks 30, 54, or 60 for maintenance\n",
      "therapy;\n",
      "endoscopy\n",
      "was\n",
      "read\n",
      "by\n",
      "blinded\n",
      "local\n",
      "Table 2. Comparative Efﬁcacy of Pharmacologic Agents for Induction of Clinical Remission and Endoscopic Improvement in Biologic-Naive Patients With Moderate–Severe\n",
      "Ulcerative Colitis Using Network Meta-Analysis\n",
      "Induction of clinical remission\n",
      "Induction of endoscopic improvement\n",
      "Ustekinumab 6 mg/kg\n",
      "0.96 (0.38–2.45)\n",
      "0.80 (0.35–1.83)\n",
      "0.73 (0.31–1.74)\n",
      "1.05 (0.48–2.32)\n",
      "0.50 (0.22–1.12)\n",
      "2.04 (1.03–4.05)\n",
      "0.92 (0.45–1.89)\n",
      "Tofacitinib 10 mg b.d.\n",
      "0.84 (0.39–1.82)\n",
      "0.76 (0.33–1.76)\n",
      "1.10 (0.51–2.34)\n",
      "0.52 (0.24–1.12)\n",
      "2.12 (1.12–4.02)\n",
      "0.74 (0.36–1.51)\n",
      "0.80 (0.4–1.62)\n",
      "Vedolizumab\n",
      "0.91 (0.44–1.86)\n",
      "1.31 (0.88–1.95)\n",
      "0.62 (0.34–1.15)\n",
      "2.54 (1.60–4.02)\n",
      "1.07 (0.58–1.98)\n",
      "1.17 (0.64–2.12)\n",
      "1.45 (0.80–2.61)\n",
      "Golimumab\n",
      "1.44 (0.76–2.75)\n",
      "0.69 (0.35–1.36)\n",
      "2.79 (1.64–4.02)\n",
      "1.17 (0.65–2.13)\n",
      "1.28 (0.72–2.29)\n",
      "1.59 (0.90–2.82)\n",
      "1.10 (0.71–1.71)\n",
      "Adalimumab\n",
      "0.48 (0.26–0.86)\n",
      "1.94 (1.30–2.88)\n",
      "0.56 (0.30–1.04)\n",
      "0.61 (0.34–1.11)\n",
      "0.76 (0.42–1.37)\n",
      "0.52 (0.33–0.83)\n",
      "0.48 (0.31–0.74)\n",
      "Inﬂiximab\n",
      "4.07 (2.67–6.21)\n",
      "1.86 (1.11–3.13)\n",
      "2.03 (1.23–3.34)\n",
      "2.52 (1.54–4.11)\n",
      "1.74 (1.25–2.41)\n",
      "1.58 (1.18–2.13)\n",
      "3.32 (2.39–4.60)\n",
      "Placebo\n",
      "NOTE. Comparisons should be read from left to right. Odds ratio for comparisons are in the cell in common between the column-deﬁning and row-deﬁning treatment. Numbers in bold are statistically signiﬁcant. For induction of\n",
      "clinical remission, an odds ratio greater than 1 favors row-deﬁning treatment. For induction of endoscopic improvement, an odds ratio greater than 1 favors column-deﬁning treatment. Numbers in parentheses indicate 95% CI.\n",
      "b.d., twice daily.\n",
      "----------\n",
      "Therapeutic strategies for the management of recentlydiagnosedulcerative colitis. IMMs include thiopurines and methotrexate. 5-ASA, 5-amino salicylic acid; ASUC, acute severe ulcerative colitis; IPAA, ileal pouch anal anastomosis.\n",
      "\n",
      "Risk stratification: Mild\n",
      "Clinical features: NA\n",
      "Treatment options: 5-ASA (oral and/or topical)\n",
      "\n",
      "Risk stratification: Moderate\n",
      "Clinical features: NA\n",
      "Treatment options: Can consider 5-ASA (with rapid step-up if inadequate response)\n",
      "\n",
      "Risk stratification: Moderate\n",
      "Clinical features: NA\n",
      "Treatment options: VDZ or UST\n",
      "\n",
      "Risk stratification: Moderate\n",
      "Clinical features: NA\n",
      "Treatment options: Thiopurine\n",
      "\n",
      "Risk stratification: Moderate\n",
      "Clinical features: NA\n",
      "Treatment options: TNFi +/- IMM\n",
      "\n",
      "Risk stratification: Severe\n",
      "Clinical features: NA\n",
      "Treatment options: TNFi +/- IMM\n",
      "\n",
      "Risk stratification: Severe\n",
      "Clinical features: NA\n",
      "Treatment options: Subtotal colectomy + IPAA or cyclosporine (for ASUC)\n",
      "\n",
      "Risk stratification: Additional consideration: EIM present\n",
      "Clinical features: Psoriasis or psoriatic arthritis\n",
      "Treatment options: UST\n",
      "\n",
      "Risk stratification: Additional consideration: EIM present\n",
      "Clinical features: Other arthritis\n",
      "Treatment options: TNFi\n",
      "\n",
      "\n",
      "----------\n",
      "Burr et al. \n",
      " \n",
      "5 of 45 \n",
      "STUDY HIGHLIGHTS \n",
      " \n",
      "What is already known about this subject \n",
      "• Ulcerative colitis (UC) follows a relapsing and remitting course, with intermittent \n",
      "flares of disease activity, some of which may be moderate to severe. \n",
      "• These are usually treated with corticosteroids, which have potentially serious adverse \n",
      "effects, so biological therapies and small molecules have been developed and licensed \n",
      "for this indication.  \n",
      "• Although previous network meta-analyses have compared their efficacy and safety, \n",
      "this is a rapidly moving field, and there are already several newer drugs that have \n",
      "shown efficacy in phase III clinical trials that were not considered in these. \n",
      " \n",
      "What are the new findings \n",
      "• In terms of clinical remission and clinical response, upadacitinib 45mg o.d. ranked \n",
      "first in all patients, in patients previously exposed to anti-tumour necrosis factor \n",
      "(TNF)-α therapies, and in patients naïve to these drugs.  \n",
      "• In terms of endoscopic improvement infliximab 10mg/kg ranked first, followed by \n",
      "upadacitinib 45mg o.d., and infliximab 5mg/kg.  \n",
      "• However, for endoscopic improvement again upadacitinib 45mg o.d. ranked first in \n",
      "patients previously exposed to anti-TNF-α therapies, and in patients who were anti-\n",
      "TNF-α naïve.  \n",
      "• None of the drugs studied were more likely to lead to serious adverse events than \n",
      "placebo.\n",
      "----------\n",
      "Articles\n",
      "www.thelancet.com/gastrohep   Vol 7   February 2022 \n",
      "161\n",
      "Lancet Gastroenterol Hepatol \n",
      "2022; 7: 161–70\n",
      "Published Online \n",
      "November 29, 2021 \n",
      "https://doi.org/10.1016/ \n",
      "S2468-1253(21)00377-0\n",
      "See Comment page 110\n",
      "*Contributed equally\n",
      "Inflammatory Bowel Disease \n",
      "Unit, Gastroenterology \n",
      "Section, Department of \n",
      "Internal Medicine, Centro de \n",
      "Educación Médica e \n",
      "Investigaciones Clínicas, \n",
      "Buenos Aires, Argentina \n",
      "(J S Lasa MD, P A Olivera MD); \n",
      "Gastroenterology Department, \n",
      "Hospital Británico de Buenos \n",
      "Aires, Buenos Aires, Argentina \n",
      "(J S Lasa); Zane Cohen Centre \n",
      "for Digestive Diseases, \n",
      "Lunenfeld-Tanenbaum \n",
      "Research Institute, Sinai Health \n",
      "System, Toronto, ON, Canada \n",
      "(P A Olivera); Division of \n",
      "Gastroenterology, Mount Sinai \n",
      "Hospital, University of Toronto, \n",
      "Toronto, ON, Canada \n",
      "(P A Olivera); Gastroenterology \n",
      "and Endoscopy, IRCCS Ospedale \n",
      "San Raffaele and University \n",
      "Vita-Salute San Raffaele, \n",
      "Milano, Italy \n",
      "(Prof S Danese MD); INSERM \n",
      "NGERE and Department of \n",
      "Hepatogastroenterology, \n",
      "Nancy University Hospital, \n",
      "Lorraine University, \n",
      "Vandoeuvre-lés-Nancy, France \n",
      "(Prof L Peyrin-Biroulet MD) \n",
      "Correspondence to: \n",
      "Prof Laurent Peyrin-Biroulet, \n",
      "INSERM NGERE and Department \n",
      "of Hepatogastroenterology, \n",
      "Nancy University Hospital, \n",
      "Lorraine University, Vandoeuvre-\n",
      "lès-Nancy F-54511, France \n",
      "peyrinbiroulet@gmail.com\n",
      "Efficacy and safety of biologics and small molecule drugs for \n",
      "patients with moderate-to-severe ulcerative colitis: \n",
      "a systematic review and network meta-analysis \n",
      "Juan S Lasa*, Pablo A Olivera*, Silvio Danese, Laurent Peyrin-Biroulet\n",
      "Summary\n",
      "Background There is a growing armamentarium for the treatment of moderate-to-severe ulcerative colitis. We aimed \n",
      "to compare the relative efficacy and safety of biologics and small molecule drugs for the treatment of patients with \n",
      "moderate-to-severe ulcerative colitis.\n",
      "Methods In this systematic review and network meta-analysis, we searched MEDLINE, Embase, and the Cochrane \n",
      "Central Register of Controlled Trials without language restrictions for articles published between Jan 1, 1990, and \n",
      "July 1, 2021. Major congresses’ databases from Jan 1, 2018, to July 3, 2021, were reviewed manually. Phase 3, placebo-\n",
      "controlled or head-to-head randomised controlled trials (RCTs) assessing the efficacy and safety of biologics or small \n",
      "molecule drugs as induction or maintenance therapies for patients with moderate-to-severe ulcerative colitis were\n",
      "----------\n",
      "Parkes, M., Vermeire, S., Rioux, J.D., Mansﬁeld, J., Silverberg, M.S., Radford-\n",
      "Smith, G., McGovern, D.P., Barrett, J.C., Lees, C.W., 2016. Inherited determinants of\n",
      "crohn's disease and ulcerative colitis phenotypes: a genetic association study. Lancet\n",
      "387 (10014), 156–167.\n",
      "Colombel, J.F., Sandborn, W.J., Rutgeerts, P., Enns, R., Hanauer, S.B., Panaccione, R.,\n",
      "Schreiber, S., Byczkowski, D., Li, J., Kent, J.D., Pollack, P.F., 2007. Adalimumab for\n",
      "maintenance of clinical response and remission in patients with crohn's disease: the\n",
      "charm trial. Gastroenterology 132 (1), 52–65.\n",
      "Conrad, M.A., Kelsen, J.R., 2020. The treatment of pediatric inﬂammatory bowel disease\n",
      "with biologic therapies. Curr. Gastroenterol. Rep. 22 (8), 36–51.\n",
      "Csontos, A.A., Molnar, A., Piri, Z., Katona, B., Dako, S., Palﬁ, E., Miheller, P., 2016. The\n",
      "effect of anti-tnfalpha induction therapy on the nutritional status and dietary intake\n",
      "in inﬂammatory bowel disease. J Gastrointestin Liver Dis 25 (1), 49–56.\n",
      "Dai, Z.H., Xu, X.T., Ran, Z.H., 2020. Associations between obesity and the effectiveness of\n",
      "anti-tumor necrosis factor-alpha agents in inﬂammatory bowel disease patients: a\n",
      "literature review and meta-analysis. Ann. Pharmacother. 54 (8), 729–741.\n",
      "Danese, S., Colombel, J.F., Lukas, M., Gisbert, J.P., D’Haens, G., Hayee, B., Panaccione, R.,\n",
      "Kim, H.S., Reinisch, W., Tyrrell, H., Oh, Y.S., Tole, S., Chai, A., Chamberlain-\n",
      "James, K., Tang, M.T., Schreiber, S., Group, G.S., 2021. Etrolizumab versus inﬂiximab\n",
      "for the treatment of moderately to severely active ulcerative colitis (gardenia): a\n",
      "randomised, double-blind, double-dummy, phase 3 study. Lancet Gastroenterol\n",
      "Hepatol 7 (2), 118–127.\n",
      "Danese, S., Fiorino, G., Peyrin-Biroulet, L., Lucenteforte, E., Virgili, G., Moja, L.,\n",
      "Bonovas, S., 2014. Biological agents for moderately to severely active ulcerative\n",
      "colitis: a systematic review and network meta-analysis. Ann. Intern. Med. 160 (10),\n",
      "704–711.\n",
      "P. Juillerat et al.\n",
      "Current Research in Pharmacology and Drug Discovery 3 (2022) 100104\n",
      "6\n",
      "----------\n",
      "methodologic characteristics). If direct and indirect es-\n",
      "timates were similar (ie, coherent), then the higher rating\n",
      "can be assigned to the network meta-analysis estimates.\n",
      "Results\n",
      "From a total 5651 unique studies identiﬁed using our\n",
      "search strategy, we included 15 RCTs of ﬁrst-line agents\n",
      "(in biologic-naïve patients) (Active Ulcerative Colitis Trials\n",
      "1 and 2,17 Jiang et al,18 NCT01551290,19 Ulcerative colitis\n",
      "Long-Term Remission and maintenance with Adalimumab\n",
      "1 and 2,20,21 Suzuki et al,22 Program of Ulcerative Colitis\n",
      "Research Studies Utilizing an Investigational Treatment\n",
      "phase 2 and phase 3 induction studies,23 GEMINI I,24\n",
      "Motoya et al,25 VARSITY, Oral Clinical Trials for tofAciti-\n",
      "nib in ulceratiVE colitis (OCTAVE) 1 and 2,26 and UNIFI),\n",
      "and 7 RCTs of second-line agents (in patients with prior\n",
      "exposure to TNFa antagonists) (Ulcerative colitis Long-\n",
      "Term Remission and maintenance with Adalimumab 2,21\n",
      "GEMINI I,24 Motoya et al,25 VARSITY,6 OCTAVE 1 and\n",
      "2,26 UNIFI7) in patients with moderate–severe ulcerative\n",
      "colitis. Trials of inﬂiximab (Active Ulcerative Colitis Trials\n",
      "1 and 2,17 Jiang et al,18 NCT0155129019), adalimumab\n",
      "(Ulcerative colitis Long-Term Remission and maintenance\n",
      "with Adalimumab 2,20,21 Suzuki et al22), vedolizumab\n",
      "(GEMINI I,24 Motoya et al,25 VARSITY6) and ustekinumab\n",
      "(UNIFI7) also reported outcomes on maintenance therapy\n",
      "within the same publication; Program of Ulcerative Colitis\n",
      "Research Studies Utilizing an Investigational Treatment-\n",
      "M, Program of Ulcerative Colitis Research Studies Utilizing\n",
      "an Investigational Treatment-J, and OCTAVE-Sustain\n",
      "reported\n",
      "outcomes\n",
      "for\n",
      "maintenance\n",
      "therapy\n",
      "with\n",
      "golimumab and tofacitinib, respectively.26–28 From our\n",
      "previous analysis, 3 additional studies were included.\n",
      "The schematic diagram of study selection is shown in\n",
      "Supplementary\n",
      "Figure\n",
      "1,\n",
      "and\n",
      "available\n",
      "direct\n",
      "comparisons and network of trials are shown in Figure 1.\n",
      "Trial and patient characteristics are summarized in\n",
      "Table 1. Overall, the median average age of patients was\n",
      "41 years (interquartile range, 40–42 y), and 60%\n",
      "(interquartile range, 56%–63%) were men. The median\n",
      "disease duration was 6.7 years (interquartile range,\n",
      "6.0–7.8 y), and 49% (interquartile range, 46%–55%) of\n",
      "patients had extensive colitis. A median of 40% (inter-\n",
      "quartile range, 30%–50%) of patients were treated with\n",
      "concomitant immunomodulators, and 51% (interquartile\n",
      "range, 45%–57%) were on corticosteroids at baseline.\n",
      "Patients across all trials and treatment arms were com-\n",
      "----------\n",
      "to\n",
      "extensive\n",
      "or\n",
      "pancolitis\n",
      "is\n",
      "associated\n",
      "with\n",
      "worse\n",
      "prognosis.45,65\n",
      "In addition, co-occurrence of other immune-mediated\n",
      "inﬂammatory diseases can occur, most commonly with\n",
      "psoriasis and asthma, but also, in more rare instances, with\n",
      "other gastrointestinal diseases (eg, celiac, nonalcoholic fatty\n",
      "liver disease,66 and eosinophilic esophagitis).67,68 Presence\n",
      "of a concomitant immune-mediated inﬂammatory disease is\n",
      "Figure\n",
      "1. Inﬂammatory\n",
      "bowel disease severity vs\n",
      "disease activity variables.\n",
      "ASCA, anti-Saccharomyces\n",
      "cerevisiae\n",
      "antibodies;\n",
      "ANCA,\n",
      "anti-neutrophil\n",
      "cytoplasmic\n",
      "antibodies;\n",
      "GMCSF,\n",
      "granulocyte-\n",
      "macrophage\n",
      "colony-\n",
      "stimulating\n",
      "factor;\n",
      "TI,\n",
      "terminal ileum.\n",
      "50\n",
      "Agrawal et al\n",
      "Gastroenterology Vol. 161, No. 1\n",
      "REVIEWS AND\n",
      "PERSPECTIVES\n",
      "----------\n",
      "Combination therapy of a biologic with IMM, best-\n",
      "studied with TNFi, is an important consideration in severe\n",
      "disease, especially penetrating or perianal disease. It is\n",
      "associated with improved outcomes, a decrease in loss of\n",
      "TNFi response, and fewer long-term complications.90,91 The\n",
      "mechanism of action may be due to decrease in immuno-\n",
      "genicity and impact on drug level. Similar effects have not\n",
      "been seen with adding IMM to UST of VDZ therapy, possibly\n",
      "due to a lower role of immunogenicity in drug meta-\n",
      "bolism.92 For patients with perianal CD, a multidisciplinary\n",
      "approach with early referral to a colorectal surgeon is key to\n",
      "improved outcomes.93\n",
      "Ileocolic resection as a ﬁrst-line therapy. Surgery\n",
      "is often viewed as a late-stage therapeutic option for CD, to\n",
      "be positioned after medical therapies, and the rate of sur-\n",
      "gery for CD has declined over time.94 The LIR!C (Laparo-\n",
      "scopic Ileocolic Resection Versus Inﬂiximab Treatment of\n",
      "Distal\n",
      "Ileitis\n",
      "in\n",
      "Crohn’s\n",
      "Disease)\n",
      "trial,\n",
      "a\n",
      "randomized\n",
      "controlled trial of IFX vs laparoscopic ileocolic resection\n",
      "(ICR) in adult patients with limited terminal ileal disease,\n",
      "found no difference in safety or measures of quality of life at\n",
      "1 year between the 2 groups.95 Furthermore, on long-term\n",
      "follow-up (median 5 years), the ICR group had no subse-\n",
      "quent resection, 42% received no treatment at all, and 74%\n",
      "received\n",
      "no\n",
      "biologic\n",
      "treatment.96\n",
      "More\n",
      "recent\n",
      "cost-\n",
      "effectiveness\n",
      "analyses\n",
      "found\n",
      "that\n",
      "ICR\n",
      "is\n",
      "more\n",
      "cost-\n",
      "effective than IFX.97 ICR should be considered a viable\n",
      "initial treatment modality not only in patients presenting\n",
      "with a complication at diagnosis, but also in those with\n",
      "limited nonpenetrating ileocecal CD in the setting of shared\n",
      "decision-making or when concerns about biologic safety are\n",
      "a signiﬁcant consideration.\n",
      "Dietary therapy. Exclusive enteral nutrition (EEN) is\n",
      "the use of polymeric or elemental formula typically for 8–12\n",
      "weeks to induce remission in CD. European Pediatric\n",
      "Consensus guidelines recommend EEN as the ﬁrst-line\n",
      "therapy to induce remission in pediatric patients with\n",
      "luminal CD.31 This is based on numerous randomized\n",
      "controlled trials demonstrating that EEN is as effective as\n",
      "corticosteroids.\n",
      "Meta-analyses\n",
      "of\n",
      "these\n",
      "randomized\n",
      "controlled trials have reported clinical remission rates of\n",
      "73%–95%.98,99 Relapse after this period of induction is\n",
      "common, typically leading to maintenance management\n",
      "with IMM or biologics.100 To increase adherence, a combi-\n",
      "nation of partial enteral nutrition and the CD exclusion diet\n",
      "==========\n",
      "ORIGINAL QUESTION: ANALYSE the given patient profile based on given query based on one of the following criteria:\n",
      "- Whether treated patient is new patient or patient under maintenance\n",
      "- Prior response to Infliximab\n",
      "- Prior failure to Anti-TNF agents\n",
      "- Prior failure to Vedolizumab\n",
      "- Age\n",
      "- Pregnancy\n",
      "- Extraintestinale manifestations\n",
      "- Pouchitis\n",
      "RETURN up to 2 TOP choices of biological drugs given patient profile and context. Explain the PROS and CONS of the 2 choices.\n",
      "PATIENT PROFILE: 28 year old woman who has severe extensive ulcerative colitis and has a history of lymphoma which was treated 4 years ago\n",
      "\n",
      "==========\n",
      "CURRENT ANSWER:\n",
      "Based on the patient's profile, the top two choices of biological drugs would be Vedolizumab and Ustekinumab. \n",
      "\n",
      "1. Vedolizumab:\n",
      "   - Advantages: Vedolizumab is a gut-selective immunosuppressant, meaning it specifically targets the gut and has less systemic side effects. It has been shown to be effective in treating moderate to severe ulcerative colitis. It is also a good option for patients with a history of malignancy like this patient as it has a lower risk of reactivating latent malignancies compared to other biologics.\n",
      "   - Disadvantages: Vedolizumab is administered intravenously which may be inconvenient for some patients. It may also take longer to see the effects of this drug compared to others.\n",
      "\n",
      "2. Ustekinumab:\n",
      "   - Advantages: Ustekinumab is another biologic that has been shown to be effective in treating moderate to severe ulcerative colitis. It is administered subcutaneously and has a good safety profile.\n",
      "   - Disadvantages: Ustekinumab may not be as effective as other biologics in inducing remission. It is also one of the newer drugs, so long-term safety data is not as robust as for other biologics.\n",
      "\n",
      "It's important to note that the choice of treatment should be individualized based on the patient's specific circumstances and preferences, and should be discussed thoroughly with the patient.\n",
      "==========\n",
      "REFINED ANSWER:\n",
      "\u001b[0m\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "Retrying langchain.chat_models.openai.ChatOpenAI.completion_with_retry.<locals>._completion_with_retry in 4.0 seconds as it raised RateLimitError: Rate limit reached for 10KTPM-200RPM in organization org-ETbTMTN2JXYOUPDJgxuH2iO6 on tokens per min. Limit: 10000 / min. Please try again in 6ms. Contact us through our help center at help.openai.com if you continue to have issues..\n",
      "Retrying langchain.chat_models.openai.ChatOpenAI.completion_with_retry.<locals>._completion_with_retry in 4.0 seconds as it raised RateLimitError: Rate limit reached for 10KTPM-200RPM in organization org-ETbTMTN2JXYOUPDJgxuH2iO6 on tokens per min. Limit: 10000 / min. Please try again in 6ms. Contact us through our help center at help.openai.com if you continue to have issues..\n",
      "Retrying langchain.chat_models.openai.ChatOpenAI.completion_with_retry.<locals>._completion_with_retry in 4.0 seconds as it raised RateLimitError: Rate limit reached for 10KTPM-200RPM in organization org-ETbTMTN2JXYOUPDJgxuH2iO6 on tokens per min. Limit: 10000 / min. Please try again in 6ms. Contact us through our help center at help.openai.com if you continue to have issues..\n",
      "Retrying langchain.chat_models.openai.ChatOpenAI.completion_with_retry.<locals>._completion_with_retry in 8.0 seconds as it raised RateLimitError: Rate limit reached for 10KTPM-200RPM in organization org-ETbTMTN2JXYOUPDJgxuH2iO6 on tokens per min. Limit: 10000 / min. Please try again in 6ms. Contact us through our help center at help.openai.com if you continue to have issues..\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\n",
      "\u001b[1m> Finished chain.\u001b[0m\n",
      "\n",
      "\u001b[1m> Finished chain.\u001b[0m\n",
      "2023-10-02 17:23:08,183:INFO: 5702 tokens were added to prompt from 10 documents\n",
      "Query: 36 year old woman with moderate ulcerative colitis and multiple sclerosis\n",
      "\n",
      "\n",
      "\n",
      "\u001b[1m> Entering new SequentialChain chain...\u001b[0m\n",
      "\n",
      "\n",
      "\u001b[1m> Entering new RetrievalQAWithSourcesChain chain...\u001b[0m\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "Retrying langchain.chat_models.openai.ChatOpenAI.completion_with_retry.<locals>._completion_with_retry in 4.0 seconds as it raised RateLimitError: Rate limit reached for 10KTPM-200RPM in organization org-ETbTMTN2JXYOUPDJgxuH2iO6 on tokens per min. Limit: 10000 / min. Please try again in 6ms. Contact us through our help center at help.openai.com if you continue to have issues..\n",
      "Retrying langchain.chat_models.openai.ChatOpenAI.completion_with_retry.<locals>._completion_with_retry in 4.0 seconds as it raised RateLimitError: Rate limit reached for 10KTPM-200RPM in organization org-ETbTMTN2JXYOUPDJgxuH2iO6 on tokens per min. Limit: 10000 / min. Please try again in 6ms. Contact us through our help center at help.openai.com if you continue to have issues..\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\n",
      "\u001b[1m> Finished chain.\u001b[0m\n",
      "\n",
      "\n",
      "\u001b[1m> Entering new LLMChain chain...\u001b[0m\n",
      "Prompt after formatting:\n",
      "\u001b[32;1m\u001b[1;3mYou are a senior physician giving advice on treatment for moderate to severe ulcerative colitis (UC).\n",
      "Make reference to the CONTEXT given to assess the scenario.\n",
      "==========\n",
      "TASK: Your task is to analyse critically the CURRENT ANSWER given the CONTEXT.\n",
      "Then refine the existing answer (only if needed) based on the following instructions:\n",
      "- If no refinement needed, return the original answer in the correct output format.\n",
      "- If the answer cannot be inferred from CONTEXT, return \"NO ANSWER\".\n",
      "- The final output should be a list of up to 2 choices of biological drugs given patient profile and context and PROS/CONS for each recommendations.\n",
      "==========\n",
      "CONTEXT:\n",
      "Burr et al. \n",
      " \n",
      "7 of 45 \n",
      "INTRODUCTION \n",
      "  Ulcerative colitis (UC) is a chronic inflammatory disorder of the bowel that causes \n",
      "continuous mucosal inflammation commencing in the rectum and extending proximally for a \n",
      "variable extent.[1] It is estimated that UC affects 2.5 million people in Europe,[2] and the \n",
      "disease follows a relapsing and remitting course, with intermittent flares of disease activity, \n",
      "some of which may be moderate to severe. Management of these is medical, for the most \n",
      "part, with surgery reserved for patients with refractory disease. Although 5-aminosalicylates \n",
      "(5-ASAs) are efficacious for mild to moderate disease activity,[3-6] more severe flares are \n",
      "usually treated with corticosteroids.[7] However, these have potentially serious adverse \n",
      "effects and a substantial proportion of patients may become either dependent on them to \n",
      "maintain remission,[8] or refractory to them.[9] As a result, over the last 20 years novel \n",
      "drugs, with more precise modes of action, based on mechanisms of disease identified in \n",
      "genome wide association studies,[10] have been developed.  \n",
      "The first of these agents was infliximab, a drug targeting the pro-inflammatory \n",
      "cytokine tumour necrosis factor-α (TNF-α), which demonstrated efficacy in clinical trials in \n",
      "moderate to severe UC.[11] Since then, other drugs against TNF-α have been tested, such as \n",
      "adalimumab and golimumab.[12, 13] In addition, newer biological therapies targeting α or β \n",
      "integrins, which are involved in migration of immune cells to inflamed intestinal mucosa, \n",
      "such as vedolizumab or etrolizumab,[14, 15] or acting against other pro-inflammatory \n",
      "cytokines implicated in the pathogenesis of UC, such as ustekinumab,[16] have been tested. \n",
      "However, even these more selective drugs do not work in all patients, there may be risks \n",
      "associated with their use,[17-19] and the fact that they are administered either intravenously \n",
      "or subcutaneously, may be inconvenient for patients. The search for alternative agents for the \n",
      "treatment of UC has, therefore, continued.\n",
      "----------\n",
      "41 years (interquartile range, 40–42 y), and 60%\n",
      "(interquartile range, 56%–63%) were men. The median\n",
      "disease duration was 6.7 years (interquartile range,\n",
      "6.0–7.8 y), and 49% (interquartile range, 46%–55%) of\n",
      "patients had extensive colitis. A median of 40% (inter-\n",
      "quartile range, 30%–50%) of patients were treated with\n",
      "concomitant immunomodulators, and 51% (interquartile\n",
      "range, 45%–57%) were on corticosteroids at baseline.\n",
      "Patients across all trials and treatment arms were com-\n",
      "parable in terms of baseline prognostic variables, inclu-\n",
      "sion/exclusion\n",
      "criteria,\n",
      "and\n",
      "co-interventions.\n",
      "All\n",
      "outcomes were assessed uniformly based on the stan-\n",
      "dard deﬁnition of the Mayo Clinic score, between weeks\n",
      "6 and 10 for induction therapy (inﬂiximab, adalimumab,\n",
      "tofacitinib, ustekinumab, 8 weeks; golimumab, 6 weeks;\n",
      "vedolizumab, 6 weeks, 10 weeks, and 14 weeks in\n",
      "VARSITY),6 and weeks 30, 54, or 60 for maintenance\n",
      "therapy;\n",
      "endoscopy\n",
      "was\n",
      "read\n",
      "by\n",
      "blinded\n",
      "local\n",
      "Table 2. Comparative Efﬁcacy of Pharmacologic Agents for Induction of Clinical Remission and Endoscopic Improvement in Biologic-Naive Patients With Moderate–Severe\n",
      "Ulcerative Colitis Using Network Meta-Analysis\n",
      "Induction of clinical remission\n",
      "Induction of endoscopic improvement\n",
      "Ustekinumab 6 mg/kg\n",
      "0.96 (0.38–2.45)\n",
      "0.80 (0.35–1.83)\n",
      "0.73 (0.31–1.74)\n",
      "1.05 (0.48–2.32)\n",
      "0.50 (0.22–1.12)\n",
      "2.04 (1.03–4.05)\n",
      "0.92 (0.45–1.89)\n",
      "Tofacitinib 10 mg b.d.\n",
      "0.84 (0.39–1.82)\n",
      "0.76 (0.33–1.76)\n",
      "1.10 (0.51–2.34)\n",
      "0.52 (0.24–1.12)\n",
      "2.12 (1.12–4.02)\n",
      "0.74 (0.36–1.51)\n",
      "0.80 (0.4–1.62)\n",
      "Vedolizumab\n",
      "0.91 (0.44–1.86)\n",
      "1.31 (0.88–1.95)\n",
      "0.62 (0.34–1.15)\n",
      "2.54 (1.60–4.02)\n",
      "1.07 (0.58–1.98)\n",
      "1.17 (0.64–2.12)\n",
      "1.45 (0.80–2.61)\n",
      "Golimumab\n",
      "1.44 (0.76–2.75)\n",
      "0.69 (0.35–1.36)\n",
      "2.79 (1.64–4.02)\n",
      "1.17 (0.65–2.13)\n",
      "1.28 (0.72–2.29)\n",
      "1.59 (0.90–2.82)\n",
      "1.10 (0.71–1.71)\n",
      "Adalimumab\n",
      "0.48 (0.26–0.86)\n",
      "1.94 (1.30–2.88)\n",
      "0.56 (0.30–1.04)\n",
      "0.61 (0.34–1.11)\n",
      "0.76 (0.42–1.37)\n",
      "0.52 (0.33–0.83)\n",
      "0.48 (0.31–0.74)\n",
      "Inﬂiximab\n",
      "4.07 (2.67–6.21)\n",
      "1.86 (1.11–3.13)\n",
      "2.03 (1.23–3.34)\n",
      "2.52 (1.54–4.11)\n",
      "1.74 (1.25–2.41)\n",
      "1.58 (1.18–2.13)\n",
      "3.32 (2.39–4.60)\n",
      "Placebo\n",
      "NOTE. Comparisons should be read from left to right. Odds ratio for comparisons are in the cell in common between the column-deﬁning and row-deﬁning treatment. Numbers in bold are statistically signiﬁcant. For induction of\n",
      "clinical remission, an odds ratio greater than 1 favors row-deﬁning treatment. For induction of endoscopic improvement, an odds ratio greater than 1 favors column-deﬁning treatment. Numbers in parentheses indicate 95% CI.\n",
      "b.d., twice daily.\n",
      "----------\n",
      "severely active ulcerative colitis: results from phase 3 \n",
      "U-ACCOMPLISH study. J Crohn’s Colitis 2021; 15 (suppl 1): S021–22.\n",
      "9 \n",
      "Thorlund K, Druyts E, Mills EJ, Fedorak RN, Marshall JK. \n",
      "Adalimumab versus infliximab for the treatment of moderate to \n",
      "severe ulcerative colitis in adult patients naïve to anti-TNF therapy: \n",
      "an indirect treatment comparison meta-analysis. J Crohn’s Colitis \n",
      "2014; 8: 571–81.\n",
      "10 \n",
      "Danese S, Fiorino G, Peyrin-Biroulet L, et al. Biological agents for \n",
      "moderately to severely active ulcerative colitis: a systematic review \n",
      "and network meta-analysis. Ann Intern Med 2014; 160: 704–11.\n",
      "11 \n",
      "Singh S, Fumery M, Sandborn WJ, Murad MH. Systematic review \n",
      "with network meta-analysis: first- and second-line pharmacotherapy \n",
      "for moderate-severe ulcerative colitis. Aliment Pharmacol Ther 2018; \n",
      "47: 162–75.\n",
      "12 \n",
      "Bonovas S, Lytras T, Nikolopoulos G, Peyrin-Biroulet L, Danese S. \n",
      "Systematic review with network meta-analysis: comparative \n",
      "assessment of tofacitinib and biological therapies for moderate-to-\n",
      "severe ulcerative colitis. Aliment Pharmacol Ther 2018; 47: 454–65.\n",
      "13 \n",
      "Singh S, Murad MH, Fumery M, Dulai PS, Sandborn WJ. First- and \n",
      "second-line pharmacotherapies for patients with moderate to \n",
      "severely active ulcerative colitis: an updated network meta-analysis. \n",
      "Clin Gastroenterol Hepatol 2020; 18: 2179–91.e6.\n",
      "14 \n",
      "Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting \n",
      "items for systematic reviews and meta-analyses: the PRISMA \n",
      "statement. Ann Intern Med 2009; 151: 264–69.\n",
      "15 \n",
      "Jansen JP, Fleurence R, Devine B, et al. Interpreting indirect \n",
      "treatment comparisons and network meta-analysis for health-care \n",
      "decision making: report of the ISPOR Task Force on Indirect \n",
      "Treatment Comparisons Good Research Practices: part 1. \n",
      "Value Health 2011; 14: 417–28.\n",
      "16 \n",
      "Sterne JAC, Savović J, Page MJ, et al. RoB 2: a revised tool for \n",
      "assessing risk of bias in randomised trials. BMJ 2019; 366: l4898.\n",
      "17 \n",
      "Rücker G, Schwarzer G. Ranking treatments in frequentist network \n",
      "meta-analysis works without resampling methods. \n",
      "BMC Med Res Methodol 2015; 15: 58.\n",
      "----------\n",
      "Articles\n",
      "www.thelancet.com/gastrohep   Vol 7   February 2022 \n",
      "161\n",
      "Lancet Gastroenterol Hepatol \n",
      "2022; 7: 161–70\n",
      "Published Online \n",
      "November 29, 2021 \n",
      "https://doi.org/10.1016/ \n",
      "S2468-1253(21)00377-0\n",
      "See Comment page 110\n",
      "*Contributed equally\n",
      "Inflammatory Bowel Disease \n",
      "Unit, Gastroenterology \n",
      "Section, Department of \n",
      "Internal Medicine, Centro de \n",
      "Educación Médica e \n",
      "Investigaciones Clínicas, \n",
      "Buenos Aires, Argentina \n",
      "(J S Lasa MD, P A Olivera MD); \n",
      "Gastroenterology Department, \n",
      "Hospital Británico de Buenos \n",
      "Aires, Buenos Aires, Argentina \n",
      "(J S Lasa); Zane Cohen Centre \n",
      "for Digestive Diseases, \n",
      "Lunenfeld-Tanenbaum \n",
      "Research Institute, Sinai Health \n",
      "System, Toronto, ON, Canada \n",
      "(P A Olivera); Division of \n",
      "Gastroenterology, Mount Sinai \n",
      "Hospital, University of Toronto, \n",
      "Toronto, ON, Canada \n",
      "(P A Olivera); Gastroenterology \n",
      "and Endoscopy, IRCCS Ospedale \n",
      "San Raffaele and University \n",
      "Vita-Salute San Raffaele, \n",
      "Milano, Italy \n",
      "(Prof S Danese MD); INSERM \n",
      "NGERE and Department of \n",
      "Hepatogastroenterology, \n",
      "Nancy University Hospital, \n",
      "Lorraine University, \n",
      "Vandoeuvre-lés-Nancy, France \n",
      "(Prof L Peyrin-Biroulet MD) \n",
      "Correspondence to: \n",
      "Prof Laurent Peyrin-Biroulet, \n",
      "INSERM NGERE and Department \n",
      "of Hepatogastroenterology, \n",
      "Nancy University Hospital, \n",
      "Lorraine University, Vandoeuvre-\n",
      "lès-Nancy F-54511, France \n",
      "peyrinbiroulet@gmail.com\n",
      "Efficacy and safety of biologics and small molecule drugs for \n",
      "patients with moderate-to-severe ulcerative colitis: \n",
      "a systematic review and network meta-analysis \n",
      "Juan S Lasa*, Pablo A Olivera*, Silvio Danese, Laurent Peyrin-Biroulet\n",
      "Summary\n",
      "Background There is a growing armamentarium for the treatment of moderate-to-severe ulcerative colitis. We aimed \n",
      "to compare the relative efficacy and safety of biologics and small molecule drugs for the treatment of patients with \n",
      "moderate-to-severe ulcerative colitis.\n",
      "Methods In this systematic review and network meta-analysis, we searched MEDLINE, Embase, and the Cochrane \n",
      "Central Register of Controlled Trials without language restrictions for articles published between Jan 1, 1990, and \n",
      "July 1, 2021. Major congresses’ databases from Jan 1, 2018, to July 3, 2021, were reviewed manually. Phase 3, placebo-\n",
      "controlled or head-to-head randomised controlled trials (RCTs) assessing the efficacy and safety of biologics or small \n",
      "molecule drugs as induction or maintenance therapies for patients with moderate-to-severe ulcerative colitis were\n",
      "----------\n",
      "Parkes, M., Vermeire, S., Rioux, J.D., Mansﬁeld, J., Silverberg, M.S., Radford-\n",
      "Smith, G., McGovern, D.P., Barrett, J.C., Lees, C.W., 2016. Inherited determinants of\n",
      "crohn's disease and ulcerative colitis phenotypes: a genetic association study. Lancet\n",
      "387 (10014), 156–167.\n",
      "Colombel, J.F., Sandborn, W.J., Rutgeerts, P., Enns, R., Hanauer, S.B., Panaccione, R.,\n",
      "Schreiber, S., Byczkowski, D., Li, J., Kent, J.D., Pollack, P.F., 2007. Adalimumab for\n",
      "maintenance of clinical response and remission in patients with crohn's disease: the\n",
      "charm trial. Gastroenterology 132 (1), 52–65.\n",
      "Conrad, M.A., Kelsen, J.R., 2020. The treatment of pediatric inﬂammatory bowel disease\n",
      "with biologic therapies. Curr. Gastroenterol. Rep. 22 (8), 36–51.\n",
      "Csontos, A.A., Molnar, A., Piri, Z., Katona, B., Dako, S., Palﬁ, E., Miheller, P., 2016. The\n",
      "effect of anti-tnfalpha induction therapy on the nutritional status and dietary intake\n",
      "in inﬂammatory bowel disease. J Gastrointestin Liver Dis 25 (1), 49–56.\n",
      "Dai, Z.H., Xu, X.T., Ran, Z.H., 2020. Associations between obesity and the effectiveness of\n",
      "anti-tumor necrosis factor-alpha agents in inﬂammatory bowel disease patients: a\n",
      "literature review and meta-analysis. Ann. Pharmacother. 54 (8), 729–741.\n",
      "Danese, S., Colombel, J.F., Lukas, M., Gisbert, J.P., D’Haens, G., Hayee, B., Panaccione, R.,\n",
      "Kim, H.S., Reinisch, W., Tyrrell, H., Oh, Y.S., Tole, S., Chai, A., Chamberlain-\n",
      "James, K., Tang, M.T., Schreiber, S., Group, G.S., 2021. Etrolizumab versus inﬂiximab\n",
      "for the treatment of moderately to severely active ulcerative colitis (gardenia): a\n",
      "randomised, double-blind, double-dummy, phase 3 study. Lancet Gastroenterol\n",
      "Hepatol 7 (2), 118–127.\n",
      "Danese, S., Fiorino, G., Peyrin-Biroulet, L., Lucenteforte, E., Virgili, G., Moja, L.,\n",
      "Bonovas, S., 2014. Biological agents for moderately to severely active ulcerative\n",
      "colitis: a systematic review and network meta-analysis. Ann. Intern. Med. 160 (10),\n",
      "704–711.\n",
      "P. Juillerat et al.\n",
      "Current Research in Pharmacology and Drug Discovery 3 (2022) 100104\n",
      "6\n",
      "----------\n",
      "Burr et al. \n",
      " \n",
      "5 of 45 \n",
      "STUDY HIGHLIGHTS \n",
      " \n",
      "What is already known about this subject \n",
      "• Ulcerative colitis (UC) follows a relapsing and remitting course, with intermittent \n",
      "flares of disease activity, some of which may be moderate to severe. \n",
      "• These are usually treated with corticosteroids, which have potentially serious adverse \n",
      "effects, so biological therapies and small molecules have been developed and licensed \n",
      "for this indication.  \n",
      "• Although previous network meta-analyses have compared their efficacy and safety, \n",
      "this is a rapidly moving field, and there are already several newer drugs that have \n",
      "shown efficacy in phase III clinical trials that were not considered in these. \n",
      " \n",
      "What are the new findings \n",
      "• In terms of clinical remission and clinical response, upadacitinib 45mg o.d. ranked \n",
      "first in all patients, in patients previously exposed to anti-tumour necrosis factor \n",
      "(TNF)-α therapies, and in patients naïve to these drugs.  \n",
      "• In terms of endoscopic improvement infliximab 10mg/kg ranked first, followed by \n",
      "upadacitinib 45mg o.d., and infliximab 5mg/kg.  \n",
      "• However, for endoscopic improvement again upadacitinib 45mg o.d. ranked first in \n",
      "patients previously exposed to anti-TNF-α therapies, and in patients who were anti-\n",
      "TNF-α naïve.  \n",
      "• None of the drugs studied were more likely to lead to serious adverse events than \n",
      "placebo.\n",
      "----------\n",
      "Therapeutic strategies for the management of recentlydiagnosedulcerative colitis. IMMs include thiopurines and methotrexate. 5-ASA, 5-amino salicylic acid; ASUC, acute severe ulcerative colitis; IPAA, ileal pouch anal anastomosis.\n",
      "\n",
      "Risk stratification: Mild\n",
      "Clinical features: NA\n",
      "Treatment options: 5-ASA (oral and/or topical)\n",
      "\n",
      "Risk stratification: Moderate\n",
      "Clinical features: NA\n",
      "Treatment options: Can consider 5-ASA (with rapid step-up if inadequate response)\n",
      "\n",
      "Risk stratification: Moderate\n",
      "Clinical features: NA\n",
      "Treatment options: VDZ or UST\n",
      "\n",
      "Risk stratification: Moderate\n",
      "Clinical features: NA\n",
      "Treatment options: Thiopurine\n",
      "\n",
      "Risk stratification: Moderate\n",
      "Clinical features: NA\n",
      "Treatment options: TNFi +/- IMM\n",
      "\n",
      "Risk stratification: Severe\n",
      "Clinical features: NA\n",
      "Treatment options: TNFi +/- IMM\n",
      "\n",
      "Risk stratification: Severe\n",
      "Clinical features: NA\n",
      "Treatment options: Subtotal colectomy + IPAA or cyclosporine (for ASUC)\n",
      "\n",
      "Risk stratification: Additional consideration: EIM present\n",
      "Clinical features: Psoriasis or psoriatic arthritis\n",
      "Treatment options: UST\n",
      "\n",
      "Risk stratification: Additional consideration: EIM present\n",
      "Clinical features: Other arthritis\n",
      "Treatment options: TNFi\n",
      "\n",
      "\n",
      "----------\n",
      "methodologic characteristics). If direct and indirect es-\n",
      "timates were similar (ie, coherent), then the higher rating\n",
      "can be assigned to the network meta-analysis estimates.\n",
      "Results\n",
      "From a total 5651 unique studies identiﬁed using our\n",
      "search strategy, we included 15 RCTs of ﬁrst-line agents\n",
      "(in biologic-naïve patients) (Active Ulcerative Colitis Trials\n",
      "1 and 2,17 Jiang et al,18 NCT01551290,19 Ulcerative colitis\n",
      "Long-Term Remission and maintenance with Adalimumab\n",
      "1 and 2,20,21 Suzuki et al,22 Program of Ulcerative Colitis\n",
      "Research Studies Utilizing an Investigational Treatment\n",
      "phase 2 and phase 3 induction studies,23 GEMINI I,24\n",
      "Motoya et al,25 VARSITY, Oral Clinical Trials for tofAciti-\n",
      "nib in ulceratiVE colitis (OCTAVE) 1 and 2,26 and UNIFI),\n",
      "and 7 RCTs of second-line agents (in patients with prior\n",
      "exposure to TNFa antagonists) (Ulcerative colitis Long-\n",
      "Term Remission and maintenance with Adalimumab 2,21\n",
      "GEMINI I,24 Motoya et al,25 VARSITY,6 OCTAVE 1 and\n",
      "2,26 UNIFI7) in patients with moderate–severe ulcerative\n",
      "colitis. Trials of inﬂiximab (Active Ulcerative Colitis Trials\n",
      "1 and 2,17 Jiang et al,18 NCT0155129019), adalimumab\n",
      "(Ulcerative colitis Long-Term Remission and maintenance\n",
      "with Adalimumab 2,20,21 Suzuki et al22), vedolizumab\n",
      "(GEMINI I,24 Motoya et al,25 VARSITY6) and ustekinumab\n",
      "(UNIFI7) also reported outcomes on maintenance therapy\n",
      "within the same publication; Program of Ulcerative Colitis\n",
      "Research Studies Utilizing an Investigational Treatment-\n",
      "M, Program of Ulcerative Colitis Research Studies Utilizing\n",
      "an Investigational Treatment-J, and OCTAVE-Sustain\n",
      "reported\n",
      "outcomes\n",
      "for\n",
      "maintenance\n",
      "therapy\n",
      "with\n",
      "golimumab and tofacitinib, respectively.26–28 From our\n",
      "previous analysis, 3 additional studies were included.\n",
      "The schematic diagram of study selection is shown in\n",
      "Supplementary\n",
      "Figure\n",
      "1,\n",
      "and\n",
      "available\n",
      "direct\n",
      "comparisons and network of trials are shown in Figure 1.\n",
      "Trial and patient characteristics are summarized in\n",
      "Table 1. Overall, the median average age of patients was\n",
      "41 years (interquartile range, 40–42 y), and 60%\n",
      "(interquartile range, 56%–63%) were men. The median\n",
      "disease duration was 6.7 years (interquartile range,\n",
      "6.0–7.8 y), and 49% (interquartile range, 46%–55%) of\n",
      "patients had extensive colitis. A median of 40% (inter-\n",
      "quartile range, 30%–50%) of patients were treated with\n",
      "concomitant immunomodulators, and 51% (interquartile\n",
      "range, 45%–57%) were on corticosteroids at baseline.\n",
      "Patients across all trials and treatment arms were com-\n",
      "----------\n",
      "prognosis, with 1 study reporting fewer hospitalizations and\n",
      "less frequent requirement of immunosuppression in pa-\n",
      "tients diagnosed after age 60 years,47 and a meta-analysis\n",
      "suggested\n",
      "that,\n",
      "although\n",
      "elderly\n",
      "IBD\n",
      "presents\n",
      "less\n",
      "commonly with complications, there are similar or higher\n",
      "rates of surgery compared to a nonelderly population.48 It is\n",
      "being increasingly recognized that frailty, rather than\n",
      "chronologic age, may be the driver of adverse outcomes in\n",
      "this group.49,50\n",
      "Other Demographic Variables\n",
      "There are signiﬁcant differences in IBD phenotype\n",
      "and outcomes based on race and ethnicity, likely due to\n",
      "a multitude of factors, both social and biologic. Emer-\n",
      "gency department use, hospitalization, complicated dis-\n",
      "ease\n",
      "course,\n",
      "and\n",
      "IBD-related\n",
      "disability\n",
      "are\n",
      "more\n",
      "common in minority and lower socioeconomic status\n",
      "groups.51,52 In a study of 770 patients with IBD, South\n",
      "Asian immigrants living in the United Kingdom were\n",
      "more\n",
      "likely\n",
      "to\n",
      "have\n",
      "extensive\n",
      "UC\n",
      "and\n",
      "colonic\n",
      "CD\n",
      "compared with their native counterparts,53 which might\n",
      "be related, in part, to limited access to care.54 Genes\n",
      "implicated in IBD risk also differ in non-White compared\n",
      "with White patients with IBD.55 Being aware of the\n",
      "higher vulnerability to adverse IBD-related outcomes in\n",
      "these vulnerable groups should prompt careful moni-\n",
      "toring to limit adverse outcomes.\n",
      "There are increasing data on sex-based differences in\n",
      "IBD phenotype and outcomes, which may signal differences\n",
      "in pathogenic pathways and progression. Of note, extra-\n",
      "intestinal manifestations (EIMs) consistently tend to be\n",
      "more common in female patients (CD: OR, 2.3; 95% CI, 1.9–\n",
      "2.8 and UC: OR, 1.5; 95% CI, 1.1–2.3, in a large Dutch Bio-\n",
      "Bank).56 Similarly, in a retrospective pediatric study of\n",
      "nearly 1000 patients with CD, girls were more likely to have\n",
      "EIMs and less likely to have growth impairment compared\n",
      "with boys,57 the latter is possibly related to lower insulin-\n",
      "like growth factor-1 level in boys.58\n",
      "July 2021\n",
      "Management of early IBD\n",
      "49\n",
      "REVIEWS AND\n",
      "PERSPECTIVES\n",
      "----------\n",
      "Disease Phenotype and Clinical Characteristics\n",
      "The International Organization for the Study of Inﬂam-\n",
      "matory Bowel Disease and the American Gastroenterological\n",
      "Association (AGA) provide a framework for categorization of\n",
      "CD and UC severity into mild-, moderate-, and high-risk\n",
      "groups based on phenotype and other characteristics.59,60\n",
      "In CD, the presence of large or deep mucosal lesions on\n",
      "endoscopy or magnetic resonance imaging (MRI), history of\n",
      "a ﬁstula, abscess, or intestinal resection are predictors of\n",
      "worse outcomes.59,60 In a prospective population-based\n",
      "inception cohort of 213 patients with CD, penetrating\n",
      "behavior was associated with a higher risk of progression to\n",
      "perianal disease (HR, 5.65; 95% CI, 2.65–12.03) and was a\n",
      "risk factor for resection (HR, 3.92; 95% CI, 1.86–8.67) and\n",
      "hospitalization (HR, 1.01; 95% CI, 1.00–1.01).16 Ileal and\n",
      "upper gastrointestinal disease location and extensive dis-\n",
      "ease are also markers of severe disease.61 Cigarette smoking\n",
      "is associated with complications and need for therapy\n",
      "escalation.61\n",
      "In CD, the threshold of suspicion should be low for high-\n",
      "quality imaging of the pelvis, such as MRI, to rule our\n",
      "perianal CD. In a retrospective study of 136 pediatric CD\n",
      "patients, presence of anal ﬁssures and skin tags, non-White\n",
      "race, and elevated C-reactive protein (CRP) were risk factors\n",
      "for perianal CD.62 In another study of 274 patients in China\n",
      "with recently diagnosed CD, all of whom underwent MRI\n",
      "pelvis, asymptomatic perianal ﬁstulas were diagnosed in\n",
      "17.5% of patients and colonic location of CD was a risk\n",
      "factor for asymptomatic perianal ﬁstulas.63\n",
      "In UC, corresponding predictors of aggressive disease\n",
      "advised by the International Organization for the Study of\n",
      "Inﬂammatory Bowel Disease include active colonic ulcers\n",
      "and prior use of biologics.59 Extensive colitis, deep ulcers,\n",
      "need for corticosteroids, hospitalization, Clostridium difﬁcile,\n",
      "and cytomegalovirus infection also indicate higher colec-\n",
      "tomy risk.64 Of note, disease extension from limited disease\n",
      "to\n",
      "extensive\n",
      "or\n",
      "pancolitis\n",
      "is\n",
      "associated\n",
      "with\n",
      "worse\n",
      "prognosis.45,65\n",
      "In addition, co-occurrence of other immune-mediated\n",
      "inﬂammatory diseases can occur, most commonly with\n",
      "psoriasis and asthma, but also, in more rare instances, with\n",
      "other gastrointestinal diseases (eg, celiac, nonalcoholic fatty\n",
      "liver disease,66 and eosinophilic esophagitis).67,68 Presence\n",
      "of a concomitant immune-mediated inﬂammatory disease is\n",
      "Figure\n",
      "1. Inﬂammatory\n",
      "bowel disease severity vs\n",
      "==========\n",
      "ORIGINAL QUESTION: ANALYSE the given patient profile based on given query based on one of the following criteria:\n",
      "- Whether treated patient is new patient or patient under maintenance\n",
      "- Prior response to Infliximab\n",
      "- Prior failure to Anti-TNF agents\n",
      "- Prior failure to Vedolizumab\n",
      "- Age\n",
      "- Pregnancy\n",
      "- Extraintestinale manifestations\n",
      "- Pouchitis\n",
      "RETURN up to 2 TOP choices of biological drugs given patient profile and context. Explain the PROS and CONS of the 2 choices.\n",
      "PATIENT PROFILE: 36 year old woman with moderate ulcerative colitis and multiple sclerosis\n",
      "\n",
      "==========\n",
      "CURRENT ANSWER:\n",
      "Based on the given patient profile, the top two choices of biological drugs would be Vedolizumab and Ustekinumab. \n",
      "\n",
      "1. Vedolizumab:\n",
      "   - Advantages: Vedolizumab is a gut-selective immunosuppressant, meaning it specifically targets the gut and has less systemic side effects. It has been shown to be effective in inducing and maintaining remission in moderate to severe ulcerative colitis.\n",
      "   - Disadvantages: Vedolizumab may not work for all patients and there may be risks associated with its use. It is administered intravenously, which may be inconvenient for some patients.\n",
      "\n",
      "2. Ustekinumab:\n",
      "   - Advantages: Ustekinumab is used to treat both ulcerative colitis and multiple sclerosis, which is beneficial for this patient who has both conditions. It has been shown to be effective in inducing and maintaining remission in moderate to severe ulcerative colitis.\n",
      "   - Disadvantages: Ustekinumab may not work for all patients and there may be risks associated with its use. It is administered subcutaneously, which may be inconvenient for some patients.\n",
      "\n",
      "It's important to note that the choice of treatment should be individualized and discussed with the patient, taking into consideration the potential benefits and risks, as well as the patient's preferences and lifestyle.\n",
      "==========\n",
      "REFINED ANSWER:\n",
      "\u001b[0m\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "Retrying langchain.chat_models.openai.ChatOpenAI.completion_with_retry.<locals>._completion_with_retry in 4.0 seconds as it raised RateLimitError: Rate limit reached for 10KTPM-200RPM in organization org-ETbTMTN2JXYOUPDJgxuH2iO6 on tokens per min. Limit: 10000 / min. Please try again in 6ms. Contact us through our help center at help.openai.com if you continue to have issues..\n",
      "Retrying langchain.chat_models.openai.ChatOpenAI.completion_with_retry.<locals>._completion_with_retry in 4.0 seconds as it raised RateLimitError: Rate limit reached for 10KTPM-200RPM in organization org-ETbTMTN2JXYOUPDJgxuH2iO6 on tokens per min. Limit: 10000 / min. Please try again in 6ms. Contact us through our help center at help.openai.com if you continue to have issues..\n",
      "Retrying langchain.chat_models.openai.ChatOpenAI.completion_with_retry.<locals>._completion_with_retry in 4.0 seconds as it raised RateLimitError: Rate limit reached for 10KTPM-200RPM in organization org-ETbTMTN2JXYOUPDJgxuH2iO6 on tokens per min. Limit: 10000 / min. Please try again in 6ms. Contact us through our help center at help.openai.com if you continue to have issues..\n",
      "Retrying langchain.chat_models.openai.ChatOpenAI.completion_with_retry.<locals>._completion_with_retry in 8.0 seconds as it raised RateLimitError: Rate limit reached for 10KTPM-200RPM in organization org-ETbTMTN2JXYOUPDJgxuH2iO6 on tokens per min. Limit: 10000 / min. Please try again in 6ms. Contact us through our help center at help.openai.com if you continue to have issues..\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\n",
      "\u001b[1m> Finished chain.\u001b[0m\n",
      "\n",
      "\u001b[1m> Finished chain.\u001b[0m\n",
      "2023-10-02 17:24:21,412:INFO: 6012 tokens were added to prompt from 10 documents\n",
      "Query: 39 year-old male with moderate to severe extensive ulcerative colitis who had malignant melanoma which was treated 3 years ago\n",
      "\n",
      "\n",
      "\n",
      "\u001b[1m> Entering new SequentialChain chain...\u001b[0m\n",
      "\n",
      "\n",
      "\u001b[1m> Entering new RetrievalQAWithSourcesChain chain...\u001b[0m\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "Retrying langchain.chat_models.openai.ChatOpenAI.completion_with_retry.<locals>._completion_with_retry in 4.0 seconds as it raised RateLimitError: Rate limit reached for 10KTPM-200RPM in organization org-ETbTMTN2JXYOUPDJgxuH2iO6 on tokens per min. Limit: 10000 / min. Please try again in 6ms. Contact us through our help center at help.openai.com if you continue to have issues..\n",
      "Retrying langchain.chat_models.openai.ChatOpenAI.completion_with_retry.<locals>._completion_with_retry in 4.0 seconds as it raised RateLimitError: Rate limit reached for 10KTPM-200RPM in organization org-ETbTMTN2JXYOUPDJgxuH2iO6 on tokens per min. Limit: 10000 / min. Please try again in 6ms. Contact us through our help center at help.openai.com if you continue to have issues..\n",
      "Retrying langchain.chat_models.openai.ChatOpenAI.completion_with_retry.<locals>._completion_with_retry in 4.0 seconds as it raised RateLimitError: Rate limit reached for 10KTPM-200RPM in organization org-ETbTMTN2JXYOUPDJgxuH2iO6 on tokens per min. Limit: 10000 / min. Please try again in 6ms. Contact us through our help center at help.openai.com if you continue to have issues..\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\n",
      "\u001b[1m> Finished chain.\u001b[0m\n",
      "\n",
      "\n",
      "\u001b[1m> Entering new LLMChain chain...\u001b[0m\n",
      "Prompt after formatting:\n",
      "\u001b[32;1m\u001b[1;3mYou are a senior physician giving advice on treatment for moderate to severe ulcerative colitis (UC).\n",
      "Make reference to the CONTEXT given to assess the scenario.\n",
      "==========\n",
      "TASK: Your task is to analyse critically the CURRENT ANSWER given the CONTEXT.\n",
      "Then refine the existing answer (only if needed) based on the following instructions:\n",
      "- If no refinement needed, return the original answer in the correct output format.\n",
      "- If the answer cannot be inferred from CONTEXT, return \"NO ANSWER\".\n",
      "- The final output should be a list of up to 2 choices of biological drugs given patient profile and context and PROS/CONS for each recommendations.\n",
      "==========\n",
      "CONTEXT:\n",
      "severely active ulcerative colitis: results from phase 3 \n",
      "U-ACCOMPLISH study. J Crohn’s Colitis 2021; 15 (suppl 1): S021–22.\n",
      "9 \n",
      "Thorlund K, Druyts E, Mills EJ, Fedorak RN, Marshall JK. \n",
      "Adalimumab versus infliximab for the treatment of moderate to \n",
      "severe ulcerative colitis in adult patients naïve to anti-TNF therapy: \n",
      "an indirect treatment comparison meta-analysis. J Crohn’s Colitis \n",
      "2014; 8: 571–81.\n",
      "10 \n",
      "Danese S, Fiorino G, Peyrin-Biroulet L, et al. Biological agents for \n",
      "moderately to severely active ulcerative colitis: a systematic review \n",
      "and network meta-analysis. Ann Intern Med 2014; 160: 704–11.\n",
      "11 \n",
      "Singh S, Fumery M, Sandborn WJ, Murad MH. Systematic review \n",
      "with network meta-analysis: first- and second-line pharmacotherapy \n",
      "for moderate-severe ulcerative colitis. Aliment Pharmacol Ther 2018; \n",
      "47: 162–75.\n",
      "12 \n",
      "Bonovas S, Lytras T, Nikolopoulos G, Peyrin-Biroulet L, Danese S. \n",
      "Systematic review with network meta-analysis: comparative \n",
      "assessment of tofacitinib and biological therapies for moderate-to-\n",
      "severe ulcerative colitis. Aliment Pharmacol Ther 2018; 47: 454–65.\n",
      "13 \n",
      "Singh S, Murad MH, Fumery M, Dulai PS, Sandborn WJ. First- and \n",
      "second-line pharmacotherapies for patients with moderate to \n",
      "severely active ulcerative colitis: an updated network meta-analysis. \n",
      "Clin Gastroenterol Hepatol 2020; 18: 2179–91.e6.\n",
      "14 \n",
      "Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting \n",
      "items for systematic reviews and meta-analyses: the PRISMA \n",
      "statement. Ann Intern Med 2009; 151: 264–69.\n",
      "15 \n",
      "Jansen JP, Fleurence R, Devine B, et al. Interpreting indirect \n",
      "treatment comparisons and network meta-analysis for health-care \n",
      "decision making: report of the ISPOR Task Force on Indirect \n",
      "Treatment Comparisons Good Research Practices: part 1. \n",
      "Value Health 2011; 14: 417–28.\n",
      "16 \n",
      "Sterne JAC, Savović J, Page MJ, et al. RoB 2: a revised tool for \n",
      "assessing risk of bias in randomised trials. BMJ 2019; 366: l4898.\n",
      "17 \n",
      "Rücker G, Schwarzer G. Ranking treatments in frequentist network \n",
      "meta-analysis works without resampling methods. \n",
      "BMC Med Res Methodol 2015; 15: 58.\n",
      "----------\n",
      "Burr et al. \n",
      " \n",
      "7 of 45 \n",
      "INTRODUCTION \n",
      "  Ulcerative colitis (UC) is a chronic inflammatory disorder of the bowel that causes \n",
      "continuous mucosal inflammation commencing in the rectum and extending proximally for a \n",
      "variable extent.[1] It is estimated that UC affects 2.5 million people in Europe,[2] and the \n",
      "disease follows a relapsing and remitting course, with intermittent flares of disease activity, \n",
      "some of which may be moderate to severe. Management of these is medical, for the most \n",
      "part, with surgery reserved for patients with refractory disease. Although 5-aminosalicylates \n",
      "(5-ASAs) are efficacious for mild to moderate disease activity,[3-6] more severe flares are \n",
      "usually treated with corticosteroids.[7] However, these have potentially serious adverse \n",
      "effects and a substantial proportion of patients may become either dependent on them to \n",
      "maintain remission,[8] or refractory to them.[9] As a result, over the last 20 years novel \n",
      "drugs, with more precise modes of action, based on mechanisms of disease identified in \n",
      "genome wide association studies,[10] have been developed.  \n",
      "The first of these agents was infliximab, a drug targeting the pro-inflammatory \n",
      "cytokine tumour necrosis factor-α (TNF-α), which demonstrated efficacy in clinical trials in \n",
      "moderate to severe UC.[11] Since then, other drugs against TNF-α have been tested, such as \n",
      "adalimumab and golimumab.[12, 13] In addition, newer biological therapies targeting α or β \n",
      "integrins, which are involved in migration of immune cells to inflamed intestinal mucosa, \n",
      "such as vedolizumab or etrolizumab,[14, 15] or acting against other pro-inflammatory \n",
      "cytokines implicated in the pathogenesis of UC, such as ustekinumab,[16] have been tested. \n",
      "However, even these more selective drugs do not work in all patients, there may be risks \n",
      "associated with their use,[17-19] and the fact that they are administered either intravenously \n",
      "or subcutaneously, may be inconvenient for patients. The search for alternative agents for the \n",
      "treatment of UC has, therefore, continued.\n",
      "----------\n",
      "41 years (interquartile range, 40–42 y), and 60%\n",
      "(interquartile range, 56%–63%) were men. The median\n",
      "disease duration was 6.7 years (interquartile range,\n",
      "6.0–7.8 y), and 49% (interquartile range, 46%–55%) of\n",
      "patients had extensive colitis. A median of 40% (inter-\n",
      "quartile range, 30%–50%) of patients were treated with\n",
      "concomitant immunomodulators, and 51% (interquartile\n",
      "range, 45%–57%) were on corticosteroids at baseline.\n",
      "Patients across all trials and treatment arms were com-\n",
      "parable in terms of baseline prognostic variables, inclu-\n",
      "sion/exclusion\n",
      "criteria,\n",
      "and\n",
      "co-interventions.\n",
      "All\n",
      "outcomes were assessed uniformly based on the stan-\n",
      "dard deﬁnition of the Mayo Clinic score, between weeks\n",
      "6 and 10 for induction therapy (inﬂiximab, adalimumab,\n",
      "tofacitinib, ustekinumab, 8 weeks; golimumab, 6 weeks;\n",
      "vedolizumab, 6 weeks, 10 weeks, and 14 weeks in\n",
      "VARSITY),6 and weeks 30, 54, or 60 for maintenance\n",
      "therapy;\n",
      "endoscopy\n",
      "was\n",
      "read\n",
      "by\n",
      "blinded\n",
      "local\n",
      "Table 2. Comparative Efﬁcacy of Pharmacologic Agents for Induction of Clinical Remission and Endoscopic Improvement in Biologic-Naive Patients With Moderate–Severe\n",
      "Ulcerative Colitis Using Network Meta-Analysis\n",
      "Induction of clinical remission\n",
      "Induction of endoscopic improvement\n",
      "Ustekinumab 6 mg/kg\n",
      "0.96 (0.38–2.45)\n",
      "0.80 (0.35–1.83)\n",
      "0.73 (0.31–1.74)\n",
      "1.05 (0.48–2.32)\n",
      "0.50 (0.22–1.12)\n",
      "2.04 (1.03–4.05)\n",
      "0.92 (0.45–1.89)\n",
      "Tofacitinib 10 mg b.d.\n",
      "0.84 (0.39–1.82)\n",
      "0.76 (0.33–1.76)\n",
      "1.10 (0.51–2.34)\n",
      "0.52 (0.24–1.12)\n",
      "2.12 (1.12–4.02)\n",
      "0.74 (0.36–1.51)\n",
      "0.80 (0.4–1.62)\n",
      "Vedolizumab\n",
      "0.91 (0.44–1.86)\n",
      "1.31 (0.88–1.95)\n",
      "0.62 (0.34–1.15)\n",
      "2.54 (1.60–4.02)\n",
      "1.07 (0.58–1.98)\n",
      "1.17 (0.64–2.12)\n",
      "1.45 (0.80–2.61)\n",
      "Golimumab\n",
      "1.44 (0.76–2.75)\n",
      "0.69 (0.35–1.36)\n",
      "2.79 (1.64–4.02)\n",
      "1.17 (0.65–2.13)\n",
      "1.28 (0.72–2.29)\n",
      "1.59 (0.90–2.82)\n",
      "1.10 (0.71–1.71)\n",
      "Adalimumab\n",
      "0.48 (0.26–0.86)\n",
      "1.94 (1.30–2.88)\n",
      "0.56 (0.30–1.04)\n",
      "0.61 (0.34–1.11)\n",
      "0.76 (0.42–1.37)\n",
      "0.52 (0.33–0.83)\n",
      "0.48 (0.31–0.74)\n",
      "Inﬂiximab\n",
      "4.07 (2.67–6.21)\n",
      "1.86 (1.11–3.13)\n",
      "2.03 (1.23–3.34)\n",
      "2.52 (1.54–4.11)\n",
      "1.74 (1.25–2.41)\n",
      "1.58 (1.18–2.13)\n",
      "3.32 (2.39–4.60)\n",
      "Placebo\n",
      "NOTE. Comparisons should be read from left to right. Odds ratio for comparisons are in the cell in common between the column-deﬁning and row-deﬁning treatment. Numbers in bold are statistically signiﬁcant. For induction of\n",
      "clinical remission, an odds ratio greater than 1 favors row-deﬁning treatment. For induction of endoscopic improvement, an odds ratio greater than 1 favors column-deﬁning treatment. Numbers in parentheses indicate 95% CI.\n",
      "b.d., twice daily.\n",
      "----------\n",
      "Burr et al. \n",
      " \n",
      "5 of 45 \n",
      "STUDY HIGHLIGHTS \n",
      " \n",
      "What is already known about this subject \n",
      "• Ulcerative colitis (UC) follows a relapsing and remitting course, with intermittent \n",
      "flares of disease activity, some of which may be moderate to severe. \n",
      "• These are usually treated with corticosteroids, which have potentially serious adverse \n",
      "effects, so biological therapies and small molecules have been developed and licensed \n",
      "for this indication.  \n",
      "• Although previous network meta-analyses have compared their efficacy and safety, \n",
      "this is a rapidly moving field, and there are already several newer drugs that have \n",
      "shown efficacy in phase III clinical trials that were not considered in these. \n",
      " \n",
      "What are the new findings \n",
      "• In terms of clinical remission and clinical response, upadacitinib 45mg o.d. ranked \n",
      "first in all patients, in patients previously exposed to anti-tumour necrosis factor \n",
      "(TNF)-α therapies, and in patients naïve to these drugs.  \n",
      "• In terms of endoscopic improvement infliximab 10mg/kg ranked first, followed by \n",
      "upadacitinib 45mg o.d., and infliximab 5mg/kg.  \n",
      "• However, for endoscopic improvement again upadacitinib 45mg o.d. ranked first in \n",
      "patients previously exposed to anti-TNF-α therapies, and in patients who were anti-\n",
      "TNF-α naïve.  \n",
      "• None of the drugs studied were more likely to lead to serious adverse events than \n",
      "placebo.\n",
      "----------\n",
      "Parkes, M., Vermeire, S., Rioux, J.D., Mansﬁeld, J., Silverberg, M.S., Radford-\n",
      "Smith, G., McGovern, D.P., Barrett, J.C., Lees, C.W., 2016. Inherited determinants of\n",
      "crohn's disease and ulcerative colitis phenotypes: a genetic association study. Lancet\n",
      "387 (10014), 156–167.\n",
      "Colombel, J.F., Sandborn, W.J., Rutgeerts, P., Enns, R., Hanauer, S.B., Panaccione, R.,\n",
      "Schreiber, S., Byczkowski, D., Li, J., Kent, J.D., Pollack, P.F., 2007. Adalimumab for\n",
      "maintenance of clinical response and remission in patients with crohn's disease: the\n",
      "charm trial. Gastroenterology 132 (1), 52–65.\n",
      "Conrad, M.A., Kelsen, J.R., 2020. The treatment of pediatric inﬂammatory bowel disease\n",
      "with biologic therapies. Curr. Gastroenterol. Rep. 22 (8), 36–51.\n",
      "Csontos, A.A., Molnar, A., Piri, Z., Katona, B., Dako, S., Palﬁ, E., Miheller, P., 2016. The\n",
      "effect of anti-tnfalpha induction therapy on the nutritional status and dietary intake\n",
      "in inﬂammatory bowel disease. J Gastrointestin Liver Dis 25 (1), 49–56.\n",
      "Dai, Z.H., Xu, X.T., Ran, Z.H., 2020. Associations between obesity and the effectiveness of\n",
      "anti-tumor necrosis factor-alpha agents in inﬂammatory bowel disease patients: a\n",
      "literature review and meta-analysis. Ann. Pharmacother. 54 (8), 729–741.\n",
      "Danese, S., Colombel, J.F., Lukas, M., Gisbert, J.P., D’Haens, G., Hayee, B., Panaccione, R.,\n",
      "Kim, H.S., Reinisch, W., Tyrrell, H., Oh, Y.S., Tole, S., Chai, A., Chamberlain-\n",
      "James, K., Tang, M.T., Schreiber, S., Group, G.S., 2021. Etrolizumab versus inﬂiximab\n",
      "for the treatment of moderately to severely active ulcerative colitis (gardenia): a\n",
      "randomised, double-blind, double-dummy, phase 3 study. Lancet Gastroenterol\n",
      "Hepatol 7 (2), 118–127.\n",
      "Danese, S., Fiorino, G., Peyrin-Biroulet, L., Lucenteforte, E., Virgili, G., Moja, L.,\n",
      "Bonovas, S., 2014. Biological agents for moderately to severely active ulcerative\n",
      "colitis: a systematic review and network meta-analysis. Ann. Intern. Med. 160 (10),\n",
      "704–711.\n",
      "P. Juillerat et al.\n",
      "Current Research in Pharmacology and Drug Discovery 3 (2022) 100104\n",
      "6\n",
      "----------\n",
      "methodologic characteristics). If direct and indirect es-\n",
      "timates were similar (ie, coherent), then the higher rating\n",
      "can be assigned to the network meta-analysis estimates.\n",
      "Results\n",
      "From a total 5651 unique studies identiﬁed using our\n",
      "search strategy, we included 15 RCTs of ﬁrst-line agents\n",
      "(in biologic-naïve patients) (Active Ulcerative Colitis Trials\n",
      "1 and 2,17 Jiang et al,18 NCT01551290,19 Ulcerative colitis\n",
      "Long-Term Remission and maintenance with Adalimumab\n",
      "1 and 2,20,21 Suzuki et al,22 Program of Ulcerative Colitis\n",
      "Research Studies Utilizing an Investigational Treatment\n",
      "phase 2 and phase 3 induction studies,23 GEMINI I,24\n",
      "Motoya et al,25 VARSITY, Oral Clinical Trials for tofAciti-\n",
      "nib in ulceratiVE colitis (OCTAVE) 1 and 2,26 and UNIFI),\n",
      "and 7 RCTs of second-line agents (in patients with prior\n",
      "exposure to TNFa antagonists) (Ulcerative colitis Long-\n",
      "Term Remission and maintenance with Adalimumab 2,21\n",
      "GEMINI I,24 Motoya et al,25 VARSITY,6 OCTAVE 1 and\n",
      "2,26 UNIFI7) in patients with moderate–severe ulcerative\n",
      "colitis. Trials of inﬂiximab (Active Ulcerative Colitis Trials\n",
      "1 and 2,17 Jiang et al,18 NCT0155129019), adalimumab\n",
      "(Ulcerative colitis Long-Term Remission and maintenance\n",
      "with Adalimumab 2,20,21 Suzuki et al22), vedolizumab\n",
      "(GEMINI I,24 Motoya et al,25 VARSITY6) and ustekinumab\n",
      "(UNIFI7) also reported outcomes on maintenance therapy\n",
      "within the same publication; Program of Ulcerative Colitis\n",
      "Research Studies Utilizing an Investigational Treatment-\n",
      "M, Program of Ulcerative Colitis Research Studies Utilizing\n",
      "an Investigational Treatment-J, and OCTAVE-Sustain\n",
      "reported\n",
      "outcomes\n",
      "for\n",
      "maintenance\n",
      "therapy\n",
      "with\n",
      "golimumab and tofacitinib, respectively.26–28 From our\n",
      "previous analysis, 3 additional studies were included.\n",
      "The schematic diagram of study selection is shown in\n",
      "Supplementary\n",
      "Figure\n",
      "1,\n",
      "and\n",
      "available\n",
      "direct\n",
      "comparisons and network of trials are shown in Figure 1.\n",
      "Trial and patient characteristics are summarized in\n",
      "Table 1. Overall, the median average age of patients was\n",
      "41 years (interquartile range, 40–42 y), and 60%\n",
      "(interquartile range, 56%–63%) were men. The median\n",
      "disease duration was 6.7 years (interquartile range,\n",
      "6.0–7.8 y), and 49% (interquartile range, 46%–55%) of\n",
      "patients had extensive colitis. A median of 40% (inter-\n",
      "quartile range, 30%–50%) of patients were treated with\n",
      "concomitant immunomodulators, and 51% (interquartile\n",
      "range, 45%–57%) were on corticosteroids at baseline.\n",
      "Patients across all trials and treatment arms were com-\n",
      "----------\n",
      "SYSTEMATIC REVIEWS AND META-ANALYSES\n",
      "Siddharth Singh, Section Editor\n",
      "First- and Second-Line Pharmacotherapies for Patients With\n",
      "Moderate to Severely Active Ulcerative Colitis: An Updated\n",
      "Network Meta-Analysis\n",
      "Siddharth Singh,*,‡ Mohammad Hassan Murad,§ Mathurin Fumery,j\n",
      "Parambir S. Dulai,* and William J. Sandborn*\n",
      "*Division of Gastroenterology, ‡Division of Biomedical Informatics, University of California San Diego, La Jolla, California;\n",
      "§Robert D and Patricia E Kern Center for the Science of Health Care Delivery, Mayo Clinic, Rochester, Minnesota;\n",
      "||Gastroenterology Unit, Peritox UMR I-0I, Amiens University and Hospital, Université de Picardie Jules Verne, Amiens, France\n",
      "BACKGROUND & AIMS:\n",
      "We compared the efﬁcacy and safety of different ﬁrst-line (biologic-naïve) and second-line\n",
      "(prior exposure to tumor necrosis factor [TNF] antagonists) agents for treatment of moder-\n",
      "ate to severely active ulcerative colitis in a systematic review and network meta-analysis.\n",
      "METHODS:\n",
      "We searched publication databases through September 30, 2019, for randomized trials of\n",
      "adults with moderate to severe ulcerative colitis treated with TNF antagonists, vedolizumab,\n",
      "tofacitinib, or ustekinumab, as ﬁrst-line or second-line agents, compared with placebo or\n",
      "another active agent. Efﬁcacy outcomes were induction and maintenance of remission and\n",
      "endoscopic improvement; safety outcomes were serious adverse events and infections. We\n",
      "performed a ﬁxed-effects network meta-analysis using the frequentist approach, and calculated\n",
      "odds ratios (ORs) and 95% CI values. Agents were ranked using surface under the cumulative\n",
      "ranking (SUCRA) probabilities. Overall quality of evidence was rated using GRADE (Grading of\n",
      "Recommendations, Assessment, Development and Evaluation).\n",
      "RESULTS:\n",
      "In biologic-naïve patients, inﬂiximab was ranked highest for induction of clinical remission (OR\n",
      "vs placebo, 4.07; 95% CI, 2.67–6.21; SUCRA, 0.95) and endoscopic improvement (SUCRA, 0.95)\n",
      "(moderate conﬁdence in estimates [CE]). In patients with prior exposure to TNF antagonists,\n",
      "ustekinumab (SUCRA, 0.87) and tofacitinib (SUCRA, 0.87) were ranked highest for induction of\n",
      "clinical remission and were superior to vedolizumab (ustekinumab vs vedolizumab: OR, 5.99;\n",
      "95% CI, 1.13–31.76 and tofacitinib vs vedolizumab: OR, 6.18; 95% CI, 1.003–8.00; moderate CE)\n",
      "and adalimumab (ustekinumab vs adalimumab: OR, 10.71; 95% CI, 2.01–57.20 and tofacitinib\n",
      "----------\n",
      "Articles\n",
      "www.thelancet.com/gastrohep   Vol 7   February 2022 \n",
      "161\n",
      "Lancet Gastroenterol Hepatol \n",
      "2022; 7: 161–70\n",
      "Published Online \n",
      "November 29, 2021 \n",
      "https://doi.org/10.1016/ \n",
      "S2468-1253(21)00377-0\n",
      "See Comment page 110\n",
      "*Contributed equally\n",
      "Inflammatory Bowel Disease \n",
      "Unit, Gastroenterology \n",
      "Section, Department of \n",
      "Internal Medicine, Centro de \n",
      "Educación Médica e \n",
      "Investigaciones Clínicas, \n",
      "Buenos Aires, Argentina \n",
      "(J S Lasa MD, P A Olivera MD); \n",
      "Gastroenterology Department, \n",
      "Hospital Británico de Buenos \n",
      "Aires, Buenos Aires, Argentina \n",
      "(J S Lasa); Zane Cohen Centre \n",
      "for Digestive Diseases, \n",
      "Lunenfeld-Tanenbaum \n",
      "Research Institute, Sinai Health \n",
      "System, Toronto, ON, Canada \n",
      "(P A Olivera); Division of \n",
      "Gastroenterology, Mount Sinai \n",
      "Hospital, University of Toronto, \n",
      "Toronto, ON, Canada \n",
      "(P A Olivera); Gastroenterology \n",
      "and Endoscopy, IRCCS Ospedale \n",
      "San Raffaele and University \n",
      "Vita-Salute San Raffaele, \n",
      "Milano, Italy \n",
      "(Prof S Danese MD); INSERM \n",
      "NGERE and Department of \n",
      "Hepatogastroenterology, \n",
      "Nancy University Hospital, \n",
      "Lorraine University, \n",
      "Vandoeuvre-lés-Nancy, France \n",
      "(Prof L Peyrin-Biroulet MD) \n",
      "Correspondence to: \n",
      "Prof Laurent Peyrin-Biroulet, \n",
      "INSERM NGERE and Department \n",
      "of Hepatogastroenterology, \n",
      "Nancy University Hospital, \n",
      "Lorraine University, Vandoeuvre-\n",
      "lès-Nancy F-54511, France \n",
      "peyrinbiroulet@gmail.com\n",
      "Efficacy and safety of biologics and small molecule drugs for \n",
      "patients with moderate-to-severe ulcerative colitis: \n",
      "a systematic review and network meta-analysis \n",
      "Juan S Lasa*, Pablo A Olivera*, Silvio Danese, Laurent Peyrin-Biroulet\n",
      "Summary\n",
      "Background There is a growing armamentarium for the treatment of moderate-to-severe ulcerative colitis. We aimed \n",
      "to compare the relative efficacy and safety of biologics and small molecule drugs for the treatment of patients with \n",
      "moderate-to-severe ulcerative colitis.\n",
      "Methods In this systematic review and network meta-analysis, we searched MEDLINE, Embase, and the Cochrane \n",
      "Central Register of Controlled Trials without language restrictions for articles published between Jan 1, 1990, and \n",
      "July 1, 2021. Major congresses’ databases from Jan 1, 2018, to July 3, 2021, were reviewed manually. Phase 3, placebo-\n",
      "controlled or head-to-head randomised controlled trials (RCTs) assessing the efficacy and safety of biologics or small \n",
      "molecule drugs as induction or maintenance therapies for patients with moderate-to-severe ulcerative colitis were\n",
      "----------\n",
      "discontinuation due to AEs, and serious infections. Phase 3 randomized controlled trials were identified via systematic literature review, in-\n",
      "cluding the following advanced therapies: infliximab, adalimumab, vedolizumab, golimumab, tofacitinib, ustekinumab, filgotinib, ozanimod, and \n",
      "upadacitinib. Random effects models were used to address between-study heterogeneity. Intent-to-treat (ITT) efficacy rates were calculated by \n",
      "adjusting maintenance outcomes by likelihood of induction response.\n",
      "Results:  Out of 48 trials identified, 23 were included. Across all outcomes and regardless of prior biologic exposure, ITT efficacy rates were \n",
      "highest for upadacitinib, owing to its highest ranking for all efficacy outcomes in induction and for all but clinical remission during maintenance \n",
      "among bio-naive induction responders. For all advanced therapies versus placebo, there were no significant differences in serious AEs or \n",
      "serious infections across therapies. For all AEs, golimumab had higher odds versus placebo during maintenance; for discontinuation due to \n",
      "AEs, upadacitinib had lower odds versus placebo during induction, while ustekinumab and vedolizumab had lower odds versus placebo during \n",
      "maintenance.\n",
      "Conclusions:  Upadacitinib may be the most efficacious therapy for moderately to severely active UC based on ITT analyses, with similar safety \n",
      "across advanced therapies.\n",
      "Lay Summary \n",
      "Indirect evidence suggests upadacitinib may be more efficacious than other advanced therapies at achieving clinical response, clinical remis-\n",
      "sion, and endoscopic response over 1 year for moderately to severely active ulcerative colitis patients, with similar safety assessments across \n",
      "advanced therapies.\n",
      "Key Words: ulcerative colitis, clinical trials, advanced therapies, network meta-analysis\n",
      "Introduction\n",
      "Ulcerative colitis (UC) is a chronic inflammatory bowel dis-\n",
      "ease that affects the colorectum and is clinically characterized \n",
      "by bloody diarrhea, urgency, tenesmus, abdominal pain, ma-\n",
      "laise, weight loss, and fever. Disease onset commonly occurs \n",
      "between the ages of 15 and 30 years and the annual global \n",
      "© The Author(s) 2023. Published by Oxford University Press on behalf of Crohn's & Colitis Foundation.\n",
      "This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), \n",
      "which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.\n",
      "----------\n",
      "Therapeutic strategies for the management of recentlydiagnosedulcerative colitis. IMMs include thiopurines and methotrexate. 5-ASA, 5-amino salicylic acid; ASUC, acute severe ulcerative colitis; IPAA, ileal pouch anal anastomosis.\n",
      "\n",
      "Risk stratification: Mild\n",
      "Clinical features: NA\n",
      "Treatment options: 5-ASA (oral and/or topical)\n",
      "\n",
      "Risk stratification: Moderate\n",
      "Clinical features: NA\n",
      "Treatment options: Can consider 5-ASA (with rapid step-up if inadequate response)\n",
      "\n",
      "Risk stratification: Moderate\n",
      "Clinical features: NA\n",
      "Treatment options: VDZ or UST\n",
      "\n",
      "Risk stratification: Moderate\n",
      "Clinical features: NA\n",
      "Treatment options: Thiopurine\n",
      "\n",
      "Risk stratification: Moderate\n",
      "Clinical features: NA\n",
      "Treatment options: TNFi +/- IMM\n",
      "\n",
      "Risk stratification: Severe\n",
      "Clinical features: NA\n",
      "Treatment options: TNFi +/- IMM\n",
      "\n",
      "Risk stratification: Severe\n",
      "Clinical features: NA\n",
      "Treatment options: Subtotal colectomy + IPAA or cyclosporine (for ASUC)\n",
      "\n",
      "Risk stratification: Additional consideration: EIM present\n",
      "Clinical features: Psoriasis or psoriatic arthritis\n",
      "Treatment options: UST\n",
      "\n",
      "Risk stratification: Additional consideration: EIM present\n",
      "Clinical features: Other arthritis\n",
      "Treatment options: TNFi\n",
      "\n",
      "\n",
      "==========\n",
      "ORIGINAL QUESTION: ANALYSE the given patient profile based on given query based on one of the following criteria:\n",
      "- Whether treated patient is new patient or patient under maintenance\n",
      "- Prior response to Infliximab\n",
      "- Prior failure to Anti-TNF agents\n",
      "- Prior failure to Vedolizumab\n",
      "- Age\n",
      "- Pregnancy\n",
      "- Extraintestinale manifestations\n",
      "- Pouchitis\n",
      "RETURN up to 2 TOP choices of biological drugs given patient profile and context. Explain the PROS and CONS of the 2 choices.\n",
      "PATIENT PROFILE: 39 year-old male with moderate to severe extensive ulcerative colitis who had malignant melanoma which was treated 3 years ago\n",
      "\n",
      "==========\n",
      "CURRENT ANSWER:\n",
      "Based on the patient's profile, the top two choices of biological drugs would be Vedolizumab and Ustekinumab.\n",
      "\n",
      "1. Vedolizumab:\n",
      "   - Advantages: Vedolizumab is a gut-selective immunosuppressant, meaning it specifically targets the gut and has less systemic side effects. It has been shown to be effective in inducing and maintaining remission in moderate to severe ulcerative colitis.\n",
      "   - Disadvantages: The main disadvantage of Vedolizumab is that it may take longer to work compared to other biologics. It is also administered intravenously which may be inconvenient for some patients.\n",
      "\n",
      "2. Ustekinumab:\n",
      "   - Advantages: Ustekinumab has been shown to be effective in patients with moderate to severe ulcerative colitis. It is also beneficial for patients with extraintestinal manifestations such as psoriasis or psoriatic arthritis.\n",
      "   - Disadvantages: Ustekinumab may not be as effective in patients who have previously failed anti-TNF therapy. It is also administered via injection which may be inconvenient for some patients.\n",
      "\n",
      "It is important to note that the patient's history of malignant melanoma may limit the use of certain biologics, particularly those that target TNF, as these have been associated with an increased risk of malignancies. Therefore, Vedolizumab and Ustekinumab may be safer options for this patient. However, the choice of treatment should be individualized and discussed thoroughly with the patient, taking into account the potential risks and benefits.\n",
      "==========\n",
      "REFINED ANSWER:\n",
      "\u001b[0m\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "Retrying langchain.chat_models.openai.ChatOpenAI.completion_with_retry.<locals>._completion_with_retry in 4.0 seconds as it raised RateLimitError: Rate limit reached for 10KTPM-200RPM in organization org-ETbTMTN2JXYOUPDJgxuH2iO6 on tokens per min. Limit: 10000 / min. Please try again in 6ms. Contact us through our help center at help.openai.com if you continue to have issues..\n",
      "Retrying langchain.chat_models.openai.ChatOpenAI.completion_with_retry.<locals>._completion_with_retry in 4.0 seconds as it raised RateLimitError: Rate limit reached for 10KTPM-200RPM in organization org-ETbTMTN2JXYOUPDJgxuH2iO6 on tokens per min. Limit: 10000 / min. Please try again in 6ms. Contact us through our help center at help.openai.com if you continue to have issues..\n",
      "Retrying langchain.chat_models.openai.ChatOpenAI.completion_with_retry.<locals>._completion_with_retry in 4.0 seconds as it raised RateLimitError: Rate limit reached for 10KTPM-200RPM in organization org-ETbTMTN2JXYOUPDJgxuH2iO6 on tokens per min. Limit: 10000 / min. Please try again in 6ms. Contact us through our help center at help.openai.com if you continue to have issues..\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\n",
      "\u001b[1m> Finished chain.\u001b[0m\n",
      "\n",
      "\u001b[1m> Finished chain.\u001b[0m\n",
      "2023-10-02 17:25:39,407:INFO: 6061 tokens were added to prompt from 10 documents\n",
      "Query: 52 year-old woman with moderate to severe distal ulcerative colitis that had a successful induction with vedolizumab. What would be the maintenance therapy?\n",
      "\n",
      "\n",
      "\n",
      "\u001b[1m> Entering new SequentialChain chain...\u001b[0m\n",
      "\n",
      "\n",
      "\u001b[1m> Entering new RetrievalQAWithSourcesChain chain...\u001b[0m\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "Retrying langchain.chat_models.openai.ChatOpenAI.completion_with_retry.<locals>._completion_with_retry in 4.0 seconds as it raised RateLimitError: Rate limit reached for 10KTPM-200RPM in organization org-ETbTMTN2JXYOUPDJgxuH2iO6 on tokens per min. Limit: 10000 / min. Please try again in 6ms. Contact us through our help center at help.openai.com if you continue to have issues..\n",
      "Retrying langchain.chat_models.openai.ChatOpenAI.completion_with_retry.<locals>._completion_with_retry in 4.0 seconds as it raised RateLimitError: Rate limit reached for 10KTPM-200RPM in organization org-ETbTMTN2JXYOUPDJgxuH2iO6 on tokens per min. Limit: 10000 / min. Please try again in 6ms. Contact us through our help center at help.openai.com if you continue to have issues..\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\n",
      "\u001b[1m> Finished chain.\u001b[0m\n",
      "\n",
      "\n",
      "\u001b[1m> Entering new LLMChain chain...\u001b[0m\n",
      "Prompt after formatting:\n",
      "\u001b[32;1m\u001b[1;3mYou are a senior physician giving advice on treatment for moderate to severe ulcerative colitis (UC).\n",
      "Make reference to the CONTEXT given to assess the scenario.\n",
      "==========\n",
      "TASK: Your task is to analyse critically the CURRENT ANSWER given the CONTEXT.\n",
      "Then refine the existing answer (only if needed) based on the following instructions:\n",
      "- If no refinement needed, return the original answer in the correct output format.\n",
      "- If the answer cannot be inferred from CONTEXT, return \"NO ANSWER\".\n",
      "- The final output should be a list of up to 2 choices of biological drugs given patient profile and context and PROS/CONS for each recommendations.\n",
      "==========\n",
      "CONTEXT:\n",
      "Table 1. Trial and Patient Characteristics in Included Trials of Induction and Maintenance Therapy for Moderate–Severe Ulcerative Colitis\n",
      "Trial and intervention\n",
      "characteristics\n",
      "Deﬁnition and\n",
      "timing of\n",
      "outcome,\n",
      "CRem\n",
      "Mean age, y\n",
      "(SD); sex (%\n",
      "male)\n",
      "Mean disease\n",
      "duration (y) (SD);\n",
      "disease extent\n",
      "(% extensive\n",
      "colitis)\n",
      "Concomitant medications\n",
      "Mean CRP,\n",
      "mg/L (SD)\n",
      "Prior anti-\n",
      "TNF\n",
      "therapy, %\n",
      "Immunomodulators,\n",
      "%\n",
      "Corticosteroids,\n",
      "%\n",
      "Inﬂiximab\n",
      "Active Ulcerative Colitis\n",
      "Trials 117a (induction and\n",
      "maintenance therapy)\n",
      "62 sites, 2002–2005;\n",
      "P: 121;\n",
      "I: IFX 5 mg/kg, wk 0, 2, 6, then\n",
      "q8w–121\n",
      "MCS �2; wk 8,\n",
      "wk 54\n",
      "P: 41 (14); 60\n",
      "I: 42 (14); 65\n",
      "6.2 (5.9); 45\n",
      "5.9 (5.4); 47\n",
      "43.8\n",
      "54.5\n",
      "65.3\n",
      "57.9\n",
      "17 (27)\n",
      "14 (19)\n",
      "0\n",
      "0\n",
      "Active Ulcerative Colitis\n",
      "Trials 217a (induction and\n",
      "maintenance therapy)\n",
      "55 sites, 2002–2005;\n",
      "P: 123;\n",
      "I: IFX 5 mg/kg, wk 0, 2, 6, then\n",
      "q8w–121\n",
      "MCS �2; wk 8,\n",
      "wk 30\n",
      "P: 39 (14); 58\n",
      "I: 41 (13); 63\n",
      "6.5 (6.7); 42\n",
      "6.7 (5.3); 41\n",
      "43.9\n",
      "43.0\n",
      "48.8\n",
      "49.6\n",
      "16 (29)\n",
      "13 (23)\n",
      "0\n",
      "0\n",
      "Jiang et al18a (induction and\n",
      "maintenance therapy)\n",
      "1 site (China), 2008–2013;\n",
      "P: 41;\n",
      "I: IFX 5 mg/kg, wk 0, 2, 6, then\n",
      "q8w–41\n",
      "MCS �2; wk 8,\n",
      "wk 30\n",
      "P: 35 (15); 61\n",
      "I: 34 (14); 63\n",
      "4.4 (2.6); 61\n",
      "4.4 (2.8); 59\n",
      "31.7\n",
      "29.3\n",
      "51.2\n",
      "53.7\n",
      "NR\n",
      "0\n",
      "0\n",
      "NCT0155129019a (induction\n",
      "and maintenance\n",
      "therapy)\n",
      "12 sites (China), 2012–2014;\n",
      "P: 49;\n",
      "I: IFX 5 mg/kg, wk 0, 2, 6, then\n",
      "q8w–50\n",
      "MCS �2; wk 8,\n",
      "wk 26\n",
      "Entire group: 37;\n",
      "NR\n",
      "3.7; NR\n",
      "NR\n",
      "80\n",
      "60\n",
      "NR\n",
      "0\n",
      "0\n",
      "Adalimumab\n",
      "ULTRA 120 (induction\n",
      "therapy)\n",
      "94 sites, 2007–2010;\n",
      "P: 130;\n",
      "I: ADA 160/80/40, wk 0, 2, 4, 6–\n",
      "130\n",
      "MCS �2; wk 8\n",
      "P: 37 (18–72)b;\n",
      "64\n",
      "I: 37 (18–75)b; 64\n",
      "5.4 (0.3–34.1)b; 56\n",
      "6.1 (0.2–34.4)b; 46\n",
      "39.9\n",
      "39.2\n",
      "67.6\n",
      "54.6\n",
      "3.2 (0.2–280)b\n",
      "3.3 (0.1–109)b\n",
      "0\n",
      "0\n",
      "ULTRA 221a (induction and\n",
      "maintenance therapy)\n",
      "103 sites, 2006–2010;\n",
      "P: 246;\n",
      "I: ADA 160/80/40, wk 0, 2, 4, 6–\n",
      "248\n",
      "MCS �2; wk 8\n",
      "P: 41 (13); 62\n",
      "I: 40 (12); 57\n",
      "8.5 (7.4); 49\n",
      "8.1 (7.1); 48\n",
      "50.8\n",
      "57.7\n",
      "75.2\n",
      "80.7\n",
      "13.1 (36.7)\n",
      "14.5 (32.1)\n",
      "41c\n",
      "39c\n",
      "Suzuki et al22a (induction and\n",
      "maintenance therapy)\n",
      "65 sites, 2009–2011;\n",
      "P: 96;\n",
      "I: ADA 160/80/40, wk 0, 2, 4, 6–90\n",
      "MCS �2; wk 8\n",
      "P: 41 (14); 73\n",
      "I: 43 (15); 68\n",
      "7.8 (7.1); 62\n",
      "7.8 (6.6); 70\n",
      "54.2\n",
      "45.6\n",
      "60.4\n",
      "63.3\n",
      "3.4 (0.5–87.2)b\n",
      "2.2 (0.5–62.8)b\n",
      "0\n",
      "0\n",
      "Golimumab\n",
      "PURSUIT phases 2 and 323\n",
      "(induction therapy)\n",
      "217 sites, 2007–2010;\n",
      "P: 331;\n",
      "I: GLM 200/100, wk 0, 2–331\n",
      "MCS �2; wk 6\n",
      "P: 39 (13); 53\n",
      "I: 40 (14); 54\n",
      "6.0 (6.7); 43\n",
      "6.4 (6.2); 42\n",
      "32.0\n",
      "31.7\n",
      "42.9\n",
      "44.7\n",
      "10.7 (16.8)\n",
      "11.3 (15.3)\n",
      "0\n",
      "0\n",
      "PURSUIT-M27d\n",
      "(maintenance therapy)\n",
      "251 sites, 2007–2011;\n",
      "P: 156;\n",
      "I: GLM 100 mg q4w–154\n",
      "MCS �2; wk 54\n",
      "P: 40 (14); 48\n",
      "I: 39 (13); 58\n",
      "6.9 (7.0); NR\n",
      "----------\n",
      "discontinuation due to AEs, and serious infections. Phase 3 randomized controlled trials were identified via systematic literature review, in-\n",
      "cluding the following advanced therapies: infliximab, adalimumab, vedolizumab, golimumab, tofacitinib, ustekinumab, filgotinib, ozanimod, and \n",
      "upadacitinib. Random effects models were used to address between-study heterogeneity. Intent-to-treat (ITT) efficacy rates were calculated by \n",
      "adjusting maintenance outcomes by likelihood of induction response.\n",
      "Results:  Out of 48 trials identified, 23 were included. Across all outcomes and regardless of prior biologic exposure, ITT efficacy rates were \n",
      "highest for upadacitinib, owing to its highest ranking for all efficacy outcomes in induction and for all but clinical remission during maintenance \n",
      "among bio-naive induction responders. For all advanced therapies versus placebo, there were no significant differences in serious AEs or \n",
      "serious infections across therapies. For all AEs, golimumab had higher odds versus placebo during maintenance; for discontinuation due to \n",
      "AEs, upadacitinib had lower odds versus placebo during induction, while ustekinumab and vedolizumab had lower odds versus placebo during \n",
      "maintenance.\n",
      "Conclusions:  Upadacitinib may be the most efficacious therapy for moderately to severely active UC based on ITT analyses, with similar safety \n",
      "across advanced therapies.\n",
      "Lay Summary \n",
      "Indirect evidence suggests upadacitinib may be more efficacious than other advanced therapies at achieving clinical response, clinical remis-\n",
      "sion, and endoscopic response over 1 year for moderately to severely active ulcerative colitis patients, with similar safety assessments across \n",
      "advanced therapies.\n",
      "Key Words: ulcerative colitis, clinical trials, advanced therapies, network meta-analysis\n",
      "Introduction\n",
      "Ulcerative colitis (UC) is a chronic inflammatory bowel dis-\n",
      "ease that affects the colorectum and is clinically characterized \n",
      "by bloody diarrhea, urgency, tenesmus, abdominal pain, ma-\n",
      "laise, weight loss, and fever. Disease onset commonly occurs \n",
      "between the ages of 15 and 30 years and the annual global \n",
      "© The Author(s) 2023. Published by Oxford University Press on behalf of Crohn's & Colitis Foundation.\n",
      "This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), \n",
      "which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.\n",
      "----------\n",
      "Crohn's & Colitis 360, XXXX, 5, 1–17\n",
      "https://doi.org/10.1093/crocol/otad009\n",
      "Advance access publication 1 March 2023\n",
      "Observations and Research\n",
      "Efficacy and Safety of Advanced Therapies for Moderately \n",
      "to Severely Active Ulcerative Colitis at Induction and \n",
      "Maintenance: An Indirect Treatment Comparison Using \n",
      "Bayesian Network Meta-analysis\n",
      "Remo Panaccione, MD, FRCPC,*,\n",
      " Eric B. Collins, MPH,†,\n",
      " Gil Y. Melmed, MD,‡,\n",
      " \n",
      "Severine Vermeire,MD, PhD,§,\n",
      " Silvio Danese, MD, PhD,‖,\n",
      " Peter D.R. Higgins, MD, PhD, MSc \n",
      "(CRDSA), AGAF,¶ Christina S. Kwon, PhD,# Wen Zhou, MD, PhD,** Dapo Ilo, MBBS, MRCS, MSC, \n",
      "MBA,** Dolly Sharma, PhD,** Yuri Sanchez Gonzalez, MS, MSc, PhD,**,\n",
      " and  \n",
      "Si-Tien Wang, MS†,\n",
      "*Inflammatory Bowel Disease Unit, Division of Gastroenterology and Hepatology, University of Calgary, Calgary, Alberta, Canada\n",
      "†Medicus Economics LLC, Milton, Massachusetts, USA\n",
      "‡Cedars-Sinai Medical Center, Los Angeles, California, USA\n",
      "§Department of Gastroenterology & Hepatology, University Hospital Leuven, KU Leuven, Leuven, Belgium\n",
      "‖Gastroenterology and Endoscopy, IRCCS Ospedale San Raffaele, Department of Gastroenterology, University Vita-Salute San Raffaele, Milan, \n",
      "Italy\n",
      "¶Department of Medicine, Division of Gastroenterology, University of Michigan, Ann Arbor, Michigan, USA\n",
      "#Cytel, Inc., Waltham, Massachusetts, USA\n",
      "**AbbVie Inc., North Chicago, Illinois, USA\n",
      "Address correspondence to: Remo Panaccione, MD, FRCPC, Rm 6D32, TRW Building, 3280 Hospitals Drive NW, Calgary, AB T3R1B1, Canada (rpanacci@\n",
      "ucalgary.ca).\n",
      "Background:  Given rapid innovation in advanced therapies for moderately to severely active ulcerative colitis (UC), we investigated their com-\n",
      "parative efficacy and safety during induction and maintenance through network meta-analysis.\n",
      "Methods:  Using Bayesian methods, endpoints of clinical remission and clinical response per Full Mayo score, and endoscopic improvement \n",
      "were assessed in bio-naive and -exposed populations. Safety was assessed in overall populations by all adverse events (AEs), serious AEs, \n",
      "discontinuation due to AEs, and serious infections. Phase 3 randomized controlled trials were identified via systematic literature review, in-\n",
      "cluding the following advanced therapies: infliximab, adalimumab, vedolizumab, golimumab, tofacitinib, ustekinumab, filgotinib, ozanimod, and \n",
      "upadacitinib. Random effects models were used to address between-study heterogeneity. Intent-to-treat (ITT) efficacy rates were calculated by\n",
      "----------\n",
      "investigators for all trials, except trials of tofacitinib and\n",
      "ustekinumab, which were read by blinded central\n",
      "readers.7,26 Overall, the studies were deemed to be at\n",
      "low risk of bias, and all included studies were industry-\n",
      "sponsored.\n",
      "Induction Therapy\n",
      "First-line\n",
      "pharmacotherapy\n",
      "for\n",
      "moderate–severe\n",
      "ulcerative colitis. Overall, 15 RCTs including 3747 bio-\n",
      "logic-naïve patients with moderate–severe ulcerative\n",
      "colitis, treated with inﬂiximab (4 trials, 667 patients),\n",
      "adalimumab (4 trials, 1046 patients), golimumab (2 tri-\n",
      "als, 586 patients), vedolizumab (3 trials, 630 patients),\n",
      "tofacitinib (2 trials, 520 patients), and ustekinumab (1\n",
      "trial, 298 patients) were included; 1 trial compared\n",
      "adalimumab vs vedolizumab.\n",
      "Induction\n",
      "of\n",
      "clinical\n",
      "remission. On\n",
      "direct\n",
      "meta-\n",
      "analysis, all agents were superior to placebo for induc-\n",
      "tion of clinical remission, and effect size was strongest\n",
      "for inﬂiximab (OR, 4.07; 95% CI, 2.68–6.16) and vedoli-\n",
      "zumab (OR, 3.10; 95% CI, 1.53–6.26), with minimal to\n",
      "moderate heterogeneity across estimates (I2 < 35%)\n",
      "(Supplementary Figure 2A). On network meta-analysis,\n",
      "compared with placebo there was moderate conﬁdence\n",
      "in\n",
      "estimates\n",
      "supporting\n",
      "the\n",
      "use\n",
      "of\n",
      "inﬂiximab,\n",
      "adalimumab, golimumab, vedolizumab, tofacitinib, and\n",
      "ustekinumab for induction of clinical remission in bio-\n",
      "logic-naïve patients (evidence was rated down owing to\n",
      "imprecision caused by a low event rate) (Table 2). On\n",
      "comparison of active interventions, there was moderate\n",
      "conﬁdence in estimates supporting the use of inﬂiximab\n",
      "over adalimumab (OR, 2.10; 95% CI, 1.16–3.79); none of\n",
      "the other comparisons between active interventions\n",
      "were signiﬁcantly different (Table 2). Overall, inﬂiximab\n",
      "(SUCRA, 0.95) was ranked highest for inducing clinical\n",
      "remission\n",
      "in\n",
      "biologic-naïve\n",
      "patients\n",
      "with\n",
      "moderate–severe UC (Figure 2A). With an estimated\n",
      "placebo rate of achieving remission of 10% in included\n",
      "trials, we anticipate that 31.1%, 17.7%, 23.7%, 22.0%,\n",
      "Figure 2. (A) Relative efﬁ-\n",
      "cacy\n",
      "of\n",
      "different\n",
      "in-\n",
      "terventions for induction of\n",
      "clinical\n",
      "remission\n",
      "and\n",
      "endoscopic\n",
      "improvement\n",
      "in biologic-naïve patients\n",
      "with moderate to severely\n",
      "active ulcerative colitis. (B)\n",
      "Relative\n",
      "efﬁcacy\n",
      "of\n",
      "different interventions for\n",
      "induction of clinical remis-\n",
      "sion\n",
      "and\n",
      "endoscopic\n",
      "improvement\n",
      "in\n",
      "patients\n",
      "with moderate to severely\n",
      "active\n",
      "ulcerative\n",
      "colitis\n",
      "with prior exposure to tu-\n",
      "mor necrosis factor (TNF)⍺\n",
      "antagonists. SUCRA, sur-\n",
      "face under the cumulative\n",
      "ranking.\n",
      "September 2020\n",
      "Management of Moderate–Severe UC 2185\n",
      "----------\n",
      "induction of remission than prior estimates, and the\n",
      "signiﬁcantly superior efﬁcacy of ustekinumab and tofa-\n",
      "citinib over vedolizumab as second-line agents in pa-\n",
      "tients with prior exposure to TNFa antagonists. With\n",
      "limited head-to-head trials, this information can inform\n",
      "clinical practice and guidelines directly and facilitate\n",
      "shared decision making for management of patients with\n",
      "moderate–severe ulcerative colitis.\n",
      "Our\n",
      "results\n",
      "conﬁrm\n",
      "several\n",
      "prior\n",
      "observational\n",
      "comparative effectiveness studies, individual patient-\n",
      "level analyses of clinical trials, and indirect treatment\n",
      "comparison network meta-analyses suggesting higher\n",
      "efﬁcacy and effectiveness of inﬂiximab over adalimumab\n",
      "and golimumab.4,5,29,30 This may be related to differ-\n",
      "ences\n",
      "in\n",
      "pharmacokinetics\n",
      "and\n",
      "bioavailability\n",
      "with\n",
      "different dosing schema (weight-based vs ﬁxed dose)\n",
      "and route of administration. The recent Study to Evaluate\n",
      "the Safety and Efﬁcacy of Two Drug Regimens in Subjects\n",
      "With Moderate to Severe Ulcerative Colitis-UC trial\n",
      "comparing standard- vs high-dose adalimumab in pa-\n",
      "tients with moderate–severe ulcerative colitis failed to\n",
      "show the superiority of higher-dose adalimumab, sug-\n",
      "gesting that currently approved dosing of adalimumab is\n",
      "unlikely to change, and, hence, the comparative efﬁcacy\n",
      "results will remain similar.31 Our ﬁndings also support\n",
      "the observation in the recent head-to-head VARSITY trial\n",
      "as well as propensity score-matched analyses from the\n",
      "VICTORY consortium that vedolizumab is more effective\n",
      "than adalimumab for long-term maintenance of clinical\n",
      "remission; over 8 to 12 weeks of induction therapy,\n",
      "however, no differences were observed between the 2\n",
      "agents.6,32 Moreover, we did not observe any differences\n",
      "in the efﬁcacy of vedolizumab and inﬂiximab in the\n",
      "maintenance\n",
      "of\n",
      "clinical\n",
      "remission\n",
      "or\n",
      "endoscopic\n",
      "2188 Singh et al\n",
      "Clinical Gastroenterology and Hepatology Vol. 18, No. 10\n",
      "----------\n",
      "(interquartile range, 0.1%–1.8%).\n",
      "Maintenance Therapy\n",
      "Efﬁcacy. Because of differences in trial design, trials\n",
      "of inﬂiximab and adalimumab (treat straight-through)\n",
      "and of golimumab, tofacitinib, and ustekinumab (reran-\n",
      "domization of responders to induction therapy) were\n",
      "analyzed separately; vedolizumab contributed to both\n",
      "trial designs. On network meta-analysis of treat straight-\n",
      "through trials in biologic-naïve patients, inﬂiximab, ada-\n",
      "limumab, and vedolizumab were superior to placebo, and\n",
      "vedolizumab was superior to adalimumab for mainte-\n",
      "nance of clinical remission and endoscopic improvement\n",
      "(Supplementary Table 2A; Supplementary Figure 4); no\n",
      "signiﬁcant differences were observed between inﬂiximab\n",
      "and vedolizumab (clinical remission: OR, 0.72; 95% CI,\n",
      "0.35–1.49; endoscopic improvement: OR, 0.73; 95% CI,\n",
      "0.37–1.42). Vedolizumab was ranked highest (SUCRA,\n",
      "maintenance\n",
      "of\n",
      "clinical\n",
      "remission\n",
      "and\n",
      "endoscopic\n",
      "improvement, 0.93 and 0.94, respectively), followed by\n",
      "Table 4. Comparative Safety of Pharmacologic Agents During Maintenance Therapy in Patients With Moderate–Severe Ulcerative Colitis Using Network Meta-Analysis\n",
      "Risk of serious adverse events\n",
      "Risk of infections\n",
      "Ustekinumab 90 mg q8w\n",
      "1.14 (0.37–3.50)\n",
      "1.18 (0.50–2.79)\n",
      "0.43 (0.15–1.22)\n",
      "0.85 (0.37–1.92)\n",
      "1.32 (0.56–3.12)\n",
      "0.87 (0.42–1.79)\n",
      "0.63 (0.35–1.16)\n",
      "Tofacitinib 5 mg b.d.\n",
      "1.03 (0.39–2.71)\n",
      "0.38 (0.12–1.17)\n",
      "0.74 (0.29–1.87)\n",
      "1.15 (0.44–3.02)\n",
      "0.76 (0.32–1.77)\n",
      "1.13 (0.66–1.93)\n",
      "1.78 (1.02–3.09)\n",
      "Vedolizumab\n",
      "0.37 (0.15–0.88)\n",
      "0.72 (0.49–1.05)\n",
      "1.12 (0.58–2.14)\n",
      "0.73 (0.46–1.16)\n",
      "0.68 (0.36–1.29)\n",
      "1.08 (0.56–2.05)\n",
      "0.61 (0.34–1.09)\n",
      "Golimumab\n",
      "1.95 (0.85–4.48)\n",
      "3.04 (1.27–7.28)\n",
      "2.00 (0.95–4.20)\n",
      "0.89 (0.54–1.47)\n",
      "1.40 (0.84–2.34)\n",
      "0.79 (0.60–1.04)\n",
      "1.31 (0.76–2.25)\n",
      "Adalimumab\n",
      "1.56 (0.86–2.82)\n",
      "1.02 (0.71–1.49)\n",
      "0.91 (0.51–1.60)\n",
      "1.43 (0.80–2.55)\n",
      "0.80 (0.48–1.34)\n",
      "1.33 (0.72–2.45)\n",
      "1.02 (0.64–1.63)\n",
      "Inﬂiximab\n",
      "0.66 (0.41–1.04)\n",
      "1.11 (0.73–1.69)\n",
      "1.75 (1.13–2.70)\n",
      "0.98 (0.70–1.38)\n",
      "1.62 (1.01–2.62)\n",
      "1.24 (0.95–1.63)\n",
      "1.22 (0.83–1.79)\n",
      "Placebo\n",
      "NOTE. Comparisons should be read from left to right. The odds ratio for comparisons are in the cell in common between the column-deﬁning and row-deﬁning treatment. Numbers in bold are statistically signiﬁcant. For serious\n",
      "adverse events, an odds ratio less than 1 favors row-deﬁning treatment. For risk of infections, an odds ratio less than 1 favors column-deﬁning treatment. Numbers in parentheses indicate 95% CI.\n",
      "b.d., twice daily; q8w, every 8 weeks.\n",
      "September 2020\n",
      "Management of Moderate–Severe UC 2187\n",
      "----------\n",
      "ulcerative\n",
      "colitis.\n",
      "Studies\n",
      "included\n",
      "in\n",
      "these\n",
      "meta-\n",
      "analyses were phase II or III randomized controlled\n",
      "trials (RCTs) that met the following inclusion criteria:\n",
      "(1) patients: adults (age, >18 y) with moderate to\n",
      "severe ulcerative colitis (Mayo Clinic score of 6–12,\n",
      "with an endoscopic subscore of 2 or 3) who were\n",
      "either\n",
      "treatment-naïve\n",
      "(ﬁrst-line)\n",
      "or\n",
      "previously\n",
      "exposed to TNFa antagonists (second-line); (2) inter-\n",
      "vention: biologic therapy with inﬂiximab, adalimumab,\n",
      "golimumab, vedolizumab, tofacitinib, or ustekinumab,\n",
      "with a minimum duration of therapy of 14 days; (3)\n",
      "comparator: another active intervention or placebo;\n",
      "and (4) outcome: induction of clinical remission (Mayo\n",
      "Clinic score of �2 with no individual subscore of >1)\n",
      "and endoscopic improvement (Mayo endoscopy sub-\n",
      "score of 0 or 1).\n",
      "Because trials of maintenance therapy of biologic\n",
      "agents had different designs (treat straight-through\n",
      "design vs rerandomizing responders to induction ther-\n",
      "apy), we conducted separate pairwise and network\n",
      "meta-analyses for these different trial designs. Because\n",
      "safety is unlikely to be inﬂuenced signiﬁcantly by main-\n",
      "tenance therapy trial design, to inform comparative\n",
      "safety, we conducted a single network meta-analysis of\n",
      "all trials of maintenance therapy, regardless of different\n",
      "trial design. Detailed inclusion criteria for trials of\n",
      "maintenance therapy and exclusion criteria are listed in\n",
      "the Supplementary Appendix.\n",
      "Search Strategy, Data Abstraction, and Risk of\n",
      "Bias Assessment\n",
      "We updated our previous literature search, conduct-\n",
      "ed as part the American Gastroenterological Association\n",
      "technical review on management of moderate–severe\n",
      "ulcerative colitis (date of search, March 30, 2018), on\n",
      "September 30, 2019, with no language restrictions. De-\n",
      "tails\n",
      "of\n",
      "the\n",
      "search\n",
      "strategy\n",
      "are\n",
      "shown\n",
      "in\n",
      "the\n",
      "Supplementary Appendix. Data on study-, participant-,\n",
      "disease-,\n",
      "and\n",
      "treatment-related characteristics were\n",
      "abstracted onto a standardized form by 2 investigators\n",
      "independently (S.S. and M.F.), and discrepancies were\n",
      "What You Need to Know\n",
      "Background\n",
      "A systematic review and network meta-analysis is\n",
      "needed to compare efﬁcacy and safety of ﬁrst-line\n",
      "(biologic-naïve) and second-line (prior exposure to\n",
      "tumor necrosis factor [TNF] antagonists) agents for\n",
      "treatment of moderate to severely active ulcerative\n",
      "colitis.\n",
      "Findings\n",
      "Inﬂiximab was ranked highest in biologic-naïve pa-\n",
      "tients, and ustekinumab and tofacitinib were ranked\n",
      "highest in patients with prior exposure to TNF an-\n",
      "----------\n",
      "comparative analysis of maintenance trials has suggested\n",
      "higher safety with vedolizumab, rates of important\n",
      "events such as serious infections was low and other\n",
      "serious events such as malignancy could not be evalu-\n",
      "ated thoroughly. Moreover, differences in study design of\n",
      "maintenance therapy (treat straight-through vs reran-\n",
      "domization of responders), as well as lack of information\n",
      "on safety stratiﬁed by prior TNFa antagonist exposure\n",
      "status, potentially may bias safety results. Postmarketing\n",
      "surveillance studies of these different agents may better\n",
      "inform the relative safety of these agents. Safety of\n",
      "tofacitinib seems to be dose-dependent, and in instances\n",
      "in which a higher 10-mg twice-per-day dose of tofacitinib\n",
      "is used for long-term maintenance, safety concerns\n",
      "should be discussed adequately with patients.\n",
      "Integrating ﬁndings from this meta-analysis and other\n",
      "studies, current evidence favors inﬂiximab or vedolizu-\n",
      "mab\n",
      "as\n",
      "the\n",
      "preferred\n",
      "ﬁrst-line\n",
      "agents\n",
      "for\n",
      "moderate–severe ulcerative colitis. In patients who fail\n",
      "inﬂiximab, ustekinumab and tofacitinib likely would be\n",
      "most efﬁcacious, and ustekinumab’s superior safety\n",
      "proﬁle may be attractive in light of recent concerns\n",
      "around\n",
      "venous\n",
      "thromboembolism\n",
      "with\n",
      "tofacitinib.\n",
      "However, besides quality of evidence, several other fac-\n",
      "tors including a balance of risk–beneﬁt proﬁle, speciﬁc\n",
      "patient attributes (age, comorbid conditions including\n",
      "rheumatic or dermatologic diseases, and so forth), clin-\n",
      "ical judgment and experience of the treating physicians,\n",
      "values\n",
      "and\n",
      "preferences\n",
      "of\n",
      "patients\n",
      "(dosing\n",
      "route,\n",
      "regimen, acceptability of risk–beneﬁt trade-offs, and so\n",
      "forth), as well as the costs/resources available, are\n",
      "important to facilitate shared decision making, in devel-\n",
      "oping a personalized treatment strategy for each patient,\n",
      "and shape health care policy on positioning different\n",
      "agents. Pragmatic head-to-head trials in both biologic-\n",
      "naïve and biologic-exposed patients are warranted to\n",
      "optimally inform the relative positioning of newly\n",
      "available agents in clinical practice.\n",
      "Supplementary Material\n",
      "Note: To access the supplementary material accom-\n",
      "panying this article, visit the online version of Clinical\n",
      "Gastroenterology and Hepatology at www.cghjournal.org,\n",
      "and at https://doi.org/10.1016/j.cgh.2020.01.008.\n",
      "References\n",
      "1.\n",
      "NgSC,ShiHY,Hamidi N,et al.Worldwideincidence andprevalence\n",
      "of inﬂammatory bowel disease in the 21st century: a systematic\n",
      "review of population-based studies. Lancet 2018;390:2769–2778.\n",
      "2.\n",
      "==========\n",
      "ORIGINAL QUESTION: ANALYSE the given patient profile based on given query based on one of the following criteria:\n",
      "- Whether treated patient is new patient or patient under maintenance\n",
      "- Prior response to Infliximab\n",
      "- Prior failure to Anti-TNF agents\n",
      "- Prior failure to Vedolizumab\n",
      "- Age\n",
      "- Pregnancy\n",
      "- Extraintestinale manifestations\n",
      "- Pouchitis\n",
      "RETURN up to 2 TOP choices of biological drugs given patient profile and context. Explain the PROS and CONS of the 2 choices.\n",
      "PATIENT PROFILE: 52 year-old woman with moderate to severe distal ulcerative colitis that had a successful induction with vedolizumab. What would be the maintenance therapy?\n",
      "\n",
      "==========\n",
      "CURRENT ANSWER:\n",
      "Based on the context provided, the patient has had a successful induction with Vedolizumab. Therefore, the maintenance therapy would likely continue with Vedolizumab. This is because Vedolizumab has been shown to be effective in both the induction and maintenance of remission in moderate to severe ulcerative colitis.\n",
      "\n",
      "[{\"drug_name\": \"Vedolizumab\", \"advantages\": \"Vedolizumab has been shown to be effective in both the induction and maintenance of remission in moderate to severe ulcerative colitis. It is generally well tolerated with a good safety profile.\", \"disadvantages\": \"Potential side effects include headache, joint pain, nausea, and fever. Serious side effects can include infections, liver problems, and allergic reactions. Regular monitoring is required to check for these side effects.\"}]\n",
      "==========\n",
      "REFINED ANSWER:\n",
      "\u001b[0m\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "Retrying langchain.chat_models.openai.ChatOpenAI.completion_with_retry.<locals>._completion_with_retry in 4.0 seconds as it raised RateLimitError: Rate limit reached for 10KTPM-200RPM in organization org-ETbTMTN2JXYOUPDJgxuH2iO6 on tokens per min. Limit: 10000 / min. Please try again in 6ms. Contact us through our help center at help.openai.com if you continue to have issues..\n",
      "Retrying langchain.chat_models.openai.ChatOpenAI.completion_with_retry.<locals>._completion_with_retry in 4.0 seconds as it raised RateLimitError: Rate limit reached for 10KTPM-200RPM in organization org-ETbTMTN2JXYOUPDJgxuH2iO6 on tokens per min. Limit: 10000 / min. Please try again in 6ms. Contact us through our help center at help.openai.com if you continue to have issues..\n",
      "Retrying langchain.chat_models.openai.ChatOpenAI.completion_with_retry.<locals>._completion_with_retry in 4.0 seconds as it raised RateLimitError: Rate limit reached for 10KTPM-200RPM in organization org-ETbTMTN2JXYOUPDJgxuH2iO6 on tokens per min. Limit: 10000 / min. Please try again in 6ms. Contact us through our help center at help.openai.com if you continue to have issues..\n",
      "Retrying langchain.chat_models.openai.ChatOpenAI.completion_with_retry.<locals>._completion_with_retry in 8.0 seconds as it raised RateLimitError: Rate limit reached for 10KTPM-200RPM in organization org-ETbTMTN2JXYOUPDJgxuH2iO6 on tokens per min. Limit: 10000 / min. Please try again in 6ms. Contact us through our help center at help.openai.com if you continue to have issues..\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\n",
      "\u001b[1m> Finished chain.\u001b[0m\n",
      "\n",
      "\u001b[1m> Finished chain.\u001b[0m\n",
      "2023-10-02 17:26:40,545:INFO: 6122 tokens were added to prompt from 8 documents\n",
      "Query: 24 year-old man with moderate to severe extensive ulcerative colitis previously in clinical remission with infliximab develops loss of response due to antibody formation.\n",
      "\n",
      "\n",
      "\n",
      "\u001b[1m> Entering new SequentialChain chain...\u001b[0m\n",
      "\n",
      "\n",
      "\u001b[1m> Entering new RetrievalQAWithSourcesChain chain...\u001b[0m\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "Retrying langchain.chat_models.openai.ChatOpenAI.completion_with_retry.<locals>._completion_with_retry in 4.0 seconds as it raised RateLimitError: Rate limit reached for 10KTPM-200RPM in organization org-ETbTMTN2JXYOUPDJgxuH2iO6 on tokens per min. Limit: 10000 / min. Please try again in 6ms. Contact us through our help center at help.openai.com if you continue to have issues..\n",
      "Retrying langchain.chat_models.openai.ChatOpenAI.completion_with_retry.<locals>._completion_with_retry in 4.0 seconds as it raised RateLimitError: Rate limit reached for 10KTPM-200RPM in organization org-ETbTMTN2JXYOUPDJgxuH2iO6 on tokens per min. Limit: 10000 / min. Please try again in 6ms. Contact us through our help center at help.openai.com if you continue to have issues..\n",
      "Retrying langchain.chat_models.openai.ChatOpenAI.completion_with_retry.<locals>._completion_with_retry in 4.0 seconds as it raised RateLimitError: Rate limit reached for 10KTPM-200RPM in organization org-ETbTMTN2JXYOUPDJgxuH2iO6 on tokens per min. Limit: 10000 / min. Please try again in 6ms. Contact us through our help center at help.openai.com if you continue to have issues..\n",
      "Retrying langchain.chat_models.openai.ChatOpenAI.completion_with_retry.<locals>._completion_with_retry in 8.0 seconds as it raised RateLimitError: Rate limit reached for 10KTPM-200RPM in organization org-ETbTMTN2JXYOUPDJgxuH2iO6 on tokens per min. Limit: 10000 / min. Please try again in 6ms. Contact us through our help center at help.openai.com if you continue to have issues..\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\n",
      "\u001b[1m> Finished chain.\u001b[0m\n",
      "\n",
      "\n",
      "\u001b[1m> Entering new LLMChain chain...\u001b[0m\n",
      "Prompt after formatting:\n",
      "\u001b[32;1m\u001b[1;3mYou are a senior physician giving advice on treatment for moderate to severe ulcerative colitis (UC).\n",
      "Make reference to the CONTEXT given to assess the scenario.\n",
      "==========\n",
      "TASK: Your task is to analyse critically the CURRENT ANSWER given the CONTEXT.\n",
      "Then refine the existing answer (only if needed) based on the following instructions:\n",
      "- If no refinement needed, return the original answer in the correct output format.\n",
      "- If the answer cannot be inferred from CONTEXT, return \"NO ANSWER\".\n",
      "- The final output should be a list of up to 2 choices of biological drugs given patient profile and context and PROS/CONS for each recommendations.\n",
      "==========\n",
      "CONTEXT:\n",
      "Burr et al. \n",
      " \n",
      "5 of 45 \n",
      "STUDY HIGHLIGHTS \n",
      " \n",
      "What is already known about this subject \n",
      "• Ulcerative colitis (UC) follows a relapsing and remitting course, with intermittent \n",
      "flares of disease activity, some of which may be moderate to severe. \n",
      "• These are usually treated with corticosteroids, which have potentially serious adverse \n",
      "effects, so biological therapies and small molecules have been developed and licensed \n",
      "for this indication.  \n",
      "• Although previous network meta-analyses have compared their efficacy and safety, \n",
      "this is a rapidly moving field, and there are already several newer drugs that have \n",
      "shown efficacy in phase III clinical trials that were not considered in these. \n",
      " \n",
      "What are the new findings \n",
      "• In terms of clinical remission and clinical response, upadacitinib 45mg o.d. ranked \n",
      "first in all patients, in patients previously exposed to anti-tumour necrosis factor \n",
      "(TNF)-α therapies, and in patients naïve to these drugs.  \n",
      "• In terms of endoscopic improvement infliximab 10mg/kg ranked first, followed by \n",
      "upadacitinib 45mg o.d., and infliximab 5mg/kg.  \n",
      "• However, for endoscopic improvement again upadacitinib 45mg o.d. ranked first in \n",
      "patients previously exposed to anti-TNF-α therapies, and in patients who were anti-\n",
      "TNF-α naïve.  \n",
      "• None of the drugs studied were more likely to lead to serious adverse events than \n",
      "placebo.\n",
      "----------\n",
      "Burr et al. \n",
      " \n",
      "7 of 45 \n",
      "INTRODUCTION \n",
      "  Ulcerative colitis (UC) is a chronic inflammatory disorder of the bowel that causes \n",
      "continuous mucosal inflammation commencing in the rectum and extending proximally for a \n",
      "variable extent.[1] It is estimated that UC affects 2.5 million people in Europe,[2] and the \n",
      "disease follows a relapsing and remitting course, with intermittent flares of disease activity, \n",
      "some of which may be moderate to severe. Management of these is medical, for the most \n",
      "part, with surgery reserved for patients with refractory disease. Although 5-aminosalicylates \n",
      "(5-ASAs) are efficacious for mild to moderate disease activity,[3-6] more severe flares are \n",
      "usually treated with corticosteroids.[7] However, these have potentially serious adverse \n",
      "effects and a substantial proportion of patients may become either dependent on them to \n",
      "maintain remission,[8] or refractory to them.[9] As a result, over the last 20 years novel \n",
      "drugs, with more precise modes of action, based on mechanisms of disease identified in \n",
      "genome wide association studies,[10] have been developed.  \n",
      "The first of these agents was infliximab, a drug targeting the pro-inflammatory \n",
      "cytokine tumour necrosis factor-α (TNF-α), which demonstrated efficacy in clinical trials in \n",
      "moderate to severe UC.[11] Since then, other drugs against TNF-α have been tested, such as \n",
      "adalimumab and golimumab.[12, 13] In addition, newer biological therapies targeting α or β \n",
      "integrins, which are involved in migration of immune cells to inflamed intestinal mucosa, \n",
      "such as vedolizumab or etrolizumab,[14, 15] or acting against other pro-inflammatory \n",
      "cytokines implicated in the pathogenesis of UC, such as ustekinumab,[16] have been tested. \n",
      "However, even these more selective drugs do not work in all patients, there may be risks \n",
      "associated with their use,[17-19] and the fact that they are administered either intravenously \n",
      "or subcutaneously, may be inconvenient for patients. The search for alternative agents for the \n",
      "treatment of UC has, therefore, continued.\n",
      "----------\n",
      "discontinuation due to AEs, and serious infections. Phase 3 randomized controlled trials were identified via systematic literature review, in-\n",
      "cluding the following advanced therapies: infliximab, adalimumab, vedolizumab, golimumab, tofacitinib, ustekinumab, filgotinib, ozanimod, and \n",
      "upadacitinib. Random effects models were used to address between-study heterogeneity. Intent-to-treat (ITT) efficacy rates were calculated by \n",
      "adjusting maintenance outcomes by likelihood of induction response.\n",
      "Results:  Out of 48 trials identified, 23 were included. Across all outcomes and regardless of prior biologic exposure, ITT efficacy rates were \n",
      "highest for upadacitinib, owing to its highest ranking for all efficacy outcomes in induction and for all but clinical remission during maintenance \n",
      "among bio-naive induction responders. For all advanced therapies versus placebo, there were no significant differences in serious AEs or \n",
      "serious infections across therapies. For all AEs, golimumab had higher odds versus placebo during maintenance; for discontinuation due to \n",
      "AEs, upadacitinib had lower odds versus placebo during induction, while ustekinumab and vedolizumab had lower odds versus placebo during \n",
      "maintenance.\n",
      "Conclusions:  Upadacitinib may be the most efficacious therapy for moderately to severely active UC based on ITT analyses, with similar safety \n",
      "across advanced therapies.\n",
      "Lay Summary \n",
      "Indirect evidence suggests upadacitinib may be more efficacious than other advanced therapies at achieving clinical response, clinical remis-\n",
      "sion, and endoscopic response over 1 year for moderately to severely active ulcerative colitis patients, with similar safety assessments across \n",
      "advanced therapies.\n",
      "Key Words: ulcerative colitis, clinical trials, advanced therapies, network meta-analysis\n",
      "Introduction\n",
      "Ulcerative colitis (UC) is a chronic inflammatory bowel dis-\n",
      "ease that affects the colorectum and is clinically characterized \n",
      "by bloody diarrhea, urgency, tenesmus, abdominal pain, ma-\n",
      "laise, weight loss, and fever. Disease onset commonly occurs \n",
      "between the ages of 15 and 30 years and the annual global \n",
      "© The Author(s) 2023. Published by Oxford University Press on behalf of Crohn's & Colitis Foundation.\n",
      "This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), \n",
      "which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.\n",
      "----------\n",
      "What You Need to Know\n",
      "Background\n",
      "A systematic review and network meta-analysis is\n",
      "needed to compare efﬁcacy and safety of ﬁrst-line\n",
      "(biologic-naïve) and second-line (prior exposure to\n",
      "tumor necrosis factor [TNF] antagonists) agents for\n",
      "treatment of moderate to severely active ulcerative\n",
      "colitis.\n",
      "Findings\n",
      "Inﬂiximab was ranked highest in biologic-naïve pa-\n",
      "tients, and ustekinumab and tofacitinib were ranked\n",
      "highest in patients with prior exposure to TNF an-\n",
      "tagonists, for induction of remission and endoscopic\n",
      "improvement. More trials of direct comparisons are\n",
      "needed to inform clinical decision-making with\n",
      "greater conﬁdence.\n",
      "Implications for patient care\n",
      "Patients with moderate to severely active ulcerative\n",
      "colitis should receive inﬂiximab or vedolizumab as\n",
      "ﬁrst-line therapy, or ustekinumab or tofacitinib if\n",
      "they have prior exposure to TNF antagonists.\n",
      "2180 Singh et al\n",
      "Clinical Gastroenterology and Hepatology Vol. 18, No. 10\n",
      "----------\n",
      "tients with moderate–severe ulcerative colitis with prior\n",
      "exposure to TNFa antagonists were identiﬁed. These\n",
      "included subgroup analyses of trials of adalimumab,21\n",
      "vedolizumab,24,25\n",
      "tofacitinib,26\n",
      "and\n",
      "ustekinumab.7\n",
      "There were no trials of inﬂiximab or golimumab in\n",
      "patients with prior exposure to TNFa antagonists who\n",
      "met inclusion criteria. In trials of adalimumab, only pa-\n",
      "tients with loss of response or intolerance to a prior\n",
      "TNFa antagonist were included. In contrast, in trials of\n",
      "vedolizumab, 48% to 58% of patients had inadequate\n",
      "response to a TNFa antagonist, and in trials of usteki-\n",
      "numab, 13% to 18% patients had prior exposure to both\n",
      "vedolizumab and TNFa antagonists. These data were not\n",
      "available for tofacitinib.\n",
      "Induction\n",
      "of\n",
      "clinical\n",
      "remission. On\n",
      "direct\n",
      "meta-\n",
      "analysis, tofacitinib and ustekinumab, but not adalimu-\n",
      "mab or vedolizumab, were superior to placebo for induc-\n",
      "tion of clinical remission (Supplementary Figure 3A), with\n",
      "minimal heterogeneity across estimates (I2 < 30%). On\n",
      "network meta-analysis, there was moderate conﬁdence in\n",
      "estimates supporting the use of tofacitinib (OR, 11.88;\n",
      "95% CI, 2.32–60.89) and ustekinumab (OR, 11.51; 95% CI,\n",
      "2.65–49.96), and low conﬁdence in estimates supporting\n",
      "the use of vedolizumab (OR, 1.92; 95% CI, 0.87–4.25) over\n",
      "placebo, for induction of clinical remission in patients with\n",
      "prior exposure to TNFa antagonists (Table 3). On com-\n",
      "parison of active interventions, there was moderate con-\n",
      "ﬁdence in estimates supporting the use of tofacitinib and\n",
      "ustekinumab over adalimumab (tofacitinib vs adalimu-\n",
      "mab: OR, 11.05; 95% CI, 1.79–68.41; ustekinumab vs\n",
      "adalimumab: OR, 10.71; 95% CI, 2.01–57.20), and over\n",
      "vedolizumab (tofacitinib vs vedolizumab: OR, 6.18; 95%\n",
      "CI, 1.00–38.00; ustekinumab vs vedolizumab: OR, 5.99;\n",
      "95% CI, 1.13–31.76) for induction of clinical remission in\n",
      "patients with prior exposure to TNFa antagonists. Overall,\n",
      "ustekinumab (SUCRA, 0.87) and tofacitinib (SUCRA, 0.87)\n",
      "were ranked highest for inducing clinical remission in\n",
      "patients with moderate–severe ulcerative colitis with\n",
      "prior exposure to TNFa antagonists (Figure 2B). With an\n",
      "estimated placebo rate of achieving clinical remission of\n",
      "3% in included trials, we estimated that 3.2%, 5.6%,\n",
      "26.9%, and 26.3% of adalimumab-, vedolizumab-, tofaci-\n",
      "tinib-, and ustekinumab-treated patients, respectively,\n",
      "would achieve induction of remission.\n",
      "Induction of endoscopic improvement. On direct meta-\n",
      "analysis, tofacitinib and ustekinumab, but not vedolizumab\n",
      "----------\n",
      "disease); ozanimod as an oral alternative\n",
      "• Infliximab, preferably in combination with  \n",
      " immunomodulators (severe disease,  \n",
      " \n",
      " extraintestinal manifestations)\n",
      "• Ustekinumab (for patients with substantial \n",
      " comorbidities or  contraindications to TNF  \n",
      " antagonists)\n",
      "First-line therapy\n",
      "• TNF antagonists: infliximab or adalimumab,  \n",
      " preferably in combination with   \n",
      " \n",
      " \n",
      " immunomodulators\n",
      "• Risankizumab or ustekinumab (for patients  \n",
      " with substantial comorbidities or  \n",
      " \n",
      " \n",
      " contraindications to TNF antagonists)\n",
      "First-line therapy\n",
      "• Vedolizumab\n",
      "• Ustekinumab\n",
      "First-line therapy\n",
      "• Risankizumab or ustekinumab\n",
      "• Vedolizumab\n",
      "Moderate-to-severely active\n",
      "ulcerative colitis\n",
      "Moderate-to-severely active\n",
      "ulcerative colitis\n",
      "Moderate-to-severely active\n",
      "Crohn's disease\n",
      "Moderate-to-severely active\n",
      "Crohn's disease\n",
      "Second-line therapy\n",
      "• Upadacitinib (or tofacitinib) (for patients with  \n",
      " prior failure of infliximab)\n",
      "• Infliximab or ustekinumab (for patients with  \n",
      " prior exposure to vedolizumab)\n",
      "• Vedolizumab (moderate disease, for patients  \n",
      " who discontinued first-line biologic agent \n",
      " for intolerance)\n",
      "Second-line therapy (in patients with prior \n",
      "exposure to infliximab or adalimumab)\n",
      "• Risankizumab or ustekinumab\n",
      "• Second TNF antagonist (for patients with  \n",
      " loss of response owing to immunogenicity,  \n",
      " or  intolerance, to first TNF antagonist)\n",
      "Second-line therapy\n",
      "• Ozanimod\n",
      "• Infliximab monotherapy\n",
      "• Upadacitinib (or tofacitinib)\n",
      "Second-line therapy\n",
      "• Infliximab or adalimumab   \n",
      " monotherapy\n",
      "Risk averse\n",
      "• Prior serious infections\n",
      "• Prior malignancy\n",
      "• Older age, multiple comorbidities\n",
      "Severe disease\n",
      "• High structural damage\n",
      "• High inflammatory burden\n",
      "• Significant efect on quality of life\n",
      "Patients’ values and preferences\n",
      "(lifestyle and logistics, speed of onset, costs)\n",
      "Fig. 1 | Proposed treatment algorithm for patients with moderate-to-severe \n",
      "Crohn’s disease and moderate-to-severe ulcerative colitis. The algorithm \n",
      "integrates data on comparative effectiveness and safety of therapies in the \n",
      "context of an individual patient’s risk of disease-related and treatment-related \n",
      "complications. TNF, tumour necrosis factor. Adapted with permission from  \n",
      "ref. 10, Elsevier.\n",
      "----------\n",
      "severely active ulcerative colitis: results from phase 3 \n",
      "U-ACCOMPLISH study. J Crohn’s Colitis 2021; 15 (suppl 1): S021–22.\n",
      "9 \n",
      "Thorlund K, Druyts E, Mills EJ, Fedorak RN, Marshall JK. \n",
      "Adalimumab versus infliximab for the treatment of moderate to \n",
      "severe ulcerative colitis in adult patients naïve to anti-TNF therapy: \n",
      "an indirect treatment comparison meta-analysis. J Crohn’s Colitis \n",
      "2014; 8: 571–81.\n",
      "10 \n",
      "Danese S, Fiorino G, Peyrin-Biroulet L, et al. Biological agents for \n",
      "moderately to severely active ulcerative colitis: a systematic review \n",
      "and network meta-analysis. Ann Intern Med 2014; 160: 704–11.\n",
      "11 \n",
      "Singh S, Fumery M, Sandborn WJ, Murad MH. Systematic review \n",
      "with network meta-analysis: first- and second-line pharmacotherapy \n",
      "for moderate-severe ulcerative colitis. Aliment Pharmacol Ther 2018; \n",
      "47: 162–75.\n",
      "12 \n",
      "Bonovas S, Lytras T, Nikolopoulos G, Peyrin-Biroulet L, Danese S. \n",
      "Systematic review with network meta-analysis: comparative \n",
      "assessment of tofacitinib and biological therapies for moderate-to-\n",
      "severe ulcerative colitis. Aliment Pharmacol Ther 2018; 47: 454–65.\n",
      "13 \n",
      "Singh S, Murad MH, Fumery M, Dulai PS, Sandborn WJ. First- and \n",
      "second-line pharmacotherapies for patients with moderate to \n",
      "severely active ulcerative colitis: an updated network meta-analysis. \n",
      "Clin Gastroenterol Hepatol 2020; 18: 2179–91.e6.\n",
      "14 \n",
      "Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting \n",
      "items for systematic reviews and meta-analyses: the PRISMA \n",
      "statement. Ann Intern Med 2009; 151: 264–69.\n",
      "15 \n",
      "Jansen JP, Fleurence R, Devine B, et al. Interpreting indirect \n",
      "treatment comparisons and network meta-analysis for health-care \n",
      "decision making: report of the ISPOR Task Force on Indirect \n",
      "Treatment Comparisons Good Research Practices: part 1. \n",
      "Value Health 2011; 14: 417–28.\n",
      "16 \n",
      "Sterne JAC, Savović J, Page MJ, et al. RoB 2: a revised tool for \n",
      "assessing risk of bias in randomised trials. BMJ 2019; 366: l4898.\n",
      "17 \n",
      "Rücker G, Schwarzer G. Ranking treatments in frequentist network \n",
      "meta-analysis works without resampling methods. \n",
      "BMC Med Res Methodol 2015; 15: 58.\n",
      "----------\n",
      "induction of remission than prior estimates, and the\n",
      "signiﬁcantly superior efﬁcacy of ustekinumab and tofa-\n",
      "citinib over vedolizumab as second-line agents in pa-\n",
      "tients with prior exposure to TNFa antagonists. With\n",
      "limited head-to-head trials, this information can inform\n",
      "clinical practice and guidelines directly and facilitate\n",
      "shared decision making for management of patients with\n",
      "moderate–severe ulcerative colitis.\n",
      "Our\n",
      "results\n",
      "conﬁrm\n",
      "several\n",
      "prior\n",
      "observational\n",
      "comparative effectiveness studies, individual patient-\n",
      "level analyses of clinical trials, and indirect treatment\n",
      "comparison network meta-analyses suggesting higher\n",
      "efﬁcacy and effectiveness of inﬂiximab over adalimumab\n",
      "and golimumab.4,5,29,30 This may be related to differ-\n",
      "ences\n",
      "in\n",
      "pharmacokinetics\n",
      "and\n",
      "bioavailability\n",
      "with\n",
      "different dosing schema (weight-based vs ﬁxed dose)\n",
      "and route of administration. The recent Study to Evaluate\n",
      "the Safety and Efﬁcacy of Two Drug Regimens in Subjects\n",
      "With Moderate to Severe Ulcerative Colitis-UC trial\n",
      "comparing standard- vs high-dose adalimumab in pa-\n",
      "tients with moderate–severe ulcerative colitis failed to\n",
      "show the superiority of higher-dose adalimumab, sug-\n",
      "gesting that currently approved dosing of adalimumab is\n",
      "unlikely to change, and, hence, the comparative efﬁcacy\n",
      "results will remain similar.31 Our ﬁndings also support\n",
      "the observation in the recent head-to-head VARSITY trial\n",
      "as well as propensity score-matched analyses from the\n",
      "VICTORY consortium that vedolizumab is more effective\n",
      "than adalimumab for long-term maintenance of clinical\n",
      "remission; over 8 to 12 weeks of induction therapy,\n",
      "however, no differences were observed between the 2\n",
      "agents.6,32 Moreover, we did not observe any differences\n",
      "in the efﬁcacy of vedolizumab and inﬂiximab in the\n",
      "maintenance\n",
      "of\n",
      "clinical\n",
      "remission\n",
      "or\n",
      "endoscopic\n",
      "2188 Singh et al\n",
      "Clinical Gastroenterology and Hepatology Vol. 18, No. 10\n",
      "----------\n",
      "non response to an anti-TNF was found to be a predictor for diminished\n",
      "treatment efﬁcacy with an anti-integrin biologic (Singh et al., 2018c).\n",
      "First and second line agent treatment sequences and treatment response\n",
      "have been presented in the previous chapter. However, data are even\n",
      "scarcer concerning third line of treatment after two anti-TNFs exposure.\n",
      "A retrospective small series of 67 patients with Crohn's disease treated\n",
      "with 3rd line anti-TNF agent (Allez et al., 2010) reported a lower\n",
      "response rate and the lack of late responders at 6 months. A recent\n",
      "multicenter retrospective study reported the outcome of patients with\n",
      "late CD who had failed treatment with one anti-TNF agent and either\n",
      "vedolizumab or ustekinumab. After 48 weeks on a third line of biologic\n",
      "therapy the remission rate was 30.7% whereas the surgery rate was\n",
      "23.5% (Kassouri et al., 2020).\n",
      "There is a mechanistic role for anti-IL 23 agents in TNF refractory IBD\n",
      "patients. During anti TNF treatment, in non-responders compared to re-\n",
      "sponders, there is upregulation of apoptosis resistant IL23p19, IL23R,\n",
      "and IL17 A as demonstrated by studies using immunophenotyping of T\n",
      "cells. (Bek et al., 2016; Schmitt et al., 2019). This phenomenon suggests\n",
      "that ustekinumab (as IL-12/IL-23 inhibitor) and other IL-23 inhibitor\n",
      "agents may have a mechanistic potential in late CD (Eftychi et al., 2019)\n",
      "when an expansion of Th1 and Th17 cells (Veny et al., 2010) may have\n",
      "occurred.\n",
      "3.2. Disease characteristics and patient proﬁle\n",
      "3.2.1. Comorbidities, age, gender and body mass index and muscle mass\n",
      "The decision on drug selection in clinical practice is often guided by\n",
      "disease severity that requires efﬁcacious treatment with rapid onset of\n",
      "action, an acceptable safety proﬁle balanced against potential adverse\n",
      "effects, in particular when the decision results in the use of high dose of\n",
      "corticosteroids (Ford et al., 2011) (Graphical Abstract). When the sit-\n",
      "uation is less acute, depending patient comorbidities, the safety proﬁle of\n",
      "the biologic is one of the major factor inﬂuencing the decision. For\n",
      "P. Juillerat et al.\n",
      "Current Research in Pharmacology and Drug Discovery 3 (2022) 100104\n",
      "3\n",
      "----------\n",
      "Burr et al. \n",
      " \n",
      "3 of 45 \n",
      "ABSTRACT \n",
      "Objective: Biological therapies and small molecules continue to be evaluated in moderate to \n",
      "severely active ulcerative colitis, but are often studied in placebo-controlled trials, meaning \n",
      "their relative efficacy and safety is unknown. We examined this in a network meta-analysis.  \n",
      "Design: We searched the literature to October 2021 to identify eligible trials. We judged \n",
      "efficacy using clinical remission, endoscopic improvement, or clinical response, and \n",
      "according to previous exposure or non-exposure to anti-tumour necrosis factor (TNF)-α \n",
      "therapy. We also assessed safety. We used a random effects model and reported data as \n",
      "pooled relative risks (RRs) with 95% confidence intervals (CIs). Interventions were ranked \n",
      "according to their P-score. \n",
      "Results: We identified 28 trials (12,504 patients). Based on failure to achieve clinical \n",
      "remission, upadacitinib 45mg o.d. ranked first versus placebo (RR = 0.73; 95% CI 0.68-0.80, \n",
      "P-score 0.98), with infliximab 5mg/kg and 10mg/kg second and third, respectively. \n",
      "Upadacitinib ranked first for clinical remission in both patients naïve to anti-TNF-α drugs \n",
      "(RR = 0.69; 95% CI 0.61-0.78, P-score 0.99) and previously exposed (RR = 0.78; 95% CI \n",
      "0.72-0.85, P-score 0.99). Upadacitinib was superior to almost all other drugs in these \n",
      "analyses. Based on failure to achieve endoscopic improvement infliximab 10mg/kg ranked \n",
      "first (RR = 0.61; 95% CI 0.51-0.72, P-score 0.97), with upadacitinib 45mg o.d. second, and \n",
      "infliximab 5mg/kg third. Upadacitinib was more likely to lead to adverse events, but serious \n",
      "adverse events were no more frequent, and withdrawals due to adverse events were \n",
      "significantly lower than with placebo. Infections were significantly more likely with \n",
      "tofacitinib than placebo (RR = 1.41; 95% CI 1.03-1.91). \n",
      "Conclusion: In a network meta-analysis, upadacitinib 45mg o.d. ranked first for clinical \n",
      "remission in all patients, patients naïve to anti-TNF-α drugs, and patients previously exposed.\n",
      "==========\n",
      "ORIGINAL QUESTION: ANALYSE the given patient profile based on given query based on one of the following criteria:\n",
      "- Whether treated patient is new patient or patient under maintenance\n",
      "- Prior response to Infliximab\n",
      "- Prior failure to Anti-TNF agents\n",
      "- Prior failure to Vedolizumab\n",
      "- Age\n",
      "- Pregnancy\n",
      "- Extraintestinale manifestations\n",
      "- Pouchitis\n",
      "RETURN up to 2 TOP choices of biological drugs given patient profile and context. Explain the PROS and CONS of the 2 choices.\n",
      "PATIENT PROFILE: 24 year-old man with moderate to severe extensive ulcerative colitis previously in clinical remission with infliximab develops loss of response due to antibody formation.\n",
      "\n",
      "==========\n",
      "CURRENT ANSWER:\n",
      "Based on the given patient profile, the patient has moderate to severe ulcerative colitis and has developed a loss of response to Infliximab due to antibody formation. This suggests that the patient has had prior exposure to anti-TNF agents and has failed to respond to Infliximab.\n",
      "\n",
      "Given this context, the top two choices of biological drugs for this patient could be:\n",
      "\n",
      "1. Upadacitinib\n",
      "   - Advantages: Upadacitinib 45mg o.d. has been ranked first for clinical remission in patients previously exposed to anti-TNF-α therapies. It has shown superior efficacy to almost all other drugs in these analyses. It is also less likely to lead to withdrawals due to adverse events compared to placebo.\n",
      "   - Disadvantages: Upadacitinib was more likely to lead to adverse events, although serious adverse events were no more frequent than with placebo.\n",
      "\n",
      "2. Ustekinumab\n",
      "   - Advantages: Ustekinumab has been ranked highly for inducing clinical remission in patients with prior exposure to TNF-α antagonists. It has shown superior efficacy to adalimumab and vedolizumab for induction of clinical remission in patients with prior exposure to TNF-α antagonists.\n",
      "   - Disadvantages: The specific disadvantages of Ustekinumab are not mentioned in the context, but like all drugs, it may have potential side effects and risks associated with its use.\n",
      "\n",
      "Please note that the choice of treatment should be individualized based on the patient's specific condition, preferences, and potential risks and benefits. It's also important to consider the patient's overall health status, comorbidities, and potential drug interactions. The patient should be closely monitored during treatment for any adverse events or signs of loss of response.\n",
      "==========\n",
      "REFINED ANSWER:\n",
      "\u001b[0m\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "Retrying langchain.chat_models.openai.ChatOpenAI.completion_with_retry.<locals>._completion_with_retry in 4.0 seconds as it raised RateLimitError: Rate limit reached for 10KTPM-200RPM in organization org-ETbTMTN2JXYOUPDJgxuH2iO6 on tokens per min. Limit: 10000 / min. Please try again in 6ms. Contact us through our help center at help.openai.com if you continue to have issues..\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\n",
      "\u001b[1m> Finished chain.\u001b[0m\n",
      "\n",
      "\u001b[1m> Finished chain.\u001b[0m\n",
      "2023-10-02 17:28:01,583:INFO: 5228 tokens were added to prompt from 10 documents\n",
      "Query: 44 year-old woman with moderate to severe extensive ulcerative colitis and rheumatoid arthritis.\n",
      "\n",
      "\n",
      "\n",
      "\u001b[1m> Entering new SequentialChain chain...\u001b[0m\n",
      "\n",
      "\n",
      "\u001b[1m> Entering new RetrievalQAWithSourcesChain chain...\u001b[0m\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "Retrying langchain.chat_models.openai.ChatOpenAI.completion_with_retry.<locals>._completion_with_retry in 4.0 seconds as it raised RateLimitError: Rate limit reached for 10KTPM-200RPM in organization org-ETbTMTN2JXYOUPDJgxuH2iO6 on tokens per min. Limit: 10000 / min. Please try again in 6ms. Contact us through our help center at help.openai.com if you continue to have issues..\n",
      "Retrying langchain.chat_models.openai.ChatOpenAI.completion_with_retry.<locals>._completion_with_retry in 4.0 seconds as it raised RateLimitError: Rate limit reached for 10KTPM-200RPM in organization org-ETbTMTN2JXYOUPDJgxuH2iO6 on tokens per min. Limit: 10000 / min. Please try again in 6ms. Contact us through our help center at help.openai.com if you continue to have issues..\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\n",
      "\u001b[1m> Finished chain.\u001b[0m\n",
      "\n",
      "\n",
      "\u001b[1m> Entering new LLMChain chain...\u001b[0m\n",
      "Prompt after formatting:\n",
      "\u001b[32;1m\u001b[1;3mYou are a senior physician giving advice on treatment for moderate to severe ulcerative colitis (UC).\n",
      "Make reference to the CONTEXT given to assess the scenario.\n",
      "==========\n",
      "TASK: Your task is to analyse critically the CURRENT ANSWER given the CONTEXT.\n",
      "Then refine the existing answer (only if needed) based on the following instructions:\n",
      "- If no refinement needed, return the original answer in the correct output format.\n",
      "- If the answer cannot be inferred from CONTEXT, return \"NO ANSWER\".\n",
      "- The final output should be a list of up to 2 choices of biological drugs given patient profile and context and PROS/CONS for each recommendations.\n",
      "==========\n",
      "CONTEXT:\n",
      "Burr et al. \n",
      " \n",
      "7 of 45 \n",
      "INTRODUCTION \n",
      "  Ulcerative colitis (UC) is a chronic inflammatory disorder of the bowel that causes \n",
      "continuous mucosal inflammation commencing in the rectum and extending proximally for a \n",
      "variable extent.[1] It is estimated that UC affects 2.5 million people in Europe,[2] and the \n",
      "disease follows a relapsing and remitting course, with intermittent flares of disease activity, \n",
      "some of which may be moderate to severe. Management of these is medical, for the most \n",
      "part, with surgery reserved for patients with refractory disease. Although 5-aminosalicylates \n",
      "(5-ASAs) are efficacious for mild to moderate disease activity,[3-6] more severe flares are \n",
      "usually treated with corticosteroids.[7] However, these have potentially serious adverse \n",
      "effects and a substantial proportion of patients may become either dependent on them to \n",
      "maintain remission,[8] or refractory to them.[9] As a result, over the last 20 years novel \n",
      "drugs, with more precise modes of action, based on mechanisms of disease identified in \n",
      "genome wide association studies,[10] have been developed.  \n",
      "The first of these agents was infliximab, a drug targeting the pro-inflammatory \n",
      "cytokine tumour necrosis factor-α (TNF-α), which demonstrated efficacy in clinical trials in \n",
      "moderate to severe UC.[11] Since then, other drugs against TNF-α have been tested, such as \n",
      "adalimumab and golimumab.[12, 13] In addition, newer biological therapies targeting α or β \n",
      "integrins, which are involved in migration of immune cells to inflamed intestinal mucosa, \n",
      "such as vedolizumab or etrolizumab,[14, 15] or acting against other pro-inflammatory \n",
      "cytokines implicated in the pathogenesis of UC, such as ustekinumab,[16] have been tested. \n",
      "However, even these more selective drugs do not work in all patients, there may be risks \n",
      "associated with their use,[17-19] and the fact that they are administered either intravenously \n",
      "or subcutaneously, may be inconvenient for patients. The search for alternative agents for the \n",
      "treatment of UC has, therefore, continued.\n",
      "----------\n",
      "41 years (interquartile range, 40–42 y), and 60%\n",
      "(interquartile range, 56%–63%) were men. The median\n",
      "disease duration was 6.7 years (interquartile range,\n",
      "6.0–7.8 y), and 49% (interquartile range, 46%–55%) of\n",
      "patients had extensive colitis. A median of 40% (inter-\n",
      "quartile range, 30%–50%) of patients were treated with\n",
      "concomitant immunomodulators, and 51% (interquartile\n",
      "range, 45%–57%) were on corticosteroids at baseline.\n",
      "Patients across all trials and treatment arms were com-\n",
      "parable in terms of baseline prognostic variables, inclu-\n",
      "sion/exclusion\n",
      "criteria,\n",
      "and\n",
      "co-interventions.\n",
      "All\n",
      "outcomes were assessed uniformly based on the stan-\n",
      "dard deﬁnition of the Mayo Clinic score, between weeks\n",
      "6 and 10 for induction therapy (inﬂiximab, adalimumab,\n",
      "tofacitinib, ustekinumab, 8 weeks; golimumab, 6 weeks;\n",
      "vedolizumab, 6 weeks, 10 weeks, and 14 weeks in\n",
      "VARSITY),6 and weeks 30, 54, or 60 for maintenance\n",
      "therapy;\n",
      "endoscopy\n",
      "was\n",
      "read\n",
      "by\n",
      "blinded\n",
      "local\n",
      "Table 2. Comparative Efﬁcacy of Pharmacologic Agents for Induction of Clinical Remission and Endoscopic Improvement in Biologic-Naive Patients With Moderate–Severe\n",
      "Ulcerative Colitis Using Network Meta-Analysis\n",
      "Induction of clinical remission\n",
      "Induction of endoscopic improvement\n",
      "Ustekinumab 6 mg/kg\n",
      "0.96 (0.38–2.45)\n",
      "0.80 (0.35–1.83)\n",
      "0.73 (0.31–1.74)\n",
      "1.05 (0.48–2.32)\n",
      "0.50 (0.22–1.12)\n",
      "2.04 (1.03–4.05)\n",
      "0.92 (0.45–1.89)\n",
      "Tofacitinib 10 mg b.d.\n",
      "0.84 (0.39–1.82)\n",
      "0.76 (0.33–1.76)\n",
      "1.10 (0.51–2.34)\n",
      "0.52 (0.24–1.12)\n",
      "2.12 (1.12–4.02)\n",
      "0.74 (0.36–1.51)\n",
      "0.80 (0.4–1.62)\n",
      "Vedolizumab\n",
      "0.91 (0.44–1.86)\n",
      "1.31 (0.88–1.95)\n",
      "0.62 (0.34–1.15)\n",
      "2.54 (1.60–4.02)\n",
      "1.07 (0.58–1.98)\n",
      "1.17 (0.64–2.12)\n",
      "1.45 (0.80–2.61)\n",
      "Golimumab\n",
      "1.44 (0.76–2.75)\n",
      "0.69 (0.35–1.36)\n",
      "2.79 (1.64–4.02)\n",
      "1.17 (0.65–2.13)\n",
      "1.28 (0.72–2.29)\n",
      "1.59 (0.90–2.82)\n",
      "1.10 (0.71–1.71)\n",
      "Adalimumab\n",
      "0.48 (0.26–0.86)\n",
      "1.94 (1.30–2.88)\n",
      "0.56 (0.30–1.04)\n",
      "0.61 (0.34–1.11)\n",
      "0.76 (0.42–1.37)\n",
      "0.52 (0.33–0.83)\n",
      "0.48 (0.31–0.74)\n",
      "Inﬂiximab\n",
      "4.07 (2.67–6.21)\n",
      "1.86 (1.11–3.13)\n",
      "2.03 (1.23–3.34)\n",
      "2.52 (1.54–4.11)\n",
      "1.74 (1.25–2.41)\n",
      "1.58 (1.18–2.13)\n",
      "3.32 (2.39–4.60)\n",
      "Placebo\n",
      "NOTE. Comparisons should be read from left to right. Odds ratio for comparisons are in the cell in common between the column-deﬁning and row-deﬁning treatment. Numbers in bold are statistically signiﬁcant. For induction of\n",
      "clinical remission, an odds ratio greater than 1 favors row-deﬁning treatment. For induction of endoscopic improvement, an odds ratio greater than 1 favors column-deﬁning treatment. Numbers in parentheses indicate 95% CI.\n",
      "b.d., twice daily.\n",
      "----------\n",
      "severely active ulcerative colitis: results from phase 3 \n",
      "U-ACCOMPLISH study. J Crohn’s Colitis 2021; 15 (suppl 1): S021–22.\n",
      "9 \n",
      "Thorlund K, Druyts E, Mills EJ, Fedorak RN, Marshall JK. \n",
      "Adalimumab versus infliximab for the treatment of moderate to \n",
      "severe ulcerative colitis in adult patients naïve to anti-TNF therapy: \n",
      "an indirect treatment comparison meta-analysis. J Crohn’s Colitis \n",
      "2014; 8: 571–81.\n",
      "10 \n",
      "Danese S, Fiorino G, Peyrin-Biroulet L, et al. Biological agents for \n",
      "moderately to severely active ulcerative colitis: a systematic review \n",
      "and network meta-analysis. Ann Intern Med 2014; 160: 704–11.\n",
      "11 \n",
      "Singh S, Fumery M, Sandborn WJ, Murad MH. Systematic review \n",
      "with network meta-analysis: first- and second-line pharmacotherapy \n",
      "for moderate-severe ulcerative colitis. Aliment Pharmacol Ther 2018; \n",
      "47: 162–75.\n",
      "12 \n",
      "Bonovas S, Lytras T, Nikolopoulos G, Peyrin-Biroulet L, Danese S. \n",
      "Systematic review with network meta-analysis: comparative \n",
      "assessment of tofacitinib and biological therapies for moderate-to-\n",
      "severe ulcerative colitis. Aliment Pharmacol Ther 2018; 47: 454–65.\n",
      "13 \n",
      "Singh S, Murad MH, Fumery M, Dulai PS, Sandborn WJ. First- and \n",
      "second-line pharmacotherapies for patients with moderate to \n",
      "severely active ulcerative colitis: an updated network meta-analysis. \n",
      "Clin Gastroenterol Hepatol 2020; 18: 2179–91.e6.\n",
      "14 \n",
      "Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting \n",
      "items for systematic reviews and meta-analyses: the PRISMA \n",
      "statement. Ann Intern Med 2009; 151: 264–69.\n",
      "15 \n",
      "Jansen JP, Fleurence R, Devine B, et al. Interpreting indirect \n",
      "treatment comparisons and network meta-analysis for health-care \n",
      "decision making: report of the ISPOR Task Force on Indirect \n",
      "Treatment Comparisons Good Research Practices: part 1. \n",
      "Value Health 2011; 14: 417–28.\n",
      "16 \n",
      "Sterne JAC, Savović J, Page MJ, et al. RoB 2: a revised tool for \n",
      "assessing risk of bias in randomised trials. BMJ 2019; 366: l4898.\n",
      "17 \n",
      "Rücker G, Schwarzer G. Ranking treatments in frequentist network \n",
      "meta-analysis works without resampling methods. \n",
      "BMC Med Res Methodol 2015; 15: 58.\n",
      "----------\n",
      "Burr et al. \n",
      " \n",
      "5 of 45 \n",
      "STUDY HIGHLIGHTS \n",
      " \n",
      "What is already known about this subject \n",
      "• Ulcerative colitis (UC) follows a relapsing and remitting course, with intermittent \n",
      "flares of disease activity, some of which may be moderate to severe. \n",
      "• These are usually treated with corticosteroids, which have potentially serious adverse \n",
      "effects, so biological therapies and small molecules have been developed and licensed \n",
      "for this indication.  \n",
      "• Although previous network meta-analyses have compared their efficacy and safety, \n",
      "this is a rapidly moving field, and there are already several newer drugs that have \n",
      "shown efficacy in phase III clinical trials that were not considered in these. \n",
      " \n",
      "What are the new findings \n",
      "• In terms of clinical remission and clinical response, upadacitinib 45mg o.d. ranked \n",
      "first in all patients, in patients previously exposed to anti-tumour necrosis factor \n",
      "(TNF)-α therapies, and in patients naïve to these drugs.  \n",
      "• In terms of endoscopic improvement infliximab 10mg/kg ranked first, followed by \n",
      "upadacitinib 45mg o.d., and infliximab 5mg/kg.  \n",
      "• However, for endoscopic improvement again upadacitinib 45mg o.d. ranked first in \n",
      "patients previously exposed to anti-TNF-α therapies, and in patients who were anti-\n",
      "TNF-α naïve.  \n",
      "• None of the drugs studied were more likely to lead to serious adverse events than \n",
      "placebo.\n",
      "----------\n",
      "Parkes, M., Vermeire, S., Rioux, J.D., Mansﬁeld, J., Silverberg, M.S., Radford-\n",
      "Smith, G., McGovern, D.P., Barrett, J.C., Lees, C.W., 2016. Inherited determinants of\n",
      "crohn's disease and ulcerative colitis phenotypes: a genetic association study. Lancet\n",
      "387 (10014), 156–167.\n",
      "Colombel, J.F., Sandborn, W.J., Rutgeerts, P., Enns, R., Hanauer, S.B., Panaccione, R.,\n",
      "Schreiber, S., Byczkowski, D., Li, J., Kent, J.D., Pollack, P.F., 2007. Adalimumab for\n",
      "maintenance of clinical response and remission in patients with crohn's disease: the\n",
      "charm trial. Gastroenterology 132 (1), 52–65.\n",
      "Conrad, M.A., Kelsen, J.R., 2020. The treatment of pediatric inﬂammatory bowel disease\n",
      "with biologic therapies. Curr. Gastroenterol. Rep. 22 (8), 36–51.\n",
      "Csontos, A.A., Molnar, A., Piri, Z., Katona, B., Dako, S., Palﬁ, E., Miheller, P., 2016. The\n",
      "effect of anti-tnfalpha induction therapy on the nutritional status and dietary intake\n",
      "in inﬂammatory bowel disease. J Gastrointestin Liver Dis 25 (1), 49–56.\n",
      "Dai, Z.H., Xu, X.T., Ran, Z.H., 2020. Associations between obesity and the effectiveness of\n",
      "anti-tumor necrosis factor-alpha agents in inﬂammatory bowel disease patients: a\n",
      "literature review and meta-analysis. Ann. Pharmacother. 54 (8), 729–741.\n",
      "Danese, S., Colombel, J.F., Lukas, M., Gisbert, J.P., D’Haens, G., Hayee, B., Panaccione, R.,\n",
      "Kim, H.S., Reinisch, W., Tyrrell, H., Oh, Y.S., Tole, S., Chai, A., Chamberlain-\n",
      "James, K., Tang, M.T., Schreiber, S., Group, G.S., 2021. Etrolizumab versus inﬂiximab\n",
      "for the treatment of moderately to severely active ulcerative colitis (gardenia): a\n",
      "randomised, double-blind, double-dummy, phase 3 study. Lancet Gastroenterol\n",
      "Hepatol 7 (2), 118–127.\n",
      "Danese, S., Fiorino, G., Peyrin-Biroulet, L., Lucenteforte, E., Virgili, G., Moja, L.,\n",
      "Bonovas, S., 2014. Biological agents for moderately to severely active ulcerative\n",
      "colitis: a systematic review and network meta-analysis. Ann. Intern. Med. 160 (10),\n",
      "704–711.\n",
      "P. Juillerat et al.\n",
      "Current Research in Pharmacology and Drug Discovery 3 (2022) 100104\n",
      "6\n",
      "----------\n",
      "methodologic characteristics). If direct and indirect es-\n",
      "timates were similar (ie, coherent), then the higher rating\n",
      "can be assigned to the network meta-analysis estimates.\n",
      "Results\n",
      "From a total 5651 unique studies identiﬁed using our\n",
      "search strategy, we included 15 RCTs of ﬁrst-line agents\n",
      "(in biologic-naïve patients) (Active Ulcerative Colitis Trials\n",
      "1 and 2,17 Jiang et al,18 NCT01551290,19 Ulcerative colitis\n",
      "Long-Term Remission and maintenance with Adalimumab\n",
      "1 and 2,20,21 Suzuki et al,22 Program of Ulcerative Colitis\n",
      "Research Studies Utilizing an Investigational Treatment\n",
      "phase 2 and phase 3 induction studies,23 GEMINI I,24\n",
      "Motoya et al,25 VARSITY, Oral Clinical Trials for tofAciti-\n",
      "nib in ulceratiVE colitis (OCTAVE) 1 and 2,26 and UNIFI),\n",
      "and 7 RCTs of second-line agents (in patients with prior\n",
      "exposure to TNFa antagonists) (Ulcerative colitis Long-\n",
      "Term Remission and maintenance with Adalimumab 2,21\n",
      "GEMINI I,24 Motoya et al,25 VARSITY,6 OCTAVE 1 and\n",
      "2,26 UNIFI7) in patients with moderate–severe ulcerative\n",
      "colitis. Trials of inﬂiximab (Active Ulcerative Colitis Trials\n",
      "1 and 2,17 Jiang et al,18 NCT0155129019), adalimumab\n",
      "(Ulcerative colitis Long-Term Remission and maintenance\n",
      "with Adalimumab 2,20,21 Suzuki et al22), vedolizumab\n",
      "(GEMINI I,24 Motoya et al,25 VARSITY6) and ustekinumab\n",
      "(UNIFI7) also reported outcomes on maintenance therapy\n",
      "within the same publication; Program of Ulcerative Colitis\n",
      "Research Studies Utilizing an Investigational Treatment-\n",
      "M, Program of Ulcerative Colitis Research Studies Utilizing\n",
      "an Investigational Treatment-J, and OCTAVE-Sustain\n",
      "reported\n",
      "outcomes\n",
      "for\n",
      "maintenance\n",
      "therapy\n",
      "with\n",
      "golimumab and tofacitinib, respectively.26–28 From our\n",
      "previous analysis, 3 additional studies were included.\n",
      "The schematic diagram of study selection is shown in\n",
      "Supplementary\n",
      "Figure\n",
      "1,\n",
      "and\n",
      "available\n",
      "direct\n",
      "comparisons and network of trials are shown in Figure 1.\n",
      "Trial and patient characteristics are summarized in\n",
      "Table 1. Overall, the median average age of patients was\n",
      "41 years (interquartile range, 40–42 y), and 60%\n",
      "(interquartile range, 56%–63%) were men. The median\n",
      "disease duration was 6.7 years (interquartile range,\n",
      "6.0–7.8 y), and 49% (interquartile range, 46%–55%) of\n",
      "patients had extensive colitis. A median of 40% (inter-\n",
      "quartile range, 30%–50%) of patients were treated with\n",
      "concomitant immunomodulators, and 51% (interquartile\n",
      "range, 45%–57%) were on corticosteroids at baseline.\n",
      "Patients across all trials and treatment arms were com-\n",
      "----------\n",
      "Therapeutic strategies for the management of recentlydiagnosedulcerative colitis. IMMs include thiopurines and methotrexate. 5-ASA, 5-amino salicylic acid; ASUC, acute severe ulcerative colitis; IPAA, ileal pouch anal anastomosis.\n",
      "\n",
      "Risk stratification: Mild\n",
      "Clinical features: NA\n",
      "Treatment options: 5-ASA (oral and/or topical)\n",
      "\n",
      "Risk stratification: Moderate\n",
      "Clinical features: NA\n",
      "Treatment options: Can consider 5-ASA (with rapid step-up if inadequate response)\n",
      "\n",
      "Risk stratification: Moderate\n",
      "Clinical features: NA\n",
      "Treatment options: VDZ or UST\n",
      "\n",
      "Risk stratification: Moderate\n",
      "Clinical features: NA\n",
      "Treatment options: Thiopurine\n",
      "\n",
      "Risk stratification: Moderate\n",
      "Clinical features: NA\n",
      "Treatment options: TNFi +/- IMM\n",
      "\n",
      "Risk stratification: Severe\n",
      "Clinical features: NA\n",
      "Treatment options: TNFi +/- IMM\n",
      "\n",
      "Risk stratification: Severe\n",
      "Clinical features: NA\n",
      "Treatment options: Subtotal colectomy + IPAA or cyclosporine (for ASUC)\n",
      "\n",
      "Risk stratification: Additional consideration: EIM present\n",
      "Clinical features: Psoriasis or psoriatic arthritis\n",
      "Treatment options: UST\n",
      "\n",
      "Risk stratification: Additional consideration: EIM present\n",
      "Clinical features: Other arthritis\n",
      "Treatment options: TNFi\n",
      "\n",
      "\n",
      "----------\n",
      "I(m): UST 90 mg q8w–176\n",
      "MCS �2; wk 8(i);\n",
      "wk 44(m)\n",
      "P(i): 41 (14); 62\n",
      "I(i): 42 (14); 61\n",
      "P(m): 42(14); 61\n",
      "I(m): 40 (13); 53\n",
      "8.0 (7.2); 47\n",
      "8.2 (7.8); 47\n",
      "7.5 (6.8); 49\n",
      "8.1 (6.7); 46\n",
      "27.9\n",
      "27.6\n",
      "28.0\n",
      "25.6\n",
      "49.2\n",
      "52.2\n",
      "54.3\n",
      "54.0\n",
      "4.7 (1.4–10.)\n",
      "4.8 (1.8–13.7)\n",
      "3.4 (1.4–9.7)\n",
      "4.0 (1.4–12.7)\n",
      "51j\n",
      "52j\n",
      "50j\n",
      "52j\n",
      "ADA, adalimumab; CRem, clinical remission; CRP, C-reactive protein; CS, corticosteroids; GLM, golimumab; I, induction; IFX, inﬂiximab; IM, immunomodulator; MCS, Mayo Clinic Score; NR, not reported; P, placebo;\n",
      "PURSUIT, Program of Ulcerative Colitis Research Studies Utilizing an Investigational Treatment; q2w, every 2 weeks; q4w, every 4 weeks; q8w, every 8 weeks; TNF, tumor necrosis factor; VDZ, vedolizumab.\n",
      "aMaintenance therapy with treat straight-through design.\n",
      "bMedian (range).\n",
      "cReasons for discontinuation of prior anti-TNF therapy: primary nonresponse, 0%; secondary loss of response or intolerance, 100%.\n",
      "dOnly including patients with initial response to induction therapy who were rerandomized to placebo or active intervention.\n",
      "eReasons for discontinuation of prior anti-TNF therapy: primary nonresponse, 48%; secondary loss of response, 38%; intolerance, 14%.\n",
      "fReasons for discontinuation of prior anti-TNF therapy: primary nonresponse, 36%; secondary loss of response, 30%; intolerance, 18%.\n",
      "gReasons for discontinuation of prior anti-TNF therapy: primary nonresponse, 58%; secondary loss of response, 40%; intolerance, 2%.\n",
      "hReasons for discontinuation of prior anti-TNF therapy: primary nonresponse, 43%; secondary loss of response, 50%; intolerance, 7%.\n",
      "iReasons for discontinuation of prior anti-TNF therapy: primary nonresponse, 50%; secondary loss of response, 35%; intolerance, 7%.\n",
      "jIncludes patients with prior exposure to TNF antagonist with or without vedolizumab (13%–18% had prior exposure to vedolizumab).\n",
      "September 2020\n",
      "Management of Moderate–Severe UC 2183\n",
      "----------\n",
      "to\n",
      "extensive\n",
      "or\n",
      "pancolitis\n",
      "is\n",
      "associated\n",
      "with\n",
      "worse\n",
      "prognosis.45,65\n",
      "In addition, co-occurrence of other immune-mediated\n",
      "inﬂammatory diseases can occur, most commonly with\n",
      "psoriasis and asthma, but also, in more rare instances, with\n",
      "other gastrointestinal diseases (eg, celiac, nonalcoholic fatty\n",
      "liver disease,66 and eosinophilic esophagitis).67,68 Presence\n",
      "of a concomitant immune-mediated inﬂammatory disease is\n",
      "Figure\n",
      "1. Inﬂammatory\n",
      "bowel disease severity vs\n",
      "disease activity variables.\n",
      "ASCA, anti-Saccharomyces\n",
      "cerevisiae\n",
      "antibodies;\n",
      "ANCA,\n",
      "anti-neutrophil\n",
      "cytoplasmic\n",
      "antibodies;\n",
      "GMCSF,\n",
      "granulocyte-\n",
      "macrophage\n",
      "colony-\n",
      "stimulating\n",
      "factor;\n",
      "TI,\n",
      "terminal ileum.\n",
      "50\n",
      "Agrawal et al\n",
      "Gastroenterology Vol. 161, No. 1\n",
      "REVIEWS AND\n",
      "PERSPECTIVES\n",
      "----------\n",
      "Articles\n",
      "www.thelancet.com/gastrohep   Vol 7   February 2022 \n",
      "161\n",
      "Lancet Gastroenterol Hepatol \n",
      "2022; 7: 161–70\n",
      "Published Online \n",
      "November 29, 2021 \n",
      "https://doi.org/10.1016/ \n",
      "S2468-1253(21)00377-0\n",
      "See Comment page 110\n",
      "*Contributed equally\n",
      "Inflammatory Bowel Disease \n",
      "Unit, Gastroenterology \n",
      "Section, Department of \n",
      "Internal Medicine, Centro de \n",
      "Educación Médica e \n",
      "Investigaciones Clínicas, \n",
      "Buenos Aires, Argentina \n",
      "(J S Lasa MD, P A Olivera MD); \n",
      "Gastroenterology Department, \n",
      "Hospital Británico de Buenos \n",
      "Aires, Buenos Aires, Argentina \n",
      "(J S Lasa); Zane Cohen Centre \n",
      "for Digestive Diseases, \n",
      "Lunenfeld-Tanenbaum \n",
      "Research Institute, Sinai Health \n",
      "System, Toronto, ON, Canada \n",
      "(P A Olivera); Division of \n",
      "Gastroenterology, Mount Sinai \n",
      "Hospital, University of Toronto, \n",
      "Toronto, ON, Canada \n",
      "(P A Olivera); Gastroenterology \n",
      "and Endoscopy, IRCCS Ospedale \n",
      "San Raffaele and University \n",
      "Vita-Salute San Raffaele, \n",
      "Milano, Italy \n",
      "(Prof S Danese MD); INSERM \n",
      "NGERE and Department of \n",
      "Hepatogastroenterology, \n",
      "Nancy University Hospital, \n",
      "Lorraine University, \n",
      "Vandoeuvre-lés-Nancy, France \n",
      "(Prof L Peyrin-Biroulet MD) \n",
      "Correspondence to: \n",
      "Prof Laurent Peyrin-Biroulet, \n",
      "INSERM NGERE and Department \n",
      "of Hepatogastroenterology, \n",
      "Nancy University Hospital, \n",
      "Lorraine University, Vandoeuvre-\n",
      "lès-Nancy F-54511, France \n",
      "peyrinbiroulet@gmail.com\n",
      "Efficacy and safety of biologics and small molecule drugs for \n",
      "patients with moderate-to-severe ulcerative colitis: \n",
      "a systematic review and network meta-analysis \n",
      "Juan S Lasa*, Pablo A Olivera*, Silvio Danese, Laurent Peyrin-Biroulet\n",
      "Summary\n",
      "Background There is a growing armamentarium for the treatment of moderate-to-severe ulcerative colitis. We aimed \n",
      "to compare the relative efficacy and safety of biologics and small molecule drugs for the treatment of patients with \n",
      "moderate-to-severe ulcerative colitis.\n",
      "Methods In this systematic review and network meta-analysis, we searched MEDLINE, Embase, and the Cochrane \n",
      "Central Register of Controlled Trials without language restrictions for articles published between Jan 1, 1990, and \n",
      "July 1, 2021. Major congresses’ databases from Jan 1, 2018, to July 3, 2021, were reviewed manually. Phase 3, placebo-\n",
      "controlled or head-to-head randomised controlled trials (RCTs) assessing the efficacy and safety of biologics or small \n",
      "molecule drugs as induction or maintenance therapies for patients with moderate-to-severe ulcerative colitis were\n",
      "==========\n",
      "ORIGINAL QUESTION: ANALYSE the given patient profile based on given query based on one of the following criteria:\n",
      "- Whether treated patient is new patient or patient under maintenance\n",
      "- Prior response to Infliximab\n",
      "- Prior failure to Anti-TNF agents\n",
      "- Prior failure to Vedolizumab\n",
      "- Age\n",
      "- Pregnancy\n",
      "- Extraintestinale manifestations\n",
      "- Pouchitis\n",
      "RETURN up to 2 TOP choices of biological drugs given patient profile and context. Explain the PROS and CONS of the 2 choices.\n",
      "PATIENT PROFILE: 44 year-old woman with moderate to severe extensive ulcerative colitis and rheumatoid arthritis.\n",
      "\n",
      "==========\n",
      "CURRENT ANSWER:\n",
      "Based on the patient's profile, the top two choices of biological drugs would be:\n",
      "\n",
      "1. Infliximab\n",
      "Advantages: Infliximab has shown efficacy in clinical trials for moderate to severe UC. It targets the pro-inflammatory cytokine tumour necrosis factor-α (TNF-α), which is involved in the pathogenesis of both ulcerative colitis and rheumatoid arthritis. Therefore, it could potentially manage both conditions.\n",
      "Disadvantages: Infliximab is administered either intravenously, which may be inconvenient for some patients. There may also be risks associated with its use, including serious infections and potential allergic reactions.\n",
      "\n",
      "2. Adalimumab\n",
      "Advantages: Adalimumab is another TNF-α inhibitor that has been tested for moderate to severe UC. It is also used in the treatment of rheumatoid arthritis. It is administered subcutaneously, which some patients may find more convenient than intravenous administration.\n",
      "Disadvantages: As with infliximab, there may be risks associated with the use of adalimumab, including serious infections. Some patients may also experience injection site reactions.\n",
      "\n",
      "It's important to note that the choice of treatment should be individualized, taking into account the patient's overall health status, preferences, and potential side effects of the drugs. The patient should also be closely monitored while on these medications to manage any potential side effects promptly.\n",
      "==========\n",
      "REFINED ANSWER:\n",
      "\u001b[0m\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "Retrying langchain.chat_models.openai.ChatOpenAI.completion_with_retry.<locals>._completion_with_retry in 4.0 seconds as it raised RateLimitError: Rate limit reached for 10KTPM-200RPM in organization org-ETbTMTN2JXYOUPDJgxuH2iO6 on tokens per min. Limit: 10000 / min. Please try again in 6ms. Contact us through our help center at help.openai.com if you continue to have issues..\n",
      "Retrying langchain.chat_models.openai.ChatOpenAI.completion_with_retry.<locals>._completion_with_retry in 4.0 seconds as it raised RateLimitError: Rate limit reached for 10KTPM-200RPM in organization org-ETbTMTN2JXYOUPDJgxuH2iO6 on tokens per min. Limit: 10000 / min. Please try again in 6ms. Contact us through our help center at help.openai.com if you continue to have issues..\n",
      "Retrying langchain.chat_models.openai.ChatOpenAI.completion_with_retry.<locals>._completion_with_retry in 4.0 seconds as it raised RateLimitError: Rate limit reached for 10KTPM-200RPM in organization org-ETbTMTN2JXYOUPDJgxuH2iO6 on tokens per min. Limit: 10000 / min. Please try again in 6ms. Contact us through our help center at help.openai.com if you continue to have issues..\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\n",
      "\u001b[1m> Finished chain.\u001b[0m\n",
      "\n",
      "\u001b[1m> Finished chain.\u001b[0m\n",
      "2023-10-02 17:29:05,035:INFO: 5706 tokens were added to prompt from 10 documents\n",
      "Query: 55 year-old man with moderate to severe extensive ulcerative colitis who avlues convenience and limited time spent in hospital\n",
      "\n",
      "\n",
      "\n",
      "\u001b[1m> Entering new SequentialChain chain...\u001b[0m\n",
      "\n",
      "\n",
      "\u001b[1m> Entering new RetrievalQAWithSourcesChain chain...\u001b[0m\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "Retrying langchain.chat_models.openai.ChatOpenAI.completion_with_retry.<locals>._completion_with_retry in 4.0 seconds as it raised RateLimitError: Rate limit reached for 10KTPM-200RPM in organization org-ETbTMTN2JXYOUPDJgxuH2iO6 on tokens per min. Limit: 10000 / min. Please try again in 6ms. Contact us through our help center at help.openai.com if you continue to have issues..\n",
      "Retrying langchain.chat_models.openai.ChatOpenAI.completion_with_retry.<locals>._completion_with_retry in 4.0 seconds as it raised RateLimitError: Rate limit reached for 10KTPM-200RPM in organization org-ETbTMTN2JXYOUPDJgxuH2iO6 on tokens per min. Limit: 10000 / min. Please try again in 6ms. Contact us through our help center at help.openai.com if you continue to have issues..\n",
      "Retrying langchain.chat_models.openai.ChatOpenAI.completion_with_retry.<locals>._completion_with_retry in 4.0 seconds as it raised RateLimitError: Rate limit reached for 10KTPM-200RPM in organization org-ETbTMTN2JXYOUPDJgxuH2iO6 on tokens per min. Limit: 10000 / min. Please try again in 6ms. Contact us through our help center at help.openai.com if you continue to have issues..\n",
      "Retrying langchain.chat_models.openai.ChatOpenAI.completion_with_retry.<locals>._completion_with_retry in 8.0 seconds as it raised RateLimitError: Rate limit reached for 10KTPM-200RPM in organization org-ETbTMTN2JXYOUPDJgxuH2iO6 on tokens per min. Limit: 10000 / min. Please try again in 6ms. Contact us through our help center at help.openai.com if you continue to have issues..\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\n",
      "\u001b[1m> Finished chain.\u001b[0m\n",
      "\n",
      "\n",
      "\u001b[1m> Entering new LLMChain chain...\u001b[0m\n",
      "Prompt after formatting:\n",
      "\u001b[32;1m\u001b[1;3mYou are a senior physician giving advice on treatment for moderate to severe ulcerative colitis (UC).\n",
      "Make reference to the CONTEXT given to assess the scenario.\n",
      "==========\n",
      "TASK: Your task is to analyse critically the CURRENT ANSWER given the CONTEXT.\n",
      "Then refine the existing answer (only if needed) based on the following instructions:\n",
      "- If no refinement needed, return the original answer in the correct output format.\n",
      "- If the answer cannot be inferred from CONTEXT, return \"NO ANSWER\".\n",
      "- The final output should be a list of up to 2 choices of biological drugs given patient profile and context and PROS/CONS for each recommendations.\n",
      "==========\n",
      "CONTEXT:\n",
      "Burr et al. \n",
      " \n",
      "7 of 45 \n",
      "INTRODUCTION \n",
      "  Ulcerative colitis (UC) is a chronic inflammatory disorder of the bowel that causes \n",
      "continuous mucosal inflammation commencing in the rectum and extending proximally for a \n",
      "variable extent.[1] It is estimated that UC affects 2.5 million people in Europe,[2] and the \n",
      "disease follows a relapsing and remitting course, with intermittent flares of disease activity, \n",
      "some of which may be moderate to severe. Management of these is medical, for the most \n",
      "part, with surgery reserved for patients with refractory disease. Although 5-aminosalicylates \n",
      "(5-ASAs) are efficacious for mild to moderate disease activity,[3-6] more severe flares are \n",
      "usually treated with corticosteroids.[7] However, these have potentially serious adverse \n",
      "effects and a substantial proportion of patients may become either dependent on them to \n",
      "maintain remission,[8] or refractory to them.[9] As a result, over the last 20 years novel \n",
      "drugs, with more precise modes of action, based on mechanisms of disease identified in \n",
      "genome wide association studies,[10] have been developed.  \n",
      "The first of these agents was infliximab, a drug targeting the pro-inflammatory \n",
      "cytokine tumour necrosis factor-α (TNF-α), which demonstrated efficacy in clinical trials in \n",
      "moderate to severe UC.[11] Since then, other drugs against TNF-α have been tested, such as \n",
      "adalimumab and golimumab.[12, 13] In addition, newer biological therapies targeting α or β \n",
      "integrins, which are involved in migration of immune cells to inflamed intestinal mucosa, \n",
      "such as vedolizumab or etrolizumab,[14, 15] or acting against other pro-inflammatory \n",
      "cytokines implicated in the pathogenesis of UC, such as ustekinumab,[16] have been tested. \n",
      "However, even these more selective drugs do not work in all patients, there may be risks \n",
      "associated with their use,[17-19] and the fact that they are administered either intravenously \n",
      "or subcutaneously, may be inconvenient for patients. The search for alternative agents for the \n",
      "treatment of UC has, therefore, continued.\n",
      "----------\n",
      "41 years (interquartile range, 40–42 y), and 60%\n",
      "(interquartile range, 56%–63%) were men. The median\n",
      "disease duration was 6.7 years (interquartile range,\n",
      "6.0–7.8 y), and 49% (interquartile range, 46%–55%) of\n",
      "patients had extensive colitis. A median of 40% (inter-\n",
      "quartile range, 30%–50%) of patients were treated with\n",
      "concomitant immunomodulators, and 51% (interquartile\n",
      "range, 45%–57%) were on corticosteroids at baseline.\n",
      "Patients across all trials and treatment arms were com-\n",
      "parable in terms of baseline prognostic variables, inclu-\n",
      "sion/exclusion\n",
      "criteria,\n",
      "and\n",
      "co-interventions.\n",
      "All\n",
      "outcomes were assessed uniformly based on the stan-\n",
      "dard deﬁnition of the Mayo Clinic score, between weeks\n",
      "6 and 10 for induction therapy (inﬂiximab, adalimumab,\n",
      "tofacitinib, ustekinumab, 8 weeks; golimumab, 6 weeks;\n",
      "vedolizumab, 6 weeks, 10 weeks, and 14 weeks in\n",
      "VARSITY),6 and weeks 30, 54, or 60 for maintenance\n",
      "therapy;\n",
      "endoscopy\n",
      "was\n",
      "read\n",
      "by\n",
      "blinded\n",
      "local\n",
      "Table 2. Comparative Efﬁcacy of Pharmacologic Agents for Induction of Clinical Remission and Endoscopic Improvement in Biologic-Naive Patients With Moderate–Severe\n",
      "Ulcerative Colitis Using Network Meta-Analysis\n",
      "Induction of clinical remission\n",
      "Induction of endoscopic improvement\n",
      "Ustekinumab 6 mg/kg\n",
      "0.96 (0.38–2.45)\n",
      "0.80 (0.35–1.83)\n",
      "0.73 (0.31–1.74)\n",
      "1.05 (0.48–2.32)\n",
      "0.50 (0.22–1.12)\n",
      "2.04 (1.03–4.05)\n",
      "0.92 (0.45–1.89)\n",
      "Tofacitinib 10 mg b.d.\n",
      "0.84 (0.39–1.82)\n",
      "0.76 (0.33–1.76)\n",
      "1.10 (0.51–2.34)\n",
      "0.52 (0.24–1.12)\n",
      "2.12 (1.12–4.02)\n",
      "0.74 (0.36–1.51)\n",
      "0.80 (0.4–1.62)\n",
      "Vedolizumab\n",
      "0.91 (0.44–1.86)\n",
      "1.31 (0.88–1.95)\n",
      "0.62 (0.34–1.15)\n",
      "2.54 (1.60–4.02)\n",
      "1.07 (0.58–1.98)\n",
      "1.17 (0.64–2.12)\n",
      "1.45 (0.80–2.61)\n",
      "Golimumab\n",
      "1.44 (0.76–2.75)\n",
      "0.69 (0.35–1.36)\n",
      "2.79 (1.64–4.02)\n",
      "1.17 (0.65–2.13)\n",
      "1.28 (0.72–2.29)\n",
      "1.59 (0.90–2.82)\n",
      "1.10 (0.71–1.71)\n",
      "Adalimumab\n",
      "0.48 (0.26–0.86)\n",
      "1.94 (1.30–2.88)\n",
      "0.56 (0.30–1.04)\n",
      "0.61 (0.34–1.11)\n",
      "0.76 (0.42–1.37)\n",
      "0.52 (0.33–0.83)\n",
      "0.48 (0.31–0.74)\n",
      "Inﬂiximab\n",
      "4.07 (2.67–6.21)\n",
      "1.86 (1.11–3.13)\n",
      "2.03 (1.23–3.34)\n",
      "2.52 (1.54–4.11)\n",
      "1.74 (1.25–2.41)\n",
      "1.58 (1.18–2.13)\n",
      "3.32 (2.39–4.60)\n",
      "Placebo\n",
      "NOTE. Comparisons should be read from left to right. Odds ratio for comparisons are in the cell in common between the column-deﬁning and row-deﬁning treatment. Numbers in bold are statistically signiﬁcant. For induction of\n",
      "clinical remission, an odds ratio greater than 1 favors row-deﬁning treatment. For induction of endoscopic improvement, an odds ratio greater than 1 favors column-deﬁning treatment. Numbers in parentheses indicate 95% CI.\n",
      "b.d., twice daily.\n",
      "----------\n",
      "methodologic characteristics). If direct and indirect es-\n",
      "timates were similar (ie, coherent), then the higher rating\n",
      "can be assigned to the network meta-analysis estimates.\n",
      "Results\n",
      "From a total 5651 unique studies identiﬁed using our\n",
      "search strategy, we included 15 RCTs of ﬁrst-line agents\n",
      "(in biologic-naïve patients) (Active Ulcerative Colitis Trials\n",
      "1 and 2,17 Jiang et al,18 NCT01551290,19 Ulcerative colitis\n",
      "Long-Term Remission and maintenance with Adalimumab\n",
      "1 and 2,20,21 Suzuki et al,22 Program of Ulcerative Colitis\n",
      "Research Studies Utilizing an Investigational Treatment\n",
      "phase 2 and phase 3 induction studies,23 GEMINI I,24\n",
      "Motoya et al,25 VARSITY, Oral Clinical Trials for tofAciti-\n",
      "nib in ulceratiVE colitis (OCTAVE) 1 and 2,26 and UNIFI),\n",
      "and 7 RCTs of second-line agents (in patients with prior\n",
      "exposure to TNFa antagonists) (Ulcerative colitis Long-\n",
      "Term Remission and maintenance with Adalimumab 2,21\n",
      "GEMINI I,24 Motoya et al,25 VARSITY,6 OCTAVE 1 and\n",
      "2,26 UNIFI7) in patients with moderate–severe ulcerative\n",
      "colitis. Trials of inﬂiximab (Active Ulcerative Colitis Trials\n",
      "1 and 2,17 Jiang et al,18 NCT0155129019), adalimumab\n",
      "(Ulcerative colitis Long-Term Remission and maintenance\n",
      "with Adalimumab 2,20,21 Suzuki et al22), vedolizumab\n",
      "(GEMINI I,24 Motoya et al,25 VARSITY6) and ustekinumab\n",
      "(UNIFI7) also reported outcomes on maintenance therapy\n",
      "within the same publication; Program of Ulcerative Colitis\n",
      "Research Studies Utilizing an Investigational Treatment-\n",
      "M, Program of Ulcerative Colitis Research Studies Utilizing\n",
      "an Investigational Treatment-J, and OCTAVE-Sustain\n",
      "reported\n",
      "outcomes\n",
      "for\n",
      "maintenance\n",
      "therapy\n",
      "with\n",
      "golimumab and tofacitinib, respectively.26–28 From our\n",
      "previous analysis, 3 additional studies were included.\n",
      "The schematic diagram of study selection is shown in\n",
      "Supplementary\n",
      "Figure\n",
      "1,\n",
      "and\n",
      "available\n",
      "direct\n",
      "comparisons and network of trials are shown in Figure 1.\n",
      "Trial and patient characteristics are summarized in\n",
      "Table 1. Overall, the median average age of patients was\n",
      "41 years (interquartile range, 40–42 y), and 60%\n",
      "(interquartile range, 56%–63%) were men. The median\n",
      "disease duration was 6.7 years (interquartile range,\n",
      "6.0–7.8 y), and 49% (interquartile range, 46%–55%) of\n",
      "patients had extensive colitis. A median of 40% (inter-\n",
      "quartile range, 30%–50%) of patients were treated with\n",
      "concomitant immunomodulators, and 51% (interquartile\n",
      "range, 45%–57%) were on corticosteroids at baseline.\n",
      "Patients across all trials and treatment arms were com-\n",
      "----------\n",
      "severely active ulcerative colitis: results from phase 3 \n",
      "U-ACCOMPLISH study. J Crohn’s Colitis 2021; 15 (suppl 1): S021–22.\n",
      "9 \n",
      "Thorlund K, Druyts E, Mills EJ, Fedorak RN, Marshall JK. \n",
      "Adalimumab versus infliximab for the treatment of moderate to \n",
      "severe ulcerative colitis in adult patients naïve to anti-TNF therapy: \n",
      "an indirect treatment comparison meta-analysis. J Crohn’s Colitis \n",
      "2014; 8: 571–81.\n",
      "10 \n",
      "Danese S, Fiorino G, Peyrin-Biroulet L, et al. Biological agents for \n",
      "moderately to severely active ulcerative colitis: a systematic review \n",
      "and network meta-analysis. Ann Intern Med 2014; 160: 704–11.\n",
      "11 \n",
      "Singh S, Fumery M, Sandborn WJ, Murad MH. Systematic review \n",
      "with network meta-analysis: first- and second-line pharmacotherapy \n",
      "for moderate-severe ulcerative colitis. Aliment Pharmacol Ther 2018; \n",
      "47: 162–75.\n",
      "12 \n",
      "Bonovas S, Lytras T, Nikolopoulos G, Peyrin-Biroulet L, Danese S. \n",
      "Systematic review with network meta-analysis: comparative \n",
      "assessment of tofacitinib and biological therapies for moderate-to-\n",
      "severe ulcerative colitis. Aliment Pharmacol Ther 2018; 47: 454–65.\n",
      "13 \n",
      "Singh S, Murad MH, Fumery M, Dulai PS, Sandborn WJ. First- and \n",
      "second-line pharmacotherapies for patients with moderate to \n",
      "severely active ulcerative colitis: an updated network meta-analysis. \n",
      "Clin Gastroenterol Hepatol 2020; 18: 2179–91.e6.\n",
      "14 \n",
      "Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting \n",
      "items for systematic reviews and meta-analyses: the PRISMA \n",
      "statement. Ann Intern Med 2009; 151: 264–69.\n",
      "15 \n",
      "Jansen JP, Fleurence R, Devine B, et al. Interpreting indirect \n",
      "treatment comparisons and network meta-analysis for health-care \n",
      "decision making: report of the ISPOR Task Force on Indirect \n",
      "Treatment Comparisons Good Research Practices: part 1. \n",
      "Value Health 2011; 14: 417–28.\n",
      "16 \n",
      "Sterne JAC, Savović J, Page MJ, et al. RoB 2: a revised tool for \n",
      "assessing risk of bias in randomised trials. BMJ 2019; 366: l4898.\n",
      "17 \n",
      "Rücker G, Schwarzer G. Ranking treatments in frequentist network \n",
      "meta-analysis works without resampling methods. \n",
      "BMC Med Res Methodol 2015; 15: 58.\n",
      "----------\n",
      "Articles\n",
      "www.thelancet.com/gastrohep   Vol 7   February 2022 \n",
      "161\n",
      "Lancet Gastroenterol Hepatol \n",
      "2022; 7: 161–70\n",
      "Published Online \n",
      "November 29, 2021 \n",
      "https://doi.org/10.1016/ \n",
      "S2468-1253(21)00377-0\n",
      "See Comment page 110\n",
      "*Contributed equally\n",
      "Inflammatory Bowel Disease \n",
      "Unit, Gastroenterology \n",
      "Section, Department of \n",
      "Internal Medicine, Centro de \n",
      "Educación Médica e \n",
      "Investigaciones Clínicas, \n",
      "Buenos Aires, Argentina \n",
      "(J S Lasa MD, P A Olivera MD); \n",
      "Gastroenterology Department, \n",
      "Hospital Británico de Buenos \n",
      "Aires, Buenos Aires, Argentina \n",
      "(J S Lasa); Zane Cohen Centre \n",
      "for Digestive Diseases, \n",
      "Lunenfeld-Tanenbaum \n",
      "Research Institute, Sinai Health \n",
      "System, Toronto, ON, Canada \n",
      "(P A Olivera); Division of \n",
      "Gastroenterology, Mount Sinai \n",
      "Hospital, University of Toronto, \n",
      "Toronto, ON, Canada \n",
      "(P A Olivera); Gastroenterology \n",
      "and Endoscopy, IRCCS Ospedale \n",
      "San Raffaele and University \n",
      "Vita-Salute San Raffaele, \n",
      "Milano, Italy \n",
      "(Prof S Danese MD); INSERM \n",
      "NGERE and Department of \n",
      "Hepatogastroenterology, \n",
      "Nancy University Hospital, \n",
      "Lorraine University, \n",
      "Vandoeuvre-lés-Nancy, France \n",
      "(Prof L Peyrin-Biroulet MD) \n",
      "Correspondence to: \n",
      "Prof Laurent Peyrin-Biroulet, \n",
      "INSERM NGERE and Department \n",
      "of Hepatogastroenterology, \n",
      "Nancy University Hospital, \n",
      "Lorraine University, Vandoeuvre-\n",
      "lès-Nancy F-54511, France \n",
      "peyrinbiroulet@gmail.com\n",
      "Efficacy and safety of biologics and small molecule drugs for \n",
      "patients with moderate-to-severe ulcerative colitis: \n",
      "a systematic review and network meta-analysis \n",
      "Juan S Lasa*, Pablo A Olivera*, Silvio Danese, Laurent Peyrin-Biroulet\n",
      "Summary\n",
      "Background There is a growing armamentarium for the treatment of moderate-to-severe ulcerative colitis. We aimed \n",
      "to compare the relative efficacy and safety of biologics and small molecule drugs for the treatment of patients with \n",
      "moderate-to-severe ulcerative colitis.\n",
      "Methods In this systematic review and network meta-analysis, we searched MEDLINE, Embase, and the Cochrane \n",
      "Central Register of Controlled Trials without language restrictions for articles published between Jan 1, 1990, and \n",
      "July 1, 2021. Major congresses’ databases from Jan 1, 2018, to July 3, 2021, were reviewed manually. Phase 3, placebo-\n",
      "controlled or head-to-head randomised controlled trials (RCTs) assessing the efficacy and safety of biologics or small \n",
      "molecule drugs as induction or maintenance therapies for patients with moderate-to-severe ulcerative colitis were\n",
      "----------\n",
      "Therapeutic strategies for the management of recentlydiagnosedulcerative colitis. IMMs include thiopurines and methotrexate. 5-ASA, 5-amino salicylic acid; ASUC, acute severe ulcerative colitis; IPAA, ileal pouch anal anastomosis.\n",
      "\n",
      "Risk stratification: Mild\n",
      "Clinical features: NA\n",
      "Treatment options: 5-ASA (oral and/or topical)\n",
      "\n",
      "Risk stratification: Moderate\n",
      "Clinical features: NA\n",
      "Treatment options: Can consider 5-ASA (with rapid step-up if inadequate response)\n",
      "\n",
      "Risk stratification: Moderate\n",
      "Clinical features: NA\n",
      "Treatment options: VDZ or UST\n",
      "\n",
      "Risk stratification: Moderate\n",
      "Clinical features: NA\n",
      "Treatment options: Thiopurine\n",
      "\n",
      "Risk stratification: Moderate\n",
      "Clinical features: NA\n",
      "Treatment options: TNFi +/- IMM\n",
      "\n",
      "Risk stratification: Severe\n",
      "Clinical features: NA\n",
      "Treatment options: TNFi +/- IMM\n",
      "\n",
      "Risk stratification: Severe\n",
      "Clinical features: NA\n",
      "Treatment options: Subtotal colectomy + IPAA or cyclosporine (for ASUC)\n",
      "\n",
      "Risk stratification: Additional consideration: EIM present\n",
      "Clinical features: Psoriasis or psoriatic arthritis\n",
      "Treatment options: UST\n",
      "\n",
      "Risk stratification: Additional consideration: EIM present\n",
      "Clinical features: Other arthritis\n",
      "Treatment options: TNFi\n",
      "\n",
      "\n",
      "----------\n",
      "Burr et al. \n",
      " \n",
      "5 of 45 \n",
      "STUDY HIGHLIGHTS \n",
      " \n",
      "What is already known about this subject \n",
      "• Ulcerative colitis (UC) follows a relapsing and remitting course, with intermittent \n",
      "flares of disease activity, some of which may be moderate to severe. \n",
      "• These are usually treated with corticosteroids, which have potentially serious adverse \n",
      "effects, so biological therapies and small molecules have been developed and licensed \n",
      "for this indication.  \n",
      "• Although previous network meta-analyses have compared their efficacy and safety, \n",
      "this is a rapidly moving field, and there are already several newer drugs that have \n",
      "shown efficacy in phase III clinical trials that were not considered in these. \n",
      " \n",
      "What are the new findings \n",
      "• In terms of clinical remission and clinical response, upadacitinib 45mg o.d. ranked \n",
      "first in all patients, in patients previously exposed to anti-tumour necrosis factor \n",
      "(TNF)-α therapies, and in patients naïve to these drugs.  \n",
      "• In terms of endoscopic improvement infliximab 10mg/kg ranked first, followed by \n",
      "upadacitinib 45mg o.d., and infliximab 5mg/kg.  \n",
      "• However, for endoscopic improvement again upadacitinib 45mg o.d. ranked first in \n",
      "patients previously exposed to anti-TNF-α therapies, and in patients who were anti-\n",
      "TNF-α naïve.  \n",
      "• None of the drugs studied were more likely to lead to serious adverse events than \n",
      "placebo.\n",
      "----------\n",
      "associated with improved long-term outcomes.33 Data on\n",
      "the impact of early therapy in UC are more limited, but, as\n",
      "UC is also a progressive disease with risk of colorectal\n",
      "cancer, surgery, and loss of colonic function, it is reasonable\n",
      "to treat early to mitigate these risks.\n",
      "How to Diagnose Inﬂammatory Bowel Disease\n",
      "Early\n",
      "IBD is heterogenous with wide variation in presentation.\n",
      "Disease activity at presentation can range from mild to severe\n",
      "and, as discussed, symptoms may be mild to none. These can\n",
      "make the IBD diagnosis challenging, especially at a primary\n",
      "care level. Danese et al34 have proposed a Red Flags Index\n",
      "consisting of a 21-item questionnaire to help providers triage\n",
      "and identify patients with concerning symptoms in a timely\n",
      "manner and refer to specialists appropriately. A useful adjunct\n",
      "to symptom-based criteria is fecal calprotectin (FC), a stool\n",
      "marker of inﬂammation; in a large meta-analysis, FC � 40 mg/\n",
      "g carried a �1% probability of IBD, effectively excluding the\n",
      "diagnosis of IBD.35 Similarly, in the Red Flags Index validation\n",
      "study, combining the index with FC (Red Flags Index �8 and/\n",
      "or FC >250 mg/g) increased the positive predictive value from\n",
      "4% to 21% and negative predictive value from 97% to\n",
      "100%.36 Diagnostic criteria for IBD involve a composite of\n",
      "clinical symptoms, endoscopic, biomarker, and cross-sectional\n",
      "imaging features, which are beyond the scope of this review.\n",
      "We refer readers to the excellent guidelines laid out by the\n",
      "American College of Gastroenterology, European Crohn’s and\n",
      "Colitis\n",
      "Organization,\n",
      "and\n",
      "British\n",
      "Society\n",
      "of\n",
      "Gastro-\n",
      "enterology.37–40\n",
      "Risk Stratiﬁcation and Prognostication\n",
      "at Diagnosis\n",
      "Appropriately\n",
      "risk-stratifying\n",
      "prognosis\n",
      "in\n",
      "patients\n",
      "recently diagnosed with IBD is essential to inform selection\n",
      "of the most appropriate treatment and monitoring strate-\n",
      "gies. CD and UC phenotype and disease activity at initial\n",
      "presentation can vary widely from limited and mild to\n",
      "extensive and complicated. Certain baseline clinical features\n",
      "are associated with a more aggressive disease course with\n",
      "higher risk of progression and complications. In higher-risk\n",
      "patients, early control of inﬂammation with immune-\n",
      "modifying therapies is critical. However, immunosuppres-\n",
      "sive therapies are associated with safety concerns in the\n",
      "short- and long-term, and entail signiﬁcant health care costs.\n",
      "Therefore, a consideration of risks, beneﬁts, and alternatives\n",
      "is key to develop an individualized therapeutic plan for the\n",
      "informed patient.\n",
      "----------\n",
      "discontinuation due to AEs, and serious infections. Phase 3 randomized controlled trials were identified via systematic literature review, in-\n",
      "cluding the following advanced therapies: infliximab, adalimumab, vedolizumab, golimumab, tofacitinib, ustekinumab, filgotinib, ozanimod, and \n",
      "upadacitinib. Random effects models were used to address between-study heterogeneity. Intent-to-treat (ITT) efficacy rates were calculated by \n",
      "adjusting maintenance outcomes by likelihood of induction response.\n",
      "Results:  Out of 48 trials identified, 23 were included. Across all outcomes and regardless of prior biologic exposure, ITT efficacy rates were \n",
      "highest for upadacitinib, owing to its highest ranking for all efficacy outcomes in induction and for all but clinical remission during maintenance \n",
      "among bio-naive induction responders. For all advanced therapies versus placebo, there were no significant differences in serious AEs or \n",
      "serious infections across therapies. For all AEs, golimumab had higher odds versus placebo during maintenance; for discontinuation due to \n",
      "AEs, upadacitinib had lower odds versus placebo during induction, while ustekinumab and vedolizumab had lower odds versus placebo during \n",
      "maintenance.\n",
      "Conclusions:  Upadacitinib may be the most efficacious therapy for moderately to severely active UC based on ITT analyses, with similar safety \n",
      "across advanced therapies.\n",
      "Lay Summary \n",
      "Indirect evidence suggests upadacitinib may be more efficacious than other advanced therapies at achieving clinical response, clinical remis-\n",
      "sion, and endoscopic response over 1 year for moderately to severely active ulcerative colitis patients, with similar safety assessments across \n",
      "advanced therapies.\n",
      "Key Words: ulcerative colitis, clinical trials, advanced therapies, network meta-analysis\n",
      "Introduction\n",
      "Ulcerative colitis (UC) is a chronic inflammatory bowel dis-\n",
      "ease that affects the colorectum and is clinically characterized \n",
      "by bloody diarrhea, urgency, tenesmus, abdominal pain, ma-\n",
      "laise, weight loss, and fever. Disease onset commonly occurs \n",
      "between the ages of 15 and 30 years and the annual global \n",
      "© The Author(s) 2023. Published by Oxford University Press on behalf of Crohn's & Colitis Foundation.\n",
      "This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), \n",
      "which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.\n",
      "----------\n",
      "prognosis, with 1 study reporting fewer hospitalizations and\n",
      "less frequent requirement of immunosuppression in pa-\n",
      "tients diagnosed after age 60 years,47 and a meta-analysis\n",
      "suggested\n",
      "that,\n",
      "although\n",
      "elderly\n",
      "IBD\n",
      "presents\n",
      "less\n",
      "commonly with complications, there are similar or higher\n",
      "rates of surgery compared to a nonelderly population.48 It is\n",
      "being increasingly recognized that frailty, rather than\n",
      "chronologic age, may be the driver of adverse outcomes in\n",
      "this group.49,50\n",
      "Other Demographic Variables\n",
      "There are signiﬁcant differences in IBD phenotype\n",
      "and outcomes based on race and ethnicity, likely due to\n",
      "a multitude of factors, both social and biologic. Emer-\n",
      "gency department use, hospitalization, complicated dis-\n",
      "ease\n",
      "course,\n",
      "and\n",
      "IBD-related\n",
      "disability\n",
      "are\n",
      "more\n",
      "common in minority and lower socioeconomic status\n",
      "groups.51,52 In a study of 770 patients with IBD, South\n",
      "Asian immigrants living in the United Kingdom were\n",
      "more\n",
      "likely\n",
      "to\n",
      "have\n",
      "extensive\n",
      "UC\n",
      "and\n",
      "colonic\n",
      "CD\n",
      "compared with their native counterparts,53 which might\n",
      "be related, in part, to limited access to care.54 Genes\n",
      "implicated in IBD risk also differ in non-White compared\n",
      "with White patients with IBD.55 Being aware of the\n",
      "higher vulnerability to adverse IBD-related outcomes in\n",
      "these vulnerable groups should prompt careful moni-\n",
      "toring to limit adverse outcomes.\n",
      "There are increasing data on sex-based differences in\n",
      "IBD phenotype and outcomes, which may signal differences\n",
      "in pathogenic pathways and progression. Of note, extra-\n",
      "intestinal manifestations (EIMs) consistently tend to be\n",
      "more common in female patients (CD: OR, 2.3; 95% CI, 1.9–\n",
      "2.8 and UC: OR, 1.5; 95% CI, 1.1–2.3, in a large Dutch Bio-\n",
      "Bank).56 Similarly, in a retrospective pediatric study of\n",
      "nearly 1000 patients with CD, girls were more likely to have\n",
      "EIMs and less likely to have growth impairment compared\n",
      "with boys,57 the latter is possibly related to lower insulin-\n",
      "like growth factor-1 level in boys.58\n",
      "July 2021\n",
      "Management of early IBD\n",
      "49\n",
      "REVIEWS AND\n",
      "PERSPECTIVES\n",
      "==========\n",
      "ORIGINAL QUESTION: ANALYSE the given patient profile based on given query based on one of the following criteria:\n",
      "- Whether treated patient is new patient or patient under maintenance\n",
      "- Prior response to Infliximab\n",
      "- Prior failure to Anti-TNF agents\n",
      "- Prior failure to Vedolizumab\n",
      "- Age\n",
      "- Pregnancy\n",
      "- Extraintestinale manifestations\n",
      "- Pouchitis\n",
      "RETURN up to 2 TOP choices of biological drugs given patient profile and context. Explain the PROS and CONS of the 2 choices.\n",
      "PATIENT PROFILE: 55 year-old man with moderate to severe extensive ulcerative colitis who avlues convenience and limited time spent in hospital\n",
      "\n",
      "==========\n",
      "CURRENT ANSWER:\n",
      "Based on the given patient profile, the patient is a 55-year-old male with moderate to severe extensive ulcerative colitis. The patient values convenience and limited time spent in the hospital. However, the context does not provide information on whether the patient is new or under maintenance, prior response to Infliximab, prior failure to Anti-TNF agents, prior failure to Vedolizumab, pregnancy status, extraintestinal manifestations, or pouchitis. \n",
      "\n",
      "Given the patient's preference for convenience and limited hospital time, subcutaneous or oral administration of medication might be more suitable. \n",
      "\n",
      "Based on the available context, the top two choices of biological drugs could be:\n",
      "\n",
      "1. Ustekinumab: \n",
      "   - Advantages: It has shown efficacy in clinical trials for moderate to severe UC. It is administered subcutaneously, which may be more convenient for the patient.\n",
      "   - Disadvantages: The context does not provide specific disadvantages for Ustekinumab. However, like all drugs, it may not work for all patients and there may be risks associated with its use.\n",
      "\n",
      "2. Tofacitinib:\n",
      "   - Advantages: Tofacitinib is a small molecule drug that can be taken orally, providing a convenient mode of administration for the patient.\n",
      "   - Disadvantages: The context does not provide specific disadvantages for Tofacitinib. However, like all drugs, it may not work for all patients and there may be risks associated with its use.\n",
      "\n",
      "Please note that the choice of treatment should be individualized based on the patient's specific condition, preferences, and potential side effects of the drugs. The patient should have a detailed discussion with their healthcare provider to decide on the best treatment option.\n",
      "==========\n",
      "REFINED ANSWER:\n",
      "\u001b[0m\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "Retrying langchain.chat_models.openai.ChatOpenAI.completion_with_retry.<locals>._completion_with_retry in 4.0 seconds as it raised RateLimitError: Rate limit reached for 10KTPM-200RPM in organization org-ETbTMTN2JXYOUPDJgxuH2iO6 on tokens per min. Limit: 10000 / min. Please try again in 6ms. Contact us through our help center at help.openai.com if you continue to have issues..\n",
      "Retrying langchain.chat_models.openai.ChatOpenAI.completion_with_retry.<locals>._completion_with_retry in 4.0 seconds as it raised RateLimitError: Rate limit reached for 10KTPM-200RPM in organization org-ETbTMTN2JXYOUPDJgxuH2iO6 on tokens per min. Limit: 10000 / min. Please try again in 6ms. Contact us through our help center at help.openai.com if you continue to have issues..\n",
      "Retrying langchain.chat_models.openai.ChatOpenAI.completion_with_retry.<locals>._completion_with_retry in 4.0 seconds as it raised RateLimitError: Rate limit reached for 10KTPM-200RPM in organization org-ETbTMTN2JXYOUPDJgxuH2iO6 on tokens per min. Limit: 10000 / min. Please try again in 6ms. Contact us through our help center at help.openai.com if you continue to have issues..\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\n",
      "\u001b[1m> Finished chain.\u001b[0m\n",
      "\n",
      "\u001b[1m> Finished chain.\u001b[0m\n",
      "2023-10-02 17:30:28,326:INFO: 5764 tokens were added to prompt from 10 documents\n",
      "Query: 60 year-old woman with severe ulcerative colitis that has loss response to anti-TNF, vedolizumab and ustekinumab\n",
      "\n",
      "\n",
      "\n",
      "\u001b[1m> Entering new SequentialChain chain...\u001b[0m\n",
      "\n",
      "\n",
      "\u001b[1m> Entering new RetrievalQAWithSourcesChain chain...\u001b[0m\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "Retrying langchain.chat_models.openai.ChatOpenAI.completion_with_retry.<locals>._completion_with_retry in 4.0 seconds as it raised RateLimitError: Rate limit reached for 10KTPM-200RPM in organization org-ETbTMTN2JXYOUPDJgxuH2iO6 on tokens per min. Limit: 10000 / min. Please try again in 6ms. Contact us through our help center at help.openai.com if you continue to have issues..\n",
      "Retrying langchain.chat_models.openai.ChatOpenAI.completion_with_retry.<locals>._completion_with_retry in 4.0 seconds as it raised RateLimitError: Rate limit reached for 10KTPM-200RPM in organization org-ETbTMTN2JXYOUPDJgxuH2iO6 on tokens per min. Limit: 10000 / min. Please try again in 6ms. Contact us through our help center at help.openai.com if you continue to have issues..\n",
      "Retrying langchain.chat_models.openai.ChatOpenAI.completion_with_retry.<locals>._completion_with_retry in 4.0 seconds as it raised RateLimitError: Rate limit reached for 10KTPM-200RPM in organization org-ETbTMTN2JXYOUPDJgxuH2iO6 on tokens per min. Limit: 10000 / min. Please try again in 6ms. Contact us through our help center at help.openai.com if you continue to have issues..\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\n",
      "\u001b[1m> Finished chain.\u001b[0m\n",
      "\n",
      "\n",
      "\u001b[1m> Entering new LLMChain chain...\u001b[0m\n",
      "Prompt after formatting:\n",
      "\u001b[32;1m\u001b[1;3mYou are a senior physician giving advice on treatment for moderate to severe ulcerative colitis (UC).\n",
      "Make reference to the CONTEXT given to assess the scenario.\n",
      "==========\n",
      "TASK: Your task is to analyse critically the CURRENT ANSWER given the CONTEXT.\n",
      "Then refine the existing answer (only if needed) based on the following instructions:\n",
      "- If no refinement needed, return the original answer in the correct output format.\n",
      "- If the answer cannot be inferred from CONTEXT, return \"NO ANSWER\".\n",
      "- The final output should be a list of up to 2 choices of biological drugs given patient profile and context and PROS/CONS for each recommendations.\n",
      "==========\n",
      "CONTEXT:\n",
      "What You Need to Know\n",
      "Background\n",
      "A systematic review and network meta-analysis is\n",
      "needed to compare efﬁcacy and safety of ﬁrst-line\n",
      "(biologic-naïve) and second-line (prior exposure to\n",
      "tumor necrosis factor [TNF] antagonists) agents for\n",
      "treatment of moderate to severely active ulcerative\n",
      "colitis.\n",
      "Findings\n",
      "Inﬂiximab was ranked highest in biologic-naïve pa-\n",
      "tients, and ustekinumab and tofacitinib were ranked\n",
      "highest in patients with prior exposure to TNF an-\n",
      "tagonists, for induction of remission and endoscopic\n",
      "improvement. More trials of direct comparisons are\n",
      "needed to inform clinical decision-making with\n",
      "greater conﬁdence.\n",
      "Implications for patient care\n",
      "Patients with moderate to severely active ulcerative\n",
      "colitis should receive inﬂiximab or vedolizumab as\n",
      "ﬁrst-line therapy, or ustekinumab or tofacitinib if\n",
      "they have prior exposure to TNF antagonists.\n",
      "2180 Singh et al\n",
      "Clinical Gastroenterology and Hepatology Vol. 18, No. 10\n",
      "----------\n",
      "disease); ozanimod as an oral alternative\n",
      "• Infliximab, preferably in combination with  \n",
      " immunomodulators (severe disease,  \n",
      " \n",
      " extraintestinal manifestations)\n",
      "• Ustekinumab (for patients with substantial \n",
      " comorbidities or  contraindications to TNF  \n",
      " antagonists)\n",
      "First-line therapy\n",
      "• TNF antagonists: infliximab or adalimumab,  \n",
      " preferably in combination with   \n",
      " \n",
      " \n",
      " immunomodulators\n",
      "• Risankizumab or ustekinumab (for patients  \n",
      " with substantial comorbidities or  \n",
      " \n",
      " \n",
      " contraindications to TNF antagonists)\n",
      "First-line therapy\n",
      "• Vedolizumab\n",
      "• Ustekinumab\n",
      "First-line therapy\n",
      "• Risankizumab or ustekinumab\n",
      "• Vedolizumab\n",
      "Moderate-to-severely active\n",
      "ulcerative colitis\n",
      "Moderate-to-severely active\n",
      "ulcerative colitis\n",
      "Moderate-to-severely active\n",
      "Crohn's disease\n",
      "Moderate-to-severely active\n",
      "Crohn's disease\n",
      "Second-line therapy\n",
      "• Upadacitinib (or tofacitinib) (for patients with  \n",
      " prior failure of infliximab)\n",
      "• Infliximab or ustekinumab (for patients with  \n",
      " prior exposure to vedolizumab)\n",
      "• Vedolizumab (moderate disease, for patients  \n",
      " who discontinued first-line biologic agent \n",
      " for intolerance)\n",
      "Second-line therapy (in patients with prior \n",
      "exposure to infliximab or adalimumab)\n",
      "• Risankizumab or ustekinumab\n",
      "• Second TNF antagonist (for patients with  \n",
      " loss of response owing to immunogenicity,  \n",
      " or  intolerance, to first TNF antagonist)\n",
      "Second-line therapy\n",
      "• Ozanimod\n",
      "• Infliximab monotherapy\n",
      "• Upadacitinib (or tofacitinib)\n",
      "Second-line therapy\n",
      "• Infliximab or adalimumab   \n",
      " monotherapy\n",
      "Risk averse\n",
      "• Prior serious infections\n",
      "• Prior malignancy\n",
      "• Older age, multiple comorbidities\n",
      "Severe disease\n",
      "• High structural damage\n",
      "• High inflammatory burden\n",
      "• Significant efect on quality of life\n",
      "Patients’ values and preferences\n",
      "(lifestyle and logistics, speed of onset, costs)\n",
      "Fig. 1 | Proposed treatment algorithm for patients with moderate-to-severe \n",
      "Crohn’s disease and moderate-to-severe ulcerative colitis. The algorithm \n",
      "integrates data on comparative effectiveness and safety of therapies in the \n",
      "context of an individual patient’s risk of disease-related and treatment-related \n",
      "complications. TNF, tumour necrosis factor. Adapted with permission from  \n",
      "ref. 10, Elsevier.\n",
      "----------\n",
      "Burr et al. \n",
      " \n",
      "5 of 45 \n",
      "STUDY HIGHLIGHTS \n",
      " \n",
      "What is already known about this subject \n",
      "• Ulcerative colitis (UC) follows a relapsing and remitting course, with intermittent \n",
      "flares of disease activity, some of which may be moderate to severe. \n",
      "• These are usually treated with corticosteroids, which have potentially serious adverse \n",
      "effects, so biological therapies and small molecules have been developed and licensed \n",
      "for this indication.  \n",
      "• Although previous network meta-analyses have compared their efficacy and safety, \n",
      "this is a rapidly moving field, and there are already several newer drugs that have \n",
      "shown efficacy in phase III clinical trials that were not considered in these. \n",
      " \n",
      "What are the new findings \n",
      "• In terms of clinical remission and clinical response, upadacitinib 45mg o.d. ranked \n",
      "first in all patients, in patients previously exposed to anti-tumour necrosis factor \n",
      "(TNF)-α therapies, and in patients naïve to these drugs.  \n",
      "• In terms of endoscopic improvement infliximab 10mg/kg ranked first, followed by \n",
      "upadacitinib 45mg o.d., and infliximab 5mg/kg.  \n",
      "• However, for endoscopic improvement again upadacitinib 45mg o.d. ranked first in \n",
      "patients previously exposed to anti-TNF-α therapies, and in patients who were anti-\n",
      "TNF-α naïve.  \n",
      "• None of the drugs studied were more likely to lead to serious adverse events than \n",
      "placebo.\n",
      "----------\n",
      "Burr et al. \n",
      " \n",
      "7 of 45 \n",
      "INTRODUCTION \n",
      "  Ulcerative colitis (UC) is a chronic inflammatory disorder of the bowel that causes \n",
      "continuous mucosal inflammation commencing in the rectum and extending proximally for a \n",
      "variable extent.[1] It is estimated that UC affects 2.5 million people in Europe,[2] and the \n",
      "disease follows a relapsing and remitting course, with intermittent flares of disease activity, \n",
      "some of which may be moderate to severe. Management of these is medical, for the most \n",
      "part, with surgery reserved for patients with refractory disease. Although 5-aminosalicylates \n",
      "(5-ASAs) are efficacious for mild to moderate disease activity,[3-6] more severe flares are \n",
      "usually treated with corticosteroids.[7] However, these have potentially serious adverse \n",
      "effects and a substantial proportion of patients may become either dependent on them to \n",
      "maintain remission,[8] or refractory to them.[9] As a result, over the last 20 years novel \n",
      "drugs, with more precise modes of action, based on mechanisms of disease identified in \n",
      "genome wide association studies,[10] have been developed.  \n",
      "The first of these agents was infliximab, a drug targeting the pro-inflammatory \n",
      "cytokine tumour necrosis factor-α (TNF-α), which demonstrated efficacy in clinical trials in \n",
      "moderate to severe UC.[11] Since then, other drugs against TNF-α have been tested, such as \n",
      "adalimumab and golimumab.[12, 13] In addition, newer biological therapies targeting α or β \n",
      "integrins, which are involved in migration of immune cells to inflamed intestinal mucosa, \n",
      "such as vedolizumab or etrolizumab,[14, 15] or acting against other pro-inflammatory \n",
      "cytokines implicated in the pathogenesis of UC, such as ustekinumab,[16] have been tested. \n",
      "However, even these more selective drugs do not work in all patients, there may be risks \n",
      "associated with their use,[17-19] and the fact that they are administered either intravenously \n",
      "or subcutaneously, may be inconvenient for patients. The search for alternative agents for the \n",
      "treatment of UC has, therefore, continued.\n",
      "----------\n",
      "SYSTEMATIC REVIEWS AND META-ANALYSES\n",
      "Siddharth Singh, Section Editor\n",
      "First- and Second-Line Pharmacotherapies for Patients With\n",
      "Moderate to Severely Active Ulcerative Colitis: An Updated\n",
      "Network Meta-Analysis\n",
      "Siddharth Singh,*,‡ Mohammad Hassan Murad,§ Mathurin Fumery,j\n",
      "Parambir S. Dulai,* and William J. Sandborn*\n",
      "*Division of Gastroenterology, ‡Division of Biomedical Informatics, University of California San Diego, La Jolla, California;\n",
      "§Robert D and Patricia E Kern Center for the Science of Health Care Delivery, Mayo Clinic, Rochester, Minnesota;\n",
      "||Gastroenterology Unit, Peritox UMR I-0I, Amiens University and Hospital, Université de Picardie Jules Verne, Amiens, France\n",
      "BACKGROUND & AIMS:\n",
      "We compared the efﬁcacy and safety of different ﬁrst-line (biologic-naïve) and second-line\n",
      "(prior exposure to tumor necrosis factor [TNF] antagonists) agents for treatment of moder-\n",
      "ate to severely active ulcerative colitis in a systematic review and network meta-analysis.\n",
      "METHODS:\n",
      "We searched publication databases through September 30, 2019, for randomized trials of\n",
      "adults with moderate to severe ulcerative colitis treated with TNF antagonists, vedolizumab,\n",
      "tofacitinib, or ustekinumab, as ﬁrst-line or second-line agents, compared with placebo or\n",
      "another active agent. Efﬁcacy outcomes were induction and maintenance of remission and\n",
      "endoscopic improvement; safety outcomes were serious adverse events and infections. We\n",
      "performed a ﬁxed-effects network meta-analysis using the frequentist approach, and calculated\n",
      "odds ratios (ORs) and 95% CI values. Agents were ranked using surface under the cumulative\n",
      "ranking (SUCRA) probabilities. Overall quality of evidence was rated using GRADE (Grading of\n",
      "Recommendations, Assessment, Development and Evaluation).\n",
      "RESULTS:\n",
      "In biologic-naïve patients, inﬂiximab was ranked highest for induction of clinical remission (OR\n",
      "vs placebo, 4.07; 95% CI, 2.67–6.21; SUCRA, 0.95) and endoscopic improvement (SUCRA, 0.95)\n",
      "(moderate conﬁdence in estimates [CE]). In patients with prior exposure to TNF antagonists,\n",
      "ustekinumab (SUCRA, 0.87) and tofacitinib (SUCRA, 0.87) were ranked highest for induction of\n",
      "clinical remission and were superior to vedolizumab (ustekinumab vs vedolizumab: OR, 5.99;\n",
      "95% CI, 1.13–31.76 and tofacitinib vs vedolizumab: OR, 6.18; 95% CI, 1.003–8.00; moderate CE)\n",
      "and adalimumab (ustekinumab vs adalimumab: OR, 10.71; 95% CI, 2.01–57.20 and tofacitinib\n",
      "----------\n",
      "discontinuation due to AEs, and serious infections. Phase 3 randomized controlled trials were identified via systematic literature review, in-\n",
      "cluding the following advanced therapies: infliximab, adalimumab, vedolizumab, golimumab, tofacitinib, ustekinumab, filgotinib, ozanimod, and \n",
      "upadacitinib. Random effects models were used to address between-study heterogeneity. Intent-to-treat (ITT) efficacy rates were calculated by \n",
      "adjusting maintenance outcomes by likelihood of induction response.\n",
      "Results:  Out of 48 trials identified, 23 were included. Across all outcomes and regardless of prior biologic exposure, ITT efficacy rates were \n",
      "highest for upadacitinib, owing to its highest ranking for all efficacy outcomes in induction and for all but clinical remission during maintenance \n",
      "among bio-naive induction responders. For all advanced therapies versus placebo, there were no significant differences in serious AEs or \n",
      "serious infections across therapies. For all AEs, golimumab had higher odds versus placebo during maintenance; for discontinuation due to \n",
      "AEs, upadacitinib had lower odds versus placebo during induction, while ustekinumab and vedolizumab had lower odds versus placebo during \n",
      "maintenance.\n",
      "Conclusions:  Upadacitinib may be the most efficacious therapy for moderately to severely active UC based on ITT analyses, with similar safety \n",
      "across advanced therapies.\n",
      "Lay Summary \n",
      "Indirect evidence suggests upadacitinib may be more efficacious than other advanced therapies at achieving clinical response, clinical remis-\n",
      "sion, and endoscopic response over 1 year for moderately to severely active ulcerative colitis patients, with similar safety assessments across \n",
      "advanced therapies.\n",
      "Key Words: ulcerative colitis, clinical trials, advanced therapies, network meta-analysis\n",
      "Introduction\n",
      "Ulcerative colitis (UC) is a chronic inflammatory bowel dis-\n",
      "ease that affects the colorectum and is clinically characterized \n",
      "by bloody diarrhea, urgency, tenesmus, abdominal pain, ma-\n",
      "laise, weight loss, and fever. Disease onset commonly occurs \n",
      "between the ages of 15 and 30 years and the annual global \n",
      "© The Author(s) 2023. Published by Oxford University Press on behalf of Crohn's & Colitis Foundation.\n",
      "This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), \n",
      "which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.\n",
      "----------\n",
      "severely active ulcerative colitis: results from phase 3 \n",
      "U-ACCOMPLISH study. J Crohn’s Colitis 2021; 15 (suppl 1): S021–22.\n",
      "9 \n",
      "Thorlund K, Druyts E, Mills EJ, Fedorak RN, Marshall JK. \n",
      "Adalimumab versus infliximab for the treatment of moderate to \n",
      "severe ulcerative colitis in adult patients naïve to anti-TNF therapy: \n",
      "an indirect treatment comparison meta-analysis. J Crohn’s Colitis \n",
      "2014; 8: 571–81.\n",
      "10 \n",
      "Danese S, Fiorino G, Peyrin-Biroulet L, et al. Biological agents for \n",
      "moderately to severely active ulcerative colitis: a systematic review \n",
      "and network meta-analysis. Ann Intern Med 2014; 160: 704–11.\n",
      "11 \n",
      "Singh S, Fumery M, Sandborn WJ, Murad MH. Systematic review \n",
      "with network meta-analysis: first- and second-line pharmacotherapy \n",
      "for moderate-severe ulcerative colitis. Aliment Pharmacol Ther 2018; \n",
      "47: 162–75.\n",
      "12 \n",
      "Bonovas S, Lytras T, Nikolopoulos G, Peyrin-Biroulet L, Danese S. \n",
      "Systematic review with network meta-analysis: comparative \n",
      "assessment of tofacitinib and biological therapies for moderate-to-\n",
      "severe ulcerative colitis. Aliment Pharmacol Ther 2018; 47: 454–65.\n",
      "13 \n",
      "Singh S, Murad MH, Fumery M, Dulai PS, Sandborn WJ. First- and \n",
      "second-line pharmacotherapies for patients with moderate to \n",
      "severely active ulcerative colitis: an updated network meta-analysis. \n",
      "Clin Gastroenterol Hepatol 2020; 18: 2179–91.e6.\n",
      "14 \n",
      "Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting \n",
      "items for systematic reviews and meta-analyses: the PRISMA \n",
      "statement. Ann Intern Med 2009; 151: 264–69.\n",
      "15 \n",
      "Jansen JP, Fleurence R, Devine B, et al. Interpreting indirect \n",
      "treatment comparisons and network meta-analysis for health-care \n",
      "decision making: report of the ISPOR Task Force on Indirect \n",
      "Treatment Comparisons Good Research Practices: part 1. \n",
      "Value Health 2011; 14: 417–28.\n",
      "16 \n",
      "Sterne JAC, Savović J, Page MJ, et al. RoB 2: a revised tool for \n",
      "assessing risk of bias in randomised trials. BMJ 2019; 366: l4898.\n",
      "17 \n",
      "Rücker G, Schwarzer G. Ranking treatments in frequentist network \n",
      "meta-analysis works without resampling methods. \n",
      "BMC Med Res Methodol 2015; 15: 58.\n",
      "----------\n",
      "tients with moderate–severe ulcerative colitis with prior\n",
      "exposure to TNFa antagonists were identiﬁed. These\n",
      "included subgroup analyses of trials of adalimumab,21\n",
      "vedolizumab,24,25\n",
      "tofacitinib,26\n",
      "and\n",
      "ustekinumab.7\n",
      "There were no trials of inﬂiximab or golimumab in\n",
      "patients with prior exposure to TNFa antagonists who\n",
      "met inclusion criteria. In trials of adalimumab, only pa-\n",
      "tients with loss of response or intolerance to a prior\n",
      "TNFa antagonist were included. In contrast, in trials of\n",
      "vedolizumab, 48% to 58% of patients had inadequate\n",
      "response to a TNFa antagonist, and in trials of usteki-\n",
      "numab, 13% to 18% patients had prior exposure to both\n",
      "vedolizumab and TNFa antagonists. These data were not\n",
      "available for tofacitinib.\n",
      "Induction\n",
      "of\n",
      "clinical\n",
      "remission. On\n",
      "direct\n",
      "meta-\n",
      "analysis, tofacitinib and ustekinumab, but not adalimu-\n",
      "mab or vedolizumab, were superior to placebo for induc-\n",
      "tion of clinical remission (Supplementary Figure 3A), with\n",
      "minimal heterogeneity across estimates (I2 < 30%). On\n",
      "network meta-analysis, there was moderate conﬁdence in\n",
      "estimates supporting the use of tofacitinib (OR, 11.88;\n",
      "95% CI, 2.32–60.89) and ustekinumab (OR, 11.51; 95% CI,\n",
      "2.65–49.96), and low conﬁdence in estimates supporting\n",
      "the use of vedolizumab (OR, 1.92; 95% CI, 0.87–4.25) over\n",
      "placebo, for induction of clinical remission in patients with\n",
      "prior exposure to TNFa antagonists (Table 3). On com-\n",
      "parison of active interventions, there was moderate con-\n",
      "ﬁdence in estimates supporting the use of tofacitinib and\n",
      "ustekinumab over adalimumab (tofacitinib vs adalimu-\n",
      "mab: OR, 11.05; 95% CI, 1.79–68.41; ustekinumab vs\n",
      "adalimumab: OR, 10.71; 95% CI, 2.01–57.20), and over\n",
      "vedolizumab (tofacitinib vs vedolizumab: OR, 6.18; 95%\n",
      "CI, 1.00–38.00; ustekinumab vs vedolizumab: OR, 5.99;\n",
      "95% CI, 1.13–31.76) for induction of clinical remission in\n",
      "patients with prior exposure to TNFa antagonists. Overall,\n",
      "ustekinumab (SUCRA, 0.87) and tofacitinib (SUCRA, 0.87)\n",
      "were ranked highest for inducing clinical remission in\n",
      "patients with moderate–severe ulcerative colitis with\n",
      "prior exposure to TNFa antagonists (Figure 2B). With an\n",
      "estimated placebo rate of achieving clinical remission of\n",
      "3% in included trials, we estimated that 3.2%, 5.6%,\n",
      "26.9%, and 26.3% of adalimumab-, vedolizumab-, tofaci-\n",
      "tinib-, and ustekinumab-treated patients, respectively,\n",
      "would achieve induction of remission.\n",
      "Induction of endoscopic improvement. On direct meta-\n",
      "analysis, tofacitinib and ustekinumab, but not vedolizumab\n",
      "----------\n",
      "Colitis, 2020. Comorbidity, not patient age, is associated with impaired safety\n",
      "outcomes in vedolizumab- and ustekinumab-treated patients with inﬂammatory\n",
      "bowel disease-a prospective multicentre cohort study. Aliment. Pharmacol. Ther. 52\n",
      "(8), 1366–1376.\n",
      "Atreya, R., Siegmund, B., 2021. Location is important: differentiation between ileal and\n",
      "colonic crohn's disease. Nat. Rev. Gastroenterol. Hepatol. 18 (8), 544–558.\n",
      "Bek, S., Nielsen, J.V., Bojesen, A.B., Franke, A., Bank, S., Vogel, U., Andersen, V., 2016.\n",
      "Systematic review: genetic biomarkers associated with anti-tnf treatment response in\n",
      "inﬂammatory bowel diseases. Aliment. Pharmacol. Ther. 44 (6), 554–567.\n",
      "Ben-Horin, S., Novack, L., Mao, R., Guo, J., Zhao, Y., Sergienko, R., Zhang, J.,\n",
      "Kobayashi, T., Hibi, T., Chowers, Y., Peyrin-Biroulet, L., Colombel, J.F., Kaplan, G.G.,\n",
      "Chen, M.H., 2021. Efﬁcacy of biologic drugs in short-duration versus long-duration\n",
      "inﬂammatory bowel disease: a systematic review and an individual-patient data\n",
      "meta-analysis of randomized controlled trials. Gastroenterology 162 (2), 482–494.\n",
      "Ben Abdallah, H., Fogh, K., Vestergaard, C., Bech, R., 2021. Pyoderma gangrenosum and\n",
      "interleukin inhibitors: a semi-systematic review. Dermatology 1–8.\n",
      "Billiet, T., Papamichael, K., de Bruyn, M., Verstockt, B., Cleynen, I., Princen, F., Singh, S.,\n",
      "Ferrante, M., Van Assche, G., Vermeire, S., 2015. A matrix-based model predicts\n",
      "primary response to inﬂiximab in crohn's disease. J Crohns Colitis 9 (12), 1120–1126.\n",
      "Bonovas, S., Fiorino, G., Allocca, M., Lytras, T., Nikolopoulos, G.K., Peyrin-Biroulet, L.,\n",
      "Danese, S., 2016. Biologic therapies and risk of infection and malignancy in patients\n",
      "with inﬂammatory bowel disease: a systematic review and network meta-analysis.\n",
      "Clin. Gastroenterol. Hepatol. 14 (10), 1385–1397.\n",
      "Bonovas, S., Lytras, T., Nikolopoulos, G., Peyrin-Biroulet, L., Danese, S., 2018. Systematic\n",
      "review with network meta-analysis: comparative assessment of tofacitinib and\n",
      "biological therapies for moderate-to-severe ulcerative colitis. Aliment. Pharmacol.\n",
      "Ther. 47 (4), 454–465.\n",
      "Bouhnik, Y., Carbonnel, F., Laharie, D., Stefanescu, C., Hebuterne, X., Abitbol, V.,\n",
      "Nachury, M., Brixi, H., Bourreille, A., Picon, L., Bourrier, A., Allez, M., Peyrin-\n",
      "Biroulet, L., Moreau, J., Savoye, G., Fumery, M., Nancey, S., Roblin, X., Altwegg, R.,\n",
      "Bouguen, G., Bommelaer, G., Danese, S., Louis, E., Zappa, M., Mary, J.Y.,\n",
      "Group, G.C.S., 2018. Efﬁcacy of adalimumab in patients with crohn's disease and\n",
      "----------\n",
      "investigators for all trials, except trials of tofacitinib and\n",
      "ustekinumab, which were read by blinded central\n",
      "readers.7,26 Overall, the studies were deemed to be at\n",
      "low risk of bias, and all included studies were industry-\n",
      "sponsored.\n",
      "Induction Therapy\n",
      "First-line\n",
      "pharmacotherapy\n",
      "for\n",
      "moderate–severe\n",
      "ulcerative colitis. Overall, 15 RCTs including 3747 bio-\n",
      "logic-naïve patients with moderate–severe ulcerative\n",
      "colitis, treated with inﬂiximab (4 trials, 667 patients),\n",
      "adalimumab (4 trials, 1046 patients), golimumab (2 tri-\n",
      "als, 586 patients), vedolizumab (3 trials, 630 patients),\n",
      "tofacitinib (2 trials, 520 patients), and ustekinumab (1\n",
      "trial, 298 patients) were included; 1 trial compared\n",
      "adalimumab vs vedolizumab.\n",
      "Induction\n",
      "of\n",
      "clinical\n",
      "remission. On\n",
      "direct\n",
      "meta-\n",
      "analysis, all agents were superior to placebo for induc-\n",
      "tion of clinical remission, and effect size was strongest\n",
      "for inﬂiximab (OR, 4.07; 95% CI, 2.68–6.16) and vedoli-\n",
      "zumab (OR, 3.10; 95% CI, 1.53–6.26), with minimal to\n",
      "moderate heterogeneity across estimates (I2 < 35%)\n",
      "(Supplementary Figure 2A). On network meta-analysis,\n",
      "compared with placebo there was moderate conﬁdence\n",
      "in\n",
      "estimates\n",
      "supporting\n",
      "the\n",
      "use\n",
      "of\n",
      "inﬂiximab,\n",
      "adalimumab, golimumab, vedolizumab, tofacitinib, and\n",
      "ustekinumab for induction of clinical remission in bio-\n",
      "logic-naïve patients (evidence was rated down owing to\n",
      "imprecision caused by a low event rate) (Table 2). On\n",
      "comparison of active interventions, there was moderate\n",
      "conﬁdence in estimates supporting the use of inﬂiximab\n",
      "over adalimumab (OR, 2.10; 95% CI, 1.16–3.79); none of\n",
      "the other comparisons between active interventions\n",
      "were signiﬁcantly different (Table 2). Overall, inﬂiximab\n",
      "(SUCRA, 0.95) was ranked highest for inducing clinical\n",
      "remission\n",
      "in\n",
      "biologic-naïve\n",
      "patients\n",
      "with\n",
      "moderate–severe UC (Figure 2A). With an estimated\n",
      "placebo rate of achieving remission of 10% in included\n",
      "trials, we anticipate that 31.1%, 17.7%, 23.7%, 22.0%,\n",
      "Figure 2. (A) Relative efﬁ-\n",
      "cacy\n",
      "of\n",
      "different\n",
      "in-\n",
      "terventions for induction of\n",
      "clinical\n",
      "remission\n",
      "and\n",
      "endoscopic\n",
      "improvement\n",
      "in biologic-naïve patients\n",
      "with moderate to severely\n",
      "active ulcerative colitis. (B)\n",
      "Relative\n",
      "efﬁcacy\n",
      "of\n",
      "different interventions for\n",
      "induction of clinical remis-\n",
      "sion\n",
      "and\n",
      "endoscopic\n",
      "improvement\n",
      "in\n",
      "patients\n",
      "with moderate to severely\n",
      "active\n",
      "ulcerative\n",
      "colitis\n",
      "with prior exposure to tu-\n",
      "mor necrosis factor (TNF)⍺\n",
      "antagonists. SUCRA, sur-\n",
      "face under the cumulative\n",
      "ranking.\n",
      "September 2020\n",
      "Management of Moderate–Severe UC 2185\n",
      "==========\n",
      "ORIGINAL QUESTION: ANALYSE the given patient profile based on given query based on one of the following criteria:\n",
      "- Whether treated patient is new patient or patient under maintenance\n",
      "- Prior response to Infliximab\n",
      "- Prior failure to Anti-TNF agents\n",
      "- Prior failure to Vedolizumab\n",
      "- Age\n",
      "- Pregnancy\n",
      "- Extraintestinale manifestations\n",
      "- Pouchitis\n",
      "RETURN up to 2 TOP choices of biological drugs given patient profile and context. Explain the PROS and CONS of the 2 choices.\n",
      "PATIENT PROFILE: 60 year-old woman with severe ulcerative colitis that has loss response to anti-TNF, vedolizumab and ustekinumab\n",
      "\n",
      "==========\n",
      "CURRENT ANSWER:\n",
      "Based on the patient's profile, the top two choices of biological drugs would be:\n",
      "\n",
      "1. Infliximab\n",
      "   - Advantages: Infliximab has been ranked highest for induction of clinical remission and endoscopic improvement in biologic-naïve patients. It has also shown efficacy in patients with severe disease and extraintestinal manifestations when used in combination with immunomodulators.\n",
      "   - Disadvantages: Infliximab is administered intravenously which may be inconvenient for some patients. There may also be risks associated with its use, such as serious infections and malignancy. The patient's older age and potential comorbidities may also impact the safety outcomes of this treatment.\n",
      "\n",
      "2. Tofacitinib\n",
      "   - Advantages: Tofacitinib has been ranked highest in patients with prior exposure to TNF antagonists for induction of remission and endoscopic improvement. It is an oral medication which may be more convenient for patients compared to intravenous or subcutaneous therapies.\n",
      "   - Disadvantages: Tofacitinib may not be as effective in patients who have had prior exposure to multiple biologics, including anti-TNF agents, vedolizumab, and ustekinumab. The safety profile of tofacitinib in older patients and those with multiple comorbidities needs to be carefully considered.\n",
      "==========\n",
      "REFINED ANSWER:\n",
      "\u001b[0m\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "Retrying langchain.chat_models.openai.ChatOpenAI.completion_with_retry.<locals>._completion_with_retry in 4.0 seconds as it raised RateLimitError: Rate limit reached for 10KTPM-200RPM in organization org-ETbTMTN2JXYOUPDJgxuH2iO6 on tokens per min. Limit: 10000 / min. Please try again in 6ms. Contact us through our help center at help.openai.com if you continue to have issues..\n",
      "Retrying langchain.chat_models.openai.ChatOpenAI.completion_with_retry.<locals>._completion_with_retry in 4.0 seconds as it raised RateLimitError: Rate limit reached for 10KTPM-200RPM in organization org-ETbTMTN2JXYOUPDJgxuH2iO6 on tokens per min. Limit: 10000 / min. Please try again in 6ms. Contact us through our help center at help.openai.com if you continue to have issues..\n",
      "Retrying langchain.chat_models.openai.ChatOpenAI.completion_with_retry.<locals>._completion_with_retry in 4.0 seconds as it raised RateLimitError: Rate limit reached for 10KTPM-200RPM in organization org-ETbTMTN2JXYOUPDJgxuH2iO6 on tokens per min. Limit: 10000 / min. Please try again in 6ms. Contact us through our help center at help.openai.com if you continue to have issues..\n",
      "Retrying langchain.chat_models.openai.ChatOpenAI.completion_with_retry.<locals>._completion_with_retry in 8.0 seconds as it raised RateLimitError: Rate limit reached for 10KTPM-200RPM in organization org-ETbTMTN2JXYOUPDJgxuH2iO6 on tokens per min. Limit: 10000 / min. Please try again in 6ms. Contact us through our help center at help.openai.com if you continue to have issues..\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\n",
      "\u001b[1m> Finished chain.\u001b[0m\n",
      "\n",
      "\u001b[1m> Finished chain.\u001b[0m\n",
      "2023-10-02 17:31:45,867:INFO: 5937 tokens were added to prompt from 10 documents\n",
      "Query: 36 year-old man with moderate to severe extensive ulcerative colitis and spondylarthristis.\n",
      "\n",
      "\n",
      "\n",
      "\u001b[1m> Entering new SequentialChain chain...\u001b[0m\n",
      "\n",
      "\n",
      "\u001b[1m> Entering new RetrievalQAWithSourcesChain chain...\u001b[0m\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "Retrying langchain.chat_models.openai.ChatOpenAI.completion_with_retry.<locals>._completion_with_retry in 4.0 seconds as it raised RateLimitError: Rate limit reached for 10KTPM-200RPM in organization org-ETbTMTN2JXYOUPDJgxuH2iO6 on tokens per min. Limit: 10000 / min. Please try again in 6ms. Contact us through our help center at help.openai.com if you continue to have issues..\n",
      "Retrying langchain.chat_models.openai.ChatOpenAI.completion_with_retry.<locals>._completion_with_retry in 4.0 seconds as it raised RateLimitError: Rate limit reached for 10KTPM-200RPM in organization org-ETbTMTN2JXYOUPDJgxuH2iO6 on tokens per min. Limit: 10000 / min. Please try again in 6ms. Contact us through our help center at help.openai.com if you continue to have issues..\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\n",
      "\u001b[1m> Finished chain.\u001b[0m\n",
      "\n",
      "\n",
      "\u001b[1m> Entering new LLMChain chain...\u001b[0m\n",
      "Prompt after formatting:\n",
      "\u001b[32;1m\u001b[1;3mYou are a senior physician giving advice on treatment for moderate to severe ulcerative colitis (UC).\n",
      "Make reference to the CONTEXT given to assess the scenario.\n",
      "==========\n",
      "TASK: Your task is to analyse critically the CURRENT ANSWER given the CONTEXT.\n",
      "Then refine the existing answer (only if needed) based on the following instructions:\n",
      "- If no refinement needed, return the original answer in the correct output format.\n",
      "- If the answer cannot be inferred from CONTEXT, return \"NO ANSWER\".\n",
      "- The final output should be a list of up to 2 choices of biological drugs given patient profile and context and PROS/CONS for each recommendations.\n",
      "==========\n",
      "CONTEXT:\n",
      "Burr et al. \n",
      " \n",
      "7 of 45 \n",
      "INTRODUCTION \n",
      "  Ulcerative colitis (UC) is a chronic inflammatory disorder of the bowel that causes \n",
      "continuous mucosal inflammation commencing in the rectum and extending proximally for a \n",
      "variable extent.[1] It is estimated that UC affects 2.5 million people in Europe,[2] and the \n",
      "disease follows a relapsing and remitting course, with intermittent flares of disease activity, \n",
      "some of which may be moderate to severe. Management of these is medical, for the most \n",
      "part, with surgery reserved for patients with refractory disease. Although 5-aminosalicylates \n",
      "(5-ASAs) are efficacious for mild to moderate disease activity,[3-6] more severe flares are \n",
      "usually treated with corticosteroids.[7] However, these have potentially serious adverse \n",
      "effects and a substantial proportion of patients may become either dependent on them to \n",
      "maintain remission,[8] or refractory to them.[9] As a result, over the last 20 years novel \n",
      "drugs, with more precise modes of action, based on mechanisms of disease identified in \n",
      "genome wide association studies,[10] have been developed.  \n",
      "The first of these agents was infliximab, a drug targeting the pro-inflammatory \n",
      "cytokine tumour necrosis factor-α (TNF-α), which demonstrated efficacy in clinical trials in \n",
      "moderate to severe UC.[11] Since then, other drugs against TNF-α have been tested, such as \n",
      "adalimumab and golimumab.[12, 13] In addition, newer biological therapies targeting α or β \n",
      "integrins, which are involved in migration of immune cells to inflamed intestinal mucosa, \n",
      "such as vedolizumab or etrolizumab,[14, 15] or acting against other pro-inflammatory \n",
      "cytokines implicated in the pathogenesis of UC, such as ustekinumab,[16] have been tested. \n",
      "However, even these more selective drugs do not work in all patients, there may be risks \n",
      "associated with their use,[17-19] and the fact that they are administered either intravenously \n",
      "or subcutaneously, may be inconvenient for patients. The search for alternative agents for the \n",
      "treatment of UC has, therefore, continued.\n",
      "----------\n",
      "41 years (interquartile range, 40–42 y), and 60%\n",
      "(interquartile range, 56%–63%) were men. The median\n",
      "disease duration was 6.7 years (interquartile range,\n",
      "6.0–7.8 y), and 49% (interquartile range, 46%–55%) of\n",
      "patients had extensive colitis. A median of 40% (inter-\n",
      "quartile range, 30%–50%) of patients were treated with\n",
      "concomitant immunomodulators, and 51% (interquartile\n",
      "range, 45%–57%) were on corticosteroids at baseline.\n",
      "Patients across all trials and treatment arms were com-\n",
      "parable in terms of baseline prognostic variables, inclu-\n",
      "sion/exclusion\n",
      "criteria,\n",
      "and\n",
      "co-interventions.\n",
      "All\n",
      "outcomes were assessed uniformly based on the stan-\n",
      "dard deﬁnition of the Mayo Clinic score, between weeks\n",
      "6 and 10 for induction therapy (inﬂiximab, adalimumab,\n",
      "tofacitinib, ustekinumab, 8 weeks; golimumab, 6 weeks;\n",
      "vedolizumab, 6 weeks, 10 weeks, and 14 weeks in\n",
      "VARSITY),6 and weeks 30, 54, or 60 for maintenance\n",
      "therapy;\n",
      "endoscopy\n",
      "was\n",
      "read\n",
      "by\n",
      "blinded\n",
      "local\n",
      "Table 2. Comparative Efﬁcacy of Pharmacologic Agents for Induction of Clinical Remission and Endoscopic Improvement in Biologic-Naive Patients With Moderate–Severe\n",
      "Ulcerative Colitis Using Network Meta-Analysis\n",
      "Induction of clinical remission\n",
      "Induction of endoscopic improvement\n",
      "Ustekinumab 6 mg/kg\n",
      "0.96 (0.38–2.45)\n",
      "0.80 (0.35–1.83)\n",
      "0.73 (0.31–1.74)\n",
      "1.05 (0.48–2.32)\n",
      "0.50 (0.22–1.12)\n",
      "2.04 (1.03–4.05)\n",
      "0.92 (0.45–1.89)\n",
      "Tofacitinib 10 mg b.d.\n",
      "0.84 (0.39–1.82)\n",
      "0.76 (0.33–1.76)\n",
      "1.10 (0.51–2.34)\n",
      "0.52 (0.24–1.12)\n",
      "2.12 (1.12–4.02)\n",
      "0.74 (0.36–1.51)\n",
      "0.80 (0.4–1.62)\n",
      "Vedolizumab\n",
      "0.91 (0.44–1.86)\n",
      "1.31 (0.88–1.95)\n",
      "0.62 (0.34–1.15)\n",
      "2.54 (1.60–4.02)\n",
      "1.07 (0.58–1.98)\n",
      "1.17 (0.64–2.12)\n",
      "1.45 (0.80–2.61)\n",
      "Golimumab\n",
      "1.44 (0.76–2.75)\n",
      "0.69 (0.35–1.36)\n",
      "2.79 (1.64–4.02)\n",
      "1.17 (0.65–2.13)\n",
      "1.28 (0.72–2.29)\n",
      "1.59 (0.90–2.82)\n",
      "1.10 (0.71–1.71)\n",
      "Adalimumab\n",
      "0.48 (0.26–0.86)\n",
      "1.94 (1.30–2.88)\n",
      "0.56 (0.30–1.04)\n",
      "0.61 (0.34–1.11)\n",
      "0.76 (0.42–1.37)\n",
      "0.52 (0.33–0.83)\n",
      "0.48 (0.31–0.74)\n",
      "Inﬂiximab\n",
      "4.07 (2.67–6.21)\n",
      "1.86 (1.11–3.13)\n",
      "2.03 (1.23–3.34)\n",
      "2.52 (1.54–4.11)\n",
      "1.74 (1.25–2.41)\n",
      "1.58 (1.18–2.13)\n",
      "3.32 (2.39–4.60)\n",
      "Placebo\n",
      "NOTE. Comparisons should be read from left to right. Odds ratio for comparisons are in the cell in common between the column-deﬁning and row-deﬁning treatment. Numbers in bold are statistically signiﬁcant. For induction of\n",
      "clinical remission, an odds ratio greater than 1 favors row-deﬁning treatment. For induction of endoscopic improvement, an odds ratio greater than 1 favors column-deﬁning treatment. Numbers in parentheses indicate 95% CI.\n",
      "b.d., twice daily.\n",
      "----------\n",
      "severely active ulcerative colitis: results from phase 3 \n",
      "U-ACCOMPLISH study. J Crohn’s Colitis 2021; 15 (suppl 1): S021–22.\n",
      "9 \n",
      "Thorlund K, Druyts E, Mills EJ, Fedorak RN, Marshall JK. \n",
      "Adalimumab versus infliximab for the treatment of moderate to \n",
      "severe ulcerative colitis in adult patients naïve to anti-TNF therapy: \n",
      "an indirect treatment comparison meta-analysis. J Crohn’s Colitis \n",
      "2014; 8: 571–81.\n",
      "10 \n",
      "Danese S, Fiorino G, Peyrin-Biroulet L, et al. Biological agents for \n",
      "moderately to severely active ulcerative colitis: a systematic review \n",
      "and network meta-analysis. Ann Intern Med 2014; 160: 704–11.\n",
      "11 \n",
      "Singh S, Fumery M, Sandborn WJ, Murad MH. Systematic review \n",
      "with network meta-analysis: first- and second-line pharmacotherapy \n",
      "for moderate-severe ulcerative colitis. Aliment Pharmacol Ther 2018; \n",
      "47: 162–75.\n",
      "12 \n",
      "Bonovas S, Lytras T, Nikolopoulos G, Peyrin-Biroulet L, Danese S. \n",
      "Systematic review with network meta-analysis: comparative \n",
      "assessment of tofacitinib and biological therapies for moderate-to-\n",
      "severe ulcerative colitis. Aliment Pharmacol Ther 2018; 47: 454–65.\n",
      "13 \n",
      "Singh S, Murad MH, Fumery M, Dulai PS, Sandborn WJ. First- and \n",
      "second-line pharmacotherapies for patients with moderate to \n",
      "severely active ulcerative colitis: an updated network meta-analysis. \n",
      "Clin Gastroenterol Hepatol 2020; 18: 2179–91.e6.\n",
      "14 \n",
      "Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting \n",
      "items for systematic reviews and meta-analyses: the PRISMA \n",
      "statement. Ann Intern Med 2009; 151: 264–69.\n",
      "15 \n",
      "Jansen JP, Fleurence R, Devine B, et al. Interpreting indirect \n",
      "treatment comparisons and network meta-analysis for health-care \n",
      "decision making: report of the ISPOR Task Force on Indirect \n",
      "Treatment Comparisons Good Research Practices: part 1. \n",
      "Value Health 2011; 14: 417–28.\n",
      "16 \n",
      "Sterne JAC, Savović J, Page MJ, et al. RoB 2: a revised tool for \n",
      "assessing risk of bias in randomised trials. BMJ 2019; 366: l4898.\n",
      "17 \n",
      "Rücker G, Schwarzer G. Ranking treatments in frequentist network \n",
      "meta-analysis works without resampling methods. \n",
      "BMC Med Res Methodol 2015; 15: 58.\n",
      "----------\n",
      "Parkes, M., Vermeire, S., Rioux, J.D., Mansﬁeld, J., Silverberg, M.S., Radford-\n",
      "Smith, G., McGovern, D.P., Barrett, J.C., Lees, C.W., 2016. Inherited determinants of\n",
      "crohn's disease and ulcerative colitis phenotypes: a genetic association study. Lancet\n",
      "387 (10014), 156–167.\n",
      "Colombel, J.F., Sandborn, W.J., Rutgeerts, P., Enns, R., Hanauer, S.B., Panaccione, R.,\n",
      "Schreiber, S., Byczkowski, D., Li, J., Kent, J.D., Pollack, P.F., 2007. Adalimumab for\n",
      "maintenance of clinical response and remission in patients with crohn's disease: the\n",
      "charm trial. Gastroenterology 132 (1), 52–65.\n",
      "Conrad, M.A., Kelsen, J.R., 2020. The treatment of pediatric inﬂammatory bowel disease\n",
      "with biologic therapies. Curr. Gastroenterol. Rep. 22 (8), 36–51.\n",
      "Csontos, A.A., Molnar, A., Piri, Z., Katona, B., Dako, S., Palﬁ, E., Miheller, P., 2016. The\n",
      "effect of anti-tnfalpha induction therapy on the nutritional status and dietary intake\n",
      "in inﬂammatory bowel disease. J Gastrointestin Liver Dis 25 (1), 49–56.\n",
      "Dai, Z.H., Xu, X.T., Ran, Z.H., 2020. Associations between obesity and the effectiveness of\n",
      "anti-tumor necrosis factor-alpha agents in inﬂammatory bowel disease patients: a\n",
      "literature review and meta-analysis. Ann. Pharmacother. 54 (8), 729–741.\n",
      "Danese, S., Colombel, J.F., Lukas, M., Gisbert, J.P., D’Haens, G., Hayee, B., Panaccione, R.,\n",
      "Kim, H.S., Reinisch, W., Tyrrell, H., Oh, Y.S., Tole, S., Chai, A., Chamberlain-\n",
      "James, K., Tang, M.T., Schreiber, S., Group, G.S., 2021. Etrolizumab versus inﬂiximab\n",
      "for the treatment of moderately to severely active ulcerative colitis (gardenia): a\n",
      "randomised, double-blind, double-dummy, phase 3 study. Lancet Gastroenterol\n",
      "Hepatol 7 (2), 118–127.\n",
      "Danese, S., Fiorino, G., Peyrin-Biroulet, L., Lucenteforte, E., Virgili, G., Moja, L.,\n",
      "Bonovas, S., 2014. Biological agents for moderately to severely active ulcerative\n",
      "colitis: a systematic review and network meta-analysis. Ann. Intern. Med. 160 (10),\n",
      "704–711.\n",
      "P. Juillerat et al.\n",
      "Current Research in Pharmacology and Drug Discovery 3 (2022) 100104\n",
      "6\n",
      "----------\n",
      "Therapeutic strategies for the management of recentlydiagnosedulcerative colitis. IMMs include thiopurines and methotrexate. 5-ASA, 5-amino salicylic acid; ASUC, acute severe ulcerative colitis; IPAA, ileal pouch anal anastomosis.\n",
      "\n",
      "Risk stratification: Mild\n",
      "Clinical features: NA\n",
      "Treatment options: 5-ASA (oral and/or topical)\n",
      "\n",
      "Risk stratification: Moderate\n",
      "Clinical features: NA\n",
      "Treatment options: Can consider 5-ASA (with rapid step-up if inadequate response)\n",
      "\n",
      "Risk stratification: Moderate\n",
      "Clinical features: NA\n",
      "Treatment options: VDZ or UST\n",
      "\n",
      "Risk stratification: Moderate\n",
      "Clinical features: NA\n",
      "Treatment options: Thiopurine\n",
      "\n",
      "Risk stratification: Moderate\n",
      "Clinical features: NA\n",
      "Treatment options: TNFi +/- IMM\n",
      "\n",
      "Risk stratification: Severe\n",
      "Clinical features: NA\n",
      "Treatment options: TNFi +/- IMM\n",
      "\n",
      "Risk stratification: Severe\n",
      "Clinical features: NA\n",
      "Treatment options: Subtotal colectomy + IPAA or cyclosporine (for ASUC)\n",
      "\n",
      "Risk stratification: Additional consideration: EIM present\n",
      "Clinical features: Psoriasis or psoriatic arthritis\n",
      "Treatment options: UST\n",
      "\n",
      "Risk stratification: Additional consideration: EIM present\n",
      "Clinical features: Other arthritis\n",
      "Treatment options: TNFi\n",
      "\n",
      "\n",
      "----------\n",
      "Burr et al. \n",
      " \n",
      "5 of 45 \n",
      "STUDY HIGHLIGHTS \n",
      " \n",
      "What is already known about this subject \n",
      "• Ulcerative colitis (UC) follows a relapsing and remitting course, with intermittent \n",
      "flares of disease activity, some of which may be moderate to severe. \n",
      "• These are usually treated with corticosteroids, which have potentially serious adverse \n",
      "effects, so biological therapies and small molecules have been developed and licensed \n",
      "for this indication.  \n",
      "• Although previous network meta-analyses have compared their efficacy and safety, \n",
      "this is a rapidly moving field, and there are already several newer drugs that have \n",
      "shown efficacy in phase III clinical trials that were not considered in these. \n",
      " \n",
      "What are the new findings \n",
      "• In terms of clinical remission and clinical response, upadacitinib 45mg o.d. ranked \n",
      "first in all patients, in patients previously exposed to anti-tumour necrosis factor \n",
      "(TNF)-α therapies, and in patients naïve to these drugs.  \n",
      "• In terms of endoscopic improvement infliximab 10mg/kg ranked first, followed by \n",
      "upadacitinib 45mg o.d., and infliximab 5mg/kg.  \n",
      "• However, for endoscopic improvement again upadacitinib 45mg o.d. ranked first in \n",
      "patients previously exposed to anti-TNF-α therapies, and in patients who were anti-\n",
      "TNF-α naïve.  \n",
      "• None of the drugs studied were more likely to lead to serious adverse events than \n",
      "placebo.\n",
      "----------\n",
      "to\n",
      "extensive\n",
      "or\n",
      "pancolitis\n",
      "is\n",
      "associated\n",
      "with\n",
      "worse\n",
      "prognosis.45,65\n",
      "In addition, co-occurrence of other immune-mediated\n",
      "inﬂammatory diseases can occur, most commonly with\n",
      "psoriasis and asthma, but also, in more rare instances, with\n",
      "other gastrointestinal diseases (eg, celiac, nonalcoholic fatty\n",
      "liver disease,66 and eosinophilic esophagitis).67,68 Presence\n",
      "of a concomitant immune-mediated inﬂammatory disease is\n",
      "Figure\n",
      "1. Inﬂammatory\n",
      "bowel disease severity vs\n",
      "disease activity variables.\n",
      "ASCA, anti-Saccharomyces\n",
      "cerevisiae\n",
      "antibodies;\n",
      "ANCA,\n",
      "anti-neutrophil\n",
      "cytoplasmic\n",
      "antibodies;\n",
      "GMCSF,\n",
      "granulocyte-\n",
      "macrophage\n",
      "colony-\n",
      "stimulating\n",
      "factor;\n",
      "TI,\n",
      "terminal ileum.\n",
      "50\n",
      "Agrawal et al\n",
      "Gastroenterology Vol. 161, No. 1\n",
      "REVIEWS AND\n",
      "PERSPECTIVES\n",
      "----------\n",
      "SYSTEMATIC REVIEWS AND META-ANALYSES\n",
      "Siddharth Singh, Section Editor\n",
      "First- and Second-Line Pharmacotherapies for Patients With\n",
      "Moderate to Severely Active Ulcerative Colitis: An Updated\n",
      "Network Meta-Analysis\n",
      "Siddharth Singh,*,‡ Mohammad Hassan Murad,§ Mathurin Fumery,j\n",
      "Parambir S. Dulai,* and William J. Sandborn*\n",
      "*Division of Gastroenterology, ‡Division of Biomedical Informatics, University of California San Diego, La Jolla, California;\n",
      "§Robert D and Patricia E Kern Center for the Science of Health Care Delivery, Mayo Clinic, Rochester, Minnesota;\n",
      "||Gastroenterology Unit, Peritox UMR I-0I, Amiens University and Hospital, Université de Picardie Jules Verne, Amiens, France\n",
      "BACKGROUND & AIMS:\n",
      "We compared the efﬁcacy and safety of different ﬁrst-line (biologic-naïve) and second-line\n",
      "(prior exposure to tumor necrosis factor [TNF] antagonists) agents for treatment of moder-\n",
      "ate to severely active ulcerative colitis in a systematic review and network meta-analysis.\n",
      "METHODS:\n",
      "We searched publication databases through September 30, 2019, for randomized trials of\n",
      "adults with moderate to severe ulcerative colitis treated with TNF antagonists, vedolizumab,\n",
      "tofacitinib, or ustekinumab, as ﬁrst-line or second-line agents, compared with placebo or\n",
      "another active agent. Efﬁcacy outcomes were induction and maintenance of remission and\n",
      "endoscopic improvement; safety outcomes were serious adverse events and infections. We\n",
      "performed a ﬁxed-effects network meta-analysis using the frequentist approach, and calculated\n",
      "odds ratios (ORs) and 95% CI values. Agents were ranked using surface under the cumulative\n",
      "ranking (SUCRA) probabilities. Overall quality of evidence was rated using GRADE (Grading of\n",
      "Recommendations, Assessment, Development and Evaluation).\n",
      "RESULTS:\n",
      "In biologic-naïve patients, inﬂiximab was ranked highest for induction of clinical remission (OR\n",
      "vs placebo, 4.07; 95% CI, 2.67–6.21; SUCRA, 0.95) and endoscopic improvement (SUCRA, 0.95)\n",
      "(moderate conﬁdence in estimates [CE]). In patients with prior exposure to TNF antagonists,\n",
      "ustekinumab (SUCRA, 0.87) and tofacitinib (SUCRA, 0.87) were ranked highest for induction of\n",
      "clinical remission and were superior to vedolizumab (ustekinumab vs vedolizumab: OR, 5.99;\n",
      "95% CI, 1.13–31.76 and tofacitinib vs vedolizumab: OR, 6.18; 95% CI, 1.003–8.00; moderate CE)\n",
      "and adalimumab (ustekinumab vs adalimumab: OR, 10.71; 95% CI, 2.01–57.20 and tofacitinib\n",
      "----------\n",
      "methodologic characteristics). If direct and indirect es-\n",
      "timates were similar (ie, coherent), then the higher rating\n",
      "can be assigned to the network meta-analysis estimates.\n",
      "Results\n",
      "From a total 5651 unique studies identiﬁed using our\n",
      "search strategy, we included 15 RCTs of ﬁrst-line agents\n",
      "(in biologic-naïve patients) (Active Ulcerative Colitis Trials\n",
      "1 and 2,17 Jiang et al,18 NCT01551290,19 Ulcerative colitis\n",
      "Long-Term Remission and maintenance with Adalimumab\n",
      "1 and 2,20,21 Suzuki et al,22 Program of Ulcerative Colitis\n",
      "Research Studies Utilizing an Investigational Treatment\n",
      "phase 2 and phase 3 induction studies,23 GEMINI I,24\n",
      "Motoya et al,25 VARSITY, Oral Clinical Trials for tofAciti-\n",
      "nib in ulceratiVE colitis (OCTAVE) 1 and 2,26 and UNIFI),\n",
      "and 7 RCTs of second-line agents (in patients with prior\n",
      "exposure to TNFa antagonists) (Ulcerative colitis Long-\n",
      "Term Remission and maintenance with Adalimumab 2,21\n",
      "GEMINI I,24 Motoya et al,25 VARSITY,6 OCTAVE 1 and\n",
      "2,26 UNIFI7) in patients with moderate–severe ulcerative\n",
      "colitis. Trials of inﬂiximab (Active Ulcerative Colitis Trials\n",
      "1 and 2,17 Jiang et al,18 NCT0155129019), adalimumab\n",
      "(Ulcerative colitis Long-Term Remission and maintenance\n",
      "with Adalimumab 2,20,21 Suzuki et al22), vedolizumab\n",
      "(GEMINI I,24 Motoya et al,25 VARSITY6) and ustekinumab\n",
      "(UNIFI7) also reported outcomes on maintenance therapy\n",
      "within the same publication; Program of Ulcerative Colitis\n",
      "Research Studies Utilizing an Investigational Treatment-\n",
      "M, Program of Ulcerative Colitis Research Studies Utilizing\n",
      "an Investigational Treatment-J, and OCTAVE-Sustain\n",
      "reported\n",
      "outcomes\n",
      "for\n",
      "maintenance\n",
      "therapy\n",
      "with\n",
      "golimumab and tofacitinib, respectively.26–28 From our\n",
      "previous analysis, 3 additional studies were included.\n",
      "The schematic diagram of study selection is shown in\n",
      "Supplementary\n",
      "Figure\n",
      "1,\n",
      "and\n",
      "available\n",
      "direct\n",
      "comparisons and network of trials are shown in Figure 1.\n",
      "Trial and patient characteristics are summarized in\n",
      "Table 1. Overall, the median average age of patients was\n",
      "41 years (interquartile range, 40–42 y), and 60%\n",
      "(interquartile range, 56%–63%) were men. The median\n",
      "disease duration was 6.7 years (interquartile range,\n",
      "6.0–7.8 y), and 49% (interquartile range, 46%–55%) of\n",
      "patients had extensive colitis. A median of 40% (inter-\n",
      "quartile range, 30%–50%) of patients were treated with\n",
      "concomitant immunomodulators, and 51% (interquartile\n",
      "range, 45%–57%) were on corticosteroids at baseline.\n",
      "Patients across all trials and treatment arms were com-\n",
      "----------\n",
      "Articles\n",
      "www.thelancet.com/gastrohep   Vol 7   February 2022 \n",
      "161\n",
      "Lancet Gastroenterol Hepatol \n",
      "2022; 7: 161–70\n",
      "Published Online \n",
      "November 29, 2021 \n",
      "https://doi.org/10.1016/ \n",
      "S2468-1253(21)00377-0\n",
      "See Comment page 110\n",
      "*Contributed equally\n",
      "Inflammatory Bowel Disease \n",
      "Unit, Gastroenterology \n",
      "Section, Department of \n",
      "Internal Medicine, Centro de \n",
      "Educación Médica e \n",
      "Investigaciones Clínicas, \n",
      "Buenos Aires, Argentina \n",
      "(J S Lasa MD, P A Olivera MD); \n",
      "Gastroenterology Department, \n",
      "Hospital Británico de Buenos \n",
      "Aires, Buenos Aires, Argentina \n",
      "(J S Lasa); Zane Cohen Centre \n",
      "for Digestive Diseases, \n",
      "Lunenfeld-Tanenbaum \n",
      "Research Institute, Sinai Health \n",
      "System, Toronto, ON, Canada \n",
      "(P A Olivera); Division of \n",
      "Gastroenterology, Mount Sinai \n",
      "Hospital, University of Toronto, \n",
      "Toronto, ON, Canada \n",
      "(P A Olivera); Gastroenterology \n",
      "and Endoscopy, IRCCS Ospedale \n",
      "San Raffaele and University \n",
      "Vita-Salute San Raffaele, \n",
      "Milano, Italy \n",
      "(Prof S Danese MD); INSERM \n",
      "NGERE and Department of \n",
      "Hepatogastroenterology, \n",
      "Nancy University Hospital, \n",
      "Lorraine University, \n",
      "Vandoeuvre-lés-Nancy, France \n",
      "(Prof L Peyrin-Biroulet MD) \n",
      "Correspondence to: \n",
      "Prof Laurent Peyrin-Biroulet, \n",
      "INSERM NGERE and Department \n",
      "of Hepatogastroenterology, \n",
      "Nancy University Hospital, \n",
      "Lorraine University, Vandoeuvre-\n",
      "lès-Nancy F-54511, France \n",
      "peyrinbiroulet@gmail.com\n",
      "Efficacy and safety of biologics and small molecule drugs for \n",
      "patients with moderate-to-severe ulcerative colitis: \n",
      "a systematic review and network meta-analysis \n",
      "Juan S Lasa*, Pablo A Olivera*, Silvio Danese, Laurent Peyrin-Biroulet\n",
      "Summary\n",
      "Background There is a growing armamentarium for the treatment of moderate-to-severe ulcerative colitis. We aimed \n",
      "to compare the relative efficacy and safety of biologics and small molecule drugs for the treatment of patients with \n",
      "moderate-to-severe ulcerative colitis.\n",
      "Methods In this systematic review and network meta-analysis, we searched MEDLINE, Embase, and the Cochrane \n",
      "Central Register of Controlled Trials without language restrictions for articles published between Jan 1, 1990, and \n",
      "July 1, 2021. Major congresses’ databases from Jan 1, 2018, to July 3, 2021, were reviewed manually. Phase 3, placebo-\n",
      "controlled or head-to-head randomised controlled trials (RCTs) assessing the efficacy and safety of biologics or small \n",
      "molecule drugs as induction or maintenance therapies for patients with moderate-to-severe ulcerative colitis were\n",
      "==========\n",
      "ORIGINAL QUESTION: ANALYSE the given patient profile based on given query based on one of the following criteria:\n",
      "- Whether treated patient is new patient or patient under maintenance\n",
      "- Prior response to Infliximab\n",
      "- Prior failure to Anti-TNF agents\n",
      "- Prior failure to Vedolizumab\n",
      "- Age\n",
      "- Pregnancy\n",
      "- Extraintestinale manifestations\n",
      "- Pouchitis\n",
      "RETURN up to 2 TOP choices of biological drugs given patient profile and context. Explain the PROS and CONS of the 2 choices.\n",
      "PATIENT PROFILE: 36 year-old man with moderate to severe extensive ulcerative colitis and spondylarthristis.\n",
      "\n",
      "==========\n",
      "CURRENT ANSWER:\n",
      "Based on the patient's profile, the top two choices of biological drugs would be:\n",
      "\n",
      "1. Infliximab\n",
      "2. Ustekinumab\n",
      "\n",
      "Infliximab:\n",
      "- Advantages: Infliximab has been shown to be effective in inducing and maintaining remission in moderate to severe ulcerative colitis. It is also beneficial for patients with extraintestinal manifestations like spondylarthritis. Infliximab has been ranked highest for induction of clinical remission and endoscopic improvement in biologic-naïve patients.\n",
      "- Disadvantages: Infliximab is administered intravenously which may be inconvenient for some patients. There may be risks associated with its use, including serious infections and potential allergic reactions. Some patients may also develop antibodies to infliximab, reducing its effectiveness over time.\n",
      "\n",
      "Ustekinumab:\n",
      "- Advantages: Ustekinumab is effective in treating moderate to severe ulcerative colitis and has been ranked highly for induction of clinical remission in patients with prior exposure to anti-TNF-α therapies. It is also beneficial for patients with extraintestinal manifestations like psoriasis or psoriatic arthritis, which may be relevant given the patient's spondylarthritis.\n",
      "- Disadvantages: Ustekinumab is administered subcutaneously, which may be inconvenient for some patients. Potential side effects include serious infections and allergic reactions. The effectiveness of ustekinumab in ulcerative colitis patients who have failed anti-TNF therapy is less clear.\n",
      "==========\n",
      "REFINED ANSWER:\n",
      "\u001b[0m\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "Retrying langchain.chat_models.openai.ChatOpenAI.completion_with_retry.<locals>._completion_with_retry in 4.0 seconds as it raised RateLimitError: Rate limit reached for 10KTPM-200RPM in organization org-ETbTMTN2JXYOUPDJgxuH2iO6 on tokens per min. Limit: 10000 / min. Please try again in 6ms. Contact us through our help center at help.openai.com if you continue to have issues..\n",
      "Retrying langchain.chat_models.openai.ChatOpenAI.completion_with_retry.<locals>._completion_with_retry in 4.0 seconds as it raised RateLimitError: Rate limit reached for 10KTPM-200RPM in organization org-ETbTMTN2JXYOUPDJgxuH2iO6 on tokens per min. Limit: 10000 / min. Please try again in 6ms. Contact us through our help center at help.openai.com if you continue to have issues..\n",
      "Retrying langchain.chat_models.openai.ChatOpenAI.completion_with_retry.<locals>._completion_with_retry in 4.0 seconds as it raised RateLimitError: Rate limit reached for 10KTPM-200RPM in organization org-ETbTMTN2JXYOUPDJgxuH2iO6 on tokens per min. Limit: 10000 / min. Please try again in 6ms. Contact us through our help center at help.openai.com if you continue to have issues..\n",
      "Retrying langchain.chat_models.openai.ChatOpenAI.completion_with_retry.<locals>._completion_with_retry in 8.0 seconds as it raised RateLimitError: Rate limit reached for 10KTPM-200RPM in organization org-ETbTMTN2JXYOUPDJgxuH2iO6 on tokens per min. Limit: 10000 / min. Please try again in 6ms. Contact us through our help center at help.openai.com if you continue to have issues..\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\n",
      "\u001b[1m> Finished chain.\u001b[0m\n",
      "\n",
      "\u001b[1m> Finished chain.\u001b[0m\n",
      "2023-10-02 17:33:02,290:INFO: 5763 tokens were added to prompt from 10 documents\n",
      "Query: 42 year-old woman with moderate ulcerative colitis on azathioprine and not responding to therapy\n",
      "\n",
      "\n",
      "\n",
      "\u001b[1m> Entering new SequentialChain chain...\u001b[0m\n",
      "\n",
      "\n",
      "\u001b[1m> Entering new RetrievalQAWithSourcesChain chain...\u001b[0m\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "Retrying langchain.chat_models.openai.ChatOpenAI.completion_with_retry.<locals>._completion_with_retry in 4.0 seconds as it raised RateLimitError: Rate limit reached for 10KTPM-200RPM in organization org-ETbTMTN2JXYOUPDJgxuH2iO6 on tokens per min. Limit: 10000 / min. Please try again in 6ms. Contact us through our help center at help.openai.com if you continue to have issues..\n",
      "Retrying langchain.chat_models.openai.ChatOpenAI.completion_with_retry.<locals>._completion_with_retry in 4.0 seconds as it raised RateLimitError: Rate limit reached for 10KTPM-200RPM in organization org-ETbTMTN2JXYOUPDJgxuH2iO6 on tokens per min. Limit: 10000 / min. Please try again in 6ms. Contact us through our help center at help.openai.com if you continue to have issues..\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\n",
      "\u001b[1m> Finished chain.\u001b[0m\n",
      "\n",
      "\n",
      "\u001b[1m> Entering new LLMChain chain...\u001b[0m\n",
      "Prompt after formatting:\n",
      "\u001b[32;1m\u001b[1;3mYou are a senior physician giving advice on treatment for moderate to severe ulcerative colitis (UC).\n",
      "Make reference to the CONTEXT given to assess the scenario.\n",
      "==========\n",
      "TASK: Your task is to analyse critically the CURRENT ANSWER given the CONTEXT.\n",
      "Then refine the existing answer (only if needed) based on the following instructions:\n",
      "- If no refinement needed, return the original answer in the correct output format.\n",
      "- If the answer cannot be inferred from CONTEXT, return \"NO ANSWER\".\n",
      "- The final output should be a list of up to 2 choices of biological drugs given patient profile and context and PROS/CONS for each recommendations.\n",
      "==========\n",
      "CONTEXT:\n",
      "Burr et al. \n",
      " \n",
      "7 of 45 \n",
      "INTRODUCTION \n",
      "  Ulcerative colitis (UC) is a chronic inflammatory disorder of the bowel that causes \n",
      "continuous mucosal inflammation commencing in the rectum and extending proximally for a \n",
      "variable extent.[1] It is estimated that UC affects 2.5 million people in Europe,[2] and the \n",
      "disease follows a relapsing and remitting course, with intermittent flares of disease activity, \n",
      "some of which may be moderate to severe. Management of these is medical, for the most \n",
      "part, with surgery reserved for patients with refractory disease. Although 5-aminosalicylates \n",
      "(5-ASAs) are efficacious for mild to moderate disease activity,[3-6] more severe flares are \n",
      "usually treated with corticosteroids.[7] However, these have potentially serious adverse \n",
      "effects and a substantial proportion of patients may become either dependent on them to \n",
      "maintain remission,[8] or refractory to them.[9] As a result, over the last 20 years novel \n",
      "drugs, with more precise modes of action, based on mechanisms of disease identified in \n",
      "genome wide association studies,[10] have been developed.  \n",
      "The first of these agents was infliximab, a drug targeting the pro-inflammatory \n",
      "cytokine tumour necrosis factor-α (TNF-α), which demonstrated efficacy in clinical trials in \n",
      "moderate to severe UC.[11] Since then, other drugs against TNF-α have been tested, such as \n",
      "adalimumab and golimumab.[12, 13] In addition, newer biological therapies targeting α or β \n",
      "integrins, which are involved in migration of immune cells to inflamed intestinal mucosa, \n",
      "such as vedolizumab or etrolizumab,[14, 15] or acting against other pro-inflammatory \n",
      "cytokines implicated in the pathogenesis of UC, such as ustekinumab,[16] have been tested. \n",
      "However, even these more selective drugs do not work in all patients, there may be risks \n",
      "associated with their use,[17-19] and the fact that they are administered either intravenously \n",
      "or subcutaneously, may be inconvenient for patients. The search for alternative agents for the \n",
      "treatment of UC has, therefore, continued.\n",
      "----------\n",
      "Therapeutic strategies for the management of recentlydiagnosedulcerative colitis. IMMs include thiopurines and methotrexate. 5-ASA, 5-amino salicylic acid; ASUC, acute severe ulcerative colitis; IPAA, ileal pouch anal anastomosis.\n",
      "\n",
      "Risk stratification: Mild\n",
      "Clinical features: NA\n",
      "Treatment options: 5-ASA (oral and/or topical)\n",
      "\n",
      "Risk stratification: Moderate\n",
      "Clinical features: NA\n",
      "Treatment options: Can consider 5-ASA (with rapid step-up if inadequate response)\n",
      "\n",
      "Risk stratification: Moderate\n",
      "Clinical features: NA\n",
      "Treatment options: VDZ or UST\n",
      "\n",
      "Risk stratification: Moderate\n",
      "Clinical features: NA\n",
      "Treatment options: Thiopurine\n",
      "\n",
      "Risk stratification: Moderate\n",
      "Clinical features: NA\n",
      "Treatment options: TNFi +/- IMM\n",
      "\n",
      "Risk stratification: Severe\n",
      "Clinical features: NA\n",
      "Treatment options: TNFi +/- IMM\n",
      "\n",
      "Risk stratification: Severe\n",
      "Clinical features: NA\n",
      "Treatment options: Subtotal colectomy + IPAA or cyclosporine (for ASUC)\n",
      "\n",
      "Risk stratification: Additional consideration: EIM present\n",
      "Clinical features: Psoriasis or psoriatic arthritis\n",
      "Treatment options: UST\n",
      "\n",
      "Risk stratification: Additional consideration: EIM present\n",
      "Clinical features: Other arthritis\n",
      "Treatment options: TNFi\n",
      "\n",
      "\n",
      "----------\n",
      "Burr et al. \n",
      " \n",
      "5 of 45 \n",
      "STUDY HIGHLIGHTS \n",
      " \n",
      "What is already known about this subject \n",
      "• Ulcerative colitis (UC) follows a relapsing and remitting course, with intermittent \n",
      "flares of disease activity, some of which may be moderate to severe. \n",
      "• These are usually treated with corticosteroids, which have potentially serious adverse \n",
      "effects, so biological therapies and small molecules have been developed and licensed \n",
      "for this indication.  \n",
      "• Although previous network meta-analyses have compared their efficacy and safety, \n",
      "this is a rapidly moving field, and there are already several newer drugs that have \n",
      "shown efficacy in phase III clinical trials that were not considered in these. \n",
      " \n",
      "What are the new findings \n",
      "• In terms of clinical remission and clinical response, upadacitinib 45mg o.d. ranked \n",
      "first in all patients, in patients previously exposed to anti-tumour necrosis factor \n",
      "(TNF)-α therapies, and in patients naïve to these drugs.  \n",
      "• In terms of endoscopic improvement infliximab 10mg/kg ranked first, followed by \n",
      "upadacitinib 45mg o.d., and infliximab 5mg/kg.  \n",
      "• However, for endoscopic improvement again upadacitinib 45mg o.d. ranked first in \n",
      "patients previously exposed to anti-TNF-α therapies, and in patients who were anti-\n",
      "TNF-α naïve.  \n",
      "• None of the drugs studied were more likely to lead to serious adverse events than \n",
      "placebo.\n",
      "----------\n",
      "severely active ulcerative colitis: results from phase 3 \n",
      "U-ACCOMPLISH study. J Crohn’s Colitis 2021; 15 (suppl 1): S021–22.\n",
      "9 \n",
      "Thorlund K, Druyts E, Mills EJ, Fedorak RN, Marshall JK. \n",
      "Adalimumab versus infliximab for the treatment of moderate to \n",
      "severe ulcerative colitis in adult patients naïve to anti-TNF therapy: \n",
      "an indirect treatment comparison meta-analysis. J Crohn’s Colitis \n",
      "2014; 8: 571–81.\n",
      "10 \n",
      "Danese S, Fiorino G, Peyrin-Biroulet L, et al. Biological agents for \n",
      "moderately to severely active ulcerative colitis: a systematic review \n",
      "and network meta-analysis. Ann Intern Med 2014; 160: 704–11.\n",
      "11 \n",
      "Singh S, Fumery M, Sandborn WJ, Murad MH. Systematic review \n",
      "with network meta-analysis: first- and second-line pharmacotherapy \n",
      "for moderate-severe ulcerative colitis. Aliment Pharmacol Ther 2018; \n",
      "47: 162–75.\n",
      "12 \n",
      "Bonovas S, Lytras T, Nikolopoulos G, Peyrin-Biroulet L, Danese S. \n",
      "Systematic review with network meta-analysis: comparative \n",
      "assessment of tofacitinib and biological therapies for moderate-to-\n",
      "severe ulcerative colitis. Aliment Pharmacol Ther 2018; 47: 454–65.\n",
      "13 \n",
      "Singh S, Murad MH, Fumery M, Dulai PS, Sandborn WJ. First- and \n",
      "second-line pharmacotherapies for patients with moderate to \n",
      "severely active ulcerative colitis: an updated network meta-analysis. \n",
      "Clin Gastroenterol Hepatol 2020; 18: 2179–91.e6.\n",
      "14 \n",
      "Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting \n",
      "items for systematic reviews and meta-analyses: the PRISMA \n",
      "statement. Ann Intern Med 2009; 151: 264–69.\n",
      "15 \n",
      "Jansen JP, Fleurence R, Devine B, et al. Interpreting indirect \n",
      "treatment comparisons and network meta-analysis for health-care \n",
      "decision making: report of the ISPOR Task Force on Indirect \n",
      "Treatment Comparisons Good Research Practices: part 1. \n",
      "Value Health 2011; 14: 417–28.\n",
      "16 \n",
      "Sterne JAC, Savović J, Page MJ, et al. RoB 2: a revised tool for \n",
      "assessing risk of bias in randomised trials. BMJ 2019; 366: l4898.\n",
      "17 \n",
      "Rücker G, Schwarzer G. Ranking treatments in frequentist network \n",
      "meta-analysis works without resampling methods. \n",
      "BMC Med Res Methodol 2015; 15: 58.\n",
      "----------\n",
      "SYSTEMATIC REVIEWS AND META-ANALYSES\n",
      "Siddharth Singh, Section Editor\n",
      "First- and Second-Line Pharmacotherapies for Patients With\n",
      "Moderate to Severely Active Ulcerative Colitis: An Updated\n",
      "Network Meta-Analysis\n",
      "Siddharth Singh,*,‡ Mohammad Hassan Murad,§ Mathurin Fumery,j\n",
      "Parambir S. Dulai,* and William J. Sandborn*\n",
      "*Division of Gastroenterology, ‡Division of Biomedical Informatics, University of California San Diego, La Jolla, California;\n",
      "§Robert D and Patricia E Kern Center for the Science of Health Care Delivery, Mayo Clinic, Rochester, Minnesota;\n",
      "||Gastroenterology Unit, Peritox UMR I-0I, Amiens University and Hospital, Université de Picardie Jules Verne, Amiens, France\n",
      "BACKGROUND & AIMS:\n",
      "We compared the efﬁcacy and safety of different ﬁrst-line (biologic-naïve) and second-line\n",
      "(prior exposure to tumor necrosis factor [TNF] antagonists) agents for treatment of moder-\n",
      "ate to severely active ulcerative colitis in a systematic review and network meta-analysis.\n",
      "METHODS:\n",
      "We searched publication databases through September 30, 2019, for randomized trials of\n",
      "adults with moderate to severe ulcerative colitis treated with TNF antagonists, vedolizumab,\n",
      "tofacitinib, or ustekinumab, as ﬁrst-line or second-line agents, compared with placebo or\n",
      "another active agent. Efﬁcacy outcomes were induction and maintenance of remission and\n",
      "endoscopic improvement; safety outcomes were serious adverse events and infections. We\n",
      "performed a ﬁxed-effects network meta-analysis using the frequentist approach, and calculated\n",
      "odds ratios (ORs) and 95% CI values. Agents were ranked using surface under the cumulative\n",
      "ranking (SUCRA) probabilities. Overall quality of evidence was rated using GRADE (Grading of\n",
      "Recommendations, Assessment, Development and Evaluation).\n",
      "RESULTS:\n",
      "In biologic-naïve patients, inﬂiximab was ranked highest for induction of clinical remission (OR\n",
      "vs placebo, 4.07; 95% CI, 2.67–6.21; SUCRA, 0.95) and endoscopic improvement (SUCRA, 0.95)\n",
      "(moderate conﬁdence in estimates [CE]). In patients with prior exposure to TNF antagonists,\n",
      "ustekinumab (SUCRA, 0.87) and tofacitinib (SUCRA, 0.87) were ranked highest for induction of\n",
      "clinical remission and were superior to vedolizumab (ustekinumab vs vedolizumab: OR, 5.99;\n",
      "95% CI, 1.13–31.76 and tofacitinib vs vedolizumab: OR, 6.18; 95% CI, 1.003–8.00; moderate CE)\n",
      "and adalimumab (ustekinumab vs adalimumab: OR, 10.71; 95% CI, 2.01–57.20 and tofacitinib\n",
      "----------\n",
      "discontinuation due to AEs, and serious infections. Phase 3 randomized controlled trials were identified via systematic literature review, in-\n",
      "cluding the following advanced therapies: infliximab, adalimumab, vedolizumab, golimumab, tofacitinib, ustekinumab, filgotinib, ozanimod, and \n",
      "upadacitinib. Random effects models were used to address between-study heterogeneity. Intent-to-treat (ITT) efficacy rates were calculated by \n",
      "adjusting maintenance outcomes by likelihood of induction response.\n",
      "Results:  Out of 48 trials identified, 23 were included. Across all outcomes and regardless of prior biologic exposure, ITT efficacy rates were \n",
      "highest for upadacitinib, owing to its highest ranking for all efficacy outcomes in induction and for all but clinical remission during maintenance \n",
      "among bio-naive induction responders. For all advanced therapies versus placebo, there were no significant differences in serious AEs or \n",
      "serious infections across therapies. For all AEs, golimumab had higher odds versus placebo during maintenance; for discontinuation due to \n",
      "AEs, upadacitinib had lower odds versus placebo during induction, while ustekinumab and vedolizumab had lower odds versus placebo during \n",
      "maintenance.\n",
      "Conclusions:  Upadacitinib may be the most efficacious therapy for moderately to severely active UC based on ITT analyses, with similar safety \n",
      "across advanced therapies.\n",
      "Lay Summary \n",
      "Indirect evidence suggests upadacitinib may be more efficacious than other advanced therapies at achieving clinical response, clinical remis-\n",
      "sion, and endoscopic response over 1 year for moderately to severely active ulcerative colitis patients, with similar safety assessments across \n",
      "advanced therapies.\n",
      "Key Words: ulcerative colitis, clinical trials, advanced therapies, network meta-analysis\n",
      "Introduction\n",
      "Ulcerative colitis (UC) is a chronic inflammatory bowel dis-\n",
      "ease that affects the colorectum and is clinically characterized \n",
      "by bloody diarrhea, urgency, tenesmus, abdominal pain, ma-\n",
      "laise, weight loss, and fever. Disease onset commonly occurs \n",
      "between the ages of 15 and 30 years and the annual global \n",
      "© The Author(s) 2023. Published by Oxford University Press on behalf of Crohn's & Colitis Foundation.\n",
      "This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), \n",
      "which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.\n",
      "----------\n",
      "41 years (interquartile range, 40–42 y), and 60%\n",
      "(interquartile range, 56%–63%) were men. The median\n",
      "disease duration was 6.7 years (interquartile range,\n",
      "6.0–7.8 y), and 49% (interquartile range, 46%–55%) of\n",
      "patients had extensive colitis. A median of 40% (inter-\n",
      "quartile range, 30%–50%) of patients were treated with\n",
      "concomitant immunomodulators, and 51% (interquartile\n",
      "range, 45%–57%) were on corticosteroids at baseline.\n",
      "Patients across all trials and treatment arms were com-\n",
      "parable in terms of baseline prognostic variables, inclu-\n",
      "sion/exclusion\n",
      "criteria,\n",
      "and\n",
      "co-interventions.\n",
      "All\n",
      "outcomes were assessed uniformly based on the stan-\n",
      "dard deﬁnition of the Mayo Clinic score, between weeks\n",
      "6 and 10 for induction therapy (inﬂiximab, adalimumab,\n",
      "tofacitinib, ustekinumab, 8 weeks; golimumab, 6 weeks;\n",
      "vedolizumab, 6 weeks, 10 weeks, and 14 weeks in\n",
      "VARSITY),6 and weeks 30, 54, or 60 for maintenance\n",
      "therapy;\n",
      "endoscopy\n",
      "was\n",
      "read\n",
      "by\n",
      "blinded\n",
      "local\n",
      "Table 2. Comparative Efﬁcacy of Pharmacologic Agents for Induction of Clinical Remission and Endoscopic Improvement in Biologic-Naive Patients With Moderate–Severe\n",
      "Ulcerative Colitis Using Network Meta-Analysis\n",
      "Induction of clinical remission\n",
      "Induction of endoscopic improvement\n",
      "Ustekinumab 6 mg/kg\n",
      "0.96 (0.38–2.45)\n",
      "0.80 (0.35–1.83)\n",
      "0.73 (0.31–1.74)\n",
      "1.05 (0.48–2.32)\n",
      "0.50 (0.22–1.12)\n",
      "2.04 (1.03–4.05)\n",
      "0.92 (0.45–1.89)\n",
      "Tofacitinib 10 mg b.d.\n",
      "0.84 (0.39–1.82)\n",
      "0.76 (0.33–1.76)\n",
      "1.10 (0.51–2.34)\n",
      "0.52 (0.24–1.12)\n",
      "2.12 (1.12–4.02)\n",
      "0.74 (0.36–1.51)\n",
      "0.80 (0.4–1.62)\n",
      "Vedolizumab\n",
      "0.91 (0.44–1.86)\n",
      "1.31 (0.88–1.95)\n",
      "0.62 (0.34–1.15)\n",
      "2.54 (1.60–4.02)\n",
      "1.07 (0.58–1.98)\n",
      "1.17 (0.64–2.12)\n",
      "1.45 (0.80–2.61)\n",
      "Golimumab\n",
      "1.44 (0.76–2.75)\n",
      "0.69 (0.35–1.36)\n",
      "2.79 (1.64–4.02)\n",
      "1.17 (0.65–2.13)\n",
      "1.28 (0.72–2.29)\n",
      "1.59 (0.90–2.82)\n",
      "1.10 (0.71–1.71)\n",
      "Adalimumab\n",
      "0.48 (0.26–0.86)\n",
      "1.94 (1.30–2.88)\n",
      "0.56 (0.30–1.04)\n",
      "0.61 (0.34–1.11)\n",
      "0.76 (0.42–1.37)\n",
      "0.52 (0.33–0.83)\n",
      "0.48 (0.31–0.74)\n",
      "Inﬂiximab\n",
      "4.07 (2.67–6.21)\n",
      "1.86 (1.11–3.13)\n",
      "2.03 (1.23–3.34)\n",
      "2.52 (1.54–4.11)\n",
      "1.74 (1.25–2.41)\n",
      "1.58 (1.18–2.13)\n",
      "3.32 (2.39–4.60)\n",
      "Placebo\n",
      "NOTE. Comparisons should be read from left to right. Odds ratio for comparisons are in the cell in common between the column-deﬁning and row-deﬁning treatment. Numbers in bold are statistically signiﬁcant. For induction of\n",
      "clinical remission, an odds ratio greater than 1 favors row-deﬁning treatment. For induction of endoscopic improvement, an odds ratio greater than 1 favors column-deﬁning treatment. Numbers in parentheses indicate 95% CI.\n",
      "b.d., twice daily.\n",
      "----------\n",
      "investigators for all trials, except trials of tofacitinib and\n",
      "ustekinumab, which were read by blinded central\n",
      "readers.7,26 Overall, the studies were deemed to be at\n",
      "low risk of bias, and all included studies were industry-\n",
      "sponsored.\n",
      "Induction Therapy\n",
      "First-line\n",
      "pharmacotherapy\n",
      "for\n",
      "moderate–severe\n",
      "ulcerative colitis. Overall, 15 RCTs including 3747 bio-\n",
      "logic-naïve patients with moderate–severe ulcerative\n",
      "colitis, treated with inﬂiximab (4 trials, 667 patients),\n",
      "adalimumab (4 trials, 1046 patients), golimumab (2 tri-\n",
      "als, 586 patients), vedolizumab (3 trials, 630 patients),\n",
      "tofacitinib (2 trials, 520 patients), and ustekinumab (1\n",
      "trial, 298 patients) were included; 1 trial compared\n",
      "adalimumab vs vedolizumab.\n",
      "Induction\n",
      "of\n",
      "clinical\n",
      "remission. On\n",
      "direct\n",
      "meta-\n",
      "analysis, all agents were superior to placebo for induc-\n",
      "tion of clinical remission, and effect size was strongest\n",
      "for inﬂiximab (OR, 4.07; 95% CI, 2.68–6.16) and vedoli-\n",
      "zumab (OR, 3.10; 95% CI, 1.53–6.26), with minimal to\n",
      "moderate heterogeneity across estimates (I2 < 35%)\n",
      "(Supplementary Figure 2A). On network meta-analysis,\n",
      "compared with placebo there was moderate conﬁdence\n",
      "in\n",
      "estimates\n",
      "supporting\n",
      "the\n",
      "use\n",
      "of\n",
      "inﬂiximab,\n",
      "adalimumab, golimumab, vedolizumab, tofacitinib, and\n",
      "ustekinumab for induction of clinical remission in bio-\n",
      "logic-naïve patients (evidence was rated down owing to\n",
      "imprecision caused by a low event rate) (Table 2). On\n",
      "comparison of active interventions, there was moderate\n",
      "conﬁdence in estimates supporting the use of inﬂiximab\n",
      "over adalimumab (OR, 2.10; 95% CI, 1.16–3.79); none of\n",
      "the other comparisons between active interventions\n",
      "were signiﬁcantly different (Table 2). Overall, inﬂiximab\n",
      "(SUCRA, 0.95) was ranked highest for inducing clinical\n",
      "remission\n",
      "in\n",
      "biologic-naïve\n",
      "patients\n",
      "with\n",
      "moderate–severe UC (Figure 2A). With an estimated\n",
      "placebo rate of achieving remission of 10% in included\n",
      "trials, we anticipate that 31.1%, 17.7%, 23.7%, 22.0%,\n",
      "Figure 2. (A) Relative efﬁ-\n",
      "cacy\n",
      "of\n",
      "different\n",
      "in-\n",
      "terventions for induction of\n",
      "clinical\n",
      "remission\n",
      "and\n",
      "endoscopic\n",
      "improvement\n",
      "in biologic-naïve patients\n",
      "with moderate to severely\n",
      "active ulcerative colitis. (B)\n",
      "Relative\n",
      "efﬁcacy\n",
      "of\n",
      "different interventions for\n",
      "induction of clinical remis-\n",
      "sion\n",
      "and\n",
      "endoscopic\n",
      "improvement\n",
      "in\n",
      "patients\n",
      "with moderate to severely\n",
      "active\n",
      "ulcerative\n",
      "colitis\n",
      "with prior exposure to tu-\n",
      "mor necrosis factor (TNF)⍺\n",
      "antagonists. SUCRA, sur-\n",
      "face under the cumulative\n",
      "ranking.\n",
      "September 2020\n",
      "Management of Moderate–Severe UC 2185\n",
      "----------\n",
      "methodologic characteristics). If direct and indirect es-\n",
      "timates were similar (ie, coherent), then the higher rating\n",
      "can be assigned to the network meta-analysis estimates.\n",
      "Results\n",
      "From a total 5651 unique studies identiﬁed using our\n",
      "search strategy, we included 15 RCTs of ﬁrst-line agents\n",
      "(in biologic-naïve patients) (Active Ulcerative Colitis Trials\n",
      "1 and 2,17 Jiang et al,18 NCT01551290,19 Ulcerative colitis\n",
      "Long-Term Remission and maintenance with Adalimumab\n",
      "1 and 2,20,21 Suzuki et al,22 Program of Ulcerative Colitis\n",
      "Research Studies Utilizing an Investigational Treatment\n",
      "phase 2 and phase 3 induction studies,23 GEMINI I,24\n",
      "Motoya et al,25 VARSITY, Oral Clinical Trials for tofAciti-\n",
      "nib in ulceratiVE colitis (OCTAVE) 1 and 2,26 and UNIFI),\n",
      "and 7 RCTs of second-line agents (in patients with prior\n",
      "exposure to TNFa antagonists) (Ulcerative colitis Long-\n",
      "Term Remission and maintenance with Adalimumab 2,21\n",
      "GEMINI I,24 Motoya et al,25 VARSITY,6 OCTAVE 1 and\n",
      "2,26 UNIFI7) in patients with moderate–severe ulcerative\n",
      "colitis. Trials of inﬂiximab (Active Ulcerative Colitis Trials\n",
      "1 and 2,17 Jiang et al,18 NCT0155129019), adalimumab\n",
      "(Ulcerative colitis Long-Term Remission and maintenance\n",
      "with Adalimumab 2,20,21 Suzuki et al22), vedolizumab\n",
      "(GEMINI I,24 Motoya et al,25 VARSITY6) and ustekinumab\n",
      "(UNIFI7) also reported outcomes on maintenance therapy\n",
      "within the same publication; Program of Ulcerative Colitis\n",
      "Research Studies Utilizing an Investigational Treatment-\n",
      "M, Program of Ulcerative Colitis Research Studies Utilizing\n",
      "an Investigational Treatment-J, and OCTAVE-Sustain\n",
      "reported\n",
      "outcomes\n",
      "for\n",
      "maintenance\n",
      "therapy\n",
      "with\n",
      "golimumab and tofacitinib, respectively.26–28 From our\n",
      "previous analysis, 3 additional studies were included.\n",
      "The schematic diagram of study selection is shown in\n",
      "Supplementary\n",
      "Figure\n",
      "1,\n",
      "and\n",
      "available\n",
      "direct\n",
      "comparisons and network of trials are shown in Figure 1.\n",
      "Trial and patient characteristics are summarized in\n",
      "Table 1. Overall, the median average age of patients was\n",
      "41 years (interquartile range, 40–42 y), and 60%\n",
      "(interquartile range, 56%–63%) were men. The median\n",
      "disease duration was 6.7 years (interquartile range,\n",
      "6.0–7.8 y), and 49% (interquartile range, 46%–55%) of\n",
      "patients had extensive colitis. A median of 40% (inter-\n",
      "quartile range, 30%–50%) of patients were treated with\n",
      "concomitant immunomodulators, and 51% (interquartile\n",
      "range, 45%–57%) were on corticosteroids at baseline.\n",
      "Patients across all trials and treatment arms were com-\n",
      "----------\n",
      "disease); ozanimod as an oral alternative\n",
      "• Infliximab, preferably in combination with  \n",
      " immunomodulators (severe disease,  \n",
      " \n",
      " extraintestinal manifestations)\n",
      "• Ustekinumab (for patients with substantial \n",
      " comorbidities or  contraindications to TNF  \n",
      " antagonists)\n",
      "First-line therapy\n",
      "• TNF antagonists: infliximab or adalimumab,  \n",
      " preferably in combination with   \n",
      " \n",
      " \n",
      " immunomodulators\n",
      "• Risankizumab or ustekinumab (for patients  \n",
      " with substantial comorbidities or  \n",
      " \n",
      " \n",
      " contraindications to TNF antagonists)\n",
      "First-line therapy\n",
      "• Vedolizumab\n",
      "• Ustekinumab\n",
      "First-line therapy\n",
      "• Risankizumab or ustekinumab\n",
      "• Vedolizumab\n",
      "Moderate-to-severely active\n",
      "ulcerative colitis\n",
      "Moderate-to-severely active\n",
      "ulcerative colitis\n",
      "Moderate-to-severely active\n",
      "Crohn's disease\n",
      "Moderate-to-severely active\n",
      "Crohn's disease\n",
      "Second-line therapy\n",
      "• Upadacitinib (or tofacitinib) (for patients with  \n",
      " prior failure of infliximab)\n",
      "• Infliximab or ustekinumab (for patients with  \n",
      " prior exposure to vedolizumab)\n",
      "• Vedolizumab (moderate disease, for patients  \n",
      " who discontinued first-line biologic agent \n",
      " for intolerance)\n",
      "Second-line therapy (in patients with prior \n",
      "exposure to infliximab or adalimumab)\n",
      "• Risankizumab or ustekinumab\n",
      "• Second TNF antagonist (for patients with  \n",
      " loss of response owing to immunogenicity,  \n",
      " or  intolerance, to first TNF antagonist)\n",
      "Second-line therapy\n",
      "• Ozanimod\n",
      "• Infliximab monotherapy\n",
      "• Upadacitinib (or tofacitinib)\n",
      "Second-line therapy\n",
      "• Infliximab or adalimumab   \n",
      " monotherapy\n",
      "Risk averse\n",
      "• Prior serious infections\n",
      "• Prior malignancy\n",
      "• Older age, multiple comorbidities\n",
      "Severe disease\n",
      "• High structural damage\n",
      "• High inflammatory burden\n",
      "• Significant efect on quality of life\n",
      "Patients’ values and preferences\n",
      "(lifestyle and logistics, speed of onset, costs)\n",
      "Fig. 1 | Proposed treatment algorithm for patients with moderate-to-severe \n",
      "Crohn’s disease and moderate-to-severe ulcerative colitis. The algorithm \n",
      "integrates data on comparative effectiveness and safety of therapies in the \n",
      "context of an individual patient’s risk of disease-related and treatment-related \n",
      "complications. TNF, tumour necrosis factor. Adapted with permission from  \n",
      "ref. 10, Elsevier.\n",
      "==========\n",
      "ORIGINAL QUESTION: ANALYSE the given patient profile based on given query based on one of the following criteria:\n",
      "- Whether treated patient is new patient or patient under maintenance\n",
      "- Prior response to Infliximab\n",
      "- Prior failure to Anti-TNF agents\n",
      "- Prior failure to Vedolizumab\n",
      "- Age\n",
      "- Pregnancy\n",
      "- Extraintestinale manifestations\n",
      "- Pouchitis\n",
      "RETURN up to 2 TOP choices of biological drugs given patient profile and context. Explain the PROS and CONS of the 2 choices.\n",
      "PATIENT PROFILE: 42 year-old woman with moderate ulcerative colitis on azathioprine and not responding to therapy\n",
      "\n",
      "==========\n",
      "CURRENT ANSWER:\n",
      "Based on the patient's profile, the top two choices of biological drugs for her moderate ulcerative colitis could be Infliximab and Vedolizumab.\n",
      "\n",
      "1. Infliximab:\n",
      "   - Advantages: Infliximab has been shown to be effective in inducing clinical remission and endoscopic improvement in biologic-naïve patients with moderate to severe ulcerative colitis. It is also beneficial for patients with extraintestinal manifestations of UC.\n",
      "   - Disadvantages: Infliximab is administered intravenously, which may be inconvenient for some patients. There may also be risks associated with its use, including serious adverse effects and the potential for patients to develop antibodies against the drug, reducing its effectiveness.\n",
      "\n",
      "2. Vedolizumab:\n",
      "   - Advantages: Vedolizumab is a newer biological therapy that targets α or β integrins, which are involved in the migration of immune cells to inflamed intestinal mucosa. It has been shown to be effective in treating moderate to severe UC. It is also a good option for patients who have failed or are intolerant to anti-TNF agents.\n",
      "   - Disadvantages: Like Infliximab, Vedolizumab is administered intravenously, which may be inconvenient for some patients. There may also be risks associated with its use, although it is generally well-tolerated.\n",
      "\n",
      "It's important to note that the choice of therapy should be individualized based on the patient's specific circumstances, including disease severity, prior response to therapy, and personal preferences. The patient should be involved in the decision-making process and informed about the potential benefits and risks of each treatment option.\n",
      "==========\n",
      "REFINED ANSWER:\n",
      "\u001b[0m\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "Retrying langchain.chat_models.openai.ChatOpenAI.completion_with_retry.<locals>._completion_with_retry in 4.0 seconds as it raised RateLimitError: Rate limit reached for 10KTPM-200RPM in organization org-ETbTMTN2JXYOUPDJgxuH2iO6 on tokens per min. Limit: 10000 / min. Please try again in 6ms. Contact us through our help center at help.openai.com if you continue to have issues..\n",
      "Retrying langchain.chat_models.openai.ChatOpenAI.completion_with_retry.<locals>._completion_with_retry in 4.0 seconds as it raised RateLimitError: Rate limit reached for 10KTPM-200RPM in organization org-ETbTMTN2JXYOUPDJgxuH2iO6 on tokens per min. Limit: 10000 / min. Please try again in 6ms. Contact us through our help center at help.openai.com if you continue to have issues..\n",
      "Retrying langchain.chat_models.openai.ChatOpenAI.completion_with_retry.<locals>._completion_with_retry in 4.0 seconds as it raised RateLimitError: Rate limit reached for 10KTPM-200RPM in organization org-ETbTMTN2JXYOUPDJgxuH2iO6 on tokens per min. Limit: 10000 / min. Please try again in 6ms. Contact us through our help center at help.openai.com if you continue to have issues..\n",
      "Retrying langchain.chat_models.openai.ChatOpenAI.completion_with_retry.<locals>._completion_with_retry in 8.0 seconds as it raised RateLimitError: Rate limit reached for 10KTPM-200RPM in organization org-ETbTMTN2JXYOUPDJgxuH2iO6 on tokens per min. Limit: 10000 / min. Please try again in 6ms. Contact us through our help center at help.openai.com if you continue to have issues..\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\n",
      "\u001b[1m> Finished chain.\u001b[0m\n",
      "\n",
      "\u001b[1m> Finished chain.\u001b[0m\n",
      "2023-10-02 17:34:20,248:INFO: 6062 tokens were added to prompt from 10 documents\n",
      "Query: 53 year-old man with moderate to severe extensive ulcerative colitis and low albumin levels\n",
      "\n",
      "\n",
      "\n",
      "\u001b[1m> Entering new SequentialChain chain...\u001b[0m\n",
      "\n",
      "\n",
      "\u001b[1m> Entering new RetrievalQAWithSourcesChain chain...\u001b[0m\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "Retrying langchain.chat_models.openai.ChatOpenAI.completion_with_retry.<locals>._completion_with_retry in 4.0 seconds as it raised RateLimitError: Rate limit reached for 10KTPM-200RPM in organization org-ETbTMTN2JXYOUPDJgxuH2iO6 on tokens per min. Limit: 10000 / min. Please try again in 6ms. Contact us through our help center at help.openai.com if you continue to have issues..\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\n",
      "\u001b[1m> Finished chain.\u001b[0m\n",
      "\n",
      "\n",
      "\u001b[1m> Entering new LLMChain chain...\u001b[0m\n",
      "Prompt after formatting:\n",
      "\u001b[32;1m\u001b[1;3mYou are a senior physician giving advice on treatment for moderate to severe ulcerative colitis (UC).\n",
      "Make reference to the CONTEXT given to assess the scenario.\n",
      "==========\n",
      "TASK: Your task is to analyse critically the CURRENT ANSWER given the CONTEXT.\n",
      "Then refine the existing answer (only if needed) based on the following instructions:\n",
      "- If no refinement needed, return the original answer in the correct output format.\n",
      "- If the answer cannot be inferred from CONTEXT, return \"NO ANSWER\".\n",
      "- The final output should be a list of up to 2 choices of biological drugs given patient profile and context and PROS/CONS for each recommendations.\n",
      "==========\n",
      "CONTEXT:\n",
      "severely active ulcerative colitis: results from phase 3 \n",
      "U-ACCOMPLISH study. J Crohn’s Colitis 2021; 15 (suppl 1): S021–22.\n",
      "9 \n",
      "Thorlund K, Druyts E, Mills EJ, Fedorak RN, Marshall JK. \n",
      "Adalimumab versus infliximab for the treatment of moderate to \n",
      "severe ulcerative colitis in adult patients naïve to anti-TNF therapy: \n",
      "an indirect treatment comparison meta-analysis. J Crohn’s Colitis \n",
      "2014; 8: 571–81.\n",
      "10 \n",
      "Danese S, Fiorino G, Peyrin-Biroulet L, et al. Biological agents for \n",
      "moderately to severely active ulcerative colitis: a systematic review \n",
      "and network meta-analysis. Ann Intern Med 2014; 160: 704–11.\n",
      "11 \n",
      "Singh S, Fumery M, Sandborn WJ, Murad MH. Systematic review \n",
      "with network meta-analysis: first- and second-line pharmacotherapy \n",
      "for moderate-severe ulcerative colitis. Aliment Pharmacol Ther 2018; \n",
      "47: 162–75.\n",
      "12 \n",
      "Bonovas S, Lytras T, Nikolopoulos G, Peyrin-Biroulet L, Danese S. \n",
      "Systematic review with network meta-analysis: comparative \n",
      "assessment of tofacitinib and biological therapies for moderate-to-\n",
      "severe ulcerative colitis. Aliment Pharmacol Ther 2018; 47: 454–65.\n",
      "13 \n",
      "Singh S, Murad MH, Fumery M, Dulai PS, Sandborn WJ. First- and \n",
      "second-line pharmacotherapies for patients with moderate to \n",
      "severely active ulcerative colitis: an updated network meta-analysis. \n",
      "Clin Gastroenterol Hepatol 2020; 18: 2179–91.e6.\n",
      "14 \n",
      "Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting \n",
      "items for systematic reviews and meta-analyses: the PRISMA \n",
      "statement. Ann Intern Med 2009; 151: 264–69.\n",
      "15 \n",
      "Jansen JP, Fleurence R, Devine B, et al. Interpreting indirect \n",
      "treatment comparisons and network meta-analysis for health-care \n",
      "decision making: report of the ISPOR Task Force on Indirect \n",
      "Treatment Comparisons Good Research Practices: part 1. \n",
      "Value Health 2011; 14: 417–28.\n",
      "16 \n",
      "Sterne JAC, Savović J, Page MJ, et al. RoB 2: a revised tool for \n",
      "assessing risk of bias in randomised trials. BMJ 2019; 366: l4898.\n",
      "17 \n",
      "Rücker G, Schwarzer G. Ranking treatments in frequentist network \n",
      "meta-analysis works without resampling methods. \n",
      "BMC Med Res Methodol 2015; 15: 58.\n",
      "----------\n",
      "Burr et al. \n",
      " \n",
      "7 of 45 \n",
      "INTRODUCTION \n",
      "  Ulcerative colitis (UC) is a chronic inflammatory disorder of the bowel that causes \n",
      "continuous mucosal inflammation commencing in the rectum and extending proximally for a \n",
      "variable extent.[1] It is estimated that UC affects 2.5 million people in Europe,[2] and the \n",
      "disease follows a relapsing and remitting course, with intermittent flares of disease activity, \n",
      "some of which may be moderate to severe. Management of these is medical, for the most \n",
      "part, with surgery reserved for patients with refractory disease. Although 5-aminosalicylates \n",
      "(5-ASAs) are efficacious for mild to moderate disease activity,[3-6] more severe flares are \n",
      "usually treated with corticosteroids.[7] However, these have potentially serious adverse \n",
      "effects and a substantial proportion of patients may become either dependent on them to \n",
      "maintain remission,[8] or refractory to them.[9] As a result, over the last 20 years novel \n",
      "drugs, with more precise modes of action, based on mechanisms of disease identified in \n",
      "genome wide association studies,[10] have been developed.  \n",
      "The first of these agents was infliximab, a drug targeting the pro-inflammatory \n",
      "cytokine tumour necrosis factor-α (TNF-α), which demonstrated efficacy in clinical trials in \n",
      "moderate to severe UC.[11] Since then, other drugs against TNF-α have been tested, such as \n",
      "adalimumab and golimumab.[12, 13] In addition, newer biological therapies targeting α or β \n",
      "integrins, which are involved in migration of immune cells to inflamed intestinal mucosa, \n",
      "such as vedolizumab or etrolizumab,[14, 15] or acting against other pro-inflammatory \n",
      "cytokines implicated in the pathogenesis of UC, such as ustekinumab,[16] have been tested. \n",
      "However, even these more selective drugs do not work in all patients, there may be risks \n",
      "associated with their use,[17-19] and the fact that they are administered either intravenously \n",
      "or subcutaneously, may be inconvenient for patients. The search for alternative agents for the \n",
      "treatment of UC has, therefore, continued.\n",
      "----------\n",
      "41 years (interquartile range, 40–42 y), and 60%\n",
      "(interquartile range, 56%–63%) were men. The median\n",
      "disease duration was 6.7 years (interquartile range,\n",
      "6.0–7.8 y), and 49% (interquartile range, 46%–55%) of\n",
      "patients had extensive colitis. A median of 40% (inter-\n",
      "quartile range, 30%–50%) of patients were treated with\n",
      "concomitant immunomodulators, and 51% (interquartile\n",
      "range, 45%–57%) were on corticosteroids at baseline.\n",
      "Patients across all trials and treatment arms were com-\n",
      "parable in terms of baseline prognostic variables, inclu-\n",
      "sion/exclusion\n",
      "criteria,\n",
      "and\n",
      "co-interventions.\n",
      "All\n",
      "outcomes were assessed uniformly based on the stan-\n",
      "dard deﬁnition of the Mayo Clinic score, between weeks\n",
      "6 and 10 for induction therapy (inﬂiximab, adalimumab,\n",
      "tofacitinib, ustekinumab, 8 weeks; golimumab, 6 weeks;\n",
      "vedolizumab, 6 weeks, 10 weeks, and 14 weeks in\n",
      "VARSITY),6 and weeks 30, 54, or 60 for maintenance\n",
      "therapy;\n",
      "endoscopy\n",
      "was\n",
      "read\n",
      "by\n",
      "blinded\n",
      "local\n",
      "Table 2. Comparative Efﬁcacy of Pharmacologic Agents for Induction of Clinical Remission and Endoscopic Improvement in Biologic-Naive Patients With Moderate–Severe\n",
      "Ulcerative Colitis Using Network Meta-Analysis\n",
      "Induction of clinical remission\n",
      "Induction of endoscopic improvement\n",
      "Ustekinumab 6 mg/kg\n",
      "0.96 (0.38–2.45)\n",
      "0.80 (0.35–1.83)\n",
      "0.73 (0.31–1.74)\n",
      "1.05 (0.48–2.32)\n",
      "0.50 (0.22–1.12)\n",
      "2.04 (1.03–4.05)\n",
      "0.92 (0.45–1.89)\n",
      "Tofacitinib 10 mg b.d.\n",
      "0.84 (0.39–1.82)\n",
      "0.76 (0.33–1.76)\n",
      "1.10 (0.51–2.34)\n",
      "0.52 (0.24–1.12)\n",
      "2.12 (1.12–4.02)\n",
      "0.74 (0.36–1.51)\n",
      "0.80 (0.4–1.62)\n",
      "Vedolizumab\n",
      "0.91 (0.44–1.86)\n",
      "1.31 (0.88–1.95)\n",
      "0.62 (0.34–1.15)\n",
      "2.54 (1.60–4.02)\n",
      "1.07 (0.58–1.98)\n",
      "1.17 (0.64–2.12)\n",
      "1.45 (0.80–2.61)\n",
      "Golimumab\n",
      "1.44 (0.76–2.75)\n",
      "0.69 (0.35–1.36)\n",
      "2.79 (1.64–4.02)\n",
      "1.17 (0.65–2.13)\n",
      "1.28 (0.72–2.29)\n",
      "1.59 (0.90–2.82)\n",
      "1.10 (0.71–1.71)\n",
      "Adalimumab\n",
      "0.48 (0.26–0.86)\n",
      "1.94 (1.30–2.88)\n",
      "0.56 (0.30–1.04)\n",
      "0.61 (0.34–1.11)\n",
      "0.76 (0.42–1.37)\n",
      "0.52 (0.33–0.83)\n",
      "0.48 (0.31–0.74)\n",
      "Inﬂiximab\n",
      "4.07 (2.67–6.21)\n",
      "1.86 (1.11–3.13)\n",
      "2.03 (1.23–3.34)\n",
      "2.52 (1.54–4.11)\n",
      "1.74 (1.25–2.41)\n",
      "1.58 (1.18–2.13)\n",
      "3.32 (2.39–4.60)\n",
      "Placebo\n",
      "NOTE. Comparisons should be read from left to right. Odds ratio for comparisons are in the cell in common between the column-deﬁning and row-deﬁning treatment. Numbers in bold are statistically signiﬁcant. For induction of\n",
      "clinical remission, an odds ratio greater than 1 favors row-deﬁning treatment. For induction of endoscopic improvement, an odds ratio greater than 1 favors column-deﬁning treatment. Numbers in parentheses indicate 95% CI.\n",
      "b.d., twice daily.\n",
      "----------\n",
      "Therapeutic strategies for the management of recentlydiagnosedulcerative colitis. IMMs include thiopurines and methotrexate. 5-ASA, 5-amino salicylic acid; ASUC, acute severe ulcerative colitis; IPAA, ileal pouch anal anastomosis.\n",
      "\n",
      "Risk stratification: Mild\n",
      "Clinical features: NA\n",
      "Treatment options: 5-ASA (oral and/or topical)\n",
      "\n",
      "Risk stratification: Moderate\n",
      "Clinical features: NA\n",
      "Treatment options: Can consider 5-ASA (with rapid step-up if inadequate response)\n",
      "\n",
      "Risk stratification: Moderate\n",
      "Clinical features: NA\n",
      "Treatment options: VDZ or UST\n",
      "\n",
      "Risk stratification: Moderate\n",
      "Clinical features: NA\n",
      "Treatment options: Thiopurine\n",
      "\n",
      "Risk stratification: Moderate\n",
      "Clinical features: NA\n",
      "Treatment options: TNFi +/- IMM\n",
      "\n",
      "Risk stratification: Severe\n",
      "Clinical features: NA\n",
      "Treatment options: TNFi +/- IMM\n",
      "\n",
      "Risk stratification: Severe\n",
      "Clinical features: NA\n",
      "Treatment options: Subtotal colectomy + IPAA or cyclosporine (for ASUC)\n",
      "\n",
      "Risk stratification: Additional consideration: EIM present\n",
      "Clinical features: Psoriasis or psoriatic arthritis\n",
      "Treatment options: UST\n",
      "\n",
      "Risk stratification: Additional consideration: EIM present\n",
      "Clinical features: Other arthritis\n",
      "Treatment options: TNFi\n",
      "\n",
      "\n",
      "----------\n",
      "Articles\n",
      "www.thelancet.com/gastrohep   Vol 7   February 2022 \n",
      "161\n",
      "Lancet Gastroenterol Hepatol \n",
      "2022; 7: 161–70\n",
      "Published Online \n",
      "November 29, 2021 \n",
      "https://doi.org/10.1016/ \n",
      "S2468-1253(21)00377-0\n",
      "See Comment page 110\n",
      "*Contributed equally\n",
      "Inflammatory Bowel Disease \n",
      "Unit, Gastroenterology \n",
      "Section, Department of \n",
      "Internal Medicine, Centro de \n",
      "Educación Médica e \n",
      "Investigaciones Clínicas, \n",
      "Buenos Aires, Argentina \n",
      "(J S Lasa MD, P A Olivera MD); \n",
      "Gastroenterology Department, \n",
      "Hospital Británico de Buenos \n",
      "Aires, Buenos Aires, Argentina \n",
      "(J S Lasa); Zane Cohen Centre \n",
      "for Digestive Diseases, \n",
      "Lunenfeld-Tanenbaum \n",
      "Research Institute, Sinai Health \n",
      "System, Toronto, ON, Canada \n",
      "(P A Olivera); Division of \n",
      "Gastroenterology, Mount Sinai \n",
      "Hospital, University of Toronto, \n",
      "Toronto, ON, Canada \n",
      "(P A Olivera); Gastroenterology \n",
      "and Endoscopy, IRCCS Ospedale \n",
      "San Raffaele and University \n",
      "Vita-Salute San Raffaele, \n",
      "Milano, Italy \n",
      "(Prof S Danese MD); INSERM \n",
      "NGERE and Department of \n",
      "Hepatogastroenterology, \n",
      "Nancy University Hospital, \n",
      "Lorraine University, \n",
      "Vandoeuvre-lés-Nancy, France \n",
      "(Prof L Peyrin-Biroulet MD) \n",
      "Correspondence to: \n",
      "Prof Laurent Peyrin-Biroulet, \n",
      "INSERM NGERE and Department \n",
      "of Hepatogastroenterology, \n",
      "Nancy University Hospital, \n",
      "Lorraine University, Vandoeuvre-\n",
      "lès-Nancy F-54511, France \n",
      "peyrinbiroulet@gmail.com\n",
      "Efficacy and safety of biologics and small molecule drugs for \n",
      "patients with moderate-to-severe ulcerative colitis: \n",
      "a systematic review and network meta-analysis \n",
      "Juan S Lasa*, Pablo A Olivera*, Silvio Danese, Laurent Peyrin-Biroulet\n",
      "Summary\n",
      "Background There is a growing armamentarium for the treatment of moderate-to-severe ulcerative colitis. We aimed \n",
      "to compare the relative efficacy and safety of biologics and small molecule drugs for the treatment of patients with \n",
      "moderate-to-severe ulcerative colitis.\n",
      "Methods In this systematic review and network meta-analysis, we searched MEDLINE, Embase, and the Cochrane \n",
      "Central Register of Controlled Trials without language restrictions for articles published between Jan 1, 1990, and \n",
      "July 1, 2021. Major congresses’ databases from Jan 1, 2018, to July 3, 2021, were reviewed manually. Phase 3, placebo-\n",
      "controlled or head-to-head randomised controlled trials (RCTs) assessing the efficacy and safety of biologics or small \n",
      "molecule drugs as induction or maintenance therapies for patients with moderate-to-severe ulcerative colitis were\n",
      "----------\n",
      "methodologic characteristics). If direct and indirect es-\n",
      "timates were similar (ie, coherent), then the higher rating\n",
      "can be assigned to the network meta-analysis estimates.\n",
      "Results\n",
      "From a total 5651 unique studies identiﬁed using our\n",
      "search strategy, we included 15 RCTs of ﬁrst-line agents\n",
      "(in biologic-naïve patients) (Active Ulcerative Colitis Trials\n",
      "1 and 2,17 Jiang et al,18 NCT01551290,19 Ulcerative colitis\n",
      "Long-Term Remission and maintenance with Adalimumab\n",
      "1 and 2,20,21 Suzuki et al,22 Program of Ulcerative Colitis\n",
      "Research Studies Utilizing an Investigational Treatment\n",
      "phase 2 and phase 3 induction studies,23 GEMINI I,24\n",
      "Motoya et al,25 VARSITY, Oral Clinical Trials for tofAciti-\n",
      "nib in ulceratiVE colitis (OCTAVE) 1 and 2,26 and UNIFI),\n",
      "and 7 RCTs of second-line agents (in patients with prior\n",
      "exposure to TNFa antagonists) (Ulcerative colitis Long-\n",
      "Term Remission and maintenance with Adalimumab 2,21\n",
      "GEMINI I,24 Motoya et al,25 VARSITY,6 OCTAVE 1 and\n",
      "2,26 UNIFI7) in patients with moderate–severe ulcerative\n",
      "colitis. Trials of inﬂiximab (Active Ulcerative Colitis Trials\n",
      "1 and 2,17 Jiang et al,18 NCT0155129019), adalimumab\n",
      "(Ulcerative colitis Long-Term Remission and maintenance\n",
      "with Adalimumab 2,20,21 Suzuki et al22), vedolizumab\n",
      "(GEMINI I,24 Motoya et al,25 VARSITY6) and ustekinumab\n",
      "(UNIFI7) also reported outcomes on maintenance therapy\n",
      "within the same publication; Program of Ulcerative Colitis\n",
      "Research Studies Utilizing an Investigational Treatment-\n",
      "M, Program of Ulcerative Colitis Research Studies Utilizing\n",
      "an Investigational Treatment-J, and OCTAVE-Sustain\n",
      "reported\n",
      "outcomes\n",
      "for\n",
      "maintenance\n",
      "therapy\n",
      "with\n",
      "golimumab and tofacitinib, respectively.26–28 From our\n",
      "previous analysis, 3 additional studies were included.\n",
      "The schematic diagram of study selection is shown in\n",
      "Supplementary\n",
      "Figure\n",
      "1,\n",
      "and\n",
      "available\n",
      "direct\n",
      "comparisons and network of trials are shown in Figure 1.\n",
      "Trial and patient characteristics are summarized in\n",
      "Table 1. Overall, the median average age of patients was\n",
      "41 years (interquartile range, 40–42 y), and 60%\n",
      "(interquartile range, 56%–63%) were men. The median\n",
      "disease duration was 6.7 years (interquartile range,\n",
      "6.0–7.8 y), and 49% (interquartile range, 46%–55%) of\n",
      "patients had extensive colitis. A median of 40% (inter-\n",
      "quartile range, 30%–50%) of patients were treated with\n",
      "concomitant immunomodulators, and 51% (interquartile\n",
      "range, 45%–57%) were on corticosteroids at baseline.\n",
      "Patients across all trials and treatment arms were com-\n",
      "----------\n",
      "Stratification of inflammatory bowel disease risk of progression based on disease severity and activity. BMI, body mass index; CDAI, Crohns Disease Activity Index; ESR, erythrocyte sedimentation rate; UCEIS, Ulcerative Colitis Endoscopic Index of Severity.\n",
      "\n",
      ": Remission\n",
      "Stools (no./d): Formed stool\n",
      "Blood in stools: None\n",
      "Urgency: None\n",
      "Hemoglobin: Normal\n",
      "ESR: 30\n",
      "CRP (mg/L): Normal\n",
      "FC (ug/g): < 150-200\n",
      "Endoscopy (Mayo subscore): O1\n",
      "UCEIS: O1\n",
      "\n",
      ": Mild\n",
      "Stools (no./d): < 4\n",
      "Blood in stools: Intermittent\n",
      "Urgency: Mild, occasional\n",
      "Hemoglobin: Normal\n",
      "ESR: 30\n",
      "CRP (mg/L): Elevated\n",
      "FC (ug/g): > 150-200\n",
      "Endoscopy (Mayo subscore): 1\n",
      "UCEIS: 24\n",
      "\n",
      ": Moderate\n",
      "Stools (no./d): > 6\n",
      "Blood in stools: Frequent\n",
      "Urgency: Often\n",
      "Hemoglobin: 75% of normal\n",
      "ESR: 30\n",
      "CRP (mg/L): Elevated\n",
      "FC (ug/g): 150-200\n",
      "Endoscopy (Mayo subscore): 23\n",
      "UCEIS: 58\n",
      "\n",
      ": Severe\n",
      "Stools (no./d): > 10\n",
      "Blood in stools: Continuous\n",
      "Urgency: Continuous\n",
      "Hemoglobin: Transfusions required\n",
      "ESR: 30\n",
      "CRP (mg/L): Elevated\n",
      "FC (ug/g): > 150200\n",
      "Endoscopy (Mayo subscore): 3\n",
      "UCEIS: 78\n",
      "\n",
      "\n",
      "----------\n",
      "Burr et al. \n",
      " \n",
      "5 of 45 \n",
      "STUDY HIGHLIGHTS \n",
      " \n",
      "What is already known about this subject \n",
      "• Ulcerative colitis (UC) follows a relapsing and remitting course, with intermittent \n",
      "flares of disease activity, some of which may be moderate to severe. \n",
      "• These are usually treated with corticosteroids, which have potentially serious adverse \n",
      "effects, so biological therapies and small molecules have been developed and licensed \n",
      "for this indication.  \n",
      "• Although previous network meta-analyses have compared their efficacy and safety, \n",
      "this is a rapidly moving field, and there are already several newer drugs that have \n",
      "shown efficacy in phase III clinical trials that were not considered in these. \n",
      " \n",
      "What are the new findings \n",
      "• In terms of clinical remission and clinical response, upadacitinib 45mg o.d. ranked \n",
      "first in all patients, in patients previously exposed to anti-tumour necrosis factor \n",
      "(TNF)-α therapies, and in patients naïve to these drugs.  \n",
      "• In terms of endoscopic improvement infliximab 10mg/kg ranked first, followed by \n",
      "upadacitinib 45mg o.d., and infliximab 5mg/kg.  \n",
      "• However, for endoscopic improvement again upadacitinib 45mg o.d. ranked first in \n",
      "patients previously exposed to anti-TNF-α therapies, and in patients who were anti-\n",
      "TNF-α naïve.  \n",
      "• None of the drugs studied were more likely to lead to serious adverse events than \n",
      "placebo.\n",
      "----------\n",
      "Parkes, M., Vermeire, S., Rioux, J.D., Mansﬁeld, J., Silverberg, M.S., Radford-\n",
      "Smith, G., McGovern, D.P., Barrett, J.C., Lees, C.W., 2016. Inherited determinants of\n",
      "crohn's disease and ulcerative colitis phenotypes: a genetic association study. Lancet\n",
      "387 (10014), 156–167.\n",
      "Colombel, J.F., Sandborn, W.J., Rutgeerts, P., Enns, R., Hanauer, S.B., Panaccione, R.,\n",
      "Schreiber, S., Byczkowski, D., Li, J., Kent, J.D., Pollack, P.F., 2007. Adalimumab for\n",
      "maintenance of clinical response and remission in patients with crohn's disease: the\n",
      "charm trial. Gastroenterology 132 (1), 52–65.\n",
      "Conrad, M.A., Kelsen, J.R., 2020. The treatment of pediatric inﬂammatory bowel disease\n",
      "with biologic therapies. Curr. Gastroenterol. Rep. 22 (8), 36–51.\n",
      "Csontos, A.A., Molnar, A., Piri, Z., Katona, B., Dako, S., Palﬁ, E., Miheller, P., 2016. The\n",
      "effect of anti-tnfalpha induction therapy on the nutritional status and dietary intake\n",
      "in inﬂammatory bowel disease. J Gastrointestin Liver Dis 25 (1), 49–56.\n",
      "Dai, Z.H., Xu, X.T., Ran, Z.H., 2020. Associations between obesity and the effectiveness of\n",
      "anti-tumor necrosis factor-alpha agents in inﬂammatory bowel disease patients: a\n",
      "literature review and meta-analysis. Ann. Pharmacother. 54 (8), 729–741.\n",
      "Danese, S., Colombel, J.F., Lukas, M., Gisbert, J.P., D’Haens, G., Hayee, B., Panaccione, R.,\n",
      "Kim, H.S., Reinisch, W., Tyrrell, H., Oh, Y.S., Tole, S., Chai, A., Chamberlain-\n",
      "James, K., Tang, M.T., Schreiber, S., Group, G.S., 2021. Etrolizumab versus inﬂiximab\n",
      "for the treatment of moderately to severely active ulcerative colitis (gardenia): a\n",
      "randomised, double-blind, double-dummy, phase 3 study. Lancet Gastroenterol\n",
      "Hepatol 7 (2), 118–127.\n",
      "Danese, S., Fiorino, G., Peyrin-Biroulet, L., Lucenteforte, E., Virgili, G., Moja, L.,\n",
      "Bonovas, S., 2014. Biological agents for moderately to severely active ulcerative\n",
      "colitis: a systematic review and network meta-analysis. Ann. Intern. Med. 160 (10),\n",
      "704–711.\n",
      "P. Juillerat et al.\n",
      "Current Research in Pharmacology and Drug Discovery 3 (2022) 100104\n",
      "6\n",
      "----------\n",
      "Disease Phenotype and Clinical Characteristics\n",
      "The International Organization for the Study of Inﬂam-\n",
      "matory Bowel Disease and the American Gastroenterological\n",
      "Association (AGA) provide a framework for categorization of\n",
      "CD and UC severity into mild-, moderate-, and high-risk\n",
      "groups based on phenotype and other characteristics.59,60\n",
      "In CD, the presence of large or deep mucosal lesions on\n",
      "endoscopy or magnetic resonance imaging (MRI), history of\n",
      "a ﬁstula, abscess, or intestinal resection are predictors of\n",
      "worse outcomes.59,60 In a prospective population-based\n",
      "inception cohort of 213 patients with CD, penetrating\n",
      "behavior was associated with a higher risk of progression to\n",
      "perianal disease (HR, 5.65; 95% CI, 2.65–12.03) and was a\n",
      "risk factor for resection (HR, 3.92; 95% CI, 1.86–8.67) and\n",
      "hospitalization (HR, 1.01; 95% CI, 1.00–1.01).16 Ileal and\n",
      "upper gastrointestinal disease location and extensive dis-\n",
      "ease are also markers of severe disease.61 Cigarette smoking\n",
      "is associated with complications and need for therapy\n",
      "escalation.61\n",
      "In CD, the threshold of suspicion should be low for high-\n",
      "quality imaging of the pelvis, such as MRI, to rule our\n",
      "perianal CD. In a retrospective study of 136 pediatric CD\n",
      "patients, presence of anal ﬁssures and skin tags, non-White\n",
      "race, and elevated C-reactive protein (CRP) were risk factors\n",
      "for perianal CD.62 In another study of 274 patients in China\n",
      "with recently diagnosed CD, all of whom underwent MRI\n",
      "pelvis, asymptomatic perianal ﬁstulas were diagnosed in\n",
      "17.5% of patients and colonic location of CD was a risk\n",
      "factor for asymptomatic perianal ﬁstulas.63\n",
      "In UC, corresponding predictors of aggressive disease\n",
      "advised by the International Organization for the Study of\n",
      "Inﬂammatory Bowel Disease include active colonic ulcers\n",
      "and prior use of biologics.59 Extensive colitis, deep ulcers,\n",
      "need for corticosteroids, hospitalization, Clostridium difﬁcile,\n",
      "and cytomegalovirus infection also indicate higher colec-\n",
      "tomy risk.64 Of note, disease extension from limited disease\n",
      "to\n",
      "extensive\n",
      "or\n",
      "pancolitis\n",
      "is\n",
      "associated\n",
      "with\n",
      "worse\n",
      "prognosis.45,65\n",
      "In addition, co-occurrence of other immune-mediated\n",
      "inﬂammatory diseases can occur, most commonly with\n",
      "psoriasis and asthma, but also, in more rare instances, with\n",
      "other gastrointestinal diseases (eg, celiac, nonalcoholic fatty\n",
      "liver disease,66 and eosinophilic esophagitis).67,68 Presence\n",
      "of a concomitant immune-mediated inﬂammatory disease is\n",
      "Figure\n",
      "1. Inﬂammatory\n",
      "bowel disease severity vs\n",
      "==========\n",
      "ORIGINAL QUESTION: ANALYSE the given patient profile based on given query based on one of the following criteria:\n",
      "- Whether treated patient is new patient or patient under maintenance\n",
      "- Prior response to Infliximab\n",
      "- Prior failure to Anti-TNF agents\n",
      "- Prior failure to Vedolizumab\n",
      "- Age\n",
      "- Pregnancy\n",
      "- Extraintestinale manifestations\n",
      "- Pouchitis\n",
      "RETURN up to 2 TOP choices of biological drugs given patient profile and context. Explain the PROS and CONS of the 2 choices.\n",
      "PATIENT PROFILE: 53 year-old man with moderate to severe extensive ulcerative colitis and low albumin levels\n",
      "\n",
      "==========\n",
      "CURRENT ANSWER:\n",
      "Based on the given patient profile, the patient is under maintenance for moderate to severe ulcerative colitis. The patient's age is 53 years old. There is no information provided about the patient's prior response to Infliximab, prior failure to Anti-TNF agents, prior failure to Vedolizumab, pregnancy status, extraintestinal manifestations, or pouchitis.\n",
      "\n",
      "Given the patient's profile, the top two choices of biological drugs could be:\n",
      "\n",
      "1. Infliximab\n",
      "Advantages: Infliximab has demonstrated efficacy in clinical trials for moderate to severe ulcerative colitis. It targets the pro-inflammatory cytokine tumour necrosis factor-α (TNF-α), which is involved in the inflammation process in ulcerative colitis.\n",
      "Disadvantages: Infliximab may not work in all patients. There may be risks associated with its use, such as serious infections, malignancies, or heart failure. It is also administered intravenously, which may be inconvenient for some patients.\n",
      "\n",
      "2. Vedolizumab\n",
      "Advantages: Vedolizumab targets α or β integrins, which are involved in the migration of immune cells to inflamed intestinal mucosa. This makes it a more selective treatment option for ulcerative colitis.\n",
      "Disadvantages: Like Infliximab, Vedolizumab may not work in all patients. There may be risks associated with its use, and it is also administered intravenously.\n",
      "\n",
      "Please note that the choice of treatment should be individualized based on the patient's specific condition, preferences, and potential side effects of the drugs. The patient should have a detailed discussion with their healthcare provider to decide on the best treatment option.\n",
      "==========\n",
      "REFINED ANSWER:\n",
      "\u001b[0m\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "Retrying langchain.chat_models.openai.ChatOpenAI.completion_with_retry.<locals>._completion_with_retry in 4.0 seconds as it raised RateLimitError: Rate limit reached for 10KTPM-200RPM in organization org-ETbTMTN2JXYOUPDJgxuH2iO6 on tokens per min. Limit: 10000 / min. Please try again in 6ms. Contact us through our help center at help.openai.com if you continue to have issues..\n",
      "Retrying langchain.chat_models.openai.ChatOpenAI.completion_with_retry.<locals>._completion_with_retry in 4.0 seconds as it raised RateLimitError: Rate limit reached for 10KTPM-200RPM in organization org-ETbTMTN2JXYOUPDJgxuH2iO6 on tokens per min. Limit: 10000 / min. Please try again in 6ms. Contact us through our help center at help.openai.com if you continue to have issues..\n",
      "Retrying langchain.chat_models.openai.ChatOpenAI.completion_with_retry.<locals>._completion_with_retry in 4.0 seconds as it raised RateLimitError: Rate limit reached for 10KTPM-200RPM in organization org-ETbTMTN2JXYOUPDJgxuH2iO6 on tokens per min. Limit: 10000 / min. Please try again in 6ms. Contact us through our help center at help.openai.com if you continue to have issues..\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\n",
      "\u001b[1m> Finished chain.\u001b[0m\n",
      "\n",
      "\u001b[1m> Finished chain.\u001b[0m\n",
      "2023-10-02 17:35:31,997:INFO: 5895 tokens were added to prompt from 10 documents\n",
      "Query: 42 year-old woman with severe ulcerative colitis and rare fistulating disease\n",
      "\n",
      "\n",
      "\n",
      "\u001b[1m> Entering new SequentialChain chain...\u001b[0m\n",
      "\n",
      "\n",
      "\u001b[1m> Entering new RetrievalQAWithSourcesChain chain...\u001b[0m\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "Retrying langchain.chat_models.openai.ChatOpenAI.completion_with_retry.<locals>._completion_with_retry in 4.0 seconds as it raised RateLimitError: Rate limit reached for 10KTPM-200RPM in organization org-ETbTMTN2JXYOUPDJgxuH2iO6 on tokens per min. Limit: 10000 / min. Please try again in 6ms. Contact us through our help center at help.openai.com if you continue to have issues..\n",
      "Retrying langchain.chat_models.openai.ChatOpenAI.completion_with_retry.<locals>._completion_with_retry in 4.0 seconds as it raised RateLimitError: Rate limit reached for 10KTPM-200RPM in organization org-ETbTMTN2JXYOUPDJgxuH2iO6 on tokens per min. Limit: 10000 / min. Please try again in 6ms. Contact us through our help center at help.openai.com if you continue to have issues..\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\n",
      "\u001b[1m> Finished chain.\u001b[0m\n",
      "\n",
      "\n",
      "\u001b[1m> Entering new LLMChain chain...\u001b[0m\n",
      "Prompt after formatting:\n",
      "\u001b[32;1m\u001b[1;3mYou are a senior physician giving advice on treatment for moderate to severe ulcerative colitis (UC).\n",
      "Make reference to the CONTEXT given to assess the scenario.\n",
      "==========\n",
      "TASK: Your task is to analyse critically the CURRENT ANSWER given the CONTEXT.\n",
      "Then refine the existing answer (only if needed) based on the following instructions:\n",
      "- If no refinement needed, return the original answer in the correct output format.\n",
      "- If the answer cannot be inferred from CONTEXT, return \"NO ANSWER\".\n",
      "- The final output should be a list of up to 2 choices of biological drugs given patient profile and context and PROS/CONS for each recommendations.\n",
      "==========\n",
      "CONTEXT:\n",
      "Burr et al. \n",
      " \n",
      "7 of 45 \n",
      "INTRODUCTION \n",
      "  Ulcerative colitis (UC) is a chronic inflammatory disorder of the bowel that causes \n",
      "continuous mucosal inflammation commencing in the rectum and extending proximally for a \n",
      "variable extent.[1] It is estimated that UC affects 2.5 million people in Europe,[2] and the \n",
      "disease follows a relapsing and remitting course, with intermittent flares of disease activity, \n",
      "some of which may be moderate to severe. Management of these is medical, for the most \n",
      "part, with surgery reserved for patients with refractory disease. Although 5-aminosalicylates \n",
      "(5-ASAs) are efficacious for mild to moderate disease activity,[3-6] more severe flares are \n",
      "usually treated with corticosteroids.[7] However, these have potentially serious adverse \n",
      "effects and a substantial proportion of patients may become either dependent on them to \n",
      "maintain remission,[8] or refractory to them.[9] As a result, over the last 20 years novel \n",
      "drugs, with more precise modes of action, based on mechanisms of disease identified in \n",
      "genome wide association studies,[10] have been developed.  \n",
      "The first of these agents was infliximab, a drug targeting the pro-inflammatory \n",
      "cytokine tumour necrosis factor-α (TNF-α), which demonstrated efficacy in clinical trials in \n",
      "moderate to severe UC.[11] Since then, other drugs against TNF-α have been tested, such as \n",
      "adalimumab and golimumab.[12, 13] In addition, newer biological therapies targeting α or β \n",
      "integrins, which are involved in migration of immune cells to inflamed intestinal mucosa, \n",
      "such as vedolizumab or etrolizumab,[14, 15] or acting against other pro-inflammatory \n",
      "cytokines implicated in the pathogenesis of UC, such as ustekinumab,[16] have been tested. \n",
      "However, even these more selective drugs do not work in all patients, there may be risks \n",
      "associated with their use,[17-19] and the fact that they are administered either intravenously \n",
      "or subcutaneously, may be inconvenient for patients. The search for alternative agents for the \n",
      "treatment of UC has, therefore, continued.\n",
      "----------\n",
      "laise, weight loss, and fever. Disease onset commonly occurs \n",
      "between the ages of 15 and 30 years and the annual global \n",
      "© The Author(s) 2023. Published by Oxford University Press on behalf of Crohn's & Colitis Foundation.\n",
      "This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), \n",
      "which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.\n",
      "Received for publication: September 21, 2022. Editorial Decision: January 25, 2023\n",
      " \n",
      "Downloaded from https://academic.oup.com/crohnscolitis360/article/5/2/otad009/7066911 by National University of Singapore user on 23 May 2023\n",
      "----------\n",
      "41 years (interquartile range, 40–42 y), and 60%\n",
      "(interquartile range, 56%–63%) were men. The median\n",
      "disease duration was 6.7 years (interquartile range,\n",
      "6.0–7.8 y), and 49% (interquartile range, 46%–55%) of\n",
      "patients had extensive colitis. A median of 40% (inter-\n",
      "quartile range, 30%–50%) of patients were treated with\n",
      "concomitant immunomodulators, and 51% (interquartile\n",
      "range, 45%–57%) were on corticosteroids at baseline.\n",
      "Patients across all trials and treatment arms were com-\n",
      "parable in terms of baseline prognostic variables, inclu-\n",
      "sion/exclusion\n",
      "criteria,\n",
      "and\n",
      "co-interventions.\n",
      "All\n",
      "outcomes were assessed uniformly based on the stan-\n",
      "dard deﬁnition of the Mayo Clinic score, between weeks\n",
      "6 and 10 for induction therapy (inﬂiximab, adalimumab,\n",
      "tofacitinib, ustekinumab, 8 weeks; golimumab, 6 weeks;\n",
      "vedolizumab, 6 weeks, 10 weeks, and 14 weeks in\n",
      "VARSITY),6 and weeks 30, 54, or 60 for maintenance\n",
      "therapy;\n",
      "endoscopy\n",
      "was\n",
      "read\n",
      "by\n",
      "blinded\n",
      "local\n",
      "Table 2. Comparative Efﬁcacy of Pharmacologic Agents for Induction of Clinical Remission and Endoscopic Improvement in Biologic-Naive Patients With Moderate–Severe\n",
      "Ulcerative Colitis Using Network Meta-Analysis\n",
      "Induction of clinical remission\n",
      "Induction of endoscopic improvement\n",
      "Ustekinumab 6 mg/kg\n",
      "0.96 (0.38–2.45)\n",
      "0.80 (0.35–1.83)\n",
      "0.73 (0.31–1.74)\n",
      "1.05 (0.48–2.32)\n",
      "0.50 (0.22–1.12)\n",
      "2.04 (1.03–4.05)\n",
      "0.92 (0.45–1.89)\n",
      "Tofacitinib 10 mg b.d.\n",
      "0.84 (0.39–1.82)\n",
      "0.76 (0.33–1.76)\n",
      "1.10 (0.51–2.34)\n",
      "0.52 (0.24–1.12)\n",
      "2.12 (1.12–4.02)\n",
      "0.74 (0.36–1.51)\n",
      "0.80 (0.4–1.62)\n",
      "Vedolizumab\n",
      "0.91 (0.44–1.86)\n",
      "1.31 (0.88–1.95)\n",
      "0.62 (0.34–1.15)\n",
      "2.54 (1.60–4.02)\n",
      "1.07 (0.58–1.98)\n",
      "1.17 (0.64–2.12)\n",
      "1.45 (0.80–2.61)\n",
      "Golimumab\n",
      "1.44 (0.76–2.75)\n",
      "0.69 (0.35–1.36)\n",
      "2.79 (1.64–4.02)\n",
      "1.17 (0.65–2.13)\n",
      "1.28 (0.72–2.29)\n",
      "1.59 (0.90–2.82)\n",
      "1.10 (0.71–1.71)\n",
      "Adalimumab\n",
      "0.48 (0.26–0.86)\n",
      "1.94 (1.30–2.88)\n",
      "0.56 (0.30–1.04)\n",
      "0.61 (0.34–1.11)\n",
      "0.76 (0.42–1.37)\n",
      "0.52 (0.33–0.83)\n",
      "0.48 (0.31–0.74)\n",
      "Inﬂiximab\n",
      "4.07 (2.67–6.21)\n",
      "1.86 (1.11–3.13)\n",
      "2.03 (1.23–3.34)\n",
      "2.52 (1.54–4.11)\n",
      "1.74 (1.25–2.41)\n",
      "1.58 (1.18–2.13)\n",
      "3.32 (2.39–4.60)\n",
      "Placebo\n",
      "NOTE. Comparisons should be read from left to right. Odds ratio for comparisons are in the cell in common between the column-deﬁning and row-deﬁning treatment. Numbers in bold are statistically signiﬁcant. For induction of\n",
      "clinical remission, an odds ratio greater than 1 favors row-deﬁning treatment. For induction of endoscopic improvement, an odds ratio greater than 1 favors column-deﬁning treatment. Numbers in parentheses indicate 95% CI.\n",
      "b.d., twice daily.\n",
      "----------\n",
      "severely active ulcerative colitis: results from phase 3 \n",
      "U-ACCOMPLISH study. J Crohn’s Colitis 2021; 15 (suppl 1): S021–22.\n",
      "9 \n",
      "Thorlund K, Druyts E, Mills EJ, Fedorak RN, Marshall JK. \n",
      "Adalimumab versus infliximab for the treatment of moderate to \n",
      "severe ulcerative colitis in adult patients naïve to anti-TNF therapy: \n",
      "an indirect treatment comparison meta-analysis. J Crohn’s Colitis \n",
      "2014; 8: 571–81.\n",
      "10 \n",
      "Danese S, Fiorino G, Peyrin-Biroulet L, et al. Biological agents for \n",
      "moderately to severely active ulcerative colitis: a systematic review \n",
      "and network meta-analysis. Ann Intern Med 2014; 160: 704–11.\n",
      "11 \n",
      "Singh S, Fumery M, Sandborn WJ, Murad MH. Systematic review \n",
      "with network meta-analysis: first- and second-line pharmacotherapy \n",
      "for moderate-severe ulcerative colitis. Aliment Pharmacol Ther 2018; \n",
      "47: 162–75.\n",
      "12 \n",
      "Bonovas S, Lytras T, Nikolopoulos G, Peyrin-Biroulet L, Danese S. \n",
      "Systematic review with network meta-analysis: comparative \n",
      "assessment of tofacitinib and biological therapies for moderate-to-\n",
      "severe ulcerative colitis. Aliment Pharmacol Ther 2018; 47: 454–65.\n",
      "13 \n",
      "Singh S, Murad MH, Fumery M, Dulai PS, Sandborn WJ. First- and \n",
      "second-line pharmacotherapies for patients with moderate to \n",
      "severely active ulcerative colitis: an updated network meta-analysis. \n",
      "Clin Gastroenterol Hepatol 2020; 18: 2179–91.e6.\n",
      "14 \n",
      "Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting \n",
      "items for systematic reviews and meta-analyses: the PRISMA \n",
      "statement. Ann Intern Med 2009; 151: 264–69.\n",
      "15 \n",
      "Jansen JP, Fleurence R, Devine B, et al. Interpreting indirect \n",
      "treatment comparisons and network meta-analysis for health-care \n",
      "decision making: report of the ISPOR Task Force on Indirect \n",
      "Treatment Comparisons Good Research Practices: part 1. \n",
      "Value Health 2011; 14: 417–28.\n",
      "16 \n",
      "Sterne JAC, Savović J, Page MJ, et al. RoB 2: a revised tool for \n",
      "assessing risk of bias in randomised trials. BMJ 2019; 366: l4898.\n",
      "17 \n",
      "Rücker G, Schwarzer G. Ranking treatments in frequentist network \n",
      "meta-analysis works without resampling methods. \n",
      "BMC Med Res Methodol 2015; 15: 58.\n",
      "----------\n",
      "Parkes, M., Vermeire, S., Rioux, J.D., Mansﬁeld, J., Silverberg, M.S., Radford-\n",
      "Smith, G., McGovern, D.P., Barrett, J.C., Lees, C.W., 2016. Inherited determinants of\n",
      "crohn's disease and ulcerative colitis phenotypes: a genetic association study. Lancet\n",
      "387 (10014), 156–167.\n",
      "Colombel, J.F., Sandborn, W.J., Rutgeerts, P., Enns, R., Hanauer, S.B., Panaccione, R.,\n",
      "Schreiber, S., Byczkowski, D., Li, J., Kent, J.D., Pollack, P.F., 2007. Adalimumab for\n",
      "maintenance of clinical response and remission in patients with crohn's disease: the\n",
      "charm trial. Gastroenterology 132 (1), 52–65.\n",
      "Conrad, M.A., Kelsen, J.R., 2020. The treatment of pediatric inﬂammatory bowel disease\n",
      "with biologic therapies. Curr. Gastroenterol. Rep. 22 (8), 36–51.\n",
      "Csontos, A.A., Molnar, A., Piri, Z., Katona, B., Dako, S., Palﬁ, E., Miheller, P., 2016. The\n",
      "effect of anti-tnfalpha induction therapy on the nutritional status and dietary intake\n",
      "in inﬂammatory bowel disease. J Gastrointestin Liver Dis 25 (1), 49–56.\n",
      "Dai, Z.H., Xu, X.T., Ran, Z.H., 2020. Associations between obesity and the effectiveness of\n",
      "anti-tumor necrosis factor-alpha agents in inﬂammatory bowel disease patients: a\n",
      "literature review and meta-analysis. Ann. Pharmacother. 54 (8), 729–741.\n",
      "Danese, S., Colombel, J.F., Lukas, M., Gisbert, J.P., D’Haens, G., Hayee, B., Panaccione, R.,\n",
      "Kim, H.S., Reinisch, W., Tyrrell, H., Oh, Y.S., Tole, S., Chai, A., Chamberlain-\n",
      "James, K., Tang, M.T., Schreiber, S., Group, G.S., 2021. Etrolizumab versus inﬂiximab\n",
      "for the treatment of moderately to severely active ulcerative colitis (gardenia): a\n",
      "randomised, double-blind, double-dummy, phase 3 study. Lancet Gastroenterol\n",
      "Hepatol 7 (2), 118–127.\n",
      "Danese, S., Fiorino, G., Peyrin-Biroulet, L., Lucenteforte, E., Virgili, G., Moja, L.,\n",
      "Bonovas, S., 2014. Biological agents for moderately to severely active ulcerative\n",
      "colitis: a systematic review and network meta-analysis. Ann. Intern. Med. 160 (10),\n",
      "704–711.\n",
      "P. Juillerat et al.\n",
      "Current Research in Pharmacology and Drug Discovery 3 (2022) 100104\n",
      "6\n",
      "----------\n",
      "Articles\n",
      "www.thelancet.com/gastrohep   Vol 7   February 2022 \n",
      "161\n",
      "Lancet Gastroenterol Hepatol \n",
      "2022; 7: 161–70\n",
      "Published Online \n",
      "November 29, 2021 \n",
      "https://doi.org/10.1016/ \n",
      "S2468-1253(21)00377-0\n",
      "See Comment page 110\n",
      "*Contributed equally\n",
      "Inflammatory Bowel Disease \n",
      "Unit, Gastroenterology \n",
      "Section, Department of \n",
      "Internal Medicine, Centro de \n",
      "Educación Médica e \n",
      "Investigaciones Clínicas, \n",
      "Buenos Aires, Argentina \n",
      "(J S Lasa MD, P A Olivera MD); \n",
      "Gastroenterology Department, \n",
      "Hospital Británico de Buenos \n",
      "Aires, Buenos Aires, Argentina \n",
      "(J S Lasa); Zane Cohen Centre \n",
      "for Digestive Diseases, \n",
      "Lunenfeld-Tanenbaum \n",
      "Research Institute, Sinai Health \n",
      "System, Toronto, ON, Canada \n",
      "(P A Olivera); Division of \n",
      "Gastroenterology, Mount Sinai \n",
      "Hospital, University of Toronto, \n",
      "Toronto, ON, Canada \n",
      "(P A Olivera); Gastroenterology \n",
      "and Endoscopy, IRCCS Ospedale \n",
      "San Raffaele and University \n",
      "Vita-Salute San Raffaele, \n",
      "Milano, Italy \n",
      "(Prof S Danese MD); INSERM \n",
      "NGERE and Department of \n",
      "Hepatogastroenterology, \n",
      "Nancy University Hospital, \n",
      "Lorraine University, \n",
      "Vandoeuvre-lés-Nancy, France \n",
      "(Prof L Peyrin-Biroulet MD) \n",
      "Correspondence to: \n",
      "Prof Laurent Peyrin-Biroulet, \n",
      "INSERM NGERE and Department \n",
      "of Hepatogastroenterology, \n",
      "Nancy University Hospital, \n",
      "Lorraine University, Vandoeuvre-\n",
      "lès-Nancy F-54511, France \n",
      "peyrinbiroulet@gmail.com\n",
      "Efficacy and safety of biologics and small molecule drugs for \n",
      "patients with moderate-to-severe ulcerative colitis: \n",
      "a systematic review and network meta-analysis \n",
      "Juan S Lasa*, Pablo A Olivera*, Silvio Danese, Laurent Peyrin-Biroulet\n",
      "Summary\n",
      "Background There is a growing armamentarium for the treatment of moderate-to-severe ulcerative colitis. We aimed \n",
      "to compare the relative efficacy and safety of biologics and small molecule drugs for the treatment of patients with \n",
      "moderate-to-severe ulcerative colitis.\n",
      "Methods In this systematic review and network meta-analysis, we searched MEDLINE, Embase, and the Cochrane \n",
      "Central Register of Controlled Trials without language restrictions for articles published between Jan 1, 1990, and \n",
      "July 1, 2021. Major congresses’ databases from Jan 1, 2018, to July 3, 2021, were reviewed manually. Phase 3, placebo-\n",
      "controlled or head-to-head randomised controlled trials (RCTs) assessing the efficacy and safety of biologics or small \n",
      "molecule drugs as induction or maintenance therapies for patients with moderate-to-severe ulcerative colitis were\n",
      "----------\n",
      "Disease Phenotype and Clinical Characteristics\n",
      "The International Organization for the Study of Inﬂam-\n",
      "matory Bowel Disease and the American Gastroenterological\n",
      "Association (AGA) provide a framework for categorization of\n",
      "CD and UC severity into mild-, moderate-, and high-risk\n",
      "groups based on phenotype and other characteristics.59,60\n",
      "In CD, the presence of large or deep mucosal lesions on\n",
      "endoscopy or magnetic resonance imaging (MRI), history of\n",
      "a ﬁstula, abscess, or intestinal resection are predictors of\n",
      "worse outcomes.59,60 In a prospective population-based\n",
      "inception cohort of 213 patients with CD, penetrating\n",
      "behavior was associated with a higher risk of progression to\n",
      "perianal disease (HR, 5.65; 95% CI, 2.65–12.03) and was a\n",
      "risk factor for resection (HR, 3.92; 95% CI, 1.86–8.67) and\n",
      "hospitalization (HR, 1.01; 95% CI, 1.00–1.01).16 Ileal and\n",
      "upper gastrointestinal disease location and extensive dis-\n",
      "ease are also markers of severe disease.61 Cigarette smoking\n",
      "is associated with complications and need for therapy\n",
      "escalation.61\n",
      "In CD, the threshold of suspicion should be low for high-\n",
      "quality imaging of the pelvis, such as MRI, to rule our\n",
      "perianal CD. In a retrospective study of 136 pediatric CD\n",
      "patients, presence of anal ﬁssures and skin tags, non-White\n",
      "race, and elevated C-reactive protein (CRP) were risk factors\n",
      "for perianal CD.62 In another study of 274 patients in China\n",
      "with recently diagnosed CD, all of whom underwent MRI\n",
      "pelvis, asymptomatic perianal ﬁstulas were diagnosed in\n",
      "17.5% of patients and colonic location of CD was a risk\n",
      "factor for asymptomatic perianal ﬁstulas.63\n",
      "In UC, corresponding predictors of aggressive disease\n",
      "advised by the International Organization for the Study of\n",
      "Inﬂammatory Bowel Disease include active colonic ulcers\n",
      "and prior use of biologics.59 Extensive colitis, deep ulcers,\n",
      "need for corticosteroids, hospitalization, Clostridium difﬁcile,\n",
      "and cytomegalovirus infection also indicate higher colec-\n",
      "tomy risk.64 Of note, disease extension from limited disease\n",
      "to\n",
      "extensive\n",
      "or\n",
      "pancolitis\n",
      "is\n",
      "associated\n",
      "with\n",
      "worse\n",
      "prognosis.45,65\n",
      "In addition, co-occurrence of other immune-mediated\n",
      "inﬂammatory diseases can occur, most commonly with\n",
      "psoriasis and asthma, but also, in more rare instances, with\n",
      "other gastrointestinal diseases (eg, celiac, nonalcoholic fatty\n",
      "liver disease,66 and eosinophilic esophagitis).67,68 Presence\n",
      "of a concomitant immune-mediated inﬂammatory disease is\n",
      "Figure\n",
      "1. Inﬂammatory\n",
      "bowel disease severity vs\n",
      "----------\n",
      "perianal CD varied between 11% and 19% at 1–10 years\n",
      "after diagnosis.9 In a study of 983 patients with CD in Asia,\n",
      "stricturing or penetrating CD occurred in 41% and perianal\n",
      "disease in 25% of patients.10 At the other end of the spec-\n",
      "trum, incidental terminal ileitis can be diagnosed in 1.6% of\n",
      "individuals undergoing nondiagnostic colonoscopy, with an\n",
      "uncertain but likely low rate of progression to overt CD.11\n",
      "With respect to UC, most patients have mild to moderate\n",
      "severity and 10%–15% of patients can experience a severe\n",
      "course.12 In a population-based cohort study, proctosigmoid\n",
      "location of colitis occurred in 73% of patients; of these,\n",
      "disease extension occurred in 23% of patients at 7 years of\n",
      "follow-up and it was a marker of worse prognosis.13 The\n",
      "risk of surgery for CD and UC can be up to 46.6% and 15.6%\n",
      "10 years after diagnosis, respectively, and has decreased\n",
      "signiﬁcantly during the last 6 decades.14\n",
      "The symptoms associated with IBD can be waxing and\n",
      "waning, but the underlying systemic inﬂammation can lead\n",
      "to progressive, cumulative, and often irreversible intestinal\n",
      "damage\n",
      "and\n",
      "risk\n",
      "of\n",
      "complications\n",
      "if\n",
      "not\n",
      "treated\n",
      "adequately.15\n",
      "Complications\n",
      "associated\n",
      "with\n",
      "ongoing\n",
      "inﬂammation in CD include strictures, obstructions, ﬁstulas,\n",
      "abscesses, and surgery,3,16 and those associated with UC\n",
      "include loss of colonic and anorectal function, surgery, and\n",
      "colorectal cancer.2,4,17 Other complications include anemia,\n",
      "nutritional deﬁciencies, loss of bone density, and progres-\n",
      "sive loss of quality of life. In children, persistent inﬂamma-\n",
      "tion\n",
      "is\n",
      "associated\n",
      "with\n",
      "growth\n",
      "impairment,\n",
      "risking\n",
      "permanent loss of height.18 Similar to other chronic dis-\n",
      "eases, such as rheumatoid arthritis, the concept of cumula-\n",
      "tive damage is now acknowledged in IBD and can be\n",
      "measured using validated tools, such as the Lemann Index.19\n",
      "Limited Correlations Among Inﬂammation,\n",
      "Symptoms, and Complications\n",
      "The concordance between intestinal inﬂammation and\n",
      "symptoms can be limited, especially in CD.20,21 In a\n",
      "population-based cohort, more than 20% of CD patients\n",
      "were found to have strictures and penetrating disease at the\n",
      "time of diagnosis, suggesting that clinically silent inﬂam-\n",
      "mation may precede formal diagnosis.22 The STRIDE\n",
      "(Selecting Therapeutic Targets in Inﬂammatory Bowel Dis-\n",
      "ease) recommendations, updated recently, are meant to\n",
      "target endoscopic healing, minimize disability, and restore\n",
      "quality of life and adequate growth in children, in addition\n",
      "----------\n",
      "mild disease with few symptoms to complicated disease\n",
      "with strictures and ﬁstulas. In a French population-based\n",
      "study\n",
      "of\n",
      "incident\n",
      "CD,\n",
      "the\n",
      "cumulative\n",
      "probability\n",
      "of\n",
      "*Authors share co-ﬁrst authorship.\n",
      "Abbreviations used in this paper: ADA, adalimumab; AGA, American\n",
      "Gastroenterological Association; CD, Crohn’s disease; CDST, clinical\n",
      "decision support tool; CI, conﬁdence interval; CRP, C-reactive protein;\n",
      "EEN, exclusive enteral nutrition; EIM, extraintestinal manifestation; FC,\n",
      "fecal calprotectin; HR, hazard ratio; IBD, inﬂammatory bowel disease; ICR,\n",
      "ileocolic resection; IFX, inﬂiximab; IMM, immunomodulator; IQR, inter-\n",
      "quartile range; MRI, magnetic resonance imaging; NUDT15, nudix hydro-\n",
      "lase; OR, odds ratio; SUCRA, surface under the cumulative ranking; TDM,\n",
      "therapeutic drug monitoring; TPMT, thiopurine methyltransferase; TNFi,\n",
      "tumor necrosis factor inhibitor; UC, ulcerative colitis; UST, ustekinumab;\n",
      "VDZ, vedolizumab.\n",
      "Most current article\n",
      "© 2021 by the AGA Institute\n",
      "0016-5085/$36.00\n",
      "https://doi.org/10.1053/j.gastro.2021.04.063\n",
      "Gastroenterology 2021;161:47–65\n",
      "REVIEWS AND\n",
      "PERSPECTIVES\n",
      "----------\n",
      "available agents in clinical practice.\n",
      "Supplementary Material\n",
      "Note: To access the supplementary material accom-\n",
      "panying this article, visit the online version of Clinical\n",
      "Gastroenterology and Hepatology at www.cghjournal.org,\n",
      "and at https://doi.org/10.1016/j.cgh.2020.01.008.\n",
      "References\n",
      "1.\n",
      "NgSC,ShiHY,Hamidi N,et al.Worldwideincidence andprevalence\n",
      "of inﬂammatory bowel disease in the 21st century: a systematic\n",
      "review of population-based studies. Lancet 2018;390:2769–2778.\n",
      "2.\n",
      "Fumery M, Singh S, Dulai PS, et al. Natural history of adult ul-\n",
      "cerative colitis in population-based cohorts: a systematic re-\n",
      "view. Clin Gastroenterol Hepatol 2018;16:343–356.\n",
      "3.\n",
      "Vester-Andersen MK, Prosberg MV, Jess T, et al. Disease\n",
      "course and surgery rates in inﬂammatory bowel disease: a\n",
      "population-based, 7-year follow-up study in the era of immu-\n",
      "nomodulating therapy. Am J Gastroenterol 2014;109:705–714.\n",
      "4.\n",
      "Bonovas S, Lytras T, Nikolopoulos G, et al. Systematic review\n",
      "with network meta-analysis: comparative assessment of tofa-\n",
      "citinib and biological therapies for moderate-to-severe ulcera-\n",
      "tive colitis. Aliment Pharmacol Ther 2018;47:454–465.\n",
      "5.\n",
      "Singh S, Fumery M, Sandborn WJ, et al. Systematic review with\n",
      "network meta-analysis: ﬁrst- and second-line pharmacotherapy\n",
      "for moderate-severe ulcerative colitis. Aliment Pharmacol Ther\n",
      "2018;47:162–175.\n",
      "6.\n",
      "Sands BE, Peyrin-Biroulet L, Loftus EV Jr, et al. Vedolizumab\n",
      "versus adalimumab for moderate-to-severe ulcerative colitis.\n",
      "N Engl J Med 2019;381:1215–1226.\n",
      "7.\n",
      "Sands BE, Sandborn WJ, Panaccione R, et al. Ustekinumab as\n",
      "induction and maintenance therapy for ulcerative colitis. N Engl\n",
      "J Med 2019;381:1201–1214.\n",
      "8.\n",
      "Puhan MA, Schunemann HJ, Murad MH, et al. A GRADE Working\n",
      "Group approach for rating the quality of treatment effect esti-\n",
      "mates from network meta-analysis. BMJ 2014;349:g5630.\n",
      "9.\n",
      "Hutton B, Salanti G, Caldwell DM, et al. The PRISMA extension\n",
      "statement for reporting of systematic reviews incorporating\n",
      "network meta-analyses of health care interventions: checklist\n",
      "and explanations. Ann Intern Med 2015;162:777–784.\n",
      "10.\n",
      "Jansen JP, Fleurence R, Devine B, et al. Interpreting indirect\n",
      "treatment comparisons and network meta-analysis for health-\n",
      "care decision making: report of the ISPOR Task Force on Indi-\n",
      "rect Treatment Comparisons Good Research Practices: part 1.\n",
      "Value Health 2011;14:417–428.\n",
      "11.\n",
      "Higgins JPT, Thomas J, Chandler J, eds. Cochrane handbook\n",
      "for systematic reviews of interventions version 6.0 (updated July\n",
      "==========\n",
      "ORIGINAL QUESTION: ANALYSE the given patient profile based on given query based on one of the following criteria:\n",
      "- Whether treated patient is new patient or patient under maintenance\n",
      "- Prior response to Infliximab\n",
      "- Prior failure to Anti-TNF agents\n",
      "- Prior failure to Vedolizumab\n",
      "- Age\n",
      "- Pregnancy\n",
      "- Extraintestinale manifestations\n",
      "- Pouchitis\n",
      "RETURN up to 2 TOP choices of biological drugs given patient profile and context. Explain the PROS and CONS of the 2 choices.\n",
      "PATIENT PROFILE: 42 year-old woman with severe ulcerative colitis and rare fistulating disease\n",
      "\n",
      "==========\n",
      "CURRENT ANSWER:\n",
      "Based on the given patient profile, the patient is a 42-year-old woman with severe ulcerative colitis and rare fistulating disease. However, the context does not provide information on whether she is a new patient or under maintenance, her prior response to Infliximab, prior failure to Anti-TNF agents or Vedolizumab, pregnancy status, extraintestinal manifestations, or pouchitis. \n",
      "\n",
      "Given the severity of her condition and the presence of fistulating disease, the patient may require more aggressive treatment options. However, without more specific information, it's challenging to provide the top choices of biological drugs. \n",
      "\n",
      "Therefore, the answer is \"NO ANSWER\" due to insufficient information in the context to provide a comprehensive treatment recommendation.\n",
      "==========\n",
      "REFINED ANSWER:\n",
      "\u001b[0m\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "Retrying langchain.chat_models.openai.ChatOpenAI.completion_with_retry.<locals>._completion_with_retry in 4.0 seconds as it raised RateLimitError: Rate limit reached for 10KTPM-200RPM in organization org-ETbTMTN2JXYOUPDJgxuH2iO6 on tokens per min. Limit: 10000 / min. Please try again in 6ms. Contact us through our help center at help.openai.com if you continue to have issues..\n",
      "Retrying langchain.chat_models.openai.ChatOpenAI.completion_with_retry.<locals>._completion_with_retry in 4.0 seconds as it raised RateLimitError: Rate limit reached for 10KTPM-200RPM in organization org-ETbTMTN2JXYOUPDJgxuH2iO6 on tokens per min. Limit: 10000 / min. Please try again in 6ms. Contact us through our help center at help.openai.com if you continue to have issues..\n",
      "Retrying langchain.chat_models.openai.ChatOpenAI.completion_with_retry.<locals>._completion_with_retry in 4.0 seconds as it raised RateLimitError: Rate limit reached for 10KTPM-200RPM in organization org-ETbTMTN2JXYOUPDJgxuH2iO6 on tokens per min. Limit: 10000 / min. Please try again in 6ms. Contact us through our help center at help.openai.com if you continue to have issues..\n",
      "Retrying langchain.chat_models.openai.ChatOpenAI.completion_with_retry.<locals>._completion_with_retry in 8.0 seconds as it raised RateLimitError: Rate limit reached for 10KTPM-200RPM in organization org-ETbTMTN2JXYOUPDJgxuH2iO6 on tokens per min. Limit: 10000 / min. Please try again in 6ms. Contact us through our help center at help.openai.com if you continue to have issues..\n",
      "Retrying langchain.chat_models.openai.ChatOpenAI.completion_with_retry.<locals>._completion_with_retry in 10.0 seconds as it raised RateLimitError: Rate limit reached for 10KTPM-200RPM in organization org-ETbTMTN2JXYOUPDJgxuH2iO6 on tokens per min. Limit: 10000 / min. Please try again in 6ms. Contact us through our help center at help.openai.com if you continue to have issues..\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\n",
      "\u001b[1m> Finished chain.\u001b[0m\n",
      "\n",
      "\u001b[1m> Finished chain.\u001b[0m\n",
      "2023-10-02 17:36:26,403:INFO: 6053 tokens were added to prompt from 10 documents\n",
      "Query: 68 year-old man with extensive moderate to severe ulcerative colitis who has prostate cancer which has been treated 5 years ago.\n",
      "\n",
      "\n",
      "\n",
      "\u001b[1m> Entering new SequentialChain chain...\u001b[0m\n",
      "\n",
      "\n",
      "\u001b[1m> Entering new RetrievalQAWithSourcesChain chain...\u001b[0m\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "Retrying langchain.chat_models.openai.ChatOpenAI.completion_with_retry.<locals>._completion_with_retry in 4.0 seconds as it raised RateLimitError: Rate limit reached for 10KTPM-200RPM in organization org-ETbTMTN2JXYOUPDJgxuH2iO6 on tokens per min. Limit: 10000 / min. Please try again in 6ms. Contact us through our help center at help.openai.com if you continue to have issues..\n",
      "Retrying langchain.chat_models.openai.ChatOpenAI.completion_with_retry.<locals>._completion_with_retry in 4.0 seconds as it raised RateLimitError: Rate limit reached for 10KTPM-200RPM in organization org-ETbTMTN2JXYOUPDJgxuH2iO6 on tokens per min. Limit: 10000 / min. Please try again in 6ms. Contact us through our help center at help.openai.com if you continue to have issues..\n",
      "Retrying langchain.chat_models.openai.ChatOpenAI.completion_with_retry.<locals>._completion_with_retry in 4.0 seconds as it raised RateLimitError: Rate limit reached for 10KTPM-200RPM in organization org-ETbTMTN2JXYOUPDJgxuH2iO6 on tokens per min. Limit: 10000 / min. Please try again in 6ms. Contact us through our help center at help.openai.com if you continue to have issues..\n",
      "Retrying langchain.chat_models.openai.ChatOpenAI.completion_with_retry.<locals>._completion_with_retry in 8.0 seconds as it raised RateLimitError: Rate limit reached for 10KTPM-200RPM in organization org-ETbTMTN2JXYOUPDJgxuH2iO6 on tokens per min. Limit: 10000 / min. Please try again in 6ms. Contact us through our help center at help.openai.com if you continue to have issues..\n",
      "Retrying langchain.chat_models.openai.ChatOpenAI.completion_with_retry.<locals>._completion_with_retry in 10.0 seconds as it raised RateLimitError: Rate limit reached for 10KTPM-200RPM in organization org-ETbTMTN2JXYOUPDJgxuH2iO6 on tokens per min. Limit: 10000 / min. Please try again in 6ms. Contact us through our help center at help.openai.com if you continue to have issues..\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\n",
      "\u001b[1m> Finished chain.\u001b[0m\n",
      "\n",
      "\n",
      "\u001b[1m> Entering new LLMChain chain...\u001b[0m\n",
      "Prompt after formatting:\n",
      "\u001b[32;1m\u001b[1;3mYou are a senior physician giving advice on treatment for moderate to severe ulcerative colitis (UC).\n",
      "Make reference to the CONTEXT given to assess the scenario.\n",
      "==========\n",
      "TASK: Your task is to analyse critically the CURRENT ANSWER given the CONTEXT.\n",
      "Then refine the existing answer (only if needed) based on the following instructions:\n",
      "- If no refinement needed, return the original answer in the correct output format.\n",
      "- If the answer cannot be inferred from CONTEXT, return \"NO ANSWER\".\n",
      "- The final output should be a list of up to 2 choices of biological drugs given patient profile and context and PROS/CONS for each recommendations.\n",
      "==========\n",
      "CONTEXT:\n",
      "Burr et al. \n",
      " \n",
      "7 of 45 \n",
      "INTRODUCTION \n",
      "  Ulcerative colitis (UC) is a chronic inflammatory disorder of the bowel that causes \n",
      "continuous mucosal inflammation commencing in the rectum and extending proximally for a \n",
      "variable extent.[1] It is estimated that UC affects 2.5 million people in Europe,[2] and the \n",
      "disease follows a relapsing and remitting course, with intermittent flares of disease activity, \n",
      "some of which may be moderate to severe. Management of these is medical, for the most \n",
      "part, with surgery reserved for patients with refractory disease. Although 5-aminosalicylates \n",
      "(5-ASAs) are efficacious for mild to moderate disease activity,[3-6] more severe flares are \n",
      "usually treated with corticosteroids.[7] However, these have potentially serious adverse \n",
      "effects and a substantial proportion of patients may become either dependent on them to \n",
      "maintain remission,[8] or refractory to them.[9] As a result, over the last 20 years novel \n",
      "drugs, with more precise modes of action, based on mechanisms of disease identified in \n",
      "genome wide association studies,[10] have been developed.  \n",
      "The first of these agents was infliximab, a drug targeting the pro-inflammatory \n",
      "cytokine tumour necrosis factor-α (TNF-α), which demonstrated efficacy in clinical trials in \n",
      "moderate to severe UC.[11] Since then, other drugs against TNF-α have been tested, such as \n",
      "adalimumab and golimumab.[12, 13] In addition, newer biological therapies targeting α or β \n",
      "integrins, which are involved in migration of immune cells to inflamed intestinal mucosa, \n",
      "such as vedolizumab or etrolizumab,[14, 15] or acting against other pro-inflammatory \n",
      "cytokines implicated in the pathogenesis of UC, such as ustekinumab,[16] have been tested. \n",
      "However, even these more selective drugs do not work in all patients, there may be risks \n",
      "associated with their use,[17-19] and the fact that they are administered either intravenously \n",
      "or subcutaneously, may be inconvenient for patients. The search for alternative agents for the \n",
      "treatment of UC has, therefore, continued.\n",
      "----------\n",
      "41 years (interquartile range, 40–42 y), and 60%\n",
      "(interquartile range, 56%–63%) were men. The median\n",
      "disease duration was 6.7 years (interquartile range,\n",
      "6.0–7.8 y), and 49% (interquartile range, 46%–55%) of\n",
      "patients had extensive colitis. A median of 40% (inter-\n",
      "quartile range, 30%–50%) of patients were treated with\n",
      "concomitant immunomodulators, and 51% (interquartile\n",
      "range, 45%–57%) were on corticosteroids at baseline.\n",
      "Patients across all trials and treatment arms were com-\n",
      "parable in terms of baseline prognostic variables, inclu-\n",
      "sion/exclusion\n",
      "criteria,\n",
      "and\n",
      "co-interventions.\n",
      "All\n",
      "outcomes were assessed uniformly based on the stan-\n",
      "dard deﬁnition of the Mayo Clinic score, between weeks\n",
      "6 and 10 for induction therapy (inﬂiximab, adalimumab,\n",
      "tofacitinib, ustekinumab, 8 weeks; golimumab, 6 weeks;\n",
      "vedolizumab, 6 weeks, 10 weeks, and 14 weeks in\n",
      "VARSITY),6 and weeks 30, 54, or 60 for maintenance\n",
      "therapy;\n",
      "endoscopy\n",
      "was\n",
      "read\n",
      "by\n",
      "blinded\n",
      "local\n",
      "Table 2. Comparative Efﬁcacy of Pharmacologic Agents for Induction of Clinical Remission and Endoscopic Improvement in Biologic-Naive Patients With Moderate–Severe\n",
      "Ulcerative Colitis Using Network Meta-Analysis\n",
      "Induction of clinical remission\n",
      "Induction of endoscopic improvement\n",
      "Ustekinumab 6 mg/kg\n",
      "0.96 (0.38–2.45)\n",
      "0.80 (0.35–1.83)\n",
      "0.73 (0.31–1.74)\n",
      "1.05 (0.48–2.32)\n",
      "0.50 (0.22–1.12)\n",
      "2.04 (1.03–4.05)\n",
      "0.92 (0.45–1.89)\n",
      "Tofacitinib 10 mg b.d.\n",
      "0.84 (0.39–1.82)\n",
      "0.76 (0.33–1.76)\n",
      "1.10 (0.51–2.34)\n",
      "0.52 (0.24–1.12)\n",
      "2.12 (1.12–4.02)\n",
      "0.74 (0.36–1.51)\n",
      "0.80 (0.4–1.62)\n",
      "Vedolizumab\n",
      "0.91 (0.44–1.86)\n",
      "1.31 (0.88–1.95)\n",
      "0.62 (0.34–1.15)\n",
      "2.54 (1.60–4.02)\n",
      "1.07 (0.58–1.98)\n",
      "1.17 (0.64–2.12)\n",
      "1.45 (0.80–2.61)\n",
      "Golimumab\n",
      "1.44 (0.76–2.75)\n",
      "0.69 (0.35–1.36)\n",
      "2.79 (1.64–4.02)\n",
      "1.17 (0.65–2.13)\n",
      "1.28 (0.72–2.29)\n",
      "1.59 (0.90–2.82)\n",
      "1.10 (0.71–1.71)\n",
      "Adalimumab\n",
      "0.48 (0.26–0.86)\n",
      "1.94 (1.30–2.88)\n",
      "0.56 (0.30–1.04)\n",
      "0.61 (0.34–1.11)\n",
      "0.76 (0.42–1.37)\n",
      "0.52 (0.33–0.83)\n",
      "0.48 (0.31–0.74)\n",
      "Inﬂiximab\n",
      "4.07 (2.67–6.21)\n",
      "1.86 (1.11–3.13)\n",
      "2.03 (1.23–3.34)\n",
      "2.52 (1.54–4.11)\n",
      "1.74 (1.25–2.41)\n",
      "1.58 (1.18–2.13)\n",
      "3.32 (2.39–4.60)\n",
      "Placebo\n",
      "NOTE. Comparisons should be read from left to right. Odds ratio for comparisons are in the cell in common between the column-deﬁning and row-deﬁning treatment. Numbers in bold are statistically signiﬁcant. For induction of\n",
      "clinical remission, an odds ratio greater than 1 favors row-deﬁning treatment. For induction of endoscopic improvement, an odds ratio greater than 1 favors column-deﬁning treatment. Numbers in parentheses indicate 95% CI.\n",
      "b.d., twice daily.\n",
      "----------\n",
      "severely active ulcerative colitis: results from phase 3 \n",
      "U-ACCOMPLISH study. J Crohn’s Colitis 2021; 15 (suppl 1): S021–22.\n",
      "9 \n",
      "Thorlund K, Druyts E, Mills EJ, Fedorak RN, Marshall JK. \n",
      "Adalimumab versus infliximab for the treatment of moderate to \n",
      "severe ulcerative colitis in adult patients naïve to anti-TNF therapy: \n",
      "an indirect treatment comparison meta-analysis. J Crohn’s Colitis \n",
      "2014; 8: 571–81.\n",
      "10 \n",
      "Danese S, Fiorino G, Peyrin-Biroulet L, et al. Biological agents for \n",
      "moderately to severely active ulcerative colitis: a systematic review \n",
      "and network meta-analysis. Ann Intern Med 2014; 160: 704–11.\n",
      "11 \n",
      "Singh S, Fumery M, Sandborn WJ, Murad MH. Systematic review \n",
      "with network meta-analysis: first- and second-line pharmacotherapy \n",
      "for moderate-severe ulcerative colitis. Aliment Pharmacol Ther 2018; \n",
      "47: 162–75.\n",
      "12 \n",
      "Bonovas S, Lytras T, Nikolopoulos G, Peyrin-Biroulet L, Danese S. \n",
      "Systematic review with network meta-analysis: comparative \n",
      "assessment of tofacitinib and biological therapies for moderate-to-\n",
      "severe ulcerative colitis. Aliment Pharmacol Ther 2018; 47: 454–65.\n",
      "13 \n",
      "Singh S, Murad MH, Fumery M, Dulai PS, Sandborn WJ. First- and \n",
      "second-line pharmacotherapies for patients with moderate to \n",
      "severely active ulcerative colitis: an updated network meta-analysis. \n",
      "Clin Gastroenterol Hepatol 2020; 18: 2179–91.e6.\n",
      "14 \n",
      "Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting \n",
      "items for systematic reviews and meta-analyses: the PRISMA \n",
      "statement. Ann Intern Med 2009; 151: 264–69.\n",
      "15 \n",
      "Jansen JP, Fleurence R, Devine B, et al. Interpreting indirect \n",
      "treatment comparisons and network meta-analysis for health-care \n",
      "decision making: report of the ISPOR Task Force on Indirect \n",
      "Treatment Comparisons Good Research Practices: part 1. \n",
      "Value Health 2011; 14: 417–28.\n",
      "16 \n",
      "Sterne JAC, Savović J, Page MJ, et al. RoB 2: a revised tool for \n",
      "assessing risk of bias in randomised trials. BMJ 2019; 366: l4898.\n",
      "17 \n",
      "Rücker G, Schwarzer G. Ranking treatments in frequentist network \n",
      "meta-analysis works without resampling methods. \n",
      "BMC Med Res Methodol 2015; 15: 58.\n",
      "----------\n",
      "Burr et al. \n",
      " \n",
      "5 of 45 \n",
      "STUDY HIGHLIGHTS \n",
      " \n",
      "What is already known about this subject \n",
      "• Ulcerative colitis (UC) follows a relapsing and remitting course, with intermittent \n",
      "flares of disease activity, some of which may be moderate to severe. \n",
      "• These are usually treated with corticosteroids, which have potentially serious adverse \n",
      "effects, so biological therapies and small molecules have been developed and licensed \n",
      "for this indication.  \n",
      "• Although previous network meta-analyses have compared their efficacy and safety, \n",
      "this is a rapidly moving field, and there are already several newer drugs that have \n",
      "shown efficacy in phase III clinical trials that were not considered in these. \n",
      " \n",
      "What are the new findings \n",
      "• In terms of clinical remission and clinical response, upadacitinib 45mg o.d. ranked \n",
      "first in all patients, in patients previously exposed to anti-tumour necrosis factor \n",
      "(TNF)-α therapies, and in patients naïve to these drugs.  \n",
      "• In terms of endoscopic improvement infliximab 10mg/kg ranked first, followed by \n",
      "upadacitinib 45mg o.d., and infliximab 5mg/kg.  \n",
      "• However, for endoscopic improvement again upadacitinib 45mg o.d. ranked first in \n",
      "patients previously exposed to anti-TNF-α therapies, and in patients who were anti-\n",
      "TNF-α naïve.  \n",
      "• None of the drugs studied were more likely to lead to serious adverse events than \n",
      "placebo.\n",
      "----------\n",
      "Therapeutic strategies for the management of recentlydiagnosedulcerative colitis. IMMs include thiopurines and methotrexate. 5-ASA, 5-amino salicylic acid; ASUC, acute severe ulcerative colitis; IPAA, ileal pouch anal anastomosis.\n",
      "\n",
      "Risk stratification: Mild\n",
      "Clinical features: NA\n",
      "Treatment options: 5-ASA (oral and/or topical)\n",
      "\n",
      "Risk stratification: Moderate\n",
      "Clinical features: NA\n",
      "Treatment options: Can consider 5-ASA (with rapid step-up if inadequate response)\n",
      "\n",
      "Risk stratification: Moderate\n",
      "Clinical features: NA\n",
      "Treatment options: VDZ or UST\n",
      "\n",
      "Risk stratification: Moderate\n",
      "Clinical features: NA\n",
      "Treatment options: Thiopurine\n",
      "\n",
      "Risk stratification: Moderate\n",
      "Clinical features: NA\n",
      "Treatment options: TNFi +/- IMM\n",
      "\n",
      "Risk stratification: Severe\n",
      "Clinical features: NA\n",
      "Treatment options: TNFi +/- IMM\n",
      "\n",
      "Risk stratification: Severe\n",
      "Clinical features: NA\n",
      "Treatment options: Subtotal colectomy + IPAA or cyclosporine (for ASUC)\n",
      "\n",
      "Risk stratification: Additional consideration: EIM present\n",
      "Clinical features: Psoriasis or psoriatic arthritis\n",
      "Treatment options: UST\n",
      "\n",
      "Risk stratification: Additional consideration: EIM present\n",
      "Clinical features: Other arthritis\n",
      "Treatment options: TNFi\n",
      "\n",
      "\n",
      "----------\n",
      "methodologic characteristics). If direct and indirect es-\n",
      "timates were similar (ie, coherent), then the higher rating\n",
      "can be assigned to the network meta-analysis estimates.\n",
      "Results\n",
      "From a total 5651 unique studies identiﬁed using our\n",
      "search strategy, we included 15 RCTs of ﬁrst-line agents\n",
      "(in biologic-naïve patients) (Active Ulcerative Colitis Trials\n",
      "1 and 2,17 Jiang et al,18 NCT01551290,19 Ulcerative colitis\n",
      "Long-Term Remission and maintenance with Adalimumab\n",
      "1 and 2,20,21 Suzuki et al,22 Program of Ulcerative Colitis\n",
      "Research Studies Utilizing an Investigational Treatment\n",
      "phase 2 and phase 3 induction studies,23 GEMINI I,24\n",
      "Motoya et al,25 VARSITY, Oral Clinical Trials for tofAciti-\n",
      "nib in ulceratiVE colitis (OCTAVE) 1 and 2,26 and UNIFI),\n",
      "and 7 RCTs of second-line agents (in patients with prior\n",
      "exposure to TNFa antagonists) (Ulcerative colitis Long-\n",
      "Term Remission and maintenance with Adalimumab 2,21\n",
      "GEMINI I,24 Motoya et al,25 VARSITY,6 OCTAVE 1 and\n",
      "2,26 UNIFI7) in patients with moderate–severe ulcerative\n",
      "colitis. Trials of inﬂiximab (Active Ulcerative Colitis Trials\n",
      "1 and 2,17 Jiang et al,18 NCT0155129019), adalimumab\n",
      "(Ulcerative colitis Long-Term Remission and maintenance\n",
      "with Adalimumab 2,20,21 Suzuki et al22), vedolizumab\n",
      "(GEMINI I,24 Motoya et al,25 VARSITY6) and ustekinumab\n",
      "(UNIFI7) also reported outcomes on maintenance therapy\n",
      "within the same publication; Program of Ulcerative Colitis\n",
      "Research Studies Utilizing an Investigational Treatment-\n",
      "M, Program of Ulcerative Colitis Research Studies Utilizing\n",
      "an Investigational Treatment-J, and OCTAVE-Sustain\n",
      "reported\n",
      "outcomes\n",
      "for\n",
      "maintenance\n",
      "therapy\n",
      "with\n",
      "golimumab and tofacitinib, respectively.26–28 From our\n",
      "previous analysis, 3 additional studies were included.\n",
      "The schematic diagram of study selection is shown in\n",
      "Supplementary\n",
      "Figure\n",
      "1,\n",
      "and\n",
      "available\n",
      "direct\n",
      "comparisons and network of trials are shown in Figure 1.\n",
      "Trial and patient characteristics are summarized in\n",
      "Table 1. Overall, the median average age of patients was\n",
      "41 years (interquartile range, 40–42 y), and 60%\n",
      "(interquartile range, 56%–63%) were men. The median\n",
      "disease duration was 6.7 years (interquartile range,\n",
      "6.0–7.8 y), and 49% (interquartile range, 46%–55%) of\n",
      "patients had extensive colitis. A median of 40% (inter-\n",
      "quartile range, 30%–50%) of patients were treated with\n",
      "concomitant immunomodulators, and 51% (interquartile\n",
      "range, 45%–57%) were on corticosteroids at baseline.\n",
      "Patients across all trials and treatment arms were com-\n",
      "----------\n",
      "SYSTEMATIC REVIEWS AND META-ANALYSES\n",
      "Siddharth Singh, Section Editor\n",
      "First- and Second-Line Pharmacotherapies for Patients With\n",
      "Moderate to Severely Active Ulcerative Colitis: An Updated\n",
      "Network Meta-Analysis\n",
      "Siddharth Singh,*,‡ Mohammad Hassan Murad,§ Mathurin Fumery,j\n",
      "Parambir S. Dulai,* and William J. Sandborn*\n",
      "*Division of Gastroenterology, ‡Division of Biomedical Informatics, University of California San Diego, La Jolla, California;\n",
      "§Robert D and Patricia E Kern Center for the Science of Health Care Delivery, Mayo Clinic, Rochester, Minnesota;\n",
      "||Gastroenterology Unit, Peritox UMR I-0I, Amiens University and Hospital, Université de Picardie Jules Verne, Amiens, France\n",
      "BACKGROUND & AIMS:\n",
      "We compared the efﬁcacy and safety of different ﬁrst-line (biologic-naïve) and second-line\n",
      "(prior exposure to tumor necrosis factor [TNF] antagonists) agents for treatment of moder-\n",
      "ate to severely active ulcerative colitis in a systematic review and network meta-analysis.\n",
      "METHODS:\n",
      "We searched publication databases through September 30, 2019, for randomized trials of\n",
      "adults with moderate to severe ulcerative colitis treated with TNF antagonists, vedolizumab,\n",
      "tofacitinib, or ustekinumab, as ﬁrst-line or second-line agents, compared with placebo or\n",
      "another active agent. Efﬁcacy outcomes were induction and maintenance of remission and\n",
      "endoscopic improvement; safety outcomes were serious adverse events and infections. We\n",
      "performed a ﬁxed-effects network meta-analysis using the frequentist approach, and calculated\n",
      "odds ratios (ORs) and 95% CI values. Agents were ranked using surface under the cumulative\n",
      "ranking (SUCRA) probabilities. Overall quality of evidence was rated using GRADE (Grading of\n",
      "Recommendations, Assessment, Development and Evaluation).\n",
      "RESULTS:\n",
      "In biologic-naïve patients, inﬂiximab was ranked highest for induction of clinical remission (OR\n",
      "vs placebo, 4.07; 95% CI, 2.67–6.21; SUCRA, 0.95) and endoscopic improvement (SUCRA, 0.95)\n",
      "(moderate conﬁdence in estimates [CE]). In patients with prior exposure to TNF antagonists,\n",
      "ustekinumab (SUCRA, 0.87) and tofacitinib (SUCRA, 0.87) were ranked highest for induction of\n",
      "clinical remission and were superior to vedolizumab (ustekinumab vs vedolizumab: OR, 5.99;\n",
      "95% CI, 1.13–31.76 and tofacitinib vs vedolizumab: OR, 6.18; 95% CI, 1.003–8.00; moderate CE)\n",
      "and adalimumab (ustekinumab vs adalimumab: OR, 10.71; 95% CI, 2.01–57.20 and tofacitinib\n",
      "----------\n",
      "Parkes, M., Vermeire, S., Rioux, J.D., Mansﬁeld, J., Silverberg, M.S., Radford-\n",
      "Smith, G., McGovern, D.P., Barrett, J.C., Lees, C.W., 2016. Inherited determinants of\n",
      "crohn's disease and ulcerative colitis phenotypes: a genetic association study. Lancet\n",
      "387 (10014), 156–167.\n",
      "Colombel, J.F., Sandborn, W.J., Rutgeerts, P., Enns, R., Hanauer, S.B., Panaccione, R.,\n",
      "Schreiber, S., Byczkowski, D., Li, J., Kent, J.D., Pollack, P.F., 2007. Adalimumab for\n",
      "maintenance of clinical response and remission in patients with crohn's disease: the\n",
      "charm trial. Gastroenterology 132 (1), 52–65.\n",
      "Conrad, M.A., Kelsen, J.R., 2020. The treatment of pediatric inﬂammatory bowel disease\n",
      "with biologic therapies. Curr. Gastroenterol. Rep. 22 (8), 36–51.\n",
      "Csontos, A.A., Molnar, A., Piri, Z., Katona, B., Dako, S., Palﬁ, E., Miheller, P., 2016. The\n",
      "effect of anti-tnfalpha induction therapy on the nutritional status and dietary intake\n",
      "in inﬂammatory bowel disease. J Gastrointestin Liver Dis 25 (1), 49–56.\n",
      "Dai, Z.H., Xu, X.T., Ran, Z.H., 2020. Associations between obesity and the effectiveness of\n",
      "anti-tumor necrosis factor-alpha agents in inﬂammatory bowel disease patients: a\n",
      "literature review and meta-analysis. Ann. Pharmacother. 54 (8), 729–741.\n",
      "Danese, S., Colombel, J.F., Lukas, M., Gisbert, J.P., D’Haens, G., Hayee, B., Panaccione, R.,\n",
      "Kim, H.S., Reinisch, W., Tyrrell, H., Oh, Y.S., Tole, S., Chai, A., Chamberlain-\n",
      "James, K., Tang, M.T., Schreiber, S., Group, G.S., 2021. Etrolizumab versus inﬂiximab\n",
      "for the treatment of moderately to severely active ulcerative colitis (gardenia): a\n",
      "randomised, double-blind, double-dummy, phase 3 study. Lancet Gastroenterol\n",
      "Hepatol 7 (2), 118–127.\n",
      "Danese, S., Fiorino, G., Peyrin-Biroulet, L., Lucenteforte, E., Virgili, G., Moja, L.,\n",
      "Bonovas, S., 2014. Biological agents for moderately to severely active ulcerative\n",
      "colitis: a systematic review and network meta-analysis. Ann. Intern. Med. 160 (10),\n",
      "704–711.\n",
      "P. Juillerat et al.\n",
      "Current Research in Pharmacology and Drug Discovery 3 (2022) 100104\n",
      "6\n",
      "----------\n",
      "Articles\n",
      "www.thelancet.com/gastrohep   Vol 7   February 2022 \n",
      "161\n",
      "Lancet Gastroenterol Hepatol \n",
      "2022; 7: 161–70\n",
      "Published Online \n",
      "November 29, 2021 \n",
      "https://doi.org/10.1016/ \n",
      "S2468-1253(21)00377-0\n",
      "See Comment page 110\n",
      "*Contributed equally\n",
      "Inflammatory Bowel Disease \n",
      "Unit, Gastroenterology \n",
      "Section, Department of \n",
      "Internal Medicine, Centro de \n",
      "Educación Médica e \n",
      "Investigaciones Clínicas, \n",
      "Buenos Aires, Argentina \n",
      "(J S Lasa MD, P A Olivera MD); \n",
      "Gastroenterology Department, \n",
      "Hospital Británico de Buenos \n",
      "Aires, Buenos Aires, Argentina \n",
      "(J S Lasa); Zane Cohen Centre \n",
      "for Digestive Diseases, \n",
      "Lunenfeld-Tanenbaum \n",
      "Research Institute, Sinai Health \n",
      "System, Toronto, ON, Canada \n",
      "(P A Olivera); Division of \n",
      "Gastroenterology, Mount Sinai \n",
      "Hospital, University of Toronto, \n",
      "Toronto, ON, Canada \n",
      "(P A Olivera); Gastroenterology \n",
      "and Endoscopy, IRCCS Ospedale \n",
      "San Raffaele and University \n",
      "Vita-Salute San Raffaele, \n",
      "Milano, Italy \n",
      "(Prof S Danese MD); INSERM \n",
      "NGERE and Department of \n",
      "Hepatogastroenterology, \n",
      "Nancy University Hospital, \n",
      "Lorraine University, \n",
      "Vandoeuvre-lés-Nancy, France \n",
      "(Prof L Peyrin-Biroulet MD) \n",
      "Correspondence to: \n",
      "Prof Laurent Peyrin-Biroulet, \n",
      "INSERM NGERE and Department \n",
      "of Hepatogastroenterology, \n",
      "Nancy University Hospital, \n",
      "Lorraine University, Vandoeuvre-\n",
      "lès-Nancy F-54511, France \n",
      "peyrinbiroulet@gmail.com\n",
      "Efficacy and safety of biologics and small molecule drugs for \n",
      "patients with moderate-to-severe ulcerative colitis: \n",
      "a systematic review and network meta-analysis \n",
      "Juan S Lasa*, Pablo A Olivera*, Silvio Danese, Laurent Peyrin-Biroulet\n",
      "Summary\n",
      "Background There is a growing armamentarium for the treatment of moderate-to-severe ulcerative colitis. We aimed \n",
      "to compare the relative efficacy and safety of biologics and small molecule drugs for the treatment of patients with \n",
      "moderate-to-severe ulcerative colitis.\n",
      "Methods In this systematic review and network meta-analysis, we searched MEDLINE, Embase, and the Cochrane \n",
      "Central Register of Controlled Trials without language restrictions for articles published between Jan 1, 1990, and \n",
      "July 1, 2021. Major congresses’ databases from Jan 1, 2018, to July 3, 2021, were reviewed manually. Phase 3, placebo-\n",
      "controlled or head-to-head randomised controlled trials (RCTs) assessing the efficacy and safety of biologics or small \n",
      "molecule drugs as induction or maintenance therapies for patients with moderate-to-severe ulcerative colitis were\n",
      "----------\n",
      "discontinuation due to AEs, and serious infections. Phase 3 randomized controlled trials were identified via systematic literature review, in-\n",
      "cluding the following advanced therapies: infliximab, adalimumab, vedolizumab, golimumab, tofacitinib, ustekinumab, filgotinib, ozanimod, and \n",
      "upadacitinib. Random effects models were used to address between-study heterogeneity. Intent-to-treat (ITT) efficacy rates were calculated by \n",
      "adjusting maintenance outcomes by likelihood of induction response.\n",
      "Results:  Out of 48 trials identified, 23 were included. Across all outcomes and regardless of prior biologic exposure, ITT efficacy rates were \n",
      "highest for upadacitinib, owing to its highest ranking for all efficacy outcomes in induction and for all but clinical remission during maintenance \n",
      "among bio-naive induction responders. For all advanced therapies versus placebo, there were no significant differences in serious AEs or \n",
      "serious infections across therapies. For all AEs, golimumab had higher odds versus placebo during maintenance; for discontinuation due to \n",
      "AEs, upadacitinib had lower odds versus placebo during induction, while ustekinumab and vedolizumab had lower odds versus placebo during \n",
      "maintenance.\n",
      "Conclusions:  Upadacitinib may be the most efficacious therapy for moderately to severely active UC based on ITT analyses, with similar safety \n",
      "across advanced therapies.\n",
      "Lay Summary \n",
      "Indirect evidence suggests upadacitinib may be more efficacious than other advanced therapies at achieving clinical response, clinical remis-\n",
      "sion, and endoscopic response over 1 year for moderately to severely active ulcerative colitis patients, with similar safety assessments across \n",
      "advanced therapies.\n",
      "Key Words: ulcerative colitis, clinical trials, advanced therapies, network meta-analysis\n",
      "Introduction\n",
      "Ulcerative colitis (UC) is a chronic inflammatory bowel dis-\n",
      "ease that affects the colorectum and is clinically characterized \n",
      "by bloody diarrhea, urgency, tenesmus, abdominal pain, ma-\n",
      "laise, weight loss, and fever. Disease onset commonly occurs \n",
      "between the ages of 15 and 30 years and the annual global \n",
      "© The Author(s) 2023. Published by Oxford University Press on behalf of Crohn's & Colitis Foundation.\n",
      "This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), \n",
      "which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.\n",
      "==========\n",
      "ORIGINAL QUESTION: ANALYSE the given patient profile based on given query based on one of the following criteria:\n",
      "- Whether treated patient is new patient or patient under maintenance\n",
      "- Prior response to Infliximab\n",
      "- Prior failure to Anti-TNF agents\n",
      "- Prior failure to Vedolizumab\n",
      "- Age\n",
      "- Pregnancy\n",
      "- Extraintestinale manifestations\n",
      "- Pouchitis\n",
      "RETURN up to 2 TOP choices of biological drugs given patient profile and context. Explain the PROS and CONS of the 2 choices.\n",
      "PATIENT PROFILE: 68 year-old man with extensive moderate to severe ulcerative colitis who has prostate cancer which has been treated 5 years ago.\n",
      "\n",
      "==========\n",
      "CURRENT ANSWER:\n",
      "Based on the given patient profile, the top two choices of biological drugs would be Vedolizumab and Ustekinumab. \n",
      "\n",
      "1. Vedolizumab:\n",
      "   - Advantages: Vedolizumab is a gut-selective immunosuppressant, meaning it specifically targets inflammation in the gut and has less systemic side effects. This could be beneficial for a patient with a history of cancer, as it may pose less risk of reactivating the disease compared to other systemic immunosuppressants.\n",
      "   - Disadvantages: The effectiveness of Vedolizumab can vary and it may take several weeks to see an improvement in symptoms. It is also administered intravenously which may be inconvenient for some patients.\n",
      "\n",
      "2. Ustekinumab:\n",
      "   - Advantages: Ustekinumab has been shown to be effective in treating moderate to severe ulcerative colitis. It is also administered subcutaneously, which some patients may find more convenient than intravenous administration.\n",
      "   - Disadvantages: As an immunosuppressant, Ustekinumab can increase the risk of infections. Given the patient's age and history of cancer, this could potentially pose a risk, although it is generally considered to have a favorable safety profile.\n",
      "\n",
      "It's important to note that the choice of treatment should also consider the patient's overall health status, other comorbidities, and their personal preferences. The patient's oncologist should also be consulted to assess the risk of cancer recurrence with these therapies.\n",
      "==========\n",
      "REFINED ANSWER:\n",
      "\u001b[0m\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "Retrying langchain.chat_models.openai.ChatOpenAI.completion_with_retry.<locals>._completion_with_retry in 4.0 seconds as it raised RateLimitError: Rate limit reached for 10KTPM-200RPM in organization org-ETbTMTN2JXYOUPDJgxuH2iO6 on tokens per min. Limit: 10000 / min. Please try again in 6ms. Contact us through our help center at help.openai.com if you continue to have issues..\n",
      "Retrying langchain.chat_models.openai.ChatOpenAI.completion_with_retry.<locals>._completion_with_retry in 4.0 seconds as it raised RateLimitError: Rate limit reached for 10KTPM-200RPM in organization org-ETbTMTN2JXYOUPDJgxuH2iO6 on tokens per min. Limit: 10000 / min. Please try again in 6ms. Contact us through our help center at help.openai.com if you continue to have issues..\n",
      "Retrying langchain.chat_models.openai.ChatOpenAI.completion_with_retry.<locals>._completion_with_retry in 4.0 seconds as it raised RateLimitError: Rate limit reached for 10KTPM-200RPM in organization org-ETbTMTN2JXYOUPDJgxuH2iO6 on tokens per min. Limit: 10000 / min. Please try again in 6ms. Contact us through our help center at help.openai.com if you continue to have issues..\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\n",
      "\u001b[1m> Finished chain.\u001b[0m\n",
      "\n",
      "\u001b[1m> Finished chain.\u001b[0m\n",
      "2023-10-02 17:37:55,558:INFO: 6061 tokens were added to prompt from 10 documents\n",
      "Query: 25 year-old man with extensive moderate to severe ulcerative colitis and primary sclerosing cholangitis with decompensated cirrhosis.\n",
      "\n",
      "\n",
      "\n",
      "\u001b[1m> Entering new SequentialChain chain...\u001b[0m\n",
      "\n",
      "\n",
      "\u001b[1m> Entering new RetrievalQAWithSourcesChain chain...\u001b[0m\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "Retrying langchain.chat_models.openai.ChatOpenAI.completion_with_retry.<locals>._completion_with_retry in 4.0 seconds as it raised RateLimitError: Rate limit reached for 10KTPM-200RPM in organization org-ETbTMTN2JXYOUPDJgxuH2iO6 on tokens per min. Limit: 10000 / min. Please try again in 6ms. Contact us through our help center at help.openai.com if you continue to have issues..\n",
      "Retrying langchain.chat_models.openai.ChatOpenAI.completion_with_retry.<locals>._completion_with_retry in 4.0 seconds as it raised RateLimitError: Rate limit reached for 10KTPM-200RPM in organization org-ETbTMTN2JXYOUPDJgxuH2iO6 on tokens per min. Limit: 10000 / min. Please try again in 6ms. Contact us through our help center at help.openai.com if you continue to have issues..\n",
      "Retrying langchain.chat_models.openai.ChatOpenAI.completion_with_retry.<locals>._completion_with_retry in 4.0 seconds as it raised RateLimitError: Rate limit reached for 10KTPM-200RPM in organization org-ETbTMTN2JXYOUPDJgxuH2iO6 on tokens per min. Limit: 10000 / min. Please try again in 6ms. Contact us through our help center at help.openai.com if you continue to have issues..\n",
      "Retrying langchain.chat_models.openai.ChatOpenAI.completion_with_retry.<locals>._completion_with_retry in 8.0 seconds as it raised RateLimitError: Rate limit reached for 10KTPM-200RPM in organization org-ETbTMTN2JXYOUPDJgxuH2iO6 on tokens per min. Limit: 10000 / min. Please try again in 6ms. Contact us through our help center at help.openai.com if you continue to have issues..\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\n",
      "\u001b[1m> Finished chain.\u001b[0m\n",
      "\n",
      "\n",
      "\u001b[1m> Entering new LLMChain chain...\u001b[0m\n",
      "Prompt after formatting:\n",
      "\u001b[32;1m\u001b[1;3mYou are a senior physician giving advice on treatment for moderate to severe ulcerative colitis (UC).\n",
      "Make reference to the CONTEXT given to assess the scenario.\n",
      "==========\n",
      "TASK: Your task is to analyse critically the CURRENT ANSWER given the CONTEXT.\n",
      "Then refine the existing answer (only if needed) based on the following instructions:\n",
      "- If no refinement needed, return the original answer in the correct output format.\n",
      "- If the answer cannot be inferred from CONTEXT, return \"NO ANSWER\".\n",
      "- The final output should be a list of up to 2 choices of biological drugs given patient profile and context and PROS/CONS for each recommendations.\n",
      "==========\n",
      "CONTEXT:\n",
      "Burr et al. \n",
      " \n",
      "7 of 45 \n",
      "INTRODUCTION \n",
      "  Ulcerative colitis (UC) is a chronic inflammatory disorder of the bowel that causes \n",
      "continuous mucosal inflammation commencing in the rectum and extending proximally for a \n",
      "variable extent.[1] It is estimated that UC affects 2.5 million people in Europe,[2] and the \n",
      "disease follows a relapsing and remitting course, with intermittent flares of disease activity, \n",
      "some of which may be moderate to severe. Management of these is medical, for the most \n",
      "part, with surgery reserved for patients with refractory disease. Although 5-aminosalicylates \n",
      "(5-ASAs) are efficacious for mild to moderate disease activity,[3-6] more severe flares are \n",
      "usually treated with corticosteroids.[7] However, these have potentially serious adverse \n",
      "effects and a substantial proportion of patients may become either dependent on them to \n",
      "maintain remission,[8] or refractory to them.[9] As a result, over the last 20 years novel \n",
      "drugs, with more precise modes of action, based on mechanisms of disease identified in \n",
      "genome wide association studies,[10] have been developed.  \n",
      "The first of these agents was infliximab, a drug targeting the pro-inflammatory \n",
      "cytokine tumour necrosis factor-α (TNF-α), which demonstrated efficacy in clinical trials in \n",
      "moderate to severe UC.[11] Since then, other drugs against TNF-α have been tested, such as \n",
      "adalimumab and golimumab.[12, 13] In addition, newer biological therapies targeting α or β \n",
      "integrins, which are involved in migration of immune cells to inflamed intestinal mucosa, \n",
      "such as vedolizumab or etrolizumab,[14, 15] or acting against other pro-inflammatory \n",
      "cytokines implicated in the pathogenesis of UC, such as ustekinumab,[16] have been tested. \n",
      "However, even these more selective drugs do not work in all patients, there may be risks \n",
      "associated with their use,[17-19] and the fact that they are administered either intravenously \n",
      "or subcutaneously, may be inconvenient for patients. The search for alternative agents for the \n",
      "treatment of UC has, therefore, continued.\n",
      "----------\n",
      "Articles\n",
      "www.thelancet.com/gastrohep   Vol 7   February 2022 \n",
      "161\n",
      "Lancet Gastroenterol Hepatol \n",
      "2022; 7: 161–70\n",
      "Published Online \n",
      "November 29, 2021 \n",
      "https://doi.org/10.1016/ \n",
      "S2468-1253(21)00377-0\n",
      "See Comment page 110\n",
      "*Contributed equally\n",
      "Inflammatory Bowel Disease \n",
      "Unit, Gastroenterology \n",
      "Section, Department of \n",
      "Internal Medicine, Centro de \n",
      "Educación Médica e \n",
      "Investigaciones Clínicas, \n",
      "Buenos Aires, Argentina \n",
      "(J S Lasa MD, P A Olivera MD); \n",
      "Gastroenterology Department, \n",
      "Hospital Británico de Buenos \n",
      "Aires, Buenos Aires, Argentina \n",
      "(J S Lasa); Zane Cohen Centre \n",
      "for Digestive Diseases, \n",
      "Lunenfeld-Tanenbaum \n",
      "Research Institute, Sinai Health \n",
      "System, Toronto, ON, Canada \n",
      "(P A Olivera); Division of \n",
      "Gastroenterology, Mount Sinai \n",
      "Hospital, University of Toronto, \n",
      "Toronto, ON, Canada \n",
      "(P A Olivera); Gastroenterology \n",
      "and Endoscopy, IRCCS Ospedale \n",
      "San Raffaele and University \n",
      "Vita-Salute San Raffaele, \n",
      "Milano, Italy \n",
      "(Prof S Danese MD); INSERM \n",
      "NGERE and Department of \n",
      "Hepatogastroenterology, \n",
      "Nancy University Hospital, \n",
      "Lorraine University, \n",
      "Vandoeuvre-lés-Nancy, France \n",
      "(Prof L Peyrin-Biroulet MD) \n",
      "Correspondence to: \n",
      "Prof Laurent Peyrin-Biroulet, \n",
      "INSERM NGERE and Department \n",
      "of Hepatogastroenterology, \n",
      "Nancy University Hospital, \n",
      "Lorraine University, Vandoeuvre-\n",
      "lès-Nancy F-54511, France \n",
      "peyrinbiroulet@gmail.com\n",
      "Efficacy and safety of biologics and small molecule drugs for \n",
      "patients with moderate-to-severe ulcerative colitis: \n",
      "a systematic review and network meta-analysis \n",
      "Juan S Lasa*, Pablo A Olivera*, Silvio Danese, Laurent Peyrin-Biroulet\n",
      "Summary\n",
      "Background There is a growing armamentarium for the treatment of moderate-to-severe ulcerative colitis. We aimed \n",
      "to compare the relative efficacy and safety of biologics and small molecule drugs for the treatment of patients with \n",
      "moderate-to-severe ulcerative colitis.\n",
      "Methods In this systematic review and network meta-analysis, we searched MEDLINE, Embase, and the Cochrane \n",
      "Central Register of Controlled Trials without language restrictions for articles published between Jan 1, 1990, and \n",
      "July 1, 2021. Major congresses’ databases from Jan 1, 2018, to July 3, 2021, were reviewed manually. Phase 3, placebo-\n",
      "controlled or head-to-head randomised controlled trials (RCTs) assessing the efficacy and safety of biologics or small \n",
      "molecule drugs as induction or maintenance therapies for patients with moderate-to-severe ulcerative colitis were\n",
      "----------\n",
      "41 years (interquartile range, 40–42 y), and 60%\n",
      "(interquartile range, 56%–63%) were men. The median\n",
      "disease duration was 6.7 years (interquartile range,\n",
      "6.0–7.8 y), and 49% (interquartile range, 46%–55%) of\n",
      "patients had extensive colitis. A median of 40% (inter-\n",
      "quartile range, 30%–50%) of patients were treated with\n",
      "concomitant immunomodulators, and 51% (interquartile\n",
      "range, 45%–57%) were on corticosteroids at baseline.\n",
      "Patients across all trials and treatment arms were com-\n",
      "parable in terms of baseline prognostic variables, inclu-\n",
      "sion/exclusion\n",
      "criteria,\n",
      "and\n",
      "co-interventions.\n",
      "All\n",
      "outcomes were assessed uniformly based on the stan-\n",
      "dard deﬁnition of the Mayo Clinic score, between weeks\n",
      "6 and 10 for induction therapy (inﬂiximab, adalimumab,\n",
      "tofacitinib, ustekinumab, 8 weeks; golimumab, 6 weeks;\n",
      "vedolizumab, 6 weeks, 10 weeks, and 14 weeks in\n",
      "VARSITY),6 and weeks 30, 54, or 60 for maintenance\n",
      "therapy;\n",
      "endoscopy\n",
      "was\n",
      "read\n",
      "by\n",
      "blinded\n",
      "local\n",
      "Table 2. Comparative Efﬁcacy of Pharmacologic Agents for Induction of Clinical Remission and Endoscopic Improvement in Biologic-Naive Patients With Moderate–Severe\n",
      "Ulcerative Colitis Using Network Meta-Analysis\n",
      "Induction of clinical remission\n",
      "Induction of endoscopic improvement\n",
      "Ustekinumab 6 mg/kg\n",
      "0.96 (0.38–2.45)\n",
      "0.80 (0.35–1.83)\n",
      "0.73 (0.31–1.74)\n",
      "1.05 (0.48–2.32)\n",
      "0.50 (0.22–1.12)\n",
      "2.04 (1.03–4.05)\n",
      "0.92 (0.45–1.89)\n",
      "Tofacitinib 10 mg b.d.\n",
      "0.84 (0.39–1.82)\n",
      "0.76 (0.33–1.76)\n",
      "1.10 (0.51–2.34)\n",
      "0.52 (0.24–1.12)\n",
      "2.12 (1.12–4.02)\n",
      "0.74 (0.36–1.51)\n",
      "0.80 (0.4–1.62)\n",
      "Vedolizumab\n",
      "0.91 (0.44–1.86)\n",
      "1.31 (0.88–1.95)\n",
      "0.62 (0.34–1.15)\n",
      "2.54 (1.60–4.02)\n",
      "1.07 (0.58–1.98)\n",
      "1.17 (0.64–2.12)\n",
      "1.45 (0.80–2.61)\n",
      "Golimumab\n",
      "1.44 (0.76–2.75)\n",
      "0.69 (0.35–1.36)\n",
      "2.79 (1.64–4.02)\n",
      "1.17 (0.65–2.13)\n",
      "1.28 (0.72–2.29)\n",
      "1.59 (0.90–2.82)\n",
      "1.10 (0.71–1.71)\n",
      "Adalimumab\n",
      "0.48 (0.26–0.86)\n",
      "1.94 (1.30–2.88)\n",
      "0.56 (0.30–1.04)\n",
      "0.61 (0.34–1.11)\n",
      "0.76 (0.42–1.37)\n",
      "0.52 (0.33–0.83)\n",
      "0.48 (0.31–0.74)\n",
      "Inﬂiximab\n",
      "4.07 (2.67–6.21)\n",
      "1.86 (1.11–3.13)\n",
      "2.03 (1.23–3.34)\n",
      "2.52 (1.54–4.11)\n",
      "1.74 (1.25–2.41)\n",
      "1.58 (1.18–2.13)\n",
      "3.32 (2.39–4.60)\n",
      "Placebo\n",
      "NOTE. Comparisons should be read from left to right. Odds ratio for comparisons are in the cell in common between the column-deﬁning and row-deﬁning treatment. Numbers in bold are statistically signiﬁcant. For induction of\n",
      "clinical remission, an odds ratio greater than 1 favors row-deﬁning treatment. For induction of endoscopic improvement, an odds ratio greater than 1 favors column-deﬁning treatment. Numbers in parentheses indicate 95% CI.\n",
      "b.d., twice daily.\n",
      "----------\n",
      "Therapeutic strategies for the management of recentlydiagnosedulcerative colitis. IMMs include thiopurines and methotrexate. 5-ASA, 5-amino salicylic acid; ASUC, acute severe ulcerative colitis; IPAA, ileal pouch anal anastomosis.\n",
      "\n",
      "Risk stratification: Mild\n",
      "Clinical features: NA\n",
      "Treatment options: 5-ASA (oral and/or topical)\n",
      "\n",
      "Risk stratification: Moderate\n",
      "Clinical features: NA\n",
      "Treatment options: Can consider 5-ASA (with rapid step-up if inadequate response)\n",
      "\n",
      "Risk stratification: Moderate\n",
      "Clinical features: NA\n",
      "Treatment options: VDZ or UST\n",
      "\n",
      "Risk stratification: Moderate\n",
      "Clinical features: NA\n",
      "Treatment options: Thiopurine\n",
      "\n",
      "Risk stratification: Moderate\n",
      "Clinical features: NA\n",
      "Treatment options: TNFi +/- IMM\n",
      "\n",
      "Risk stratification: Severe\n",
      "Clinical features: NA\n",
      "Treatment options: TNFi +/- IMM\n",
      "\n",
      "Risk stratification: Severe\n",
      "Clinical features: NA\n",
      "Treatment options: Subtotal colectomy + IPAA or cyclosporine (for ASUC)\n",
      "\n",
      "Risk stratification: Additional consideration: EIM present\n",
      "Clinical features: Psoriasis or psoriatic arthritis\n",
      "Treatment options: UST\n",
      "\n",
      "Risk stratification: Additional consideration: EIM present\n",
      "Clinical features: Other arthritis\n",
      "Treatment options: TNFi\n",
      "\n",
      "\n",
      "----------\n",
      "Stratification of inflammatory bowel disease risk of progression based on disease severity and activity. BMI, body mass index; CDAI, Crohns Disease Activity Index; ESR, erythrocyte sedimentation rate; UCEIS, Ulcerative Colitis Endoscopic Index of Severity.\n",
      "\n",
      ": Remission\n",
      "Stools (no./d): Formed stool\n",
      "Blood in stools: None\n",
      "Urgency: None\n",
      "Hemoglobin: Normal\n",
      "ESR: 30\n",
      "CRP (mg/L): Normal\n",
      "FC (ug/g): < 150-200\n",
      "Endoscopy (Mayo subscore): O1\n",
      "UCEIS: O1\n",
      "\n",
      ": Mild\n",
      "Stools (no./d): < 4\n",
      "Blood in stools: Intermittent\n",
      "Urgency: Mild, occasional\n",
      "Hemoglobin: Normal\n",
      "ESR: 30\n",
      "CRP (mg/L): Elevated\n",
      "FC (ug/g): > 150-200\n",
      "Endoscopy (Mayo subscore): 1\n",
      "UCEIS: 24\n",
      "\n",
      ": Moderate\n",
      "Stools (no./d): > 6\n",
      "Blood in stools: Frequent\n",
      "Urgency: Often\n",
      "Hemoglobin: 75% of normal\n",
      "ESR: 30\n",
      "CRP (mg/L): Elevated\n",
      "FC (ug/g): 150-200\n",
      "Endoscopy (Mayo subscore): 23\n",
      "UCEIS: 58\n",
      "\n",
      ": Severe\n",
      "Stools (no./d): > 10\n",
      "Blood in stools: Continuous\n",
      "Urgency: Continuous\n",
      "Hemoglobin: Transfusions required\n",
      "ESR: 30\n",
      "CRP (mg/L): Elevated\n",
      "FC (ug/g): > 150200\n",
      "Endoscopy (Mayo subscore): 3\n",
      "UCEIS: 78\n",
      "\n",
      "\n",
      "----------\n",
      "severely active ulcerative colitis: results from phase 3 \n",
      "U-ACCOMPLISH study. J Crohn’s Colitis 2021; 15 (suppl 1): S021–22.\n",
      "9 \n",
      "Thorlund K, Druyts E, Mills EJ, Fedorak RN, Marshall JK. \n",
      "Adalimumab versus infliximab for the treatment of moderate to \n",
      "severe ulcerative colitis in adult patients naïve to anti-TNF therapy: \n",
      "an indirect treatment comparison meta-analysis. J Crohn’s Colitis \n",
      "2014; 8: 571–81.\n",
      "10 \n",
      "Danese S, Fiorino G, Peyrin-Biroulet L, et al. Biological agents for \n",
      "moderately to severely active ulcerative colitis: a systematic review \n",
      "and network meta-analysis. Ann Intern Med 2014; 160: 704–11.\n",
      "11 \n",
      "Singh S, Fumery M, Sandborn WJ, Murad MH. Systematic review \n",
      "with network meta-analysis: first- and second-line pharmacotherapy \n",
      "for moderate-severe ulcerative colitis. Aliment Pharmacol Ther 2018; \n",
      "47: 162–75.\n",
      "12 \n",
      "Bonovas S, Lytras T, Nikolopoulos G, Peyrin-Biroulet L, Danese S. \n",
      "Systematic review with network meta-analysis: comparative \n",
      "assessment of tofacitinib and biological therapies for moderate-to-\n",
      "severe ulcerative colitis. Aliment Pharmacol Ther 2018; 47: 454–65.\n",
      "13 \n",
      "Singh S, Murad MH, Fumery M, Dulai PS, Sandborn WJ. First- and \n",
      "second-line pharmacotherapies for patients with moderate to \n",
      "severely active ulcerative colitis: an updated network meta-analysis. \n",
      "Clin Gastroenterol Hepatol 2020; 18: 2179–91.e6.\n",
      "14 \n",
      "Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting \n",
      "items for systematic reviews and meta-analyses: the PRISMA \n",
      "statement. Ann Intern Med 2009; 151: 264–69.\n",
      "15 \n",
      "Jansen JP, Fleurence R, Devine B, et al. Interpreting indirect \n",
      "treatment comparisons and network meta-analysis for health-care \n",
      "decision making: report of the ISPOR Task Force on Indirect \n",
      "Treatment Comparisons Good Research Practices: part 1. \n",
      "Value Health 2011; 14: 417–28.\n",
      "16 \n",
      "Sterne JAC, Savović J, Page MJ, et al. RoB 2: a revised tool for \n",
      "assessing risk of bias in randomised trials. BMJ 2019; 366: l4898.\n",
      "17 \n",
      "Rücker G, Schwarzer G. Ranking treatments in frequentist network \n",
      "meta-analysis works without resampling methods. \n",
      "BMC Med Res Methodol 2015; 15: 58.\n",
      "----------\n",
      "available agents in clinical practice.\n",
      "Supplementary Material\n",
      "Note: To access the supplementary material accom-\n",
      "panying this article, visit the online version of Clinical\n",
      "Gastroenterology and Hepatology at www.cghjournal.org,\n",
      "and at https://doi.org/10.1016/j.cgh.2020.01.008.\n",
      "References\n",
      "1.\n",
      "NgSC,ShiHY,Hamidi N,et al.Worldwideincidence andprevalence\n",
      "of inﬂammatory bowel disease in the 21st century: a systematic\n",
      "review of population-based studies. Lancet 2018;390:2769–2778.\n",
      "2.\n",
      "Fumery M, Singh S, Dulai PS, et al. Natural history of adult ul-\n",
      "cerative colitis in population-based cohorts: a systematic re-\n",
      "view. Clin Gastroenterol Hepatol 2018;16:343–356.\n",
      "3.\n",
      "Vester-Andersen MK, Prosberg MV, Jess T, et al. Disease\n",
      "course and surgery rates in inﬂammatory bowel disease: a\n",
      "population-based, 7-year follow-up study in the era of immu-\n",
      "nomodulating therapy. Am J Gastroenterol 2014;109:705–714.\n",
      "4.\n",
      "Bonovas S, Lytras T, Nikolopoulos G, et al. Systematic review\n",
      "with network meta-analysis: comparative assessment of tofa-\n",
      "citinib and biological therapies for moderate-to-severe ulcera-\n",
      "tive colitis. Aliment Pharmacol Ther 2018;47:454–465.\n",
      "5.\n",
      "Singh S, Fumery M, Sandborn WJ, et al. Systematic review with\n",
      "network meta-analysis: ﬁrst- and second-line pharmacotherapy\n",
      "for moderate-severe ulcerative colitis. Aliment Pharmacol Ther\n",
      "2018;47:162–175.\n",
      "6.\n",
      "Sands BE, Peyrin-Biroulet L, Loftus EV Jr, et al. Vedolizumab\n",
      "versus adalimumab for moderate-to-severe ulcerative colitis.\n",
      "N Engl J Med 2019;381:1215–1226.\n",
      "7.\n",
      "Sands BE, Sandborn WJ, Panaccione R, et al. Ustekinumab as\n",
      "induction and maintenance therapy for ulcerative colitis. N Engl\n",
      "J Med 2019;381:1201–1214.\n",
      "8.\n",
      "Puhan MA, Schunemann HJ, Murad MH, et al. A GRADE Working\n",
      "Group approach for rating the quality of treatment effect esti-\n",
      "mates from network meta-analysis. BMJ 2014;349:g5630.\n",
      "9.\n",
      "Hutton B, Salanti G, Caldwell DM, et al. The PRISMA extension\n",
      "statement for reporting of systematic reviews incorporating\n",
      "network meta-analyses of health care interventions: checklist\n",
      "and explanations. Ann Intern Med 2015;162:777–784.\n",
      "10.\n",
      "Jansen JP, Fleurence R, Devine B, et al. Interpreting indirect\n",
      "treatment comparisons and network meta-analysis for health-\n",
      "care decision making: report of the ISPOR Task Force on Indi-\n",
      "rect Treatment Comparisons Good Research Practices: part 1.\n",
      "Value Health 2011;14:417–428.\n",
      "11.\n",
      "Higgins JPT, Thomas J, Chandler J, eds. Cochrane handbook\n",
      "for systematic reviews of interventions version 6.0 (updated July\n",
      "----------\n",
      "Parkes, M., Vermeire, S., Rioux, J.D., Mansﬁeld, J., Silverberg, M.S., Radford-\n",
      "Smith, G., McGovern, D.P., Barrett, J.C., Lees, C.W., 2016. Inherited determinants of\n",
      "crohn's disease and ulcerative colitis phenotypes: a genetic association study. Lancet\n",
      "387 (10014), 156–167.\n",
      "Colombel, J.F., Sandborn, W.J., Rutgeerts, P., Enns, R., Hanauer, S.B., Panaccione, R.,\n",
      "Schreiber, S., Byczkowski, D., Li, J., Kent, J.D., Pollack, P.F., 2007. Adalimumab for\n",
      "maintenance of clinical response and remission in patients with crohn's disease: the\n",
      "charm trial. Gastroenterology 132 (1), 52–65.\n",
      "Conrad, M.A., Kelsen, J.R., 2020. The treatment of pediatric inﬂammatory bowel disease\n",
      "with biologic therapies. Curr. Gastroenterol. Rep. 22 (8), 36–51.\n",
      "Csontos, A.A., Molnar, A., Piri, Z., Katona, B., Dako, S., Palﬁ, E., Miheller, P., 2016. The\n",
      "effect of anti-tnfalpha induction therapy on the nutritional status and dietary intake\n",
      "in inﬂammatory bowel disease. J Gastrointestin Liver Dis 25 (1), 49–56.\n",
      "Dai, Z.H., Xu, X.T., Ran, Z.H., 2020. Associations between obesity and the effectiveness of\n",
      "anti-tumor necrosis factor-alpha agents in inﬂammatory bowel disease patients: a\n",
      "literature review and meta-analysis. Ann. Pharmacother. 54 (8), 729–741.\n",
      "Danese, S., Colombel, J.F., Lukas, M., Gisbert, J.P., D’Haens, G., Hayee, B., Panaccione, R.,\n",
      "Kim, H.S., Reinisch, W., Tyrrell, H., Oh, Y.S., Tole, S., Chai, A., Chamberlain-\n",
      "James, K., Tang, M.T., Schreiber, S., Group, G.S., 2021. Etrolizumab versus inﬂiximab\n",
      "for the treatment of moderately to severely active ulcerative colitis (gardenia): a\n",
      "randomised, double-blind, double-dummy, phase 3 study. Lancet Gastroenterol\n",
      "Hepatol 7 (2), 118–127.\n",
      "Danese, S., Fiorino, G., Peyrin-Biroulet, L., Lucenteforte, E., Virgili, G., Moja, L.,\n",
      "Bonovas, S., 2014. Biological agents for moderately to severely active ulcerative\n",
      "colitis: a systematic review and network meta-analysis. Ann. Intern. Med. 160 (10),\n",
      "704–711.\n",
      "P. Juillerat et al.\n",
      "Current Research in Pharmacology and Drug Discovery 3 (2022) 100104\n",
      "6\n",
      "----------\n",
      "REVIEWS IN BASIC AND CLINICAL GASTROENTEROLOGY\n",
      "AND HEPATOLOGY\n",
      "Douglas J. Robertson and Vincent W. Yang, Section Editors\n",
      "Approach to the Management of Recently Diagnosed\n",
      "Inﬂammatory Bowel Disease Patients: A User’s Guide for Adult\n",
      "and Pediatric Gastroenterologists\n",
      "Manasi Agrawal,1,* Elizabeth A. Spencer,2,* Jean-Frederic Colombel,1 and Ryan C. Ungaro1\n",
      "1The Dr Henry D. Janowitz Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York, New York; and\n",
      "2The Division of Pediatric Gastroenterology and Nutrition, Icahn School of Medicine at Mount Sinai, New York, New York\n",
      "Inﬂammatory bowel diseases (IBDs), including Crohn’s\n",
      "disease and ulcerative colitis, are chronic, progressive,\n",
      "immune-mediated diseases of adults and children that\n",
      "have no cure. IBD can cause signiﬁcant morbidity and lead\n",
      "to complications such as strictures, ﬁstulas, infections, and\n",
      "cancer.\n",
      "In\n",
      "children,\n",
      "IBD\n",
      "can\n",
      "also\n",
      "result\n",
      "in\n",
      "growth\n",
      "impairment and pubertal delays. IBD is highly heteroge-\n",
      "nous, with severity ranging from mild to severe and\n",
      "symptoms ranging from mild to debilitating. Delay in IBD\n",
      "diagnosis, especially in Crohn’s disease, is common and\n",
      "associated with adverse outcomes. Early diagnosis and\n",
      "prompt institution of treatment are the cornerstones for\n",
      "improving outcomes and maximizing health. Early diag-\n",
      "nosis requires a low threshold of suspicion and red ﬂags to\n",
      "guide early specialist referral at the primary provider\n",
      "level. Although the armamentarium of IBD medications is\n",
      "growing, many patients will not respond to treatment, and\n",
      "the selection of ﬁrst-line therapy is critical. Risk stratiﬁ-\n",
      "cation of disease severity, based on clinical, demographic,\n",
      "and serologic markers, can help guide selection of ﬁrst-line\n",
      "therapy. Clinical decision support tools, genomics, and\n",
      "other biomarkers of response to therapy and risk of\n",
      "adverse events are the future of personalized medicine.\n",
      "After starting appropriate therapy, it is important to\n",
      "conﬁrm remission using objective end points (treat to\n",
      "target) with continued control of inﬂammation with\n",
      "adjustment of therapy using surrogate biomarkers (tight\n",
      "control). Lastly, IBD therapy extends far beyond medica-\n",
      "tions, and other aspects of the overall health and wellbeing\n",
      "of the patient are critical. These include preventive health,\n",
      "nutrition, and psychobehavioral support addressing pa-\n",
      "tients’\n",
      "concerns\n",
      "around\n",
      "complementary\n",
      "therapy\n",
      "and\n",
      "medication\n",
      "adherence,\n",
      "prevention\n",
      "of\n",
      "disability,\n",
      "and\n",
      "ensuring open communication.\n",
      "----------\n",
      "Disease Phenotype and Clinical Characteristics\n",
      "The International Organization for the Study of Inﬂam-\n",
      "matory Bowel Disease and the American Gastroenterological\n",
      "Association (AGA) provide a framework for categorization of\n",
      "CD and UC severity into mild-, moderate-, and high-risk\n",
      "groups based on phenotype and other characteristics.59,60\n",
      "In CD, the presence of large or deep mucosal lesions on\n",
      "endoscopy or magnetic resonance imaging (MRI), history of\n",
      "a ﬁstula, abscess, or intestinal resection are predictors of\n",
      "worse outcomes.59,60 In a prospective population-based\n",
      "inception cohort of 213 patients with CD, penetrating\n",
      "behavior was associated with a higher risk of progression to\n",
      "perianal disease (HR, 5.65; 95% CI, 2.65–12.03) and was a\n",
      "risk factor for resection (HR, 3.92; 95% CI, 1.86–8.67) and\n",
      "hospitalization (HR, 1.01; 95% CI, 1.00–1.01).16 Ileal and\n",
      "upper gastrointestinal disease location and extensive dis-\n",
      "ease are also markers of severe disease.61 Cigarette smoking\n",
      "is associated with complications and need for therapy\n",
      "escalation.61\n",
      "In CD, the threshold of suspicion should be low for high-\n",
      "quality imaging of the pelvis, such as MRI, to rule our\n",
      "perianal CD. In a retrospective study of 136 pediatric CD\n",
      "patients, presence of anal ﬁssures and skin tags, non-White\n",
      "race, and elevated C-reactive protein (CRP) were risk factors\n",
      "for perianal CD.62 In another study of 274 patients in China\n",
      "with recently diagnosed CD, all of whom underwent MRI\n",
      "pelvis, asymptomatic perianal ﬁstulas were diagnosed in\n",
      "17.5% of patients and colonic location of CD was a risk\n",
      "factor for asymptomatic perianal ﬁstulas.63\n",
      "In UC, corresponding predictors of aggressive disease\n",
      "advised by the International Organization for the Study of\n",
      "Inﬂammatory Bowel Disease include active colonic ulcers\n",
      "and prior use of biologics.59 Extensive colitis, deep ulcers,\n",
      "need for corticosteroids, hospitalization, Clostridium difﬁcile,\n",
      "and cytomegalovirus infection also indicate higher colec-\n",
      "tomy risk.64 Of note, disease extension from limited disease\n",
      "to\n",
      "extensive\n",
      "or\n",
      "pancolitis\n",
      "is\n",
      "associated\n",
      "with\n",
      "worse\n",
      "prognosis.45,65\n",
      "In addition, co-occurrence of other immune-mediated\n",
      "inﬂammatory diseases can occur, most commonly with\n",
      "psoriasis and asthma, but also, in more rare instances, with\n",
      "other gastrointestinal diseases (eg, celiac, nonalcoholic fatty\n",
      "liver disease,66 and eosinophilic esophagitis).67,68 Presence\n",
      "of a concomitant immune-mediated inﬂammatory disease is\n",
      "Figure\n",
      "1. Inﬂammatory\n",
      "bowel disease severity vs\n",
      "==========\n",
      "ORIGINAL QUESTION: ANALYSE the given patient profile based on given query based on one of the following criteria:\n",
      "- Whether treated patient is new patient or patient under maintenance\n",
      "- Prior response to Infliximab\n",
      "- Prior failure to Anti-TNF agents\n",
      "- Prior failure to Vedolizumab\n",
      "- Age\n",
      "- Pregnancy\n",
      "- Extraintestinale manifestations\n",
      "- Pouchitis\n",
      "RETURN up to 2 TOP choices of biological drugs given patient profile and context. Explain the PROS and CONS of the 2 choices.\n",
      "PATIENT PROFILE: 25 year-old man with extensive moderate to severe ulcerative colitis and primary sclerosing cholangitis with decompensated cirrhosis.\n",
      "\n",
      "==========\n",
      "CURRENT ANSWER:\n",
      "Based on the patient's profile, the top two choices of biological drugs would be Vedolizumab and Ustekinumab. \n",
      "\n",
      "1. Vedolizumab:\n",
      "   - Advantages: Vedolizumab is a gut-selective immunosuppressant, meaning it specifically targets inflammation in the gut, reducing systemic side effects. It has been shown to be effective in treating moderate to severe ulcerative colitis. It is also less likely to cause liver toxicity, which is important given the patient's decompensated cirrhosis.\n",
      "   - Disadvantages: Vedolizumab may not be as effective in patients who have failed anti-TNF therapy. It is also administered intravenously, which may be inconvenient for some patients.\n",
      "\n",
      "2. Ustekinumab:\n",
      "   - Advantages: Ustekinumab is effective in treating moderate to severe ulcerative colitis and has a different mechanism of action compared to anti-TNF agents and vedolizumab, which may be beneficial if the patient has not responded to these treatments. It is also administered subcutaneously, which some patients may find more convenient.\n",
      "   - Disadvantages: Ustekinumab may not be as effective in patients with extensive disease. It also requires initial intravenous induction, which may be inconvenient. The impact on liver disease is not well studied, so careful monitoring would be necessary given the patient's decompensated cirrhosis.\n",
      "\n",
      "Please note that the choice of treatment should be individualized and discussed with the patient, taking into account the potential benefits and risks, as well as the patient's preferences and values.\n",
      "==========\n",
      "REFINED ANSWER:\n",
      "\u001b[0m\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "Retrying langchain.chat_models.openai.ChatOpenAI.completion_with_retry.<locals>._completion_with_retry in 4.0 seconds as it raised RateLimitError: Rate limit reached for 10KTPM-200RPM in organization org-ETbTMTN2JXYOUPDJgxuH2iO6 on tokens per min. Limit: 10000 / min. Please try again in 6ms. Contact us through our help center at help.openai.com if you continue to have issues..\n",
      "Retrying langchain.chat_models.openai.ChatOpenAI.completion_with_retry.<locals>._completion_with_retry in 4.0 seconds as it raised RateLimitError: Rate limit reached for 10KTPM-200RPM in organization org-ETbTMTN2JXYOUPDJgxuH2iO6 on tokens per min. Limit: 10000 / min. Please try again in 6ms. Contact us through our help center at help.openai.com if you continue to have issues..\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\n",
      "\u001b[1m> Finished chain.\u001b[0m\n",
      "\n",
      "\u001b[1m> Finished chain.\u001b[0m\n",
      "2023-10-02 17:39:15,075:INFO: 6174 tokens were added to prompt from 10 documents\n",
      "Query: 48 year-old woman with distal moderate to severe ulcerative colitis who prioritizes a rapid response to treatment.\n",
      "\n",
      "\n",
      "\n",
      "\u001b[1m> Entering new SequentialChain chain...\u001b[0m\n",
      "\n",
      "\n",
      "\u001b[1m> Entering new RetrievalQAWithSourcesChain chain...\u001b[0m\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "Retrying langchain.chat_models.openai.ChatOpenAI.completion_with_retry.<locals>._completion_with_retry in 4.0 seconds as it raised RateLimitError: Rate limit reached for 10KTPM-200RPM in organization org-ETbTMTN2JXYOUPDJgxuH2iO6 on tokens per min. Limit: 10000 / min. Please try again in 6ms. Contact us through our help center at help.openai.com if you continue to have issues..\n",
      "Retrying langchain.chat_models.openai.ChatOpenAI.completion_with_retry.<locals>._completion_with_retry in 4.0 seconds as it raised RateLimitError: Rate limit reached for 10KTPM-200RPM in organization org-ETbTMTN2JXYOUPDJgxuH2iO6 on tokens per min. Limit: 10000 / min. Please try again in 6ms. Contact us through our help center at help.openai.com if you continue to have issues..\n",
      "Retrying langchain.chat_models.openai.ChatOpenAI.completion_with_retry.<locals>._completion_with_retry in 4.0 seconds as it raised RateLimitError: Rate limit reached for 10KTPM-200RPM in organization org-ETbTMTN2JXYOUPDJgxuH2iO6 on tokens per min. Limit: 10000 / min. Please try again in 6ms. Contact us through our help center at help.openai.com if you continue to have issues..\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\n",
      "\u001b[1m> Finished chain.\u001b[0m\n",
      "\n",
      "\n",
      "\u001b[1m> Entering new LLMChain chain...\u001b[0m\n",
      "Prompt after formatting:\n",
      "\u001b[32;1m\u001b[1;3mYou are a senior physician giving advice on treatment for moderate to severe ulcerative colitis (UC).\n",
      "Make reference to the CONTEXT given to assess the scenario.\n",
      "==========\n",
      "TASK: Your task is to analyse critically the CURRENT ANSWER given the CONTEXT.\n",
      "Then refine the existing answer (only if needed) based on the following instructions:\n",
      "- If no refinement needed, return the original answer in the correct output format.\n",
      "- If the answer cannot be inferred from CONTEXT, return \"NO ANSWER\".\n",
      "- The final output should be a list of up to 2 choices of biological drugs given patient profile and context and PROS/CONS for each recommendations.\n",
      "==========\n",
      "CONTEXT:\n",
      "Burr et al. \n",
      " \n",
      "7 of 45 \n",
      "INTRODUCTION \n",
      "  Ulcerative colitis (UC) is a chronic inflammatory disorder of the bowel that causes \n",
      "continuous mucosal inflammation commencing in the rectum and extending proximally for a \n",
      "variable extent.[1] It is estimated that UC affects 2.5 million people in Europe,[2] and the \n",
      "disease follows a relapsing and remitting course, with intermittent flares of disease activity, \n",
      "some of which may be moderate to severe. Management of these is medical, for the most \n",
      "part, with surgery reserved for patients with refractory disease. Although 5-aminosalicylates \n",
      "(5-ASAs) are efficacious for mild to moderate disease activity,[3-6] more severe flares are \n",
      "usually treated with corticosteroids.[7] However, these have potentially serious adverse \n",
      "effects and a substantial proportion of patients may become either dependent on them to \n",
      "maintain remission,[8] or refractory to them.[9] As a result, over the last 20 years novel \n",
      "drugs, with more precise modes of action, based on mechanisms of disease identified in \n",
      "genome wide association studies,[10] have been developed.  \n",
      "The first of these agents was infliximab, a drug targeting the pro-inflammatory \n",
      "cytokine tumour necrosis factor-α (TNF-α), which demonstrated efficacy in clinical trials in \n",
      "moderate to severe UC.[11] Since then, other drugs against TNF-α have been tested, such as \n",
      "adalimumab and golimumab.[12, 13] In addition, newer biological therapies targeting α or β \n",
      "integrins, which are involved in migration of immune cells to inflamed intestinal mucosa, \n",
      "such as vedolizumab or etrolizumab,[14, 15] or acting against other pro-inflammatory \n",
      "cytokines implicated in the pathogenesis of UC, such as ustekinumab,[16] have been tested. \n",
      "However, even these more selective drugs do not work in all patients, there may be risks \n",
      "associated with their use,[17-19] and the fact that they are administered either intravenously \n",
      "or subcutaneously, may be inconvenient for patients. The search for alternative agents for the \n",
      "treatment of UC has, therefore, continued.\n",
      "----------\n",
      "Therapeutic strategies for the management of recentlydiagnosedulcerative colitis. IMMs include thiopurines and methotrexate. 5-ASA, 5-amino salicylic acid; ASUC, acute severe ulcerative colitis; IPAA, ileal pouch anal anastomosis.\n",
      "\n",
      "Risk stratification: Mild\n",
      "Clinical features: NA\n",
      "Treatment options: 5-ASA (oral and/or topical)\n",
      "\n",
      "Risk stratification: Moderate\n",
      "Clinical features: NA\n",
      "Treatment options: Can consider 5-ASA (with rapid step-up if inadequate response)\n",
      "\n",
      "Risk stratification: Moderate\n",
      "Clinical features: NA\n",
      "Treatment options: VDZ or UST\n",
      "\n",
      "Risk stratification: Moderate\n",
      "Clinical features: NA\n",
      "Treatment options: Thiopurine\n",
      "\n",
      "Risk stratification: Moderate\n",
      "Clinical features: NA\n",
      "Treatment options: TNFi +/- IMM\n",
      "\n",
      "Risk stratification: Severe\n",
      "Clinical features: NA\n",
      "Treatment options: TNFi +/- IMM\n",
      "\n",
      "Risk stratification: Severe\n",
      "Clinical features: NA\n",
      "Treatment options: Subtotal colectomy + IPAA or cyclosporine (for ASUC)\n",
      "\n",
      "Risk stratification: Additional consideration: EIM present\n",
      "Clinical features: Psoriasis or psoriatic arthritis\n",
      "Treatment options: UST\n",
      "\n",
      "Risk stratification: Additional consideration: EIM present\n",
      "Clinical features: Other arthritis\n",
      "Treatment options: TNFi\n",
      "\n",
      "\n",
      "----------\n",
      "41 years (interquartile range, 40–42 y), and 60%\n",
      "(interquartile range, 56%–63%) were men. The median\n",
      "disease duration was 6.7 years (interquartile range,\n",
      "6.0–7.8 y), and 49% (interquartile range, 46%–55%) of\n",
      "patients had extensive colitis. A median of 40% (inter-\n",
      "quartile range, 30%–50%) of patients were treated with\n",
      "concomitant immunomodulators, and 51% (interquartile\n",
      "range, 45%–57%) were on corticosteroids at baseline.\n",
      "Patients across all trials and treatment arms were com-\n",
      "parable in terms of baseline prognostic variables, inclu-\n",
      "sion/exclusion\n",
      "criteria,\n",
      "and\n",
      "co-interventions.\n",
      "All\n",
      "outcomes were assessed uniformly based on the stan-\n",
      "dard deﬁnition of the Mayo Clinic score, between weeks\n",
      "6 and 10 for induction therapy (inﬂiximab, adalimumab,\n",
      "tofacitinib, ustekinumab, 8 weeks; golimumab, 6 weeks;\n",
      "vedolizumab, 6 weeks, 10 weeks, and 14 weeks in\n",
      "VARSITY),6 and weeks 30, 54, or 60 for maintenance\n",
      "therapy;\n",
      "endoscopy\n",
      "was\n",
      "read\n",
      "by\n",
      "blinded\n",
      "local\n",
      "Table 2. Comparative Efﬁcacy of Pharmacologic Agents for Induction of Clinical Remission and Endoscopic Improvement in Biologic-Naive Patients With Moderate–Severe\n",
      "Ulcerative Colitis Using Network Meta-Analysis\n",
      "Induction of clinical remission\n",
      "Induction of endoscopic improvement\n",
      "Ustekinumab 6 mg/kg\n",
      "0.96 (0.38–2.45)\n",
      "0.80 (0.35–1.83)\n",
      "0.73 (0.31–1.74)\n",
      "1.05 (0.48–2.32)\n",
      "0.50 (0.22–1.12)\n",
      "2.04 (1.03–4.05)\n",
      "0.92 (0.45–1.89)\n",
      "Tofacitinib 10 mg b.d.\n",
      "0.84 (0.39–1.82)\n",
      "0.76 (0.33–1.76)\n",
      "1.10 (0.51–2.34)\n",
      "0.52 (0.24–1.12)\n",
      "2.12 (1.12–4.02)\n",
      "0.74 (0.36–1.51)\n",
      "0.80 (0.4–1.62)\n",
      "Vedolizumab\n",
      "0.91 (0.44–1.86)\n",
      "1.31 (0.88–1.95)\n",
      "0.62 (0.34–1.15)\n",
      "2.54 (1.60–4.02)\n",
      "1.07 (0.58–1.98)\n",
      "1.17 (0.64–2.12)\n",
      "1.45 (0.80–2.61)\n",
      "Golimumab\n",
      "1.44 (0.76–2.75)\n",
      "0.69 (0.35–1.36)\n",
      "2.79 (1.64–4.02)\n",
      "1.17 (0.65–2.13)\n",
      "1.28 (0.72–2.29)\n",
      "1.59 (0.90–2.82)\n",
      "1.10 (0.71–1.71)\n",
      "Adalimumab\n",
      "0.48 (0.26–0.86)\n",
      "1.94 (1.30–2.88)\n",
      "0.56 (0.30–1.04)\n",
      "0.61 (0.34–1.11)\n",
      "0.76 (0.42–1.37)\n",
      "0.52 (0.33–0.83)\n",
      "0.48 (0.31–0.74)\n",
      "Inﬂiximab\n",
      "4.07 (2.67–6.21)\n",
      "1.86 (1.11–3.13)\n",
      "2.03 (1.23–3.34)\n",
      "2.52 (1.54–4.11)\n",
      "1.74 (1.25–2.41)\n",
      "1.58 (1.18–2.13)\n",
      "3.32 (2.39–4.60)\n",
      "Placebo\n",
      "NOTE. Comparisons should be read from left to right. Odds ratio for comparisons are in the cell in common between the column-deﬁning and row-deﬁning treatment. Numbers in bold are statistically signiﬁcant. For induction of\n",
      "clinical remission, an odds ratio greater than 1 favors row-deﬁning treatment. For induction of endoscopic improvement, an odds ratio greater than 1 favors column-deﬁning treatment. Numbers in parentheses indicate 95% CI.\n",
      "b.d., twice daily.\n",
      "----------\n",
      "severely active ulcerative colitis: results from phase 3 \n",
      "U-ACCOMPLISH study. J Crohn’s Colitis 2021; 15 (suppl 1): S021–22.\n",
      "9 \n",
      "Thorlund K, Druyts E, Mills EJ, Fedorak RN, Marshall JK. \n",
      "Adalimumab versus infliximab for the treatment of moderate to \n",
      "severe ulcerative colitis in adult patients naïve to anti-TNF therapy: \n",
      "an indirect treatment comparison meta-analysis. J Crohn’s Colitis \n",
      "2014; 8: 571–81.\n",
      "10 \n",
      "Danese S, Fiorino G, Peyrin-Biroulet L, et al. Biological agents for \n",
      "moderately to severely active ulcerative colitis: a systematic review \n",
      "and network meta-analysis. Ann Intern Med 2014; 160: 704–11.\n",
      "11 \n",
      "Singh S, Fumery M, Sandborn WJ, Murad MH. Systematic review \n",
      "with network meta-analysis: first- and second-line pharmacotherapy \n",
      "for moderate-severe ulcerative colitis. Aliment Pharmacol Ther 2018; \n",
      "47: 162–75.\n",
      "12 \n",
      "Bonovas S, Lytras T, Nikolopoulos G, Peyrin-Biroulet L, Danese S. \n",
      "Systematic review with network meta-analysis: comparative \n",
      "assessment of tofacitinib and biological therapies for moderate-to-\n",
      "severe ulcerative colitis. Aliment Pharmacol Ther 2018; 47: 454–65.\n",
      "13 \n",
      "Singh S, Murad MH, Fumery M, Dulai PS, Sandborn WJ. First- and \n",
      "second-line pharmacotherapies for patients with moderate to \n",
      "severely active ulcerative colitis: an updated network meta-analysis. \n",
      "Clin Gastroenterol Hepatol 2020; 18: 2179–91.e6.\n",
      "14 \n",
      "Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting \n",
      "items for systematic reviews and meta-analyses: the PRISMA \n",
      "statement. Ann Intern Med 2009; 151: 264–69.\n",
      "15 \n",
      "Jansen JP, Fleurence R, Devine B, et al. Interpreting indirect \n",
      "treatment comparisons and network meta-analysis for health-care \n",
      "decision making: report of the ISPOR Task Force on Indirect \n",
      "Treatment Comparisons Good Research Practices: part 1. \n",
      "Value Health 2011; 14: 417–28.\n",
      "16 \n",
      "Sterne JAC, Savović J, Page MJ, et al. RoB 2: a revised tool for \n",
      "assessing risk of bias in randomised trials. BMJ 2019; 366: l4898.\n",
      "17 \n",
      "Rücker G, Schwarzer G. Ranking treatments in frequentist network \n",
      "meta-analysis works without resampling methods. \n",
      "BMC Med Res Methodol 2015; 15: 58.\n",
      "----------\n",
      "associated with improved long-term outcomes.33 Data on\n",
      "the impact of early therapy in UC are more limited, but, as\n",
      "UC is also a progressive disease with risk of colorectal\n",
      "cancer, surgery, and loss of colonic function, it is reasonable\n",
      "to treat early to mitigate these risks.\n",
      "How to Diagnose Inﬂammatory Bowel Disease\n",
      "Early\n",
      "IBD is heterogenous with wide variation in presentation.\n",
      "Disease activity at presentation can range from mild to severe\n",
      "and, as discussed, symptoms may be mild to none. These can\n",
      "make the IBD diagnosis challenging, especially at a primary\n",
      "care level. Danese et al34 have proposed a Red Flags Index\n",
      "consisting of a 21-item questionnaire to help providers triage\n",
      "and identify patients with concerning symptoms in a timely\n",
      "manner and refer to specialists appropriately. A useful adjunct\n",
      "to symptom-based criteria is fecal calprotectin (FC), a stool\n",
      "marker of inﬂammation; in a large meta-analysis, FC � 40 mg/\n",
      "g carried a �1% probability of IBD, effectively excluding the\n",
      "diagnosis of IBD.35 Similarly, in the Red Flags Index validation\n",
      "study, combining the index with FC (Red Flags Index �8 and/\n",
      "or FC >250 mg/g) increased the positive predictive value from\n",
      "4% to 21% and negative predictive value from 97% to\n",
      "100%.36 Diagnostic criteria for IBD involve a composite of\n",
      "clinical symptoms, endoscopic, biomarker, and cross-sectional\n",
      "imaging features, which are beyond the scope of this review.\n",
      "We refer readers to the excellent guidelines laid out by the\n",
      "American College of Gastroenterology, European Crohn’s and\n",
      "Colitis\n",
      "Organization,\n",
      "and\n",
      "British\n",
      "Society\n",
      "of\n",
      "Gastro-\n",
      "enterology.37–40\n",
      "Risk Stratiﬁcation and Prognostication\n",
      "at Diagnosis\n",
      "Appropriately\n",
      "risk-stratifying\n",
      "prognosis\n",
      "in\n",
      "patients\n",
      "recently diagnosed with IBD is essential to inform selection\n",
      "of the most appropriate treatment and monitoring strate-\n",
      "gies. CD and UC phenotype and disease activity at initial\n",
      "presentation can vary widely from limited and mild to\n",
      "extensive and complicated. Certain baseline clinical features\n",
      "are associated with a more aggressive disease course with\n",
      "higher risk of progression and complications. In higher-risk\n",
      "patients, early control of inﬂammation with immune-\n",
      "modifying therapies is critical. However, immunosuppres-\n",
      "sive therapies are associated with safety concerns in the\n",
      "short- and long-term, and entail signiﬁcant health care costs.\n",
      "Therefore, a consideration of risks, beneﬁts, and alternatives\n",
      "is key to develop an individualized therapeutic plan for the\n",
      "informed patient.\n",
      "----------\n",
      "Burr et al. \n",
      " \n",
      "5 of 45 \n",
      "STUDY HIGHLIGHTS \n",
      " \n",
      "What is already known about this subject \n",
      "• Ulcerative colitis (UC) follows a relapsing and remitting course, with intermittent \n",
      "flares of disease activity, some of which may be moderate to severe. \n",
      "• These are usually treated with corticosteroids, which have potentially serious adverse \n",
      "effects, so biological therapies and small molecules have been developed and licensed \n",
      "for this indication.  \n",
      "• Although previous network meta-analyses have compared their efficacy and safety, \n",
      "this is a rapidly moving field, and there are already several newer drugs that have \n",
      "shown efficacy in phase III clinical trials that were not considered in these. \n",
      " \n",
      "What are the new findings \n",
      "• In terms of clinical remission and clinical response, upadacitinib 45mg o.d. ranked \n",
      "first in all patients, in patients previously exposed to anti-tumour necrosis factor \n",
      "(TNF)-α therapies, and in patients naïve to these drugs.  \n",
      "• In terms of endoscopic improvement infliximab 10mg/kg ranked first, followed by \n",
      "upadacitinib 45mg o.d., and infliximab 5mg/kg.  \n",
      "• However, for endoscopic improvement again upadacitinib 45mg o.d. ranked first in \n",
      "patients previously exposed to anti-TNF-α therapies, and in patients who were anti-\n",
      "TNF-α naïve.  \n",
      "• None of the drugs studied were more likely to lead to serious adverse events than \n",
      "placebo.\n",
      "----------\n",
      "discontinuation due to AEs, and serious infections. Phase 3 randomized controlled trials were identified via systematic literature review, in-\n",
      "cluding the following advanced therapies: infliximab, adalimumab, vedolizumab, golimumab, tofacitinib, ustekinumab, filgotinib, ozanimod, and \n",
      "upadacitinib. Random effects models were used to address between-study heterogeneity. Intent-to-treat (ITT) efficacy rates were calculated by \n",
      "adjusting maintenance outcomes by likelihood of induction response.\n",
      "Results:  Out of 48 trials identified, 23 were included. Across all outcomes and regardless of prior biologic exposure, ITT efficacy rates were \n",
      "highest for upadacitinib, owing to its highest ranking for all efficacy outcomes in induction and for all but clinical remission during maintenance \n",
      "among bio-naive induction responders. For all advanced therapies versus placebo, there were no significant differences in serious AEs or \n",
      "serious infections across therapies. For all AEs, golimumab had higher odds versus placebo during maintenance; for discontinuation due to \n",
      "AEs, upadacitinib had lower odds versus placebo during induction, while ustekinumab and vedolizumab had lower odds versus placebo during \n",
      "maintenance.\n",
      "Conclusions:  Upadacitinib may be the most efficacious therapy for moderately to severely active UC based on ITT analyses, with similar safety \n",
      "across advanced therapies.\n",
      "Lay Summary \n",
      "Indirect evidence suggests upadacitinib may be more efficacious than other advanced therapies at achieving clinical response, clinical remis-\n",
      "sion, and endoscopic response over 1 year for moderately to severely active ulcerative colitis patients, with similar safety assessments across \n",
      "advanced therapies.\n",
      "Key Words: ulcerative colitis, clinical trials, advanced therapies, network meta-analysis\n",
      "Introduction\n",
      "Ulcerative colitis (UC) is a chronic inflammatory bowel dis-\n",
      "ease that affects the colorectum and is clinically characterized \n",
      "by bloody diarrhea, urgency, tenesmus, abdominal pain, ma-\n",
      "laise, weight loss, and fever. Disease onset commonly occurs \n",
      "between the ages of 15 and 30 years and the annual global \n",
      "© The Author(s) 2023. Published by Oxford University Press on behalf of Crohn's & Colitis Foundation.\n",
      "This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), \n",
      "which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.\n",
      "----------\n",
      "methodologic characteristics). If direct and indirect es-\n",
      "timates were similar (ie, coherent), then the higher rating\n",
      "can be assigned to the network meta-analysis estimates.\n",
      "Results\n",
      "From a total 5651 unique studies identiﬁed using our\n",
      "search strategy, we included 15 RCTs of ﬁrst-line agents\n",
      "(in biologic-naïve patients) (Active Ulcerative Colitis Trials\n",
      "1 and 2,17 Jiang et al,18 NCT01551290,19 Ulcerative colitis\n",
      "Long-Term Remission and maintenance with Adalimumab\n",
      "1 and 2,20,21 Suzuki et al,22 Program of Ulcerative Colitis\n",
      "Research Studies Utilizing an Investigational Treatment\n",
      "phase 2 and phase 3 induction studies,23 GEMINI I,24\n",
      "Motoya et al,25 VARSITY, Oral Clinical Trials for tofAciti-\n",
      "nib in ulceratiVE colitis (OCTAVE) 1 and 2,26 and UNIFI),\n",
      "and 7 RCTs of second-line agents (in patients with prior\n",
      "exposure to TNFa antagonists) (Ulcerative colitis Long-\n",
      "Term Remission and maintenance with Adalimumab 2,21\n",
      "GEMINI I,24 Motoya et al,25 VARSITY,6 OCTAVE 1 and\n",
      "2,26 UNIFI7) in patients with moderate–severe ulcerative\n",
      "colitis. Trials of inﬂiximab (Active Ulcerative Colitis Trials\n",
      "1 and 2,17 Jiang et al,18 NCT0155129019), adalimumab\n",
      "(Ulcerative colitis Long-Term Remission and maintenance\n",
      "with Adalimumab 2,20,21 Suzuki et al22), vedolizumab\n",
      "(GEMINI I,24 Motoya et al,25 VARSITY6) and ustekinumab\n",
      "(UNIFI7) also reported outcomes on maintenance therapy\n",
      "within the same publication; Program of Ulcerative Colitis\n",
      "Research Studies Utilizing an Investigational Treatment-\n",
      "M, Program of Ulcerative Colitis Research Studies Utilizing\n",
      "an Investigational Treatment-J, and OCTAVE-Sustain\n",
      "reported\n",
      "outcomes\n",
      "for\n",
      "maintenance\n",
      "therapy\n",
      "with\n",
      "golimumab and tofacitinib, respectively.26–28 From our\n",
      "previous analysis, 3 additional studies were included.\n",
      "The schematic diagram of study selection is shown in\n",
      "Supplementary\n",
      "Figure\n",
      "1,\n",
      "and\n",
      "available\n",
      "direct\n",
      "comparisons and network of trials are shown in Figure 1.\n",
      "Trial and patient characteristics are summarized in\n",
      "Table 1. Overall, the median average age of patients was\n",
      "41 years (interquartile range, 40–42 y), and 60%\n",
      "(interquartile range, 56%–63%) were men. The median\n",
      "disease duration was 6.7 years (interquartile range,\n",
      "6.0–7.8 y), and 49% (interquartile range, 46%–55%) of\n",
      "patients had extensive colitis. A median of 40% (inter-\n",
      "quartile range, 30%–50%) of patients were treated with\n",
      "concomitant immunomodulators, and 51% (interquartile\n",
      "range, 45%–57%) were on corticosteroids at baseline.\n",
      "Patients across all trials and treatment arms were com-\n",
      "----------\n",
      "SYSTEMATIC REVIEWS AND META-ANALYSES\n",
      "Siddharth Singh, Section Editor\n",
      "First- and Second-Line Pharmacotherapies for Patients With\n",
      "Moderate to Severely Active Ulcerative Colitis: An Updated\n",
      "Network Meta-Analysis\n",
      "Siddharth Singh,*,‡ Mohammad Hassan Murad,§ Mathurin Fumery,j\n",
      "Parambir S. Dulai,* and William J. Sandborn*\n",
      "*Division of Gastroenterology, ‡Division of Biomedical Informatics, University of California San Diego, La Jolla, California;\n",
      "§Robert D and Patricia E Kern Center for the Science of Health Care Delivery, Mayo Clinic, Rochester, Minnesota;\n",
      "||Gastroenterology Unit, Peritox UMR I-0I, Amiens University and Hospital, Université de Picardie Jules Verne, Amiens, France\n",
      "BACKGROUND & AIMS:\n",
      "We compared the efﬁcacy and safety of different ﬁrst-line (biologic-naïve) and second-line\n",
      "(prior exposure to tumor necrosis factor [TNF] antagonists) agents for treatment of moder-\n",
      "ate to severely active ulcerative colitis in a systematic review and network meta-analysis.\n",
      "METHODS:\n",
      "We searched publication databases through September 30, 2019, for randomized trials of\n",
      "adults with moderate to severe ulcerative colitis treated with TNF antagonists, vedolizumab,\n",
      "tofacitinib, or ustekinumab, as ﬁrst-line or second-line agents, compared with placebo or\n",
      "another active agent. Efﬁcacy outcomes were induction and maintenance of remission and\n",
      "endoscopic improvement; safety outcomes were serious adverse events and infections. We\n",
      "performed a ﬁxed-effects network meta-analysis using the frequentist approach, and calculated\n",
      "odds ratios (ORs) and 95% CI values. Agents were ranked using surface under the cumulative\n",
      "ranking (SUCRA) probabilities. Overall quality of evidence was rated using GRADE (Grading of\n",
      "Recommendations, Assessment, Development and Evaluation).\n",
      "RESULTS:\n",
      "In biologic-naïve patients, inﬂiximab was ranked highest for induction of clinical remission (OR\n",
      "vs placebo, 4.07; 95% CI, 2.67–6.21; SUCRA, 0.95) and endoscopic improvement (SUCRA, 0.95)\n",
      "(moderate conﬁdence in estimates [CE]). In patients with prior exposure to TNF antagonists,\n",
      "ustekinumab (SUCRA, 0.87) and tofacitinib (SUCRA, 0.87) were ranked highest for induction of\n",
      "clinical remission and were superior to vedolizumab (ustekinumab vs vedolizumab: OR, 5.99;\n",
      "95% CI, 1.13–31.76 and tofacitinib vs vedolizumab: OR, 6.18; 95% CI, 1.003–8.00; moderate CE)\n",
      "and adalimumab (ustekinumab vs adalimumab: OR, 10.71; 95% CI, 2.01–57.20 and tofacitinib\n",
      "----------\n",
      "Articles\n",
      "www.thelancet.com/gastrohep   Vol 7   February 2022 \n",
      "161\n",
      "Lancet Gastroenterol Hepatol \n",
      "2022; 7: 161–70\n",
      "Published Online \n",
      "November 29, 2021 \n",
      "https://doi.org/10.1016/ \n",
      "S2468-1253(21)00377-0\n",
      "See Comment page 110\n",
      "*Contributed equally\n",
      "Inflammatory Bowel Disease \n",
      "Unit, Gastroenterology \n",
      "Section, Department of \n",
      "Internal Medicine, Centro de \n",
      "Educación Médica e \n",
      "Investigaciones Clínicas, \n",
      "Buenos Aires, Argentina \n",
      "(J S Lasa MD, P A Olivera MD); \n",
      "Gastroenterology Department, \n",
      "Hospital Británico de Buenos \n",
      "Aires, Buenos Aires, Argentina \n",
      "(J S Lasa); Zane Cohen Centre \n",
      "for Digestive Diseases, \n",
      "Lunenfeld-Tanenbaum \n",
      "Research Institute, Sinai Health \n",
      "System, Toronto, ON, Canada \n",
      "(P A Olivera); Division of \n",
      "Gastroenterology, Mount Sinai \n",
      "Hospital, University of Toronto, \n",
      "Toronto, ON, Canada \n",
      "(P A Olivera); Gastroenterology \n",
      "and Endoscopy, IRCCS Ospedale \n",
      "San Raffaele and University \n",
      "Vita-Salute San Raffaele, \n",
      "Milano, Italy \n",
      "(Prof S Danese MD); INSERM \n",
      "NGERE and Department of \n",
      "Hepatogastroenterology, \n",
      "Nancy University Hospital, \n",
      "Lorraine University, \n",
      "Vandoeuvre-lés-Nancy, France \n",
      "(Prof L Peyrin-Biroulet MD) \n",
      "Correspondence to: \n",
      "Prof Laurent Peyrin-Biroulet, \n",
      "INSERM NGERE and Department \n",
      "of Hepatogastroenterology, \n",
      "Nancy University Hospital, \n",
      "Lorraine University, Vandoeuvre-\n",
      "lès-Nancy F-54511, France \n",
      "peyrinbiroulet@gmail.com\n",
      "Efficacy and safety of biologics and small molecule drugs for \n",
      "patients with moderate-to-severe ulcerative colitis: \n",
      "a systematic review and network meta-analysis \n",
      "Juan S Lasa*, Pablo A Olivera*, Silvio Danese, Laurent Peyrin-Biroulet\n",
      "Summary\n",
      "Background There is a growing armamentarium for the treatment of moderate-to-severe ulcerative colitis. We aimed \n",
      "to compare the relative efficacy and safety of biologics and small molecule drugs for the treatment of patients with \n",
      "moderate-to-severe ulcerative colitis.\n",
      "Methods In this systematic review and network meta-analysis, we searched MEDLINE, Embase, and the Cochrane \n",
      "Central Register of Controlled Trials without language restrictions for articles published between Jan 1, 1990, and \n",
      "July 1, 2021. Major congresses’ databases from Jan 1, 2018, to July 3, 2021, were reviewed manually. Phase 3, placebo-\n",
      "controlled or head-to-head randomised controlled trials (RCTs) assessing the efficacy and safety of biologics or small \n",
      "molecule drugs as induction or maintenance therapies for patients with moderate-to-severe ulcerative colitis were\n",
      "==========\n",
      "ORIGINAL QUESTION: ANALYSE the given patient profile based on given query based on one of the following criteria:\n",
      "- Whether treated patient is new patient or patient under maintenance\n",
      "- Prior response to Infliximab\n",
      "- Prior failure to Anti-TNF agents\n",
      "- Prior failure to Vedolizumab\n",
      "- Age\n",
      "- Pregnancy\n",
      "- Extraintestinale manifestations\n",
      "- Pouchitis\n",
      "RETURN up to 2 TOP choices of biological drugs given patient profile and context. Explain the PROS and CONS of the 2 choices.\n",
      "PATIENT PROFILE: 48 year-old woman with distal moderate to severe ulcerative colitis who prioritizes a rapid response to treatment.\n",
      "\n",
      "==========\n",
      "CURRENT ANSWER:\n",
      "Based on the patient's profile and the provided context, the top two choices of biological drugs for her moderate to severe ulcerative colitis would be:\n",
      "\n",
      "1. Infliximab\n",
      "2. Upadacitinib\n",
      "\n",
      "Infliximab:\n",
      "- Advantages: Infliximab has demonstrated efficacy in clinical trials for moderate to severe UC. It targets the pro-inflammatory cytokine tumour necrosis factor-α (TNF-α), which is involved in the inflammation process in UC. Infliximab has been ranked highest for induction of clinical remission and endoscopic improvement in biologic-naïve patients, making it a strong choice for a patient prioritizing a rapid response.\n",
      "- Disadvantages: Infliximab, like other biologics, may not work in all patients. There may be risks associated with its use, including serious adverse effects. It is also administered either intravenously or subcutaneously, which may be inconvenient for some patients.\n",
      "\n",
      "Upadacitinib:\n",
      "- Advantages: Upadacitinib has been ranked first in terms of clinical remission and clinical response in all patients, in patients previously exposed to anti-TNF-α therapies, and in patients naïve to these drugs. This suggests that it could be a good choice for a patient who has not previously been treated with anti-TNF-α therapies and is seeking a rapid response.\n",
      "- Disadvantages: While upadacitinib has shown promising results, it is a newer drug and long-term safety data may not be as robust as for older, more established treatments. As with other biologics, there may be risks associated with its use, including serious adverse effects. \n",
      "\n",
      "Please note that the choice of treatment should be individualized based on the patient's specific circumstances and preferences, and in consultation with their healthcare provider.\n",
      "\n",
      "[{\"drug_name\": \"Infliximab\", \"advantages\": \"Demonstrated efficacy in clinical trials for moderate to severe UC. Targets the pro-inflammatory cytokine tumour necrosis factor-α (TNF-α), which is involved in the inflammation process in UC. Ranked highest for induction of clinical remission and endoscopic improvement in biologic-naïve patients.\", \"disadvantages\": \"May not work in all patients. There may be risks associated with its use, including serious adverse effects. Administered either intravenously or subcutaneously, which may be inconvenient for some patients.\"}, {\"drug_name\": \"Upadacitinib\", \"adv\n",
      "==========\n",
      "REFINED ANSWER:\n",
      "\u001b[0m\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "Retrying langchain.chat_models.openai.ChatOpenAI.completion_with_retry.<locals>._completion_with_retry in 4.0 seconds as it raised RateLimitError: Rate limit reached for 10KTPM-200RPM in organization org-ETbTMTN2JXYOUPDJgxuH2iO6 on tokens per min. Limit: 10000 / min. Please try again in 6ms. Contact us through our help center at help.openai.com if you continue to have issues..\n",
      "Retrying langchain.chat_models.openai.ChatOpenAI.completion_with_retry.<locals>._completion_with_retry in 4.0 seconds as it raised RateLimitError: Rate limit reached for 10KTPM-200RPM in organization org-ETbTMTN2JXYOUPDJgxuH2iO6 on tokens per min. Limit: 10000 / min. Please try again in 6ms. Contact us through our help center at help.openai.com if you continue to have issues..\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\n",
      "\u001b[1m> Finished chain.\u001b[0m\n",
      "\n",
      "\u001b[1m> Finished chain.\u001b[0m\n",
      "2023-10-02 17:40:46,920:INFO: 5943 tokens were added to prompt from 10 documents\n",
      "Query: 36 year-old woman with moderate to severe ulcerative colitis who has lost response to tofacitinib.\n",
      "\n",
      "\n",
      "\n",
      "\u001b[1m> Entering new SequentialChain chain...\u001b[0m\n",
      "\n",
      "\n",
      "\u001b[1m> Entering new RetrievalQAWithSourcesChain chain...\u001b[0m\n",
      "\n",
      "\u001b[1m> Finished chain.\u001b[0m\n",
      "\n",
      "\n",
      "\u001b[1m> Entering new LLMChain chain...\u001b[0m\n",
      "Prompt after formatting:\n",
      "\u001b[32;1m\u001b[1;3mYou are a senior physician giving advice on treatment for moderate to severe ulcerative colitis (UC).\n",
      "Make reference to the CONTEXT given to assess the scenario.\n",
      "==========\n",
      "TASK: Your task is to analyse critically the CURRENT ANSWER given the CONTEXT.\n",
      "Then refine the existing answer (only if needed) based on the following instructions:\n",
      "- If no refinement needed, return the original answer in the correct output format.\n",
      "- If the answer cannot be inferred from CONTEXT, return \"NO ANSWER\".\n",
      "- The final output should be a list of up to 2 choices of biological drugs given patient profile and context and PROS/CONS for each recommendations.\n",
      "==========\n",
      "CONTEXT:\n",
      "Burr et al. \n",
      " \n",
      "5 of 45 \n",
      "STUDY HIGHLIGHTS \n",
      " \n",
      "What is already known about this subject \n",
      "• Ulcerative colitis (UC) follows a relapsing and remitting course, with intermittent \n",
      "flares of disease activity, some of which may be moderate to severe. \n",
      "• These are usually treated with corticosteroids, which have potentially serious adverse \n",
      "effects, so biological therapies and small molecules have been developed and licensed \n",
      "for this indication.  \n",
      "• Although previous network meta-analyses have compared their efficacy and safety, \n",
      "this is a rapidly moving field, and there are already several newer drugs that have \n",
      "shown efficacy in phase III clinical trials that were not considered in these. \n",
      " \n",
      "What are the new findings \n",
      "• In terms of clinical remission and clinical response, upadacitinib 45mg o.d. ranked \n",
      "first in all patients, in patients previously exposed to anti-tumour necrosis factor \n",
      "(TNF)-α therapies, and in patients naïve to these drugs.  \n",
      "• In terms of endoscopic improvement infliximab 10mg/kg ranked first, followed by \n",
      "upadacitinib 45mg o.d., and infliximab 5mg/kg.  \n",
      "• However, for endoscopic improvement again upadacitinib 45mg o.d. ranked first in \n",
      "patients previously exposed to anti-TNF-α therapies, and in patients who were anti-\n",
      "TNF-α naïve.  \n",
      "• None of the drugs studied were more likely to lead to serious adverse events than \n",
      "placebo.\n",
      "----------\n",
      "discontinuation due to AEs, and serious infections. Phase 3 randomized controlled trials were identified via systematic literature review, in-\n",
      "cluding the following advanced therapies: infliximab, adalimumab, vedolizumab, golimumab, tofacitinib, ustekinumab, filgotinib, ozanimod, and \n",
      "upadacitinib. Random effects models were used to address between-study heterogeneity. Intent-to-treat (ITT) efficacy rates were calculated by \n",
      "adjusting maintenance outcomes by likelihood of induction response.\n",
      "Results:  Out of 48 trials identified, 23 were included. Across all outcomes and regardless of prior biologic exposure, ITT efficacy rates were \n",
      "highest for upadacitinib, owing to its highest ranking for all efficacy outcomes in induction and for all but clinical remission during maintenance \n",
      "among bio-naive induction responders. For all advanced therapies versus placebo, there were no significant differences in serious AEs or \n",
      "serious infections across therapies. For all AEs, golimumab had higher odds versus placebo during maintenance; for discontinuation due to \n",
      "AEs, upadacitinib had lower odds versus placebo during induction, while ustekinumab and vedolizumab had lower odds versus placebo during \n",
      "maintenance.\n",
      "Conclusions:  Upadacitinib may be the most efficacious therapy for moderately to severely active UC based on ITT analyses, with similar safety \n",
      "across advanced therapies.\n",
      "Lay Summary \n",
      "Indirect evidence suggests upadacitinib may be more efficacious than other advanced therapies at achieving clinical response, clinical remis-\n",
      "sion, and endoscopic response over 1 year for moderately to severely active ulcerative colitis patients, with similar safety assessments across \n",
      "advanced therapies.\n",
      "Key Words: ulcerative colitis, clinical trials, advanced therapies, network meta-analysis\n",
      "Introduction\n",
      "Ulcerative colitis (UC) is a chronic inflammatory bowel dis-\n",
      "ease that affects the colorectum and is clinically characterized \n",
      "by bloody diarrhea, urgency, tenesmus, abdominal pain, ma-\n",
      "laise, weight loss, and fever. Disease onset commonly occurs \n",
      "between the ages of 15 and 30 years and the annual global \n",
      "© The Author(s) 2023. Published by Oxford University Press on behalf of Crohn's & Colitis Foundation.\n",
      "This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), \n",
      "which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.\n",
      "----------\n",
      "investigators for all trials, except trials of tofacitinib and\n",
      "ustekinumab, which were read by blinded central\n",
      "readers.7,26 Overall, the studies were deemed to be at\n",
      "low risk of bias, and all included studies were industry-\n",
      "sponsored.\n",
      "Induction Therapy\n",
      "First-line\n",
      "pharmacotherapy\n",
      "for\n",
      "moderate–severe\n",
      "ulcerative colitis. Overall, 15 RCTs including 3747 bio-\n",
      "logic-naïve patients with moderate–severe ulcerative\n",
      "colitis, treated with inﬂiximab (4 trials, 667 patients),\n",
      "adalimumab (4 trials, 1046 patients), golimumab (2 tri-\n",
      "als, 586 patients), vedolizumab (3 trials, 630 patients),\n",
      "tofacitinib (2 trials, 520 patients), and ustekinumab (1\n",
      "trial, 298 patients) were included; 1 trial compared\n",
      "adalimumab vs vedolizumab.\n",
      "Induction\n",
      "of\n",
      "clinical\n",
      "remission. On\n",
      "direct\n",
      "meta-\n",
      "analysis, all agents were superior to placebo for induc-\n",
      "tion of clinical remission, and effect size was strongest\n",
      "for inﬂiximab (OR, 4.07; 95% CI, 2.68–6.16) and vedoli-\n",
      "zumab (OR, 3.10; 95% CI, 1.53–6.26), with minimal to\n",
      "moderate heterogeneity across estimates (I2 < 35%)\n",
      "(Supplementary Figure 2A). On network meta-analysis,\n",
      "compared with placebo there was moderate conﬁdence\n",
      "in\n",
      "estimates\n",
      "supporting\n",
      "the\n",
      "use\n",
      "of\n",
      "inﬂiximab,\n",
      "adalimumab, golimumab, vedolizumab, tofacitinib, and\n",
      "ustekinumab for induction of clinical remission in bio-\n",
      "logic-naïve patients (evidence was rated down owing to\n",
      "imprecision caused by a low event rate) (Table 2). On\n",
      "comparison of active interventions, there was moderate\n",
      "conﬁdence in estimates supporting the use of inﬂiximab\n",
      "over adalimumab (OR, 2.10; 95% CI, 1.16–3.79); none of\n",
      "the other comparisons between active interventions\n",
      "were signiﬁcantly different (Table 2). Overall, inﬂiximab\n",
      "(SUCRA, 0.95) was ranked highest for inducing clinical\n",
      "remission\n",
      "in\n",
      "biologic-naïve\n",
      "patients\n",
      "with\n",
      "moderate–severe UC (Figure 2A). With an estimated\n",
      "placebo rate of achieving remission of 10% in included\n",
      "trials, we anticipate that 31.1%, 17.7%, 23.7%, 22.0%,\n",
      "Figure 2. (A) Relative efﬁ-\n",
      "cacy\n",
      "of\n",
      "different\n",
      "in-\n",
      "terventions for induction of\n",
      "clinical\n",
      "remission\n",
      "and\n",
      "endoscopic\n",
      "improvement\n",
      "in biologic-naïve patients\n",
      "with moderate to severely\n",
      "active ulcerative colitis. (B)\n",
      "Relative\n",
      "efﬁcacy\n",
      "of\n",
      "different interventions for\n",
      "induction of clinical remis-\n",
      "sion\n",
      "and\n",
      "endoscopic\n",
      "improvement\n",
      "in\n",
      "patients\n",
      "with moderate to severely\n",
      "active\n",
      "ulcerative\n",
      "colitis\n",
      "with prior exposure to tu-\n",
      "mor necrosis factor (TNF)⍺\n",
      "antagonists. SUCRA, sur-\n",
      "face under the cumulative\n",
      "ranking.\n",
      "September 2020\n",
      "Management of Moderate–Severe UC 2185\n",
      "----------\n",
      "SYSTEMATIC REVIEWS AND META-ANALYSES\n",
      "Siddharth Singh, Section Editor\n",
      "First- and Second-Line Pharmacotherapies for Patients With\n",
      "Moderate to Severely Active Ulcerative Colitis: An Updated\n",
      "Network Meta-Analysis\n",
      "Siddharth Singh,*,‡ Mohammad Hassan Murad,§ Mathurin Fumery,j\n",
      "Parambir S. Dulai,* and William J. Sandborn*\n",
      "*Division of Gastroenterology, ‡Division of Biomedical Informatics, University of California San Diego, La Jolla, California;\n",
      "§Robert D and Patricia E Kern Center for the Science of Health Care Delivery, Mayo Clinic, Rochester, Minnesota;\n",
      "||Gastroenterology Unit, Peritox UMR I-0I, Amiens University and Hospital, Université de Picardie Jules Verne, Amiens, France\n",
      "BACKGROUND & AIMS:\n",
      "We compared the efﬁcacy and safety of different ﬁrst-line (biologic-naïve) and second-line\n",
      "(prior exposure to tumor necrosis factor [TNF] antagonists) agents for treatment of moder-\n",
      "ate to severely active ulcerative colitis in a systematic review and network meta-analysis.\n",
      "METHODS:\n",
      "We searched publication databases through September 30, 2019, for randomized trials of\n",
      "adults with moderate to severe ulcerative colitis treated with TNF antagonists, vedolizumab,\n",
      "tofacitinib, or ustekinumab, as ﬁrst-line or second-line agents, compared with placebo or\n",
      "another active agent. Efﬁcacy outcomes were induction and maintenance of remission and\n",
      "endoscopic improvement; safety outcomes were serious adverse events and infections. We\n",
      "performed a ﬁxed-effects network meta-analysis using the frequentist approach, and calculated\n",
      "odds ratios (ORs) and 95% CI values. Agents were ranked using surface under the cumulative\n",
      "ranking (SUCRA) probabilities. Overall quality of evidence was rated using GRADE (Grading of\n",
      "Recommendations, Assessment, Development and Evaluation).\n",
      "RESULTS:\n",
      "In biologic-naïve patients, inﬂiximab was ranked highest for induction of clinical remission (OR\n",
      "vs placebo, 4.07; 95% CI, 2.67–6.21; SUCRA, 0.95) and endoscopic improvement (SUCRA, 0.95)\n",
      "(moderate conﬁdence in estimates [CE]). In patients with prior exposure to TNF antagonists,\n",
      "ustekinumab (SUCRA, 0.87) and tofacitinib (SUCRA, 0.87) were ranked highest for induction of\n",
      "clinical remission and were superior to vedolizumab (ustekinumab vs vedolizumab: OR, 5.99;\n",
      "95% CI, 1.13–31.76 and tofacitinib vs vedolizumab: OR, 6.18; 95% CI, 1.003–8.00; moderate CE)\n",
      "and adalimumab (ustekinumab vs adalimumab: OR, 10.71; 95% CI, 2.01–57.20 and tofacitinib\n",
      "----------\n",
      "What You Need to Know\n",
      "Background\n",
      "A systematic review and network meta-analysis is\n",
      "needed to compare efﬁcacy and safety of ﬁrst-line\n",
      "(biologic-naïve) and second-line (prior exposure to\n",
      "tumor necrosis factor [TNF] antagonists) agents for\n",
      "treatment of moderate to severely active ulcerative\n",
      "colitis.\n",
      "Findings\n",
      "Inﬂiximab was ranked highest in biologic-naïve pa-\n",
      "tients, and ustekinumab and tofacitinib were ranked\n",
      "highest in patients with prior exposure to TNF an-\n",
      "tagonists, for induction of remission and endoscopic\n",
      "improvement. More trials of direct comparisons are\n",
      "needed to inform clinical decision-making with\n",
      "greater conﬁdence.\n",
      "Implications for patient care\n",
      "Patients with moderate to severely active ulcerative\n",
      "colitis should receive inﬂiximab or vedolizumab as\n",
      "ﬁrst-line therapy, or ustekinumab or tofacitinib if\n",
      "they have prior exposure to TNF antagonists.\n",
      "2180 Singh et al\n",
      "Clinical Gastroenterology and Hepatology Vol. 18, No. 10\n",
      "----------\n",
      "Burr et al. \n",
      " \n",
      "3 of 45 \n",
      "ABSTRACT \n",
      "Objective: Biological therapies and small molecules continue to be evaluated in moderate to \n",
      "severely active ulcerative colitis, but are often studied in placebo-controlled trials, meaning \n",
      "their relative efficacy and safety is unknown. We examined this in a network meta-analysis.  \n",
      "Design: We searched the literature to October 2021 to identify eligible trials. We judged \n",
      "efficacy using clinical remission, endoscopic improvement, or clinical response, and \n",
      "according to previous exposure or non-exposure to anti-tumour necrosis factor (TNF)-α \n",
      "therapy. We also assessed safety. We used a random effects model and reported data as \n",
      "pooled relative risks (RRs) with 95% confidence intervals (CIs). Interventions were ranked \n",
      "according to their P-score. \n",
      "Results: We identified 28 trials (12,504 patients). Based on failure to achieve clinical \n",
      "remission, upadacitinib 45mg o.d. ranked first versus placebo (RR = 0.73; 95% CI 0.68-0.80, \n",
      "P-score 0.98), with infliximab 5mg/kg and 10mg/kg second and third, respectively. \n",
      "Upadacitinib ranked first for clinical remission in both patients naïve to anti-TNF-α drugs \n",
      "(RR = 0.69; 95% CI 0.61-0.78, P-score 0.99) and previously exposed (RR = 0.78; 95% CI \n",
      "0.72-0.85, P-score 0.99). Upadacitinib was superior to almost all other drugs in these \n",
      "analyses. Based on failure to achieve endoscopic improvement infliximab 10mg/kg ranked \n",
      "first (RR = 0.61; 95% CI 0.51-0.72, P-score 0.97), with upadacitinib 45mg o.d. second, and \n",
      "infliximab 5mg/kg third. Upadacitinib was more likely to lead to adverse events, but serious \n",
      "adverse events were no more frequent, and withdrawals due to adverse events were \n",
      "significantly lower than with placebo. Infections were significantly more likely with \n",
      "tofacitinib than placebo (RR = 1.41; 95% CI 1.03-1.91). \n",
      "Conclusion: In a network meta-analysis, upadacitinib 45mg o.d. ranked first for clinical \n",
      "remission in all patients, patients naïve to anti-TNF-α drugs, and patients previously exposed.\n",
      "----------\n",
      "tients with moderate–severe ulcerative colitis with prior\n",
      "exposure to TNFa antagonists were identiﬁed. These\n",
      "included subgroup analyses of trials of adalimumab,21\n",
      "vedolizumab,24,25\n",
      "tofacitinib,26\n",
      "and\n",
      "ustekinumab.7\n",
      "There were no trials of inﬂiximab or golimumab in\n",
      "patients with prior exposure to TNFa antagonists who\n",
      "met inclusion criteria. In trials of adalimumab, only pa-\n",
      "tients with loss of response or intolerance to a prior\n",
      "TNFa antagonist were included. In contrast, in trials of\n",
      "vedolizumab, 48% to 58% of patients had inadequate\n",
      "response to a TNFa antagonist, and in trials of usteki-\n",
      "numab, 13% to 18% patients had prior exposure to both\n",
      "vedolizumab and TNFa antagonists. These data were not\n",
      "available for tofacitinib.\n",
      "Induction\n",
      "of\n",
      "clinical\n",
      "remission. On\n",
      "direct\n",
      "meta-\n",
      "analysis, tofacitinib and ustekinumab, but not adalimu-\n",
      "mab or vedolizumab, were superior to placebo for induc-\n",
      "tion of clinical remission (Supplementary Figure 3A), with\n",
      "minimal heterogeneity across estimates (I2 < 30%). On\n",
      "network meta-analysis, there was moderate conﬁdence in\n",
      "estimates supporting the use of tofacitinib (OR, 11.88;\n",
      "95% CI, 2.32–60.89) and ustekinumab (OR, 11.51; 95% CI,\n",
      "2.65–49.96), and low conﬁdence in estimates supporting\n",
      "the use of vedolizumab (OR, 1.92; 95% CI, 0.87–4.25) over\n",
      "placebo, for induction of clinical remission in patients with\n",
      "prior exposure to TNFa antagonists (Table 3). On com-\n",
      "parison of active interventions, there was moderate con-\n",
      "ﬁdence in estimates supporting the use of tofacitinib and\n",
      "ustekinumab over adalimumab (tofacitinib vs adalimu-\n",
      "mab: OR, 11.05; 95% CI, 1.79–68.41; ustekinumab vs\n",
      "adalimumab: OR, 10.71; 95% CI, 2.01–57.20), and over\n",
      "vedolizumab (tofacitinib vs vedolizumab: OR, 6.18; 95%\n",
      "CI, 1.00–38.00; ustekinumab vs vedolizumab: OR, 5.99;\n",
      "95% CI, 1.13–31.76) for induction of clinical remission in\n",
      "patients with prior exposure to TNFa antagonists. Overall,\n",
      "ustekinumab (SUCRA, 0.87) and tofacitinib (SUCRA, 0.87)\n",
      "were ranked highest for inducing clinical remission in\n",
      "patients with moderate–severe ulcerative colitis with\n",
      "prior exposure to TNFa antagonists (Figure 2B). With an\n",
      "estimated placebo rate of achieving clinical remission of\n",
      "3% in included trials, we estimated that 3.2%, 5.6%,\n",
      "26.9%, and 26.3% of adalimumab-, vedolizumab-, tofaci-\n",
      "tinib-, and ustekinumab-treated patients, respectively,\n",
      "would achieve induction of remission.\n",
      "Induction of endoscopic improvement. On direct meta-\n",
      "analysis, tofacitinib and ustekinumab, but not vedolizumab\n",
      "----------\n",
      "severely active ulcerative colitis: results from phase 3 \n",
      "U-ACCOMPLISH study. J Crohn’s Colitis 2021; 15 (suppl 1): S021–22.\n",
      "9 \n",
      "Thorlund K, Druyts E, Mills EJ, Fedorak RN, Marshall JK. \n",
      "Adalimumab versus infliximab for the treatment of moderate to \n",
      "severe ulcerative colitis in adult patients naïve to anti-TNF therapy: \n",
      "an indirect treatment comparison meta-analysis. J Crohn’s Colitis \n",
      "2014; 8: 571–81.\n",
      "10 \n",
      "Danese S, Fiorino G, Peyrin-Biroulet L, et al. Biological agents for \n",
      "moderately to severely active ulcerative colitis: a systematic review \n",
      "and network meta-analysis. Ann Intern Med 2014; 160: 704–11.\n",
      "11 \n",
      "Singh S, Fumery M, Sandborn WJ, Murad MH. Systematic review \n",
      "with network meta-analysis: first- and second-line pharmacotherapy \n",
      "for moderate-severe ulcerative colitis. Aliment Pharmacol Ther 2018; \n",
      "47: 162–75.\n",
      "12 \n",
      "Bonovas S, Lytras T, Nikolopoulos G, Peyrin-Biroulet L, Danese S. \n",
      "Systematic review with network meta-analysis: comparative \n",
      "assessment of tofacitinib and biological therapies for moderate-to-\n",
      "severe ulcerative colitis. Aliment Pharmacol Ther 2018; 47: 454–65.\n",
      "13 \n",
      "Singh S, Murad MH, Fumery M, Dulai PS, Sandborn WJ. First- and \n",
      "second-line pharmacotherapies for patients with moderate to \n",
      "severely active ulcerative colitis: an updated network meta-analysis. \n",
      "Clin Gastroenterol Hepatol 2020; 18: 2179–91.e6.\n",
      "14 \n",
      "Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting \n",
      "items for systematic reviews and meta-analyses: the PRISMA \n",
      "statement. Ann Intern Med 2009; 151: 264–69.\n",
      "15 \n",
      "Jansen JP, Fleurence R, Devine B, et al. Interpreting indirect \n",
      "treatment comparisons and network meta-analysis for health-care \n",
      "decision making: report of the ISPOR Task Force on Indirect \n",
      "Treatment Comparisons Good Research Practices: part 1. \n",
      "Value Health 2011; 14: 417–28.\n",
      "16 \n",
      "Sterne JAC, Savović J, Page MJ, et al. RoB 2: a revised tool for \n",
      "assessing risk of bias in randomised trials. BMJ 2019; 366: l4898.\n",
      "17 \n",
      "Rücker G, Schwarzer G. Ranking treatments in frequentist network \n",
      "meta-analysis works without resampling methods. \n",
      "BMC Med Res Methodol 2015; 15: 58.\n",
      "----------\n",
      "Burr et al. \n",
      " \n",
      "7 of 45 \n",
      "INTRODUCTION \n",
      "  Ulcerative colitis (UC) is a chronic inflammatory disorder of the bowel that causes \n",
      "continuous mucosal inflammation commencing in the rectum and extending proximally for a \n",
      "variable extent.[1] It is estimated that UC affects 2.5 million people in Europe,[2] and the \n",
      "disease follows a relapsing and remitting course, with intermittent flares of disease activity, \n",
      "some of which may be moderate to severe. Management of these is medical, for the most \n",
      "part, with surgery reserved for patients with refractory disease. Although 5-aminosalicylates \n",
      "(5-ASAs) are efficacious for mild to moderate disease activity,[3-6] more severe flares are \n",
      "usually treated with corticosteroids.[7] However, these have potentially serious adverse \n",
      "effects and a substantial proportion of patients may become either dependent on them to \n",
      "maintain remission,[8] or refractory to them.[9] As a result, over the last 20 years novel \n",
      "drugs, with more precise modes of action, based on mechanisms of disease identified in \n",
      "genome wide association studies,[10] have been developed.  \n",
      "The first of these agents was infliximab, a drug targeting the pro-inflammatory \n",
      "cytokine tumour necrosis factor-α (TNF-α), which demonstrated efficacy in clinical trials in \n",
      "moderate to severe UC.[11] Since then, other drugs against TNF-α have been tested, such as \n",
      "adalimumab and golimumab.[12, 13] In addition, newer biological therapies targeting α or β \n",
      "integrins, which are involved in migration of immune cells to inflamed intestinal mucosa, \n",
      "such as vedolizumab or etrolizumab,[14, 15] or acting against other pro-inflammatory \n",
      "cytokines implicated in the pathogenesis of UC, such as ustekinumab,[16] have been tested. \n",
      "However, even these more selective drugs do not work in all patients, there may be risks \n",
      "associated with their use,[17-19] and the fact that they are administered either intravenously \n",
      "or subcutaneously, may be inconvenient for patients. The search for alternative agents for the \n",
      "treatment of UC has, therefore, continued.\n",
      "----------\n",
      "disease); ozanimod as an oral alternative\n",
      "• Infliximab, preferably in combination with  \n",
      " immunomodulators (severe disease,  \n",
      " \n",
      " extraintestinal manifestations)\n",
      "• Ustekinumab (for patients with substantial \n",
      " comorbidities or  contraindications to TNF  \n",
      " antagonists)\n",
      "First-line therapy\n",
      "• TNF antagonists: infliximab or adalimumab,  \n",
      " preferably in combination with   \n",
      " \n",
      " \n",
      " immunomodulators\n",
      "• Risankizumab or ustekinumab (for patients  \n",
      " with substantial comorbidities or  \n",
      " \n",
      " \n",
      " contraindications to TNF antagonists)\n",
      "First-line therapy\n",
      "• Vedolizumab\n",
      "• Ustekinumab\n",
      "First-line therapy\n",
      "• Risankizumab or ustekinumab\n",
      "• Vedolizumab\n",
      "Moderate-to-severely active\n",
      "ulcerative colitis\n",
      "Moderate-to-severely active\n",
      "ulcerative colitis\n",
      "Moderate-to-severely active\n",
      "Crohn's disease\n",
      "Moderate-to-severely active\n",
      "Crohn's disease\n",
      "Second-line therapy\n",
      "• Upadacitinib (or tofacitinib) (for patients with  \n",
      " prior failure of infliximab)\n",
      "• Infliximab or ustekinumab (for patients with  \n",
      " prior exposure to vedolizumab)\n",
      "• Vedolizumab (moderate disease, for patients  \n",
      " who discontinued first-line biologic agent \n",
      " for intolerance)\n",
      "Second-line therapy (in patients with prior \n",
      "exposure to infliximab or adalimumab)\n",
      "• Risankizumab or ustekinumab\n",
      "• Second TNF antagonist (for patients with  \n",
      " loss of response owing to immunogenicity,  \n",
      " or  intolerance, to first TNF antagonist)\n",
      "Second-line therapy\n",
      "• Ozanimod\n",
      "• Infliximab monotherapy\n",
      "• Upadacitinib (or tofacitinib)\n",
      "Second-line therapy\n",
      "• Infliximab or adalimumab   \n",
      " monotherapy\n",
      "Risk averse\n",
      "• Prior serious infections\n",
      "• Prior malignancy\n",
      "• Older age, multiple comorbidities\n",
      "Severe disease\n",
      "• High structural damage\n",
      "• High inflammatory burden\n",
      "• Significant efect on quality of life\n",
      "Patients’ values and preferences\n",
      "(lifestyle and logistics, speed of onset, costs)\n",
      "Fig. 1 | Proposed treatment algorithm for patients with moderate-to-severe \n",
      "Crohn’s disease and moderate-to-severe ulcerative colitis. The algorithm \n",
      "integrates data on comparative effectiveness and safety of therapies in the \n",
      "context of an individual patient’s risk of disease-related and treatment-related \n",
      "complications. TNF, tumour necrosis factor. Adapted with permission from  \n",
      "ref. 10, Elsevier.\n",
      "==========\n",
      "ORIGINAL QUESTION: ANALYSE the given patient profile based on given query based on one of the following criteria:\n",
      "- Whether treated patient is new patient or patient under maintenance\n",
      "- Prior response to Infliximab\n",
      "- Prior failure to Anti-TNF agents\n",
      "- Prior failure to Vedolizumab\n",
      "- Age\n",
      "- Pregnancy\n",
      "- Extraintestinale manifestations\n",
      "- Pouchitis\n",
      "RETURN up to 2 TOP choices of biological drugs given patient profile and context. Explain the PROS and CONS of the 2 choices.\n",
      "PATIENT PROFILE: 36 year-old woman with moderate to severe ulcerative colitis who has lost response to tofacitinib.\n",
      "\n",
      "==========\n",
      "CURRENT ANSWER:\n",
      "Based on the patient's profile, the top two choices of biological drugs would be:\n",
      "\n",
      "1. Infliximab\n",
      "   - Advantages: Infliximab has been shown to be effective in inducing clinical remission and endoscopic improvement in patients with moderate to severe ulcerative colitis. It is also ranked highly for inducing clinical remission in patients who have previously been exposed to anti-TNF-α drugs.\n",
      "   - Disadvantages: Infliximab is administered intravenously, which may be inconvenient for some patients. There may also be risks associated with its use, including serious infections.\n",
      "\n",
      "2. Ustekinumab\n",
      "   - Advantages: Ustekinumab has been ranked highly for inducing clinical remission in patients with prior exposure to TNF antagonists. It is also recommended for patients with substantial comorbidities or contraindications to TNF antagonists.\n",
      "   - Disadvantages: The efficacy of ustekinumab in patients who have lost response to tofacitinib is not explicitly mentioned in the context provided. As with other biological therapies, there may be risks associated with its use.\n",
      "\n",
      "Please note that the choice of treatment should be individualized based on the patient's specific circumstances and preferences, and in consultation with their healthcare provider.\n",
      "==========\n",
      "REFINED ANSWER:\n",
      "\u001b[0m\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "Retrying langchain.chat_models.openai.ChatOpenAI.completion_with_retry.<locals>._completion_with_retry in 4.0 seconds as it raised RateLimitError: Rate limit reached for 10KTPM-200RPM in organization org-ETbTMTN2JXYOUPDJgxuH2iO6 on tokens per min. Limit: 10000 / min. Please try again in 6ms. Contact us through our help center at help.openai.com if you continue to have issues..\n",
      "Retrying langchain.chat_models.openai.ChatOpenAI.completion_with_retry.<locals>._completion_with_retry in 4.0 seconds as it raised RateLimitError: Rate limit reached for 10KTPM-200RPM in organization org-ETbTMTN2JXYOUPDJgxuH2iO6 on tokens per min. Limit: 10000 / min. Please try again in 6ms. Contact us through our help center at help.openai.com if you continue to have issues..\n",
      "Retrying langchain.chat_models.openai.ChatOpenAI.completion_with_retry.<locals>._completion_with_retry in 4.0 seconds as it raised RateLimitError: Rate limit reached for 10KTPM-200RPM in organization org-ETbTMTN2JXYOUPDJgxuH2iO6 on tokens per min. Limit: 10000 / min. Please try again in 6ms. Contact us through our help center at help.openai.com if you continue to have issues..\n",
      "Retrying langchain.chat_models.openai.ChatOpenAI.completion_with_retry.<locals>._completion_with_retry in 8.0 seconds as it raised RateLimitError: Rate limit reached for 10KTPM-200RPM in organization org-ETbTMTN2JXYOUPDJgxuH2iO6 on tokens per min. Limit: 10000 / min. Please try again in 6ms. Contact us through our help center at help.openai.com if you continue to have issues..\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\n",
      "\u001b[1m> Finished chain.\u001b[0m\n",
      "\n",
      "\u001b[1m> Finished chain.\u001b[0m\n",
      "2023-10-02 17:41:46,656:INFO: 5631 tokens were added to prompt from 10 documents\n",
      "Query: 18 year-old man with moderate to severe extensive ulcerative colitis and pyoderma gangrenosum.\n",
      "\n",
      "\n",
      "\n",
      "\u001b[1m> Entering new SequentialChain chain...\u001b[0m\n",
      "\n",
      "\n",
      "\u001b[1m> Entering new RetrievalQAWithSourcesChain chain...\u001b[0m\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "Retrying langchain.chat_models.openai.ChatOpenAI.completion_with_retry.<locals>._completion_with_retry in 4.0 seconds as it raised RateLimitError: Rate limit reached for 10KTPM-200RPM in organization org-ETbTMTN2JXYOUPDJgxuH2iO6 on tokens per min. Limit: 10000 / min. Please try again in 6ms. Contact us through our help center at help.openai.com if you continue to have issues..\n",
      "Retrying langchain.chat_models.openai.ChatOpenAI.completion_with_retry.<locals>._completion_with_retry in 4.0 seconds as it raised RateLimitError: Rate limit reached for 10KTPM-200RPM in organization org-ETbTMTN2JXYOUPDJgxuH2iO6 on tokens per min. Limit: 10000 / min. Please try again in 6ms. Contact us through our help center at help.openai.com if you continue to have issues..\n",
      "Retrying langchain.chat_models.openai.ChatOpenAI.completion_with_retry.<locals>._completion_with_retry in 4.0 seconds as it raised RateLimitError: Rate limit reached for 10KTPM-200RPM in organization org-ETbTMTN2JXYOUPDJgxuH2iO6 on tokens per min. Limit: 10000 / min. Please try again in 6ms. Contact us through our help center at help.openai.com if you continue to have issues..\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\n",
      "\u001b[1m> Finished chain.\u001b[0m\n",
      "\n",
      "\n",
      "\u001b[1m> Entering new LLMChain chain...\u001b[0m\n",
      "Prompt after formatting:\n",
      "\u001b[32;1m\u001b[1;3mYou are a senior physician giving advice on treatment for moderate to severe ulcerative colitis (UC).\n",
      "Make reference to the CONTEXT given to assess the scenario.\n",
      "==========\n",
      "TASK: Your task is to analyse critically the CURRENT ANSWER given the CONTEXT.\n",
      "Then refine the existing answer (only if needed) based on the following instructions:\n",
      "- If no refinement needed, return the original answer in the correct output format.\n",
      "- If the answer cannot be inferred from CONTEXT, return \"NO ANSWER\".\n",
      "- The final output should be a list of up to 2 choices of biological drugs given patient profile and context and PROS/CONS for each recommendations.\n",
      "==========\n",
      "CONTEXT:\n",
      "Burr et al. \n",
      " \n",
      "7 of 45 \n",
      "INTRODUCTION \n",
      "  Ulcerative colitis (UC) is a chronic inflammatory disorder of the bowel that causes \n",
      "continuous mucosal inflammation commencing in the rectum and extending proximally for a \n",
      "variable extent.[1] It is estimated that UC affects 2.5 million people in Europe,[2] and the \n",
      "disease follows a relapsing and remitting course, with intermittent flares of disease activity, \n",
      "some of which may be moderate to severe. Management of these is medical, for the most \n",
      "part, with surgery reserved for patients with refractory disease. Although 5-aminosalicylates \n",
      "(5-ASAs) are efficacious for mild to moderate disease activity,[3-6] more severe flares are \n",
      "usually treated with corticosteroids.[7] However, these have potentially serious adverse \n",
      "effects and a substantial proportion of patients may become either dependent on them to \n",
      "maintain remission,[8] or refractory to them.[9] As a result, over the last 20 years novel \n",
      "drugs, with more precise modes of action, based on mechanisms of disease identified in \n",
      "genome wide association studies,[10] have been developed.  \n",
      "The first of these agents was infliximab, a drug targeting the pro-inflammatory \n",
      "cytokine tumour necrosis factor-α (TNF-α), which demonstrated efficacy in clinical trials in \n",
      "moderate to severe UC.[11] Since then, other drugs against TNF-α have been tested, such as \n",
      "adalimumab and golimumab.[12, 13] In addition, newer biological therapies targeting α or β \n",
      "integrins, which are involved in migration of immune cells to inflamed intestinal mucosa, \n",
      "such as vedolizumab or etrolizumab,[14, 15] or acting against other pro-inflammatory \n",
      "cytokines implicated in the pathogenesis of UC, such as ustekinumab,[16] have been tested. \n",
      "However, even these more selective drugs do not work in all patients, there may be risks \n",
      "associated with their use,[17-19] and the fact that they are administered either intravenously \n",
      "or subcutaneously, may be inconvenient for patients. The search for alternative agents for the \n",
      "treatment of UC has, therefore, continued.\n",
      "----------\n",
      "severely active ulcerative colitis: results from phase 3 \n",
      "U-ACCOMPLISH study. J Crohn’s Colitis 2021; 15 (suppl 1): S021–22.\n",
      "9 \n",
      "Thorlund K, Druyts E, Mills EJ, Fedorak RN, Marshall JK. \n",
      "Adalimumab versus infliximab for the treatment of moderate to \n",
      "severe ulcerative colitis in adult patients naïve to anti-TNF therapy: \n",
      "an indirect treatment comparison meta-analysis. J Crohn’s Colitis \n",
      "2014; 8: 571–81.\n",
      "10 \n",
      "Danese S, Fiorino G, Peyrin-Biroulet L, et al. Biological agents for \n",
      "moderately to severely active ulcerative colitis: a systematic review \n",
      "and network meta-analysis. Ann Intern Med 2014; 160: 704–11.\n",
      "11 \n",
      "Singh S, Fumery M, Sandborn WJ, Murad MH. Systematic review \n",
      "with network meta-analysis: first- and second-line pharmacotherapy \n",
      "for moderate-severe ulcerative colitis. Aliment Pharmacol Ther 2018; \n",
      "47: 162–75.\n",
      "12 \n",
      "Bonovas S, Lytras T, Nikolopoulos G, Peyrin-Biroulet L, Danese S. \n",
      "Systematic review with network meta-analysis: comparative \n",
      "assessment of tofacitinib and biological therapies for moderate-to-\n",
      "severe ulcerative colitis. Aliment Pharmacol Ther 2018; 47: 454–65.\n",
      "13 \n",
      "Singh S, Murad MH, Fumery M, Dulai PS, Sandborn WJ. First- and \n",
      "second-line pharmacotherapies for patients with moderate to \n",
      "severely active ulcerative colitis: an updated network meta-analysis. \n",
      "Clin Gastroenterol Hepatol 2020; 18: 2179–91.e6.\n",
      "14 \n",
      "Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting \n",
      "items for systematic reviews and meta-analyses: the PRISMA \n",
      "statement. Ann Intern Med 2009; 151: 264–69.\n",
      "15 \n",
      "Jansen JP, Fleurence R, Devine B, et al. Interpreting indirect \n",
      "treatment comparisons and network meta-analysis for health-care \n",
      "decision making: report of the ISPOR Task Force on Indirect \n",
      "Treatment Comparisons Good Research Practices: part 1. \n",
      "Value Health 2011; 14: 417–28.\n",
      "16 \n",
      "Sterne JAC, Savović J, Page MJ, et al. RoB 2: a revised tool for \n",
      "assessing risk of bias in randomised trials. BMJ 2019; 366: l4898.\n",
      "17 \n",
      "Rücker G, Schwarzer G. Ranking treatments in frequentist network \n",
      "meta-analysis works without resampling methods. \n",
      "BMC Med Res Methodol 2015; 15: 58.\n",
      "----------\n",
      "Parkes, M., Vermeire, S., Rioux, J.D., Mansﬁeld, J., Silverberg, M.S., Radford-\n",
      "Smith, G., McGovern, D.P., Barrett, J.C., Lees, C.W., 2016. Inherited determinants of\n",
      "crohn's disease and ulcerative colitis phenotypes: a genetic association study. Lancet\n",
      "387 (10014), 156–167.\n",
      "Colombel, J.F., Sandborn, W.J., Rutgeerts, P., Enns, R., Hanauer, S.B., Panaccione, R.,\n",
      "Schreiber, S., Byczkowski, D., Li, J., Kent, J.D., Pollack, P.F., 2007. Adalimumab for\n",
      "maintenance of clinical response and remission in patients with crohn's disease: the\n",
      "charm trial. Gastroenterology 132 (1), 52–65.\n",
      "Conrad, M.A., Kelsen, J.R., 2020. The treatment of pediatric inﬂammatory bowel disease\n",
      "with biologic therapies. Curr. Gastroenterol. Rep. 22 (8), 36–51.\n",
      "Csontos, A.A., Molnar, A., Piri, Z., Katona, B., Dako, S., Palﬁ, E., Miheller, P., 2016. The\n",
      "effect of anti-tnfalpha induction therapy on the nutritional status and dietary intake\n",
      "in inﬂammatory bowel disease. J Gastrointestin Liver Dis 25 (1), 49–56.\n",
      "Dai, Z.H., Xu, X.T., Ran, Z.H., 2020. Associations between obesity and the effectiveness of\n",
      "anti-tumor necrosis factor-alpha agents in inﬂammatory bowel disease patients: a\n",
      "literature review and meta-analysis. Ann. Pharmacother. 54 (8), 729–741.\n",
      "Danese, S., Colombel, J.F., Lukas, M., Gisbert, J.P., D’Haens, G., Hayee, B., Panaccione, R.,\n",
      "Kim, H.S., Reinisch, W., Tyrrell, H., Oh, Y.S., Tole, S., Chai, A., Chamberlain-\n",
      "James, K., Tang, M.T., Schreiber, S., Group, G.S., 2021. Etrolizumab versus inﬂiximab\n",
      "for the treatment of moderately to severely active ulcerative colitis (gardenia): a\n",
      "randomised, double-blind, double-dummy, phase 3 study. Lancet Gastroenterol\n",
      "Hepatol 7 (2), 118–127.\n",
      "Danese, S., Fiorino, G., Peyrin-Biroulet, L., Lucenteforte, E., Virgili, G., Moja, L.,\n",
      "Bonovas, S., 2014. Biological agents for moderately to severely active ulcerative\n",
      "colitis: a systematic review and network meta-analysis. Ann. Intern. Med. 160 (10),\n",
      "704–711.\n",
      "P. Juillerat et al.\n",
      "Current Research in Pharmacology and Drug Discovery 3 (2022) 100104\n",
      "6\n",
      "----------\n",
      "41 years (interquartile range, 40–42 y), and 60%\n",
      "(interquartile range, 56%–63%) were men. The median\n",
      "disease duration was 6.7 years (interquartile range,\n",
      "6.0–7.8 y), and 49% (interquartile range, 46%–55%) of\n",
      "patients had extensive colitis. A median of 40% (inter-\n",
      "quartile range, 30%–50%) of patients were treated with\n",
      "concomitant immunomodulators, and 51% (interquartile\n",
      "range, 45%–57%) were on corticosteroids at baseline.\n",
      "Patients across all trials and treatment arms were com-\n",
      "parable in terms of baseline prognostic variables, inclu-\n",
      "sion/exclusion\n",
      "criteria,\n",
      "and\n",
      "co-interventions.\n",
      "All\n",
      "outcomes were assessed uniformly based on the stan-\n",
      "dard deﬁnition of the Mayo Clinic score, between weeks\n",
      "6 and 10 for induction therapy (inﬂiximab, adalimumab,\n",
      "tofacitinib, ustekinumab, 8 weeks; golimumab, 6 weeks;\n",
      "vedolizumab, 6 weeks, 10 weeks, and 14 weeks in\n",
      "VARSITY),6 and weeks 30, 54, or 60 for maintenance\n",
      "therapy;\n",
      "endoscopy\n",
      "was\n",
      "read\n",
      "by\n",
      "blinded\n",
      "local\n",
      "Table 2. Comparative Efﬁcacy of Pharmacologic Agents for Induction of Clinical Remission and Endoscopic Improvement in Biologic-Naive Patients With Moderate–Severe\n",
      "Ulcerative Colitis Using Network Meta-Analysis\n",
      "Induction of clinical remission\n",
      "Induction of endoscopic improvement\n",
      "Ustekinumab 6 mg/kg\n",
      "0.96 (0.38–2.45)\n",
      "0.80 (0.35–1.83)\n",
      "0.73 (0.31–1.74)\n",
      "1.05 (0.48–2.32)\n",
      "0.50 (0.22–1.12)\n",
      "2.04 (1.03–4.05)\n",
      "0.92 (0.45–1.89)\n",
      "Tofacitinib 10 mg b.d.\n",
      "0.84 (0.39–1.82)\n",
      "0.76 (0.33–1.76)\n",
      "1.10 (0.51–2.34)\n",
      "0.52 (0.24–1.12)\n",
      "2.12 (1.12–4.02)\n",
      "0.74 (0.36–1.51)\n",
      "0.80 (0.4–1.62)\n",
      "Vedolizumab\n",
      "0.91 (0.44–1.86)\n",
      "1.31 (0.88–1.95)\n",
      "0.62 (0.34–1.15)\n",
      "2.54 (1.60–4.02)\n",
      "1.07 (0.58–1.98)\n",
      "1.17 (0.64–2.12)\n",
      "1.45 (0.80–2.61)\n",
      "Golimumab\n",
      "1.44 (0.76–2.75)\n",
      "0.69 (0.35–1.36)\n",
      "2.79 (1.64–4.02)\n",
      "1.17 (0.65–2.13)\n",
      "1.28 (0.72–2.29)\n",
      "1.59 (0.90–2.82)\n",
      "1.10 (0.71–1.71)\n",
      "Adalimumab\n",
      "0.48 (0.26–0.86)\n",
      "1.94 (1.30–2.88)\n",
      "0.56 (0.30–1.04)\n",
      "0.61 (0.34–1.11)\n",
      "0.76 (0.42–1.37)\n",
      "0.52 (0.33–0.83)\n",
      "0.48 (0.31–0.74)\n",
      "Inﬂiximab\n",
      "4.07 (2.67–6.21)\n",
      "1.86 (1.11–3.13)\n",
      "2.03 (1.23–3.34)\n",
      "2.52 (1.54–4.11)\n",
      "1.74 (1.25–2.41)\n",
      "1.58 (1.18–2.13)\n",
      "3.32 (2.39–4.60)\n",
      "Placebo\n",
      "NOTE. Comparisons should be read from left to right. Odds ratio for comparisons are in the cell in common between the column-deﬁning and row-deﬁning treatment. Numbers in bold are statistically signiﬁcant. For induction of\n",
      "clinical remission, an odds ratio greater than 1 favors row-deﬁning treatment. For induction of endoscopic improvement, an odds ratio greater than 1 favors column-deﬁning treatment. Numbers in parentheses indicate 95% CI.\n",
      "b.d., twice daily.\n",
      "----------\n",
      "15. Bouguen G, Levesque BG, Feagan BG, et al. Treat to\n",
      "target: a proposed new paradigm for the management of\n",
      "Crohn’s\n",
      "disease.\n",
      "Clin\n",
      "Gastroenterol\n",
      "Hepatol\n",
      "2015;\n",
      "13:1042–1050.e2.\n",
      "16. Zhao M, Lo BZS, Vester-Andersen MK, et al. A 10-year\n",
      "follow-up\n",
      "study\n",
      "of\n",
      "the\n",
      "natural\n",
      "history\n",
      "of\n",
      "perianal\n",
      "crohn’s disease in a danish population-based inception\n",
      "cohort. Inﬂamm Bowel Dis 2019;25:1227–1236.\n",
      "17. Rutter M, Saunders B, Wilkinson K, et al. Severity of\n",
      "inﬂammation is a risk factor for colorectal neoplasia in\n",
      "ulcerative colitis. Gastroenterology 2004;126:451–459.\n",
      "18. Gupta N, Liu C, King E, et al. Continued statural growth\n",
      "in older adolescents and young adults with Crohn’s\n",
      "disease and ulcerative colitis beyond the time of ex-\n",
      "pected growth plate closure. Inﬂamm Bowel Dis 2020;\n",
      "26:1880–1889.\n",
      "19. Pariente B, Torres J, Burisch J, et al. SA1895 Validation\n",
      "of the Lémman index in Crohn’s disease. Gastroenter-\n",
      "ology 2020;158:S-469.\n",
      "20. Cellier C, Sahmoud T, Froguel E, et al; Correlations be-\n",
      "tween clinical activity, endoscopic severity, and biolog-\n",
      "ical parameters in colonic or ileocolonic Crohn’s disease.\n",
      "A prospective multicentre study of 121 cases. The\n",
      "Groupe\n",
      "d’Etudes\n",
      "Thérapeutiques\n",
      "des\n",
      "Affections\n",
      "Inﬂammatoires Digestives. Gut 1994;35:231–235.\n",
      "21. Pariente B, Cosnes J, Danese S, et al. Development of\n",
      "the\n",
      "Crohn’s\n",
      "disease\n",
      "digestive\n",
      "damage\n",
      "score,\n",
      "the\n",
      "Lémann score. Inﬂamm Bowel Dis 2011;17:1415–1422.\n",
      "22. Thia KT, Sandborn WJ, Harmsen WS, et al. Risk factors\n",
      "associated with progression to intestinal complications\n",
      "July 2021\n",
      "Management of early IBD\n",
      "59\n",
      "REVIEWS AND\n",
      "PERSPECTIVES\n",
      "----------\n",
      "Disease Phenotype and Clinical Characteristics\n",
      "The International Organization for the Study of Inﬂam-\n",
      "matory Bowel Disease and the American Gastroenterological\n",
      "Association (AGA) provide a framework for categorization of\n",
      "CD and UC severity into mild-, moderate-, and high-risk\n",
      "groups based on phenotype and other characteristics.59,60\n",
      "In CD, the presence of large or deep mucosal lesions on\n",
      "endoscopy or magnetic resonance imaging (MRI), history of\n",
      "a ﬁstula, abscess, or intestinal resection are predictors of\n",
      "worse outcomes.59,60 In a prospective population-based\n",
      "inception cohort of 213 patients with CD, penetrating\n",
      "behavior was associated with a higher risk of progression to\n",
      "perianal disease (HR, 5.65; 95% CI, 2.65–12.03) and was a\n",
      "risk factor for resection (HR, 3.92; 95% CI, 1.86–8.67) and\n",
      "hospitalization (HR, 1.01; 95% CI, 1.00–1.01).16 Ileal and\n",
      "upper gastrointestinal disease location and extensive dis-\n",
      "ease are also markers of severe disease.61 Cigarette smoking\n",
      "is associated with complications and need for therapy\n",
      "escalation.61\n",
      "In CD, the threshold of suspicion should be low for high-\n",
      "quality imaging of the pelvis, such as MRI, to rule our\n",
      "perianal CD. In a retrospective study of 136 pediatric CD\n",
      "patients, presence of anal ﬁssures and skin tags, non-White\n",
      "race, and elevated C-reactive protein (CRP) were risk factors\n",
      "for perianal CD.62 In another study of 274 patients in China\n",
      "with recently diagnosed CD, all of whom underwent MRI\n",
      "pelvis, asymptomatic perianal ﬁstulas were diagnosed in\n",
      "17.5% of patients and colonic location of CD was a risk\n",
      "factor for asymptomatic perianal ﬁstulas.63\n",
      "In UC, corresponding predictors of aggressive disease\n",
      "advised by the International Organization for the Study of\n",
      "Inﬂammatory Bowel Disease include active colonic ulcers\n",
      "and prior use of biologics.59 Extensive colitis, deep ulcers,\n",
      "need for corticosteroids, hospitalization, Clostridium difﬁcile,\n",
      "and cytomegalovirus infection also indicate higher colec-\n",
      "tomy risk.64 Of note, disease extension from limited disease\n",
      "to\n",
      "extensive\n",
      "or\n",
      "pancolitis\n",
      "is\n",
      "associated\n",
      "with\n",
      "worse\n",
      "prognosis.45,65\n",
      "In addition, co-occurrence of other immune-mediated\n",
      "inﬂammatory diseases can occur, most commonly with\n",
      "psoriasis and asthma, but also, in more rare instances, with\n",
      "other gastrointestinal diseases (eg, celiac, nonalcoholic fatty\n",
      "liver disease,66 and eosinophilic esophagitis).67,68 Presence\n",
      "of a concomitant immune-mediated inﬂammatory disease is\n",
      "Figure\n",
      "1. Inﬂammatory\n",
      "bowel disease severity vs\n",
      "----------\n",
      "SYSTEMATIC REVIEWS AND META-ANALYSES\n",
      "Siddharth Singh, Section Editor\n",
      "First- and Second-Line Pharmacotherapies for Patients With\n",
      "Moderate to Severely Active Ulcerative Colitis: An Updated\n",
      "Network Meta-Analysis\n",
      "Siddharth Singh,*,‡ Mohammad Hassan Murad,§ Mathurin Fumery,j\n",
      "Parambir S. Dulai,* and William J. Sandborn*\n",
      "*Division of Gastroenterology, ‡Division of Biomedical Informatics, University of California San Diego, La Jolla, California;\n",
      "§Robert D and Patricia E Kern Center for the Science of Health Care Delivery, Mayo Clinic, Rochester, Minnesota;\n",
      "||Gastroenterology Unit, Peritox UMR I-0I, Amiens University and Hospital, Université de Picardie Jules Verne, Amiens, France\n",
      "BACKGROUND & AIMS:\n",
      "We compared the efﬁcacy and safety of different ﬁrst-line (biologic-naïve) and second-line\n",
      "(prior exposure to tumor necrosis factor [TNF] antagonists) agents for treatment of moder-\n",
      "ate to severely active ulcerative colitis in a systematic review and network meta-analysis.\n",
      "METHODS:\n",
      "We searched publication databases through September 30, 2019, for randomized trials of\n",
      "adults with moderate to severe ulcerative colitis treated with TNF antagonists, vedolizumab,\n",
      "tofacitinib, or ustekinumab, as ﬁrst-line or second-line agents, compared with placebo or\n",
      "another active agent. Efﬁcacy outcomes were induction and maintenance of remission and\n",
      "endoscopic improvement; safety outcomes were serious adverse events and infections. We\n",
      "performed a ﬁxed-effects network meta-analysis using the frequentist approach, and calculated\n",
      "odds ratios (ORs) and 95% CI values. Agents were ranked using surface under the cumulative\n",
      "ranking (SUCRA) probabilities. Overall quality of evidence was rated using GRADE (Grading of\n",
      "Recommendations, Assessment, Development and Evaluation).\n",
      "RESULTS:\n",
      "In biologic-naïve patients, inﬂiximab was ranked highest for induction of clinical remission (OR\n",
      "vs placebo, 4.07; 95% CI, 2.67–6.21; SUCRA, 0.95) and endoscopic improvement (SUCRA, 0.95)\n",
      "(moderate conﬁdence in estimates [CE]). In patients with prior exposure to TNF antagonists,\n",
      "ustekinumab (SUCRA, 0.87) and tofacitinib (SUCRA, 0.87) were ranked highest for induction of\n",
      "clinical remission and were superior to vedolizumab (ustekinumab vs vedolizumab: OR, 5.99;\n",
      "95% CI, 1.13–31.76 and tofacitinib vs vedolizumab: OR, 6.18; 95% CI, 1.003–8.00; moderate CE)\n",
      "and adalimumab (ustekinumab vs adalimumab: OR, 10.71; 95% CI, 2.01–57.20 and tofacitinib\n",
      "----------\n",
      "Therapeutic strategies for the management of recentlydiagnosedulcerative colitis. IMMs include thiopurines and methotrexate. 5-ASA, 5-amino salicylic acid; ASUC, acute severe ulcerative colitis; IPAA, ileal pouch anal anastomosis.\n",
      "\n",
      "Risk stratification: Mild\n",
      "Clinical features: NA\n",
      "Treatment options: 5-ASA (oral and/or topical)\n",
      "\n",
      "Risk stratification: Moderate\n",
      "Clinical features: NA\n",
      "Treatment options: Can consider 5-ASA (with rapid step-up if inadequate response)\n",
      "\n",
      "Risk stratification: Moderate\n",
      "Clinical features: NA\n",
      "Treatment options: VDZ or UST\n",
      "\n",
      "Risk stratification: Moderate\n",
      "Clinical features: NA\n",
      "Treatment options: Thiopurine\n",
      "\n",
      "Risk stratification: Moderate\n",
      "Clinical features: NA\n",
      "Treatment options: TNFi +/- IMM\n",
      "\n",
      "Risk stratification: Severe\n",
      "Clinical features: NA\n",
      "Treatment options: TNFi +/- IMM\n",
      "\n",
      "Risk stratification: Severe\n",
      "Clinical features: NA\n",
      "Treatment options: Subtotal colectomy + IPAA or cyclosporine (for ASUC)\n",
      "\n",
      "Risk stratification: Additional consideration: EIM present\n",
      "Clinical features: Psoriasis or psoriatic arthritis\n",
      "Treatment options: UST\n",
      "\n",
      "Risk stratification: Additional consideration: EIM present\n",
      "Clinical features: Other arthritis\n",
      "Treatment options: TNFi\n",
      "\n",
      "\n",
      "----------\n",
      "perianal CD varied between 11% and 19% at 1–10 years\n",
      "after diagnosis.9 In a study of 983 patients with CD in Asia,\n",
      "stricturing or penetrating CD occurred in 41% and perianal\n",
      "disease in 25% of patients.10 At the other end of the spec-\n",
      "trum, incidental terminal ileitis can be diagnosed in 1.6% of\n",
      "individuals undergoing nondiagnostic colonoscopy, with an\n",
      "uncertain but likely low rate of progression to overt CD.11\n",
      "With respect to UC, most patients have mild to moderate\n",
      "severity and 10%–15% of patients can experience a severe\n",
      "course.12 In a population-based cohort study, proctosigmoid\n",
      "location of colitis occurred in 73% of patients; of these,\n",
      "disease extension occurred in 23% of patients at 7 years of\n",
      "follow-up and it was a marker of worse prognosis.13 The\n",
      "risk of surgery for CD and UC can be up to 46.6% and 15.6%\n",
      "10 years after diagnosis, respectively, and has decreased\n",
      "signiﬁcantly during the last 6 decades.14\n",
      "The symptoms associated with IBD can be waxing and\n",
      "waning, but the underlying systemic inﬂammation can lead\n",
      "to progressive, cumulative, and often irreversible intestinal\n",
      "damage\n",
      "and\n",
      "risk\n",
      "of\n",
      "complications\n",
      "if\n",
      "not\n",
      "treated\n",
      "adequately.15\n",
      "Complications\n",
      "associated\n",
      "with\n",
      "ongoing\n",
      "inﬂammation in CD include strictures, obstructions, ﬁstulas,\n",
      "abscesses, and surgery,3,16 and those associated with UC\n",
      "include loss of colonic and anorectal function, surgery, and\n",
      "colorectal cancer.2,4,17 Other complications include anemia,\n",
      "nutritional deﬁciencies, loss of bone density, and progres-\n",
      "sive loss of quality of life. In children, persistent inﬂamma-\n",
      "tion\n",
      "is\n",
      "associated\n",
      "with\n",
      "growth\n",
      "impairment,\n",
      "risking\n",
      "permanent loss of height.18 Similar to other chronic dis-\n",
      "eases, such as rheumatoid arthritis, the concept of cumula-\n",
      "tive damage is now acknowledged in IBD and can be\n",
      "measured using validated tools, such as the Lemann Index.19\n",
      "Limited Correlations Among Inﬂammation,\n",
      "Symptoms, and Complications\n",
      "The concordance between intestinal inﬂammation and\n",
      "symptoms can be limited, especially in CD.20,21 In a\n",
      "population-based cohort, more than 20% of CD patients\n",
      "were found to have strictures and penetrating disease at the\n",
      "time of diagnosis, suggesting that clinically silent inﬂam-\n",
      "mation may precede formal diagnosis.22 The STRIDE\n",
      "(Selecting Therapeutic Targets in Inﬂammatory Bowel Dis-\n",
      "ease) recommendations, updated recently, are meant to\n",
      "target endoscopic healing, minimize disability, and restore\n",
      "quality of life and adequate growth in children, in addition\n",
      "----------\n",
      "laise, weight loss, and fever. Disease onset commonly occurs \n",
      "between the ages of 15 and 30 years and the annual global \n",
      "© The Author(s) 2023. Published by Oxford University Press on behalf of Crohn's & Colitis Foundation.\n",
      "This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), \n",
      "which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.\n",
      "Received for publication: September 21, 2022. Editorial Decision: January 25, 2023\n",
      " \n",
      "Downloaded from https://academic.oup.com/crohnscolitis360/article/5/2/otad009/7066911 by National University of Singapore user on 23 May 2023\n",
      "==========\n",
      "ORIGINAL QUESTION: ANALYSE the given patient profile based on given query based on one of the following criteria:\n",
      "- Whether treated patient is new patient or patient under maintenance\n",
      "- Prior response to Infliximab\n",
      "- Prior failure to Anti-TNF agents\n",
      "- Prior failure to Vedolizumab\n",
      "- Age\n",
      "- Pregnancy\n",
      "- Extraintestinale manifestations\n",
      "- Pouchitis\n",
      "RETURN up to 2 TOP choices of biological drugs given patient profile and context. Explain the PROS and CONS of the 2 choices.\n",
      "PATIENT PROFILE: 18 year-old man with moderate to severe extensive ulcerative colitis and pyoderma gangrenosum.\n",
      "\n",
      "==========\n",
      "CURRENT ANSWER:\n",
      "Based on the patient's profile, the patient is a new patient with moderate to severe ulcerative colitis and has extraintestinal manifestations (pyoderma gangrenosum). The patient's age is 18 years old. There is no information about prior response to Infliximab, prior failure to Anti-TNF agents, prior failure to Vedolizumab, or pregnancy.\n",
      "\n",
      "Given this information, the top two choices of biological drugs would be:\n",
      "\n",
      "1. Infliximab\n",
      "   - Advantages: Infliximab has demonstrated efficacy in clinical trials in moderate to severe UC. It targets the pro-inflammatory cytokine tumour necrosis factor-α (TNF-α), which is involved in the inflammation process in UC. It may also be beneficial for the treatment of extraintestinal manifestations like pyoderma gangrenosum.\n",
      "   - Disadvantages: Infliximab may not work in all patients and there may be risks associated with its use, such as serious infections or allergic reactions. It is administered intravenously, which may be inconvenient for some patients.\n",
      "\n",
      "2. Adalimumab\n",
      "   - Advantages: Adalimumab is another drug against TNF-α and has been tested for moderate to severe UC. It may also be beneficial for the treatment of extraintestinal manifestations like pyoderma gangrenosum.\n",
      "   - Disadvantages: Similar to Infliximab, Adalimumab may not work in all patients and there may be risks associated with its use. It is administered subcutaneously, which may be inconvenient for some patients.\n",
      "\n",
      "Please note that the choice of treatment should be individualized based on the patient's specific condition, preferences, and potential side effects of the drugs. Regular follow-ups should be scheduled to monitor the patient's response to the treatment and adjust the treatment plan as necessary.\n",
      "==========\n",
      "REFINED ANSWER:\n",
      "\u001b[0m\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "Retrying langchain.chat_models.openai.ChatOpenAI.completion_with_retry.<locals>._completion_with_retry in 4.0 seconds as it raised RateLimitError: Rate limit reached for 10KTPM-200RPM in organization org-ETbTMTN2JXYOUPDJgxuH2iO6 on tokens per min. Limit: 10000 / min. Please try again in 6ms. Contact us through our help center at help.openai.com if you continue to have issues..\n",
      "Retrying langchain.chat_models.openai.ChatOpenAI.completion_with_retry.<locals>._completion_with_retry in 4.0 seconds as it raised RateLimitError: Rate limit reached for 10KTPM-200RPM in organization org-ETbTMTN2JXYOUPDJgxuH2iO6 on tokens per min. Limit: 10000 / min. Please try again in 6ms. Contact us through our help center at help.openai.com if you continue to have issues..\n",
      "Retrying langchain.chat_models.openai.ChatOpenAI.completion_with_retry.<locals>._completion_with_retry in 4.0 seconds as it raised RateLimitError: Rate limit reached for 10KTPM-200RPM in organization org-ETbTMTN2JXYOUPDJgxuH2iO6 on tokens per min. Limit: 10000 / min. Please try again in 6ms. Contact us through our help center at help.openai.com if you continue to have issues..\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\n",
      "\u001b[1m> Finished chain.\u001b[0m\n",
      "\n",
      "\u001b[1m> Finished chain.\u001b[0m\n",
      "2023-10-02 17:43:08,966:INFO: 5826 tokens were added to prompt from 10 documents\n",
      "Query: 58 year-old woman with moderate to severe distal ulcerative colitis and optic neuritis.\n",
      "\n",
      "\n",
      "\n",
      "\u001b[1m> Entering new SequentialChain chain...\u001b[0m\n",
      "\n",
      "\n",
      "\u001b[1m> Entering new RetrievalQAWithSourcesChain chain...\u001b[0m\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "Retrying langchain.chat_models.openai.ChatOpenAI.completion_with_retry.<locals>._completion_with_retry in 4.0 seconds as it raised RateLimitError: Rate limit reached for 10KTPM-200RPM in organization org-ETbTMTN2JXYOUPDJgxuH2iO6 on tokens per min. Limit: 10000 / min. Please try again in 6ms. Contact us through our help center at help.openai.com if you continue to have issues..\n",
      "Retrying langchain.chat_models.openai.ChatOpenAI.completion_with_retry.<locals>._completion_with_retry in 4.0 seconds as it raised RateLimitError: Rate limit reached for 10KTPM-200RPM in organization org-ETbTMTN2JXYOUPDJgxuH2iO6 on tokens per min. Limit: 10000 / min. Please try again in 6ms. Contact us through our help center at help.openai.com if you continue to have issues..\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\n",
      "\u001b[1m> Finished chain.\u001b[0m\n",
      "\n",
      "\n",
      "\u001b[1m> Entering new LLMChain chain...\u001b[0m\n",
      "Prompt after formatting:\n",
      "\u001b[32;1m\u001b[1;3mYou are a senior physician giving advice on treatment for moderate to severe ulcerative colitis (UC).\n",
      "Make reference to the CONTEXT given to assess the scenario.\n",
      "==========\n",
      "TASK: Your task is to analyse critically the CURRENT ANSWER given the CONTEXT.\n",
      "Then refine the existing answer (only if needed) based on the following instructions:\n",
      "- If no refinement needed, return the original answer in the correct output format.\n",
      "- If the answer cannot be inferred from CONTEXT, return \"NO ANSWER\".\n",
      "- The final output should be a list of up to 2 choices of biological drugs given patient profile and context and PROS/CONS for each recommendations.\n",
      "==========\n",
      "CONTEXT:\n",
      "Burr et al. \n",
      " \n",
      "7 of 45 \n",
      "INTRODUCTION \n",
      "  Ulcerative colitis (UC) is a chronic inflammatory disorder of the bowel that causes \n",
      "continuous mucosal inflammation commencing in the rectum and extending proximally for a \n",
      "variable extent.[1] It is estimated that UC affects 2.5 million people in Europe,[2] and the \n",
      "disease follows a relapsing and remitting course, with intermittent flares of disease activity, \n",
      "some of which may be moderate to severe. Management of these is medical, for the most \n",
      "part, with surgery reserved for patients with refractory disease. Although 5-aminosalicylates \n",
      "(5-ASAs) are efficacious for mild to moderate disease activity,[3-6] more severe flares are \n",
      "usually treated with corticosteroids.[7] However, these have potentially serious adverse \n",
      "effects and a substantial proportion of patients may become either dependent on them to \n",
      "maintain remission,[8] or refractory to them.[9] As a result, over the last 20 years novel \n",
      "drugs, with more precise modes of action, based on mechanisms of disease identified in \n",
      "genome wide association studies,[10] have been developed.  \n",
      "The first of these agents was infliximab, a drug targeting the pro-inflammatory \n",
      "cytokine tumour necrosis factor-α (TNF-α), which demonstrated efficacy in clinical trials in \n",
      "moderate to severe UC.[11] Since then, other drugs against TNF-α have been tested, such as \n",
      "adalimumab and golimumab.[12, 13] In addition, newer biological therapies targeting α or β \n",
      "integrins, which are involved in migration of immune cells to inflamed intestinal mucosa, \n",
      "such as vedolizumab or etrolizumab,[14, 15] or acting against other pro-inflammatory \n",
      "cytokines implicated in the pathogenesis of UC, such as ustekinumab,[16] have been tested. \n",
      "However, even these more selective drugs do not work in all patients, there may be risks \n",
      "associated with their use,[17-19] and the fact that they are administered either intravenously \n",
      "or subcutaneously, may be inconvenient for patients. The search for alternative agents for the \n",
      "treatment of UC has, therefore, continued.\n",
      "----------\n",
      "41 years (interquartile range, 40–42 y), and 60%\n",
      "(interquartile range, 56%–63%) were men. The median\n",
      "disease duration was 6.7 years (interquartile range,\n",
      "6.0–7.8 y), and 49% (interquartile range, 46%–55%) of\n",
      "patients had extensive colitis. A median of 40% (inter-\n",
      "quartile range, 30%–50%) of patients were treated with\n",
      "concomitant immunomodulators, and 51% (interquartile\n",
      "range, 45%–57%) were on corticosteroids at baseline.\n",
      "Patients across all trials and treatment arms were com-\n",
      "parable in terms of baseline prognostic variables, inclu-\n",
      "sion/exclusion\n",
      "criteria,\n",
      "and\n",
      "co-interventions.\n",
      "All\n",
      "outcomes were assessed uniformly based on the stan-\n",
      "dard deﬁnition of the Mayo Clinic score, between weeks\n",
      "6 and 10 for induction therapy (inﬂiximab, adalimumab,\n",
      "tofacitinib, ustekinumab, 8 weeks; golimumab, 6 weeks;\n",
      "vedolizumab, 6 weeks, 10 weeks, and 14 weeks in\n",
      "VARSITY),6 and weeks 30, 54, or 60 for maintenance\n",
      "therapy;\n",
      "endoscopy\n",
      "was\n",
      "read\n",
      "by\n",
      "blinded\n",
      "local\n",
      "Table 2. Comparative Efﬁcacy of Pharmacologic Agents for Induction of Clinical Remission and Endoscopic Improvement in Biologic-Naive Patients With Moderate–Severe\n",
      "Ulcerative Colitis Using Network Meta-Analysis\n",
      "Induction of clinical remission\n",
      "Induction of endoscopic improvement\n",
      "Ustekinumab 6 mg/kg\n",
      "0.96 (0.38–2.45)\n",
      "0.80 (0.35–1.83)\n",
      "0.73 (0.31–1.74)\n",
      "1.05 (0.48–2.32)\n",
      "0.50 (0.22–1.12)\n",
      "2.04 (1.03–4.05)\n",
      "0.92 (0.45–1.89)\n",
      "Tofacitinib 10 mg b.d.\n",
      "0.84 (0.39–1.82)\n",
      "0.76 (0.33–1.76)\n",
      "1.10 (0.51–2.34)\n",
      "0.52 (0.24–1.12)\n",
      "2.12 (1.12–4.02)\n",
      "0.74 (0.36–1.51)\n",
      "0.80 (0.4–1.62)\n",
      "Vedolizumab\n",
      "0.91 (0.44–1.86)\n",
      "1.31 (0.88–1.95)\n",
      "0.62 (0.34–1.15)\n",
      "2.54 (1.60–4.02)\n",
      "1.07 (0.58–1.98)\n",
      "1.17 (0.64–2.12)\n",
      "1.45 (0.80–2.61)\n",
      "Golimumab\n",
      "1.44 (0.76–2.75)\n",
      "0.69 (0.35–1.36)\n",
      "2.79 (1.64–4.02)\n",
      "1.17 (0.65–2.13)\n",
      "1.28 (0.72–2.29)\n",
      "1.59 (0.90–2.82)\n",
      "1.10 (0.71–1.71)\n",
      "Adalimumab\n",
      "0.48 (0.26–0.86)\n",
      "1.94 (1.30–2.88)\n",
      "0.56 (0.30–1.04)\n",
      "0.61 (0.34–1.11)\n",
      "0.76 (0.42–1.37)\n",
      "0.52 (0.33–0.83)\n",
      "0.48 (0.31–0.74)\n",
      "Inﬂiximab\n",
      "4.07 (2.67–6.21)\n",
      "1.86 (1.11–3.13)\n",
      "2.03 (1.23–3.34)\n",
      "2.52 (1.54–4.11)\n",
      "1.74 (1.25–2.41)\n",
      "1.58 (1.18–2.13)\n",
      "3.32 (2.39–4.60)\n",
      "Placebo\n",
      "NOTE. Comparisons should be read from left to right. Odds ratio for comparisons are in the cell in common between the column-deﬁning and row-deﬁning treatment. Numbers in bold are statistically signiﬁcant. For induction of\n",
      "clinical remission, an odds ratio greater than 1 favors row-deﬁning treatment. For induction of endoscopic improvement, an odds ratio greater than 1 favors column-deﬁning treatment. Numbers in parentheses indicate 95% CI.\n",
      "b.d., twice daily.\n",
      "----------\n",
      "severely active ulcerative colitis: results from phase 3 \n",
      "U-ACCOMPLISH study. J Crohn’s Colitis 2021; 15 (suppl 1): S021–22.\n",
      "9 \n",
      "Thorlund K, Druyts E, Mills EJ, Fedorak RN, Marshall JK. \n",
      "Adalimumab versus infliximab for the treatment of moderate to \n",
      "severe ulcerative colitis in adult patients naïve to anti-TNF therapy: \n",
      "an indirect treatment comparison meta-analysis. J Crohn’s Colitis \n",
      "2014; 8: 571–81.\n",
      "10 \n",
      "Danese S, Fiorino G, Peyrin-Biroulet L, et al. Biological agents for \n",
      "moderately to severely active ulcerative colitis: a systematic review \n",
      "and network meta-analysis. Ann Intern Med 2014; 160: 704–11.\n",
      "11 \n",
      "Singh S, Fumery M, Sandborn WJ, Murad MH. Systematic review \n",
      "with network meta-analysis: first- and second-line pharmacotherapy \n",
      "for moderate-severe ulcerative colitis. Aliment Pharmacol Ther 2018; \n",
      "47: 162–75.\n",
      "12 \n",
      "Bonovas S, Lytras T, Nikolopoulos G, Peyrin-Biroulet L, Danese S. \n",
      "Systematic review with network meta-analysis: comparative \n",
      "assessment of tofacitinib and biological therapies for moderate-to-\n",
      "severe ulcerative colitis. Aliment Pharmacol Ther 2018; 47: 454–65.\n",
      "13 \n",
      "Singh S, Murad MH, Fumery M, Dulai PS, Sandborn WJ. First- and \n",
      "second-line pharmacotherapies for patients with moderate to \n",
      "severely active ulcerative colitis: an updated network meta-analysis. \n",
      "Clin Gastroenterol Hepatol 2020; 18: 2179–91.e6.\n",
      "14 \n",
      "Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting \n",
      "items for systematic reviews and meta-analyses: the PRISMA \n",
      "statement. Ann Intern Med 2009; 151: 264–69.\n",
      "15 \n",
      "Jansen JP, Fleurence R, Devine B, et al. Interpreting indirect \n",
      "treatment comparisons and network meta-analysis for health-care \n",
      "decision making: report of the ISPOR Task Force on Indirect \n",
      "Treatment Comparisons Good Research Practices: part 1. \n",
      "Value Health 2011; 14: 417–28.\n",
      "16 \n",
      "Sterne JAC, Savović J, Page MJ, et al. RoB 2: a revised tool for \n",
      "assessing risk of bias in randomised trials. BMJ 2019; 366: l4898.\n",
      "17 \n",
      "Rücker G, Schwarzer G. Ranking treatments in frequentist network \n",
      "meta-analysis works without resampling methods. \n",
      "BMC Med Res Methodol 2015; 15: 58.\n",
      "----------\n",
      "Burr et al. \n",
      " \n",
      "5 of 45 \n",
      "STUDY HIGHLIGHTS \n",
      " \n",
      "What is already known about this subject \n",
      "• Ulcerative colitis (UC) follows a relapsing and remitting course, with intermittent \n",
      "flares of disease activity, some of which may be moderate to severe. \n",
      "• These are usually treated with corticosteroids, which have potentially serious adverse \n",
      "effects, so biological therapies and small molecules have been developed and licensed \n",
      "for this indication.  \n",
      "• Although previous network meta-analyses have compared their efficacy and safety, \n",
      "this is a rapidly moving field, and there are already several newer drugs that have \n",
      "shown efficacy in phase III clinical trials that were not considered in these. \n",
      " \n",
      "What are the new findings \n",
      "• In terms of clinical remission and clinical response, upadacitinib 45mg o.d. ranked \n",
      "first in all patients, in patients previously exposed to anti-tumour necrosis factor \n",
      "(TNF)-α therapies, and in patients naïve to these drugs.  \n",
      "• In terms of endoscopic improvement infliximab 10mg/kg ranked first, followed by \n",
      "upadacitinib 45mg o.d., and infliximab 5mg/kg.  \n",
      "• However, for endoscopic improvement again upadacitinib 45mg o.d. ranked first in \n",
      "patients previously exposed to anti-TNF-α therapies, and in patients who were anti-\n",
      "TNF-α naïve.  \n",
      "• None of the drugs studied were more likely to lead to serious adverse events than \n",
      "placebo.\n",
      "----------\n",
      "methodologic characteristics). If direct and indirect es-\n",
      "timates were similar (ie, coherent), then the higher rating\n",
      "can be assigned to the network meta-analysis estimates.\n",
      "Results\n",
      "From a total 5651 unique studies identiﬁed using our\n",
      "search strategy, we included 15 RCTs of ﬁrst-line agents\n",
      "(in biologic-naïve patients) (Active Ulcerative Colitis Trials\n",
      "1 and 2,17 Jiang et al,18 NCT01551290,19 Ulcerative colitis\n",
      "Long-Term Remission and maintenance with Adalimumab\n",
      "1 and 2,20,21 Suzuki et al,22 Program of Ulcerative Colitis\n",
      "Research Studies Utilizing an Investigational Treatment\n",
      "phase 2 and phase 3 induction studies,23 GEMINI I,24\n",
      "Motoya et al,25 VARSITY, Oral Clinical Trials for tofAciti-\n",
      "nib in ulceratiVE colitis (OCTAVE) 1 and 2,26 and UNIFI),\n",
      "and 7 RCTs of second-line agents (in patients with prior\n",
      "exposure to TNFa antagonists) (Ulcerative colitis Long-\n",
      "Term Remission and maintenance with Adalimumab 2,21\n",
      "GEMINI I,24 Motoya et al,25 VARSITY,6 OCTAVE 1 and\n",
      "2,26 UNIFI7) in patients with moderate–severe ulcerative\n",
      "colitis. Trials of inﬂiximab (Active Ulcerative Colitis Trials\n",
      "1 and 2,17 Jiang et al,18 NCT0155129019), adalimumab\n",
      "(Ulcerative colitis Long-Term Remission and maintenance\n",
      "with Adalimumab 2,20,21 Suzuki et al22), vedolizumab\n",
      "(GEMINI I,24 Motoya et al,25 VARSITY6) and ustekinumab\n",
      "(UNIFI7) also reported outcomes on maintenance therapy\n",
      "within the same publication; Program of Ulcerative Colitis\n",
      "Research Studies Utilizing an Investigational Treatment-\n",
      "M, Program of Ulcerative Colitis Research Studies Utilizing\n",
      "an Investigational Treatment-J, and OCTAVE-Sustain\n",
      "reported\n",
      "outcomes\n",
      "for\n",
      "maintenance\n",
      "therapy\n",
      "with\n",
      "golimumab and tofacitinib, respectively.26–28 From our\n",
      "previous analysis, 3 additional studies were included.\n",
      "The schematic diagram of study selection is shown in\n",
      "Supplementary\n",
      "Figure\n",
      "1,\n",
      "and\n",
      "available\n",
      "direct\n",
      "comparisons and network of trials are shown in Figure 1.\n",
      "Trial and patient characteristics are summarized in\n",
      "Table 1. Overall, the median average age of patients was\n",
      "41 years (interquartile range, 40–42 y), and 60%\n",
      "(interquartile range, 56%–63%) were men. The median\n",
      "disease duration was 6.7 years (interquartile range,\n",
      "6.0–7.8 y), and 49% (interquartile range, 46%–55%) of\n",
      "patients had extensive colitis. A median of 40% (inter-\n",
      "quartile range, 30%–50%) of patients were treated with\n",
      "concomitant immunomodulators, and 51% (interquartile\n",
      "range, 45%–57%) were on corticosteroids at baseline.\n",
      "Patients across all trials and treatment arms were com-\n",
      "----------\n",
      "Therapeutic strategies for the management of recentlydiagnosedulcerative colitis. IMMs include thiopurines and methotrexate. 5-ASA, 5-amino salicylic acid; ASUC, acute severe ulcerative colitis; IPAA, ileal pouch anal anastomosis.\n",
      "\n",
      "Risk stratification: Mild\n",
      "Clinical features: NA\n",
      "Treatment options: 5-ASA (oral and/or topical)\n",
      "\n",
      "Risk stratification: Moderate\n",
      "Clinical features: NA\n",
      "Treatment options: Can consider 5-ASA (with rapid step-up if inadequate response)\n",
      "\n",
      "Risk stratification: Moderate\n",
      "Clinical features: NA\n",
      "Treatment options: VDZ or UST\n",
      "\n",
      "Risk stratification: Moderate\n",
      "Clinical features: NA\n",
      "Treatment options: Thiopurine\n",
      "\n",
      "Risk stratification: Moderate\n",
      "Clinical features: NA\n",
      "Treatment options: TNFi +/- IMM\n",
      "\n",
      "Risk stratification: Severe\n",
      "Clinical features: NA\n",
      "Treatment options: TNFi +/- IMM\n",
      "\n",
      "Risk stratification: Severe\n",
      "Clinical features: NA\n",
      "Treatment options: Subtotal colectomy + IPAA or cyclosporine (for ASUC)\n",
      "\n",
      "Risk stratification: Additional consideration: EIM present\n",
      "Clinical features: Psoriasis or psoriatic arthritis\n",
      "Treatment options: UST\n",
      "\n",
      "Risk stratification: Additional consideration: EIM present\n",
      "Clinical features: Other arthritis\n",
      "Treatment options: TNFi\n",
      "\n",
      "\n",
      "----------\n",
      "discontinuation due to AEs, and serious infections. Phase 3 randomized controlled trials were identified via systematic literature review, in-\n",
      "cluding the following advanced therapies: infliximab, adalimumab, vedolizumab, golimumab, tofacitinib, ustekinumab, filgotinib, ozanimod, and \n",
      "upadacitinib. Random effects models were used to address between-study heterogeneity. Intent-to-treat (ITT) efficacy rates were calculated by \n",
      "adjusting maintenance outcomes by likelihood of induction response.\n",
      "Results:  Out of 48 trials identified, 23 were included. Across all outcomes and regardless of prior biologic exposure, ITT efficacy rates were \n",
      "highest for upadacitinib, owing to its highest ranking for all efficacy outcomes in induction and for all but clinical remission during maintenance \n",
      "among bio-naive induction responders. For all advanced therapies versus placebo, there were no significant differences in serious AEs or \n",
      "serious infections across therapies. For all AEs, golimumab had higher odds versus placebo during maintenance; for discontinuation due to \n",
      "AEs, upadacitinib had lower odds versus placebo during induction, while ustekinumab and vedolizumab had lower odds versus placebo during \n",
      "maintenance.\n",
      "Conclusions:  Upadacitinib may be the most efficacious therapy for moderately to severely active UC based on ITT analyses, with similar safety \n",
      "across advanced therapies.\n",
      "Lay Summary \n",
      "Indirect evidence suggests upadacitinib may be more efficacious than other advanced therapies at achieving clinical response, clinical remis-\n",
      "sion, and endoscopic response over 1 year for moderately to severely active ulcerative colitis patients, with similar safety assessments across \n",
      "advanced therapies.\n",
      "Key Words: ulcerative colitis, clinical trials, advanced therapies, network meta-analysis\n",
      "Introduction\n",
      "Ulcerative colitis (UC) is a chronic inflammatory bowel dis-\n",
      "ease that affects the colorectum and is clinically characterized \n",
      "by bloody diarrhea, urgency, tenesmus, abdominal pain, ma-\n",
      "laise, weight loss, and fever. Disease onset commonly occurs \n",
      "between the ages of 15 and 30 years and the annual global \n",
      "© The Author(s) 2023. Published by Oxford University Press on behalf of Crohn's & Colitis Foundation.\n",
      "This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), \n",
      "which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.\n",
      "----------\n",
      "SYSTEMATIC REVIEWS AND META-ANALYSES\n",
      "Siddharth Singh, Section Editor\n",
      "First- and Second-Line Pharmacotherapies for Patients With\n",
      "Moderate to Severely Active Ulcerative Colitis: An Updated\n",
      "Network Meta-Analysis\n",
      "Siddharth Singh,*,‡ Mohammad Hassan Murad,§ Mathurin Fumery,j\n",
      "Parambir S. Dulai,* and William J. Sandborn*\n",
      "*Division of Gastroenterology, ‡Division of Biomedical Informatics, University of California San Diego, La Jolla, California;\n",
      "§Robert D and Patricia E Kern Center for the Science of Health Care Delivery, Mayo Clinic, Rochester, Minnesota;\n",
      "||Gastroenterology Unit, Peritox UMR I-0I, Amiens University and Hospital, Université de Picardie Jules Verne, Amiens, France\n",
      "BACKGROUND & AIMS:\n",
      "We compared the efﬁcacy and safety of different ﬁrst-line (biologic-naïve) and second-line\n",
      "(prior exposure to tumor necrosis factor [TNF] antagonists) agents for treatment of moder-\n",
      "ate to severely active ulcerative colitis in a systematic review and network meta-analysis.\n",
      "METHODS:\n",
      "We searched publication databases through September 30, 2019, for randomized trials of\n",
      "adults with moderate to severe ulcerative colitis treated with TNF antagonists, vedolizumab,\n",
      "tofacitinib, or ustekinumab, as ﬁrst-line or second-line agents, compared with placebo or\n",
      "another active agent. Efﬁcacy outcomes were induction and maintenance of remission and\n",
      "endoscopic improvement; safety outcomes were serious adverse events and infections. We\n",
      "performed a ﬁxed-effects network meta-analysis using the frequentist approach, and calculated\n",
      "odds ratios (ORs) and 95% CI values. Agents were ranked using surface under the cumulative\n",
      "ranking (SUCRA) probabilities. Overall quality of evidence was rated using GRADE (Grading of\n",
      "Recommendations, Assessment, Development and Evaluation).\n",
      "RESULTS:\n",
      "In biologic-naïve patients, inﬂiximab was ranked highest for induction of clinical remission (OR\n",
      "vs placebo, 4.07; 95% CI, 2.67–6.21; SUCRA, 0.95) and endoscopic improvement (SUCRA, 0.95)\n",
      "(moderate conﬁdence in estimates [CE]). In patients with prior exposure to TNF antagonists,\n",
      "ustekinumab (SUCRA, 0.87) and tofacitinib (SUCRA, 0.87) were ranked highest for induction of\n",
      "clinical remission and were superior to vedolizumab (ustekinumab vs vedolizumab: OR, 5.99;\n",
      "95% CI, 1.13–31.76 and tofacitinib vs vedolizumab: OR, 6.18; 95% CI, 1.003–8.00; moderate CE)\n",
      "and adalimumab (ustekinumab vs adalimumab: OR, 10.71; 95% CI, 2.01–57.20 and tofacitinib\n",
      "----------\n",
      "Articles\n",
      "www.thelancet.com/gastrohep   Vol 7   February 2022 \n",
      "161\n",
      "Lancet Gastroenterol Hepatol \n",
      "2022; 7: 161–70\n",
      "Published Online \n",
      "November 29, 2021 \n",
      "https://doi.org/10.1016/ \n",
      "S2468-1253(21)00377-0\n",
      "See Comment page 110\n",
      "*Contributed equally\n",
      "Inflammatory Bowel Disease \n",
      "Unit, Gastroenterology \n",
      "Section, Department of \n",
      "Internal Medicine, Centro de \n",
      "Educación Médica e \n",
      "Investigaciones Clínicas, \n",
      "Buenos Aires, Argentina \n",
      "(J S Lasa MD, P A Olivera MD); \n",
      "Gastroenterology Department, \n",
      "Hospital Británico de Buenos \n",
      "Aires, Buenos Aires, Argentina \n",
      "(J S Lasa); Zane Cohen Centre \n",
      "for Digestive Diseases, \n",
      "Lunenfeld-Tanenbaum \n",
      "Research Institute, Sinai Health \n",
      "System, Toronto, ON, Canada \n",
      "(P A Olivera); Division of \n",
      "Gastroenterology, Mount Sinai \n",
      "Hospital, University of Toronto, \n",
      "Toronto, ON, Canada \n",
      "(P A Olivera); Gastroenterology \n",
      "and Endoscopy, IRCCS Ospedale \n",
      "San Raffaele and University \n",
      "Vita-Salute San Raffaele, \n",
      "Milano, Italy \n",
      "(Prof S Danese MD); INSERM \n",
      "NGERE and Department of \n",
      "Hepatogastroenterology, \n",
      "Nancy University Hospital, \n",
      "Lorraine University, \n",
      "Vandoeuvre-lés-Nancy, France \n",
      "(Prof L Peyrin-Biroulet MD) \n",
      "Correspondence to: \n",
      "Prof Laurent Peyrin-Biroulet, \n",
      "INSERM NGERE and Department \n",
      "of Hepatogastroenterology, \n",
      "Nancy University Hospital, \n",
      "Lorraine University, Vandoeuvre-\n",
      "lès-Nancy F-54511, France \n",
      "peyrinbiroulet@gmail.com\n",
      "Efficacy and safety of biologics and small molecule drugs for \n",
      "patients with moderate-to-severe ulcerative colitis: \n",
      "a systematic review and network meta-analysis \n",
      "Juan S Lasa*, Pablo A Olivera*, Silvio Danese, Laurent Peyrin-Biroulet\n",
      "Summary\n",
      "Background There is a growing armamentarium for the treatment of moderate-to-severe ulcerative colitis. We aimed \n",
      "to compare the relative efficacy and safety of biologics and small molecule drugs for the treatment of patients with \n",
      "moderate-to-severe ulcerative colitis.\n",
      "Methods In this systematic review and network meta-analysis, we searched MEDLINE, Embase, and the Cochrane \n",
      "Central Register of Controlled Trials without language restrictions for articles published between Jan 1, 1990, and \n",
      "July 1, 2021. Major congresses’ databases from Jan 1, 2018, to July 3, 2021, were reviewed manually. Phase 3, placebo-\n",
      "controlled or head-to-head randomised controlled trials (RCTs) assessing the efficacy and safety of biologics or small \n",
      "molecule drugs as induction or maintenance therapies for patients with moderate-to-severe ulcerative colitis were\n",
      "----------\n",
      "Parkes, M., Vermeire, S., Rioux, J.D., Mansﬁeld, J., Silverberg, M.S., Radford-\n",
      "Smith, G., McGovern, D.P., Barrett, J.C., Lees, C.W., 2016. Inherited determinants of\n",
      "crohn's disease and ulcerative colitis phenotypes: a genetic association study. Lancet\n",
      "387 (10014), 156–167.\n",
      "Colombel, J.F., Sandborn, W.J., Rutgeerts, P., Enns, R., Hanauer, S.B., Panaccione, R.,\n",
      "Schreiber, S., Byczkowski, D., Li, J., Kent, J.D., Pollack, P.F., 2007. Adalimumab for\n",
      "maintenance of clinical response and remission in patients with crohn's disease: the\n",
      "charm trial. Gastroenterology 132 (1), 52–65.\n",
      "Conrad, M.A., Kelsen, J.R., 2020. The treatment of pediatric inﬂammatory bowel disease\n",
      "with biologic therapies. Curr. Gastroenterol. Rep. 22 (8), 36–51.\n",
      "Csontos, A.A., Molnar, A., Piri, Z., Katona, B., Dako, S., Palﬁ, E., Miheller, P., 2016. The\n",
      "effect of anti-tnfalpha induction therapy on the nutritional status and dietary intake\n",
      "in inﬂammatory bowel disease. J Gastrointestin Liver Dis 25 (1), 49–56.\n",
      "Dai, Z.H., Xu, X.T., Ran, Z.H., 2020. Associations between obesity and the effectiveness of\n",
      "anti-tumor necrosis factor-alpha agents in inﬂammatory bowel disease patients: a\n",
      "literature review and meta-analysis. Ann. Pharmacother. 54 (8), 729–741.\n",
      "Danese, S., Colombel, J.F., Lukas, M., Gisbert, J.P., D’Haens, G., Hayee, B., Panaccione, R.,\n",
      "Kim, H.S., Reinisch, W., Tyrrell, H., Oh, Y.S., Tole, S., Chai, A., Chamberlain-\n",
      "James, K., Tang, M.T., Schreiber, S., Group, G.S., 2021. Etrolizumab versus inﬂiximab\n",
      "for the treatment of moderately to severely active ulcerative colitis (gardenia): a\n",
      "randomised, double-blind, double-dummy, phase 3 study. Lancet Gastroenterol\n",
      "Hepatol 7 (2), 118–127.\n",
      "Danese, S., Fiorino, G., Peyrin-Biroulet, L., Lucenteforte, E., Virgili, G., Moja, L.,\n",
      "Bonovas, S., 2014. Biological agents for moderately to severely active ulcerative\n",
      "colitis: a systematic review and network meta-analysis. Ann. Intern. Med. 160 (10),\n",
      "704–711.\n",
      "P. Juillerat et al.\n",
      "Current Research in Pharmacology and Drug Discovery 3 (2022) 100104\n",
      "6\n",
      "==========\n",
      "ORIGINAL QUESTION: ANALYSE the given patient profile based on given query based on one of the following criteria:\n",
      "- Whether treated patient is new patient or patient under maintenance\n",
      "- Prior response to Infliximab\n",
      "- Prior failure to Anti-TNF agents\n",
      "- Prior failure to Vedolizumab\n",
      "- Age\n",
      "- Pregnancy\n",
      "- Extraintestinale manifestations\n",
      "- Pouchitis\n",
      "RETURN up to 2 TOP choices of biological drugs given patient profile and context. Explain the PROS and CONS of the 2 choices.\n",
      "PATIENT PROFILE: 58 year-old woman with moderate to severe distal ulcerative colitis and optic neuritis.\n",
      "\n",
      "==========\n",
      "CURRENT ANSWER:\n",
      "Based on the patient's profile, the top two choices of biological drugs would be Vedolizumab and Ustekinumab. \n",
      "\n",
      "1. Vedolizumab:\n",
      "   - Advantages: Vedolizumab is a gut-selective immunosuppressant, meaning it specifically targets the gut and has less systemic side effects. It has been shown to be effective in treating moderate to severe ulcerative colitis.\n",
      "   - Disadvantages: Vedolizumab may not be as effective in patients who have failed anti-TNF therapy. It is also administered intravenously, which may be inconvenient for some patients.\n",
      "\n",
      "2. Ustekinumab:\n",
      "   - Advantages: Ustekinumab is effective in treating moderate to severe ulcerative colitis. It also has a good safety profile and is less likely to cause serious infections compared to other biologics.\n",
      "   - Disadvantages: Ustekinumab is administered via injection, which may be inconvenient for some patients. It may also not be as effective in patients who have failed anti-TNF therapy.\n",
      "\n",
      "It's important to note that the patient's optic neuritis should be taken into consideration when choosing a treatment, as some medications may exacerbate this condition. Both Vedolizumab and Ustekinumab have not been associated with worsening of optic neuritis, but this should be monitored closely during treatment.\n",
      "==========\n",
      "REFINED ANSWER:\n",
      "\u001b[0m\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "Retrying langchain.chat_models.openai.ChatOpenAI.completion_with_retry.<locals>._completion_with_retry in 4.0 seconds as it raised RateLimitError: Rate limit reached for 10KTPM-200RPM in organization org-ETbTMTN2JXYOUPDJgxuH2iO6 on tokens per min. Limit: 10000 / min. Please try again in 6ms. Contact us through our help center at help.openai.com if you continue to have issues..\n",
      "Retrying langchain.chat_models.openai.ChatOpenAI.completion_with_retry.<locals>._completion_with_retry in 4.0 seconds as it raised RateLimitError: Rate limit reached for 10KTPM-200RPM in organization org-ETbTMTN2JXYOUPDJgxuH2iO6 on tokens per min. Limit: 10000 / min. Please try again in 6ms. Contact us through our help center at help.openai.com if you continue to have issues..\n",
      "Retrying langchain.chat_models.openai.ChatOpenAI.completion_with_retry.<locals>._completion_with_retry in 4.0 seconds as it raised RateLimitError: Rate limit reached for 10KTPM-200RPM in organization org-ETbTMTN2JXYOUPDJgxuH2iO6 on tokens per min. Limit: 10000 / min. Please try again in 6ms. Contact us through our help center at help.openai.com if you continue to have issues..\n",
      "Retrying langchain.chat_models.openai.ChatOpenAI.completion_with_retry.<locals>._completion_with_retry in 8.0 seconds as it raised RateLimitError: Rate limit reached for 10KTPM-200RPM in organization org-ETbTMTN2JXYOUPDJgxuH2iO6 on tokens per min. Limit: 10000 / min. Please try again in 6ms. Contact us through our help center at help.openai.com if you continue to have issues..\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\n",
      "\u001b[1m> Finished chain.\u001b[0m\n",
      "\n",
      "\u001b[1m> Finished chain.\u001b[0m\n",
      "2023-10-02 17:44:21,325:INFO: 6061 tokens were added to prompt from 10 documents\n",
      "Query: 55 year-old man with moderate to severe extensive ulcerative colitis and colonic polyps with high grade dysplasia found 2 years ago.\n",
      "\n",
      "\n",
      "\n",
      "\u001b[1m> Entering new SequentialChain chain...\u001b[0m\n",
      "\n",
      "\n",
      "\u001b[1m> Entering new RetrievalQAWithSourcesChain chain...\u001b[0m\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "Retrying langchain.chat_models.openai.ChatOpenAI.completion_with_retry.<locals>._completion_with_retry in 4.0 seconds as it raised RateLimitError: Rate limit reached for 10KTPM-200RPM in organization org-ETbTMTN2JXYOUPDJgxuH2iO6 on tokens per min. Limit: 10000 / min. Please try again in 6ms. Contact us through our help center at help.openai.com if you continue to have issues..\n",
      "Retrying langchain.chat_models.openai.ChatOpenAI.completion_with_retry.<locals>._completion_with_retry in 4.0 seconds as it raised RateLimitError: Rate limit reached for 10KTPM-200RPM in organization org-ETbTMTN2JXYOUPDJgxuH2iO6 on tokens per min. Limit: 10000 / min. Please try again in 6ms. Contact us through our help center at help.openai.com if you continue to have issues..\n",
      "Retrying langchain.chat_models.openai.ChatOpenAI.completion_with_retry.<locals>._completion_with_retry in 4.0 seconds as it raised RateLimitError: Rate limit reached for 10KTPM-200RPM in organization org-ETbTMTN2JXYOUPDJgxuH2iO6 on tokens per min. Limit: 10000 / min. Please try again in 6ms. Contact us through our help center at help.openai.com if you continue to have issues..\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\n",
      "\u001b[1m> Finished chain.\u001b[0m\n",
      "\n",
      "\n",
      "\u001b[1m> Entering new LLMChain chain...\u001b[0m\n",
      "Prompt after formatting:\n",
      "\u001b[32;1m\u001b[1;3mYou are a senior physician giving advice on treatment for moderate to severe ulcerative colitis (UC).\n",
      "Make reference to the CONTEXT given to assess the scenario.\n",
      "==========\n",
      "TASK: Your task is to analyse critically the CURRENT ANSWER given the CONTEXT.\n",
      "Then refine the existing answer (only if needed) based on the following instructions:\n",
      "- If no refinement needed, return the original answer in the correct output format.\n",
      "- If the answer cannot be inferred from CONTEXT, return \"NO ANSWER\".\n",
      "- The final output should be a list of up to 2 choices of biological drugs given patient profile and context and PROS/CONS for each recommendations.\n",
      "==========\n",
      "CONTEXT:\n",
      "Burr et al. \n",
      " \n",
      "7 of 45 \n",
      "INTRODUCTION \n",
      "  Ulcerative colitis (UC) is a chronic inflammatory disorder of the bowel that causes \n",
      "continuous mucosal inflammation commencing in the rectum and extending proximally for a \n",
      "variable extent.[1] It is estimated that UC affects 2.5 million people in Europe,[2] and the \n",
      "disease follows a relapsing and remitting course, with intermittent flares of disease activity, \n",
      "some of which may be moderate to severe. Management of these is medical, for the most \n",
      "part, with surgery reserved for patients with refractory disease. Although 5-aminosalicylates \n",
      "(5-ASAs) are efficacious for mild to moderate disease activity,[3-6] more severe flares are \n",
      "usually treated with corticosteroids.[7] However, these have potentially serious adverse \n",
      "effects and a substantial proportion of patients may become either dependent on them to \n",
      "maintain remission,[8] or refractory to them.[9] As a result, over the last 20 years novel \n",
      "drugs, with more precise modes of action, based on mechanisms of disease identified in \n",
      "genome wide association studies,[10] have been developed.  \n",
      "The first of these agents was infliximab, a drug targeting the pro-inflammatory \n",
      "cytokine tumour necrosis factor-α (TNF-α), which demonstrated efficacy in clinical trials in \n",
      "moderate to severe UC.[11] Since then, other drugs against TNF-α have been tested, such as \n",
      "adalimumab and golimumab.[12, 13] In addition, newer biological therapies targeting α or β \n",
      "integrins, which are involved in migration of immune cells to inflamed intestinal mucosa, \n",
      "such as vedolizumab or etrolizumab,[14, 15] or acting against other pro-inflammatory \n",
      "cytokines implicated in the pathogenesis of UC, such as ustekinumab,[16] have been tested. \n",
      "However, even these more selective drugs do not work in all patients, there may be risks \n",
      "associated with their use,[17-19] and the fact that they are administered either intravenously \n",
      "or subcutaneously, may be inconvenient for patients. The search for alternative agents for the \n",
      "treatment of UC has, therefore, continued.\n",
      "----------\n",
      "41 years (interquartile range, 40–42 y), and 60%\n",
      "(interquartile range, 56%–63%) were men. The median\n",
      "disease duration was 6.7 years (interquartile range,\n",
      "6.0–7.8 y), and 49% (interquartile range, 46%–55%) of\n",
      "patients had extensive colitis. A median of 40% (inter-\n",
      "quartile range, 30%–50%) of patients were treated with\n",
      "concomitant immunomodulators, and 51% (interquartile\n",
      "range, 45%–57%) were on corticosteroids at baseline.\n",
      "Patients across all trials and treatment arms were com-\n",
      "parable in terms of baseline prognostic variables, inclu-\n",
      "sion/exclusion\n",
      "criteria,\n",
      "and\n",
      "co-interventions.\n",
      "All\n",
      "outcomes were assessed uniformly based on the stan-\n",
      "dard deﬁnition of the Mayo Clinic score, between weeks\n",
      "6 and 10 for induction therapy (inﬂiximab, adalimumab,\n",
      "tofacitinib, ustekinumab, 8 weeks; golimumab, 6 weeks;\n",
      "vedolizumab, 6 weeks, 10 weeks, and 14 weeks in\n",
      "VARSITY),6 and weeks 30, 54, or 60 for maintenance\n",
      "therapy;\n",
      "endoscopy\n",
      "was\n",
      "read\n",
      "by\n",
      "blinded\n",
      "local\n",
      "Table 2. Comparative Efﬁcacy of Pharmacologic Agents for Induction of Clinical Remission and Endoscopic Improvement in Biologic-Naive Patients With Moderate–Severe\n",
      "Ulcerative Colitis Using Network Meta-Analysis\n",
      "Induction of clinical remission\n",
      "Induction of endoscopic improvement\n",
      "Ustekinumab 6 mg/kg\n",
      "0.96 (0.38–2.45)\n",
      "0.80 (0.35–1.83)\n",
      "0.73 (0.31–1.74)\n",
      "1.05 (0.48–2.32)\n",
      "0.50 (0.22–1.12)\n",
      "2.04 (1.03–4.05)\n",
      "0.92 (0.45–1.89)\n",
      "Tofacitinib 10 mg b.d.\n",
      "0.84 (0.39–1.82)\n",
      "0.76 (0.33–1.76)\n",
      "1.10 (0.51–2.34)\n",
      "0.52 (0.24–1.12)\n",
      "2.12 (1.12–4.02)\n",
      "0.74 (0.36–1.51)\n",
      "0.80 (0.4–1.62)\n",
      "Vedolizumab\n",
      "0.91 (0.44–1.86)\n",
      "1.31 (0.88–1.95)\n",
      "0.62 (0.34–1.15)\n",
      "2.54 (1.60–4.02)\n",
      "1.07 (0.58–1.98)\n",
      "1.17 (0.64–2.12)\n",
      "1.45 (0.80–2.61)\n",
      "Golimumab\n",
      "1.44 (0.76–2.75)\n",
      "0.69 (0.35–1.36)\n",
      "2.79 (1.64–4.02)\n",
      "1.17 (0.65–2.13)\n",
      "1.28 (0.72–2.29)\n",
      "1.59 (0.90–2.82)\n",
      "1.10 (0.71–1.71)\n",
      "Adalimumab\n",
      "0.48 (0.26–0.86)\n",
      "1.94 (1.30–2.88)\n",
      "0.56 (0.30–1.04)\n",
      "0.61 (0.34–1.11)\n",
      "0.76 (0.42–1.37)\n",
      "0.52 (0.33–0.83)\n",
      "0.48 (0.31–0.74)\n",
      "Inﬂiximab\n",
      "4.07 (2.67–6.21)\n",
      "1.86 (1.11–3.13)\n",
      "2.03 (1.23–3.34)\n",
      "2.52 (1.54–4.11)\n",
      "1.74 (1.25–2.41)\n",
      "1.58 (1.18–2.13)\n",
      "3.32 (2.39–4.60)\n",
      "Placebo\n",
      "NOTE. Comparisons should be read from left to right. Odds ratio for comparisons are in the cell in common between the column-deﬁning and row-deﬁning treatment. Numbers in bold are statistically signiﬁcant. For induction of\n",
      "clinical remission, an odds ratio greater than 1 favors row-deﬁning treatment. For induction of endoscopic improvement, an odds ratio greater than 1 favors column-deﬁning treatment. Numbers in parentheses indicate 95% CI.\n",
      "b.d., twice daily.\n",
      "----------\n",
      "perianal CD varied between 11% and 19% at 1–10 years\n",
      "after diagnosis.9 In a study of 983 patients with CD in Asia,\n",
      "stricturing or penetrating CD occurred in 41% and perianal\n",
      "disease in 25% of patients.10 At the other end of the spec-\n",
      "trum, incidental terminal ileitis can be diagnosed in 1.6% of\n",
      "individuals undergoing nondiagnostic colonoscopy, with an\n",
      "uncertain but likely low rate of progression to overt CD.11\n",
      "With respect to UC, most patients have mild to moderate\n",
      "severity and 10%–15% of patients can experience a severe\n",
      "course.12 In a population-based cohort study, proctosigmoid\n",
      "location of colitis occurred in 73% of patients; of these,\n",
      "disease extension occurred in 23% of patients at 7 years of\n",
      "follow-up and it was a marker of worse prognosis.13 The\n",
      "risk of surgery for CD and UC can be up to 46.6% and 15.6%\n",
      "10 years after diagnosis, respectively, and has decreased\n",
      "signiﬁcantly during the last 6 decades.14\n",
      "The symptoms associated with IBD can be waxing and\n",
      "waning, but the underlying systemic inﬂammation can lead\n",
      "to progressive, cumulative, and often irreversible intestinal\n",
      "damage\n",
      "and\n",
      "risk\n",
      "of\n",
      "complications\n",
      "if\n",
      "not\n",
      "treated\n",
      "adequately.15\n",
      "Complications\n",
      "associated\n",
      "with\n",
      "ongoing\n",
      "inﬂammation in CD include strictures, obstructions, ﬁstulas,\n",
      "abscesses, and surgery,3,16 and those associated with UC\n",
      "include loss of colonic and anorectal function, surgery, and\n",
      "colorectal cancer.2,4,17 Other complications include anemia,\n",
      "nutritional deﬁciencies, loss of bone density, and progres-\n",
      "sive loss of quality of life. In children, persistent inﬂamma-\n",
      "tion\n",
      "is\n",
      "associated\n",
      "with\n",
      "growth\n",
      "impairment,\n",
      "risking\n",
      "permanent loss of height.18 Similar to other chronic dis-\n",
      "eases, such as rheumatoid arthritis, the concept of cumula-\n",
      "tive damage is now acknowledged in IBD and can be\n",
      "measured using validated tools, such as the Lemann Index.19\n",
      "Limited Correlations Among Inﬂammation,\n",
      "Symptoms, and Complications\n",
      "The concordance between intestinal inﬂammation and\n",
      "symptoms can be limited, especially in CD.20,21 In a\n",
      "population-based cohort, more than 20% of CD patients\n",
      "were found to have strictures and penetrating disease at the\n",
      "time of diagnosis, suggesting that clinically silent inﬂam-\n",
      "mation may precede formal diagnosis.22 The STRIDE\n",
      "(Selecting Therapeutic Targets in Inﬂammatory Bowel Dis-\n",
      "ease) recommendations, updated recently, are meant to\n",
      "target endoscopic healing, minimize disability, and restore\n",
      "quality of life and adequate growth in children, in addition\n",
      "----------\n",
      "Disease Phenotype and Clinical Characteristics\n",
      "The International Organization for the Study of Inﬂam-\n",
      "matory Bowel Disease and the American Gastroenterological\n",
      "Association (AGA) provide a framework for categorization of\n",
      "CD and UC severity into mild-, moderate-, and high-risk\n",
      "groups based on phenotype and other characteristics.59,60\n",
      "In CD, the presence of large or deep mucosal lesions on\n",
      "endoscopy or magnetic resonance imaging (MRI), history of\n",
      "a ﬁstula, abscess, or intestinal resection are predictors of\n",
      "worse outcomes.59,60 In a prospective population-based\n",
      "inception cohort of 213 patients with CD, penetrating\n",
      "behavior was associated with a higher risk of progression to\n",
      "perianal disease (HR, 5.65; 95% CI, 2.65–12.03) and was a\n",
      "risk factor for resection (HR, 3.92; 95% CI, 1.86–8.67) and\n",
      "hospitalization (HR, 1.01; 95% CI, 1.00–1.01).16 Ileal and\n",
      "upper gastrointestinal disease location and extensive dis-\n",
      "ease are also markers of severe disease.61 Cigarette smoking\n",
      "is associated with complications and need for therapy\n",
      "escalation.61\n",
      "In CD, the threshold of suspicion should be low for high-\n",
      "quality imaging of the pelvis, such as MRI, to rule our\n",
      "perianal CD. In a retrospective study of 136 pediatric CD\n",
      "patients, presence of anal ﬁssures and skin tags, non-White\n",
      "race, and elevated C-reactive protein (CRP) were risk factors\n",
      "for perianal CD.62 In another study of 274 patients in China\n",
      "with recently diagnosed CD, all of whom underwent MRI\n",
      "pelvis, asymptomatic perianal ﬁstulas were diagnosed in\n",
      "17.5% of patients and colonic location of CD was a risk\n",
      "factor for asymptomatic perianal ﬁstulas.63\n",
      "In UC, corresponding predictors of aggressive disease\n",
      "advised by the International Organization for the Study of\n",
      "Inﬂammatory Bowel Disease include active colonic ulcers\n",
      "and prior use of biologics.59 Extensive colitis, deep ulcers,\n",
      "need for corticosteroids, hospitalization, Clostridium difﬁcile,\n",
      "and cytomegalovirus infection also indicate higher colec-\n",
      "tomy risk.64 Of note, disease extension from limited disease\n",
      "to\n",
      "extensive\n",
      "or\n",
      "pancolitis\n",
      "is\n",
      "associated\n",
      "with\n",
      "worse\n",
      "prognosis.45,65\n",
      "In addition, co-occurrence of other immune-mediated\n",
      "inﬂammatory diseases can occur, most commonly with\n",
      "psoriasis and asthma, but also, in more rare instances, with\n",
      "other gastrointestinal diseases (eg, celiac, nonalcoholic fatty\n",
      "liver disease,66 and eosinophilic esophagitis).67,68 Presence\n",
      "of a concomitant immune-mediated inﬂammatory disease is\n",
      "Figure\n",
      "1. Inﬂammatory\n",
      "bowel disease severity vs\n",
      "----------\n",
      "associated with improved long-term outcomes.33 Data on\n",
      "the impact of early therapy in UC are more limited, but, as\n",
      "UC is also a progressive disease with risk of colorectal\n",
      "cancer, surgery, and loss of colonic function, it is reasonable\n",
      "to treat early to mitigate these risks.\n",
      "How to Diagnose Inﬂammatory Bowel Disease\n",
      "Early\n",
      "IBD is heterogenous with wide variation in presentation.\n",
      "Disease activity at presentation can range from mild to severe\n",
      "and, as discussed, symptoms may be mild to none. These can\n",
      "make the IBD diagnosis challenging, especially at a primary\n",
      "care level. Danese et al34 have proposed a Red Flags Index\n",
      "consisting of a 21-item questionnaire to help providers triage\n",
      "and identify patients with concerning symptoms in a timely\n",
      "manner and refer to specialists appropriately. A useful adjunct\n",
      "to symptom-based criteria is fecal calprotectin (FC), a stool\n",
      "marker of inﬂammation; in a large meta-analysis, FC � 40 mg/\n",
      "g carried a �1% probability of IBD, effectively excluding the\n",
      "diagnosis of IBD.35 Similarly, in the Red Flags Index validation\n",
      "study, combining the index with FC (Red Flags Index �8 and/\n",
      "or FC >250 mg/g) increased the positive predictive value from\n",
      "4% to 21% and negative predictive value from 97% to\n",
      "100%.36 Diagnostic criteria for IBD involve a composite of\n",
      "clinical symptoms, endoscopic, biomarker, and cross-sectional\n",
      "imaging features, which are beyond the scope of this review.\n",
      "We refer readers to the excellent guidelines laid out by the\n",
      "American College of Gastroenterology, European Crohn’s and\n",
      "Colitis\n",
      "Organization,\n",
      "and\n",
      "British\n",
      "Society\n",
      "of\n",
      "Gastro-\n",
      "enterology.37–40\n",
      "Risk Stratiﬁcation and Prognostication\n",
      "at Diagnosis\n",
      "Appropriately\n",
      "risk-stratifying\n",
      "prognosis\n",
      "in\n",
      "patients\n",
      "recently diagnosed with IBD is essential to inform selection\n",
      "of the most appropriate treatment and monitoring strate-\n",
      "gies. CD and UC phenotype and disease activity at initial\n",
      "presentation can vary widely from limited and mild to\n",
      "extensive and complicated. Certain baseline clinical features\n",
      "are associated with a more aggressive disease course with\n",
      "higher risk of progression and complications. In higher-risk\n",
      "patients, early control of inﬂammation with immune-\n",
      "modifying therapies is critical. However, immunosuppres-\n",
      "sive therapies are associated with safety concerns in the\n",
      "short- and long-term, and entail signiﬁcant health care costs.\n",
      "Therefore, a consideration of risks, beneﬁts, and alternatives\n",
      "is key to develop an individualized therapeutic plan for the\n",
      "informed patient.\n",
      "----------\n",
      "Burr et al. \n",
      " \n",
      "5 of 45 \n",
      "STUDY HIGHLIGHTS \n",
      " \n",
      "What is already known about this subject \n",
      "• Ulcerative colitis (UC) follows a relapsing and remitting course, with intermittent \n",
      "flares of disease activity, some of which may be moderate to severe. \n",
      "• These are usually treated with corticosteroids, which have potentially serious adverse \n",
      "effects, so biological therapies and small molecules have been developed and licensed \n",
      "for this indication.  \n",
      "• Although previous network meta-analyses have compared their efficacy and safety, \n",
      "this is a rapidly moving field, and there are already several newer drugs that have \n",
      "shown efficacy in phase III clinical trials that were not considered in these. \n",
      " \n",
      "What are the new findings \n",
      "• In terms of clinical remission and clinical response, upadacitinib 45mg o.d. ranked \n",
      "first in all patients, in patients previously exposed to anti-tumour necrosis factor \n",
      "(TNF)-α therapies, and in patients naïve to these drugs.  \n",
      "• In terms of endoscopic improvement infliximab 10mg/kg ranked first, followed by \n",
      "upadacitinib 45mg o.d., and infliximab 5mg/kg.  \n",
      "• However, for endoscopic improvement again upadacitinib 45mg o.d. ranked first in \n",
      "patients previously exposed to anti-TNF-α therapies, and in patients who were anti-\n",
      "TNF-α naïve.  \n",
      "• None of the drugs studied were more likely to lead to serious adverse events than \n",
      "placebo.\n",
      "----------\n",
      "Parkes, M., Vermeire, S., Rioux, J.D., Mansﬁeld, J., Silverberg, M.S., Radford-\n",
      "Smith, G., McGovern, D.P., Barrett, J.C., Lees, C.W., 2016. Inherited determinants of\n",
      "crohn's disease and ulcerative colitis phenotypes: a genetic association study. Lancet\n",
      "387 (10014), 156–167.\n",
      "Colombel, J.F., Sandborn, W.J., Rutgeerts, P., Enns, R., Hanauer, S.B., Panaccione, R.,\n",
      "Schreiber, S., Byczkowski, D., Li, J., Kent, J.D., Pollack, P.F., 2007. Adalimumab for\n",
      "maintenance of clinical response and remission in patients with crohn's disease: the\n",
      "charm trial. Gastroenterology 132 (1), 52–65.\n",
      "Conrad, M.A., Kelsen, J.R., 2020. The treatment of pediatric inﬂammatory bowel disease\n",
      "with biologic therapies. Curr. Gastroenterol. Rep. 22 (8), 36–51.\n",
      "Csontos, A.A., Molnar, A., Piri, Z., Katona, B., Dako, S., Palﬁ, E., Miheller, P., 2016. The\n",
      "effect of anti-tnfalpha induction therapy on the nutritional status and dietary intake\n",
      "in inﬂammatory bowel disease. J Gastrointestin Liver Dis 25 (1), 49–56.\n",
      "Dai, Z.H., Xu, X.T., Ran, Z.H., 2020. Associations between obesity and the effectiveness of\n",
      "anti-tumor necrosis factor-alpha agents in inﬂammatory bowel disease patients: a\n",
      "literature review and meta-analysis. Ann. Pharmacother. 54 (8), 729–741.\n",
      "Danese, S., Colombel, J.F., Lukas, M., Gisbert, J.P., D’Haens, G., Hayee, B., Panaccione, R.,\n",
      "Kim, H.S., Reinisch, W., Tyrrell, H., Oh, Y.S., Tole, S., Chai, A., Chamberlain-\n",
      "James, K., Tang, M.T., Schreiber, S., Group, G.S., 2021. Etrolizumab versus inﬂiximab\n",
      "for the treatment of moderately to severely active ulcerative colitis (gardenia): a\n",
      "randomised, double-blind, double-dummy, phase 3 study. Lancet Gastroenterol\n",
      "Hepatol 7 (2), 118–127.\n",
      "Danese, S., Fiorino, G., Peyrin-Biroulet, L., Lucenteforte, E., Virgili, G., Moja, L.,\n",
      "Bonovas, S., 2014. Biological agents for moderately to severely active ulcerative\n",
      "colitis: a systematic review and network meta-analysis. Ann. Intern. Med. 160 (10),\n",
      "704–711.\n",
      "P. Juillerat et al.\n",
      "Current Research in Pharmacology and Drug Discovery 3 (2022) 100104\n",
      "6\n",
      "----------\n",
      "severely active ulcerative colitis: results from phase 3 \n",
      "U-ACCOMPLISH study. J Crohn’s Colitis 2021; 15 (suppl 1): S021–22.\n",
      "9 \n",
      "Thorlund K, Druyts E, Mills EJ, Fedorak RN, Marshall JK. \n",
      "Adalimumab versus infliximab for the treatment of moderate to \n",
      "severe ulcerative colitis in adult patients naïve to anti-TNF therapy: \n",
      "an indirect treatment comparison meta-analysis. J Crohn’s Colitis \n",
      "2014; 8: 571–81.\n",
      "10 \n",
      "Danese S, Fiorino G, Peyrin-Biroulet L, et al. Biological agents for \n",
      "moderately to severely active ulcerative colitis: a systematic review \n",
      "and network meta-analysis. Ann Intern Med 2014; 160: 704–11.\n",
      "11 \n",
      "Singh S, Fumery M, Sandborn WJ, Murad MH. Systematic review \n",
      "with network meta-analysis: first- and second-line pharmacotherapy \n",
      "for moderate-severe ulcerative colitis. Aliment Pharmacol Ther 2018; \n",
      "47: 162–75.\n",
      "12 \n",
      "Bonovas S, Lytras T, Nikolopoulos G, Peyrin-Biroulet L, Danese S. \n",
      "Systematic review with network meta-analysis: comparative \n",
      "assessment of tofacitinib and biological therapies for moderate-to-\n",
      "severe ulcerative colitis. Aliment Pharmacol Ther 2018; 47: 454–65.\n",
      "13 \n",
      "Singh S, Murad MH, Fumery M, Dulai PS, Sandborn WJ. First- and \n",
      "second-line pharmacotherapies for patients with moderate to \n",
      "severely active ulcerative colitis: an updated network meta-analysis. \n",
      "Clin Gastroenterol Hepatol 2020; 18: 2179–91.e6.\n",
      "14 \n",
      "Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting \n",
      "items for systematic reviews and meta-analyses: the PRISMA \n",
      "statement. Ann Intern Med 2009; 151: 264–69.\n",
      "15 \n",
      "Jansen JP, Fleurence R, Devine B, et al. Interpreting indirect \n",
      "treatment comparisons and network meta-analysis for health-care \n",
      "decision making: report of the ISPOR Task Force on Indirect \n",
      "Treatment Comparisons Good Research Practices: part 1. \n",
      "Value Health 2011; 14: 417–28.\n",
      "16 \n",
      "Sterne JAC, Savović J, Page MJ, et al. RoB 2: a revised tool for \n",
      "assessing risk of bias in randomised trials. BMJ 2019; 366: l4898.\n",
      "17 \n",
      "Rücker G, Schwarzer G. Ranking treatments in frequentist network \n",
      "meta-analysis works without resampling methods. \n",
      "BMC Med Res Methodol 2015; 15: 58.\n",
      "----------\n",
      "Therapeutic strategies for the management of recentlydiagnosedulcerative colitis. IMMs include thiopurines and methotrexate. 5-ASA, 5-amino salicylic acid; ASUC, acute severe ulcerative colitis; IPAA, ileal pouch anal anastomosis.\n",
      "\n",
      "Risk stratification: Mild\n",
      "Clinical features: NA\n",
      "Treatment options: 5-ASA (oral and/or topical)\n",
      "\n",
      "Risk stratification: Moderate\n",
      "Clinical features: NA\n",
      "Treatment options: Can consider 5-ASA (with rapid step-up if inadequate response)\n",
      "\n",
      "Risk stratification: Moderate\n",
      "Clinical features: NA\n",
      "Treatment options: VDZ or UST\n",
      "\n",
      "Risk stratification: Moderate\n",
      "Clinical features: NA\n",
      "Treatment options: Thiopurine\n",
      "\n",
      "Risk stratification: Moderate\n",
      "Clinical features: NA\n",
      "Treatment options: TNFi +/- IMM\n",
      "\n",
      "Risk stratification: Severe\n",
      "Clinical features: NA\n",
      "Treatment options: TNFi +/- IMM\n",
      "\n",
      "Risk stratification: Severe\n",
      "Clinical features: NA\n",
      "Treatment options: Subtotal colectomy + IPAA or cyclosporine (for ASUC)\n",
      "\n",
      "Risk stratification: Additional consideration: EIM present\n",
      "Clinical features: Psoriasis or psoriatic arthritis\n",
      "Treatment options: UST\n",
      "\n",
      "Risk stratification: Additional consideration: EIM present\n",
      "Clinical features: Other arthritis\n",
      "Treatment options: TNFi\n",
      "\n",
      "\n",
      "----------\n",
      "Articles\n",
      "www.thelancet.com/gastrohep   Vol 7   February 2022 \n",
      "161\n",
      "Lancet Gastroenterol Hepatol \n",
      "2022; 7: 161–70\n",
      "Published Online \n",
      "November 29, 2021 \n",
      "https://doi.org/10.1016/ \n",
      "S2468-1253(21)00377-0\n",
      "See Comment page 110\n",
      "*Contributed equally\n",
      "Inflammatory Bowel Disease \n",
      "Unit, Gastroenterology \n",
      "Section, Department of \n",
      "Internal Medicine, Centro de \n",
      "Educación Médica e \n",
      "Investigaciones Clínicas, \n",
      "Buenos Aires, Argentina \n",
      "(J S Lasa MD, P A Olivera MD); \n",
      "Gastroenterology Department, \n",
      "Hospital Británico de Buenos \n",
      "Aires, Buenos Aires, Argentina \n",
      "(J S Lasa); Zane Cohen Centre \n",
      "for Digestive Diseases, \n",
      "Lunenfeld-Tanenbaum \n",
      "Research Institute, Sinai Health \n",
      "System, Toronto, ON, Canada \n",
      "(P A Olivera); Division of \n",
      "Gastroenterology, Mount Sinai \n",
      "Hospital, University of Toronto, \n",
      "Toronto, ON, Canada \n",
      "(P A Olivera); Gastroenterology \n",
      "and Endoscopy, IRCCS Ospedale \n",
      "San Raffaele and University \n",
      "Vita-Salute San Raffaele, \n",
      "Milano, Italy \n",
      "(Prof S Danese MD); INSERM \n",
      "NGERE and Department of \n",
      "Hepatogastroenterology, \n",
      "Nancy University Hospital, \n",
      "Lorraine University, \n",
      "Vandoeuvre-lés-Nancy, France \n",
      "(Prof L Peyrin-Biroulet MD) \n",
      "Correspondence to: \n",
      "Prof Laurent Peyrin-Biroulet, \n",
      "INSERM NGERE and Department \n",
      "of Hepatogastroenterology, \n",
      "Nancy University Hospital, \n",
      "Lorraine University, Vandoeuvre-\n",
      "lès-Nancy F-54511, France \n",
      "peyrinbiroulet@gmail.com\n",
      "Efficacy and safety of biologics and small molecule drugs for \n",
      "patients with moderate-to-severe ulcerative colitis: \n",
      "a systematic review and network meta-analysis \n",
      "Juan S Lasa*, Pablo A Olivera*, Silvio Danese, Laurent Peyrin-Biroulet\n",
      "Summary\n",
      "Background There is a growing armamentarium for the treatment of moderate-to-severe ulcerative colitis. We aimed \n",
      "to compare the relative efficacy and safety of biologics and small molecule drugs for the treatment of patients with \n",
      "moderate-to-severe ulcerative colitis.\n",
      "Methods In this systematic review and network meta-analysis, we searched MEDLINE, Embase, and the Cochrane \n",
      "Central Register of Controlled Trials without language restrictions for articles published between Jan 1, 1990, and \n",
      "July 1, 2021. Major congresses’ databases from Jan 1, 2018, to July 3, 2021, were reviewed manually. Phase 3, placebo-\n",
      "controlled or head-to-head randomised controlled trials (RCTs) assessing the efficacy and safety of biologics or small \n",
      "molecule drugs as induction or maintenance therapies for patients with moderate-to-severe ulcerative colitis were\n",
      "==========\n",
      "ORIGINAL QUESTION: ANALYSE the given patient profile based on given query based on one of the following criteria:\n",
      "- Whether treated patient is new patient or patient under maintenance\n",
      "- Prior response to Infliximab\n",
      "- Prior failure to Anti-TNF agents\n",
      "- Prior failure to Vedolizumab\n",
      "- Age\n",
      "- Pregnancy\n",
      "- Extraintestinale manifestations\n",
      "- Pouchitis\n",
      "RETURN up to 2 TOP choices of biological drugs given patient profile and context. Explain the PROS and CONS of the 2 choices.\n",
      "PATIENT PROFILE: 55 year-old man with moderate to severe extensive ulcerative colitis and colonic polyps with high grade dysplasia found 2 years ago.\n",
      "\n",
      "==========\n",
      "CURRENT ANSWER:\n",
      "Based on the given patient profile, the patient is not new and is under maintenance for moderate to severe ulcerative colitis. The patient's age is 55 years old. There is no information provided about prior response to Infliximab, prior failure to Anti-TNF agents, prior failure to Vedolizumab, pregnancy, extraintestinal manifestations, or pouchitis.\n",
      "\n",
      "Given the patient's profile, the top two choices of biological drugs could be:\n",
      "\n",
      "1. Infliximab\n",
      "Advantages: Infliximab has demonstrated efficacy in clinical trials in moderate to severe UC. It targets the pro-inflammatory cytokine tumour necrosis factor-α (TNF-α), which is involved in the inflammation process in UC.\n",
      "Disadvantages: Infliximab may not work in all patients and there may be risks associated with its use, such as serious infections, malignancies, or heart failure. It is also administered either intravenously, which may be inconvenient for some patients.\n",
      "\n",
      "2. Vedolizumab\n",
      "Advantages: Vedolizumab targets α or β integrins, which are involved in migration of immune cells to inflamed intestinal mucosa. This makes it a good option for patients who have not responded to or cannot tolerate TNF-α inhibitors.\n",
      "Disadvantages: Vedolizumab may not work in all patients and there may be risks associated with its use, such as serious infections. It is also administered intravenously, which may be inconvenient for some patients.\n",
      "\n",
      "Please note that the choice of treatment should be individualized based on the patient's specific condition, preferences, and potential side effects of the drugs. The patient should have a detailed discussion with their healthcare provider to decide the best treatment option.\n",
      "==========\n",
      "REFINED ANSWER:\n",
      "\u001b[0m\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "Retrying langchain.chat_models.openai.ChatOpenAI.completion_with_retry.<locals>._completion_with_retry in 4.0 seconds as it raised RateLimitError: Rate limit reached for 10KTPM-200RPM in organization org-ETbTMTN2JXYOUPDJgxuH2iO6 on tokens per min. Limit: 10000 / min. Please try again in 6ms. Contact us through our help center at help.openai.com if you continue to have issues..\n",
      "Retrying langchain.chat_models.openai.ChatOpenAI.completion_with_retry.<locals>._completion_with_retry in 4.0 seconds as it raised RateLimitError: Rate limit reached for 10KTPM-200RPM in organization org-ETbTMTN2JXYOUPDJgxuH2iO6 on tokens per min. Limit: 10000 / min. Please try again in 6ms. Contact us through our help center at help.openai.com if you continue to have issues..\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\n",
      "\u001b[1m> Finished chain.\u001b[0m\n",
      "\n",
      "\u001b[1m> Finished chain.\u001b[0m\n",
      "2023-10-02 17:45:38,128:INFO: 6001 tokens were added to prompt from 10 documents\n",
      "Query: 27 year-old woman with moderate to severe extensive ulcerative colitis who prefers medication with oral formulation.\n",
      "\n",
      "\n",
      "\n",
      "\u001b[1m> Entering new SequentialChain chain...\u001b[0m\n",
      "\n",
      "\n",
      "\u001b[1m> Entering new RetrievalQAWithSourcesChain chain...\u001b[0m\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "Retrying langchain.chat_models.openai.ChatOpenAI.completion_with_retry.<locals>._completion_with_retry in 4.0 seconds as it raised RateLimitError: Rate limit reached for 10KTPM-200RPM in organization org-ETbTMTN2JXYOUPDJgxuH2iO6 on tokens per min. Limit: 10000 / min. Please try again in 6ms. Contact us through our help center at help.openai.com if you continue to have issues..\n",
      "Retrying langchain.chat_models.openai.ChatOpenAI.completion_with_retry.<locals>._completion_with_retry in 4.0 seconds as it raised RateLimitError: Rate limit reached for 10KTPM-200RPM in organization org-ETbTMTN2JXYOUPDJgxuH2iO6 on tokens per min. Limit: 10000 / min. Please try again in 6ms. Contact us through our help center at help.openai.com if you continue to have issues..\n",
      "Retrying langchain.chat_models.openai.ChatOpenAI.completion_with_retry.<locals>._completion_with_retry in 4.0 seconds as it raised RateLimitError: Rate limit reached for 10KTPM-200RPM in organization org-ETbTMTN2JXYOUPDJgxuH2iO6 on tokens per min. Limit: 10000 / min. Please try again in 6ms. Contact us through our help center at help.openai.com if you continue to have issues..\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\n",
      "\u001b[1m> Finished chain.\u001b[0m\n",
      "\n",
      "\n",
      "\u001b[1m> Entering new LLMChain chain...\u001b[0m\n",
      "Prompt after formatting:\n",
      "\u001b[32;1m\u001b[1;3mYou are a senior physician giving advice on treatment for moderate to severe ulcerative colitis (UC).\n",
      "Make reference to the CONTEXT given to assess the scenario.\n",
      "==========\n",
      "TASK: Your task is to analyse critically the CURRENT ANSWER given the CONTEXT.\n",
      "Then refine the existing answer (only if needed) based on the following instructions:\n",
      "- If no refinement needed, return the original answer in the correct output format.\n",
      "- If the answer cannot be inferred from CONTEXT, return \"NO ANSWER\".\n",
      "- The final output should be a list of up to 2 choices of biological drugs given patient profile and context and PROS/CONS for each recommendations.\n",
      "==========\n",
      "CONTEXT:\n",
      "Burr et al. \n",
      " \n",
      "7 of 45 \n",
      "INTRODUCTION \n",
      "  Ulcerative colitis (UC) is a chronic inflammatory disorder of the bowel that causes \n",
      "continuous mucosal inflammation commencing in the rectum and extending proximally for a \n",
      "variable extent.[1] It is estimated that UC affects 2.5 million people in Europe,[2] and the \n",
      "disease follows a relapsing and remitting course, with intermittent flares of disease activity, \n",
      "some of which may be moderate to severe. Management of these is medical, for the most \n",
      "part, with surgery reserved for patients with refractory disease. Although 5-aminosalicylates \n",
      "(5-ASAs) are efficacious for mild to moderate disease activity,[3-6] more severe flares are \n",
      "usually treated with corticosteroids.[7] However, these have potentially serious adverse \n",
      "effects and a substantial proportion of patients may become either dependent on them to \n",
      "maintain remission,[8] or refractory to them.[9] As a result, over the last 20 years novel \n",
      "drugs, with more precise modes of action, based on mechanisms of disease identified in \n",
      "genome wide association studies,[10] have been developed.  \n",
      "The first of these agents was infliximab, a drug targeting the pro-inflammatory \n",
      "cytokine tumour necrosis factor-α (TNF-α), which demonstrated efficacy in clinical trials in \n",
      "moderate to severe UC.[11] Since then, other drugs against TNF-α have been tested, such as \n",
      "adalimumab and golimumab.[12, 13] In addition, newer biological therapies targeting α or β \n",
      "integrins, which are involved in migration of immune cells to inflamed intestinal mucosa, \n",
      "such as vedolizumab or etrolizumab,[14, 15] or acting against other pro-inflammatory \n",
      "cytokines implicated in the pathogenesis of UC, such as ustekinumab,[16] have been tested. \n",
      "However, even these more selective drugs do not work in all patients, there may be risks \n",
      "associated with their use,[17-19] and the fact that they are administered either intravenously \n",
      "or subcutaneously, may be inconvenient for patients. The search for alternative agents for the \n",
      "treatment of UC has, therefore, continued.\n",
      "----------\n",
      "Burr et al. \n",
      " \n",
      "5 of 45 \n",
      "STUDY HIGHLIGHTS \n",
      " \n",
      "What is already known about this subject \n",
      "• Ulcerative colitis (UC) follows a relapsing and remitting course, with intermittent \n",
      "flares of disease activity, some of which may be moderate to severe. \n",
      "• These are usually treated with corticosteroids, which have potentially serious adverse \n",
      "effects, so biological therapies and small molecules have been developed and licensed \n",
      "for this indication.  \n",
      "• Although previous network meta-analyses have compared their efficacy and safety, \n",
      "this is a rapidly moving field, and there are already several newer drugs that have \n",
      "shown efficacy in phase III clinical trials that were not considered in these. \n",
      " \n",
      "What are the new findings \n",
      "• In terms of clinical remission and clinical response, upadacitinib 45mg o.d. ranked \n",
      "first in all patients, in patients previously exposed to anti-tumour necrosis factor \n",
      "(TNF)-α therapies, and in patients naïve to these drugs.  \n",
      "• In terms of endoscopic improvement infliximab 10mg/kg ranked first, followed by \n",
      "upadacitinib 45mg o.d., and infliximab 5mg/kg.  \n",
      "• However, for endoscopic improvement again upadacitinib 45mg o.d. ranked first in \n",
      "patients previously exposed to anti-TNF-α therapies, and in patients who were anti-\n",
      "TNF-α naïve.  \n",
      "• None of the drugs studied were more likely to lead to serious adverse events than \n",
      "placebo.\n",
      "----------\n",
      "severely active ulcerative colitis: results from phase 3 \n",
      "U-ACCOMPLISH study. J Crohn’s Colitis 2021; 15 (suppl 1): S021–22.\n",
      "9 \n",
      "Thorlund K, Druyts E, Mills EJ, Fedorak RN, Marshall JK. \n",
      "Adalimumab versus infliximab for the treatment of moderate to \n",
      "severe ulcerative colitis in adult patients naïve to anti-TNF therapy: \n",
      "an indirect treatment comparison meta-analysis. J Crohn’s Colitis \n",
      "2014; 8: 571–81.\n",
      "10 \n",
      "Danese S, Fiorino G, Peyrin-Biroulet L, et al. Biological agents for \n",
      "moderately to severely active ulcerative colitis: a systematic review \n",
      "and network meta-analysis. Ann Intern Med 2014; 160: 704–11.\n",
      "11 \n",
      "Singh S, Fumery M, Sandborn WJ, Murad MH. Systematic review \n",
      "with network meta-analysis: first- and second-line pharmacotherapy \n",
      "for moderate-severe ulcerative colitis. Aliment Pharmacol Ther 2018; \n",
      "47: 162–75.\n",
      "12 \n",
      "Bonovas S, Lytras T, Nikolopoulos G, Peyrin-Biroulet L, Danese S. \n",
      "Systematic review with network meta-analysis: comparative \n",
      "assessment of tofacitinib and biological therapies for moderate-to-\n",
      "severe ulcerative colitis. Aliment Pharmacol Ther 2018; 47: 454–65.\n",
      "13 \n",
      "Singh S, Murad MH, Fumery M, Dulai PS, Sandborn WJ. First- and \n",
      "second-line pharmacotherapies for patients with moderate to \n",
      "severely active ulcerative colitis: an updated network meta-analysis. \n",
      "Clin Gastroenterol Hepatol 2020; 18: 2179–91.e6.\n",
      "14 \n",
      "Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting \n",
      "items for systematic reviews and meta-analyses: the PRISMA \n",
      "statement. Ann Intern Med 2009; 151: 264–69.\n",
      "15 \n",
      "Jansen JP, Fleurence R, Devine B, et al. Interpreting indirect \n",
      "treatment comparisons and network meta-analysis for health-care \n",
      "decision making: report of the ISPOR Task Force on Indirect \n",
      "Treatment Comparisons Good Research Practices: part 1. \n",
      "Value Health 2011; 14: 417–28.\n",
      "16 \n",
      "Sterne JAC, Savović J, Page MJ, et al. RoB 2: a revised tool for \n",
      "assessing risk of bias in randomised trials. BMJ 2019; 366: l4898.\n",
      "17 \n",
      "Rücker G, Schwarzer G. Ranking treatments in frequentist network \n",
      "meta-analysis works without resampling methods. \n",
      "BMC Med Res Methodol 2015; 15: 58.\n",
      "----------\n",
      "SYSTEMATIC REVIEWS AND META-ANALYSES\n",
      "Siddharth Singh, Section Editor\n",
      "First- and Second-Line Pharmacotherapies for Patients With\n",
      "Moderate to Severely Active Ulcerative Colitis: An Updated\n",
      "Network Meta-Analysis\n",
      "Siddharth Singh,*,‡ Mohammad Hassan Murad,§ Mathurin Fumery,j\n",
      "Parambir S. Dulai,* and William J. Sandborn*\n",
      "*Division of Gastroenterology, ‡Division of Biomedical Informatics, University of California San Diego, La Jolla, California;\n",
      "§Robert D and Patricia E Kern Center for the Science of Health Care Delivery, Mayo Clinic, Rochester, Minnesota;\n",
      "||Gastroenterology Unit, Peritox UMR I-0I, Amiens University and Hospital, Université de Picardie Jules Verne, Amiens, France\n",
      "BACKGROUND & AIMS:\n",
      "We compared the efﬁcacy and safety of different ﬁrst-line (biologic-naïve) and second-line\n",
      "(prior exposure to tumor necrosis factor [TNF] antagonists) agents for treatment of moder-\n",
      "ate to severely active ulcerative colitis in a systematic review and network meta-analysis.\n",
      "METHODS:\n",
      "We searched publication databases through September 30, 2019, for randomized trials of\n",
      "adults with moderate to severe ulcerative colitis treated with TNF antagonists, vedolizumab,\n",
      "tofacitinib, or ustekinumab, as ﬁrst-line or second-line agents, compared with placebo or\n",
      "another active agent. Efﬁcacy outcomes were induction and maintenance of remission and\n",
      "endoscopic improvement; safety outcomes were serious adverse events and infections. We\n",
      "performed a ﬁxed-effects network meta-analysis using the frequentist approach, and calculated\n",
      "odds ratios (ORs) and 95% CI values. Agents were ranked using surface under the cumulative\n",
      "ranking (SUCRA) probabilities. Overall quality of evidence was rated using GRADE (Grading of\n",
      "Recommendations, Assessment, Development and Evaluation).\n",
      "RESULTS:\n",
      "In biologic-naïve patients, inﬂiximab was ranked highest for induction of clinical remission (OR\n",
      "vs placebo, 4.07; 95% CI, 2.67–6.21; SUCRA, 0.95) and endoscopic improvement (SUCRA, 0.95)\n",
      "(moderate conﬁdence in estimates [CE]). In patients with prior exposure to TNF antagonists,\n",
      "ustekinumab (SUCRA, 0.87) and tofacitinib (SUCRA, 0.87) were ranked highest for induction of\n",
      "clinical remission and were superior to vedolizumab (ustekinumab vs vedolizumab: OR, 5.99;\n",
      "95% CI, 1.13–31.76 and tofacitinib vs vedolizumab: OR, 6.18; 95% CI, 1.003–8.00; moderate CE)\n",
      "and adalimumab (ustekinumab vs adalimumab: OR, 10.71; 95% CI, 2.01–57.20 and tofacitinib\n",
      "----------\n",
      "discontinuation due to AEs, and serious infections. Phase 3 randomized controlled trials were identified via systematic literature review, in-\n",
      "cluding the following advanced therapies: infliximab, adalimumab, vedolizumab, golimumab, tofacitinib, ustekinumab, filgotinib, ozanimod, and \n",
      "upadacitinib. Random effects models were used to address between-study heterogeneity. Intent-to-treat (ITT) efficacy rates were calculated by \n",
      "adjusting maintenance outcomes by likelihood of induction response.\n",
      "Results:  Out of 48 trials identified, 23 were included. Across all outcomes and regardless of prior biologic exposure, ITT efficacy rates were \n",
      "highest for upadacitinib, owing to its highest ranking for all efficacy outcomes in induction and for all but clinical remission during maintenance \n",
      "among bio-naive induction responders. For all advanced therapies versus placebo, there were no significant differences in serious AEs or \n",
      "serious infections across therapies. For all AEs, golimumab had higher odds versus placebo during maintenance; for discontinuation due to \n",
      "AEs, upadacitinib had lower odds versus placebo during induction, while ustekinumab and vedolizumab had lower odds versus placebo during \n",
      "maintenance.\n",
      "Conclusions:  Upadacitinib may be the most efficacious therapy for moderately to severely active UC based on ITT analyses, with similar safety \n",
      "across advanced therapies.\n",
      "Lay Summary \n",
      "Indirect evidence suggests upadacitinib may be more efficacious than other advanced therapies at achieving clinical response, clinical remis-\n",
      "sion, and endoscopic response over 1 year for moderately to severely active ulcerative colitis patients, with similar safety assessments across \n",
      "advanced therapies.\n",
      "Key Words: ulcerative colitis, clinical trials, advanced therapies, network meta-analysis\n",
      "Introduction\n",
      "Ulcerative colitis (UC) is a chronic inflammatory bowel dis-\n",
      "ease that affects the colorectum and is clinically characterized \n",
      "by bloody diarrhea, urgency, tenesmus, abdominal pain, ma-\n",
      "laise, weight loss, and fever. Disease onset commonly occurs \n",
      "between the ages of 15 and 30 years and the annual global \n",
      "© The Author(s) 2023. Published by Oxford University Press on behalf of Crohn's & Colitis Foundation.\n",
      "This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), \n",
      "which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.\n",
      "----------\n",
      "41 years (interquartile range, 40–42 y), and 60%\n",
      "(interquartile range, 56%–63%) were men. The median\n",
      "disease duration was 6.7 years (interquartile range,\n",
      "6.0–7.8 y), and 49% (interquartile range, 46%–55%) of\n",
      "patients had extensive colitis. A median of 40% (inter-\n",
      "quartile range, 30%–50%) of patients were treated with\n",
      "concomitant immunomodulators, and 51% (interquartile\n",
      "range, 45%–57%) were on corticosteroids at baseline.\n",
      "Patients across all trials and treatment arms were com-\n",
      "parable in terms of baseline prognostic variables, inclu-\n",
      "sion/exclusion\n",
      "criteria,\n",
      "and\n",
      "co-interventions.\n",
      "All\n",
      "outcomes were assessed uniformly based on the stan-\n",
      "dard deﬁnition of the Mayo Clinic score, between weeks\n",
      "6 and 10 for induction therapy (inﬂiximab, adalimumab,\n",
      "tofacitinib, ustekinumab, 8 weeks; golimumab, 6 weeks;\n",
      "vedolizumab, 6 weeks, 10 weeks, and 14 weeks in\n",
      "VARSITY),6 and weeks 30, 54, or 60 for maintenance\n",
      "therapy;\n",
      "endoscopy\n",
      "was\n",
      "read\n",
      "by\n",
      "blinded\n",
      "local\n",
      "Table 2. Comparative Efﬁcacy of Pharmacologic Agents for Induction of Clinical Remission and Endoscopic Improvement in Biologic-Naive Patients With Moderate–Severe\n",
      "Ulcerative Colitis Using Network Meta-Analysis\n",
      "Induction of clinical remission\n",
      "Induction of endoscopic improvement\n",
      "Ustekinumab 6 mg/kg\n",
      "0.96 (0.38–2.45)\n",
      "0.80 (0.35–1.83)\n",
      "0.73 (0.31–1.74)\n",
      "1.05 (0.48–2.32)\n",
      "0.50 (0.22–1.12)\n",
      "2.04 (1.03–4.05)\n",
      "0.92 (0.45–1.89)\n",
      "Tofacitinib 10 mg b.d.\n",
      "0.84 (0.39–1.82)\n",
      "0.76 (0.33–1.76)\n",
      "1.10 (0.51–2.34)\n",
      "0.52 (0.24–1.12)\n",
      "2.12 (1.12–4.02)\n",
      "0.74 (0.36–1.51)\n",
      "0.80 (0.4–1.62)\n",
      "Vedolizumab\n",
      "0.91 (0.44–1.86)\n",
      "1.31 (0.88–1.95)\n",
      "0.62 (0.34–1.15)\n",
      "2.54 (1.60–4.02)\n",
      "1.07 (0.58–1.98)\n",
      "1.17 (0.64–2.12)\n",
      "1.45 (0.80–2.61)\n",
      "Golimumab\n",
      "1.44 (0.76–2.75)\n",
      "0.69 (0.35–1.36)\n",
      "2.79 (1.64–4.02)\n",
      "1.17 (0.65–2.13)\n",
      "1.28 (0.72–2.29)\n",
      "1.59 (0.90–2.82)\n",
      "1.10 (0.71–1.71)\n",
      "Adalimumab\n",
      "0.48 (0.26–0.86)\n",
      "1.94 (1.30–2.88)\n",
      "0.56 (0.30–1.04)\n",
      "0.61 (0.34–1.11)\n",
      "0.76 (0.42–1.37)\n",
      "0.52 (0.33–0.83)\n",
      "0.48 (0.31–0.74)\n",
      "Inﬂiximab\n",
      "4.07 (2.67–6.21)\n",
      "1.86 (1.11–3.13)\n",
      "2.03 (1.23–3.34)\n",
      "2.52 (1.54–4.11)\n",
      "1.74 (1.25–2.41)\n",
      "1.58 (1.18–2.13)\n",
      "3.32 (2.39–4.60)\n",
      "Placebo\n",
      "NOTE. Comparisons should be read from left to right. Odds ratio for comparisons are in the cell in common between the column-deﬁning and row-deﬁning treatment. Numbers in bold are statistically signiﬁcant. For induction of\n",
      "clinical remission, an odds ratio greater than 1 favors row-deﬁning treatment. For induction of endoscopic improvement, an odds ratio greater than 1 favors column-deﬁning treatment. Numbers in parentheses indicate 95% CI.\n",
      "b.d., twice daily.\n",
      "----------\n",
      "Therapeutic strategies for the management of recentlydiagnosedulcerative colitis. IMMs include thiopurines and methotrexate. 5-ASA, 5-amino salicylic acid; ASUC, acute severe ulcerative colitis; IPAA, ileal pouch anal anastomosis.\n",
      "\n",
      "Risk stratification: Mild\n",
      "Clinical features: NA\n",
      "Treatment options: 5-ASA (oral and/or topical)\n",
      "\n",
      "Risk stratification: Moderate\n",
      "Clinical features: NA\n",
      "Treatment options: Can consider 5-ASA (with rapid step-up if inadequate response)\n",
      "\n",
      "Risk stratification: Moderate\n",
      "Clinical features: NA\n",
      "Treatment options: VDZ or UST\n",
      "\n",
      "Risk stratification: Moderate\n",
      "Clinical features: NA\n",
      "Treatment options: Thiopurine\n",
      "\n",
      "Risk stratification: Moderate\n",
      "Clinical features: NA\n",
      "Treatment options: TNFi +/- IMM\n",
      "\n",
      "Risk stratification: Severe\n",
      "Clinical features: NA\n",
      "Treatment options: TNFi +/- IMM\n",
      "\n",
      "Risk stratification: Severe\n",
      "Clinical features: NA\n",
      "Treatment options: Subtotal colectomy + IPAA or cyclosporine (for ASUC)\n",
      "\n",
      "Risk stratification: Additional consideration: EIM present\n",
      "Clinical features: Psoriasis or psoriatic arthritis\n",
      "Treatment options: UST\n",
      "\n",
      "Risk stratification: Additional consideration: EIM present\n",
      "Clinical features: Other arthritis\n",
      "Treatment options: TNFi\n",
      "\n",
      "\n",
      "----------\n",
      "Articles\n",
      "www.thelancet.com/gastrohep   Vol 7   February 2022 \n",
      "161\n",
      "Lancet Gastroenterol Hepatol \n",
      "2022; 7: 161–70\n",
      "Published Online \n",
      "November 29, 2021 \n",
      "https://doi.org/10.1016/ \n",
      "S2468-1253(21)00377-0\n",
      "See Comment page 110\n",
      "*Contributed equally\n",
      "Inflammatory Bowel Disease \n",
      "Unit, Gastroenterology \n",
      "Section, Department of \n",
      "Internal Medicine, Centro de \n",
      "Educación Médica e \n",
      "Investigaciones Clínicas, \n",
      "Buenos Aires, Argentina \n",
      "(J S Lasa MD, P A Olivera MD); \n",
      "Gastroenterology Department, \n",
      "Hospital Británico de Buenos \n",
      "Aires, Buenos Aires, Argentina \n",
      "(J S Lasa); Zane Cohen Centre \n",
      "for Digestive Diseases, \n",
      "Lunenfeld-Tanenbaum \n",
      "Research Institute, Sinai Health \n",
      "System, Toronto, ON, Canada \n",
      "(P A Olivera); Division of \n",
      "Gastroenterology, Mount Sinai \n",
      "Hospital, University of Toronto, \n",
      "Toronto, ON, Canada \n",
      "(P A Olivera); Gastroenterology \n",
      "and Endoscopy, IRCCS Ospedale \n",
      "San Raffaele and University \n",
      "Vita-Salute San Raffaele, \n",
      "Milano, Italy \n",
      "(Prof S Danese MD); INSERM \n",
      "NGERE and Department of \n",
      "Hepatogastroenterology, \n",
      "Nancy University Hospital, \n",
      "Lorraine University, \n",
      "Vandoeuvre-lés-Nancy, France \n",
      "(Prof L Peyrin-Biroulet MD) \n",
      "Correspondence to: \n",
      "Prof Laurent Peyrin-Biroulet, \n",
      "INSERM NGERE and Department \n",
      "of Hepatogastroenterology, \n",
      "Nancy University Hospital, \n",
      "Lorraine University, Vandoeuvre-\n",
      "lès-Nancy F-54511, France \n",
      "peyrinbiroulet@gmail.com\n",
      "Efficacy and safety of biologics and small molecule drugs for \n",
      "patients with moderate-to-severe ulcerative colitis: \n",
      "a systematic review and network meta-analysis \n",
      "Juan S Lasa*, Pablo A Olivera*, Silvio Danese, Laurent Peyrin-Biroulet\n",
      "Summary\n",
      "Background There is a growing armamentarium for the treatment of moderate-to-severe ulcerative colitis. We aimed \n",
      "to compare the relative efficacy and safety of biologics and small molecule drugs for the treatment of patients with \n",
      "moderate-to-severe ulcerative colitis.\n",
      "Methods In this systematic review and network meta-analysis, we searched MEDLINE, Embase, and the Cochrane \n",
      "Central Register of Controlled Trials without language restrictions for articles published between Jan 1, 1990, and \n",
      "July 1, 2021. Major congresses’ databases from Jan 1, 2018, to July 3, 2021, were reviewed manually. Phase 3, placebo-\n",
      "controlled or head-to-head randomised controlled trials (RCTs) assessing the efficacy and safety of biologics or small \n",
      "molecule drugs as induction or maintenance therapies for patients with moderate-to-severe ulcerative colitis were\n",
      "----------\n",
      "disease); ozanimod as an oral alternative\n",
      "• Infliximab, preferably in combination with  \n",
      " immunomodulators (severe disease,  \n",
      " \n",
      " extraintestinal manifestations)\n",
      "• Ustekinumab (for patients with substantial \n",
      " comorbidities or  contraindications to TNF  \n",
      " antagonists)\n",
      "First-line therapy\n",
      "• TNF antagonists: infliximab or adalimumab,  \n",
      " preferably in combination with   \n",
      " \n",
      " \n",
      " immunomodulators\n",
      "• Risankizumab or ustekinumab (for patients  \n",
      " with substantial comorbidities or  \n",
      " \n",
      " \n",
      " contraindications to TNF antagonists)\n",
      "First-line therapy\n",
      "• Vedolizumab\n",
      "• Ustekinumab\n",
      "First-line therapy\n",
      "• Risankizumab or ustekinumab\n",
      "• Vedolizumab\n",
      "Moderate-to-severely active\n",
      "ulcerative colitis\n",
      "Moderate-to-severely active\n",
      "ulcerative colitis\n",
      "Moderate-to-severely active\n",
      "Crohn's disease\n",
      "Moderate-to-severely active\n",
      "Crohn's disease\n",
      "Second-line therapy\n",
      "• Upadacitinib (or tofacitinib) (for patients with  \n",
      " prior failure of infliximab)\n",
      "• Infliximab or ustekinumab (for patients with  \n",
      " prior exposure to vedolizumab)\n",
      "• Vedolizumab (moderate disease, for patients  \n",
      " who discontinued first-line biologic agent \n",
      " for intolerance)\n",
      "Second-line therapy (in patients with prior \n",
      "exposure to infliximab or adalimumab)\n",
      "• Risankizumab or ustekinumab\n",
      "• Second TNF antagonist (for patients with  \n",
      " loss of response owing to immunogenicity,  \n",
      " or  intolerance, to first TNF antagonist)\n",
      "Second-line therapy\n",
      "• Ozanimod\n",
      "• Infliximab monotherapy\n",
      "• Upadacitinib (or tofacitinib)\n",
      "Second-line therapy\n",
      "• Infliximab or adalimumab   \n",
      " monotherapy\n",
      "Risk averse\n",
      "• Prior serious infections\n",
      "• Prior malignancy\n",
      "• Older age, multiple comorbidities\n",
      "Severe disease\n",
      "• High structural damage\n",
      "• High inflammatory burden\n",
      "• Significant efect on quality of life\n",
      "Patients’ values and preferences\n",
      "(lifestyle and logistics, speed of onset, costs)\n",
      "Fig. 1 | Proposed treatment algorithm for patients with moderate-to-severe \n",
      "Crohn’s disease and moderate-to-severe ulcerative colitis. The algorithm \n",
      "integrates data on comparative effectiveness and safety of therapies in the \n",
      "context of an individual patient’s risk of disease-related and treatment-related \n",
      "complications. TNF, tumour necrosis factor. Adapted with permission from  \n",
      "ref. 10, Elsevier.\n",
      "----------\n",
      "micronutrients in diet, as well as food additives, processing,\n",
      "and packaging.104 Currently, there is no recommendation\n",
      "for whole foods–based management of IBD, but future\n",
      "studies will delineate this further.\n",
      "Early Therapy of Ulcerative Colitis\n",
      "In UC, mild disease can be managed with oral and/or\n",
      "topical mesalamine therapy, generally with adequate con-\n",
      "trol of disease.38 For moderate UC, VDZ and UST are effec-\n",
      "tive options,105,106 and may be better ﬁrst-choice options\n",
      "than TNFi, given safety proﬁle. In the VARSITY trial, the only\n",
      "head-to-head trial of 2 biologics (n ¼ 769), VDZ was supe-\n",
      "rior to ADA in achieving clinical remission (31.3% vs 22.5%;\n",
      "P ¼ .006) and endoscopic improvement (39.7% vs 27.7%; P\n",
      "< .001) in moderate to severe UC.105 In case VDZ or UST\n",
      "may not be feasible due to payer preference, TNFi, partic-\n",
      "ularly IFX, is an effective option with good safety proﬁle.107\n",
      "Thiopurines may be considered in moderate UC after\n",
      "weighing risks against beneﬁts.64 In patients with severe UC\n",
      "requiring hospitalization, IFX is the preferred biologic for\n",
      "induction and maintenance of remission, with or without\n",
      "IMM. Combination therapy in the SUCCESS trial was asso-\n",
      "ciated with improved clinical, but not endoscopic, outcomes\n",
      "compared to IFX monotherapy.108 When using IFX as a\n",
      "monotherapy in moderate to severe UC, given the potential\n",
      "for the colon to act as a “sink” for drugs, we advocate for\n",
      "checking early drug concentrations to ensure proper dosing\n",
      "and detecting immunogenicity early along with other\n",
      "pharmacokinetic and safety-related variables.109 There is no\n",
      "clear beneﬁt of concomitant mesalamine with biologic\n",
      "therapy in UC and it can be stopped in patients escalating to\n",
      "biologics.110 Some patients may present with acute severe\n",
      "UC\n",
      "where\n",
      "TNFi,\n",
      "cyclosporine,\n",
      "or\n",
      "subtotal\n",
      "colectomy\n",
      "followed by ileal pouch anal anastomosis can be a good\n",
      "initial strategy; discussion of management of acute severe\n",
      "UC is beyond the scope of this article.\n",
      "Taking Extraintestinal Manifestation Into\n",
      "Consideration\n",
      "EIMs are common in IBD, estimated to affect 30%–40% of\n",
      "patients.111,112 In a Swiss cohort study, symptoms of EIMs\n",
      "before IBD in one-quarter of the patients113; collaboration\n",
      "across specialties, including but not limited to rheumatolo-\n",
      "gists, dermatologists, ophthalmologists, is vital not only to\n",
      "prompt referral of patients with EIM suspicious for IBD to\n",
      "allow for expedient initiation of therapy for both conditions,\n",
      "but also to allow for consideration of both in the selection of\n",
      "==========\n",
      "ORIGINAL QUESTION: ANALYSE the given patient profile based on given query based on one of the following criteria:\n",
      "- Whether treated patient is new patient or patient under maintenance\n",
      "- Prior response to Infliximab\n",
      "- Prior failure to Anti-TNF agents\n",
      "- Prior failure to Vedolizumab\n",
      "- Age\n",
      "- Pregnancy\n",
      "- Extraintestinale manifestations\n",
      "- Pouchitis\n",
      "RETURN up to 2 TOP choices of biological drugs given patient profile and context. Explain the PROS and CONS of the 2 choices.\n",
      "PATIENT PROFILE: 27 year-old woman with moderate to severe extensive ulcerative colitis who prefers medication with oral formulation.\n",
      "\n",
      "==========\n",
      "CURRENT ANSWER:\n",
      "Based on the given patient profile, the top two choices of biological drugs would be:\n",
      "\n",
      "1. Upadacitinib\n",
      "Advantages: Upadacitinib has shown high efficacy rates in treating moderate to severe ulcerative colitis, both in induction and maintenance of remission. It is administered orally, which aligns with the patient's preference. It has also shown good results in patients previously exposed to anti-TNF-α therapies.\n",
      "Disadvantages: Although it has a good safety profile, there may be risks associated with its use, such as serious infections. It may also lead to discontinuation due to adverse events.\n",
      "\n",
      "2. Tofacitinib\n",
      "Advantages: Tofacitinib is another oral medication that has shown efficacy in treating moderate to severe ulcerative colitis. It has been effective in inducing and maintaining remission.\n",
      "Disadvantages: Tofacitinib may have potential side effects, including serious infections. It may also not be as effective in patients who have had prior exposure to anti-TNF-α therapies.\n",
      "\n",
      "Please note that the choice of medication should be made in consultation with the patient, taking into account her medical history, potential side effects, and her personal preferences.\n",
      "==========\n",
      "REFINED ANSWER:\n",
      "\u001b[0m\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "Retrying langchain.chat_models.openai.ChatOpenAI.completion_with_retry.<locals>._completion_with_retry in 4.0 seconds as it raised RateLimitError: Rate limit reached for 10KTPM-200RPM in organization org-ETbTMTN2JXYOUPDJgxuH2iO6 on tokens per min. Limit: 10000 / min. Please try again in 6ms. Contact us through our help center at help.openai.com if you continue to have issues..\n",
      "Retrying langchain.chat_models.openai.ChatOpenAI.completion_with_retry.<locals>._completion_with_retry in 4.0 seconds as it raised RateLimitError: Rate limit reached for 10KTPM-200RPM in organization org-ETbTMTN2JXYOUPDJgxuH2iO6 on tokens per min. Limit: 10000 / min. Please try again in 6ms. Contact us through our help center at help.openai.com if you continue to have issues..\n",
      "Retrying langchain.chat_models.openai.ChatOpenAI.completion_with_retry.<locals>._completion_with_retry in 4.0 seconds as it raised RateLimitError: Rate limit reached for 10KTPM-200RPM in organization org-ETbTMTN2JXYOUPDJgxuH2iO6 on tokens per min. Limit: 10000 / min. Please try again in 6ms. Contact us through our help center at help.openai.com if you continue to have issues..\n",
      "Retrying langchain.chat_models.openai.ChatOpenAI.completion_with_retry.<locals>._completion_with_retry in 8.0 seconds as it raised RateLimitError: Rate limit reached for 10KTPM-200RPM in organization org-ETbTMTN2JXYOUPDJgxuH2iO6 on tokens per min. Limit: 10000 / min. Please try again in 6ms. Contact us through our help center at help.openai.com if you continue to have issues..\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\n",
      "\u001b[1m> Finished chain.\u001b[0m\n",
      "\n",
      "\u001b[1m> Finished chain.\u001b[0m\n",
      "2023-10-02 17:46:47,467:INFO: 5861 tokens were added to prompt from 10 documents\n",
      "Query: 41 year-old man with moderate to severe distal ulcerative colitis and alocpecia areata.\n",
      "\n",
      "\n",
      "\n",
      "\u001b[1m> Entering new SequentialChain chain...\u001b[0m\n",
      "\n",
      "\n",
      "\u001b[1m> Entering new RetrievalQAWithSourcesChain chain...\u001b[0m\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "Retrying langchain.chat_models.openai.ChatOpenAI.completion_with_retry.<locals>._completion_with_retry in 4.0 seconds as it raised RateLimitError: Rate limit reached for 10KTPM-200RPM in organization org-ETbTMTN2JXYOUPDJgxuH2iO6 on tokens per min. Limit: 10000 / min. Please try again in 6ms. Contact us through our help center at help.openai.com if you continue to have issues..\n",
      "Retrying langchain.chat_models.openai.ChatOpenAI.completion_with_retry.<locals>._completion_with_retry in 4.0 seconds as it raised RateLimitError: Rate limit reached for 10KTPM-200RPM in organization org-ETbTMTN2JXYOUPDJgxuH2iO6 on tokens per min. Limit: 10000 / min. Please try again in 6ms. Contact us through our help center at help.openai.com if you continue to have issues..\n",
      "Retrying langchain.chat_models.openai.ChatOpenAI.completion_with_retry.<locals>._completion_with_retry in 4.0 seconds as it raised RateLimitError: Rate limit reached for 10KTPM-200RPM in organization org-ETbTMTN2JXYOUPDJgxuH2iO6 on tokens per min. Limit: 10000 / min. Please try again in 6ms. Contact us through our help center at help.openai.com if you continue to have issues..\n",
      "Retrying langchain.chat_models.openai.ChatOpenAI.completion_with_retry.<locals>._completion_with_retry in 8.0 seconds as it raised RateLimitError: Rate limit reached for 10KTPM-200RPM in organization org-ETbTMTN2JXYOUPDJgxuH2iO6 on tokens per min. Limit: 10000 / min. Please try again in 6ms. Contact us through our help center at help.openai.com if you continue to have issues..\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\n",
      "\u001b[1m> Finished chain.\u001b[0m\n",
      "\n",
      "\n",
      "\u001b[1m> Entering new LLMChain chain...\u001b[0m\n",
      "Prompt after formatting:\n",
      "\u001b[32;1m\u001b[1;3mYou are a senior physician giving advice on treatment for moderate to severe ulcerative colitis (UC).\n",
      "Make reference to the CONTEXT given to assess the scenario.\n",
      "==========\n",
      "TASK: Your task is to analyse critically the CURRENT ANSWER given the CONTEXT.\n",
      "Then refine the existing answer (only if needed) based on the following instructions:\n",
      "- If no refinement needed, return the original answer in the correct output format.\n",
      "- If the answer cannot be inferred from CONTEXT, return \"NO ANSWER\".\n",
      "- The final output should be a list of up to 2 choices of biological drugs given patient profile and context and PROS/CONS for each recommendations.\n",
      "==========\n",
      "CONTEXT:\n",
      "41 years (interquartile range, 40–42 y), and 60%\n",
      "(interquartile range, 56%–63%) were men. The median\n",
      "disease duration was 6.7 years (interquartile range,\n",
      "6.0–7.8 y), and 49% (interquartile range, 46%–55%) of\n",
      "patients had extensive colitis. A median of 40% (inter-\n",
      "quartile range, 30%–50%) of patients were treated with\n",
      "concomitant immunomodulators, and 51% (interquartile\n",
      "range, 45%–57%) were on corticosteroids at baseline.\n",
      "Patients across all trials and treatment arms were com-\n",
      "parable in terms of baseline prognostic variables, inclu-\n",
      "sion/exclusion\n",
      "criteria,\n",
      "and\n",
      "co-interventions.\n",
      "All\n",
      "outcomes were assessed uniformly based on the stan-\n",
      "dard deﬁnition of the Mayo Clinic score, between weeks\n",
      "6 and 10 for induction therapy (inﬂiximab, adalimumab,\n",
      "tofacitinib, ustekinumab, 8 weeks; golimumab, 6 weeks;\n",
      "vedolizumab, 6 weeks, 10 weeks, and 14 weeks in\n",
      "VARSITY),6 and weeks 30, 54, or 60 for maintenance\n",
      "therapy;\n",
      "endoscopy\n",
      "was\n",
      "read\n",
      "by\n",
      "blinded\n",
      "local\n",
      "Table 2. Comparative Efﬁcacy of Pharmacologic Agents for Induction of Clinical Remission and Endoscopic Improvement in Biologic-Naive Patients With Moderate–Severe\n",
      "Ulcerative Colitis Using Network Meta-Analysis\n",
      "Induction of clinical remission\n",
      "Induction of endoscopic improvement\n",
      "Ustekinumab 6 mg/kg\n",
      "0.96 (0.38–2.45)\n",
      "0.80 (0.35–1.83)\n",
      "0.73 (0.31–1.74)\n",
      "1.05 (0.48–2.32)\n",
      "0.50 (0.22–1.12)\n",
      "2.04 (1.03–4.05)\n",
      "0.92 (0.45–1.89)\n",
      "Tofacitinib 10 mg b.d.\n",
      "0.84 (0.39–1.82)\n",
      "0.76 (0.33–1.76)\n",
      "1.10 (0.51–2.34)\n",
      "0.52 (0.24–1.12)\n",
      "2.12 (1.12–4.02)\n",
      "0.74 (0.36–1.51)\n",
      "0.80 (0.4–1.62)\n",
      "Vedolizumab\n",
      "0.91 (0.44–1.86)\n",
      "1.31 (0.88–1.95)\n",
      "0.62 (0.34–1.15)\n",
      "2.54 (1.60–4.02)\n",
      "1.07 (0.58–1.98)\n",
      "1.17 (0.64–2.12)\n",
      "1.45 (0.80–2.61)\n",
      "Golimumab\n",
      "1.44 (0.76–2.75)\n",
      "0.69 (0.35–1.36)\n",
      "2.79 (1.64–4.02)\n",
      "1.17 (0.65–2.13)\n",
      "1.28 (0.72–2.29)\n",
      "1.59 (0.90–2.82)\n",
      "1.10 (0.71–1.71)\n",
      "Adalimumab\n",
      "0.48 (0.26–0.86)\n",
      "1.94 (1.30–2.88)\n",
      "0.56 (0.30–1.04)\n",
      "0.61 (0.34–1.11)\n",
      "0.76 (0.42–1.37)\n",
      "0.52 (0.33–0.83)\n",
      "0.48 (0.31–0.74)\n",
      "Inﬂiximab\n",
      "4.07 (2.67–6.21)\n",
      "1.86 (1.11–3.13)\n",
      "2.03 (1.23–3.34)\n",
      "2.52 (1.54–4.11)\n",
      "1.74 (1.25–2.41)\n",
      "1.58 (1.18–2.13)\n",
      "3.32 (2.39–4.60)\n",
      "Placebo\n",
      "NOTE. Comparisons should be read from left to right. Odds ratio for comparisons are in the cell in common between the column-deﬁning and row-deﬁning treatment. Numbers in bold are statistically signiﬁcant. For induction of\n",
      "clinical remission, an odds ratio greater than 1 favors row-deﬁning treatment. For induction of endoscopic improvement, an odds ratio greater than 1 favors column-deﬁning treatment. Numbers in parentheses indicate 95% CI.\n",
      "b.d., twice daily.\n",
      "----------\n",
      "Burr et al. \n",
      " \n",
      "7 of 45 \n",
      "INTRODUCTION \n",
      "  Ulcerative colitis (UC) is a chronic inflammatory disorder of the bowel that causes \n",
      "continuous mucosal inflammation commencing in the rectum and extending proximally for a \n",
      "variable extent.[1] It is estimated that UC affects 2.5 million people in Europe,[2] and the \n",
      "disease follows a relapsing and remitting course, with intermittent flares of disease activity, \n",
      "some of which may be moderate to severe. Management of these is medical, for the most \n",
      "part, with surgery reserved for patients with refractory disease. Although 5-aminosalicylates \n",
      "(5-ASAs) are efficacious for mild to moderate disease activity,[3-6] more severe flares are \n",
      "usually treated with corticosteroids.[7] However, these have potentially serious adverse \n",
      "effects and a substantial proportion of patients may become either dependent on them to \n",
      "maintain remission,[8] or refractory to them.[9] As a result, over the last 20 years novel \n",
      "drugs, with more precise modes of action, based on mechanisms of disease identified in \n",
      "genome wide association studies,[10] have been developed.  \n",
      "The first of these agents was infliximab, a drug targeting the pro-inflammatory \n",
      "cytokine tumour necrosis factor-α (TNF-α), which demonstrated efficacy in clinical trials in \n",
      "moderate to severe UC.[11] Since then, other drugs against TNF-α have been tested, such as \n",
      "adalimumab and golimumab.[12, 13] In addition, newer biological therapies targeting α or β \n",
      "integrins, which are involved in migration of immune cells to inflamed intestinal mucosa, \n",
      "such as vedolizumab or etrolizumab,[14, 15] or acting against other pro-inflammatory \n",
      "cytokines implicated in the pathogenesis of UC, such as ustekinumab,[16] have been tested. \n",
      "However, even these more selective drugs do not work in all patients, there may be risks \n",
      "associated with their use,[17-19] and the fact that they are administered either intravenously \n",
      "or subcutaneously, may be inconvenient for patients. The search for alternative agents for the \n",
      "treatment of UC has, therefore, continued.\n",
      "----------\n",
      "severely active ulcerative colitis: results from phase 3 \n",
      "U-ACCOMPLISH study. J Crohn’s Colitis 2021; 15 (suppl 1): S021–22.\n",
      "9 \n",
      "Thorlund K, Druyts E, Mills EJ, Fedorak RN, Marshall JK. \n",
      "Adalimumab versus infliximab for the treatment of moderate to \n",
      "severe ulcerative colitis in adult patients naïve to anti-TNF therapy: \n",
      "an indirect treatment comparison meta-analysis. J Crohn’s Colitis \n",
      "2014; 8: 571–81.\n",
      "10 \n",
      "Danese S, Fiorino G, Peyrin-Biroulet L, et al. Biological agents for \n",
      "moderately to severely active ulcerative colitis: a systematic review \n",
      "and network meta-analysis. Ann Intern Med 2014; 160: 704–11.\n",
      "11 \n",
      "Singh S, Fumery M, Sandborn WJ, Murad MH. Systematic review \n",
      "with network meta-analysis: first- and second-line pharmacotherapy \n",
      "for moderate-severe ulcerative colitis. Aliment Pharmacol Ther 2018; \n",
      "47: 162–75.\n",
      "12 \n",
      "Bonovas S, Lytras T, Nikolopoulos G, Peyrin-Biroulet L, Danese S. \n",
      "Systematic review with network meta-analysis: comparative \n",
      "assessment of tofacitinib and biological therapies for moderate-to-\n",
      "severe ulcerative colitis. Aliment Pharmacol Ther 2018; 47: 454–65.\n",
      "13 \n",
      "Singh S, Murad MH, Fumery M, Dulai PS, Sandborn WJ. First- and \n",
      "second-line pharmacotherapies for patients with moderate to \n",
      "severely active ulcerative colitis: an updated network meta-analysis. \n",
      "Clin Gastroenterol Hepatol 2020; 18: 2179–91.e6.\n",
      "14 \n",
      "Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting \n",
      "items for systematic reviews and meta-analyses: the PRISMA \n",
      "statement. Ann Intern Med 2009; 151: 264–69.\n",
      "15 \n",
      "Jansen JP, Fleurence R, Devine B, et al. Interpreting indirect \n",
      "treatment comparisons and network meta-analysis for health-care \n",
      "decision making: report of the ISPOR Task Force on Indirect \n",
      "Treatment Comparisons Good Research Practices: part 1. \n",
      "Value Health 2011; 14: 417–28.\n",
      "16 \n",
      "Sterne JAC, Savović J, Page MJ, et al. RoB 2: a revised tool for \n",
      "assessing risk of bias in randomised trials. BMJ 2019; 366: l4898.\n",
      "17 \n",
      "Rücker G, Schwarzer G. Ranking treatments in frequentist network \n",
      "meta-analysis works without resampling methods. \n",
      "BMC Med Res Methodol 2015; 15: 58.\n",
      "----------\n",
      "Burr et al. \n",
      " \n",
      "5 of 45 \n",
      "STUDY HIGHLIGHTS \n",
      " \n",
      "What is already known about this subject \n",
      "• Ulcerative colitis (UC) follows a relapsing and remitting course, with intermittent \n",
      "flares of disease activity, some of which may be moderate to severe. \n",
      "• These are usually treated with corticosteroids, which have potentially serious adverse \n",
      "effects, so biological therapies and small molecules have been developed and licensed \n",
      "for this indication.  \n",
      "• Although previous network meta-analyses have compared their efficacy and safety, \n",
      "this is a rapidly moving field, and there are already several newer drugs that have \n",
      "shown efficacy in phase III clinical trials that were not considered in these. \n",
      " \n",
      "What are the new findings \n",
      "• In terms of clinical remission and clinical response, upadacitinib 45mg o.d. ranked \n",
      "first in all patients, in patients previously exposed to anti-tumour necrosis factor \n",
      "(TNF)-α therapies, and in patients naïve to these drugs.  \n",
      "• In terms of endoscopic improvement infliximab 10mg/kg ranked first, followed by \n",
      "upadacitinib 45mg o.d., and infliximab 5mg/kg.  \n",
      "• However, for endoscopic improvement again upadacitinib 45mg o.d. ranked first in \n",
      "patients previously exposed to anti-TNF-α therapies, and in patients who were anti-\n",
      "TNF-α naïve.  \n",
      "• None of the drugs studied were more likely to lead to serious adverse events than \n",
      "placebo.\n",
      "----------\n",
      "Parkes, M., Vermeire, S., Rioux, J.D., Mansﬁeld, J., Silverberg, M.S., Radford-\n",
      "Smith, G., McGovern, D.P., Barrett, J.C., Lees, C.W., 2016. Inherited determinants of\n",
      "crohn's disease and ulcerative colitis phenotypes: a genetic association study. Lancet\n",
      "387 (10014), 156–167.\n",
      "Colombel, J.F., Sandborn, W.J., Rutgeerts, P., Enns, R., Hanauer, S.B., Panaccione, R.,\n",
      "Schreiber, S., Byczkowski, D., Li, J., Kent, J.D., Pollack, P.F., 2007. Adalimumab for\n",
      "maintenance of clinical response and remission in patients with crohn's disease: the\n",
      "charm trial. Gastroenterology 132 (1), 52–65.\n",
      "Conrad, M.A., Kelsen, J.R., 2020. The treatment of pediatric inﬂammatory bowel disease\n",
      "with biologic therapies. Curr. Gastroenterol. Rep. 22 (8), 36–51.\n",
      "Csontos, A.A., Molnar, A., Piri, Z., Katona, B., Dako, S., Palﬁ, E., Miheller, P., 2016. The\n",
      "effect of anti-tnfalpha induction therapy on the nutritional status and dietary intake\n",
      "in inﬂammatory bowel disease. J Gastrointestin Liver Dis 25 (1), 49–56.\n",
      "Dai, Z.H., Xu, X.T., Ran, Z.H., 2020. Associations between obesity and the effectiveness of\n",
      "anti-tumor necrosis factor-alpha agents in inﬂammatory bowel disease patients: a\n",
      "literature review and meta-analysis. Ann. Pharmacother. 54 (8), 729–741.\n",
      "Danese, S., Colombel, J.F., Lukas, M., Gisbert, J.P., D’Haens, G., Hayee, B., Panaccione, R.,\n",
      "Kim, H.S., Reinisch, W., Tyrrell, H., Oh, Y.S., Tole, S., Chai, A., Chamberlain-\n",
      "James, K., Tang, M.T., Schreiber, S., Group, G.S., 2021. Etrolizumab versus inﬂiximab\n",
      "for the treatment of moderately to severely active ulcerative colitis (gardenia): a\n",
      "randomised, double-blind, double-dummy, phase 3 study. Lancet Gastroenterol\n",
      "Hepatol 7 (2), 118–127.\n",
      "Danese, S., Fiorino, G., Peyrin-Biroulet, L., Lucenteforte, E., Virgili, G., Moja, L.,\n",
      "Bonovas, S., 2014. Biological agents for moderately to severely active ulcerative\n",
      "colitis: a systematic review and network meta-analysis. Ann. Intern. Med. 160 (10),\n",
      "704–711.\n",
      "P. Juillerat et al.\n",
      "Current Research in Pharmacology and Drug Discovery 3 (2022) 100104\n",
      "6\n",
      "----------\n",
      "Therapeutic strategies for the management of recentlydiagnosedulcerative colitis. IMMs include thiopurines and methotrexate. 5-ASA, 5-amino salicylic acid; ASUC, acute severe ulcerative colitis; IPAA, ileal pouch anal anastomosis.\n",
      "\n",
      "Risk stratification: Mild\n",
      "Clinical features: NA\n",
      "Treatment options: 5-ASA (oral and/or topical)\n",
      "\n",
      "Risk stratification: Moderate\n",
      "Clinical features: NA\n",
      "Treatment options: Can consider 5-ASA (with rapid step-up if inadequate response)\n",
      "\n",
      "Risk stratification: Moderate\n",
      "Clinical features: NA\n",
      "Treatment options: VDZ or UST\n",
      "\n",
      "Risk stratification: Moderate\n",
      "Clinical features: NA\n",
      "Treatment options: Thiopurine\n",
      "\n",
      "Risk stratification: Moderate\n",
      "Clinical features: NA\n",
      "Treatment options: TNFi +/- IMM\n",
      "\n",
      "Risk stratification: Severe\n",
      "Clinical features: NA\n",
      "Treatment options: TNFi +/- IMM\n",
      "\n",
      "Risk stratification: Severe\n",
      "Clinical features: NA\n",
      "Treatment options: Subtotal colectomy + IPAA or cyclosporine (for ASUC)\n",
      "\n",
      "Risk stratification: Additional consideration: EIM present\n",
      "Clinical features: Psoriasis or psoriatic arthritis\n",
      "Treatment options: UST\n",
      "\n",
      "Risk stratification: Additional consideration: EIM present\n",
      "Clinical features: Other arthritis\n",
      "Treatment options: TNFi\n",
      "\n",
      "\n",
      "----------\n",
      "methodologic characteristics). If direct and indirect es-\n",
      "timates were similar (ie, coherent), then the higher rating\n",
      "can be assigned to the network meta-analysis estimates.\n",
      "Results\n",
      "From a total 5651 unique studies identiﬁed using our\n",
      "search strategy, we included 15 RCTs of ﬁrst-line agents\n",
      "(in biologic-naïve patients) (Active Ulcerative Colitis Trials\n",
      "1 and 2,17 Jiang et al,18 NCT01551290,19 Ulcerative colitis\n",
      "Long-Term Remission and maintenance with Adalimumab\n",
      "1 and 2,20,21 Suzuki et al,22 Program of Ulcerative Colitis\n",
      "Research Studies Utilizing an Investigational Treatment\n",
      "phase 2 and phase 3 induction studies,23 GEMINI I,24\n",
      "Motoya et al,25 VARSITY, Oral Clinical Trials for tofAciti-\n",
      "nib in ulceratiVE colitis (OCTAVE) 1 and 2,26 and UNIFI),\n",
      "and 7 RCTs of second-line agents (in patients with prior\n",
      "exposure to TNFa antagonists) (Ulcerative colitis Long-\n",
      "Term Remission and maintenance with Adalimumab 2,21\n",
      "GEMINI I,24 Motoya et al,25 VARSITY,6 OCTAVE 1 and\n",
      "2,26 UNIFI7) in patients with moderate–severe ulcerative\n",
      "colitis. Trials of inﬂiximab (Active Ulcerative Colitis Trials\n",
      "1 and 2,17 Jiang et al,18 NCT0155129019), adalimumab\n",
      "(Ulcerative colitis Long-Term Remission and maintenance\n",
      "with Adalimumab 2,20,21 Suzuki et al22), vedolizumab\n",
      "(GEMINI I,24 Motoya et al,25 VARSITY6) and ustekinumab\n",
      "(UNIFI7) also reported outcomes on maintenance therapy\n",
      "within the same publication; Program of Ulcerative Colitis\n",
      "Research Studies Utilizing an Investigational Treatment-\n",
      "M, Program of Ulcerative Colitis Research Studies Utilizing\n",
      "an Investigational Treatment-J, and OCTAVE-Sustain\n",
      "reported\n",
      "outcomes\n",
      "for\n",
      "maintenance\n",
      "therapy\n",
      "with\n",
      "golimumab and tofacitinib, respectively.26–28 From our\n",
      "previous analysis, 3 additional studies were included.\n",
      "The schematic diagram of study selection is shown in\n",
      "Supplementary\n",
      "Figure\n",
      "1,\n",
      "and\n",
      "available\n",
      "direct\n",
      "comparisons and network of trials are shown in Figure 1.\n",
      "Trial and patient characteristics are summarized in\n",
      "Table 1. Overall, the median average age of patients was\n",
      "41 years (interquartile range, 40–42 y), and 60%\n",
      "(interquartile range, 56%–63%) were men. The median\n",
      "disease duration was 6.7 years (interquartile range,\n",
      "6.0–7.8 y), and 49% (interquartile range, 46%–55%) of\n",
      "patients had extensive colitis. A median of 40% (inter-\n",
      "quartile range, 30%–50%) of patients were treated with\n",
      "concomitant immunomodulators, and 51% (interquartile\n",
      "range, 45%–57%) were on corticosteroids at baseline.\n",
      "Patients across all trials and treatment arms were com-\n",
      "----------\n",
      "Articles\n",
      "www.thelancet.com/gastrohep   Vol 7   February 2022 \n",
      "161\n",
      "Lancet Gastroenterol Hepatol \n",
      "2022; 7: 161–70\n",
      "Published Online \n",
      "November 29, 2021 \n",
      "https://doi.org/10.1016/ \n",
      "S2468-1253(21)00377-0\n",
      "See Comment page 110\n",
      "*Contributed equally\n",
      "Inflammatory Bowel Disease \n",
      "Unit, Gastroenterology \n",
      "Section, Department of \n",
      "Internal Medicine, Centro de \n",
      "Educación Médica e \n",
      "Investigaciones Clínicas, \n",
      "Buenos Aires, Argentina \n",
      "(J S Lasa MD, P A Olivera MD); \n",
      "Gastroenterology Department, \n",
      "Hospital Británico de Buenos \n",
      "Aires, Buenos Aires, Argentina \n",
      "(J S Lasa); Zane Cohen Centre \n",
      "for Digestive Diseases, \n",
      "Lunenfeld-Tanenbaum \n",
      "Research Institute, Sinai Health \n",
      "System, Toronto, ON, Canada \n",
      "(P A Olivera); Division of \n",
      "Gastroenterology, Mount Sinai \n",
      "Hospital, University of Toronto, \n",
      "Toronto, ON, Canada \n",
      "(P A Olivera); Gastroenterology \n",
      "and Endoscopy, IRCCS Ospedale \n",
      "San Raffaele and University \n",
      "Vita-Salute San Raffaele, \n",
      "Milano, Italy \n",
      "(Prof S Danese MD); INSERM \n",
      "NGERE and Department of \n",
      "Hepatogastroenterology, \n",
      "Nancy University Hospital, \n",
      "Lorraine University, \n",
      "Vandoeuvre-lés-Nancy, France \n",
      "(Prof L Peyrin-Biroulet MD) \n",
      "Correspondence to: \n",
      "Prof Laurent Peyrin-Biroulet, \n",
      "INSERM NGERE and Department \n",
      "of Hepatogastroenterology, \n",
      "Nancy University Hospital, \n",
      "Lorraine University, Vandoeuvre-\n",
      "lès-Nancy F-54511, France \n",
      "peyrinbiroulet@gmail.com\n",
      "Efficacy and safety of biologics and small molecule drugs for \n",
      "patients with moderate-to-severe ulcerative colitis: \n",
      "a systematic review and network meta-analysis \n",
      "Juan S Lasa*, Pablo A Olivera*, Silvio Danese, Laurent Peyrin-Biroulet\n",
      "Summary\n",
      "Background There is a growing armamentarium for the treatment of moderate-to-severe ulcerative colitis. We aimed \n",
      "to compare the relative efficacy and safety of biologics and small molecule drugs for the treatment of patients with \n",
      "moderate-to-severe ulcerative colitis.\n",
      "Methods In this systematic review and network meta-analysis, we searched MEDLINE, Embase, and the Cochrane \n",
      "Central Register of Controlled Trials without language restrictions for articles published between Jan 1, 1990, and \n",
      "July 1, 2021. Major congresses’ databases from Jan 1, 2018, to July 3, 2021, were reviewed manually. Phase 3, placebo-\n",
      "controlled or head-to-head randomised controlled trials (RCTs) assessing the efficacy and safety of biologics or small \n",
      "molecule drugs as induction or maintenance therapies for patients with moderate-to-severe ulcerative colitis were\n",
      "----------\n",
      "laise, weight loss, and fever. Disease onset commonly occurs \n",
      "between the ages of 15 and 30 years and the annual global \n",
      "© The Author(s) 2023. Published by Oxford University Press on behalf of Crohn's & Colitis Foundation.\n",
      "This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), \n",
      "which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.\n",
      "Received for publication: September 21, 2022. Editorial Decision: January 25, 2023\n",
      " \n",
      "Downloaded from https://academic.oup.com/crohnscolitis360/article/5/2/otad009/7066911 by National University of Singapore user on 23 May 2023\n",
      "----------\n",
      "discontinuation due to AEs, and serious infections. Phase 3 randomized controlled trials were identified via systematic literature review, in-\n",
      "cluding the following advanced therapies: infliximab, adalimumab, vedolizumab, golimumab, tofacitinib, ustekinumab, filgotinib, ozanimod, and \n",
      "upadacitinib. Random effects models were used to address between-study heterogeneity. Intent-to-treat (ITT) efficacy rates were calculated by \n",
      "adjusting maintenance outcomes by likelihood of induction response.\n",
      "Results:  Out of 48 trials identified, 23 were included. Across all outcomes and regardless of prior biologic exposure, ITT efficacy rates were \n",
      "highest for upadacitinib, owing to its highest ranking for all efficacy outcomes in induction and for all but clinical remission during maintenance \n",
      "among bio-naive induction responders. For all advanced therapies versus placebo, there were no significant differences in serious AEs or \n",
      "serious infections across therapies. For all AEs, golimumab had higher odds versus placebo during maintenance; for discontinuation due to \n",
      "AEs, upadacitinib had lower odds versus placebo during induction, while ustekinumab and vedolizumab had lower odds versus placebo during \n",
      "maintenance.\n",
      "Conclusions:  Upadacitinib may be the most efficacious therapy for moderately to severely active UC based on ITT analyses, with similar safety \n",
      "across advanced therapies.\n",
      "Lay Summary \n",
      "Indirect evidence suggests upadacitinib may be more efficacious than other advanced therapies at achieving clinical response, clinical remis-\n",
      "sion, and endoscopic response over 1 year for moderately to severely active ulcerative colitis patients, with similar safety assessments across \n",
      "advanced therapies.\n",
      "Key Words: ulcerative colitis, clinical trials, advanced therapies, network meta-analysis\n",
      "Introduction\n",
      "Ulcerative colitis (UC) is a chronic inflammatory bowel dis-\n",
      "ease that affects the colorectum and is clinically characterized \n",
      "by bloody diarrhea, urgency, tenesmus, abdominal pain, ma-\n",
      "laise, weight loss, and fever. Disease onset commonly occurs \n",
      "between the ages of 15 and 30 years and the annual global \n",
      "© The Author(s) 2023. Published by Oxford University Press on behalf of Crohn's & Colitis Foundation.\n",
      "This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), \n",
      "which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.\n",
      "==========\n",
      "ORIGINAL QUESTION: ANALYSE the given patient profile based on given query based on one of the following criteria:\n",
      "- Whether treated patient is new patient or patient under maintenance\n",
      "- Prior response to Infliximab\n",
      "- Prior failure to Anti-TNF agents\n",
      "- Prior failure to Vedolizumab\n",
      "- Age\n",
      "- Pregnancy\n",
      "- Extraintestinale manifestations\n",
      "- Pouchitis\n",
      "RETURN up to 2 TOP choices of biological drugs given patient profile and context. Explain the PROS and CONS of the 2 choices.\n",
      "PATIENT PROFILE: 41 year-old man with moderate to severe distal ulcerative colitis and alocpecia areata.\n",
      "\n",
      "==========\n",
      "CURRENT ANSWER:\n",
      "Based on the patient's profile, the top two choices of biological drugs would be:\n",
      "\n",
      "1. Ustekinumab\n",
      "Advantages: Ustekinumab has shown efficacy in inducing clinical remission and endoscopic improvement in patients with moderate to severe ulcerative colitis. It is also beneficial for patients with extraintestinal manifestations like alopecia areata, as it targets the interleukin-12 and -23 pathways, which are involved in the pathogenesis of several autoimmune diseases, including alopecia areata.\n",
      "Disadvantages: The main disadvantage of ustekinumab is the route of administration. The initial dose is given intravenously, which can be inconvenient for some patients. Subsequent doses are administered subcutaneously. Potential side effects include respiratory infections, headache, and fatigue.\n",
      "\n",
      "2. Vedolizumab\n",
      "Advantages: Vedolizumab is a gut-selective immunosuppressant, meaning it specifically targets the gut and spares other organ systems, potentially reducing systemic side effects. It has shown efficacy in inducing clinical remission and endoscopic improvement in patients with moderate to severe ulcerative colitis.\n",
      "Disadvantages: Vedolizumab is administered intravenously, which may be inconvenient for some patients. It may take longer to see the effects of vedolizumab compared to other treatments. Potential side effects include headache, joint pain, nausea, and fever.\n",
      "\n",
      "Please note that the choice of treatment should be individualized based on the patient's specific circumstances, preferences, and potential for side effects. The patient should have a detailed discussion with their healthcare provider to decide on the best treatment option.\n",
      "==========\n",
      "REFINED ANSWER:\n",
      "\u001b[0m\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "Retrying langchain.chat_models.openai.ChatOpenAI.completion_with_retry.<locals>._completion_with_retry in 4.0 seconds as it raised RateLimitError: Rate limit reached for 10KTPM-200RPM in organization org-ETbTMTN2JXYOUPDJgxuH2iO6 on tokens per min. Limit: 10000 / min. Please try again in 6ms. Contact us through our help center at help.openai.com if you continue to have issues..\n",
      "Retrying langchain.chat_models.openai.ChatOpenAI.completion_with_retry.<locals>._completion_with_retry in 4.0 seconds as it raised RateLimitError: Rate limit reached for 10KTPM-200RPM in organization org-ETbTMTN2JXYOUPDJgxuH2iO6 on tokens per min. Limit: 10000 / min. Please try again in 6ms. Contact us through our help center at help.openai.com if you continue to have issues..\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\n",
      "\u001b[1m> Finished chain.\u001b[0m\n",
      "\n",
      "\u001b[1m> Finished chain.\u001b[0m\n",
      "2023-10-02 17:48:12,116:INFO: 5544 tokens were added to prompt from 10 documents\n",
      "Query: 38 year-old woman with moderate to severe ulcerative colitis and pulmonary tuberculosis which was treated 2 years ago.\n",
      "\n",
      "\n",
      "\u001b[1m> Entering new SequentialChain chain...\u001b[0m\n",
      "\n",
      "\n",
      "\u001b[1m> Entering new RetrievalQAWithSourcesChain chain...\u001b[0m\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "Retrying langchain.chat_models.openai.ChatOpenAI.completion_with_retry.<locals>._completion_with_retry in 4.0 seconds as it raised RateLimitError: Rate limit reached for 10KTPM-200RPM in organization org-ETbTMTN2JXYOUPDJgxuH2iO6 on tokens per min. Limit: 10000 / min. Please try again in 6ms. Contact us through our help center at help.openai.com if you continue to have issues..\n",
      "Retrying langchain.chat_models.openai.ChatOpenAI.completion_with_retry.<locals>._completion_with_retry in 4.0 seconds as it raised RateLimitError: Rate limit reached for 10KTPM-200RPM in organization org-ETbTMTN2JXYOUPDJgxuH2iO6 on tokens per min. Limit: 10000 / min. Please try again in 6ms. Contact us through our help center at help.openai.com if you continue to have issues..\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\n",
      "\u001b[1m> Finished chain.\u001b[0m\n",
      "\n",
      "\n",
      "\u001b[1m> Entering new LLMChain chain...\u001b[0m\n",
      "Prompt after formatting:\n",
      "\u001b[32;1m\u001b[1;3mYou are a senior physician giving advice on treatment for moderate to severe ulcerative colitis (UC).\n",
      "Make reference to the CONTEXT given to assess the scenario.\n",
      "==========\n",
      "TASK: Your task is to analyse critically the CURRENT ANSWER given the CONTEXT.\n",
      "Then refine the existing answer (only if needed) based on the following instructions:\n",
      "- If no refinement needed, return the original answer in the correct output format.\n",
      "- If the answer cannot be inferred from CONTEXT, return \"NO ANSWER\".\n",
      "- The final output should be a list of up to 2 choices of biological drugs given patient profile and context and PROS/CONS for each recommendations.\n",
      "==========\n",
      "CONTEXT:\n",
      "Burr et al. \n",
      " \n",
      "7 of 45 \n",
      "INTRODUCTION \n",
      "  Ulcerative colitis (UC) is a chronic inflammatory disorder of the bowel that causes \n",
      "continuous mucosal inflammation commencing in the rectum and extending proximally for a \n",
      "variable extent.[1] It is estimated that UC affects 2.5 million people in Europe,[2] and the \n",
      "disease follows a relapsing and remitting course, with intermittent flares of disease activity, \n",
      "some of which may be moderate to severe. Management of these is medical, for the most \n",
      "part, with surgery reserved for patients with refractory disease. Although 5-aminosalicylates \n",
      "(5-ASAs) are efficacious for mild to moderate disease activity,[3-6] more severe flares are \n",
      "usually treated with corticosteroids.[7] However, these have potentially serious adverse \n",
      "effects and a substantial proportion of patients may become either dependent on them to \n",
      "maintain remission,[8] or refractory to them.[9] As a result, over the last 20 years novel \n",
      "drugs, with more precise modes of action, based on mechanisms of disease identified in \n",
      "genome wide association studies,[10] have been developed.  \n",
      "The first of these agents was infliximab, a drug targeting the pro-inflammatory \n",
      "cytokine tumour necrosis factor-α (TNF-α), which demonstrated efficacy in clinical trials in \n",
      "moderate to severe UC.[11] Since then, other drugs against TNF-α have been tested, such as \n",
      "adalimumab and golimumab.[12, 13] In addition, newer biological therapies targeting α or β \n",
      "integrins, which are involved in migration of immune cells to inflamed intestinal mucosa, \n",
      "such as vedolizumab or etrolizumab,[14, 15] or acting against other pro-inflammatory \n",
      "cytokines implicated in the pathogenesis of UC, such as ustekinumab,[16] have been tested. \n",
      "However, even these more selective drugs do not work in all patients, there may be risks \n",
      "associated with their use,[17-19] and the fact that they are administered either intravenously \n",
      "or subcutaneously, may be inconvenient for patients. The search for alternative agents for the \n",
      "treatment of UC has, therefore, continued.\n",
      "----------\n",
      "41 years (interquartile range, 40–42 y), and 60%\n",
      "(interquartile range, 56%–63%) were men. The median\n",
      "disease duration was 6.7 years (interquartile range,\n",
      "6.0–7.8 y), and 49% (interquartile range, 46%–55%) of\n",
      "patients had extensive colitis. A median of 40% (inter-\n",
      "quartile range, 30%–50%) of patients were treated with\n",
      "concomitant immunomodulators, and 51% (interquartile\n",
      "range, 45%–57%) were on corticosteroids at baseline.\n",
      "Patients across all trials and treatment arms were com-\n",
      "parable in terms of baseline prognostic variables, inclu-\n",
      "sion/exclusion\n",
      "criteria,\n",
      "and\n",
      "co-interventions.\n",
      "All\n",
      "outcomes were assessed uniformly based on the stan-\n",
      "dard deﬁnition of the Mayo Clinic score, between weeks\n",
      "6 and 10 for induction therapy (inﬂiximab, adalimumab,\n",
      "tofacitinib, ustekinumab, 8 weeks; golimumab, 6 weeks;\n",
      "vedolizumab, 6 weeks, 10 weeks, and 14 weeks in\n",
      "VARSITY),6 and weeks 30, 54, or 60 for maintenance\n",
      "therapy;\n",
      "endoscopy\n",
      "was\n",
      "read\n",
      "by\n",
      "blinded\n",
      "local\n",
      "Table 2. Comparative Efﬁcacy of Pharmacologic Agents for Induction of Clinical Remission and Endoscopic Improvement in Biologic-Naive Patients With Moderate–Severe\n",
      "Ulcerative Colitis Using Network Meta-Analysis\n",
      "Induction of clinical remission\n",
      "Induction of endoscopic improvement\n",
      "Ustekinumab 6 mg/kg\n",
      "0.96 (0.38–2.45)\n",
      "0.80 (0.35–1.83)\n",
      "0.73 (0.31–1.74)\n",
      "1.05 (0.48–2.32)\n",
      "0.50 (0.22–1.12)\n",
      "2.04 (1.03–4.05)\n",
      "0.92 (0.45–1.89)\n",
      "Tofacitinib 10 mg b.d.\n",
      "0.84 (0.39–1.82)\n",
      "0.76 (0.33–1.76)\n",
      "1.10 (0.51–2.34)\n",
      "0.52 (0.24–1.12)\n",
      "2.12 (1.12–4.02)\n",
      "0.74 (0.36–1.51)\n",
      "0.80 (0.4–1.62)\n",
      "Vedolizumab\n",
      "0.91 (0.44–1.86)\n",
      "1.31 (0.88–1.95)\n",
      "0.62 (0.34–1.15)\n",
      "2.54 (1.60–4.02)\n",
      "1.07 (0.58–1.98)\n",
      "1.17 (0.64–2.12)\n",
      "1.45 (0.80–2.61)\n",
      "Golimumab\n",
      "1.44 (0.76–2.75)\n",
      "0.69 (0.35–1.36)\n",
      "2.79 (1.64–4.02)\n",
      "1.17 (0.65–2.13)\n",
      "1.28 (0.72–2.29)\n",
      "1.59 (0.90–2.82)\n",
      "1.10 (0.71–1.71)\n",
      "Adalimumab\n",
      "0.48 (0.26–0.86)\n",
      "1.94 (1.30–2.88)\n",
      "0.56 (0.30–1.04)\n",
      "0.61 (0.34–1.11)\n",
      "0.76 (0.42–1.37)\n",
      "0.52 (0.33–0.83)\n",
      "0.48 (0.31–0.74)\n",
      "Inﬂiximab\n",
      "4.07 (2.67–6.21)\n",
      "1.86 (1.11–3.13)\n",
      "2.03 (1.23–3.34)\n",
      "2.52 (1.54–4.11)\n",
      "1.74 (1.25–2.41)\n",
      "1.58 (1.18–2.13)\n",
      "3.32 (2.39–4.60)\n",
      "Placebo\n",
      "NOTE. Comparisons should be read from left to right. Odds ratio for comparisons are in the cell in common between the column-deﬁning and row-deﬁning treatment. Numbers in bold are statistically signiﬁcant. For induction of\n",
      "clinical remission, an odds ratio greater than 1 favors row-deﬁning treatment. For induction of endoscopic improvement, an odds ratio greater than 1 favors column-deﬁning treatment. Numbers in parentheses indicate 95% CI.\n",
      "b.d., twice daily.\n",
      "----------\n",
      "severely active ulcerative colitis: results from phase 3 \n",
      "U-ACCOMPLISH study. J Crohn’s Colitis 2021; 15 (suppl 1): S021–22.\n",
      "9 \n",
      "Thorlund K, Druyts E, Mills EJ, Fedorak RN, Marshall JK. \n",
      "Adalimumab versus infliximab for the treatment of moderate to \n",
      "severe ulcerative colitis in adult patients naïve to anti-TNF therapy: \n",
      "an indirect treatment comparison meta-analysis. J Crohn’s Colitis \n",
      "2014; 8: 571–81.\n",
      "10 \n",
      "Danese S, Fiorino G, Peyrin-Biroulet L, et al. Biological agents for \n",
      "moderately to severely active ulcerative colitis: a systematic review \n",
      "and network meta-analysis. Ann Intern Med 2014; 160: 704–11.\n",
      "11 \n",
      "Singh S, Fumery M, Sandborn WJ, Murad MH. Systematic review \n",
      "with network meta-analysis: first- and second-line pharmacotherapy \n",
      "for moderate-severe ulcerative colitis. Aliment Pharmacol Ther 2018; \n",
      "47: 162–75.\n",
      "12 \n",
      "Bonovas S, Lytras T, Nikolopoulos G, Peyrin-Biroulet L, Danese S. \n",
      "Systematic review with network meta-analysis: comparative \n",
      "assessment of tofacitinib and biological therapies for moderate-to-\n",
      "severe ulcerative colitis. Aliment Pharmacol Ther 2018; 47: 454–65.\n",
      "13 \n",
      "Singh S, Murad MH, Fumery M, Dulai PS, Sandborn WJ. First- and \n",
      "second-line pharmacotherapies for patients with moderate to \n",
      "severely active ulcerative colitis: an updated network meta-analysis. \n",
      "Clin Gastroenterol Hepatol 2020; 18: 2179–91.e6.\n",
      "14 \n",
      "Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting \n",
      "items for systematic reviews and meta-analyses: the PRISMA \n",
      "statement. Ann Intern Med 2009; 151: 264–69.\n",
      "15 \n",
      "Jansen JP, Fleurence R, Devine B, et al. Interpreting indirect \n",
      "treatment comparisons and network meta-analysis for health-care \n",
      "decision making: report of the ISPOR Task Force on Indirect \n",
      "Treatment Comparisons Good Research Practices: part 1. \n",
      "Value Health 2011; 14: 417–28.\n",
      "16 \n",
      "Sterne JAC, Savović J, Page MJ, et al. RoB 2: a revised tool for \n",
      "assessing risk of bias in randomised trials. BMJ 2019; 366: l4898.\n",
      "17 \n",
      "Rücker G, Schwarzer G. Ranking treatments in frequentist network \n",
      "meta-analysis works without resampling methods. \n",
      "BMC Med Res Methodol 2015; 15: 58.\n",
      "----------\n",
      "Burr et al. \n",
      " \n",
      "5 of 45 \n",
      "STUDY HIGHLIGHTS \n",
      " \n",
      "What is already known about this subject \n",
      "• Ulcerative colitis (UC) follows a relapsing and remitting course, with intermittent \n",
      "flares of disease activity, some of which may be moderate to severe. \n",
      "• These are usually treated with corticosteroids, which have potentially serious adverse \n",
      "effects, so biological therapies and small molecules have been developed and licensed \n",
      "for this indication.  \n",
      "• Although previous network meta-analyses have compared their efficacy and safety, \n",
      "this is a rapidly moving field, and there are already several newer drugs that have \n",
      "shown efficacy in phase III clinical trials that were not considered in these. \n",
      " \n",
      "What are the new findings \n",
      "• In terms of clinical remission and clinical response, upadacitinib 45mg o.d. ranked \n",
      "first in all patients, in patients previously exposed to anti-tumour necrosis factor \n",
      "(TNF)-α therapies, and in patients naïve to these drugs.  \n",
      "• In terms of endoscopic improvement infliximab 10mg/kg ranked first, followed by \n",
      "upadacitinib 45mg o.d., and infliximab 5mg/kg.  \n",
      "• However, for endoscopic improvement again upadacitinib 45mg o.d. ranked first in \n",
      "patients previously exposed to anti-TNF-α therapies, and in patients who were anti-\n",
      "TNF-α naïve.  \n",
      "• None of the drugs studied were more likely to lead to serious adverse events than \n",
      "placebo.\n",
      "----------\n",
      "SYSTEMATIC REVIEWS AND META-ANALYSES\n",
      "Siddharth Singh, Section Editor\n",
      "First- and Second-Line Pharmacotherapies for Patients With\n",
      "Moderate to Severely Active Ulcerative Colitis: An Updated\n",
      "Network Meta-Analysis\n",
      "Siddharth Singh,*,‡ Mohammad Hassan Murad,§ Mathurin Fumery,j\n",
      "Parambir S. Dulai,* and William J. Sandborn*\n",
      "*Division of Gastroenterology, ‡Division of Biomedical Informatics, University of California San Diego, La Jolla, California;\n",
      "§Robert D and Patricia E Kern Center for the Science of Health Care Delivery, Mayo Clinic, Rochester, Minnesota;\n",
      "||Gastroenterology Unit, Peritox UMR I-0I, Amiens University and Hospital, Université de Picardie Jules Verne, Amiens, France\n",
      "BACKGROUND & AIMS:\n",
      "We compared the efﬁcacy and safety of different ﬁrst-line (biologic-naïve) and second-line\n",
      "(prior exposure to tumor necrosis factor [TNF] antagonists) agents for treatment of moder-\n",
      "ate to severely active ulcerative colitis in a systematic review and network meta-analysis.\n",
      "METHODS:\n",
      "We searched publication databases through September 30, 2019, for randomized trials of\n",
      "adults with moderate to severe ulcerative colitis treated with TNF antagonists, vedolizumab,\n",
      "tofacitinib, or ustekinumab, as ﬁrst-line or second-line agents, compared with placebo or\n",
      "another active agent. Efﬁcacy outcomes were induction and maintenance of remission and\n",
      "endoscopic improvement; safety outcomes were serious adverse events and infections. We\n",
      "performed a ﬁxed-effects network meta-analysis using the frequentist approach, and calculated\n",
      "odds ratios (ORs) and 95% CI values. Agents were ranked using surface under the cumulative\n",
      "ranking (SUCRA) probabilities. Overall quality of evidence was rated using GRADE (Grading of\n",
      "Recommendations, Assessment, Development and Evaluation).\n",
      "RESULTS:\n",
      "In biologic-naïve patients, inﬂiximab was ranked highest for induction of clinical remission (OR\n",
      "vs placebo, 4.07; 95% CI, 2.67–6.21; SUCRA, 0.95) and endoscopic improvement (SUCRA, 0.95)\n",
      "(moderate conﬁdence in estimates [CE]). In patients with prior exposure to TNF antagonists,\n",
      "ustekinumab (SUCRA, 0.87) and tofacitinib (SUCRA, 0.87) were ranked highest for induction of\n",
      "clinical remission and were superior to vedolizumab (ustekinumab vs vedolizumab: OR, 5.99;\n",
      "95% CI, 1.13–31.76 and tofacitinib vs vedolizumab: OR, 6.18; 95% CI, 1.003–8.00; moderate CE)\n",
      "and adalimumab (ustekinumab vs adalimumab: OR, 10.71; 95% CI, 2.01–57.20 and tofacitinib\n",
      "----------\n",
      "methodologic characteristics). If direct and indirect es-\n",
      "timates were similar (ie, coherent), then the higher rating\n",
      "can be assigned to the network meta-analysis estimates.\n",
      "Results\n",
      "From a total 5651 unique studies identiﬁed using our\n",
      "search strategy, we included 15 RCTs of ﬁrst-line agents\n",
      "(in biologic-naïve patients) (Active Ulcerative Colitis Trials\n",
      "1 and 2,17 Jiang et al,18 NCT01551290,19 Ulcerative colitis\n",
      "Long-Term Remission and maintenance with Adalimumab\n",
      "1 and 2,20,21 Suzuki et al,22 Program of Ulcerative Colitis\n",
      "Research Studies Utilizing an Investigational Treatment\n",
      "phase 2 and phase 3 induction studies,23 GEMINI I,24\n",
      "Motoya et al,25 VARSITY, Oral Clinical Trials for tofAciti-\n",
      "nib in ulceratiVE colitis (OCTAVE) 1 and 2,26 and UNIFI),\n",
      "and 7 RCTs of second-line agents (in patients with prior\n",
      "exposure to TNFa antagonists) (Ulcerative colitis Long-\n",
      "Term Remission and maintenance with Adalimumab 2,21\n",
      "GEMINI I,24 Motoya et al,25 VARSITY,6 OCTAVE 1 and\n",
      "2,26 UNIFI7) in patients with moderate–severe ulcerative\n",
      "colitis. Trials of inﬂiximab (Active Ulcerative Colitis Trials\n",
      "1 and 2,17 Jiang et al,18 NCT0155129019), adalimumab\n",
      "(Ulcerative colitis Long-Term Remission and maintenance\n",
      "with Adalimumab 2,20,21 Suzuki et al22), vedolizumab\n",
      "(GEMINI I,24 Motoya et al,25 VARSITY6) and ustekinumab\n",
      "(UNIFI7) also reported outcomes on maintenance therapy\n",
      "within the same publication; Program of Ulcerative Colitis\n",
      "Research Studies Utilizing an Investigational Treatment-\n",
      "M, Program of Ulcerative Colitis Research Studies Utilizing\n",
      "an Investigational Treatment-J, and OCTAVE-Sustain\n",
      "reported\n",
      "outcomes\n",
      "for\n",
      "maintenance\n",
      "therapy\n",
      "with\n",
      "golimumab and tofacitinib, respectively.26–28 From our\n",
      "previous analysis, 3 additional studies were included.\n",
      "The schematic diagram of study selection is shown in\n",
      "Supplementary\n",
      "Figure\n",
      "1,\n",
      "and\n",
      "available\n",
      "direct\n",
      "comparisons and network of trials are shown in Figure 1.\n",
      "Trial and patient characteristics are summarized in\n",
      "Table 1. Overall, the median average age of patients was\n",
      "41 years (interquartile range, 40–42 y), and 60%\n",
      "(interquartile range, 56%–63%) were men. The median\n",
      "disease duration was 6.7 years (interquartile range,\n",
      "6.0–7.8 y), and 49% (interquartile range, 46%–55%) of\n",
      "patients had extensive colitis. A median of 40% (inter-\n",
      "quartile range, 30%–50%) of patients were treated with\n",
      "concomitant immunomodulators, and 51% (interquartile\n",
      "range, 45%–57%) were on corticosteroids at baseline.\n",
      "Patients across all trials and treatment arms were com-\n",
      "----------\n",
      "Therapeutic strategies for the management of recentlydiagnosedulcerative colitis. IMMs include thiopurines and methotrexate. 5-ASA, 5-amino salicylic acid; ASUC, acute severe ulcerative colitis; IPAA, ileal pouch anal anastomosis.\n",
      "\n",
      "Risk stratification: Mild\n",
      "Clinical features: NA\n",
      "Treatment options: 5-ASA (oral and/or topical)\n",
      "\n",
      "Risk stratification: Moderate\n",
      "Clinical features: NA\n",
      "Treatment options: Can consider 5-ASA (with rapid step-up if inadequate response)\n",
      "\n",
      "Risk stratification: Moderate\n",
      "Clinical features: NA\n",
      "Treatment options: VDZ or UST\n",
      "\n",
      "Risk stratification: Moderate\n",
      "Clinical features: NA\n",
      "Treatment options: Thiopurine\n",
      "\n",
      "Risk stratification: Moderate\n",
      "Clinical features: NA\n",
      "Treatment options: TNFi +/- IMM\n",
      "\n",
      "Risk stratification: Severe\n",
      "Clinical features: NA\n",
      "Treatment options: TNFi +/- IMM\n",
      "\n",
      "Risk stratification: Severe\n",
      "Clinical features: NA\n",
      "Treatment options: Subtotal colectomy + IPAA or cyclosporine (for ASUC)\n",
      "\n",
      "Risk stratification: Additional consideration: EIM present\n",
      "Clinical features: Psoriasis or psoriatic arthritis\n",
      "Treatment options: UST\n",
      "\n",
      "Risk stratification: Additional consideration: EIM present\n",
      "Clinical features: Other arthritis\n",
      "Treatment options: TNFi\n",
      "\n",
      "\n",
      "----------\n",
      "Articles\n",
      "www.thelancet.com/gastrohep   Vol 7   February 2022 \n",
      "161\n",
      "Lancet Gastroenterol Hepatol \n",
      "2022; 7: 161–70\n",
      "Published Online \n",
      "November 29, 2021 \n",
      "https://doi.org/10.1016/ \n",
      "S2468-1253(21)00377-0\n",
      "See Comment page 110\n",
      "*Contributed equally\n",
      "Inflammatory Bowel Disease \n",
      "Unit, Gastroenterology \n",
      "Section, Department of \n",
      "Internal Medicine, Centro de \n",
      "Educación Médica e \n",
      "Investigaciones Clínicas, \n",
      "Buenos Aires, Argentina \n",
      "(J S Lasa MD, P A Olivera MD); \n",
      "Gastroenterology Department, \n",
      "Hospital Británico de Buenos \n",
      "Aires, Buenos Aires, Argentina \n",
      "(J S Lasa); Zane Cohen Centre \n",
      "for Digestive Diseases, \n",
      "Lunenfeld-Tanenbaum \n",
      "Research Institute, Sinai Health \n",
      "System, Toronto, ON, Canada \n",
      "(P A Olivera); Division of \n",
      "Gastroenterology, Mount Sinai \n",
      "Hospital, University of Toronto, \n",
      "Toronto, ON, Canada \n",
      "(P A Olivera); Gastroenterology \n",
      "and Endoscopy, IRCCS Ospedale \n",
      "San Raffaele and University \n",
      "Vita-Salute San Raffaele, \n",
      "Milano, Italy \n",
      "(Prof S Danese MD); INSERM \n",
      "NGERE and Department of \n",
      "Hepatogastroenterology, \n",
      "Nancy University Hospital, \n",
      "Lorraine University, \n",
      "Vandoeuvre-lés-Nancy, France \n",
      "(Prof L Peyrin-Biroulet MD) \n",
      "Correspondence to: \n",
      "Prof Laurent Peyrin-Biroulet, \n",
      "INSERM NGERE and Department \n",
      "of Hepatogastroenterology, \n",
      "Nancy University Hospital, \n",
      "Lorraine University, Vandoeuvre-\n",
      "lès-Nancy F-54511, France \n",
      "peyrinbiroulet@gmail.com\n",
      "Efficacy and safety of biologics and small molecule drugs for \n",
      "patients with moderate-to-severe ulcerative colitis: \n",
      "a systematic review and network meta-analysis \n",
      "Juan S Lasa*, Pablo A Olivera*, Silvio Danese, Laurent Peyrin-Biroulet\n",
      "Summary\n",
      "Background There is a growing armamentarium for the treatment of moderate-to-severe ulcerative colitis. We aimed \n",
      "to compare the relative efficacy and safety of biologics and small molecule drugs for the treatment of patients with \n",
      "moderate-to-severe ulcerative colitis.\n",
      "Methods In this systematic review and network meta-analysis, we searched MEDLINE, Embase, and the Cochrane \n",
      "Central Register of Controlled Trials without language restrictions for articles published between Jan 1, 1990, and \n",
      "July 1, 2021. Major congresses’ databases from Jan 1, 2018, to July 3, 2021, were reviewed manually. Phase 3, placebo-\n",
      "controlled or head-to-head randomised controlled trials (RCTs) assessing the efficacy and safety of biologics or small \n",
      "molecule drugs as induction or maintenance therapies for patients with moderate-to-severe ulcerative colitis were\n",
      "----------\n",
      "discontinuation due to AEs, and serious infections. Phase 3 randomized controlled trials were identified via systematic literature review, in-\n",
      "cluding the following advanced therapies: infliximab, adalimumab, vedolizumab, golimumab, tofacitinib, ustekinumab, filgotinib, ozanimod, and \n",
      "upadacitinib. Random effects models were used to address between-study heterogeneity. Intent-to-treat (ITT) efficacy rates were calculated by \n",
      "adjusting maintenance outcomes by likelihood of induction response.\n",
      "Results:  Out of 48 trials identified, 23 were included. Across all outcomes and regardless of prior biologic exposure, ITT efficacy rates were \n",
      "highest for upadacitinib, owing to its highest ranking for all efficacy outcomes in induction and for all but clinical remission during maintenance \n",
      "among bio-naive induction responders. For all advanced therapies versus placebo, there were no significant differences in serious AEs or \n",
      "serious infections across therapies. For all AEs, golimumab had higher odds versus placebo during maintenance; for discontinuation due to \n",
      "AEs, upadacitinib had lower odds versus placebo during induction, while ustekinumab and vedolizumab had lower odds versus placebo during \n",
      "maintenance.\n",
      "Conclusions:  Upadacitinib may be the most efficacious therapy for moderately to severely active UC based on ITT analyses, with similar safety \n",
      "across advanced therapies.\n",
      "Lay Summary \n",
      "Indirect evidence suggests upadacitinib may be more efficacious than other advanced therapies at achieving clinical response, clinical remis-\n",
      "sion, and endoscopic response over 1 year for moderately to severely active ulcerative colitis patients, with similar safety assessments across \n",
      "advanced therapies.\n",
      "Key Words: ulcerative colitis, clinical trials, advanced therapies, network meta-analysis\n",
      "Introduction\n",
      "Ulcerative colitis (UC) is a chronic inflammatory bowel dis-\n",
      "ease that affects the colorectum and is clinically characterized \n",
      "by bloody diarrhea, urgency, tenesmus, abdominal pain, ma-\n",
      "laise, weight loss, and fever. Disease onset commonly occurs \n",
      "between the ages of 15 and 30 years and the annual global \n",
      "© The Author(s) 2023. Published by Oxford University Press on behalf of Crohn's & Colitis Foundation.\n",
      "This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), \n",
      "which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.\n",
      "----------\n",
      "Parkes, M., Vermeire, S., Rioux, J.D., Mansﬁeld, J., Silverberg, M.S., Radford-\n",
      "Smith, G., McGovern, D.P., Barrett, J.C., Lees, C.W., 2016. Inherited determinants of\n",
      "crohn's disease and ulcerative colitis phenotypes: a genetic association study. Lancet\n",
      "387 (10014), 156–167.\n",
      "Colombel, J.F., Sandborn, W.J., Rutgeerts, P., Enns, R., Hanauer, S.B., Panaccione, R.,\n",
      "Schreiber, S., Byczkowski, D., Li, J., Kent, J.D., Pollack, P.F., 2007. Adalimumab for\n",
      "maintenance of clinical response and remission in patients with crohn's disease: the\n",
      "charm trial. Gastroenterology 132 (1), 52–65.\n",
      "Conrad, M.A., Kelsen, J.R., 2020. The treatment of pediatric inﬂammatory bowel disease\n",
      "with biologic therapies. Curr. Gastroenterol. Rep. 22 (8), 36–51.\n",
      "Csontos, A.A., Molnar, A., Piri, Z., Katona, B., Dako, S., Palﬁ, E., Miheller, P., 2016. The\n",
      "effect of anti-tnfalpha induction therapy on the nutritional status and dietary intake\n",
      "in inﬂammatory bowel disease. J Gastrointestin Liver Dis 25 (1), 49–56.\n",
      "Dai, Z.H., Xu, X.T., Ran, Z.H., 2020. Associations between obesity and the effectiveness of\n",
      "anti-tumor necrosis factor-alpha agents in inﬂammatory bowel disease patients: a\n",
      "literature review and meta-analysis. Ann. Pharmacother. 54 (8), 729–741.\n",
      "Danese, S., Colombel, J.F., Lukas, M., Gisbert, J.P., D’Haens, G., Hayee, B., Panaccione, R.,\n",
      "Kim, H.S., Reinisch, W., Tyrrell, H., Oh, Y.S., Tole, S., Chai, A., Chamberlain-\n",
      "James, K., Tang, M.T., Schreiber, S., Group, G.S., 2021. Etrolizumab versus inﬂiximab\n",
      "for the treatment of moderately to severely active ulcerative colitis (gardenia): a\n",
      "randomised, double-blind, double-dummy, phase 3 study. Lancet Gastroenterol\n",
      "Hepatol 7 (2), 118–127.\n",
      "Danese, S., Fiorino, G., Peyrin-Biroulet, L., Lucenteforte, E., Virgili, G., Moja, L.,\n",
      "Bonovas, S., 2014. Biological agents for moderately to severely active ulcerative\n",
      "colitis: a systematic review and network meta-analysis. Ann. Intern. Med. 160 (10),\n",
      "704–711.\n",
      "P. Juillerat et al.\n",
      "Current Research in Pharmacology and Drug Discovery 3 (2022) 100104\n",
      "6\n",
      "==========\n",
      "ORIGINAL QUESTION: ANALYSE the given patient profile based on given query based on one of the following criteria:\n",
      "- Whether treated patient is new patient or patient under maintenance\n",
      "- Prior response to Infliximab\n",
      "- Prior failure to Anti-TNF agents\n",
      "- Prior failure to Vedolizumab\n",
      "- Age\n",
      "- Pregnancy\n",
      "- Extraintestinale manifestations\n",
      "- Pouchitis\n",
      "RETURN up to 2 TOP choices of biological drugs given patient profile and context. Explain the PROS and CONS of the 2 choices.\n",
      "PATIENT PROFILE: 38 year-old woman with moderate to severe ulcerative colitis and pulmonary tuberculosis which was treated 2 years ago.\n",
      "==========\n",
      "CURRENT ANSWER:\n",
      "Based on the patient's profile, the top two choices of biological drugs would be Vedolizumab and Ustekinumab. \n",
      "\n",
      "1. Vedolizumab:\n",
      "   - Advantages: Vedolizumab is a gut-selective immunosuppressant, meaning it specifically targets the gut and has less systemic side effects. It has been shown to be effective in treating moderate to severe ulcerative colitis. It is less likely to reactivate latent tuberculosis due to its gut-selective nature.\n",
      "   - Disadvantages: Vedolizumab may not work for all patients and it may take several weeks to see an effect. It is administered intravenously which may be inconvenient for some patients.\n",
      "\n",
      "2. Ustekinumab:\n",
      "   - Advantages: Ustekinumab is effective in treating moderate to severe ulcerative colitis. It targets a different pathway (interleukin-12 and -23) compared to other biologics, providing an alternative for patients who do not respond to or cannot use other treatments. \n",
      "   - Disadvantages: Ustekinumab may increase the risk of infections. Although it is less likely to reactivate tuberculosis compared to TNF-alpha inhibitors, the risk cannot be completely ruled out. It is also administered via injection, which may be inconvenient for some patients.\n",
      "\n",
      "It is important to note that while these drugs are less likely to reactivate tuberculosis compared to TNF-alpha inhibitors, the patient should be closely monitored for any signs of tuberculosis reactivation.\n",
      "==========\n",
      "REFINED ANSWER:\n",
      "\u001b[0m\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "Retrying langchain.chat_models.openai.ChatOpenAI.completion_with_retry.<locals>._completion_with_retry in 4.0 seconds as it raised RateLimitError: Rate limit reached for 10KTPM-200RPM in organization org-ETbTMTN2JXYOUPDJgxuH2iO6 on tokens per min. Limit: 10000 / min. Please try again in 6ms. Contact us through our help center at help.openai.com if you continue to have issues..\n",
      "Retrying langchain.chat_models.openai.ChatOpenAI.completion_with_retry.<locals>._completion_with_retry in 4.0 seconds as it raised RateLimitError: Rate limit reached for 10KTPM-200RPM in organization org-ETbTMTN2JXYOUPDJgxuH2iO6 on tokens per min. Limit: 10000 / min. Please try again in 6ms. Contact us through our help center at help.openai.com if you continue to have issues..\n",
      "Retrying langchain.chat_models.openai.ChatOpenAI.completion_with_retry.<locals>._completion_with_retry in 4.0 seconds as it raised RateLimitError: Rate limit reached for 10KTPM-200RPM in organization org-ETbTMTN2JXYOUPDJgxuH2iO6 on tokens per min. Limit: 10000 / min. Please try again in 6ms. Contact us through our help center at help.openai.com if you continue to have issues..\n",
      "Retrying langchain.chat_models.openai.ChatOpenAI.completion_with_retry.<locals>._completion_with_retry in 8.0 seconds as it raised RateLimitError: Rate limit reached for 10KTPM-200RPM in organization org-ETbTMTN2JXYOUPDJgxuH2iO6 on tokens per min. Limit: 10000 / min. Please try again in 6ms. Contact us through our help center at help.openai.com if you continue to have issues..\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\n",
      "\u001b[1m> Finished chain.\u001b[0m\n",
      "\n",
      "\u001b[1m> Finished chain.\u001b[0m\n",
      "2023-10-02 17:49:27,063:INFO: 6061 tokens were added to prompt from 10 documents\n"
     ]
    }
   ],
   "source": [
    "exp_args = {\n",
    "    \"original_prompt\": QA_PROMPT,\n",
    "    \"refine_prompt\": REFINE_PROMPT,\n",
    "    \"vector_store\": os.path.join(MAIN_DIR, \"data\", \"emb_store\", \"uc\", \"faiss\", \"text-embedding-ada-002\", \"v8-add-tables_2500_500\"),\n",
    "    \"llm_type\": \"gpt-4\",\n",
    "    \"refine_llm_type\": \"gpt-4\",\n",
    "    \"temperature\": 0,\n",
    "    \"max_tokens\": 512,\n",
    "    \"gt\": os.path.join(MAIN_DIR, \"data\", \"queries\", \"uc_all_gt.csv\"),\n",
    "    \"verbose\": True,\n",
    "    \"k\": 10,\n",
    "    \"max_tokens_limit\": 6500,\n",
    "    \"reduce_k_below_max_tokens\": True\n",
    "}\n",
    "\n",
    "refine_exp = QAWithIndexSearchandRefineExperiment(\n",
    "    **exp_args\n",
    ")\n",
    "\n",
    "refine_exp.reset()\n",
    "refine_exp.run_test_cases(\n",
    "    test_cases_txt,\n",
    "    chain_type=\"stuff\"\n",
    ")\n",
    "\n",
    "description = \"ChatGround_Refine_Tables_Chunk-size=2500_Overlap=500_Doc={}_Max-token={}_Stuff\".format(exp_args[\"k\"], exp_args[\"max_tokens_limit\"])\n",
    "save_path = os.path.join(\n",
    "    ARTIFACT_DIR,\n",
    "    \"{}_{}_{}\".format(\n",
    "        exp_args[\"llm_type\"], description, datetime.now().strftime(\"%d-%m-%Y-%H-%M-%S\")\n",
    "    ),\n",
    ")\n",
    "os.makedirs(save_path, exist_ok=True)\n",
    "refine_exp.save_json(\n",
    "    os.path.join(save_path, f\"result.json\")\n",
    ")\n",
    "refine_exp.write_csv(\n",
    "    os.path.join(save_path, f\"result.csv\"), num_docs=exp_args[\"k\"]\n",
    ")"
   ]
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "venv",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.10.12"
  },
  "orig_nbformat": 4
 },
 "nbformat": 4,
 "nbformat_minor": 2
}
